10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2019

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission file number 001-15925

COMMUNITY HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware	13-3893191
(State of incorporation)	(IRS Employer Identification No.)
4000 Meridian Boulevard	37067
Franklin, Tennessee (Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:

(615) 465-7000

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, $.01 par value	CYH	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☑    NO ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐    NO ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☑    NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑    No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐	Accelerated filer ☑	Smaller reporting company ☐
Non-accelerated filer ☐		Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES ☐    NO ☑

The aggregate market value of the voting stock held by non-affiliates of the Registrant was $295,833,589. Market value is determined by reference to the closing price on June 30, 2019 of the Registrant’s Common Stock as reported by the New York Stock Exchange. The Registrant does not (and did not at June 30, 2019) have any non-voting common stock outstanding. As of February 18, 2020, there were 117,856,892 shares of common stock, par value $.01 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Certain information required for Part III of this annual report is incorporated by reference to portions of the Registrant’s definitive proxy statement for its 2020 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2019.

TABLE OF CONTENTS

COMMUNITY HEALTH SYSTEMS, INC.

Year ended December 31, 2019

		Page
	PART I
Item 1.	Business	1
Item 1A.	Risk Factors	29
Item 1B.	Unresolved Staff Comments	45
Item 2.	Properties	45
Item 3.	Legal Proceedings	49
Item 4.	Mine Safety Disclosures	54
	PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	55
Item 6.	Selected Financial Data	57
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	58
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	91
Item 8.	Financial Statements and Supplementary Data	92
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	170
Item 9A.	Controls and Procedures	170
Item 9B.	Other Information	170
	PART III
Item 10.	Directors, Executive Officers and Corporate Governance	174
Item 11.	Executive Compensation	176
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	176
Item 13.	Certain Relationships and Related Transactions, and Director Independence	176
Item 14.	Principal Accountant Fees and Services	176
	PART IV
Item 15.	Exhibits and Financial Statement Schedules	177
Item 16.	Form 10-K Summary	191

Item 1. Business of Community Health Systems, Inc.

Overview of Our Company

We are one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute care hospitals and outpatient facilities in communities across the country. We were originally founded in 1986 and were reincorporated in 1996 as a Delaware corporation. We provide healthcare services through the hospitals that we own and operate and affiliated businesses in non-urban and selected urban markets throughout the United States. As of December 31, 2019, we owned or leased 102 hospitals with an aggregate of 16,240 licensed beds, comprised of 100 general acute care hospitals and two stand-alone rehabilitation or psychiatric hospitals. These hospitals are geographically diversified across 18 states, with the majority of our hospitals located in regional networks or in close geographic proximity to one or more of our other hospitals. We generate revenues by providing a broad range of general and specialized hospital healthcare services and outpatient services to patients in the communities in which we are located. Services provided through our hospitals and affiliated businesses include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric and rehabilitation services. We also provide additional outpatient services at urgent care centers, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. An integral part of providing these services is our network of affiliated physicians at our hospitals and affiliated businesses. As of December 31, 2019, we employed approximately 2,000 physicians and an additional 1,000 licensed healthcare practitioners. Through our management and operation of these businesses, we provide standardization and centralization of operations across key business areas; strategic assistance to expand and improve services and facilities; implementation of patient safety and quality of care improvement programs and assistance in the recruitment of additional physicians and licensed healthcare practitioners to the markets in which our hospitals are located. In a number of our markets, we have partnered with local physicians or not-for-profit providers, or both, in the ownership of our facilities.

We have been implementing a portfolio rationalization and deleveraging strategy by divesting hospitals and non-hospital businesses that are attractive to strategic and other buyers. Generally, these businesses are not in one of our strategically beneficial service areas, are less complementary to our business strategy and/or have lower operating margins. In connection with our divestiture initiative, we have received offers from strategic buyers to buy certain of our assets. After considering these offers, we have divested, and expect to continue to divest, hospitals and non-hospital businesses when we find such offers to be attractive and in line with our operating strategy.

During 2019, we completed the divestiture of 12 hospitals, including two hospitals the divestitures of which closed effective January 1, 2019 (for these hospitals, we received the net proceeds at a preliminary closing on December 31, 2018). Excluding the net proceeds for the two hospitals that preliminarily closed on December 31, 2018, we received total net proceeds of approximately $335 million in connection with the disposition of these hospitals. In addition, we completed the divestiture of an additional three hospitals on January 1, 2020 for which we received net proceeds of approximately $240 million at a preliminary closing on December 31, 2019. During 2018, we completed the divestiture of 11 hospitals. Including the net proceeds for the two additional hospitals that preliminarily closed on December 31, 2018 noted above, we received total net proceeds of approximately $405 million in connection with the disposition of these hospitals. During 2017, we completed the divestiture of 30 hospitals included in continuing operations, and received total net proceeds of approximately $1.7 billion in connection with the disposition of these hospitals.

Throughout this Form 10-K, we refer to Community Health Systems, Inc., or the Parent Company, and its consolidated subsidiaries in a simplified manner and on a collective basis, using words like “we,” “our,” “us” and the “Company.” This drafting style is suggested by the Securities and Exchange Commission, or SEC, and is not meant to indicate that the publicly-traded Parent Company or any particular subsidiary of the Parent Company owns or operates any asset, business or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

1

Available Information

Our website address is www.chs.net and the investor relations section of our website is located at www.chs.net/investor-relations. Notwithstanding the foregoing, the information contained on our website as noted above or elsewhere in this Form 10-K is not incorporated by reference into this Form 10-K. We make available free of charge, through the investor relations section of our website, annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K as well as amendments to those reports, as soon as reasonably practical after they are filed with, or furnished to, the SEC. The SEC maintains an Internet site that contains our reports, proxy and information statements, and other information that we file electronically with the SEC at www.sec.gov.

We also make available free of charge, through the investor relations section of our website, our By-laws, our Governance Guidelines, our Code of Conduct and the charters of our Audit and Compliance Committee, Compensation Committee and Governance and Nominating Committee.

We have included the Chief Executive Officer and the Chief Financial Officer certifications regarding the public disclosure required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2, 32.1 and 32.2 to this Form 10-K.

Our Business Strategy

Our objective is to provide safe, high-quality healthcare for our patients and the communities we serve. We are committed to efficient, cost effective and profitable operations that seek to ensure sustainable health systems and deliver long-term shareholder value. Our efforts are focused around the following key strategies, which are designed to help us achieve our objectives:

• Become a market leader and increase market share in the communities we serve;

• Increase productivity and operating efficiencies to enhance profitability;

• Continuously improve patient safety and quality of care; and

• Optimize our portfolio through select divestitures of non-core assets while investing in markets with the best opportunities for growth.

Become a market leader and increase market share in the communities we serve

We operate across diverse markets that range from sole community providers to large regional networks. We are able to leverage our significant scale and standardized systems to provide cost-effective services and best practices for our affiliate operations. Each of our markets develops and executes a strategic plan with short and long-term goals, based on their unique opportunities and the needs of their respective communities. As an organization, we also have implemented a number of strategic initiatives designed to improve market position, expand services to our patients, and capture a greater share of healthcare spending in our markets. These include:

• Strengthening regional networks and local market operations;

• Expanding patient access points, health services and infrastructure;

• Recruiting and/or employing additional primary care physicians and specialists; and

• Developing a more consumer-centric experience and facilitating connections between episodes of care.

Strengthening Regional Networks and Local Market Operations. We believe opportunities exist in select markets to create healthcare networks consisting of multiple hospitals and corresponding outpatient services.

2

Regional networks are able to expand the breadth of services provided for our patients, develop centers of excellence for key services, deliver care in an organized and efficient way across the network, improve alignment with physicians and other providers, and make services more attractive to managed care and other payers. Currently, 76 of our hospitals operate in 20 unique regional networks.

We also operate healthcare systems that are built around a single acute-care hospital. In these markets, we are focused on supporting the hospital with physician practices, outpatient services, clinical collaborations and partnerships that offer our patients health services across the continuum of care. These hospitals and their related outpatient services may operate in competitive markets or as sole community providers.

Expanding Patient Access Points, Health Services and Infrastructure. When expanding services – in both the acute and non-acute care settings – our approach is data-driven and strategic to ensure our investments are responsive to community and patient needs and produce sound financial results. While we continue to provide health services across a broad spectrum, we have focused our attention and resources on service lines we believe have the greatest potential for growth, including primary care, emergency medicine, orthopedics, neuroscience, cardiovascular care, surgical services and behavioral health. As the shift to delivering health services in outpatient settings accelerates, we continue to expand our care offerings beyond hospital walls to include more outpatient access through primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, imaging and diagnostic centers, retail clinics and direct-to-consumer virtual health visits.

We believe expanding our patient access footprint can attract new patients and increase patient retention, as well as our ability to connect patients from one episode of care to the next appropriate care setting. We also believe our investments will enhance our long-term growth and generate increased revenue, earnings, and operating margins by providing a solid return on investment.

Recruiting and/or Employing Additional Primary Care Physicians and Specialists. The physician-patient relationship is the foundation on which all healthcare services are built. Understanding this, we continuously assess our communities to identify service gaps and practice opportunities in order to recruit an optimal mix of primary care physicians and specialists. We analyze demographic data and referral trends and employ recruiters at the corporate level to support local hospital administrators in their physician recruitment efforts. In some markets, we employ physicians, often acquiring their practices at the onset of the arrangement. However, most physicians in our communities and on our medical staffs remain in private practice and are not our employees.

We work hard to develop positive, collaborative relationships with physicians. We currently participate in 15 Medicare Shared Savings Program Accountable Care Organizations which include approximately 5,200 employed and independent physicians in our communities. We look forward to realizing the benefits of these Accountable Care Organizations, including opportunities to strengthen quality, deepen clinical collaboration and demonstrate performance under a reimbursement system moving toward more value-based incentives and payments.

Developing a More Consumer-Centric Experience and Facilitating Connections between Episodes of Care. Consumers continue to take a more active role in healthcare decision-making, especially as they assume increasing responsibility for the cost of their healthcare. The rise in consumerism is highlighting customer expectations that have not always been prioritized in the healthcare setting. We are working on ways to create more enduring relationships with our patients by providing services that help people navigate their healthcare journeys and enable more seamless connections across episodes of care in our healthcare systems, hospitals, and physician practices. Some of these initiatives include:

• A centralized and proprietary transfer center offering services to connect emergency department and hospitalized patients requiring transfer to facilities that can best meet their needs;

• Centralized patient scheduling call centers and online scheduling to ease appointment scheduling;

3

• Patient navigation and next appointment scheduling from existing points of care;

• Availability of virtual health for certain services provided in the hospital and for direct-to-consumer, on-demand virtual visits with physicians;

• Digital marketing and consumer engagement campaigns; and

• Other technology enabled initiatives that support connected healthcare experiences, such as patient portals, text message appointment reminders, gaps-in-care campaigns and post-discharge surveys.

Increase productivity and operating efficiencies to enhance profitability

Our hospital management teams are supported by experienced corporate leaders who have significant industry knowledge and a proven track record of success. Local hospitals benefit from centralized clinical, operational, financial and regulatory expertise that encompasses nearly every aspect of our business. Additionally, we are able to leverage deep and meaningful data sources to facilitate informed decision-making and drive operational improvements across the enterprise in areas such as drug and supply procurement, workforce optimization and staffing and emergency department and operating room performance.

Standard policies and procedures in areas ranging from physician practice management to patient accounting to construction and facilities management help to facilitate best practices, reduce variation and improve operating results. The following areas highlight some of our standardized and centralized platforms.

Billing and Collections. We have adopted standard policies and procedures with respect to billing and collections. We have automated various components of the collection cycle, including statements and collection letters, to help facilitate timely and accurate progression of our accounts through the collection cycle. We have consolidated local billing and collection functions into six centralized business offices and have completed the transition of our hospital billing departments to this new infrastructure. We are now realizing the benefits of lower patient claim denials, higher underpayment recoveries and reduced operating expenses.

Physician Support. We support newly recruited physicians to facilitate a smooth and effective transition into our communities. Newly recruited physicians participate in orientation that covers matters related to starting up a new practice or joining an established practice. For employed physicians, we utilize software solutions that monitor and help optimize their practice performance against industry standard benchmarks and best practices. We also have implemented programs to improve physician workflow, reduce physician turnover, optimize staffing at physician clinics and standardize onboarding processes.

Procurement and Materials Management. We have standardized and centralized supply chain operations to improve procurement of the medical supplies, equipment and pharmaceuticals used in our hospitals. We have an ownership interest in and participation agreement with HealthTrust Purchasing Group, L.P., or HealthTrust, a group purchasing organization, or GPO, which benefits members through scaled pricing. HealthTrust contracts with certain vendors who supply a substantial portion of our medical supplies, equipment and pharmaceuticals.

Case and Resource Management. The primary goal of our case management program is to deliver safe, high-quality care in an efficient and cost effective manner. The program focuses on:

• Appropriate management of length of stay consistent with national standards and benchmarks;

• Reducing unnecessary utilization;

• Developing and implementing operational best practices;

• Discharge planning; and

• Compliance with applicable regulatory standards.

4

Our case management program integrates the functions of utilization review, discharge planning, assessment of medical necessity and resource management. Patients are assessed upon presentation to the hospital and throughout their course of care with ongoing reviews. Industry-standard criteria are utilized in patient assessments and discharge plans are adjusted according to patient needs. Cases are monitored to prevent delays in service or unnecessary utilization of resources. When a patient is ready for discharge, a case manager works with the patient’s attending physician to evaluate and coordinate the patient’s needs for continued care in the post-acute setting. Each hospital has the support of a physician advisor to act as a liaison to the medical staff and assist with all the activities of the program.

Other Initiatives. Numerous other initiatives have been standardized or centralized and leverage data to reduce costs and increase productivity. For example, we have improved staff scheduling and efficiency by implementing standardized time keeping systems and we have implemented initiatives to reduce unnecessary overtime and guide temporary staffing decisions that align with patient admissions and acuity. We have created a centralized team and implemented standard processes for payroll processing and management of accounts payable. Likewise, we have leveraged data and expertise to optimize our performance in clinical and operating areas such as emergency room, pharmacy, laboratory, imaging and skilled nursing services and health information management. Each time we implement a new process initiative, we work to identify and communicate best practices and we monitor progress and performance improvement throughout the organization.

Continuously Improve Patient Safety and Quality of Care

We maintain quality assurance programs to monitor, support and advance quality of care standards and to meet Medicare and Medicaid accreditation and regulatory requirements. We maintain an emphasis on patient safety and clinical outcomes and we are continuously focused on ways to improve patient, physician and employee satisfaction. We believe that a focus on continuous improvement yields the best results for patients, reduces risk and liability, and creates value for the people and communities we serve.

We have developed and implemented programs to support and monitor patient safety and quality of care that include:

• Standardized data and benchmarks to monitor clinical outcomes, hospital performance and quality improvement efforts;

• Recommended policies and procedures based on medical and scientific evidence;

• Training with evidence-based tools for improving patient safety and quality of care and patient, physician and employee satisfaction;

• Leveraging technology and information sharing around evidence-based clinical best practices;

• Training programs for hospital management and clinical staff regarding regulatory and reporting requirements; and

• Implementation of specific leadership methods and error-prevention tools to create safer care environments for patients and staff.

We have operated a Patient Safety Organization, or PSO, since 2011. Our PSO is listed by the U.S. Department of Health and Human Services, or HHS, Agency for Healthcare Research and Quality. We believe our PSO has assisted, and will continue to assist us, in improving patient safety at our hospitals. The PSO has been recertified through 2020.

Optimize our portfolio through select divestitures of non-core assets while investing in markets with the best opportunities for growth

We have been reshaping our portfolio through the divestiture of non-core hospital and non-hospital assets to strategic and other buyers. In 2019, we divested additional hospitals in select markets, and continue to pursue

5

additional divestitures. Generally, these divested assets are less complementary to our business strategies and/or have lower operating margins. We have used proceeds from these divestitures, and expect to continue to use proceeds from future divestitures, to reduce debt and/or reinvest in our facilities to strengthen our regional networks and local market operations.

By divesting non-core assets, we are able to more sharply channel our resources and capital investments into strategic markets where we have the best ability to increase access and patient care, enhance our service lines, form successful joint ventures, produce growth and increase market share. As an example, we acquired 28 physician practices in 2019.

Our portfolio optimization efforts have included a significant number of transactions to date. In 2017, we divested 30 hospitals in single and multi-hospital transactions. In 2018, we divested an additional 11 hospitals in single and multi-hospital transactions. We also closed three non-core hospitals in 2018 in locations where the operations could be absorbed by one or more hospitals in the same regional network. In 2019, we divested an additional 12 hospitals in single and multi-hospital transactions. We also divested three additional hospitals effective January 1, 2020.

Industry Overview

According to the Centers for Medicare & Medicaid Services, or CMS, national healthcare expenditures grew 4.6% in 2018 to $3.6 trillion and are projected to have grown 4.8% in 2019 to nearly $3.8 trillion. The CMS projections, published in February of 2019, indicate that total U.S. healthcare spending is expected to grow by 5.4% in 2020 and 5.6% in 2021, and at an average annual rate of 5.7% for 2020 through 2027. CMS anticipates that total U.S. healthcare annual expenditures will reach nearly $6.0 trillion by 2027, accounting for approximately 19.4% of the total U.S. gross domestic product. Healthcare spending is expected to be largely influenced by changes in economic conditions and demographics, as well as by increasing prices for medical goods and services. The CMS projections are constructed using a current-law framework. They are typically published once per year and are not updated to reflect interim changes. For example, the projections do not take into account the possibility of further modifications to, or repeal of, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act.

Hospital services, the market within the healthcare industry in which we primarily operate, is the largest single category of healthcare expenditures. In 2019, hospital care expenditures are projected to have grown 5.1%, amounting to approximately $1.3 trillion. CMS estimates that the hospital services category will amount to over $1.3 trillion in 2020 and projects growth in this category at an average of 5.8% annually from 2020 through 2027.

U.S. Hospital Industry. The U.S. hospital industry is broadly defined to include acute care, rehabilitation and psychiatric facilities that are either public (government owned and operated), not-for-profit private (religious or secular), or for-profit institutions (investor owned). According to the American Hospital Association, there are approximately 5,200 community hospitals in the U.S., which are not-for-profit owned, investor owned, or state or local government owned. Of these hospitals, approximately 35% are located in non-urban communities. We believe that a majority of these hospitals are owned by not-for-profit or governmental entities. These facilities offer a broad range of healthcare services, including internal medicine, general surgery, cardiology, oncology, orthopedics, OB/GYN and emergency services. In addition, hospitals offer other ancillary services, including psychiatric, diagnostic, rehabilitation, home care and outpatient surgery services.

Factors Affecting Performance. Among the many factors that can influence a hospital’s financial and operating performance are:

• facility size and location;

• facility ownership structure (e.g., tax-exempt or investor owned);

6

• a facility’s ability to participate in GPOs, such as HealthTrust; and

• facility payor mix.

Patients needing the most complex care are more often served by the larger and/or more specialized urban hospitals. We believe opportunities exist in selected urban markets to create networks between urban hospitals and non-urban hospitals in order to expand the breadth of services offered in the non-urban hospitals while improving physician alignment in those markets and making them more attractive to managed care organizations.

Hospital Industry Trends

Demographic Trends. According to the U.S. Census Bureau, in 2018, there were approximately 52 million Americans aged 65 or older in the U.S. comprising approximately 16.0% of the total U.S. population. By the year 2030, the number of Americans aged 65 or older is expected to climb to 72 million, or 19.3% of the total population. Due to the anticipated increasing life expectancy of Americans, the number of people aged 85 years and older is also expected to increase from 6 million in 2015 to 9 million by the year 2030. This anticipated increase in life expectancy will increase demand for healthcare services and, as importantly, the demand for innovative, more sophisticated means of delivering those services. Hospitals, as the largest category of care in the healthcare market, will be among those impacted most directly by this increase in demand. Based on data compiled for us, the populations of the service areas where our hospitals are located grew 5.5% from 2012 to 2019 and are expected to grow by 3.3% from 2019 to 2024. The number of people aged 65 or older in these service areas grew by 31.2% from 2011 to 2019 and is expected to grow by 15.5% from 2019 to 2024. People aged 65 or older comprised 18.4% of the total population in our service areas in 2019, yet they could comprise 20.6% of the total population in our service areas by 2024.

Consolidation. In addition to our own acquisitions and dispositions in recent years, consolidation activity in the hospital industry, primarily through mergers and acquisitions involving both for-profit and not-for-profit hospital systems, is continuing. Reasons for this activity include:

• ample supply of available capital;

• valuation levels;

• financial performance issues, including challenges associated with changes in reimbursement and collectability of self-pay revenue;

• the desire to enhance the local availability of healthcare in the community;

• the need and ability to recruit primary care physicians and specialists;

• the need to achieve general economies of scale and to gain access to standardized and centralized functions, including favorable supply agreements and access to malpractice coverage;

• changes to healthcare payment models that emphasize cost-effective delivery of service and quality of outcomes for the entire episode of care; and

• regulatory changes.

The payor industry is also consolidating and acquiring health services providers in an effort to offer more expansive, competitive programs.

Trends in Payment for Healthcare Services. As discussed in more detail in the Government Regulation section of this Form 10-K, the impact of healthcare reform legislation, combined with the growing financial and economic pressures on the healthcare industry, has resulted in challenges to traditional reimbursement models.

7

For example, the Affordable Care Act has encouraged the adoption of new payment models that emphasize cost-effective delivery of care and quality of outcomes. Although the number of patients with health insurance coverage has expanded since 2010, the year the Affordable Care Act was enacted, patients may face higher deductibles and increased co-payment requirements, which may result in greater write-offs of uncollectible amounts from those patients.

Shift to Outpatient Services. Because of the growing availability of stand-alone outpatient healthcare facilities, the increase in the services that can be provided at these locations, and payor policies requiring or promoting treatment in outpatient settings, many individuals are seeking a broader range of services at outpatient facilities. This trend has contributed to an increase in outpatient services while inhibiting the growth of inpatient admissions. However, recent changes to Medicare policy affecting the reimbursement methodology for certain items and services provided by off-campus provider-based hospital departments have generally resulted in reduced payment rates for these hospital outpatient settings.

8

Selected Operating Data

The following table sets forth operating statistics for each of the years presented for our hospitals that are included in our continuing operations. Statistics for 2019 include a full year of operations for 101 hospitals and partial periods for 12 hospitals divested and one hospital acquired during the year reflecting the operations of these hospitals prior to divestiture or after acquisition, as applicable. Statistics for 2018 include a full year of operations for 113 hospitals and partial periods for 11 hospitals divested during the year and three hospitals that ceased operations during the year reflecting the operations of these hospitals prior to divestiture or closure. Statistics for 2017 include a full year of operations for 125 hospitals and partial periods for 30 hospitals divested during the year reflecting the operations of these hospitals prior to divestiture. Statistics for hospitals included in discontinued operations are excluded from all periods presented.

	Year Ended December 31,
	2019			2018			2017
	(Dollars in millions)
Consolidated Data
Number of hospitals (at end of period)		102			113			125
Licensed beds (at end of period) (1)		16,240			18,227			20,850
Beds in service (at end of period) (2)		14,442			16,297			18,457
Admissions (3)		557,959			627,321			738,036
Adjusted admissions (4)		1,208,513			1,351,857			1,596,739
Patient days (5)		2,474,569			2,815,401			3,296,469
Average length of stay (days) (6)		4.4			4.5			4.5
Occupancy rate (beds in service) (7)		45.1	%		43.5	%		43.3	%
Net operating revenues	$	13,210		$	14,155		$	15,353
Net inpatient revenues as a % of net operating revenues (8)		47.0	%		47.7	%		47.7	%
Net outpatient revenues as a % of net operating revenues (8)		53.0	%		52.3	%		52.3	%
Net loss attributable to Community Health Systems Inc. stockholders	$	(675	)	$	(788	)	$	(2,459	)
Net loss attributable to Community Health Systems Inc. stockholders as a % of net operating revenues		(5.1	)%		(5.6	)%		(16.0	)%
Adjusted EBITDA (9)	$	1,628		$	1,642		$	1,703
Adjusted EBITDA as a % of net operating revenues (9)		12.3	%		11.6	%		11.1	%
Liquidity Data
Net cash flows provided by operating activities	$	385		$	274		$	773
Net cash flows provided by operating activities as a % of net operating revenues		2.9	%		1.9	%		5.0	%
Net cash flows (used in) provided by investing activities	$	(2	)	$	(245	)	$	1,069
Net cash flows used in financing activities	$	(363	)	$	(396	)	$	(1,517	)

9

	Year Ended December 31,
	2019			2018			Increase
	(Dollars in millions)
Same-Store Data (10)
Admissions (3)		538,233			531,155			1.3	%
Adjusted admissions (4)		1,166,535			1,141,212			2.2	%
Patient days (5)		2,386,557			2,372,781
Average length of stay (days) (6)		4.4			4.5
Occupancy rate (beds in service) (7)		45.6	%		45.4	%
Net operating revenues	$	12,819		$	12,301			4.2	%
Income from operations	$	1,058		$	1,052			0.6	%
Income from operations as a % of net operating revenues		8.3	%		8.6	%
Depreciation and amortization	$	590		$	600
Equity in earnings of unconsolidated affiliates	$	(15	)	$	(21	)

(1) Licensed beds are the number of beds for which the appropriate state agency licenses a facility regardless of whether the beds are actually available for patient use.

(2) Beds in service are the number of beds that are readily available for patient use.

(3) Admissions represent the number of patients admitted for inpatient treatment.

(4) Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted admissions by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues.

(5) Patient days represent the total number of days of care provided to inpatients.

(6) Average length of stay (days) represents the average number of days inpatients stay in our hospitals.

(7) We calculated occupancy rate percentages by dividing the average daily number of inpatients by the weighted-average number of beds in service.

(8) This calculation excludes the change in estimate related to net patient revenue to increase contractual allowances and additional provision for bad debts recorded during the three months ended December 31, 2017.

(9) EBITDA is a non-GAAP financial measure which consists of net loss attributable to Community Health Systems, Inc. before interest, income taxes, and depreciation and amortization. Adjusted EBITDA, also a non-GAAP financial measure, is EBITDA adjusted to add back net income attributable to noncontrolling interests and to exclude the effect of discontinued operations, loss (gain) from early extinguishment of debt, impairment and loss on sale of businesses, expense incurred related to the sale of a majority ownership interest in the Company’s home care division, expense (income) related to government and other legal settlements and related costs, expense related to employee termination benefits and other restructuring charges, expense (income) from settlement and fair value adjustments on the CVR agreement liability related to the Health Management Associates, Inc., or HMA, legal proceedings and related legal expenses, the overall impact of the change in estimate related to net patient revenue recorded in the fourth quarter of 2017 resulting from the increase in contractual allowances and the provision for bad debts, the impact of changes in estimate to increase the professional liability claims accrual recorded during the second quarter of 2019 (which estimate was further revised in the third quarter of 2019 based on updated actuarial analysis) with respect to claims incurred in 2016 and prior years, and expense related to the valuation allowance recorded in the second quarter of 2019 to reserve the outstanding balance of a promissory note received from the buyer in connection with the sale of two of the Company’s hospitals in 2017, as well as income

10

from a reduction of the valuation allowance on the outstanding balance of a promissory note from the buyer of another hospital. The Company has from time to time sold noncontrolling interests in certain of its subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. The Company believes that it is useful to present Adjusted EBITDA because it adds back the portion of EBITDA attributable to these third-party interests and clarifies for investors the Company’s portion of EBITDA generated by continuing operations. The Company reports Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess the operating performance of the Company’s hospital operations and to make decisions on the allocation of resources. Adjusted EBITDA is also used to evaluate the performance of the Company’s executive management team and is one of the primary metrics used in connection with determining short-term cash incentive compensation and the achievement of vesting criteria with respect to performance-based equity awards. In addition, management utilizes Adjusted EBITDA in assessing the Company’s consolidated results of operations and operational performance and in comparing the Company’s results of operations between periods. The Company believes it is useful to provide investors and other users of the Company’s financial statements this performance measure to align with how management assesses the Company’s results of operations. Adjusted EBITDA also is comparable to a similar metric called Consolidated EBITDA, as defined in the Company’s asset-based loan facility, or ABL Facility, which is a key component in the determination of our compliance with some of the covenants under the ABL Facility (including our ability to service debt and incur capital expenditures), and is used to determine the interest rate and commitment fee payable under the ABL Facility (although Adjusted EBITDA does not include all of the adjustments described in the ABL Facility). For further discussion of Consolidated EBITDA and how that measure is utilized in the calculation of covenants in the ABL Facility, see the Capital Resources section of Part II, Item 7 of this Form 10-K.

Adjusted EBITDA is not a measurement of financial performance under U.S. GAAP. It should not be considered in isolation or as a substitute for net income, operating income, or any other performance measure calculated in accordance with U.S. GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating financial performance. The Company believes such adjustments are appropriate as the magnitude and frequency of such items can vary significant significantly and are not related to the assessment of normal operating performance. Additionally, this calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.

11

The following table reflects the reconciliation of Adjusted EBITDA, as defined, to net loss attributable to Community Health Systems, Inc. stockholders as derived directly from our Consolidated Financial Statements for the years ended December 31, 2019, 2018 and 2017 (in millions):

	Year Ended December 31,
	2019			2018			2017
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(675	)	$	(788	)	$	(2,459	)
Adjustments:
Provision for (benefit from) income taxes		160			(11	)		(449	)
Depreciation and amortization		608			700			861
Net income attributable to noncontrolling interests		85			84			63
Loss from discontinued operations		-			-			12
Interest expense, net		1,041			976			931
Loss (gain) from early extinguishment of debt		54			(31	)		40
Impairment and loss on sale of businesses, net		138			668			2,123
Change in estimate for contractual allowances and provision for bad debts		-			-			591
Expense (income) from government and other legal settlements and related costs		93			11			(31	)
Expense from settlement and fair value adjustments and legal expenses related to cases covered by the CVR		11			13			6
Expense related to the sale of a majority interest in home care division		-			-			1
Expense related to employee termination benefits and other restructuring charges		2			20			14
Change in valuation allowances recorded for promissory notes		21			-			-
Change in estimate for professional liability claims accrual		90			-			-
Adjusted EBITDA	$	1,628		$	1,642		$	1,703

(10) Same-store data excludes discontinued operations in the periods presented. Same-store operating results also exclude the overall impact of the change in estimate related to net patient receivables recorded in the fourth quarter of 2017. For all hospitals owned throughout both periods, the same-store operating results and statistical data reflects the indicated periods.

Sources of Revenue

The following table presents the approximate percentages of net operating revenues by payor source for the periods indicated. The data for the periods presented are not strictly comparable due to the effect that hospital acquisitions and divestitures have had on these statistics. The percentages of net operating revenues for 2017 also include the overall impact of the change in estimate recorded in the fourth quarter of 2017 to increase contractual allowances and record additional provision for bad debts.

	Year Ended December 31,
	2019			2018			2017
Medicare		25.2	%		26.3	%		27.8	%
Medicaid		13.2			13.3			13.2
Managed Care and other third-party payors		60.6			59.0			59.8
Self-pay		1.0			1.4			(0.8)
Total		100.0	%		100.0	%		100.0	%

12

As shown above, we receive a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impacts of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. The trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing proposals. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net loss by an insignificant amount in each of the years ended December 31, 2019, 2018 and 2017.

The payment rates under the Medicare program for hospital inpatient and outpatient acute care services are based on a prospective payment system, depending upon the diagnosis of a patient’s condition. These rates are indexed for inflation annually, although increases have historically been less than actual inflation.

Payment rates under the Medicaid program vary by state. In addition to the base payment rates for specific claims for services rendered to Medicaid enrollees, states utilize supplemental reimbursement programs to make separate payments that are not specifically tied to an individual’s care, some of which offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. The programs are generally authorized for a specified period of time and require CMS’s approval to be extended. We are unable to predict whether or on what terms CMS will extend the supplemental programs in the states in which we operate. Under these supplemental programs, we recognize revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and included as Medicaid revenue in the table above, and fees, taxes or other program related costs are reflected in other operating expenses.

As of December 31, 2019, Florida, Texas and Indiana represented our only areas of significant geographic concentration. Net operating revenues generated by our hospitals in Florida, as a percentage of consolidated operating revenues, were 14.3% in 2019 and 2018 and 14.0% in 2017. Net operating revenues generated by our

13

hospitals in Texas, as a percentage of consolidated operating revenues, were 12.2% in 2019, 11.7% in 2018 and 10.9% in 2017. Net operating revenues generated by our hospitals in Indiana, as a percentage of consolidated operating revenues, were 13.7% in 2019, 12.5% in 2018 and 11.6% in 2017.

Hospital revenues depend upon inpatient occupancy levels, the volume of outpatient procedures and the charges or negotiated payment rates for hospital services provided. Charges and payment rates for routine inpatient services vary significantly depending on the type of service performed and the geographic location of the hospital. In recent years, we have experienced a significant increase in revenue received from outpatient services. We attribute this increase to:

• advances in technology, which have permitted us to provide more services on an outpatient basis and

• pressure from Medicare and Medicaid programs, insurance companies and managed care plans to reduce the length and number of inpatient hospital stays and to reduce costs by providing services on an outpatient rather than on an inpatient basis.

Healthcare facility operations are also subject to certain seasonal fluctuations, including decreases in patient utilization during holiday periods and increases in colder weather months.

Government Regulation

Overview. The healthcare industry is required to comply with extensive government regulation at the federal, state and local levels. If we fail to comply with applicable laws and regulations, we may be subject to criminal penalties and civil sanctions, our hospitals could lose their licenses and we could lose our ability to participate in Medicare, Medicaid and other government programs. Hospitals must meet requirements to be certified as hospitals and qualified to participate in government programs, including those relating to the adequacy of medical care, equipment, personnel, operating policies and procedures; billing and coding for services; properly handling overpayments; classifications of levels of care provided; preparing and filing of cost reports; relationships with referral sources and referral recipients; maintenance of adequate records; hospital use; rate-setting; building codes; environmental protection; and privacy and security.

Hospitals are subject to periodic inspection by federal, state and local authorities to determine their compliance with applicable regulations and requirements necessary for licensing and certification. All of our hospitals are licensed under appropriate state laws and are qualified to participate in Medicare and Medicaid programs. In addition, most of our hospitals are accredited by The Joint Commission. This accreditation indicates that a hospital satisfies the applicable health and administrative standards to participate in Medicare and Medicaid programs.

Government regulations may change. If that happens, we may have to make changes to our facilities, equipment, personnel and services so that our hospitals remain certified as hospitals and qualified to participate in these programs. We believe that our hospitals are in substantial compliance with current federal, state and local regulations and standards. We cannot be certain that governmental officials responsible for enforcing these laws or whistleblowers will not assert that we are in violation of them or that such statutes or regulations will be interpreted by the courts in a manner consistent with our interpretation.

Healthcare Reform. Over the last decade, the U.S. Congress and certain state legislatures have introduced and passed a large number of proposals and legislation designed to make major changes in the healthcare system, including changes intended to increase access to health insurance. The most prominent of these efforts, the Affordable Care Act, affects how healthcare services are covered, delivered, and reimbursed. The Affordable Care Act increased health insurance coverage through a combination of public program expansion and private sector health insurance reforms and mandated that substantially all U.S. citizens maintain health insurance coverage. However, the future of the Affordable Care Act is uncertain. The law has been subject to legislative and regulatory changes and court challenges, and the presidential administration and certain members of

14

Congress have stated their intent to repeal or make additional significant changes to, the Affordable Care Act, its implementation or its interpretation. As part of the tax reform legislation enacted in December 2017, effective January 1, 2019, the financial penalty enforcing the individual mandate was eliminated. Additionally, in December 2018, as a result of this change, a federal judge in Texas found the individual mandate unconstitutional and determined the rest of the Affordable Care Act was therefore invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. Pending the appeals process, the law remains in place. The elimination of the individual mandate penalty and other changes may impact the number of individuals that elect to obtain public or private health insurance or the scope of such coverage, if purchased. Moreover, final rules issued in 2018 expand the availability of association health plans and allow the sale of short-term, limited-duration health plans, neither of which are required to cover all of the essential health benefits mandated by the Affordable Care Act.

We believe that the Affordable Care Act has had a positive impact on net operating revenues and income from continuing operations as the result of the expansion of private sector and Medicaid coverage that has occurred. However, other provisions of the Affordable Care Act, such as requirements related to employee health insurance coverage, have increased our operating costs. In addition, the Affordable Care Act has made changes to Medicare and Medicaid reimbursement that could adversely impact the reimbursement we receive under these programs. These changes include a productivity offset to the Medicare market basket update and reductions to the Medicare and Medicaid disproportionate share hospital, or DSH, payments.

Substantial uncertainty remains regarding the ongoing net effect of the Affordable Care Act due to the possibility of repeal or significant additional changes to the law, clarifications and modifications resulting from executive orders, the rule-making process, the ultimate outcome of court challenges and the development of agency guidance, whether and how many states ultimately decide to expand Medicaid coverage and on what terms, the number of individuals who elect to purchase health insurance coverage and budgetary issues at federal and state levels. The impact on the healthcare industry and timing of any potential repeal of or further changes to the Affordable Care Act and any alternative provisions is unknown. For example, members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor proposals, which could also significantly affect healthcare providers. Other initiatives and proposals, including those aimed at price transparency and out-of-network charges, may impact prices and the relationships between hospitals and insurers. It is difficult to predict the nature and success of future financial or delivery system reforms.

Fraud and Abuse Laws. Participation in the Medicare and Medicaid programs is heavily regulated by federal statute and regulation. If a hospital fails to comply substantially with the requirements for participating in the programs, the hospital’s participation may be terminated and/or civil or criminal penalties may be imposed. For example, a hospital may lose its ability to participate in the Medicare program if it engages in any of the following acts:

• making claims to Medicare for services not provided or misrepresenting actual services provided in order to obtain higher payments;

• paying money to induce the referral of patients where services are reimbursable under a federal health program; or

• paying money to limit or reduce the services provided to Medicare beneficiaries.

Any person or entity that knowingly and willfully defrauds or attempts to defraud a healthcare benefit program, including private healthcare plans, may be subject to fines, imprisonment or both. Additionally, any person or entity that knowingly and willfully falsifies or conceals a material fact or makes any material false or fraudulent statements in connection with the delivery or payment of healthcare services by a healthcare benefit plan is subject to a fine, imprisonment or both.

15

A section of the Social Security Act, known as the “Anti-Kickback Statute” prohibits some business practices and relationships under Medicare, Medicaid and other federal healthcare programs. These practices include the payment, receipt, offer, or solicitation of remuneration of any kind in exchange for items or services that are reimbursed under most federal or state healthcare programs.

The Office of Inspector General of the Department of Health and Human Services, or OIG, is responsible for identifying and investigating fraud and abuse activities in federal healthcare programs. As part of its duties, the OIG provides guidance to healthcare providers by identifying types of activities that could violate the Anti-Kickback Statute. The OIG also publishes regulations outlining activities and business relationships that would be deemed not to violate the Anti-Kickback Statute. These regulations are known as “safe harbor” regulations. The failure of a particular activity to comply with the safe harbor regulations does not necessarily mean that the activity violates the Anti-Kickback Statute; however, such failure may lead to increased scrutiny by government enforcement authorities.

The OIG has identified the following incentive arrangements as potential violations of the Anti-Kickback Statute:

• payment of any incentive by the hospital when a physician refers a patient to the hospital;

• use of free or significantly discounted office space or equipment for physicians in facilities usually located close to the hospital;

• provision of free or significantly discounted billing, nursing, or other staff services;

• free training for a physician’s office staff, including management and laboratory techniques (but excluding compliance training);

• guarantees which provide that, if the physician’s income fails to reach a predetermined level, the hospital will pay any portion of the remainder;

• low-interest or interest-free loans, or loans which may be forgiven if a physician refers patients to the hospital;

• payment of the costs of a physician’s travel and expenses for conferences;

• payment of services which require few, if any, substantive duties by the physician, or payment for services in excess of the fair market value of the services rendered;

• coverage on the hospital’s group health insurance plans at an inappropriately low cost to the physician;

• purchasing goods or services from physicians at prices in excess of their fair market value;

• rental of space in physician offices, at other than fair market value; or

• physician-owned entities (often referred to as physician-owned distributorships, or PODS) that derive revenue from selling, or arranging for the sale of, implantable medical devices ordered by their physician-owners for use on procedures that physician-owners perform on their own patients at hospitals or ASCs.

We have a variety of financial relationships with physicians who refer patients to our hospitals. Physicians own interests in a number of our facilities. Physicians may also own our stock. We also have contracts with physicians providing for a variety of financial arrangements, including employment contracts, leases, management agreements and professional service agreements. We provide financial incentives to recruit physicians to relocate to communities served by our hospitals. These incentives include relocation,

16

reimbursement for certain direct expenses, income guarantees and, in some cases, loans. Although we strive to comply with the Anti-Kickback Statute, taking into account available guidance including the “safe harbor” regulations, we cannot assure you that regulatory authorities will not determine otherwise. If that happens, we could be subject to criminal and civil penalties and/or exclusion from participating in Medicare, Medicaid, or other government healthcare programs. Civil monetary penalties are increased annually based on updates to the consumer price index and were increased under the Bipartisan Budget Act of 2018.

The Social Security Act also includes a provision commonly known as the “Stark Law.” This law prohibits physicians from referring Medicare and Medicaid patients to healthcare entities in which they or any of their immediate family members have ownership interests or other financial arrangements. These types of referrals are commonly known as “self referrals.” Sanctions for violating the Stark Law include denial of payment, civil monetary penalties that are increased annually based on updates to the consumer price index, and exclusion from federal healthcare programs.

There are ownership and compensation arrangement exceptions to the self-referral prohibition. One exception allows a physician to refer patients to a healthcare entity in which the physician has an ownership interest if the entity is located in a rural area, as defined in the statute. There are also exceptions for many of the customary financial arrangements between physicians and providers, including employment contracts, leases and recruitment agreements. From time to time, the federal government has issued regulations that interpret the provisions included in the Stark Law.

Another exception to the Stark Law, known as the “whole hospital” exception, allows a physician to make a referral to a hospital if the physician owns an interest in the entire hospital, as opposed to an ownership interest in a department of the hospital, and the hospital meets certain “grandfathering” requirements imposed by the Affordable Care Act. These requirements prohibit physicians from increasing the aggregate percentage of their ownership in the hospital and restrict the ability of physician-owned hospitals from expanding the capacity of their aggregate licensed beds, operating rooms and procedure rooms, beyond the ownership percentage and capacities in place in 2010. The whole hospital exception also contains additional public disclosure requirements. A hospital is considered to be physician-owned if any physician, or an immediate family member of a physician, holds debt, stock or other types of investment in the hospital or in any owner of the hospital, excluding physician ownership through publicly-traded securities that meet certain conditions.

In addition to the restrictions and disclosure requirements applicable to physician-owned hospitals under the Stark Law, CMS regulations require physician-owned hospitals and their physician owners to disclose certain ownership information to patients. Physician-owned hospitals must disclose their physician ownership in writing to patients and must make a list of their physician owners available upon request. Additionally, each physician owner who is a member of a physician-owned hospital’s medical staff must agree, as a condition of continued medical staff membership or admitting privileges, to disclose in writing to all patients whom they refer to the hospital their (or an immediate family member’s) ownership interest in the hospital. If a hospital fails to comply with these regulations, the hospital could lose its Medicare provider agreement and be unable to participate in Medicare.

Evolving interpretations of current, or the adoption of new, federal or state laws or regulations could affect many of the arrangements entered into by each of our hospitals. In addition, law enforcement authorities, including the OIG, the courts and Congress have in recent years increased scrutiny of arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to improperly pay for patient referrals and/or other business. Investigators have demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purpose of payments between healthcare providers and potential referral sources.

Many states in which we operate have also adopted laws that prohibit payments to physicians in exchange for referrals, similar to the federal Anti-Kickback Statute, or that otherwise prohibit fraud and abuse activities. Many states have also passed self-referral legislation similar to the Stark Law, prohibiting the referral of patients to

17

entities with which the physician has a financial relationship. Often these state laws are broad in scope and may apply regardless of the source of payment for care. These statutes typically provide for criminal and civil penalties, as well as loss of licensure. Little precedent exists for the interpretation or enforcement of these state laws.

Our operations could be adversely affected by the failure of our arrangements to comply with the Anti-Kickback Statute, the Stark Law, billing laws and regulations, current state laws or other legislation or regulations in these areas adopted in the future. We are unable to predict whether other legislation or regulations at the federal or state level in any of these areas will be adopted, what form such legislation or regulations may take or how they may affect our operations. We are continuing to enter into new financial arrangements with physicians and other providers in a manner structured to comply in all material respects with these laws. We strive to comply with applicable fraud and abuse laws. We cannot assure you, however, that governmental officials responsible for enforcing these laws or whistleblowers will not assert that we are in violation of them or that such statutes or regulations ultimately will be interpreted by the courts in a manner consistent with our interpretation.

Federal False Claims Act and Similar State Laws. Another significant enforcement mechanism used within the healthcare industry is the federal False Claims Act, or FCA, which can be used to prosecute Medicare and other government program fraud involving issues such as coding errors, billing for service not provided and submitting false cost reports. The FCA covers payments involving federal funds in connection with the health insurance exchanges created under the Affordable Care Act, if those payments involve any federal funds. Liability under the FCA often arises when an entity knowingly submits a false claim for reimbursement to the federal government. The FCA broadly defines the term “knowingly.” Although simple negligence will not give rise to liability under the FCA, submitting a claim with reckless disregard to its truth or falsity may constitute “knowingly” submitting a false claim and result in liability. Among the many other potential bases for liability under the FCA is the knowing and improper failure to report and refund amounts owed to the government within 60 days of identifying an overpayment. An overpayment is deemed to be identified when a person has, or should have through reasonable diligence, determined that an overpayment was received and quantified the overpayment. Submission of a claim for an item or service generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. In some cases, whistleblowers, the federal government and courts have taken the position that providers who allegedly have violated other statutes, such as the Stark Law, have thereby submitted false claims under the FCA.

When a defendant is determined by a court of law to be liable under the FCA, the defendant must pay three times the actual damages sustained by the government, plus substantial civil penalties for each separate false claim. These civil monetary penalties are adjusted annually based on updates to the consumer price index. Settlements entered into prior to litigation usually involve a less severe calculation of damages. The FCA also contains “qui tam,” or whistleblower provisions, which allow private individuals to bring actions on behalf of the government alleging that the defendant has defrauded the federal government. If the government intervenes in the action and prevails, the party filing the initial complaint may share in any settlement or judgment. If the government does not intervene in the action, the whistleblower plaintiff may pursue the action independently and may receive a larger share of any settlement or judgment. When a private party brings a qui tam action under the FCA, the defendant generally will not be made aware of the lawsuit until the government commences its own investigation or determines whether it will intervene. Every entity that receives at least $5 million annually in Medicaid payments must have written policies for all employees, contractors and agents providing detailed information about false claims, false statements and whistleblower protections under certain federal laws, including the FCA, and similar state laws.

A number of states, including states in which we operate, have adopted their own false claims provisions as well as their own whistleblower provisions whereby a private party may file a civil lawsuit in state court. Federal law provides an incentive to states to enact false claims laws that are comparable to the FCA. From time to time, companies in the healthcare industry, including ours, may be subject to actions under the FCA or similar state laws.

18

Corporate Practice of Medicine; Fee-Splitting. Some states have laws that prohibit unlicensed persons or business entities, including corporations, from employing physicians. Some states also have adopted laws that prohibit direct or indirect payments to, or entering into fee-splitting arrangements with, physicians and unlicensed persons or business entities. Possible sanctions for violations of these restrictions include loss of a physician’s license, civil and criminal penalties and rescission of business arrangements. These laws vary from state to state, are often vague and have seldom been interpreted by the courts or regulatory agencies. We structure our arrangements with healthcare providers to comply with the relevant state law. However, we cannot provide assurance that governmental officials responsible for enforcing these laws will not assert that we, or transactions in which we are involved, are in violation of these laws. These laws may also be interpreted by the courts in a manner inconsistent with our interpretations.

Emergency Medical Treatment and Active Labor Act. The Emergency Medical Treatment and Active Labor Act imposes requirements as to the care that must be provided to anyone who comes to facilities providing emergency medical services seeking care before they may be transferred to another facility or otherwise denied care. Sanctions for failing to fulfill these requirements include exclusion from participation in Medicare and Medicaid programs and civil money penalties, which are increased annually based on updates to the consumer price index. In addition, the law creates private civil remedies that enable an individual who suffers personal harm as a direct result of a violation of the law to sue the offending hospital for damages and equitable relief. A medical facility that suffers a financial loss as a direct result of another participating hospital’s violation of the law also has a similar right. Although we believe that our practices are in compliance with the law, we can give no assurance that governmental officials responsible for enforcing the law will not assert we are in violation of this law.

Conversion Legislation. Many states, including some where we have hospitals and others where we may in the future acquire hospitals, have adopted legislation regarding the sale or other disposition of hospitals operated by not-for-profit entities. In other states that do not have specific legislation, the attorneys general have demonstrated an interest in these transactions under their general obligations to protect charitable assets from waste. These legislative and administrative efforts primarily focus on the appropriate valuation of the assets divested and the use of the proceeds of the sale by the not-for-profit seller. While these reviews and, in some instances, approval processes can add additional time to the closing of a hospital acquisition, we have not had any significant difficulties or delays in completing the acquisition process. There can be no assurance, however, that future actions on the state level will not seriously delay or even prevent our ability to acquire hospitals. If these activities are widespread, they could limit our ability to acquire hospitals.

Certificates of Need. The construction of new facilities, the acquisition of existing facilities, significant capital expenditures and the addition of new services at our facilities may be subject to state laws that require prior approval by state regulatory agencies. These certificate of need, or CON, laws generally require that a state agency determine the public need and give approval prior to the construction or acquisition of facilities, significant capital expenditure or the addition of new services. As of December 31, 2019, we operated 81 hospitals in 15 states that have adopted CON laws. If we fail to obtain necessary state approval, we will not be able to expand our facilities, complete acquisitions or significant capital expenditures or add new services in these states. Violation of these state laws may result in the imposition of civil sanctions or the revocation of a provider’s licenses.

HIPAA Administrative Simplification and Privacy and Security Requirements. The Health Insurance Portability and Accountability Act of 1996, or HIPAA, requires the use of uniform electronic data transmission standards for healthcare claims and payment transactions submitted or received electronically. These provisions are intended to encourage electronic commerce in the healthcare industry. HHS has established electronic data transmission standards and code sets that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically. In addition, HIPAA requires that each provider use a National Provider Identifier. The Affordable Care Act requires the HHS to adopt standards for additional electronic transactions and to establish operating rules to promote uniformity in the implementation of each standardized electronic transaction.

19

As required by HIPAA, HHS has issued privacy and security regulations that extensively regulate the use and disclosure of individually identifiable health-related information and require covered entities, including health plans and most healthcare providers, to implement administrative, physical and technical practices to protect the security of individually identifiable health information that is electronically maintained or transmitted. Business associates (entities that handle identifiable health-related information on behalf of covered entities) are subject to direct liability for violation of applicable provisions of the regulations. In addition, a covered entity may be subject to penalties as a result of a business associate violating HIPAA, if the business associate is found to be an agent of the covered entity. We have developed and utilize a HIPAA compliance plan as part of our effort to comply with HIPAA privacy and security requirements. The privacy regulations and security regulations have and will continue to impose significant costs on us in order to comply with these standards.

Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay, but not to exceed 60 days of discovery of the breach by the covered entity or its agents. Notification must also be made to HHS and, in certain situations involving large breaches, to the media. HHS is required to publish on its website a list of all covered entities that report a breach involving more than 500 individuals. All non-permitted uses or disclosures of unsecured protected health information are presumed to be breaches unless the covered entity or business associate establishes that there is a low probability the information has been compromised. Various state laws and regulations may also require us to notify affected individuals in the event of a data breach involving individually identifiable information.

Violations of the HIPAA privacy and security regulations may result in criminal penalties and in substantial civil penalties per violation. The civil penalties are adjusted annually based on updates to the consumer price index. HHS is required to perform compliance audits. In addition to enforcement by HHS, state attorneys general are authorized to bring civil actions seeking either injunction or damages in response to violations of HIPAA privacy and security regulations that threaten the privacy of state residents. HHS may resolve HIPAA violations through informal means, such as allowing a covered entity to implement a corrective action plan, but HHS has the discretion to move directly to impose monetary penalties and is required to impose penalties for violations resulting from willful neglect. Our facilities also are subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties and subject us to additional privacy and security restrictions. For example, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to data breaches. In addition, various states, including California, Nevada and Massachusetts, recently have enacted, and other states are considering, new laws and regulations concerning the privacy and security of consumer and other personal information. To the extent we are subject to such requirements, these laws and regulations often have far-reaching effects, may require us to modify our data processing practices and policies and may require us to incur substantial costs and expenses to comply. These laws and regulations often provide for civil penalties for violations, as well as a private right of action for data breaches, which may increase the likelihood or impact of data breach litigation.

Payment

Medicare. Under the Medicare program, we are paid for inpatient and outpatient services performed by our hospitals.

Payments for inpatient acute services are generally made pursuant to a prospective payment system, commonly known as “PPS.” Under PPS, our hospitals are paid a predetermined amount for each hospital discharge based on the patient’s diagnosis. Specifically, each discharge is assigned to a diagnosis-related group, commonly known as a “DRG,” based upon the patient’s condition and treatment during the relevant inpatient stay. Each DRG has a payment weight assigned to it that is based on the average resources used to treat Medicare patients in that DRG. DRG payments are based on national averages and not on charges or costs specific to a hospital. To better account for severity of illness and resource consumption, CMS uses the Medicare Severity DRG system. Medicare sets discharge base rates (standardization payment amounts), which are adjusted

20

according to the DRG relative weights and geographic factors. In addition, hospitals may qualify for an “outlier” payment when a patient’s treatment costs are extraordinarily high and exceed a specified regulatory threshold.

The DRG payment rates for inpatient acute services are adjusted by an update factor on October 1 of each year, the beginning of the federal fiscal year. The index used to adjust the DRG payment rates, known as the “market basket index,” gives consideration to the inflation experienced by hospitals in purchasing goods and services. DRG payment rates were increased by the “market basket index” update of 2.9% and 3.0% for each of federal fiscal years 2019 and 2020, respectively, subject to certain reductions. For federal fiscal year 2019, the market basket update was adjusted by the following percentage points: a positive 0.5 adjustment in accordance with MACRA, a 0.8 reduction for the multifactor productivity adjustment, and a 0.75 reduction in accordance with the Affordable Care Act. For federal fiscal year 2020, the market basket was adjusted by the following percentage points: a positive 0.5 adjustment in accordance with MACRA and a 0.4 point reduction for the multifactor productivity adjustment. A 25% reduction to the market basket index occurs if patient quality data is not submitted, and a reduction of 75% of the market basket index update occurs for hospitals that fail to demonstrate meaningful use of certified electronic health records, or EHR, technology without receiving a hardship exception. Future legislation may decrease the rate of increase for DRG payments or even decrease such payment rates, but we are unable to predict the amount of any reduction or the effect that any reduction will have on us.

The DRG payment rates are also adjusted to promote value-based purchasing, linking payments to quality and efficiency. First, hospitals that meet or exceed certain quality performance standards receive greater reimbursement under CMS’s value-based purchasing program, while hospitals that do not satisfy certain quality performance standards receive reduced Medicare inpatient hospital payments. The amount collected from the reductions is pooled and used to fund the payments that reward hospitals based on a set of quality measures that have been linked to improved clinical processes of care and patient satisfaction. CMS scores each hospital on its achievement relative to other hospitals and improvement relative to that hospital’s own past performance. Second, hospitals experiencing “excess readmissions” for conditions designated by CMS within 30 days from the patient’s date of discharge receive inpatient payments reduced by an amount determined by comparing that hospital’s readmission performance to a risk-adjusted national average. Third, the 25% of hospitals with the worst national risk-adjusted hospital acquired condition, or HAC, rates in the previous year have their total inpatient operating Medicare payments reduced by 1%. HHS has indicated that it will increase its efforts to promote, develop and use alternative payment models such as Accountable Care Organizations, or ACOs, and bundled payment arrangements.

In addition, hospitals may qualify for Medicare DSH payment adjustments when their percentage of low income patients exceeds specified regulatory thresholds. A majority of our hospitals qualify to receive these adjustments. CMS also distributes an additional payment to each DSH hospital for its proportion of uncompensated care costs relative to the uncompensated care amount of other DSH hospitals. The uncompensated care amount is hospital-specific and generally includes charity care and non-Medicare and non-reimbursable Medicare bad debt. The Medicare DSH adjustments and uncompensated care payments as a percentage of net operating revenues were 1.19% and 1.27% for the years ended December 31, 2019 and 2018, respectively. Hospitals may also qualify for Medicaid DSH payments when they qualify under the state established guidelines. These Medicaid DSH payments as a percentage of net operating revenues were 0.54% and 0.52% for the years ended December 31, 2019 and 2018, respectively. The Affordable Care Act provides for reductions to the Medicaid DSH payments, but Congress has delayed the implementation of those reductions until 2020.

We also receive Medicare reimbursement for hospital outpatient services through a PPS. Services paid under the hospital outpatient PPS are grouped into ambulatory payment classifications. APC payment rates are generally determined by applying a conversion factor, which CMS updates annually using a market basket. For calendar year 2019, CMS estimated an increase in hospital outpatient PPS payments of 0.6%. This reflected a market basket increase of 2.9%, with a 0.75 percentage point downward adjustment in accordance with the

21

Affordable Care Act, and a 0.8 percentage point downward productivity adjustment. For calendar year 2020, CMS estimated an increase in hospital outpatient PPS payments of 1.3%, reflecting a market basket increase of 3.0%, with a negative 0.4 percentage point adjustment for multi-factor productivity. An additional 2.0 percentage point reduction to the market basket update applies to hospitals that do not submit required patient quality data. We are complying with this data submission requirement.

In calendar year 2019, CMS began a two-year phase-in of an expanded site-neutral payment policy for off-campus provider-based departments paid under the outpatient PPS. Under the policy, all off-campus provider-based departments are paid the Medicare Physician Fee Schedule (“MPFS”)-equivalent rate for clinic visits, which is generally lower than the outpatient PPS rate. The MPFS-equivalent rate for calendar year 2020 is 40% of the proposed outpatient PPS rate. Before the expanded policy, the MPFS-equivalent rate did not apply to “excepted” provider-based departments. However, in September 2019, a federal judge invalidated the expansion of the site-neutral payment policy for calendar year 2019. CMS is appealing this decision, but is reprocessing the 2019 claims paid at the lower rates. CMS has announced it will implement the policy in calendar year 2020. Hospitals have also challenged the site-neutral payment policy for calendar year 2020, but the case has not yet been decided.

The Medicare reimbursement discussed above was reduced beginning in 2013 due to the Budget Control Act of 2011 that required across-the-board spending cuts to the federal budget, also known as sequestration. These sequestration cuts included reductions in payments for Medicare and other federally funded healthcare programs, including TRICARE. These reductions have been extended through 2029.

Payment under the Medicare program for physician services is based upon the MPFS, under which CMS has assigned a national relative value unit, or RVU, to most medical procedures and services that reflects the resources required to provide the services relative to all other services. Each RVU is calculated based on a combination of the time and intensity of work required, overhead expense attributable to the service, and malpractice insurance expense. These elements are each modified by a geographic adjustment factor to account for local practice costs and are then aggregated. To determine the payment rate for a particular service, the sum of the geographically adjusted RVUs is multiplied by a conversion factor. For calendar year 2020, CMS updated the conversion factor by a budget neutrality adjustment of 0.14%. In federal fiscal year 2017, CMS implemented the Quality Payment Program, or QPP, a payment methodology intended to reward high-quality patient care. Physicians and certain other healthcare clinicians must participate in one of two QPP tracks. Under both tracks, performance data collected each performance year will affect Medicare payments two years later. CMS expects to transition increasing financial risk to providers as QPP evolves. Under the Advanced Alternative Payment Model, or Advanced APM, track, incentive payments are available based on participation in specific innovative payment models approved by CMS. Providers may earn a Medicare incentive payment and will be exempt from the reporting requirements and payment adjustments imposed under the Merit-Based Incentive Payment System, or MIPS, if the provider has sufficient participation in an Advanced APM. Alternatively, providers may participate in the MIPS track, under which physicians will receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of EHR. MIPS consolidates components of certain previously established physician incentive programs.

Medicaid. Medicaid is funded jointly by state and federal government. Most state Medicaid payments are made under a PPS or under programs that negotiate payment levels with individual hospitals. In addition to the base payment rates for specific claims for services rendered to Medicaid enrollees, states utilize supplemental reimbursement programs to make separate payments that are not specifically tied to an individual’s care. Supplemental payments may be in the form of Medicaid DSH payments, which are intended to offset a portion of the costs to providers associated with providing care to Medicaid and indigent patients, or non-DSH payments, such as upper payment limit payments, which are intended to address the difference between Medicaid fee-for-service payments and Medicare reimbursement rates. These supplemental reimbursement programs are designed with input from CMS and may be funded with a combination of state and federal resources, including,

22

in certain instances, fees or taxes levied on the healthcare providers. The programs are generally authorized for a specified period of time and require CMS’s approval to be extended. CMS is considering changes to both types of programs, and we are unable to predict whether or on what terms CMS will extend the supplemental programs in the states in which we operate.

The federal government and many states are considering various strategies to reduce Medicaid expenditures. Many states currently operate, or have applied to CMS to operate, Medicaid programs under waivers to standard Medicaid program requirements. CMS has indicated that it intends to increase state flexibility in the administration of Medicaid programs, including allowing states to condition enrollment on work or other community engagement or to use a block grant funding structure. We can provide no assurance that changes to Medicaid programs or reductions to Medicaid funding will not have a material adverse effect on our consolidated results of operations.

TRICARE. TRICARE is the Department of Defense’s healthcare program for members of the armed forces. For inpatient services, TRICARE generally reimburses hospitals based on a DRG system modeled on the Medicare inpatient PPS. For outpatient services, TRICARE reimburses hospitals based on a PPS that is similar to that utilized for services furnished to Medicare beneficiaries.

Annual Cost Reports. Hospitals participating in the Medicare and some Medicaid programs, whether paid on a reasonable cost basis or under a PPS, are required to meet specified financial reporting requirements. Federal and, where applicable, state regulations require submission of annual cost reports identifying medical costs and expenses associated with the services provided by each hospital to Medicare beneficiaries and Medicaid recipients.

Annual cost reports required under the Medicare and some Medicaid programs are subject to routine governmental audits. These audits may result in adjustments to the amounts ultimately determined to be due to us under these reimbursement programs. Finalization of these audits often takes several years. Providers can appeal any final determination made in connection with an audit. DRG outlier payments have been and continue to be the subject of CMS audit and adjustment. The OIG is also actively engaged in audits and investigations into alleged abuses of the DRG outlier payment system.

Commercial Insurance and Managed Care Companies. Our hospitals provide services to individuals covered by private healthcare insurance or by health plans administered by managed care companies. These payors pay our hospitals or in some cases reimburse their policyholders based upon the hospital’s established charges and the coverage provided in the insurance policy. Payors try to limit their costs by negotiating with hospitals and other healthcare providers for discounts to established charges. Commercial insurers and managed care companies also seek to reduce payments to hospitals by establishing payment rules that in effect re-characterize the services ordered by physicians. For example, some payors vigorously review each patient’s length of stay in the hospital and recharacterize as outpatient all inpatient stays of less than a particular duration (e.g., 24 hours). Similarly, some payors have prior authorization requirements designed to shift certain procedures to outpatient settings, where payment rates are typically lower. Reductions in payments for services provided by our hospitals to individuals covered by these payors could adversely affect us.

Under the Managed Medicare program, also known as Medicare Part C, or Medicare Advantage, the federal government contracts with private health plans to provide members with Medicare benefits. The plans may choose to offer supplemental benefits and impose higher premiums and cost-sharing obligations. Similarly, managed Medicaid programs enable states to contract with private entities to handle program responsibilities like care management and claims adjudication. Enrollment in Managed Medicare and managed Medicaid programs has increased in recent years as the federal and state governments seek to control healthcare costs.

Medicare Administrative Contractors. CMS competitively bids the Medicare fiscal intermediary and Medicare carrier functions to Medicare Administrative Contractors, or MACs, in 12 jurisdictions. Each MAC is geographically assigned and serves both Part A and Part B providers within a given jurisdiction. Chain providers

23

had the option of having all hospitals use one home office MAC, and we chose to do so. However, CMS has not converted all of our hospitals to one MAC and currently does not have an established date to accomplish the conversion. CMS periodically re-solicits bids, and the MAC servicing a geographic area can change as a result of the bid competition. MAC transition periods can impact claims processing functions and the resulting cash flow.

Medicare Integrity. CMS contracts with third parties to promote the integrity of the Medicare program through review of quality concerns and detection of improper payments. Quality Improvement Organizations, or QIOs, for example, are groups of physicians and other healthcare quality experts that work on behalf of CMS to ensure that Medicare pays only for goods and services that are reasonable and necessary and that are provided in the most appropriate setting. Under the Recovery Audit Contractor, or RAC, program, CMS contracts with RACs nationwide to conduct post-payment reviews to detect and correct improper payments in the Medicare program, as required by statute. RACs review claims submitted to Medicare for billing compliance, including correct coding and medical necessity. Compensation for RACs is on a contingency basis and based upon the amount of overpayments and underpayments identified, if any. CMS limits the number of claims that RACs may audit by limiting the number of records that RACs may request from hospitals based on each provider’s claim denial rate for the previous year.

The RAC program’s scope also includes Medicaid claims. States may coordinate with Medicaid RACs regarding recoupment of overpayments and refer suspected fraud and abuse to appropriate law enforcement agencies. Under the Medicaid Integrity Program, CMS employs private contractors, referred to as Medicaid Integrity Contractors, or MICs, to perform reviews and post-payment audits of Medicaid claims and identify overpayments. MICs are assigned to five geographic jurisdictions. Besides MICs, several other contractors and state Medicaid agencies have increased their review activities. CMS is transitioning some of its other integrity programs to a consolidated model by engaging Unified Program Integrity Contractors, or UPICs, to perform audits, investigations and other integrity activities.

We maintain policies and procedures to respond to the RAC requests and payment denials. Payment recoveries resulting from RAC reviews and denials are appealable, and we pursue reversal of adverse determinations at appropriate appeal levels. Currently, there are significant delays in the assignment of new Medicare appeals to Administrative Law Judges. According to the Office of Medicare Hearings and Appeals, the average processing time in fiscal year 2019 was nearly four years. HHS has finalized rules intended to streamline the process and improve efficiency but has also stressed the need for additional funding. Thus, we may experience significant delays in appealing any RAC payment denials. To ease the backlog of appeals, CMS has announced various settlement initiatives. Depending upon the growth of RAC programs and our success in appealing claims in future periods, our cash flows and results of operations could be negatively impacted.

Accountable Care Organizations. With the aim of reducing healthcare costs by improving quality and operational efficiency, ACOs are gaining traction in both the public and private sectors. An ACO is a network of providers and suppliers (including hospitals, physicians and other designated professionals) which work together to invest in infrastructure and redesign delivery processes to achieve high quality and efficient delivery of services. ACOs are intended to produce savings as a result of improved quality and operational efficiency. Pursuant to the Affordable Care Act, HHS established a Medicare Shared Savings Program that seeks to promote accountability and coordination of care through the creation of ACOs. Medicare-approved ACOs that achieve quality performance standards established by HHS are eligible to share in a portion of the amounts saved by the Medicare program. HHS has significant discretion to determine key elements of ACO programs. Certain waivers are available from fraud and abuse laws for ACOs.

Bundled Payment Initiatives. The CMS Innovation Center is responsible for establishing demonstration projects and other initiatives in order to identify, develop, test and encourage the adoption of new methods of delivering and paying for healthcare that create savings under the Medicare and Medicaid programs, while maintaining or improving quality of care. For example, providers participating in bundled payment initiatives accept accountability for costs and quality of care by agreeing to receive one payment for services provided to Medicare patients for certain medical conditions or episodes of care. By rewarding providers for increasing

24

quality and reducing costs and penalizing providers if costs exceed a certain amount, bundled payment models are intended to lead to higher quality, more coordinated care at a lower cost to the Medicare program. The CMS Innovation Center has implemented bundled payment models, including the Bundled Payment for Care Improvement Advanced, or BPCI Advanced, initiative, which is expected to run through December 2023. We are participating in BPCI Advanced initiatives in seven of our markets. Participation in bundled payment programs is generally voluntary, but CMS requires hospitals located in certain geographic areas to participate in a mandatory bundled payment program for specified orthopedic procedures, which is scheduled to run through December 2020. CMS has indicated that it is developing more bundled payment models, some of which may be mandatory. We expect value-based purchasing programs, including models that condition reimbursement on patient outcome measures, to become more common with both governmental and non-governmental payors.

Supply Contracts

We purchase items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust, a GPO in which we are a noncontrolling partner. As of December 31, 2019, we had a 14.5% ownership interest in HealthTrust. By participating in this organization, we are able to procure items at competitively priced rates for our hospitals. There can be no assurance that our arrangement with HealthTrust will continue to provide the discounts that we have historically received.

Competition

The hospital industry is highly competitive. The competition among hospitals and other healthcare providers for patients has intensified as patients have become more conscious of rising costs and quality of care in the healthcare decision-making process. Certain of our hospitals are located in non-urban service areas in which we are the sole provider of general acute care health services. Those hospitals in non-urban service areas face no direct competition because there are no other hospitals in their primary service areas. However, these hospitals face competition from hospitals outside of their primary service area, including hospitals in urban areas that provide more complex services. Patients in those service areas may travel to these other hospitals for a variety of reasons, including the need for services we do not offer, payor networks that exclude our providers, or physician referrals. Patients who are required to seek services from these other hospitals may subsequently shift their preferences to those hospitals for services we do provide. Our other hospitals, in selected urban service areas, may face competition from hospitals that are more established than our hospitals. Some of our competitors offer services, including extensive medical research and medical education programs, that are not offered by our facilities. In addition, in certain markets where we operate, there are large teaching hospitals that provide highly specialized facilities, equipment and services that may not be available at our hospitals. We also face competition from other specialized care providers, including outpatient surgery, orthopedic, oncology and diagnostic centers. Some competitors are implementing physician alignment strategies, such as employing physicians, acquiring physician practice groups, and participating in ACOs, or other clinical integration models. Cost-reduction strategies by large employer groups and their affiliates may increase this competition. We believe that we will continue to face increased competition in outpatient service models that become more integrated through acquisitions or partnerships between physicians, specialized care providers, and managed care payors.

In most markets in which we are not the sole provider of general acute care health services, our primary competitor is a not-for-profit hospital. These hospitals are owned by tax-supported governmental agencies or not-for-profit entities supported by endowments and charitable contributions. These hospitals do not pay income or property taxes, and can make capital expenditures without paying sales tax. These financial advantages may better position such hospitals to maintain more modern and technologically upgraded facilities and equipment and offer services more specialized than those available at our hospitals. Recent consolidations of not-for-profit hospitals may intensify competitive pressures.

The number and quality of the physicians on a hospital’s staff is an important factor in a hospital’s competitive position. Physicians decide whether a patient is admitted to the hospital and the procedures to be performed. Admitting physicians may be on the medical staffs of other hospitals in addition to those of our hospitals. We

25

attempt to attract our physicians’ patients to our hospitals by offering quality services and facilities, convenient locations and state-of-the-art equipment.

Trends towards transparency may have a potential impact on our competitive position in ways that we are unable to predict. CMS publicizes on its Hospital Compare website data that hospitals submit in connection with Medicare reimbursement claims, including performance data related to quality measures and patient satisfaction surveys. Federal law provides for the future expansion of the number of quality measures that must be reported. Currently, hospitals are required to publish online a list of their standard charges for items and services. Beginning in 2021, hospitals will be required to publish additional types of standard charges for all items and services, including discounted cash prices and payor-specific and de-identified negotiated charges, in a publicly accessible online file. Hospitals will also be required to publish a consumer-friendly list of charges for certain “shoppable” services (i.e., services that can be scheduled by a patient in advance) and any associated ancillary services.

Compliance Program

We take an operations team approach to compliance and utilize corporate experts for program design efforts and facility leaders for employee-level implementation. We believe compliance is another area that demonstrates our utilization of standardization and centralization techniques and initiatives which yield efficiencies and consistency throughout our facilities. We recognize that our compliance with applicable laws and regulations depends on individual employee actions as well as company operations. Our approach focuses on integrating compliance responsibilities with operational functions. This approach is intended to reinforce our company-wide commitment to operate strictly in accordance with the laws and regulations that govern our business.

Our company-wide compliance program has been in place since 1997. Currently, the program’s elements include leadership, management and oversight at the highest levels, a Code of Conduct, risk area specific policies and procedures, employee education and training, an internal system for reporting concerns, auditing and monitoring programs and a means for enforcing the program’s policies.

The compliance program continues to be expanded and developed to meet the industry’s expectations and our needs. Specific written policies, procedures, training and educational materials and programs, as well as auditing and monitoring activities, have been prepared and implemented to address the functional and operational aspects of our business. Included within these functional areas are materials and activities for business sub-units, including laboratory, radiology, pharmacy, emergency, surgery, observation, home care, skilled nursing and clinics. Specific areas identified through regulatory interpretation and enforcement activities have also been addressed in our program. Claims preparation and submission, including coding, billing and cost reports, comprise the bulk of these areas. Financial arrangements with physicians and other referral sources, including compliance with the federal Anti-Kickback Statute and the Stark Law, emergency department treatment and transfer requirements and other patient disposition issues, are also the focus of policy and training, standardized documentation requirements and review and audit. Another focus of the program is the interpretation and implementation of the HIPAA standards for privacy and security.

We have a Code of Conduct which applies to all directors, officers, employees and consultants, and a confidential disclosure program to enhance the statement of ethical responsibility expected of our employees and business associates who work in the accounting, financial reporting and asset management areas of our Company. Our Code of Conduct is posted on our website at www.chs.net/company-overview/code-of-conduct.

Corporate Integrity Agreement

On August 4, 2014, we announced that we had entered into a civil settlement with the U.S. Department of Justice, other federal agencies and identified relators that concluded previously announced investigations and litigation related to short stay admissions through emergency departments at certain of our affiliated hospitals. See the “Legal Proceedings” discussion in Part II, Item 1 of our Quarterly Report on Form 10-Q for the quarterly

26

period ended September 30, 2014 for further discussion of the background of this matter and details of the settlement. In addition to the amounts paid in the settlement, we executed a five-year Corporate Integrity Agreement, or CIA, with the OIG that has been incorporated into our existing and comprehensive compliance program.

On September 25, 2018, we announced a global resolution and settlement agreements ending the U.S. Department of Justice investigation into certain conduct of HMA and its affiliated entities and settling certain qui tam lawsuits that were initiated and pending, and known to us, before our acquisition by merger of HMA in 2014. Under this settlement, we made payments totaling $266 million, including interest, in the fourth quarter of 2018. See the “Legal Proceedings” discussion in Part II, Item 1 of our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018 and the press release filed therewith on September 25, 2018 for further discussion of this matter and the details of the settlement. Additionally, under the terms of the global settlement, our existing CIA has been amended and extended. The extension began immediately and effectively adds two years to the existing CIA, with the amended CIA now running through 2021.

The compliance measures and reporting and auditing requirements contained in the CIA include:

• continuing the duties and activities of our Corporate Compliance Officer, Corporate Compliance Work Group, and Facility Compliance Officers and committees;

• maintaining our written Code of Conduct, which sets forth our commitment to full compliance with all statutes, regulations, and guidelines applicable to federal healthcare programs;

• maintaining our written policies and procedures addressing the operation of our Compliance Program, including adherence to medical necessity and admissions standards for inpatient hospital stays;

• continuing our general compliance training;

• providing specific training for appropriate personnel on billing, case management and clinical documentation;

• engaging an independent third party to perform an annual review of our compliance with the CIA;

• continuing our Confidential Disclosure Program and hotline to enable employees or others to disclose issues or questions regarding possible inappropriate policies or behavior;

• maintaining our screening program to ensure that we do not hire or engage employees or contractors who are ineligible persons for federal healthcare programs;

• notifying the OIG of any government investigations;

• reporting any material deficiency which resulted in an overpayment to us by a federal healthcare program; and

• submitting annual reports to the OIG which describe in detail the operations of our corporate Compliance Program for the past year.

Material, uncorrected violations of the CIA could lead to our suspension or disbarment from participation in Medicare, Medicaid and other federal and state healthcare programs and repayment obligations. In addition, we are subject to possible civil penalties for failure to substantially comply with the terms of the CIA, including stipulated penalties ranging from $1,000 to $2,500 per day. We are also subject to a stipulated penalty of $50,000 for each false certification made by us or on our behalf in connection with reports required under the CIA. The CIA increases the amount of information we must provide to the federal government regarding our healthcare practices and our compliance with federal regulations. The reports we provide in connection with the CIA could result in greater scrutiny by regulatory authorities. We believe our existing Compliance Program addresses compliance with the operational terms of the CIA.

27

Employees and Medical Staff

At December 31, 2019, we had approximately 80,000 employees, including approximately 17,000 part-time employees. References herein to “employees” refer to employees of our affiliates. We are subject to various state and federal laws that regulate wages, hours, benefits and other terms and conditions relating to employment. At December 31, 2019, certain employees at eight of our hospitals are represented by various labor unions. It is likely that union organizing efforts will take place at additional hospitals in the future. We consider our employee relations to be good and have not experienced work stoppages that have materially, adversely affected our business or results of operations. Our hospitals, like most hospitals, have experienced rising labor costs. In some markets, nurse and medical support personnel availability has become a significant operating issue to healthcare providers. To address this challenge, we have implemented several initiatives to improve retention, recruiting, compensation programs and productivity.

Our hospitals are staffed by licensed physicians, including both employed physicians and physicians who are not employees of our hospitals. Some physicians provide services in our hospitals under contracts, which generally describe a term of service, provide and establish the duties and obligations of such physicians, require the maintenance of certain performance criteria and fix compensation for such services. Any licensed physician may apply to be accepted to the medical staff of any of our hospitals, but the hospital’s medical staff and the appropriate governing board of the hospital, in accordance with established credentialing criteria, must approve acceptance to the staff. Members of the medical staffs of our hospitals often also serve on the medical staffs of other hospitals and may terminate their affiliation with one of our hospitals at any time.

We may be required to continue to enhance wages and benefits to recruit and retain nurses and other medical support personnel or to hire more expensive temporary or contract personnel. As a result, our labor costs could increase. We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we operate. Certain proposed changes in federal labor laws and the National Labor Relations Board’s pending modification of its election procedures could increase the likelihood of employee unionization attempts. To the extent a significant portion of our employee base unionizes, our costs could increase significantly. In addition, the states in which we operate could adopt mandatory nurse-staffing ratios or could reduce mandatory nurse-staffing ratios already in place. State-mandated nurse-staffing ratios could significantly affect labor costs, and have an adverse impact on revenues if we are required to limit patient admissions in order to meet the required ratios.

Professional Liability Claims

As part of our business of owning and operating hospitals, we are subject to legal actions alleging liability on our part. To cover claims arising out of the operations of hospitals, we maintain professional malpractice liability insurance and general liability insurance on a claims made basis in excess of those amounts for which we are self-insured, in amounts we believe to be sufficient for our operations. We also maintain umbrella liability coverage for claims which, due to their nature or amount, are not covered by our other insurance policies. However, our insurance coverage does not cover all claims against us or may not continue to be available at a reasonable cost for us to maintain adequate levels of insurance. For a further discussion of our insurance coverage, see our discussion of professional liability claims in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of this Form 10-K.

Environmental Matters

We are subject to various federal, state and local laws and regulations governing the use, discharge and disposal of hazardous materials, including medical and pharmaceutical waste products. We do not currently expect compliance with these laws and regulations to have a material adverse effect on us. It is possible, however, that environmental issues may arise in the future which we cannot now predict.

We are insured for damages of personal property or environmental injury arising out of environmental impairment for both above ground and underground storage tank issues under one insurance policy for all of our

28

hospitals. Our policy coverage is $5 million per occurrence with a $100,000 deductible and a $20 million annual aggregate. This policy also provides pollution legal liability coverage.

Item 1A. Risk Factors

Our business faces a variety of risks. If any of the events or circumstances described in any of the following risk factors occurs, our business, results of operations or financial condition could be materially and adversely affected, and our actual results may differ materially from those predicted in any forward-looking statements we make in any public disclosures. Additional factors that could affect our business, results of operations and financial condition are discussed elsewhere in this Report (including in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of this Form 10-K). Additional risks or uncertainties not presently known to us, or that we currently deem immaterial, also may adversely affect our business, results of operations and financial condition.

Our level of indebtedness could adversely affect our ability to refinance existing indebtedness or raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry and prevent us from meeting our obligations under the agreements related to our indebtedness.

We have a significant amount of indebtedness, which is more fully described in the Liquidity and Capital Resources section of “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of this Form 10-K and Note 6 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K. As of December 31, 2019, we had approximately $11.5 billion aggregate principal amount of senior secured indebtedness outstanding and approximately $1.9 billion of senior unsecured indebtedness outstanding, and an additional approximately $442 million of borrowing capacity under the ABL Facility (after taking into account borrowing base limitations and approximately $145 million of outstanding letters of credit).

Our substantial leverage could have important consequences, including the following:

• it may limit our ability to refinance existing indebtedness or obtain additional debt or equity financing for working capital, capital expenditures, debt service requirements, acquisitions and general corporate or other purposes;

• a substantial portion of our cash flows from operations will be dedicated to the payment of principal and interest on our indebtedness and will not be available for other purposes, including to fund our operations, capital expenditures, financial obligations and future business opportunities;

• some of our borrowings, including borrowings under the ABL Facility, accrue interest at variable rates, exposing us to the risk of increased interest rates;

• it may limit our ability to make strategic acquisitions or cause us to make nonstrategic divestitures;

• it may limit our ability to adjust to changing market conditions and place us at a competitive disadvantage compared to our competitors that are less highly leveraged; and

• it may increase our vulnerability in connection with adverse changes in general economic, industry or competitive conditions or government regulations or other adverse developments.

Despite current indebtedness levels, we may still be able to incur substantially more debt. This could further exacerbate the risks described in this section.

We and our subsidiaries have the ability to incur substantial additional indebtedness in the future, subject to restrictions contained in the ABL Facility and the indentures governing our outstanding notes. The ABL Facility provides for commitments and borrowings of up to approximately $1.0 billion in the aggregate, of which

29

$273 million was drawn on December 31, 2019. The aggregate amount we may draw under the ABL Facility may not exceed the “borrowing base” (as calculated thereunder) less outstanding letters of credit thereunder, which fluctuates from time to time. As of December 31, 2019, the borrowing base under the ABL Facility was $860 million and the outstanding letters of credit issued under the ABL Facility were $145 million. Aside from the ABL Facility, our ability to incur other additional secured debt (other than secured debt used to refinance existing secured debt) is highly limited by certain of the indentures governing our outstanding notes. If additional indebtedness is added to our current debt levels, the related risks that we currently face related to indebtedness as noted in this section could increase.

We may not be able to generate sufficient cash to service all of our indebtedness, and we may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.

Our ability to make scheduled payments on or to refinance our indebtedness depends on our financial and operating performance, which is subject to prevailing economic and competitive conditions and to financial, business, regulatory and other factors beyond our control. We cannot assure you that we will maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.

In addition, the borrower under the ABL Facility and issuer of our outstanding notes is a holding company with no direct operations. Its principal assets are the equity interests we hold in our operating subsidiaries. As a result, we are dependent upon dividends and other payments from our subsidiaries to generate the funds necessary to meet our outstanding debt service and other obligations. Our subsidiaries may not generate sufficient cash from operations to enable us to make principal and interest payments on our indebtedness. In addition, any payments of dividends, distributions, loans or advances to us by our subsidiaries could be subject to legal and contractual restrictions.

Our subsidiaries are permitted under the terms of our indebtedness to incur additional indebtedness that may restrict payments from those subsidiaries to us. The agreements governing the current and future indebtedness of our subsidiaries may not permit those subsidiaries to provide us with sufficient cash to fund payments on our indebtedness when due. Our non-guarantor subsidiaries are separate and distinct legal entities, and they have no obligation, contingent or otherwise, to pay amounts due under the terms of our indebtedness or to make any funds available to pay those amounts, whether by dividend, distribution, loan or other payment. If our cash flows and capital resources are insufficient to fund our debt service obligations, we could face substantial liquidity problems and may be forced to reduce or delay capital expenditures, sell assets or operations, seek additional capital or restructure or refinance our indebtedness. Our ability to refinance our indebtedness on favorable terms, or at all, is directly affected by the then current general economic and financial conditions. In addition, our ability to incur additional secured indebtedness (which would generally enable us to achieve better pricing than the incurrence of unsecured indebtedness) depends in part on the value of our assets, which depends, in turn, on the strength of our cash flows and results of operations, and on economic and market conditions and other factors. We may find it necessary or prudent to refinance certain of our outstanding indebtedness, the terms of which may not be favorable to us.

We cannot assure you that we would be able to take any of these actions, that these actions would be successful and permit us to meet our scheduled debt service obligations or that these actions would be permitted under the terms of our existing or future debt agreements, including the ABL Facility and the indentures governing our outstanding notes. For example, the ABL Facility and the indentures governing our outstanding notes restrict our ability to dispose of certain assets and use the proceeds from any dispositions. We may not be able to consummate those dispositions and any proceeds we receive may not be adequate to meet any debt service obligations then due.

30

Restrictive covenants in the agreements governing our indebtedness may adversely affect us.

The ABL Facility and the indentures governing our outstanding notes contain various covenants that limit our ability to take certain actions, including our ability to:

• incur, assume or guarantee additional indebtedness;

• issue redeemable stock and preferred stock;

• repurchase capital stock;

• make restricted payments, including paying dividends and making certain loans, acquisitions and investments;

• redeem subordinated debt;

• create liens;

• sell or otherwise dispose of assets, including capital stock of subsidiaries;

• impair security interests;

• enter into agreements that restrict dividends and certain other payments from subsidiaries;

• merge, consolidate, sell or otherwise dispose of substantially all our assets;

• enter into transactions with affiliates; and

• guarantee certain obligations.

In addition, the ABL Facility contains restrictive covenants and may, in certain circumstances, require us to maintain a specified financial ratio and satisfy other financial condition tests. Our ability to meet these restrictive covenants and financial ratio and tests (if applicable) may be affected by events beyond our control, and we cannot assure you that we will meet those tests.

Moreover, our ability to incur additional secured debt (other than (i) secured debt to refinance existing secured debt and (ii) indebtedness incurred in the ABL Facility) is highly limited.

A breach of any of these covenants could result in a default under the ABL Facility and the indentures governing our outstanding notes. Upon the occurrence of an event of default under the ABL Facility or any of the indentures governing our outstanding notes, all amounts outstanding under the applicable indebtedness may become immediately due and payable and all commitments under the ABL Facility to extend further credit may be terminated. If we were unable to repay those amounts, the holders of such indebtedness could, subject to applicable intercreditor agreements, proceed against the collateral granted to them to secure that indebtedness.

Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.

Our borrowings under the ABL Facility are at variable rates of interest and expose us to interest rate risk. If interest rates increase, our debt service obligations on the variable rate indebtedness would increase even though the amount borrowed remained the same, and our net income would decrease. Our interest expense, net, for the year ended December 31, 2019 was $1.0 billion. For the year ended December 31, 2019, a fluctuation in interest rates of 1% on our variable rate debt under the ABL Facility that is not hedged by interest rate swaps would have resulted in a fluctuation in our interest expense of approximately $3 million.

31

In addition, certain of our variable rate indebtedness uses London Interbank Offered Rate, or LIBOR, as a benchmark for establishing the rate of interest and may be hedged with LIBOR-based interest rate derivatives. LIBOR is the subject of recent national, international and other regulatory guidance and proposals for reform. These reforms and other pressures may cause LIBOR to be replaced with a new benchmark or to perform differently than in the past. The consequences of these developments cannot be entirely predicted, but could include an increase in the cost of our variable rate indebtedness.

If we are unable to make payments on our indebtedness, we could be in default under the terms of the agreements governing our indebtedness.

If we are unable to generate sufficient cash flow and are otherwise unable to obtain funds necessary to meet required payments of principal, premium, if any, and interest on our indebtedness, or if we otherwise fail to comply with the various covenants, including financial and operating covenants, in the instruments governing our indebtedness, including covenants in the ABL Facility and the indentures governing our outstanding notes, we could be in default under the terms of the agreements governing such indebtedness. In the event of any default, the holders of such indebtedness could elect to declare all the funds borrowed to be immediately due and payable, together with accrued and unpaid interest; the lenders under the ABL Facility could elect to terminate their commitments thereunder, cease making further loans and direct the applicable collateral agents to institute foreclosure proceedings against our assets; and we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to obtain waivers from the required lenders under the ABL Facility to avoid being in default. If we breach our covenants under the ABL Facility and seek a waiver, we may not be able to obtain a waiver from the required lenders. If this occurs, we would be in default under the ABL Facility, the lenders could exercise their rights, as described above, and we could be forced into bankruptcy or liquidation.

We have a substantial amount of indebtedness that will mature and become due in the near future.

As further described in the Liquidity and Capital Resources section of “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of this Form 10-K and Note 6 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K, we have a substantial amount of indebtedness scheduled to mature in the near future, a significant portion of which will mature in close proximity to each other. As a result, we may not have sufficient cash to repay all amounts owing under such indebtedness and there can be no assurance that we will have the ability to borrow or otherwise raise the amounts necessary to repay all such amounts. Our ability to refinance our indebtedness on favorable terms, or at all, is dependent on (among other things) conditions in the credit and capital markets which are beyond our control.

If we are unable to continue to complete divestitures as previously disclosed, our results of operations and financial condition could be adversely affected.

We have been implementing a portfolio rationalization and deleveraging strategy by divesting hospitals and non-hospital businesses that are attractive to strategic and other buyers. Generally, these businesses are not in one of our strategically beneficial service areas, are less complementary to our business strategy and/or have lower operating margins. In connection with our divestiture initiative, we have received offers from strategic buyers to buy certain of our assets. After considering these offers, we have divested, and expect to continue to divest, hospitals and non-hospital businesses when we find such offers to be attractive and in line with our operating strategy. However, there is no assurance that contemplated divestitures will be completed or, if they are completed, the aggregate amount of proceeds we will receive, that contemplated divestitures will be completed within our contemplated timeframe, or that contemplated divestitures will be completed on terms favorable to us or on terms sufficient to allow us to achieve our deleveraging strategy. Additionally, the results of operations for these hospitals we plan to divest and the potential gains or losses on the sales of those businesses may adversely affect our profitability. Moreover, we may incur asset impairment charges related to planned or completed divestitures that reduce our profitability.

32

In addition, after entering into a definitive agreement, we may be subject to the satisfaction of pre-closing conditions as well as necessary regulatory and governmental approvals, which, if not satisfied or obtained, may prevent us from completing the sale. Divestitures may also involve continued financial exposure related to the divested business, such as through indemnities or retained obligations, that present risk to us.

Our planned divestiture activities may present financial, managerial, and operational risks. Those risks include diversion of management attention from improving existing operations; additional restructuring charges and the related impact from separating personnel, renegotiating contracts, and restructuring financial and other systems; adverse effects on existing business relationships with patients and third-party payors; and the potential that the collectability of any patient accounts receivable retained from any divested hospital may be adversely impacted. Any of these factors could adversely affect our financial condition and results of operations.

We are the subject of various legal, regulatory and governmental proceedings that, if resolved unfavorably, could have an adverse effect on us, and we may be subject to other loss contingencies, both known and unknown.

We are a party to various legal, regulatory and governmental proceedings and other related matters. Those proceedings include, among other things, government investigations. In addition, we are and may become subject to other loss contingencies, both known and unknown, which may relate to past, present and future facts, events, circumstances and occurrences. Should an unfavorable outcome occur in connection with our legal, regulatory or governmental proceedings or other loss contingencies, or if we become subject to any such loss contingencies in the future, there could be an adverse impact on our financial position, results of operations and liquidity.

In particular, government investigations, as well as qui tam lawsuits, may lead to significant fines, penalties, damages payments or other sanctions, including exclusion from government healthcare programs. Settlements of lawsuits involving Medicare and Medicaid issues routinely require both monetary payments and corporate integrity agreements, each of which could have an adverse effect on our business, financial condition, results of operations and/or cash flows.

The impact of past acquisitions, as well as potential future acquisitions, could have a negative effect on our operations.

Our business strategy has historically included growth by acquisitions. However, not-for-profit hospital systems and other for-profit hospital companies generally attempt to acquire the same type of hospitals as we do. LifePoint Health, Inc. is a principal competitor for acquisitions. Other competitors include HCA Healthcare, Inc., or HCA, Universal Health Services, Inc., or UHS, other non-public, for profit hospitals and local market hospitals. Some of the competitors for our acquisitions have greater financial resources than we have. Furthermore, some hospitals are sold through an auction process, which may result in higher purchase prices than we believe are reasonable. Therefore, we may not be able to acquire additional hospitals on terms favorable to us.

In addition, many of the hospitals we have acquired have had lower operating margins than we do and operating losses incurred prior to the time we acquired them. Hospitals acquired in the future may have similar financial performance issues. In the past, we have experienced delays in improving the operating margins or effectively integrating the operations of certain acquired hospitals, including some hospitals acquired in connection with the HMA merger. In the future, if we are unable to improve the operating margins of acquired hospitals, operate them profitably, or effectively integrate their operations, our results of operations and business may be adversely affected.

Moreover, hospitals that we have acquired, or in the future could acquire, may have unknown or contingent liabilities, including liabilities associated with ongoing legal proceedings or for failure to comply with healthcare laws and regulations. Although we generally seek indemnification from sellers covering these matters, we may nevertheless have material liabilities for past activities of acquired hospitals.

33

State efforts to regulate the construction, acquisition or expansion of healthcare facilities could limit our ability to build or acquire additional healthcare facilities, renovate our facilities or expand the breadth of services we offer.

Some states in which we operate require a CON or other prior approval for the construction or acquisition of healthcare facilities, capital expenditures exceeding a prescribed amount, changes in bed capacity or services and some other matters. In evaluating a proposal, these states consider the need for additional or expanded healthcare facilities or services. If we are not able to obtain required CONs or other prior approvals, we will not be able to acquire, operate, replace or expand our facilities or expand the breadth of services we offer. Furthermore, if a CON or other prior approval upon which we relied to invest in construction of a replacement or expanded facility were to be revoked or lost through an appeal process, we may not be able to recover the value of our investment.

State efforts to regulate the sale of hospitals operated by municipal or not-for-profit entities could prevent us from acquiring these types of hospitals.

Many states have adopted legislation regarding the sale or other disposition of hospitals operated by municipal or not-for-profit entities. In some states that do not have specific legislation, the attorneys general have demonstrated an interest in these transactions under their general obligation to protect the use of charitable assets. These legislative and administrative efforts focus primarily on the appropriate valuation of the assets divested and the use of the proceeds of the sale by the non-profit seller. While these review and, in some instances, approval processes can add additional time to the closing of a hospital acquisition, we have not had any significant difficulties or delays in completing acquisitions. However, future state actions could delay or even prevent our ability to acquire hospitals once we return to our acquisition strategy.

If we are unable to effectively compete, patients could use other hospitals and healthcare providers.

The healthcare industry is highly competitive among hospitals and other healthcare providers, such as urgent care centers and other outpatient providers and other industry participants, for patients, affiliations with physicians and acquisitions. Changes in licensure or other regulations and industry consolidation could negatively impact our competitive position. For example, in states with CON or similar prior approval requirements, removal of these requirements could remove barriers to entry and increase competition in our service areas. Our hospitals, our competitors, and other healthcare industry participants are increasingly implementing physician alignment strategies, such as acquiring physician practice groups, employing physicians and participating in ACOs or other clinical integration models. Increasing consolidation within the payor industry, vertical integration efforts involving payors and healthcare providers, and cost-reduction strategies by payors, large employer groups and their affiliates may impact our ability to contract with payors on favorable terms and otherwise affect our competitive position.

The majority of our hospitals are located in non-urban service areas where we believe we are the sole provider of general acute care health services. As a result, the most significant competition from providers of general acute care services comes from hospitals outside of our primary service areas, typically hospitals in urban areas that provide more complex services. Patients in our primary service areas may travel to other hospitals because of physician referrals, payor networks that exclude our providers or the need for services we do not offer, among other reasons. Patients who receive services from these other hospitals may subsequently shift their preferences to those hospitals for the services we provide.

At December 31, 2019, 35 of our hospitals competed with more than one other non-affiliated hospital in their respective primary service areas. In most markets in which we are not the sole provider of general acute care health services, our primary competitor is a municipal or not-for-profit hospital. These hospitals are owned by tax-supported governmental agencies or not-for-profit entities supported by endowments and charitable contributions. They do not pay income or property taxes, and can make capital expenditures without paying sales tax. These financial advantages may better position these hospitals to maintain more modern and technologically upgraded facilities and equipment and offer services more specialized than those available at our hospitals. If our

34

competitors are better able to attract patients with these offerings, we may experience an overall decline in patient volume.

Trends toward transparency and value-based purchasing may have an unanticipated impact on our competitive position and patient volumes. The CMS Hospital Compare website makes available to the public certain data that hospitals submit in connection with Medicare reimbursement claims, including performance data related to quality measures and patient satisfaction surveys. Further, every hospital must establish and update annually a public, online listing of the hospital’s standard charges for items and services. Beginning in 2021, hospitals will be required to publish additional types of standard charges for all items and services, including discounted cash prices and payor-specific charges, along with a consumer-friendly list of charges for certain “shoppable” services. If any of our hospitals achieve poor results (or results that are lower than our competitors) on the quality measures or on patient satisfaction surveys, or if our standard charges are higher than our competitors, we may attract fewer patients. It is unclear how price transparency requirements and similar initiatives will affect consumer behavior, our relationships with payors, or our ability to set and negotiate practices.

We expect these competitive trends to continue. If we are unable to compete effectively with other hospitals and other healthcare providers, patients may seek healthcare services at providers other than our hospitals and affiliated businesses.

The failure to obtain our medical supplies at favorable prices could cause our operating results to decline.

We have a participation agreement with HealthTrust, a GPO. The current term of this agreement expires in January 2021, with automatic renewal terms of one year unless either party terminates by giving notice of non-renewal. GPOs attempt to obtain favorable pricing on medical supplies with manufacturers and vendors, sometimes by negotiating exclusive supply arrangements in exchange for discounts. To the extent these exclusive supply arrangements are challenged or deemed unenforceable, we could incur higher costs for our medical supplies obtained through HealthTrust. Further, costs of supplies and drugs may continue to increase due to market pressure from pharmaceutical companies and new product releases. Higher costs could continue to adversely impact our operating results. Also, there can be no assurance that our arrangement with HealthTrust will provide the discounts we expect to achieve.

If the fair value of our reporting unit declines, a material non-cash charge to earnings from impairment of our goodwill could result.

At December 31, 2019, we had approximately $4.3 billion of goodwill. We expect to recover the carrying value of this goodwill through our future cash flows. On an ongoing basis, under U.S. GAAP, we evaluate, based on the fair value of our reporting unit, whether the carrying value of our goodwill is impaired when events or changes in circumstances indicate that such carrying value may not be recoverable. U.S. GAAP requires us to test goodwill for impairment at least annually.

During 2017, we early adopted Accounting Standards Update, or ASU, 2017-04, which allows a company to record a goodwill impairment when the carrying value of a reporting unit exceeds its fair value determined in step one.

Our most recent goodwill evaluations were performed during the fourth quarter of 2019, with an October 31, 2019 measurement date and during the fourth quarter of 2018, with an October 31, 2018 measurement date, each of which indicated no impairment. However, during the three months ended December 31, 2017, in connection with the preparation of the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017, we identified certain indicators of impairment and performed an interim goodwill impairment evaluation as of November 30, 2017. Those indicators were primarily a further decline in our market capitalization and fair value of our long-term debt during November 2017. We performed an estimated calculation of fair value in step one of the impairment test at November 30, 2017, which indicated that the carrying value of our hospital operations reporting unit exceeded its fair value. As a result of this evaluation

35

and the early adoption of ASU 2017-04, we recorded a non-cash impairment charge of $1.419 billion to goodwill during the three months ended December 31, 2017. In addition, we also recorded a non-cash impairment charge of $1.395 billion during the year ended December 31, 2016.

While no impairment was indicated in our most recent annual goodwill evaluations as of the October 31, 2019 and October 31, 2018 measurement dates, the reduction in our fair value and the resulting goodwill impairment charges recorded during 2016 and 2017 reduced the carrying value of our hospital operations reporting unit to an amount equal to our estimated fair values as of such prior year measurement dates. This increases the risk that future declines in fair value could result in goodwill impairment. The determination of fair value in step one of our goodwill impairment analysis is based on an estimate of fair value for the hospital operations reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of our common stock or fair value of our long-term debt, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including further decline in our stock price or fair value of our long-term debt, lower than expected hospital volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of our fair value could result in a material impairment charge in the future.

A significant decline in operating results or other indicators of impairment at one or more of our facilities could result in a material, non-cash charge to earnings to impair the value of long-lived assets.

Our operations are capital intensive and require significant investment in long-lived assets, such as property, equipment and other long-lived intangible assets, including capitalized internal-use software. If one of our facilities experiences declining operating results or is adversely impacted by one or more of these risk factors, we may not be able to recover the carrying value of those assets through our future operating cash flows. On an ongoing basis, we evaluate whether changes in future undiscounted cash flows reflect an impairment in the fair value of our long-lived assets. Additionally, as we continue to rationalize our portfolio of hospitals, we evaluate whether a hospital or a group of hospitals is impaired based on an analysis of the selling price from a definitive agreement compared to the carrying value of the net assets being sold. If the carrying value of our long-lived assets is impaired, we may incur a material non-cash charge to earnings.

We are unable to predict the ultimate impact of health reform initiatives, including the Affordable Care Act, and our business may be adversely affected if the Affordable Care Act is repealed entirely or found to be unconstitutional or if provisions benefitting our operations are significantly modified.

In recent years, the U.S. Congress and certain state legislatures have introduced, considered or passed a large number of proposals and legislation designed to make major changes in the healthcare system, including changes intended to increase access to health insurance.

The Affordable Care Act is the most prominent of these reform efforts. The law expanded health insurance coverage through a combination of public program expansion and private sector health insurance reforms, mandated that substantially all U.S. citizens maintain health insurance coverage, reduced Medicare reimbursement to hospitals, and promotes value-based purchasing. Court challenges and efforts by the presidential administration and certain members of Congress to repeal or make significant changes to the Affordable Care Act, its implementation and/or its interpretation have cast considerable uncertainty on the future of the law. For example, a presidential executive order directs agencies to minimize “economic and regulatory burdens” of the Affordable Care Act. Moreover, in June 2018, the Department of Labor issued a final rule expanding availability of association health plans, which are not required to adhere to specific Affordable Care Act coverage mandates. Additionally, effective January 2019, the financial penalty for individuals that fail to maintain insurance coverage associated with the individual mandate was eliminated as part of the tax reform legislation that was enacted in December 2017. In December 2018, as a result of this change, a federal judge in Texas found the individual mandate unconstitutional and determined the rest of the Affordable Care Act was

36

therefore invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. The law remains in place pending the appeals process. The elimination of the individual mandate and other changes may impact the number of individuals that elect to obtain public or private health insurance or the scope of such coverage, if purchased.

There is uncertainty regarding whether, when, and how the Affordable Care Act will be further changed, the ultimate outcome of court challenges and how the Affordable Care Act will be interpreted and implemented. Court challenges and changes by Congress or government agencies could eliminate or alter provisions beneficial to us while leaving in place provisions reducing our reimbursement. The repeal or invalidation of or changes to the Affordable Care Act may have an adverse effect on our business, results of operations, cash flow, capital resources and/or liquidity.

There is also uncertainty regarding whether other health reform measures will be adopted, what alternative provisions, if any, will be enacted, the timing and implementation of alternative provisions, and the impact of alternative provisions on providers as well as other healthcare industry participants. For example, CMS administrators have indicated that they intend to grant states additional flexibility in the administration of state Medicaid programs, including expanding the scope of waivers under which states may impose different eligibility or enrollment restrictions or otherwise implementing programs that vary from federal standards. CMS administrators have also signaled interest in changing Medicaid payment models, including allowing states to obtain funding through a block grant program and adopting value-based care models. Other health reform initiatives and proposals, including those aimed at price transparency and out-of-network charges, may impact prices, our competitive position and the relationships between hospitals and insurers. Further, the outcome of the 2020 federal election and its potential impact on health reform efforts is unknown. Some presidential candidates and members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor proposals, and some states are considering similar measures. Other industry participants, such as private payors and large employer groups and their affiliates, may also introduce financial or delivery system reforms. We are unable to predict the nature and success of such initiatives, but they may have an adverse impact on our business.

If reimbursement rates paid by federal or state healthcare programs or commercial payors are reduced, if we are unable to maintain favorable contract terms with payors or comply with our payor contract obligations, if insured individuals move to insurance plans with greater coverage exclusions or narrower networks, or if insurance coverage is otherwise restricted or reduced, our net operating revenues may decline.

In 2019, 38.4% of our net operating revenues, came from the Medicare and Medicaid programs. However, as federal healthcare expenditures continue to increase and state governments continue to face budgetary shortfalls, federal and state governments have made, and continue to make, significant changes in the Medicare and Medicaid programs, including reductions in reimbursement levels. For example, on November 18, 2019, CMS proposed the Medicaid Fiscal Accountability Regulation, 84 Fed. Reg. 63, 772. If this proposed rule is adopted in its current form, this could have a significant impact on the amounts some of our hospitals receive in Medicaid funding. In addition, CMS may implement changes through new or modified demonstration projects authorized pursuant to Medicaid waivers. In January 2020, CMS announced a demonstration project allowing for a block grant funding model. Some of these changes have decreased, or could decrease, the amount of money we receive for our services relating to these programs.

In addition, government and commercial payors as well as other third parties from whom we receive payment for our services attempt to control healthcare costs by, for example, requiring hospitals to discount payments for their services in exchange for exclusive or preferred participation in their benefit plans, restricting coverage through utilization review, reducing coverage of inpatient and emergency room services and shifting care to outpatient settings, requiring prior authorizations, and implementing alternative payment models. The ability of commercial payors to control healthcare costs using these measures may be enhanced by the increasing consolidation of insurance and managed care companies and vertical integration of health insurers with

37

healthcare providers. In addition, price transparency initiatives may impact our ability to obtain or maintain favorable contract terms. For example, beginning in 2021, hospitals will be required by federal regulation to publish online payor-specific negotiated charges and de-identified minimum and maximum charges.

In 2019, 60.6% of our net operating revenues came from commercial payors. Our contracts with payors require us to comply with a number of terms related to the provision of services and billing for services. If we are unable to negotiate increased reimbursement rates, maintain existing rates or other favorable contract terms, effectively respond to payor cost controls and reimbursement policies or comply with the terms of our payor contracts, the payments we receive for our services may be reduced. Also, we are increasingly involved in disputes with payors and experience payment denials, both prospectively and retroactively. In addition, individuals have been increasingly enrolling in high-deductible health plans, which tend to have lower reimbursement rates for providers along with higher co-pays and deductibles due from the patient in comparison to traditional health plans. These higher co-pays and deductibles due from patients are subject to increased collection cost and risk. In addition, these high-deductible health plans, sometimes referred to as consumer-directed plans, may even exclude our hospitals and employed physicians from coverage.

The demand for services provided by our hospitals and affiliated providers can be impacted by factors beyond our control.

Our admissions and adjusted admissions as well as acuity trends may be impacted by factors beyond our control. For example, seasonal fluctuations in the severity of influenza and other critical illnesses, unplanned shutdowns or unavailability of our facilities due to weather or other unforeseen events, decreases in trends in high acuity service offerings, changes in competition from other service providers, turnover in physicians affiliated with our hospitals, or changes in medical technology can have an impact on the demand for services at our hospitals and affiliated providers. The impact of these or other factors beyond our control could have an adverse effect on our business, financial position and results of operations.

We may be adversely affected by consolidation among health insurers and other industry participants.

In recent years, a number of health insurers have merged or increased efforts to consolidate with other non-governmental payors. Insurers are also increasingly pursuing alignment initiatives with healthcare providers. Consolidation within the health insurance industry may result in insurers having increased negotiating leverage and competitive advantages, such as greater access to performance and pricing data. Our ability to negotiate prices and favorable terms with health insurers in certain markets could be affected negatively as a result of this consolidation. Also, the shift toward value-based payment models could be accelerated if larger insurers, including those engaging in consolidation activities, find these models to be financially beneficial. We cannot predict whether we will be able to negotiate favorable terms with payors and otherwise respond effectively to the impact of increased consolidation in the payor industry or vertical integration efforts.

If we fail to comply with extensive laws and government regulations, including fraud and abuse laws, we could suffer penalties or be required to make significant changes to our operations.

The healthcare industry is governed by laws and regulations at the federal, state and local government levels. These laws and regulations include standards addressing, among other issues, the adequacy of medical care, equipment, personnel, operating policies and procedures; billing and coding for services; properly handling overpayments; classification of levels of care provided; preparing and filing of cost reports; relationships with referral sources and referral recipients; maintenance of adequate records; compliance with building codes; environmental protection; privacy and security; debt collection; and communications with patients and consumers. Examples of these laws include, but are not limited to, HIPAA, the Stark Law, the federal Anti-Kickback Statute, the FCA, the Emergency Medical Treatment and Active Labor Act and similar state laws. If we fail to comply with applicable laws and regulations we could suffer civil sanctions and criminal penalties, including the loss of our operating licenses and our ability to participate in the Medicare, Medicaid and other federal and state healthcare programs.

38

In addition, there are heightened coordinated civil and criminal enforcement efforts by both federal and state government agencies relating to the healthcare industry, including the hospital segment. Enforcement actions have focused on financial arrangements between hospitals and physicians, billing for services without adequately documenting medical necessity and billing for services outside the coverage guidelines for such services. Specific to our hospitals, we have received inquiries and subpoenas from various governmental agencies regarding these and other matters, and we are also subject to various claims and lawsuits relating to such matters. For a further discussion of these matters, see “Legal Proceedings” in Part I, Item 3 of this Form 10-K.

In the future, evolving interpretations or enforcement of these laws and regulations could subject our current practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

We could be subject to substantial uninsured liabilities or increased insurance costs as a result of significant legal actions.

Physicians, hospitals and other healthcare providers have become subject to an increasing number of legal actions alleging malpractice, product liability, or related legal theories. Even in states that have imposed caps on damages, litigants are seeking recoveries under new theories of liability that might not be subject to the caps on damages. Many of these actions involve large claims and significant defense costs. To protect us from the cost of these claims, we maintain claims made professional malpractice liability insurance and general liability insurance coverage in excess of those amounts for which we are self-insured. This insurance coverage is in amounts that we believe to be sufficient for our operations; however, our insurance coverage may not continue to be available at a reasonable cost for us to maintain adequate levels of insurance. Additionally, our insurance coverage does not cover all claims against us, such as fines, penalties, or other damage and legal expense payments resulting from qui tam lawsuits. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us or on our insurance costs. Additionally, all professional and general liability insurance we purchase is subject to policy limitations. If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period. Furthermore, one or more of our insurance carriers could become insolvent and unable to fulfill its or their obligations to defend, pay or reimburse us when those obligations become due. In that case, or if payments of claims exceed our estimates or are not covered by our insurance, it could have an adverse effect on our business, financial condition or results of operations.

We could be subject to increased monetary penalties and/or other sanctions, including exclusion from federal healthcare programs, if we fail to comply with the terms of the CIA.

On August 4, 2014, we announced that we had entered into a civil settlement with the U.S. Department of Justice, other federal agencies and identified relators that concluded previously announced investigations and litigation related to short stay admissions through emergency departments at certain of our affiliated hospitals. In addition to the amounts paid in the settlement, we executed the CIA with the OIG that has been incorporated into our existing and comprehensive compliance program. On September 25, 2018, the CIA was amended and extended in connection with the settlement of certain qui tam lawsuits related to certain conduct of HMA and its affiliated entities that were initiated and pending, and known to us, before HMA was acquired by merger in January 2014. See our discussion of these matters under the section “Business of Community Health Systems, Inc.” in Part I, Item 1 of this Form 10-K and “Legal Proceedings” in Part II, Item 1 of our Quarterly Reports on Form 10-Q for the quarterly periods ended September 30, 2014 and September 30, 2018 for further discussion of the background of these matters and details of the settlements.

Material, uncorrected violations of the CIA could lead to our suspension or disbarment from participation in Medicare, Medicaid and other federal and state healthcare programs and repayment obligations. In addition, we are subject to possible civil penalties for failure to substantially comply with the terms of the CIA, including stipulated penalties ranging between $1,000 to $2,500 per day. We are also subject to a stipulated penalty of

39

$50,000 for each false certification made by us or on our behalf, pursuant to the reporting provisions of the CIA. The CIA increases the amount of information we must provide to the federal government regarding our healthcare practices and our compliance with federal regulations. The reports we provide in connection with the CIA could result in greater scrutiny by regulatory authorities.

If we experience growth in self-pay volume and revenues or if we experience deterioration in the collectability of patient responsibility accounts, our financial condition or results of operations could be adversely affected.

Our primary collection risks relate to uninsured patients and outstanding patient balances for which the primary insurance payor has paid some but not all of the outstanding balance, with the remaining outstanding balance (generally deductibles and co-payments) owed by the patient. Collections are impacted by the economic ability of patients to pay and the effectiveness of our collection efforts. Significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage may affect our collection of accounts receivable and are considered in our estimates of accounts receivable collectability.

Efforts to repeal or revise the Affordable Care Act have cast considerable uncertainty on the future of the law and its effects on the size of the uninsured population. For example, Congress eliminated, effective January 1, 2019, the financial penalty associated with the Affordable Care Act’s mandate that individuals enroll in an insurance plan. In December 2018, as a result of this change, a federal judge in Texas found the individual mandate unconstitutional and determined that the rest of the Affordable Care Act was therefore invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. Pending the appeals process, the law remains in place. In addition, the Medicaid program continues to evolve, both as a result of the Affordable Care At and subsequent legislation and agency initiatives. Changes include the number and identity of states that choose to expand or otherwise modify Medicaid programs and the terms of expansion and other program modifications. Some of these program changes, such as requirements that Medicaid recipients meet certain work requirements, have reduced and may continue to reduce the number of program participants in certain states. These variables, among others, make it difficult to predict the number of uninsured individuals and what percentage of our total revenue will be comprised of self-pay revenues.

We may be adversely affected by the growth in patient responsibility accounts as a result of increases in the adoption of plan structures, including health savings accounts, narrow networks and tiered networks, that shift greater responsibility for care to individuals through greater exclusions and copayment and deductible amounts. Further, our ability to collect patient responsibility accounts may be limited by statutory, regulatory and investigatory initiatives, including private lawsuits directed at hospital charges and collection practices for uninsured and underinsured patients and regulatory restrictions on charges for out-of-network services. In addition, a deterioration of economic conditions in the United States could potentially lead to higher levels of uninsured patients, result in higher levels of patients covered by lower paying government programs, result in fiscal uncertainties at both government payors and private insurers and/or limit the economic ability of patients to make payments for which they are responsible. If we experience growth in self-pay volume or deterioration in collectability of patient responsibility accounts, our financial condition or results of operations could be adversely affected.

Many of the non-urban communities in which we operate continue to face challenging economic conditions, and the failure of certain employers, or the closure of certain manufacturing and other facilities in our markets, could have a disproportionate impact on our hospitals.

Many of the non-urban communities in which we operate continue to face challenging economic conditions, including higher levels of unemployment than other regions of the United States. In addition, the economies in the non-urban communities in which our hospitals primarily operate are often dependent on a small number of large employers, especially manufacturing or similar facilities. These employers often provide income and health insurance for a disproportionately large number of community residents who may depend on our hospitals for

40

care. The failure of one or more large employers, or the closure or substantial reduction in the number of individuals employed at manufacturing or other facilities located in or near many of the non-urban communities in which our hospitals primarily operate, could cause affected employees to move elsewhere for employment or lose insurance coverage that was otherwise available to them. When patients are experiencing personal financial difficulties or have concerns about general economic conditions, they may:

• delay or forgo elective procedures;

• purchase a high-deductible insurance plan or no insurance at all, which increases a hospital’s dependence on self-pay revenue; or

• choose to seek care in emergency rooms.

The occurrence of these events may cause a reduction in our revenues and adversely impact our results of operations.

If there are delays in regulatory updates by governmental entities to federal and state healthcare programs, we may experience increased volatility in our operating results as such delays may result in a timing difference between when such program revenues are earned and when they become known or estimable for purposes of accounting recognition.

We derive a significant amount of our net operating revenues from governmental healthcare programs, primarily Medicare and Medicaid. The reimbursements due to us from those programs are subject to legislative and regulatory changes that can have a significant impact on our operating results. When delays occur in the implementation of regulations or passage of legislation, there is the potential for material increases or decreases in operating revenues to be recognized in periods subsequent to when such related services were performed, resulting in the potential for an adverse effect on our consolidated financial position and consolidated results of operations.

If our adoption and utilization of electronic health record systems fails to satisfy HHS standards, our consolidated results of operations could be adversely affected, and we may be adversely affected by changing and more burdensome interoperability requirements.

Under the Health Information Technology for Economic and Clinical Health Act, or HITECH, and other laws, eligible hospitals that fail to demonstrate meaningful use of certified EHR technology and have not applied and qualified for a hardship exception are subject to reduced reimbursement from Medicare. Eligible healthcare professionals are also subject to positive or negative payment adjustments based, in part, on their use of EHR technology. Thus, if our hospitals and employed professionals are unable to properly adopt, maintain, and utilize certified EHR systems, we could be subject to penalties and lawsuits that may have an adverse effect on our consolidated financial position and consolidated results of operations.

The federal government is also promoting the efficient exchange of health care information to improve health care. The 21^st Century Cures Act prohibits information blocking by health care providers and certain other entities, which is defined as engaging in activities that are likely to interfere with, prevent or materially discourage access, exchange or use of electronic health information, subject to limited exceptions. Initiatives related to health care technology and interoperability may require changes to our operations, impose new and complex obligations on us, affect our relationships with providers, vendors and other third parties and require investments in infrastructure. We may be subject to penalties for failure to comply.

Our operations could be significantly impacted by interruptions or restrictions in access to our information systems.

Our operations depend heavily on effective information systems to process clinical, operational and financial information. Information systems require an ongoing commitment of significant resources to maintain and

41

enhance existing systems and to develop new systems in order to keep pace with continual changes in information technology. We also sometimes rely on third-party providers of financial, clinical, patient accounting and network information services and, as a result, we face operational challenges in maintaining multiple provider platforms and facilitating the interface of such systems with one another. We rely on these third-party providers to have appropriate controls to protect confidential information. We do not control the information systems of third-party providers, and in some cases we may have difficulty accessing information archived on third-party systems.

Our networks and information systems are also subject to disruption due to events such as a major earthquake, fire, telecommunications failure, ransomware or terrorist attacks or other catastrophic events. If the information systems on which we rely fail or are interrupted or if our access to these systems is limited in the future, it could have an adverse effect on our business, financial condition or results of operations.

If we fail to comply with our obligations under license or technology agreements with third parties, we may be required to pay damages and we could lose license rights that are critical to our business.

We license certain intellectual property, including technologies and software from third parties, that is important to our business, and in the future we may enter into additional agreements that provide us with licenses to valuable intellectual property or technology. If we fail to comply with any of the obligations under our license agreements, we may be required to pay damages and the licensor may have the right to terminate the license. Termination by the licensor would cause us to lose valuable rights, and could prevent us from selling our solutions and services, or adversely impact our ability to commercialize future solutions and services. Our business would suffer if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed intellectual property are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Any of the foregoing could have an adverse effect on our business, financial condition or results of operations.

A cyber-attack or security breach could result in the compromise of our facilities, confidential data or critical data systems and give rise to potential harm to patients, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, common law or other theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business.

We rely extensively on computer systems to manage clinical and financial data, communicate with our patients, payors, vendors and other third parties and summarize and analyze operating results. We have made significant investments in technology to protect our systems, equipment and medical devices and information from cybersecurity risks. During the second quarter of 2014, our computer network was the target of an external, criminal cyber-attack in which the attacker successfully copied and transferred certain data outside the Company. This data included certain non-medical patient identification data (such as patient names, addresses, birthdates, telephone numbers and social security numbers) considered protected under HIPAA, but did not include patient credit card, medical or clinical information. The remediation efforts in response to the attack have been substantial, including continued development and enhancement of our controls, processes and practices designed to protect our systems, computers, software, data and networks from attack, damage or unauthorized access. Also in connection with the cyber-attack, we have been subject to multiple purported class action lawsuits and government investigations by various State Attorneys General and the U.S. Department of Health and Human Services Office for Civil Rights, and may be subject to additional litigation, potential governmental inquiries and potential reputation damages.

In spite of our security measures, there can be no assurance that we will not be subject to additional cyber-attacks or security breaches in the future. In the definitive agreements we enter into in connection with the divestiture of hospitals, we routinely agree to provide transition services to the buyer, including access to our legacy information systems, for a defined transition period. By providing access to our information systems to non-employees, we are exposed to cyber-attacks or security breaches that originate outside of our processes and

42

practices designed to prevent such threats from occurring. In addition, we may be at increased risk because we outsource certain services or functions to, or have systems that interface with, third parties. Some of these third parties may store or have access to our data and may not have effective controls, processes, or practices to protect our information from attack, damage, or unauthorized access. A breach or attack affecting any of these third parties could harm our business.

Cyber-attacks or security breaches could impact the integrity, availability or privacy of protected health information or other data subject to privacy laws or disrupt our information technology systems, devices or business, including our ability to provide various healthcare services. For example, medical devices that connect to hospital networks or the internet may be vulnerable to cybersecurity incidents, which may impact patient safety. Additionally, growing cyber-security threats related to the use of ransomware and other malicious software threaten the access and utilization of critical information technology and data. As a result, cybersecurity and the continued development and enhancement of our controls, process and practices designed to protect our information systems from attack, damage or unauthorized access remain a priority for us. Our ability to recover from a ransomware or other cyber-attack is dependent on these practices, including successful backup systems and other recovery procedures. As cyber-threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities, but we still might not be able to anticipate or prevent certain attack methods. If we are subject to cyber-attacks or security breaches in the future, this could result in harm to patients; business interruptions and delays; the loss, misappropriation, corruption or unauthorized access of data; litigation and potential liability under privacy, security, breach notification and consumer protection laws or other applicable laws; reputational damage and federal and state governmental inquiries, any of which could have an adverse effect on our business, financial condition or results of operations.

A pandemic, epidemic or outbreak of an infectious disease in the markets in which we operate or that otherwise impacts our facilities could adversely impact our business.

If a pandemic, epidemic, or outbreak of an infectious disease including the recent outbreak of respiratory illness caused by a novel coronavirus known as COVID-19 first identified in Wuhan, China in December 2019, or other public health crisis were to affect our markets, our business could be adversely affected. Any such crisis could diminish the public trust in healthcare facilities, especially hospitals that fail to accurately or timely diagnose, or that are treating (or have treated) patients affected by contagious diseases. If any of our facilities were involved in treating patients for such a contagious disease, other patients might cancel elective procedures or fail to seek needed care at our facilities. Further, a pandemic might adversely impact our business by causing a temporary shutdown or diversion of patients, by disrupting or delaying production and delivery of materials and products in the supply chain or by causing staffing shortages in our facilities. In particular, while it is uncertain the extent to which the coronavirus may impact our business, given that a portion of pharmaceuticals and medical supplies used at our facilities are sourced from China, in the event that the coronavirus outbreak, or any actions taken by the Chinese government or other governmental authorities in connection therewith, were to disrupt the supply of these pharmaceuticals and/or medical supplies, then our business could be adversely affected. In addition, although we have disaster plans in place and operate pursuant to infectious disease protocols, the potential impact of a pandemic, epidemic or outbreak of an infectious disease with respect to our markets or our facilities is difficult to predict and could adversely impact our business.

Our performance depends on our ability to recruit and retain quality physicians.

The success of our healthcare facilities depends in part on the number and quality of the physicians on the medical staffs of our healthcare facilities, our ability to employ quality physicians, the admitting and utilization practices of employed and independent physicians, maintaining good relations with those physicians and controlling costs related to the employment of physicians. Although we employ some physicians, physicians are often not employees at our healthcare facilities at which they practice. In many of the markets we serve, many physicians have admitting privileges at other healthcare facilities in addition to our healthcare facilities. Such physicians may terminate their affiliation with or employment by our healthcare facilities at any time. In

43

addition, we may face increased challenges in this area as the physician population reaches retirement age, especially if there is a shortage of physicians willing and able to provide comparable services. Moreover, if we are unable to provide adequate support personnel or technologically advanced equipment and facilities that meet the needs of those physicians and their patients, they may be discouraged from referring patients to our facilities, admissions may decrease and our operating performance may decline.

Our labor costs could be adversely affected by competition for staffing, the shortage of experienced nurses and labor union activity.

In addition to our physicians, the operations of our healthcare facilities are dependent on the efforts, abilities and experience of our management and medical support personnel, such as nurses, pharmacists and lab technicians. We compete with other healthcare providers in recruiting and retaining qualified management and support personnel responsible for the daily operations of our healthcare facilities, including nurses and other non-physician healthcare professionals. In some markets, the availability of nurses and other medical support personnel has been a significant operating issue to healthcare providers. We may be required to continue to enhance wages and benefits to recruit and retain nurses and other medical support personnel or to hire more expensive temporary or contract personnel. In addition, the states in which we operate could adopt mandatory nurse-staffing ratios or could reduce mandatory nurse-staffing ratios already in place. State-mandated nurse-staffing ratios could significantly affect labor costs and have an adverse impact on revenues if we are required to limit admissions in order to meet the required ratios.

Increased or ongoing labor union activity could also adversely affect our labor costs or otherwise adversely impact us. To the extent a significant portion of our employee base unionizes, our labor costs could increase significantly. In addition, when negotiating collective bargaining agreements with unions, whether such agreements are renewals or first contracts, there is the possibility that strikes could occur during the negotiation process, and our continued operation during any strikes could increase our labor costs and otherwise adversely impact us.

If our labor costs increase, we may not be able to raise rates to offset these increased costs. Because a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased labor costs is constrained. In the event we are not entirely effective at recruiting and retaining qualified management, nurses and other medical support personnel, or in controlling labor costs, this could have an adverse effect on our results of operations.

The industry trend towards value-based purchasing may negatively impact our revenues.

There is a trend toward value-based purchasing of healthcare services across the healthcare industry among both government and commercial payors. Generally, value-based purchasing initiatives tie payment to the quality and efficiency of care. For example, hospital payments may be negatively impacted by the occurrence of hospital acquired conditions, or HACs. The 25% of hospitals with the worst national risk-adjusted HAC rates for all hospitals in the previous year receive a 1% reduction in their total Medicare payments. Medicare does not reimburse for care related to HACs. In addition, federal funds may not be used under the Medicaid program to reimburse providers for services provided to treat HACs. Hospitals that experience excess readmissions for designated conditions receive reduced payments for all inpatient discharges. HHS also reduces Medicare inpatient hospital payments for all discharges by a required percentage and pools the amount collected from these reductions to fund payments to reward hospitals that meet or exceed certain quality performance standards. Further, Medicare and Medicaid require hospitals to report certain quality data to receive full reimbursement updates.

HHS has focused on tying Medicare payments to quality or value through alternative payment models, which generally aim to make providers attentive to the quality and cost of care they deliver to patients. Examples of alternative payment models include ACOs and bundled payment arrangements. An ACO is a care coordination model intended to produce savings as a result of improved quality and operational efficiency. In bundled

44

payment models, providers receive one payment for services provided to patients for certain medical conditions or episodes of care, accepting accountability for costs and quality of care. Providers may receive supplemental Medicare payments or owe repayments to CMS depending on whether spending exceeds or falls below a specified spending target and whether certain quality standards are met. Currently, participation in Medicare bundled payment programs is voluntary, except for hospitals located in certain geographic areas with respect to specified orthopedic procedures. CMS has indicated that it is developing more voluntary and mandated bundled payment models.

Several of the nation’s largest commercial payors have also expressed an intent to increase reliance on value-based reimbursement arrangements. Further, many large commercial payors require hospitals to report quality data, and several commercial payors do not reimburse hospitals for certain preventable adverse events.

We expect value-based purchasing programs, including programs that condition reimbursement on patient outcome measures, to become more common and to involve a higher percentage of reimbursement amounts. It is unclear whether these and other alternative payment models will successfully coordinate care and reduce costs or whether they will decrease aggregate reimbursement. While we believe we are adapting our business strategies to compete in a value-based reimbursement environment, we are unable at this time to predict how this trend will affect our results of operations. If we perform at a level below the outcomes demonstrated by our competitors, are unable to meet or exceed the quality performance standards under any applicable value-based purchasing program, or otherwise fail to effectively provide or coordinate the efficient delivery of quality healthcare services, our reputation in the industry may be negatively impacted, we may receive reduced reimbursement amounts and we may owe repayments to payors, causing our revenues to decline.

Our revenues are somewhat concentrated in a small number of states which will make us particularly sensitive to regulatory and economic changes in those states.

Our revenues are particularly sensitive to regulatory and economic changes in states in which we generate a significant portion of our revenues, including Florida, Indiana, Texas, Alabama and Mississippi. Accordingly, any change in the current demographic, economic, competitive, or regulatory conditions in these states could have an adverse effect on our business, financial condition, or results of operations. Changes to the Medicaid programs in these states could also have an adverse effect on our business, financial condition, results of operations, or cash flows. The Texas Healthcare Transformation and Quality Improvement Program, or the Texas Waiver Program, which provides funding for uncompensated care and delivery system reform initiatives, is operated under a waiver granted pursuant to Section 1115 of the Social Security Act. In December 2017, CMS approved an extension of this waiver through September 30, 2022. In accordance with this extension, Texas has submitted a plan to CMS for approval that outlines the state’s transition away from funding for its Delivery System Reform Incentive payment program, which currently provides support to hospitals and other providers to reform healthcare delivery systems. We cannot guarantee that revenues recognized from the program will not decrease or predict whether the Texas Waiver Program will be further extended or changed.

Item 1B. Unresolved Staff Comments

None

Item 2. Properties

Corporate Headquarters

We own our corporate headquarters building located in Franklin, Tennessee.

Hospitals

Our hospitals are general care hospitals offering a wide range of inpatient and outpatient medical services. These services generally include general acute care, emergency room, general and specialty surgery, critical care,

45

internal medicine, obstetrics, diagnostic, psychiatric and rehabilitation services. In addition, some of our hospitals provide skilled nursing and home care services based on individual community needs.

For each of our hospitals owned or leased as of December 31, 2019, the following table shows its location, the date of its acquisition or lease inception and the number of licensed beds:

Hospital	City		Licensed   Beds(1)		Date of   Acquisition/Lease   Inception		Ownership     Type
Alabama
South Baldwin Regional Medical Center		Foley		112		June, 2000		Leased
Grandview Medical Center		Birmingham		402		July, 2007		Owned
Flowers Hospital		Dothan		235		July, 2007		Owned
Medical Center Enterprise		Enterprise		131		July, 2007		Owned
Gadsden Regional Medical Center		Gadsden		346		July, 2007		Owned
Crestwood Medical Center		Huntsville		180		July, 2007		Owned
Alaska
Mat-Su Regional Medical Center		Palmer		109		July, 2007		Owned
Arizona
Western Arizona Regional Medical Center		Bullhead City		139		July, 2000		Owned
Northwest Medical Center		Tucson		300		July, 2007		Owned
Oro Valley Hospital		Oro Valley		146		July, 2007		Owned
Arkansas
Northwest Health System
Northwest Medical Center - Bentonville		Bentonville		128		July, 2007		Owned
Northwest Medical Center - Springdale		Springdale		222		July, 2007		Owned
Willow Creek Women’s Hospital		Johnson		64		July, 2007		Owned
Northwest Health Physician’s Specialty Hospital		Fayetteville		20		April, 2016		Leased
Siloam Springs Regional Hospital		Siloam Springs		73		February, 2009		Owned
Medical Center of South Arkansas		El Dorado		166		April, 2009		Leased
Florida
North Okaloosa Medical Center		Crestview		110		March, 1996		Owned
Bayfront Health Brooksville		Brooksville		120		January, 2014		Leased
Bayfront Health Port Charlotte		Port Charlotte		254		January, 2014		Owned
Bayfront Health Punta Gorda		Punta Gorda		208		January, 2014		Owned
Bayfront Health St. Petersburg		St. Petersburg		480		January, 2014		Leased
Bayfront Health Spring Hill		Spring Hill		124		January, 2014		Leased
Lower Keys Medical Center		Key West		167		January, 2014		Leased
Physicians Regional Healthcare System - Collier		Naples		100		January, 2014		Owned
Physicians Regional Healthcare System - Pine Ridge		Naples		101		January, 2014		Owned
Santa Rosa Medical Center		Milton		129		January, 2014		Leased
Seven Rivers Regional Medical Center		Crystal River		128		January, 2014		Owned
Shands Lake Shore Regional Medical Center		Lake City		99		January, 2014		Leased
Shands Live Oak Regional Medical Center		Live Oak		25		January, 2014		Owned
Shands Starke Regional Medical Center		Starke		49		January, 2014		Owned
St. Cloud Regional Medical Center		St. Cloud		84		January, 2014		Owned
Venice Regional Bayfront Health		Venice		312		January, 2014		Owned

46

Hospital	City		Licensed   Beds(1)		Date of   Acquisition/Lease   Inception		Ownership     Type
Georgia
East Georgia Regional Medical Center		Statesboro		149		January, 2014		Owned
Indiana
Porter Hospital		Valparaiso		301		May, 2007		Owned
Lutheran Health Network
Bluffton Regional Medical Center		Bluffton		79		July, 2007		Owned
Dupont Hospital		Fort Wayne		131		July, 2007		Owned
Lutheran Hospital		Fort Wayne		396		July, 2007		Owned
Lutheran Musculoskeletal Center		Fort Wayne		39		July, 2007		Owned
Lutheran Rehabilitation Hospital (rehabilitation)		Fort Wayne		36		July, 2007		Owned
St. Joseph’s Hospital		Fort Wayne		191		July, 2007		Owned
Dukes Memorial Hospital		Peru		25		July, 2007		Owned
Kosciusko Community Hospital		Warsaw		72		July, 2007		Owned
La Porte Hospital		La Porte		227		March, 2016		Owned
Starke Hospital		Knox		53		March, 2016		Leased
Louisiana
Northern Louisiana Medical Center		Ruston		151		April, 2007		Owned
Mississippi
Merit Health Wesley		Hattiesburg		211		July, 2007		Owned
Merit Health River Region		Vicksburg		361		July, 2007		Owned
Merit Health Biloxi		Biloxi		198		January, 2014		Leased
Merit Health Central		Jackson		319		January, 2014		Leased
Merit Health Rankin		Brandon		134		January, 2014		Leased
Merit Health Madison		Canton		67		January, 2014		Owned
Merit Health River Oaks		Flowood		160		January, 2014		Owned
Merit Health Woman’s Hospital		Flowood		109		January, 2014		Owned
Merit Health Natchez		Natchez		179		October, 2014		Owned
Northwest Mississippi Medical Center		Clarksdale		181		June, 2019		Leased
Missouri
Moberly Regional Medical Center		Moberly		99		November, 1993		Owned
Northeast Regional Medical Center		Kirksville		93		December, 2000		Leased
Poplar Bluff Regional Medical Center		Poplar Bluff		412		January, 2014		Owned
New Mexico
Eastern New Mexico Medical Center		Roswell		162		April, 1998		Owned
Carlsbad Medical Center		Carlsbad		99		July, 2007		Owned
Lea Regional Medical Center		Hobbs		115		July, 2007		Owned
Mountain View Regional Medical Center		Las Cruces		168		July, 2007		Owned
North Carolina
Lake Norman Regional Medical Center		Mooresville		123		January, 2014		Owned
Davis Regional Medical Center		Statesville		144		January, 2014		Owned

47

Hospital	City		Licensed   Beds(1)		Date of   Acquisition/Lease   Inception		Ownership     Type
Oklahoma
AllianceHealth Ponca City		Ponca City		140		May, 2006		Owned
AllianceHealth Woodward		Woodward		87		July, 2007		Leased
AllianceHealth Clinton		Clinton		56		January, 2014		Leased
AllianceHealth Madill		Madill		25		January, 2014		Leased
AllianceHealth Durant		Durant		148		January, 2014		Owned
AllianceHealth Midwest		Midwest City		255		January, 2014		Leased
AllianceHealth Seminole		Seminole		32		January, 2014		Leased
Pennsylvania
Commonwealth Health Network
Berwick Hospital		Berwick		90		March, 1999		Owned
Wilkes-Barre General Hospital		Wilkes-Barre		412		April, 2009		Owned
First Hospital Wyoming Valley (psychiatric)		Wilkes-Barre		193		April, 2009		Owned
Regional Hospital of Scranton		Scranton		186		May, 2011		Owned
Tyler Memorial Hospital		Tunkhannock		44		May, 2011		Owned
Moses Taylor Hospital		Scranton		213		January, 2012		Owned
Tennessee
Tennova Healthcare - Shelbyville		Shelbyville		60		July, 2005		Owned
Tennova Healthcare - Cleveland		Cleveland		351		October, 2005		Owned
Tennova Healthcare - Clarksville		Clarksville		270		July, 2007		Owned
Tennova Healthcare - Harton		Tullahoma		135		January, 2014		Owned
Tennova - Jefferson Memorial Hospital		Jefferson City		58		January, 2014		Leased
Tennova - LaFollette Medical Center		LaFollette		66		January, 2014		Leased
Tennova - Newport Medical Center		Newport		130		January, 2014		Owned
Tennova - North Knoxville Medical Center		Powell		108		January, 2014		Owned
Tennova - Turkey Creek Medical Center		Knoxville		111		January, 2014		Owned
Texas
Hill Regional Hospital		Hillsboro		25		October, 1994		Leased
Lake Granbury Medical Center		Granbury		73		January, 1997		Leased
Laredo Medical Center		Laredo		326		October, 2003		Owned
Abilene Regional Medical Center		Abilene		231		July, 2007		Owned
Brownwood Regional Medical Center		Brownwood		188		July, 2007		Owned
Navarro Regional Hospital		Corsicana		162		July, 2007		Owned
Longview Regional Medical Center		Longview		224		July, 2007		Owned
Woodland Heights Medical Center		Lufkin		149		July, 2007		Owned
San Angelo Community Medical Center		San Angelo		171		July, 2007		Owned
DeTar Healthcare System		Victoria		334		July, 2007		Owned
Cedar Park Regional Medical Center		Cedar Park		108		December, 2007		Owned
Virginia
Southern Virginia Regional Medical Center		Emporia		80		March, 1999		Owned
Southampton Memorial Hospital		Franklin		105		March, 2000		Owned
Southside Regional Medical Center		Petersburg		300		August, 2003		Owned

48

Hospital	City	Licensed   Beds(1)		Date of   Acquisition/Lease   Inception	Ownership     Type
West Virginia
Plateau Medical Center	Oak Hill		25	July, 2002		Owned
Greenbrier Valley Medical Center	Ronceverte		122	July, 2007		Owned
Total Licensed Beds at December 31, 2019			16,240
Total Hospitals at December 31, 2019			102

(1) Licensed beds are the number of beds for which the appropriate state agency licenses a facility regardless of whether the beds are actually available for patient use.

The real property of substantially all of our wholly-owned hospitals is also encumbered by mortgages to support obligations under the ABL facility and outstanding senior secured notes.

The following table lists the hospitals owned by joint venture entities in which we do not have a consolidating ownership interest, along with our percentage ownership interest in the joint venture entity as of December 31, 2019. Information on licensed beds was provided by the majority owner and manager of each joint venture. A subsidiary of HCA is the majority owner of Macon Healthcare LLC.

Joint Venture	Facility Name	City	State	Licensed     Beds
Macon Healthcare LLC	Coliseum Medical Center (38%)	Macon	GA	310
Macon Healthcare LLC	Coliseum Northside Hospital (38%)	Macon	GA	103

Item 3. Legal Proceedings

From time to time, we receive inquiries or subpoenas from state regulators, state Medicaid Fraud Control units, fiscal intermediaries, the Centers for Medicare and Medicaid Services, the Department of Justice and other government entities regarding various Medicare and Medicaid issues. In addition to the matters discussed below, we are currently responding to subpoenas and administrative demands concerning (a) an inquiry regarding sleep labs at two Louisiana hospitals (one formerly owned), (b) a subpoena related to certain services provided by a formerly-employed physician to Medicaid beneficiaries at one of our New Mexico hospitals, (c) an inquiry regarding certain services performed by one of our affiliated emergency services companies in Pennsylvania, (d) a civil investigative demand related to call coverage services provided by a cardiology group at one of our Tennessee hospitals; and (e) a civil investigative demand related to charges for certain emergency department services at our four New Mexico hospitals. In addition, we are subject to other claims and lawsuits arising in the ordinary course of our business including lawsuits and claims related to billing practices and the administration of charity care policies at our hospitals. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond our control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period. Settlements of suits involving Medicare and Medicaid issues routinely require both monetary payments as well as corporate integrity agreements. Additionally, qui tam or “whistleblower” actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act’s requirements for filing such suits. In September 2014, the Criminal Division of the United States Department of Justice, or DOJ, announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The Criminal Division has also frequently stated an intention to pursue corporations in criminal prosecutions. From time to time, we detect issues of non-compliance with Federal healthcare laws pertaining to claims submission and reimbursement practices

49

and/or financial relationships with physicians. We avail ourselves of various mechanisms to address potential overpayments arising out of these issues, including repayment of claims, rebilling of claims, and participation in voluntary disclosure protocols offered by the Centers for Medicare and Medicaid Services and the Office of the Inspector General. Participating in voluntary repayments and voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action.

The following legal proceedings are described in detail because, although they may not be required to be disclosed in this Part I, Item 3 under SEC rules, due to the nature of the business of the Company, we believe that the following discussion of these matters may provide useful information to security holders. This discussion does not include claims and lawsuits covered by medical malpractice, general liability or employment practices insurance and risk retention programs, none of which claims or lawsuits would in any event be required to be disclosed in this Part I, Item 3 under SEC rules. Certain of the matters referenced below are also discussed in Note 15 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K.

Shareholder Litigation

2011 Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of our common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for our common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on our motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint which was filed on October 5, 2015. Our motion to dismiss was filed on November 4, 2015 and oral argument took place on April 11, 2016. Our motion to dismiss was granted on June 16, 2016 and on June 27, 2016, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals. The matter was heard on May 3, 2017. On December 13, 2017, the Sixth Circuit reversed the trial court’s dismissal of the case and remanded it to the District Court. We filed a renewed partial motion to dismiss on February 9, 2018, which was denied by the District Court on September 24, 2018. We also filed a petition for writ of certiorari with the United States Supreme Court on April 18, 2018 seeking review of the Sixth Circuit’s decision. The United States Supreme Court denied the petition for a writ of certiorari on October 1, 2018. The District Court granted the Plaintiff’s motion for class certification on July 26, 2019. We filed a petition for permission to appeal the District Court’s class certification order in the Sixth Circuit Court of Appeals on August 9, 2019, and that petition was denied on October 23, 2019. On January 21, 2020, the Company and the Plaintiff filed a stipulation of settlement indicating to the District Court that the parties had reached agreement on the principal terms of a settlement for $53 million. The proposed settlement agreement is subject to the District Court’s final approval. We recorded a liability of $53 million at December 31, 2019, based on the proposed settlement agreement.

Caleb Padilla, individually and on behalf of all others similarly situated v Community Health Systems, Inc., Wayne T. Smith, Larry Cash, and Thomas J. Aaron. This purported federal securities class action was filed in the United States District Court for the Middle District of Tennessee on May 30, 2019. It seeks class certification on behalf of purchasers of our common stock between February 20, 2017 and February 27, 2018 and alleges misleading statements resulted in artificially inflated prices for our common stock. On November 20, 2019, the District Court appointed Arun Bhattacharya and Michael Gaviria as lead plaintiffs in the case. The lead plaintiffs filed a consolidated class complaint on January 21, 2020. The deadline for the Company’s response to the consolidated class complaint is March 20, 2020. We believe this matter is without merit and will vigorously defend this case.

Padilla Derivative Litigation. Four purported shareholder derivative cases have been filed in two District Courts relating to the factual allegations in the Padilla litigation; namely, Faisal Hussain v. Wayne T. Smith, et al, filed August 12, 2019 in the United States District Court for the District of Delaware; Roger Trombley v.

50

Wayne T. Smith, et al, filed August 20, 2019 in the United States District Court for the Middle District of Tennessee; Susheel Tanjavoor v. Wayne T. Smith, et al., filed August 29, 2019, in the United States District Court for the District of Delaware; and Roofers Local No. 149 Pension Fund v. John A. Clerico, et al, filed October 30, 2019, in the United States District Court for the District of Delaware. All four seek relief derivatively and on behalf of Community Health Systems, Inc. against certain Company officers and directors based on alleged breaches of fiduciary duty, unjust enrichment, and other acts related to certain Company disclosures in 2017 and 2018 regarding the Company’s adoption of Accounting Standards Update 2014-09, which the Company adopted effective January 1, 2018. All four cases have been stayed by agreement.

Section 220 Demand. On September 19, 2019, the Company received a demand from Kevin Aronson, a Company shareholder, purporting to demand inspection of certain Company books and records pursuant to Title 8, Section 220 of the Delaware General Corporation Law Code. The alleged grounds for Mr. Aronson’s demand are similar to the allegations in both the Padilla and Padilla derivative litigation. The Company has provided a response to Mr. Aronson’s demand.

Other Government Investigations

Florida LIP Program CIDs – On September 14, 2017, our hospital in St. Petersburg, Florida received a CID from the United States Department of Justice for information concerning its historic participation in the Florida Low Income Pool Program. The Low Income Pool Program, or LIP, is a funding pool to support healthcare providers that provide uncompensated care to Florida residents who are uninsured or underinsured. The CID sought documentation related to agreements between the hospital and Pinellas County. On June 13, 2019, an additional ten of our affiliated hospitals in Florida received CIDs related to the same subject matter, along with two CIDs addressed to our affiliated management company and the parent company. We are cooperating fully with this investigation.

Commercial Litigation and Other Lawsuits

Becker v. Community Health Systems, Inc. d/b/a Community Health Systems Professional Services Corporation d/b/a Community Health Systems d/b/a Community Health Systems PSC, Inc. d/b/a Rockwood Clinic P.S. and Rockwood Clinic, P.S. (Superior Court, Spokane, Washington). This suit was filed on February 29, 2012, by a former chief financial officer at Rockwood Clinic in Spokane, Washington. Becker claims he was wrongfully terminated for allegedly refusing to certify a budget for Rockwood Clinic in 2012. On February 29, 2012, he also filed an administrative complaint with the Department of Labor, Occupational Safety and Health Administration alleging that he is a whistleblower under Sarbanes-Oxley, which was dismissed by the agency and was appealed to an administrative law judge for a hearing that occurred on January 19-26, 2016. In a decision dated November 9, 2016, the law judge awarded Becker approximately $1.9 million for front pay, back pay and emotional damages with attorney fees to be later determined. We have appealed the award to the Administrative Review Board and are awaiting its decision. At a hearing on July 27, 2012, the trial court dismissed Community Health Systems, Inc. from the state case and subsequently certified the state case for an interlocutory appeal of the denial to dismiss his employer and the management company. The appellate court accepted the interlocutory appeal, and it was argued on April 30, 2014. On August 14, 2014, the court denied our appeal. On October 20, 2014, we filed a petition to review the denial with the Washington Supreme Court. Our appeal was accepted and oral argument was heard on June 9, 2015. On September 15, 2015, the court denied our appeal and remanded to the trial court; a previous trial setting of September 12, 2016 has been vacated and not reset. On October 15, 2019, the Administrative Review Board released an order to show cause requiring Becker to file a brief to show cause why the Administrative Review Board should not remand the previous administrative decision for a new hearing before a new law judge. The appeal before the Administrative Review Board is still pending. We continue to vigorously defend these actions.

Cyber Attack. As previously disclosed on a Current Report on Form 8-K filed by us on August 18, 2014, our computer network was the target of an external, criminal cyber-attack that we believe occurred between April and June, 2014. We and Mandiant (a FireEye Company), the forensic expert engaged by us in connection with

51

this matter, believe the attacker was a foreign “Advanced Persistent Threat” group who used highly sophisticated malware and technology to attack our systems. The attacker was able to bypass our security measures and successfully copy and transfer outside the Company certain non-medical patient identification data (such as patient names, addresses, birthdates, telephone numbers and social security numbers), but not including patient credit card, medical or clinical information. We worked closely with federal law enforcement authorities in connection with their investigation and prosecution of those determined to be responsible for this attack. Mandiant has conducted a thorough investigation of this incident and continues to advise us regarding security and monitoring efforts. We have provided appropriate notification to affected patients and regulatory agencies as required by federal and state law. We have offered identity theft protection services to individuals affected by this attack.

All class actions and litigation filed related to the data breach have been resolved. We are still responding to two government investigations related to the 2014 cyber-attack. The first is being conducted by various State Attorneys General, and the second is being conducted by the U.S. Department of Health and Human Services Office for Civil Rights. We are cooperating fully with both investigations.

Empire Health Foundation v. CHS/Community Health Systems, Inc., CHS Washington Holdings, LLC, Spokane Washington Hospital Company, LLC, Spokane Valley Washington Hospital Company, LLC. This suit was filed in the United States District Court for the Eastern District of Washington on June 12, 2017 by Empire Health Foundation claiming Deaconess and Valley Hospitals failed to abide by charity care obligations allegedly existing in the 2008 Asset Purchase Agreement between Empire Health System and Company affiliates. The court granted in part and denied in part the hospitals’ motion to dismiss on October 11, 2017. All parties filed motions for summary judgment, and the court granted in part and denied in part both parties’ motions on February 27, 2019 and July 9, 2019. We settled this matter during the three months ended September 30, 2019 for $22 million (and recorded a liability equal to the settlement amount as of September 30, 2019) and the settlement was paid during the three months ended December 31, 2019.

Gibson, individually and on behalf of all others similarly situated v. National Healthcare of Leesville, Inc. d/b/a Byrd Regional Medical Center. This case is a purported class action lawsuit filed in the 30^th Judicial District Court for the State of Louisiana and served on August 3, 2016, claiming our formerly affiliated Leesville, Louisiana hospital violated payor contracts by allegedly improperly asserting hospital liens against third-party tortfeasors and seeking class certifications for any similarly situated plaintiffs. The court has certified a class and denied our motion for summary judgment. We appealed both rulings to the Louisiana Third Circuit Court of Appeals, which affirmed the trial court’s decisions on March 7, 2019. We filed an application for writ of certiorari to the Louisiana Supreme Court, which was denied on May 29, 2019. Plaintiff’s motion for approval of notice of class action was granted on October 24, 2019. We believe these claims are without merit and will vigorously defend the case.

Bowden, individually and on behalf of all others similarly situated v. Ruston Louisiana Hospital Company, LLC d/b/a Northern Louisiana Medical Center. This case is a purported class action lawsuit filed in the 3^rd Judicial District Court for the State of Louisiana and served on September 7, 2016, claiming our affiliated Ruston, Louisiana hospital violated payor contracts by allegedly improperly asserting hospital liens against third-party tortfeasors and seeking class certifications for any similarly situated plaintiffs. Our motion for summary judgment is pending, as is plaintiff’s motion for class certification. We believe these claims are without merit and will vigorously defend the case.

Zwick Partners, LP and Aparna Rao, individually and on behalf of all others similarly situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller, and Michael J. Culotta. This purported class action lawsuit previously filed in the United States District Court, Middle District of Tennessee was amended on April 17, 2017 to include Community Health Systems, Inc., Wayne T. Smith and W. Larry Cash as additional defendants. The plaintiffs seek to represent a class of Quorum Health Corporation, or QHC, shareholders and allege that the failure to record a goodwill and long-lived asset impairment charge against QHC at the time of the spin-off of QHC violated federal securities laws. The District

52

Court denied all defendants’ motions to dismiss on April 20, 2018. The plaintiffs moved for class certification. Plaintiffs also amended their complaint on September 14, 2018. We moved to dismiss the additional claims in the plaintiffs’ September 14, 2018 amended complaint and responded to plaintiffs’ class certification motion. On March 29, 2019, the court granted our motion to dismiss the additional claims. The court granted the plaintiffs’ motion for class certification on that same date. On April 12, 2019, we filed a petition for permission to appeal the court’s order granting class certification with the United States Court of Appeals for the Sixth Circuit, which was denied on July 31, 2019. On May 17, 2019, the plaintiffs moved to amend their complaint for a third time to add additional claims, which the District Court denied on August 2, 2019. The trial for this matter is set for July 7, 2020. We believe the claims are without merit and will vigorously defend the case.

R2 Investments v Quorum Health Corporation; Community Health Systems, Inc.; Wayne T. Smith; W. Larry Cash; Thomas D. Miller; Michael J. Culotta; John A. Clerico; James S. Ely, III; John A. Fry; William Norris Jennings; Julia B. North; H. Mitchell Watson, Jr.; H. James Williams. This case was pending in the Circuit Court for Williamson County, Tennessee and was served on October 26, 2017. The plaintiff alleged common law fraud and violation of Tennessee securities fraud statutes in connection with its purchase of QHC stock and QHC senior secured notes. The court granted in part and denied in part the director defendants’ motion to dismiss and denied the remaining defendants’ motions to dismiss on May 11, 2018. The Company settled and paid this matter during the three months ended December 31, 2019.

Steadfast Insurance Company, et al v. Community Health Systems, Inc., CHS/Community Health Systems, Inc., CHSPSC, LLC and Pecos Valley of New Mexico, LLC. This case is filed in the Superior Court for the State of Delaware and involve suits by four excess liability insurers seeking a declaration that a $73 million judgment rendered against Pecos Valley of New Mexico, LLC in Anne Sperling, et al v. Pecos Valley of New Mexico, LLC is not a covered loss as defined by the policies at issue. The Steadfast complaint was served on November 30, 2018. On December 13, 2018, Admiral Insurance Company, Endurance Specialty Insurance Ltd, and Illinois Union Insurance Company moved to intervene in the suit as petitioners. The Company has initiated counterclaims against each insurer, including for bad faith against Steadfast. The judgment against Pecos Valley of New Mexico, LLC, which is the subject of this litigation and which was rendered on September 5, 2018, in First Judicial Court of the State of New Mexico, is currently on appeal to the Court of Appeals of New Mexico. Trial of this matter is set for December 7, 2020. We believe the claims in the Steadfast litigation are without merit and will vigorously defend the case.

Becky Kirk, Perry Ayoob, and Dawn Karzenoski, as representatives of a class of similarly situated persons, and on behalf of the CHS/Community Health Systems, Inc. Retirement Savings Plan v. Retirement Committee of CHS/Community Health Systems, Inc., John and Jane Does 1-20, Principal Life Insurance Company, Principal Management Corporation, and Principal Global Investors, LLC. This purported class action was filed in the United States District Court for the Middle District of Tennessee on August 8, 2019. The plaintiffs seek to represent a class of current and former participants in the CHS/Community Health Systems, Inc. Retirement Savings Plan and allege that the defendants breached their fiduciary duties by offering certain investments in the Plan that were more expensive and/or did not perform as well as other marketplace alternatives. We filed a motion to dismiss the complaint on October 18, 2019, which is pending. We believe these claims are without merit and will vigorously defend the case.

Qui Tam Matters Where the Government Declined Intervention

U.S. and the State of Mississippi ex rel. W. Blake Vanderlan, M.D. v. Jackson HMA, LLC d/b/a Central Mississippi Medical Center and Merit Health Central. By order filed on August 31, 2017, the United States District Court for the Southern District of Mississippi ordered the unsealing of this qui tam suit. The unsealing revealed that on August 31, 2017 the United States had declined to intervene in the allegations that certain alleged EMTALA violations at the hospital resulted in a violation of the False Claims Act. Both the hospital and the United States have filed motions to dismiss the litigation, and those motions are pending. We believe this matter is without merit and will vigorously defend this case.

53

U.S. ex rel. Derek Lewis and Joey Neiman v. Community Health Systems, Inc., Medhost, Inc., et al. By order filed on March 14, 2019, the United States District Court for the Southern District of Florida ordered the unsealing of this qui tam suit. The order revealed that the United States had declined to intervene in the action. The complaint alleges that Community Health Systems, Inc. and its affiliated hospitals (CHS Hospitals) violated the False Claims Act by submitting claims for EHR Meaningful Use incentive payments that they knew or should have known were false. The allegations regarding falsity generally relate to the CHS Hospitals’ use of certain software products sold to them by co-defendant, Medhost, Inc. The plaintiffs amended their complaint on July 26, 2019. We filed a motion to dismiss the complaint on September 24, 2019, which is pending. We believe this matter is without merit and will vigorously defend this case.

U.S. ex rel. Maur v. Elie Hage-Korban, M.D., Delta Clinics, PLC d/b/a The Heart and Vascular Center of West Tennessee. Community Health Systems, Inc., Knoxville HMA Holdings, LLC d/b/a/ Tennova Healthcare, Jackson Hospital Corporation d/b/a/ Regional Jackson, and Dyersburg Hospital Company, LLC, d/b/ Dyersburg Regional Medical Center. By order filed on April 30, 2019, the United States District Court for the Western District of Tennessee ordered the unsealing of this qui tam lawsuit. The order revealed that the United States had declined to intervene in the action. The complaint alleges the defendants violated the False Claims Act by submitting claims for payment related to certain cardiac procedures performed by defendant Dr. Elie Hage-Korban at two hospitals formerly affiliated with the Company. Dr. Hage-Korban was not employed by either hospital or their affiliates. The plaintiff amended his complaint on July 24, 2019. We filed a motion to dismiss the complaint on September 30, 2019, which is pending. We believe this matter is without merit and will vigorously defend this case.

Management of Significant Legal Proceedings

In accordance with our governance documents, including our Governance Guidelines and the charter of the Audit and Compliance Committee, our management of significant legal proceedings is overseen by the independent members of the Board of Directors and, in particular, the Audit and Compliance Committee. The Audit and Compliance Committee is charged with oversight of compliance, regulatory and litigation matters, and enterprise risk management. Management has been instructed to refer all significant legal proceedings and allegations of financial statement fraud, error, or misstatement to the Audit and Compliance Committee for its oversight and evaluation. Consistent with New York Stock Exchange and Sarbanes-Oxley independence requirements, the Audit and Compliance Committee is comprised entirely of individuals who are independent of our management, and all four members of the Audit and Compliance Committee are “audit committee financial experts” as defined in the Securities Exchange Act of 1934, as amended.

In addition, the Audit and Compliance Committee and the other independent members of the Board of Directors oversee the functions of the voluntary compliance program, including its auditing and monitoring functions and confidential disclosure program. In recent years, the voluntary compliance program has addressed the potential for a variety of billing errors that might be the subject of audits and payment denials by the CMS Recovery Audit Contractors’ permanent project, including MS-DRG coding, outpatient hospital and physician coding and billing, and medical necessity for services (including a focus on hospital stays of very short duration). Efforts by management, through the voluntary compliance program, to identify and limit risk from these government audits have included significant policy and guidance revisions, training and education, and auditing. The Board of Directors now oversees and reviews periodic reports of our compliance with the Corporate Integrity Agreement, or CIA, that we entered into with the United States Department of Health and Human Services Office of the Inspector General during 2014 and which was amended and extended in September 2018.

Item 4. Mine Safety Disclosures

Not applicable.

54

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

We completed an initial public offering of our common stock on June 14, 2000. Our common stock began trading on June 9, 2000 and is listed on the New York Stock Exchange under the symbol CYH. As of February 18, 2020, there were approximately 197 holders of record of our common stock.

Stock Performance Graph

The following graph sets forth the cumulative return of our common stock during the five year period ended December 31, 2019, as compared to the cumulative return of the Standard & Poor’s 500 Stock Index (S&P 500) and the cumulative return of the Dow Jones Healthcare Index. The graph assumes an initial investment of $100 in our common stock and in each of the foregoing indices and the reinvestment of dividends where applicable. The comparisons in the graph below are based on historical data and are not indicative of, or intended to forecast, future performance of our common stock. The market price of our common stock used to calculate the cumulative return has been adjusted in prior periods for the impact of the April 2016 QHC spin-off and related distribution of QHC common stock to our stockholders.

COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN

Among Community Health Systems, Inc., the S&P 500 Index, and the Dow Jones US Health Care Index

We are a holding company which operates through our subsidiaries. The ABL Facility and the indentures governing the senior and senior secured notes contain various covenants under which the assets of our subsidiaries are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.

The ABL Facility and the indentures governing each series of our outstanding notes restrict our subsidiaries from, among other matters, paying dividends and making distributions to us, which thereby limits our ability to

55

pay dividends and/or repurchase stock. As of December 31, 2019, under the most restrictive test in these agreements (and subject to certain exceptions), we have approximately $200 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments.

The following table contains information about our purchases of common stock during the three months ended December 31, 2019.

Period	Total Number of Shares Purchased (a)		Average Price Paid   per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (b)		Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (b)
October 1, 2019 - October 31, 2019		14,136	$	3.73		-		-
November 1, 2019 - November 30, 2019		-		-		-		-
December 1, 2019 - December 31, 2019		26,372		3.62		-		-
Total		40,508	$	3.66		-		-

(a) Includes 40,508 shares were withheld by us to satisfy the payment of tax obligations related to the vesting of restricted stock awards.

(b) We had no publicly announced plans or open market repurchase programs for shares of our common stock during the three months ended December 31, 2019.

56

Item 6. Selected Financial Data

The following table summarizes specified selected financial data and should be read in conjunction with our related Consolidated Financial Statements and accompanying Notes to Consolidated Financial Statements.

Community Health Systems, Inc.

Five Year Summary of Selected Financial Data

	Year Ended December 31,
	2019			2018			2017			2016			2015
	(in millions, except share and per share data)
Consolidated Statement of (Loss) Income Data
Net operating revenues	$	13,210		$	14,155		$	15,353		$	18,438		$	19,437
Income (loss) from operations		650			208			(1,878	)		(860	)		1,337
(Loss) income from continuing operations		(590	)		(704	)		(2,384	)		(1,611	)		295
Net (loss) income		(590	)		(704	)		(2,396	)		(1,626	)		259
Net income attributable to noncontrolling interests		85			84			63			95			101
Net (loss) income attributable to Community Health Systems, Inc. stockholders		(675	)		(788	)		(2,459	)		(1,721	)		158
Basic (loss) earnings per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(5.93	)	$	(6.99	)	$	(21.89	)	$	(15.41	)	$	1.69
Discontinued operations		–			–			(0.11	)		(0.13	)		(0.31	)
Net (loss) income	$	(5.93	)	$	(6.99	)	$	(22.00	)	$	(15.54	)	$	1.38
Diluted (loss) earnings per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(5.93	)	$	(6.99	)	$	(21.89	)	$	(15.41	)	$	1.68
Discontinued operations		–			–			(0.11	)		(0.13	)		(0.31	)
Net (loss) income	$	(5.93	)	$	(6.99	)	$	(22.00	)	$	(15.54	)	$	1.37
Weighted-average number of shares outstanding:
Basic		113,739,046			112,728,274			111,769,821			110,730,971			114,454,674
Diluted (2)		113,739,046			112,728,274			111,769,821			110,730,971			115,272,404
Consolidated Balance Sheet Data
Cash and cash equivalents	$	216		$	196		$	563		$	238		$	184
Total assets (3)		15,609			15,859			17,450			21,944			26,595
Long-term obligations (3)		14,966			14,426			15,259			16,775			18,847
Redeemable noncontrolling interests in equity of consolidated subsidiaries		502			504			527			554			571
Community Health Systems, Inc. stockholders’ (deficit) equity		(2,218	)		(1,535	)		(767	)		1,615			4,019
Noncontrolling interests in equity of consolidated subsidiaries		77			72			75			113			86

(1) Total per share amounts may not add due to rounding.

(2) See Note 12 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K.

(3) See Note 9 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K regarding the adoption of Accounting Standards Codification Topic 842, or ASC 842, effective January 1, 2019.

57

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read this discussion together with our Consolidated Financial Statements and the accompanying Notes to Consolidated Financial Statements and “Selected Financial Data” included elsewhere in this Form 10-K.

Executive Overview

We are one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals and outpatient facilities in communities across the country. We provide healthcare services through the hospitals that we own and operate and affiliated businesses in non-urban and selected urban markets throughout the United States. We generate revenues by providing a broad range of general and specialized hospital healthcare services and outpatient services to patients in the communities in which we are located. As of December 31, 2019, we owned or leased 102 hospitals, comprised of 100 general acute care hospitals and two stand-alone rehabilitation or psychiatric hospitals. For the hospitals that we own and operate, we are paid for our services by governmental agencies, private insurers and directly by the patients we serve.

We have been implementing a portfolio rationalization and deleveraging strategy by divesting hospitals and non-hospital businesses that are attractive to strategic and other buyers. Generally, these businesses are not in one of our strategically beneficial service areas, are less complementary to our business strategy and/or have lower operating margins. In connection with our announced divestiture initiative, we have received offers from strategic buyers to buy certain of our assets. After considering these offers, we have divested and expect to continue to divest, hospitals and non-hospital businesses when we find such offers to be attractive and in line with our operating strategy.

Completed Divestiture and Acquisition Activity

During 2019, we completed the divestiture of 12 hospitals, including two hospitals the divestitures of which closed effective January 1, 2019 (for these hospitals, we received the net proceeds at a preliminary closing on December 31, 2018). These 12 hospitals represented annual net operating revenues in 2018 of approximately $1.1 billion and, excluding the net proceeds for the two hospitals that preliminarily closed on December 31, 2018, we received total net proceeds of approximately $335 million in connection with the disposition of these hospitals. In addition, we completed the divestiture of three hospitals on January 1, 2020 (discussed below) for which we received net proceeds of approximately $240 million at a preliminary closing on December 31, 2019.

During 2018, we completed the divestiture of 11 hospitals. These 11 hospitals represented annual net operating revenues in 2017 of approximately $950 million and, including the net proceeds for the two additional hospitals that preliminarily closed on December 31, 2018 noted above, we received total net proceeds of approximately $405 million in connection with the disposition of these hospitals.

During 2017, we completed the divestiture of 30 hospitals included in continuing operations. These 30 hospitals represented annual net operating revenues in 2016 of approximately $3.4 billion, and we received total net proceeds of approximately $1.7 billion in connection with the disposition of these hospitals.

The following table provides a summary of hospitals included in continuing operations that we divested during the years ended December 31, 2019, 2018 and 2017:

Hospital	Buyer	City, State		Licensed Beds		Effective Date
2019 Divestitures:
Bluefield Regional Medical Center	Princeton Community Hospital Association		Bluefield, WV		92		October 1, 2019
Lake Wales Medical Center	Adventist Health System		Lake Wales, FL		160		September 1, 2019
Heart of Florida Regional Medical Center	Adventist Health System		Davenport, FL		193		September 1, 2019

58

Hospital	Buyer	City, State	Licensed Beds		Effective Date
College Station Medical Center	St. Joseph Regional Health Center	College Station, TX		167	August 1, 2019
Tennova Healthcare – Lebanon	Vanderbilt University Medical Center	Lebanon, TN		245	August 1, 2019
Chester Regional Medical Center	Medical University Hospital Authority	Chester, SC		82	March 1, 2019
Carolinas Hospital System – Florence	Medical University Hospital Authority	Florence, SC		396	March 1, 2019
Springs Memorial Hospital	Medical University Hospital Authority	Lancaster, SC		225	March 1, 2019
Carolinas Hospital System – Marion	Medical University Hospital Authority	Mullins, SC		124	March 1, 2019
Memorial Hospital of Salem County	Community Healthcare Associates, LLC	Salem, NJ		126	January 31, 2019
Mary Black Health System – Spartanburg	Spartanburg Regional Healthcare System	Spartanburg, SC		207	January 1, 2019
Mary Black Health System – Gaffney	Spartanburg Regional Healthcare System	Gaffney, SC		125	January 1, 2019
2018 Divestitures:
Sparks Regional Medical Center	Baptist Health	Fort Smith, AR		492	November 1, 2018
Sparks Medical Center – Van Buren	Baptist Health	Van Buren, AR		103	November 1, 2018
AllianceHealth Deaconess	INTEGRIS Health	Oklahoma City, OK		238	October 1, 2018
Munroe Regional Medical Center	Adventist Health System	Ocala, FL		425	August 1, 2018
Tennova Healthcare – Dyersburg Regional	West Tennessee Healthcare	Dyersburg, TN		225	June 1, 2018
Tennova Healthcare – Regional Jackson	West Tennessee Healthcare	Jackson, TN		150	June 1, 2018
Tennova Healthcare – Volunteer Martin	West Tennessee Healthcare	Martin, TN		100	June 1, 2018
Williamson Memorial Hospital	Mingo Health Partners, LLC	Williamson, WV		76	June 1, 2018
Byrd Regional Hospital	Allegiance Health Management	Leesville, LA		60	June 1, 2018
Tennova Healthcare – Jamestown	Rennova Health, Inc.	Jamestown, TN		85	June 1, 2018
Bayfront Health Dade City	Adventist Health System	Dade City, FL		120	April 1, 2018
2017 Divestitures:
Highlands Regional Medical Center	HCA	Sebring, FL		126	November 1, 2017
Merit Health Northwest Mississippi	Curae Health, Inc.	Clarksdale, MS		181	November 1, 2017
Weatherford Regional Medical Center	HCA	Weatherford, TX		103	October 1, 2017
Brandywine Hospital	Reading Health System	Coatesville, PA		169	October 1, 2017
Chestnut Hill Hospital	Reading Health System	Philadelphia, PA		148	October 1, 2017

59

Hospital	Buyer	City, State	Licensed Beds		Effective Date
Jennersville Hospital	Reading Health System	West Grove, PA		63	October 1, 2017
Phoenixville Hospital	Reading Health System	Phoenixville, PA		151	October 1, 2017
Pottstown Memorial Medical Center	Reading Health System	Pottstown, PA		232	October 1, 2017
Yakima Regional Medical and Cardiac Center	Regional Health	Yakima, WA		214	September 1, 2017
Toppenish Community Hospital	Regional Health	Toppenish, WA		63	September 1, 2017
Memorial Hospital of York	PinnacleHealth System	York, PA		100	July 1, 2017
Lancaster Regional Medical Center	PinnacleHealth System	Lancaster, PA		214	July 1, 2017
Heart of Lancaster Regional Medical Center	PinnacleHealth System	Lititz, PA		148	July 1, 2017
Carlisle Regional Medical Center	PinnacleHealth System	Carlisle, PA		165	July 1, 2017
Tomball Regional Medical Center	HCA	Tomball, TX		350	July 1, 2017
South Texas Regional Medical Center	HCA	Jourdanton, TX		67	July 1, 2017
Deaconess Hospital	MultiCare Health System	Spokane, WA		388	July 1, 2017
Valley Hospital	MultiCare Health System	Spokane Valley, WA		123	July 1, 2017
Lake Area Medical Center	CHRISTUS Health	Lake Charles, LA		88	June 30, 2017
Easton Hospital	Steward Health, Inc.	Easton, PA		196	May 1, 2017
Sharon Regional Health System	Steward Health, Inc.	Sharon, PA		258	May 1, 2017
Northside Medical Center	Steward Health, Inc.	Youngstown, OH		355	May 1, 2017
Trumbull Memorial Hospital	Steward Health, Inc.	Warren, OH		311	May 1, 2017
Hillside Rehabilitation Hospital	Steward Health, Inc.	Warren, OH		69	May 1, 2017
Wuesthoff Health System – Rockledge	Steward Health, Inc.	Rockledge, FL		298	May 1, 2017
Wuesthoff Health System – Melbourne	Steward Health, Inc.	Melbourne, FL		119	May 1, 2017
Sebastian River Medical Center	Steward Health, Inc.	Sebastian, FL		154	May 1, 2017
Stringfellow Memorial Hospital	The Health Care Authority of the City of Anniston	Anniston, AL		125	May 1, 2017
Merit Health Gilmore Memorial	Curae Health, Inc.	Amory, MS		95	May 1, 2017
Merit Health Batesville	Curae Health, Inc.	Batesville, MS		112	May 1, 2017

On January 1, 2020, we completed the sale of Southside Regional Medical Center (300 licensed beds) in Petersburg, Virginia, Southampton Memorial Hospital (105 licensed beds) in Franklin, Virginia and Southern Virginia Regional Medical Center (80 licensed beds) in Emporia, Virginia and their associated assets to Bon Secours Mercy Health System pursuant to the terms of a definitive agreement which was entered into October 28, 2019. The net proceeds from this sale were received at a preliminary closing on December 31, 2019.

On January 30, 2020, we entered into definitive agreements for the sale of substantially all of the assets of each of Shands Live Oak Regional Medical Center (25 licensed beds) in Live Oak, Florida and Shands Starke Regional Medical Center (49 licensed beds) in Starke, Florida to affiliates of HCA.

60

In addition to the divestiture of these hospitals in 2017, 2018 and 2019 as noted above, we continue to receive interest from potential buyers for certain of our hospitals. We intend to continue our portfolio rationalization strategy through at least mid-2020 and are pursuing additional sale transactions, which are currently in various stages of negotiation with potential buyers. There can be no assurance that any or all of the potential divestitures that we are currently targeting (or the potential divestitures currently subject to definitive agreements) will be completed, or if they are completed, the ultimate timing of the completion of these divestitures or the aggregate amount of proceeds we will receive from the divestitures. We expect to use proceeds from divestitures to reduce debt and/or reinvest in our facilities to strengthen our regional networks and local market operations.

On June 1, 2019, we completed the acquisition of Northwest Mississippi Medical Center in Clarksdale, Mississippi. This healthcare system includes 181 licensed beds and other outpatient and ancillary services. The total cash consideration paid for operating assets was approximately $2 million, with additional consideration of $9 million in assumed liabilities, for a total consideration of $11 million. This hospital was acquired in conjunction with the bankruptcy proceedings of the previous owner that acquired the hospital from us in 2017 as part of an agreement with the local county government associated with its lease of the hospital building. Based on our final purchase price allocation relating to this acquisition as of September 30, 2019, no goodwill has been recorded. Prior to the completion of the acquisition, we initiated a plan to sell this hospital and as such have classified this hospital as held for sale at December 31, 2019.

On September 19, 2019, we completed the sale and leaseback of four medical office buildings for net proceeds of $56 million to Carter Validus Mission Critical REIT II, Inc. The buildings, with a combined total of 285,337 square feet, are located in three states and support a wide array of diagnostic, medical and surgical services in an outpatient setting for the respective nearby hospitals. Based on our assessment of the control transfer principle in these leased buildings, the transaction does not qualify for sale treatment and the related leases have been recorded as financing obligations in long-term debt in the accompanying consolidated balance sheet at December 31, 2019. In addition, on December 18, 2019, we completed the sale and leaseback of one medical office building for net proceeds of approximately $4 million to an affiliate of Catalyst Healthcare Real Estate. The 30,000 square foot building is located in Arkansas and supports a wide array of diagnostic, medical and surgical services in an outpatient setting for the nearby hospital. Based on our assessment of the control transfer principle in this leased building, the transaction does not qualify for sale treatment and the related lease has been recorded as a financing obligation in long-term debt in the accompanying consolidated balance sheet at December 31, 2019.

During the year ended December 31, 2019, we paid approximately $8 million to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by our hospitals.

Overview of Operating Results

Our net operating revenues for the year ended December 31, 2019 decreased $945 million to approximately $13.2 billion compared to approximately $14.2 billion for the year ended December 31, 2018, primarily as a result of hospitals divested during 2018 and 2019. On a same-store basis, net operating revenues for the year ended December 31, 2019 increased $518 million.

We had a loss from continuing operations of $590 million during the year ended December 31, 2019, compared to loss from continuing operations of $704 million for the year ended December 31, 2018. Loss from continuing operations for the year ended December 31, 2019 included the following:

• an after-tax charge of $73 million for government and other legal settlements and related costs,

• an after-tax charge of $1 million for employee termination benefits and other restructuring costs,

• an after-tax charge of $16 million to reserve the outstanding balance of a promissory note outstanding that was received as part of the purchase price from the sale of two hospitals in 2017, net of income from

61

a reduction of the valuation allowance on the outstanding balance of a promissory note from the buyer of another hospital,

• an after-tax charge of $42 million for loss from early extinguishment of debt,

• an after-tax charge of $71 million for a change in estimate for professional liability claims accrual, which charge resulted from a revision to the estimate for professional liability claims accrual related to claims incurred in 2016 and prior years,

• an after-tax charge of $101 million for the impairment of goodwill and long-lived assets of hospitals sold or held for sale based on their estimated fair values,

• an after-tax charge of $9 million for legal expenses related to the final global resolution and settlement of certain HMA legal proceedings entered into with the U.S. Department of Justice in the three months ended September 30, 2018, or the HMA Legal Matters,

• a discrete tax expense of approximately $275 million due to an increase in the valuation allowance recognized on (i) IRC Section 163(j) interest carryforwards and (ii) original issue discount deferred tax asset generated with the 2019 Exchange Offer, and

• a discrete tax benefit of $15 million for tax credits claimed in lieu of deductions for the HMA Legal Matters.

Loss from continuing operations for the year ended December 31, 2018 included the following:

• an after-tax charge of $8 million for government and other legal settlements and related costs

• an after-tax charge of $526 million for the impairment of goodwill and long-lived assets of hospitals sold or held for sale based on their estimated fair values,

• an after-tax charge of $15 million for employee termination benefits and other restructuring costs,

• after-tax income of $23 million for gain from early extinguishment of debt,

• an after-tax charge of $10 million from fair value adjustments on the CVR agreement liability accounted for at fair value related to the HMA Legal Matters, and related legal expenses, and

• a deferred tax provision of $34 million related to the write-off of deferred tax assets due to the nondeductible components of the HMA Legal Matters.

Consolidated inpatient admissions for the year ended December 31, 2019, decreased 11.1%, compared to the year ended December 31, 2018, and consolidated adjusted admissions for the year ended December 31, 2019, decreased 10.6%, compared to the year ended December 31, 2018. Same-store inpatient admissions for the year ended December 31, 2019, increased 1.3%, compared to the year ended December 31, 2018, and same-store adjusted admissions for the year ended December 31, 2019, increased 2.2%, compared to the year ended December 31, 2018.

Self-pay revenues represented approximately 1.0% and 1.4% of net operating revenues for the years ended December 31, 2019 and 2018, respectively. The amount of foregone revenue related to providing charity care services as a percentage of net operating revenues was approximately 4.1% and 3.5% for the years ended December 31, 2019 and 2018, respectively. Direct and indirect costs incurred in providing charity care services as a percentage of net operating revenues was approximately 0.5% and 0.4% for the years ended December 31, 2019 and 2018, respectively.

62

Legislative Overview

The U.S. Congress and certain state legislatures have introduced and passed a large number of proposals and legislation designed to make major changes in the healthcare system, including changes that have increased access to health insurance. The most prominent of these recent efforts, the Affordable Care Act, affected how healthcare services are covered, delivered and reimbursed. The Affordable Care Act increased health insurance coverage through a combination of public program expansion and private sector health insurance reforms and mandated that substantially all U.S. citizens maintain health insurance. The Affordable Care Act also made a number of changes to Medicare and Medicaid, such as a productivity offset to the Medicare market basket update and reductions to the Medicare and Medicaid DSH payments.

However, the future of the Affordable Care Act is uncertain. Since the 2016 presidential election, significant changes have been made to the Affordable Care Act, its implementation, and its interpretation, and the current presidential administration and certain members of Congress have stated their intent to repeal or make additional significant changes to the law. For example, final rules issued in 2018 expand availability of association health plans and allow the sale of short-term, limited-duration health plans, neither of which are required to cover all of the essential health benefits mandated by the Affordable Care Act. Additionally, effective January 1, 2019, the financial penalty associated with the individual mandate was eliminated as part of the tax reform legislation that was enacted in December 2017. In December 2018, as a result of this change, a federal judge in Texas found the individual mandate unconstitutional and determined the rest of the Affordable Care Act was therefore invalid. In December 2019, the Fifth Circuit Court of Appeals upheld this decision with respect to the individual mandate, but remanded for further consideration of how this affects the rest of the law. Pending the appeals process, the law remains in effect. The elimination of the individual mandate penalty and other changes may impact the number of individuals that elect to obtain public or private health insurance or the scope of such coverage, if purchased.

Of critical importance to us will be the potential impact of any changes specific to the Medicaid program, including the funding and expansion provisions of the Affordable Care Act or any subsequent legislation or agency initiatives. Historically, the states with the greatest reductions in the number of uninsured adult residents have expanded Medicaid. A number of states have opted out of the Medicaid coverage expansion provisions, but could ultimately decide to expand their programs at a later date. Of the 18 states in which we operated hospitals as of December 31, 2019, nine states have taken action to expand their Medicaid programs. At this time, the other nine states have not, including Florida, Alabama, Tennessee and Texas, where we operated a significant number of hospitals as of December 31, 2019. Some states use, or have applied to use, waivers granted by CMS to implement expansion, impose different eligibility or enrollment restrictions, or otherwise implement programs that vary from federal standards. CMS administrators have indicated that they are increasing state flexibility in the administration of Medicaid programs. For example, CMS has granted a limited number of state applications for waivers that allow a state to condition Medicaid enrollment on work or other community engagement. Several states have similar applications pending.

We believe that the Affordable Care Act has had a positive impact on net operating revenues and income as the result of the expansion of private sector and Medicaid coverage that has occurred. However, other provisions of the Affordable Care Act, such as requirements related to employee health insurance coverage and changes to Medicare and Medicaid reimbursement, have increased our operating costs or adversely impacted the reimbursement we receive. Legislative and executive branch efforts related to healthcare reform could result in increased prices for consumers purchasing health insurance coverage or the sale of insurance plans that contain gaps in coverage, which could destabilize insurance markets and impact the rates of uninsured or underinsured adults. Some current initiatives and proposals, including those aimed at price transparency and out-of-network charges, may impact prices and the relationships between hospitals and insurers. In addition, members of Congress have proposed measures that would expand government-sponsored coverage, including single-payor models.

63

It is difficult to predict the ongoing effect of the Affordable Care Act due to executive orders, changes to the law’s implementation, clarifications and modifications resulting from the rule-making process, judicial interpretations resulting from court challenges to its constitutionality and interpretation, whether and how many states ultimately decide to expand Medicaid coverage, the number of uninsured who elect to purchase health insurance coverage, budgetary issues at federal and state levels, and efforts to change or repeal the statute. We may not be able to fully realize the positive impact the Affordable Care Act may otherwise have on our business, results of operations, cash flow, capital resources and liquidity. We cannot predict whether we will be able to modify certain aspects of our operations to offset any potential adverse consequences from the Affordable Care Act or the impact of any alternative provisions that may be adopted.

In recent years, a number of laws, including the Affordable Care Act and Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, have promoted shifting from traditional fee-for-service reimbursement models to alternative payment models that tie reimbursement to quality and cost of care. CMS currently administers various ACOs and bundled payment demonstration projects and has indicated that it will continue to pursue similar initiatives.

In June 2019, the U.S. Supreme Court ruled in Azar v. Allina Health Services that the U.S. Department of Health and Human Services failed to comply with statutory notice and comment rulemaking procedures before announcing an earlier policy related to DSH payments made under Medicare to hospitals. Following this ruling, unless the U.S. Department of Health and Human Services is able to successfully assert another legal basis for this policy, one potential outcome is the federal government could be required to reimburse hospitals, including us, for DSH Medicare payments which otherwise would have been payable over certain prior time periods absent the enactment of this policy. While the ruling in this case was specific to the DSH payments calculated for federal fiscal year 2012 for the plaintiff hospitals, we believe that prior time periods with the potential for higher DSH payments because of the precedent of this ruling could include federal fiscal years 2005 to 2013. There continues to be uncertainty regarding the extent to which, if any, DSH Medicare payments will be remitted to us as the result of this ruling, and if so the timing of any such payments. However, we anticipate that if it is ultimately determined that we are entitled to receive such DSH Medicare payments for these prior time periods, these payments could have a material positive impact on a non-recurring basis in any future period in which net income is recognized in respect thereof as well as on our cash flows from operations in any future period in which these payments are received.

As a result of our current levels of cash, available borrowing capacity, long-term outlook on our debt repayments, the refinancing of our term loans and our continued projection of our ability to generate cash flows, we anticipate that we will be able to invest the necessary capital in our business over the next twelve months. We believe there continues to be ample opportunity to strengthen our market share in substantially all of our markets by decreasing the need for patients to travel outside their communities for healthcare. Furthermore, we will continue to strive to improve operating efficiencies and procedures in order to improve the performance of our hospitals.

64

Sources of Revenue

The following table presents the approximate percentages of net operating revenues by payor source for the periods indicated. The data for the periods presented are not strictly comparable due to the effect that hospital acquisitions and divestitures have had on these statistics. The percentages of net operating revenues for 2017 also include the overall impact of the change in estimate recorded in the fourth quarter of 2017 to increase contractual allowances and record additional provision for bad debts.

	Year Ended December 31,
	2019			2018			2017
Medicare		25.2	%		26.3	%		27.8	%
Medicaid		13.2			13.3			13.2
Managed Care and other third-party payors		60.6			59.0			59.8
Self-pay		1.0			1.4			(0.8)
Total		100.0	%		100.0	%		100.0	%

As shown above, we receive a substantial portion of our revenues from the Medicare and Medicaid programs. Included in Managed Care and other third-party payors is operating revenues from insurance companies with which we have insurance provider contracts, Medicare managed care, insurance companies for which we do not have insurance provider contracts, workers’ compensation carriers and non-patient service revenue, such as rental income and cafeteria sales. In the future, we generally expect the portion of revenues received from the Medicare and Medicaid programs to increase over the long-term due to the general aging of the population and the impacts of the Affordable Care Act. The Affordable Care Act has increased the number of insured patients in states that have expanded Medicaid, which in turn, has reduced the percentage of revenues from self-pay patients. However, it is unclear whether the trend of increased coverage will continue, due in part to the elimination of the financial penalty associated with the individual mandate, effective January 1, 2019. Further, the Affordable Care Act imposes significant reductions in amounts the government pays Medicare managed care plans. The trend toward increased enrollment in Medicare and Medicaid managed care may adversely affect our operating revenue. An executive order issued in October 2019 seeks to accelerate this shift away from traditional fee-for-service Medicare to Medicare managed care. We may also be impacted by regulatory requirements imposed on insurers, such as minimum medical-loss ratios and specific benefit requirements. Furthermore, in the normal course of business, managed care programs, insurance companies and employers actively negotiate the amounts paid to hospitals. Our relationships with payors may be impacted by price transparency initiatives and out-of-network billing proposals. There can be no assurance that we will retain our existing reimbursement arrangements or that these third-party payors will not attempt to further reduce the rates they pay for our services.

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-based reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for the treatment of patients covered by Medicare, Medicaid and non-governmental payors are generally less than our standard billing rates. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which we deduct from gross revenues to arrive at net operating revenues. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net loss by an insignificant amount in each of the years ended December 31, 2019, 2018 and 2017.

The payment rates under the Medicare program for hospital inpatient and outpatient acute care services are based on a prospective payment system, depending upon the diagnosis of a patient’s condition. These rates are

65

indexed for inflation annually, although increases have historically been less than actual inflation. On August 16, 2019, CMS issued the final rule to increase this index by 3.0% for hospital inpatient acute care services that are reimbursed under the prospective payment system, beginning October 1, 2019. The final rule provides for a 0.4 percentage point multifactor productivity reduction and a positive 0.5 percentage point adjustment in accordance with MACRA, which, together with other changes to payment policies is expected to yield an average 2.9% increase in reimbursement for hospital inpatient acute care services. An additional reduction applies to hospitals that do not submit required patient quality data. We are complying with this data submission requirement. Payments may also be affected by various other adjustments, such as admission and medical review criteria for inpatient services commonly known as the “two midnight rule.” This rule limits when services to Medicare beneficiaries are payable as inpatient hospital services. Reductions in the rate of increase or overall reductions in Medicare reimbursement may cause a decline in the growth of our net operating revenues.

Payment rates under the Medicaid program vary by state. In addition to the base payment rates for specific claims for services rendered to Medicaid enrollees, states utilize supplemental reimbursement programs to make separate payments that are not specifically tied to an individual’s care, some of which offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. The programs are generally authorized for a specified period of time and require CMS’s approval to be extended. We are unable to predict whether or on what terms CMS will extend the supplemental programs in the states in which we operate. Under these supplemental programs, we recognize revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and included as Medicaid revenue in the table above, and fees, taxes or other program related costs are reflected in other operating expenses.

Results of Operations

Our hospitals offer a variety of services involving a broad range of inpatient and outpatient medical and surgical services. These include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, psychiatric and rehabilitation services. The strongest demand for hospital services generally occurs during January through April and the weakest demand for these services generally occurs during the summer months. Accordingly, eliminating the effects of new acquisitions and/or divestitures, our net operating revenues and earnings are historically highest during the first quarter and lowest during the third quarter.

66

The following tables summarize, for the periods indicated, selected operating data.

	Year Ended December 31,
	2019			2018			2017
Operating results, as a percentage of net operating revenues:
Net operating revenues		100.0	%		100.0	%		100.0	%
Operating expenses (a)		(89.5	)		(88.9	)		(92.8	)
Depreciation and amortization		(4.6	)		(4.9	)		(5.6	)
Impairment and loss on sale of businesses, net		(1.0	)		(4.7	)		(13.8	)
Income (loss) from operations		4.9			1.5			(12.2	)
Interest expense, net		(7.9	)		(6.9	)		(6.1	)
(Loss) gain from early extinguishment of debt		(0.4	)		0.2			(0.3	)
Equity in earnings of unconsolidated affiliates		0.1			0.2			0.1
Loss before income taxes		(3.3	)		(5.0	)		(18.5	)
(Provision for) benefit from income taxes		(1.2	)		-			3.0
Loss from continuing operations		(4.5	)		(5.0	)		(15.5	)
Loss from discontinued operations, net of taxes		-			-			(0.1	)
Net loss		(4.5	)		(5.0	)		(15.6	)
Less: Net income attributable to noncontrolling interests		(0.6	)		(0.6	)		(0.4	)
Net loss attributable to Community Health Systems, Inc. stockholders		(5.1	)%		(5.6	)%		(16.0	)%

	Year Ended December 31,
	2019			2018
Percentage (decrease) increase from prior year:
Net operating revenues		(6.7	)%		(7.8	)%
Admissions		(11.1	)		(15.0	)
Adjusted admissions (b)		(10.6	)		(15.3	)
Average length of stay		(2.2	)		-
Net loss attributable to Community Health Systems, Inc.		(14.3	)		(68.0	)
Same-store percentage increase (decrease) from prior year (c):
Net operating revenues		4.2	%		2.8	%
Admissions		1.3			(1.3	)
Adjusted admissions (b)		2.2			(0.4	)

(a) Operating expenses include salaries and benefits, supplies, other operating expenses, government and other legal settlements and related costs, electronic health records incentive reimbursement and rent.

(b) Adjusted admissions is a general measure of combined inpatient and outpatient volume. We computed adjusted admissions by multiplying admissions by gross patient revenues and then dividing that number by gross inpatient revenues.

(c) Includes acquired hospitals to the extent we operated them in both periods and excludes our hospitals that have previously been classified as discontinued operations for accounting purposes. In addition, also excludes information for the hospitals sold or closed during 2018 and 2019.

Year Ended December 31, 2019 Compared to Year Ended December 31, 2018

Net operating revenues decreased by 6.7% to approximately $13.2 billion for the year ended December 31, 2019, from approximately $14.2 billion for the year ended December 31, 2018. Net operating revenues on a same-store basis from hospitals that were operated throughout both periods increased $518 million or 4.2%

67

during the year ended December 31, 2019, as compared to the year ended December 31, 2018. The increase in same-store net operating revenues was attributable to improved pricing due to higher acuity, and an increase in inpatient admissions. Non-same-store net operating revenues decreased $1.5 billion during the year ended December 31, 2019, in comparison to the prior year period, with the decrease attributable primarily to the divestiture of hospitals during 2018 and 2019. On a consolidated basis, inpatient admissions decreased by 11.1% during the year ended December 31, 2019 as compared to the year ended December 31, 2018. Also on a consolidated basis, adjusted admissions decreased by 10.6% during the year ended December 31, 2019 as compared to the year ended December 31, 2018. On a same-store basis, net operating revenues per adjusted admissions increased 1.9%, while inpatient admissions increased by 1.3% and adjusted admissions increased by 2.2% for the year ended December 31, 2019, compared to the year ended December 31, 2018.

Operating expenses, as a percentage of net operating revenues, decreased from 98.5% during the year ended December 31, 2018 to 95.1% during the year ended December 31, 2019. Operating expenses, excluding depreciation and amortization and impairment and loss on sale of businesses, as a percentage of net operating revenues, increased from 88.9% for the year ended December 31, 2018 to 89.5% for the year ended December 31, 2019. Salaries and benefits, as a percentage of net operating revenues, decreased from 45.1% for the year ended December 31, 2018 to 45.0% for the year ended December 31, 2019. This decrease in salaries and benefits, as a percentage of net operating revenues, was primarily due to improved staffing and benefit expense management. Supplies, as a percentage of net operating revenues, decreased from 16.6% for the year ended December 31, 2018 to 16.3% for the year ended December 31, 2019. Other operating expenses, as a percentage of net operating revenues, increased from 24.7% for the year ended December 31, 2018 to 25.1% for the year ended December 31, 2019. Expense related to government and other legal settlements and related costs, as a percentage of net operating revenues, increased from 0.1% for the year ended December 31, 2018 to 0.7% for the year ended December 31, 2019, primarily due to the net impact of lawsuits settled in principle and related legal expenses. Lease cost and rent, as a percentage of net operating revenues, was 2.4% for both of the years ended December 31, 2019 and 2018.

Depreciation and amortization, as a percentage of net operating revenues, decreased from 4.9% for the year ended December 31, 2018 to 4.6% for the year ended December 31, 2019, primarily due to ceasing depreciation on property and equipment at hospitals sold or held for sale and a reduction in the purchase of property and equipment for the year ended December 31, 2019 compared to the same period in 2018.

Impairment and loss on sale of businesses was $138 million for the year ended December 31, 2019, compared to $668 million for the year ended December 31, 2018, related to impairment of the long-lived assets and reporting unit goodwill allocated to hospitals classified as held for sale or sold during the respective periods.

Interest expense, net, increased by $65 million to $1.0 billion for the year ended December 31, 2019 compared to $976 million for the year ended December 31, 2018, which was driven by an increase in interest rates due to the refinancing activity during the year ended December 31, 2019, compared to the same period in 2018, which resulted in an increase in interest expense of $86 million. This increase was partially offset by a decrease in our average outstanding debt during the year ended December 31, 2019, which resulted in a decrease in interest expense of $15 million, and an increase in major construction projects during the year ended December 31, 2019, which resulted in $6 million more interest being capitalized, compared to the same period in 2018.

Loss from early extinguishment of debt of $54 million was recognized during the year ended December 31, 2019, as a result of the Credit Facility amendment, repayment of the term loans under the Credit Facility, termination of the Revolving Facility, and the refinancing and exchange of certain of our outstanding notes as discussed further in Capital Resources. Gain from early extinguishment of debt of $31 million was recognized during the year ended December 31, 2018, which resulted primarily from the refinancing and exchange of certain of our outstanding notes and repayment of a portion of our term loans under the Credit Facility as discussed further in Capital Resources.

Equity in earnings of unconsolidated affiliates, as a percentage of net operating revenues, decreased from 0.2% for the year ended December 31, 2018 to 0.1% for the year ended December 31, 2019.

68

The net results of the above-mentioned changes resulted in loss before income taxes decreasing $285 million from $715 million for the year ended December 31, 2018 to $430 million for the year ended December 31, 2019.

Our provision for income taxes for the year ended December 31, 2019 was $160 million compared to a benefit from income taxes of $11 million for the year ended December 31, 2018. Our effective tax rates were (37.2%) and 1.5% for the year ended December 31, 2019 and 2018, respectively. The difference in our effective tax rate for the year ended December 31, 2019, when compared to the year ended December 31, 2018, was primarily due to an increase in the valuation allowance recognized on (i) IRC Section 163(j) interest carryforwards and (ii) original issue discount deferred tax asset generated with the 2019 Exchange Offer.

Net loss, as a percentage of net operating revenues, decreased from 5.0% for the year ended December 31, 2018 to 4.5% for the year ended December 31, 2019.

Net income attributable to noncontrolling interests, as a percentage of net operating revenues, was 0.6% for both of the years ended December 31, 2019 and 2018.

Net loss attributable to Community Health Systems, Inc. was $675 million for the year ended December 31, 2019, compared to $788 million for the year ended December 31, 2018.

Year Ended December 31, 2018 Compared to Year Ended December 31, 2017

Net operating revenues decreased by 7.8% to approximately $14.2 billion for the year ended December 31, 2018, from approximately $15.4 billion for the year ended December 31, 2017. Net operating revenues on a same-store basis from hospitals that were operated throughout both periods increased $362 million or 2.8% during the year ended December 31, 2018, as compared to the year ended December 31, 2017. The increase in same-store net operating revenues was attributable to improved pricing due to higher acuity, partially offset by a decline in inpatient admissions and adjusted admissions. Non-same-store net operating revenues decreased $1.6 billion during the year ended December 31, 2018, in comparison to the prior year period, with the decrease attributable primarily to the divestiture of hospitals during 2017 and 2018. On a consolidated basis, inpatient admissions decreased by 15.0% during the year ended December 31, 2018 as compared to the year ended December 31, 2017. Also on a consolidated basis, adjusted admissions decreased by 15.3% during the year ended December 31, 2018 as compared to the year ended December 31, 2017. On a same-store basis, net operating revenues per adjusted admissions increased 3.2%, while inpatient admissions decreased by 1.3% and adjusted admissions decreased by 0.4% for the year ended December 31, 2018, compared to the year ended December 31, 2017.

All operating expenses calculations, as a percentage of net operating revenues, were impacted during the year ended December 31, 2017 due to the overall impact of the change in estimate related to net patient receivables recorded in the fourth quarter of 2017. Total operating costs and expenses, as a percentage of net operating revenues, decreased from 112.2% during the year ended December 31, 2017 to 98.5% during the year ended December 31, 2018. Operating expenses, excluding depreciation and amortization and impairment and loss on sale of businesses, as a percentage of net operating revenues, decreased from 92.8% for the year ended December 31, 2017 to 88.9% for the year ended December 31, 2018. Salaries and benefits, as a percentage of net operating revenues, decreased from 48.0% for the year ended December 31, 2017 to 45.1% for the year ended December 31, 2018. This decrease in salaries and benefits, as a percentage of net operating revenues, was primarily due to improved staffing and benefit expense management. Supplies, as a percentage of net operating revenues, decreased from 17.4% for the year ended December 31, 2017 to 16.6% for the year ended December 31, 2018. Other operating expenses, as a percentage of net operating revenues, decreased from 25.2% for the year ended December 31, 2017 to 24.7% for the year ended December 31, 2018. Government and other legal settlements and related costs, as a percentage of net operating revenues, decreased from income of 0.2% for the year ended December 31, 2017 to expense of 0.1% for the year ended December 31, 2018 primarily as a result of the gain recorded from the previously announced settlement of the shareholder derivative action in January 2017. Rent, as a percentage of net operating revenues, decreased from 2.6% for the year ended December 31, 2017 to 2.4% for the year ended December 31, 2018.

69

Depreciation and amortization, as a percentage of net operating revenues, decreased from 5.6% for the year ended December 31, 2017 to 4.9% for the year ended December 31, 2018, primarily due to a decrease in depreciable basis of property and equipment that has been impaired and from ceasing depreciation on property and equipment at hospitals sold or held for sale.

Impairment and loss on sale of businesses was $668 million for the year ended December 31, 2018, compared to $2.1 billion for the year ended December 31, 2017. Impairment of goodwill and long-lived assets for the year ended December 31, 2018 included (i) impairment of approximately $423 million related to impairment of the long-lived assets and reporting unit goodwill allocated to hospitals that have been sold or deemed held for sale during the year ended December 31, 2018, (ii) approximately $29 million recorded to write-off the value of a promissory note received as consideration for the sale of three hospitals in 2017 where the buyer entered into bankruptcy proceedings, and (iii) approximately $216 million recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals that have ceased operations or where we are in discussions with potential buyers for divestiture at a sales price that indicates a fair value below carrying value. Impairment of goodwill and long-lived assets for the year ended December 31, 2017 included impairment of approximately $388 million related to impairment of the long-lived assets and reporting unit goodwill allocated to hospitals classified as held for sale during the year ended December 31, 2017, impairment of approximately $316 million for several underperforming hospitals as well as for the hospitals where we have received offers or executed non-binding letters of intent to sell the hospital, and impairment of $1.419 billion related to goodwill for our hospital reporting unit.

Interest expense, net, increased by $45 million to $976 million for the year ended December 31, 2018 compared to $931 million for the year ended December 31, 2017, primarily due to an increase in interest rates during the year ended December 31, 2018 of $114 million. This increase was partially offset by a decrease in our average outstanding debt during the year ended December 31, 2018, which resulted in a decrease in interest expense of $65 million. Additionally, an increase in major construction projects during the year ended December 31, 2018 resulted in more interest being capitalized, and a decrease in interest expense of $4 million, compared to the same period in 2017.

Gain from early extinguishment of debt of $31 million was recognized during the year ended December 31, 2018 which resulted primarily from the refinancing and exchange of certain of our outstanding notes and repayment of a portion of our term loans under the Credit Facility as discussed further in Capital Resources. Loss from early extinguishment of debt of $40 million was recognized during the year ended December 31, 2017, which resulted from the repayment of certain outstanding notes and term loans under the Credit Facility.

Equity in earnings of unconsolidated affiliates, as a percentage of net operating revenues, increased from 0.1% for the year ended December 31, 2017 to 0.2% for the year ended December 31, 2018.

The net results of the above-mentioned changes resulted in loss from continuing operations before income taxes decreasing $2.1 billion from loss of $2.8 billion for the year ended December 31, 2017 to loss of $715 million for the year ended December 31, 2018.

Our benefit from income taxes on loss from continuing operations decreased from $449 million for the year ended December 31, 2017 to $11 million for the year ended December 31, 2018. Our effective tax rates were 1.5% and 15.8% for the year ended December 31, 2018 and 2017, respectively. The decrease in our effective tax rate for the year ended December 31, 2018, when compared to the year ended December 31, 2017, was primarily due to the increase in valuation allowance recognized on IRC Section 163(j) interest carryforwards partially offset by the release of certain state valuation allowances on net operating loss carryforwards in certain jurisdictions.

Loss from continuing operations, as a percentage of net operating revenues, decreased from 15.5% for the year ended December 31, 2017 to 5.0% for the year ended December 31, 2018.

70

No discontinued operations were separately reported for the year ended December 31, 2018. Discontinued operations for the year ended December 31, 2017, include the results of operations of certain hospitals owned or leased by us as of December 31, 2017, which were classified as being held for sale or sold. The operation of these hospitals resulted in a loss, net of taxes, of $6 million for the year ended December 31, 2017. An after-tax impairment charge of $6 million was recorded during the year ended December 31, 2017, based on the difference between the estimated fair value and the carrying value of the assets held for sale. Overall, discontinued operations consisted of a loss, net of taxes, of $12 million for the year ended December 31, 2017.

Net loss, as a percentage of net operating revenues, decreased from 15.6% for the year ended December 31, 2017 to 5.0% for the year ended December 31, 2018.

Net income attributable to noncontrolling interests, as a percentage of net operating revenues increased from 0.4% for the year ended December 31, 2017 to 0.6% for the year ended December 31, 2018.

Net loss attributable to Community Health Systems, Inc. was $788 million for the year ended December 31, 2018, compared to $2.5 billion for the year ended December 31, 2017. The decrease in net loss attributable to Community Health Systems, Inc. was primarily due to the change in estimate recorded as a reduction of the net operating revenues and the impairment of goodwill and certain long-lived assets based on their estimated fair values for hospitals sold or held for sale in 2017.

Liquidity and Capital Resources

2019 Compared to 2018

Net cash provided by operating activities increased $111 million, from approximately $274 million for the year ended December 31, 2018, to approximately $385 million for the year ended December 31, 2019. The increase in cash provided by operating activities was primarily the result of $266 million paid during the fourth quarter of 2018 related to the global resolution and settlement of litigation and government investigation of HMA, partially offset by higher interest payments due to the refinancing activity during the year ended December 31, 2019, and higher malpractice claim payments compared to the same period in 2018. Total cash paid for interest during the year ended December 31, 2019 increased to approximately $1.0 billion compared to $936 million for the year ended December 31, 2018. Cash paid for income taxes, net of refunds received, resulted in a net refund of $3 million and $19 million during the year ended December 31, 2019 and 2018, respectively.

Our net cash used in investing activities was approximately $2 million for the year ended December 31, 2019, compared to approximately $245 million for the year ended December 31, 2018, a decrease of approximately $243 million. The cash used in investing activities during the year ended December 31, 2019, was primarily impacted by an increase in proceeds from the divestitures of hospitals and other ancillary operations of $199 million, a decrease in the cash used in the purchase of property and equipment of $89 million for the year ended December 31, 2019 compared to the same period in 2018, and a decrease in the cash used in the acquisition of facilities and other related equipment of $13 million as a result of a reduction in cash used to purchase physician practices, clinics and other ancillary businesses for the year ended December 31, 2019 compared to the same period in 2018, partially offset by the acquisition of one hospital during the year ended December 31, 2019. The decreases in cash used in investing activities were also impacted by a decrease in cash provided by the net impact of the purchases and sales of available-for-sale debt securities and equity securities of $24 million, a decrease in the proceeds from sale of property and equipment of $5 million for the year ended December 31, 2019 compared to the same period in 2018 and an increase in cash used for other investments (primarily from internal-use software expenditures and physician recruiting costs) of $29 million.

Our net cash used in financing activities was $363 million for the year ended December 31, 2019, compared to approximately $396 million for the year ended December 31, 2018, a decrease of approximately $33 million. The decrease in cash used in financing activities, in comparison to the prior year period, was primarily due to the net effect of our debt repayment, refinancing activity, and cash paid for deferred financing costs and other debt-related costs.

71

As described in Notes 6, 9 and 5 of the Notes to Consolidated Financial Statements, at December 31, 2019, we had certain cash obligations, which are due as follows (in millions):

	Total		2020		2021-2023		2024-2025		2026 and thereafter
51⁄8% Senior Secured Notes due 2021	$	1,000	$	-	$	1,000	$	-	$	-
67⁄8% Senior Notes due 2022		231		-		231		-		-
61⁄4% Senior Secured Notes due 2023		3,100		-		3,100		-		-
85⁄8% Senior Secured Notes due 2024		1,033		-		-		1,033		-
8% Senior Secured Notes due 2026		2,101		-		-		-		2,101
8% Senior Secured Notes due 2027		700		-		-		-		700
67⁄8% Senior Notes due 2028		1,700		-		-		-		1,700
97⁄8% Junior-Priority Secured Notes due 2023		1,770		-		1,770		-		-
81⁄8% Junior-Priority Secured Notes due 2024		1,355		-		-		1,355		-
ABL Facility		273		-		273		-		-
Other debt		17		13		4		-		-
Total long-term debt (1)		13,280		13		6,378		2,388		4,501
Interest on ABL Facility and notes (2)		4,966		984		2,752		741		489
Finance lease and financing obligations, including interest		379		24		64		43		248
Operating leases		825		184		357		133		151
Replacement facilities and other capital commitments (3)		85		65		5		-		15
Open purchase orders (4)		398		370		28		-		-
Liability for uncertain tax positions, including interest and penalties		1		-		-		-		1
Total	$	19,934	$	1,640	$	9,584	$	3,305	$	5,405

(1) Total long-term debt is exclusive of unamortized deferred debt issuance costs and note premium of approximately $147 million.

(2) Estimate of interest payments assumes the interest rates at December 31, 2019 remain constant during the period presented for the ABL Facility, which is variable rate debt. The 5¹⁄₈% Senior Secured Notes due 2021, 6⁷⁄₈% Senior Notes due 2022, 6¹⁄₄% Senior Secured Notes due 2023, 8⁵⁄₈% Senior Secured Notes due 2024, 9⁷⁄₈% Junior-Priority Secured Notes due 2023, 8¹⁄₈% Junior-Priority Secured Notes due 2024, 8% Senior Secured Notes due 2026, 8% Senior Secured Notes due 2027 and 6⁷⁄₈% Senior Notes due 2028 have fixed rates of interest.

(3) Pursuant to hospital purchase agreements in effect as of December 31, 2019, we have commitments to build two replacement facilities and the following capital commitments. As part of an acquisition in 2016, we agreed to build replacement facilities in La Porte and Knox, Indiana. The estimated construction costs, including equipment costs, are currently estimated to be approximately $128 million and $15 million, respectively, of which approximately $58 million has been incurred to date for the construction of the replacement facility in La Porte. In addition, under other purchase agreements, we have committed to spend approximately $2 million for costs such as capital improvements, equipment, selected leases and physician

72

recruiting. These commitments are required to be fulfilled generally over a five to seven-year period after acquisition. Through December 31, 2019, we have incurred approximately $2 million related to these commitments.

(4) Open purchase orders represent our commitment for items or services ordered but not yet received.

At December 31, 2019, we had issued letters of credit primarily in support of potential insurance related claims and specified outstanding bonds of approximately $145 million.

Our debt as a percentage of total capitalization increased from 112% for the year ended December 31, 2018 to 119% for the year ended December 31, 2019, due to an increase in accumulated deficit, offset by an overall decrease in long-term debt.

2018 Compared to 2017

Net cash provided by operating activities decreased $499 million, from approximately $773 million for the year ended December 31, 2017, to approximately $274 million for the year ended December 31, 2018. The decrease in cash provided by operating activities was primarily impacted by the $266 million paid during the fourth quarter related to the global resolution and settlement of litigation and government investigation of HMA and higher interest payments due to the timing of payments and higher interest rates resulting from the refinancing activity during the year ended December 31, 2018, as well as from a decline in cash flow from patient accounts receivable collections that was impacted as the magnitude of collections on receivables at divested hospitals decreased. Other contributors to the lower cash provided by operating activities include the loss of operating cash flow contributed from previously divested hospitals and a decrease in cash received from HITECH incentive reimbursement. Such decreases were offset by improvements in cash flow from supplies, prepaid expenses and other current assets and lower malpractice claim payments compared to the same period in 2017. Total cash paid for interest during the year ended December 31, 2018, increased to approximately $936 million compared to $852 million for the year ended December 31, 2017. Cash paid for income taxes, net of refunds received, resulted in a net refund of $19 million for the year ended December 31, 2018, compared to $4 million paid for income taxes for the year ended December 31, 2017.

Our net cash used in investing activities was approximately $245 million for the year ended December 31, 2018, compared to net cash provided by investing activities of approximately $1.1 billion for the year ended December 31, 2017, a decrease of approximately $1.3 billion. The cash used in investing activities was primarily impacted by a decrease in proceeds from the disposition of hospitals and other ancillary operations of $1.3 billion as a result of fewer hospital dispositions during the year ended December 31, 2018 compared to the same period in 2017, a decrease in cash provided by the net impact of the purchases and sales of available-for-sale debt securities and equity securities of $47 million and an increase of $20 million in the cash used in the acquisition of facilities and other related equipment (for physician practices, clinics and other ancillary businesses as there were no hospital acquisitions during either the year ended December 31, 2018 or 2017). These increases in cash outflows were offset by a decrease in the cash used in the purchase of property and equipment of $37 million, an increase in the proceeds from the sale of property and equipment of $1 million, and a decrease in cash used for other investments (primarily from internal-use software expenditures and physician recruiting costs) of $2 million for the year ended December 31, 2018 compared to the same period in 2017.

Our net cash used in financing activities was $396 million for the year ended December 31, 2018, compared to approximately $1.5 billion for the year ended December 31, 2017, a decrease of approximately $1.1 billion. The decrease in cash used in financing activities, in comparison to the prior year period, was primarily due to the net effect of our debt repayment, refinancing activity, and cash paid for deferred financing costs and other debt-related costs.

Capital Expenditures

Cash expenditures for purchases of facilities and other related businesses were $13 million in 2019, $26 million in 2018 and $6 million in 2017. Our expenditures for the year ended December 31, 2019 were

73

primarily related to the purchase of one hospital in Mississippi, physician practices and other ancillary services. Our expenditures for the years ended December 31, 2018 and 2017 were related to the purchase of physician practices and other ancillary services.

Excluding the cost to construct replacement hospitals, our cash expenditures for routine capital for the year ended December 31, 2019 totaled $386 million, compared to $521 million in 2018 and $558 million in 2017. These capital expenditures related primarily to the purchase of additional equipment, minor renovations and information systems infrastructure. Costs to construct replacement hospitals totaled $52 million in 2019 and $6 million in both 2018 and 2017. The costs to construct replacement hospitals for both of the years ended December 31, 2019 and 2018 represent both planning and construction costs for the replacement facility at La Porte, Indiana. The costs to construct replacement hospitals for the year ended December 31, 2017 represent both planning and construction costs for the replacement hospital we previously committed to build in York, Pennsylvania. In conjunction with the sale of Memorial Hospital of York on July 1, 2017, we no longer have a commitment to construct this replacement hospital or have planned costs in connection therewith.

Pursuant to a hospital purchase agreement from our March 1, 2016 acquisition of La Porte Hospital and Starke Hospital, we committed to build replacement facilities in both La Porte, Indiana and Knox, Indiana. Under the terms of such agreement, construction of the replacement hospital for LaPorte Hospital is required to be completed within five years of the date of acquisition, or March 2021. In addition, construction of the replacement facility for Starke Hospital is required to be completed within five years of the date we enter into a new lease with Starke County, Indiana, the hospital lessor, or in the event we do not enter into a new lease with Starke County, construction shall be completed by September 30, 2026. We have not entered into a new lease with the lessor for Starke Hospital and currently anticipate completing construction of the Starke Hospital replacement facility in 2026. Construction costs, including equipment costs, for the La Porte and Starke replacement facilities are currently estimated to be approximately $128 million and $15 million, respectively. We expect total capital expenditures of approximately $400 million to $500 million in 2020 (which includes amounts that are required to be expended pursuant to the terms of the hospital purchase agreements), including approximately $335 million to $435 million for renovation and equipment cost and approximately $65 million for construction costs of the replacement hospital in La Porte, Indiana.

Capital Resources

Net working capital was approximately $1.1 billion at December 31, 2019, compared to $1.2 billion at December 31, 2018. Net working capital decreased by approximately $12 million between December 31, 2018 and December 31, 2019. This decrease is primarily due to the increase in current operating lease liabilities, partially offset by an increase in cash and cash equivalents during the year ended December 31, 2019.

We had senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent, which at December 31, 2018 included (i) the Revolving Facility and (ii) a Term H facility due 2021, or the Term H Facility. The Revolving Facility included a subfacility for letters of credit. The Revolving Credit Facility was repaid in full and terminated in connection with the completion of the sale of the Additional 2026 Notes on November 19, 2019 as discussed further in Capital Resources.

The loans under the Credit Facility bore interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at our option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the NYFRB Rate (as defined) plus 0.50% or (3) the adjusted LIBOR on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. In addition, the margin in respect of the Revolving Facility was subject to adjustment determined by reference to a leverage-based pricing grid. Prior to the refinancing discussed below, loans in respect of the Revolving Facility accrued interest at a rate per annum equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. Prior to the refinancing discussed below, the Term H Loan accrued interest at a

74

rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate borrowings. The Term H Loan was subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility was required to be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 75%, subject to reduction to a lower percentage based on the Company’s first lien net leverage ratio (as defined in the Credit Facility generally as the ratio of first lien net debt on the date of determination to the Company’s consolidated EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions were permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. There were no scheduled principal amortization payments on the Term H Facility after December 31, 2018.

The borrower under the Credit Facility was our wholly-owned subsidiary CHS/Community Health Systems, Inc., or CHS. All of the obligations under the Credit Facility were unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees were secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries, and subject to the ABL Facility. Such assets constituted substantially the same assets, subject to certain exceptions, that secured (i) on a first lien basis CHS’ obligations under the 5¹⁄₈% Senior Secured Notes due 2021, the 6¹⁄₄% Senior Secured Notes due 2023, the 8⁵⁄₈% Senior Secured Notes due 2024 and the 8% Senior Secured Notes due 2026 (in each case, as defined below) and (ii) on a junior-priority basis the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 and the 8¹⁄₈% Junior-Priority Secured Notes due 2024 (in each case, as defined below).

CHS agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to LIBOR borrowings under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit also received a customary fronting fee and other customary processing charges. CHS was obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon our leverage ratio) on the unused portion of the Revolving Facility.

On February 15, 2019, the Company and CHS entered into Amendment No. 1, or the Agreement, among the Company, CHS, the subsidiary guarantors party thereto, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent, to the Credit Facility. The Credit Facility was amended by the Agreement, with requisite covenant lender approval, to amend the first lien net debt to EBITDA ratio financial covenant and to reduce the extended revolving credit commitments to $385 million. The amended financial covenant provided for a maximum first lien net debt to EBITDA ratio of 5.00 to 1.00 from July 1, 2018 through December 31, 2018, 5.25 to 1.00 from January 1, 2019 through December 31, 2019, 5.00 to 1.00 from January 1, 2020 through June 30, 2020, 4.50 to 1.00 from July 1, 2020 through September 30, 2020, and 4.25 to 1.00 thereafter. In addition, CHS agreed pursuant to the Agreement to further restrict its ability to make restricted payments. The revolving credit commitments terminated on November 19, 2019.

On April 3, 2018, we entered into an asset-based loan (ABL) credit agreement, or the ABL Credit Agreement, with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders and other agents party thereto. Pursuant to the ABL Credit Agreement, the lenders have extended to CHS a revolving asset-based loan facility, or the ABL Facility, in the maximum aggregate principal amount of $1.0 billion, subject to borrowing base capacity. On November 12, 2019, we and CHS entered into Amendment No. 2 to the ABL Facility, resulting in

75

an increase of the portion of the commitments under the ABL Facility that are available in the form of letters of credit from $50 million to $200 million. CHS and all domestic subsidiaries of CHS that guarantee CHS’ other outstanding senior and senior secured indebtedness guarantee the obligations of CHS under the ABL Facility. Subject to certain exceptions, all obligations under the ABL Facility and the related guarantees are secured by a perfected first-priority security interest in substantially all of the receivables, deposit, collection and other accounts and contract rights, books, records and other instruments related to the foregoing of the Company, CHS and the guarantors, as well as a perfected junior-priority security interest in substantially all of the other assets of the Company, CHS and the guarantors, subject to customary exceptions and intercreditor arrangements. In connection with entering into the ABL Credit Agreement and the ABL Facility, we repaid in full and terminated our accounts receivable loan agreement with a group of lenders and banks. At December 31, 2019, the available borrowing base under the ABL Facility was $860 million, of which we had outstanding borrowings of $273 million and letters of credit issued of $145 million. The issued letters of credit were primarily in support of potential insurance-related claims and certain bonds.

Borrowings under the ABL Facility bear interest at a rate per annum equal to an applicable percentage, plus, at the Borrower’s option, either (a) an Alternative base rate or (b) a LIBOR rate. From and after December 31, 2018, the applicable percentage under the ABL Facility is determined based on excess availability as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of 1.25%, 1.50% and 1.75% for loans based on the Alternative base rate and 2.25%, 2.50% and 2.75% for loans based on the LIBOR rate. From and after September 30, 2018, the applicable commitment fee rate under the ABL Facility is determined based on average utilization as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of either 0.50% or 0.625% times the unused portion of the ABL Facility.

Principal amounts outstanding under the ABL Facility will be due and payable in full on April 3, 2023. The ABL Facility includes a 91-day springing maturity applicable if more than $250 million in the aggregate principal amount of the 5¹⁄₈% Senior Secured Notes due 2021, 6⁷⁄₈% Senior Notes due 2022 or 6¹⁄₄% Senior Secured Notes due 2023 or any indebtedness incurred to refinance the foregoing are scheduled to mature or similarly become due on a date prior to April 3, 2023. In such event, principal amounts outstanding under the ABL Facility will be accelerated and all amounts outstanding under the ABL Facility will become immediately due and payable.

The ABL Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting our ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) engage in mergers, acquisitions and asset sales, (7) conduct transactions with affiliates, (8) alter the nature of our, CHS’ or the guarantors’ businesses, (9) grant certain guarantees with respect to physician practices, (10) engage in sale and leaseback transactions or (11) change our fiscal year. We are also required to comply with a consolidated fixed coverage ratio, upon certain triggering events described below, and various affirmative covenants. The consolidated fixed coverage ratio is calculated as the ratio of (x) consolidated EBITDA (as defined in the ABL Facility) less capital expenditures to (y) the sum of consolidated interest expense (as defined in the ABL Facility), scheduled principal payments, income taxes and restricted payments made in cash or in permitted investments. For purposes of calculating the consolidated fixed charge coverage ratio, the calculation of consolidated EBITDA as defined in the ABL Facility is a trailing 12-month calculation that begins with our consolidated net income, with certain adjustments for interest, taxes, depreciation and amortization, net income attributable to noncontrolling interests, stock compensation expense, restructuring costs, and the financial impact of other non-cash or non-recurring items recorded during any such 12-month period. The consolidated fixed charge coverage ratio is a required covenant only in periods where the total borrowings outstanding under the ABL Facility reduce the amount available in the facility to less than the greater of (i) $95 million and (ii) 10% of the calculated borrowing base. As a result, in the event we have less than $95 million available under the ABL Facility, we would need to comply with the consolidated fixed charge coverage ratio. At December 31, 2019, we were not subject to the

76

consolidated fixed charge coverage ratio as such triggering event had not occurred during the last twelve months ended December 31, 2019.

In addition, in the event the amount of borrowings and letters of credit outstanding at any time under the ABL Facility exceeds the borrowing base at such time, we will be required to, first, repay outstanding borrowings and, second, replace or cash collateralize outstanding letters of credit, in an aggregate amount sufficient to eliminate such excess.

Events of default under the ABL Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the ABL Credit Agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to an available cure and applicable grace periods, (4) bankruptcy and insolvency events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control (as defined), (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the ABL Agent or lenders under the ABL Facility.

On June 22, 2018, CHS completed offers to exchange, or the 2018 Exchange Offers, (i) up to $1.925 billion aggregate principal amount of its new 9⁷⁄₈% Junior-Priority Secured Notes due 2023, or the 9⁷⁄₈% Junior-Priority Secured Notes due 2023, in exchange for any and all of its $1.925 billion aggregate principal amount of outstanding 8% Senior Notes due 2019, or the 8% Senior Notes due 2019, (ii) up to $1.200 billion aggregate principal amount of its new 8¹⁄₈% Junior-Priority Secured Notes due 2024, or the 8¹⁄₈% Junior-Priority Secured Notes due 2024, in exchange for any and all of its $1.200 billion aggregate principal amount of outstanding 7¹⁄₈% Senior Notes due 2020, or the 7¹⁄₈% Senior Notes due 2020, and (iii) to the extent that less than all of the outstanding 8% Senior Notes due 2019 and 7¹⁄₈% Senior Notes due 2020 were tendered in the 2018 Exchange Offers, up to an aggregate principal amount of 8¹⁄₈% Junior-Priority Secured Notes due 2024 equal to, when taken together with the total notes issued in exchange for the validly tendered and accepted 8% Senior Notes due 2019 and 7¹⁄₈% Senior Notes due 2020, $3.125 billion, in exchange for its outstanding 6⁷⁄₈% Senior Notes due 2022, or the 6⁷⁄₈% Senior Notes due 2022. Upon completion of the 2018 Exchange Offers, CHS issued (i) approximately $1.770 billion aggregate principal amount of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 in exchange for the same amount of 8% Senior Notes due 2019, (ii) approximately $1.079 billion aggregate principal amount of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 in exchange for the same amount of 7¹⁄₈% Senior Notes due 2020 and (iii) approximately $276 million aggregate principal amount of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 in exchange for approximately $368 million of 6⁷⁄₈% Senior Notes due 2022.

On July 6, 2018, CHS completed an offering of $1.033 billion aggregate principal amount of 8⁵⁄₈% Senior Secured Notes due 2024, or the 8⁵⁄₈% Senior Secured Notes due 2024. We used the proceeds from this offering to repay the outstanding balance owed under the Term G Loan and pay fees and expenses related to the offering. The 8⁵⁄₈% Senior Secured Notes due 2024 bear interest at a rate of 8.625% per annum payable semi-annually in arrears on January 15 and July 15 of each year. The 8⁵⁄₈% Senior Secured Notes due 2024 are scheduled to mature on January 15, 2024. The 8⁵⁄₈% Senior Secured Notes due 2024 are unconditionally guaranteed on a senior-priority secured basis by us and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 8⁵⁄₈% Senior Secured Notes due 2024 are secured by a shared first-priority lien on the collateral, or the Non-ABL Priority Collateral, that also secures on a first-priority basis CHS’ senior-priority secured notes and a shared second-priority lien on the collateral, or the ABL-Priority Collateral, that secures on a first-priority basis the ABL Facility, in each case subject to certain exceptions.

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of the 8% Senior Secured Notes due 2026, or the 8% Senior Secured Notes due 2026. The net proceeds from this issuance were used to finance the repayment of approximately $1.557 billion aggregate principal amount of CHS’ then outstanding Term H Facility and related fees and expenses. On November 19, 2019, CHS completed a tack-on

77

offering of $500 million aggregate principal amount of additional 8% Senior Secured Notes due 2026, or the Additional 2026 Notes, increasing the total aggregate principal of the 8% Senior Secured Notes due 2026 to $2.101 billion. CHS used the proceeds from the Additional 2026 Notes to repay amounts outstanding under the Revolving Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7¹⁄₈% Senior Notes due 2020 and repay borrowings outstanding under the ABL Facility. The additional 2026 Notes have identical terms, other than issue date, issue price and the date from which interest initially accrued, as the 8% Senior Secured Notes due 2026 issued on March 6, 2019. The 8% Senior Secured Notes due 2026 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. The 8% Senior Secured Notes due 2026 are scheduled to mature on March 15, 2026. The 8% Senior Secured Notes due 2026 are unconditionally guaranteed on a senior-priority secured basis by us and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 8% Senior Secured Notes due 2026 are secured by a shared first-priority lien on the Non-ABL Priority Collateral and a shared second-priority lien on the ABL Priority Collateral, in each case subject to certain exceptions. CHS terminated the Revolving Facility upon consummation of the Additional 2026 Notes offering and the outstanding letters of credit were moved under the ABL Facility.

On November 19, 2019, we issued approximately $700 million aggregate principal amount of the 8% Senior Secured Notes due 2027, or the 8% Senior Secured Notes due 2027, and approximately $1.7 billion aggregate principal amount of 6⁷⁄₈% Senior Notes due 2028, or the 6⁷⁄₈% Senior Notes due 2028, in exchange for approximately $2.4 billion of 6⁷⁄₈% Senior Notes due 2022, or the 2019 Exchange Offer. No cash proceeds were received from the 2019 Exchange Offer. The 8% Senior Secured Notes due 2027 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on June 15, 2020. The 8% Senior Secured Notes due 2027 are scheduled to mature on December 15, 2027. The 8% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by us and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 8% Senior Secured Notes due 2027 are secured by shared first-priority liens on the Non-ABL Priority Collateral and shared second-priority liens on the ABL Priority Collateral, in each case subject to certain exceptions.

The 6⁷⁄₈% Senior Notes due 2028 bear interest at a rate of 6.875% per annum, payable semi-annually in arrears on April 1 and October 1 of each year, commencing on April 1, 2020. The 6⁷⁄₈% Senior Notes due 2028 are scheduled to mature on April 1, 2028. The 6⁷⁄₈% Senior Notes due 2028 are unconditionally guaranteed on a senior-priority unsecured basis by us and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

On January 23, 2020, we announced that CHS commenced a cash tender offer for any and all of the outstanding 5¹⁄₈% Senior Secured Notes due 2021. As of the early tender deadline on February 5, 2020, approximately $632 million aggregate principal amount of 5¹⁄₈% Senior Secured Notes due 2021, or approximately 63.25% of the outstanding 5¹⁄₈% Senior Secured Notes due 2021, had been validly tendered and not validly withdrawn. In connection with the commencement of the cash tender offer, CHS issued to holders of the 5¹⁄₈% Senior Secured Notes due 2021 a conditional notice of redemption to redeem all of the 5¹⁄₈% Senior Secured Notes due 2021 not purchased by CHS in the tender offer at a redemption price of 100.000% of the principal amount thereof plus accrued interest to, but not including, February 22, 2020.

On February 6, 2020, CHS completed a private offering of $1.462 billion aggregate principal amount of 6⁵⁄₈% Senior Secured Notes due 2025, or the 6⁵⁄₈% Senior Secured Notes due 2025. CHS used the net proceeds of the offering of the 6⁵⁄₈% Senior Secured Notes due 2025 to (i) purchase any and all of its 5¹⁄₈% Senior Secured Notes due 2021 validly tendered and not validly withdrawn in the cash tender offer announced on January 23, 2020, (ii) redeem all of the 5¹⁄₈% Senior Secured Notes due 2021 that were not purchased pursuant to such

78

tender offer, (iii) purchase in one or more privately negotiated transactions or redeem approximately $426 million aggregate principal amount of its 6¹⁄₄% Senior Secured Notes due 2023 and (iv) pay related fees and expenses. The 6⁵⁄₈% Senior Secured Notes due 2025 bear interest at a rate of 6.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2020. The 6⁵⁄₈% Senior Secured Notes due 2025 are scheduled to mature on February 15, 2025. The 6⁵⁄₈% Senior Secured Notes due 2025 are unconditionally guaranteed on a senior-priority secured basis by us and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 6⁵⁄₈% Senior Secured Notes due 2025 are secured by shared first-priority liens on the Non-ABL Priority Collateral and shared second-priority liens on the ABL Priority Collateral, in each case subject to certain exceptions.

As of December 31, 2019, we are currently a party to one interest rate swap agreement to limit the effect of changes in interest rates on all of our variable rate debt. We receive a variable rate of interest on this swap based on the three-month LIBOR, in exchange for the payment by us of a fixed rate of interest.

The ABL Facility and the indentures that govern our outstanding notes contain various covenants that limit our ability to take certain actions, including our ability to:

• incur, assume or guarantee additional indebtedness;

• issue redeemable stock and preferred stock;

• repurchase capital stock;

• make restricted payments, including paying dividends and making certain loans, acquisitions and investments;

• redeem debt that is subordinated in right of payment to our outstanding notes;

• create liens;

• sell or otherwise dispose of assets, including capital stock of subsidiaries;

• impair the security interests;

• enter into agreements that restrict dividends and certain other payments from subsidiaries;

• merge, consolidate, sell or otherwise dispose of substantially all of our assets;

• enter into transactions with affiliates; and

• guarantee certain obligations.

Our ability to meet the restricted covenants and financial ratios and tests in the ABL Facility and the indentures governing our outstanding notes can be affected by events beyond our control, and we cannot assure you that we will meet those tests. A breach of any of these covenants could result in a default under the ABL Facility and/or the indentures that govern our outstanding notes. Upon the occurrence of an event of default under the ABL Facility or indentures that govern our outstanding notes, all amounts outstanding under the ABL Facility and the indentures that govern our outstanding notes may become immediately due and payable and all commitments under the ABL Facility to extend further credit may be terminated.

We believe that internally generated cash flows and current levels of availability for additional borrowing under the ABL Facility, as well as our continued access to the capital markets, will be sufficient to finance acquisitions, capital expenditures, working capital requirements, and any debt repurchases or other debt repayments we may elect to make or be required to make through the next 12 months.

79

We may elect from time to time to purchase our outstanding debt in open market purchases, privately negotiated transactions or otherwise. Any such debt repurchases will depend upon prevailing market conditions, our liquidity requirements, contractual restrictions, applicable securities laws requirements, and other factors.

Off-balance Sheet Arrangements

Off-balance sheet arrangements consist of letters of credit of $145 million issued on the ABL Facility, primarily in support of potential insurance-related claims and certain bonds, as well as approximately $19 million representing the maximum potential amount of future payments under physician recruiting guarantee commitments in excess of the liability recorded at December 31, 2019.

As described more fully in Note 15 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K, at December 31, 2019, we have certain cash obligations for replacement facilities and other construction commitments of $85 million.

Noncontrolling Interests

We have sold noncontrolling interests in certain of our subsidiaries or acquired subsidiaries with existing noncontrolling interest ownership positions. As of December 31, 2019, we have hospitals in 10 of the markets we serve, with noncontrolling physician ownership interests ranging from 1% to 40%. In addition, as of December 31, 2019 we have nine other hospitals with noncontrolling interests owned by non-profit entities. On August 15, 2018, we completed the acquisition of the 20% ownership interest held by the non-profit entity that was the noncontrolling interest owner of two of our hospitals in Indiana for approximately $20 million. Redeemable noncontrolling interests in equity of consolidated subsidiaries was $502 million and $504 million as of December 31, 2019 and 2018, respectively, and noncontrolling interests in equity of consolidated subsidiaries was $77 million and $72 million as of December 31, 2019 and 2018, respectively. The amount of net income attributable to noncontrolling interests was $85 million, $84 million and $63 million for the years ended December 31, 2019, 2018 and 2017, respectively. As a result of the change in the Stark Law “whole hospital” exception included in the Affordable Care Act, we are not permitted to introduce physician ownership at any of our hospital facilities that did not have physician ownership at the time of the adoption of the Affordable Care Act, or increase the aggregate percentage of physician ownership in any of our former or existing hospital joint ventures in excess of the aggregate physician ownership level held at the time of the adoption of the Affordable Care Act.

Reimbursement, Legislative and Regulatory Changes

Ongoing legislative and regulatory efforts could reduce or otherwise adversely affect the payments we receive from Medicare and Medicaid and other payors. Within the statutory framework of the Medicare and Medicaid programs, there are substantial areas subject to agency regulations, administrative rulings, interpretations and discretion which may further affect payments made under those programs, and the federal and state governments might, in the future, reduce the funds available under those programs or require more stringent utilization and quality reviews of hospital facilities. Additionally, there may be a continued rise in managed care programs and additional restructuring of the financing and delivery of healthcare in the United States. These events could cause our future financial results to be adversely impacted. We cannot estimate the impact of Medicare and Medicaid reimbursement changes that have been enacted or are under consideration. We cannot predict whether additional reimbursement reductions will be made or whether any such changes or other restructuring of the financing and delivery of healthcare would have a material adverse effect on our business, financial conditions, results of operations, cash flow, capital resources and liquidity.

Inflation

The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. In addition, our suppliers pass along rising costs to us in the form

80

of higher prices. We have implemented cost control measures, including our case and resource management program, to curb increases in operating costs and expenses. We have generally offset increases in operating costs by increasing reimbursement for services, expanding services and reducing costs in other areas. However, we cannot predict our ability to cover or offset future cost increases, particularly any increases in our cost of providing health insurance benefits to our employees.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies are limited to those described below.

Revenue Recognition

Upon our adoption of the new revenue recognition standard in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification Topic 606, or ASC 606, we record net operating revenues at the transaction price estimated to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on our standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and patient price concessions. During the year ended December 31, 2019, the impact of changes to the inputs used to determine the transaction price was considered immaterial to the current period.

States utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the CMS and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, we recognize revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses.

Net operating revenues include amounts estimated by management to be reimbursable by Medicare and Medicaid under prospective payment systems and provisions of cost-reimbursement and other payment methods. In addition, we are reimbursed by non-governmental payors using a variety of payment methodologies. Amounts we receive for treatment of patients covered by these programs are generally less than our standard billing rates. Explicit price concessions are recorded for contractual allowances that are calculated and recorded through internally-developed data collection and analysis tools to automate the monthly estimation of required contractual allowances. Within this automated system, payors’ historical paid claims data are utilized to calculate the contractual allowances. This data is automatically updated on a monthly basis. All hospital contractual allowance calculations are subjected to monthly review by management to ensure reasonableness and accuracy. We account for the differences between the estimated program reimbursement rates and our standard billing rates as contractual allowance adjustments, which is one component of the deductions from gross revenues to arrive at net operating revenues. The process of estimating contractual allowances requires us to estimate the amount expected to be received based on payor contract provisions. The key assumption in this process is the estimated

81

contractual reimbursement percentage, which is based on payor classification, historical paid claims data and, when applicable, application of the expected managed care plan reimbursement based on contract terms.

Due to the complexities involved in these estimates, actual payments we receive could be different from the amounts we estimate and record. If the actual contractual reimbursement percentage under government programs and managed care contracts differed by 1% at December 31, 2019 from our estimated reimbursement percentage, net loss for the year ended December 31, 2019 would have changed by approximately $80 million, and net accounts receivable at December 31, 2019 would have changed by $102 million. Final settlements under some of these programs are subject to adjustment based on administrative review and audit by third parties. We account for adjustments to previous program reimbursement estimates as contractual allowance adjustments and report them in the periods that such adjustments become known. Contractual allowance adjustments related to final settlements and previous program reimbursement estimates impacted net operating revenues and net loss by an insignificant amount for each of the years ended December 31, 2019, 2018 and 2017.

Patient Accounts Receivable

Substantially all of our accounts receivable are related to providing healthcare services to patients at our hospitals and affiliated businesses. Collection of these accounts receivable is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to uninsured patients and outstanding patient balances for which the primary insurance payor has paid some but not all of the outstanding balance, with the remaining outstanding balance (generally deductibles and co-payments) owed by the patient. For all procedures scheduled in advance, our policy is to verify insurance coverage prior to the date of the procedure. Insurance coverage is not verified in advance of procedures for walk-in and emergency room patients.

We estimate any adjustments to the transaction price for implicit price concessions by reserving a percentage of all self-pay accounts receivable without regard to aging category, based on collection history, adjusted for expected recoveries and any anticipated changes in trends. Our ability to estimate the transaction price and any implicit price concessions is not impacted by not utilizing an aging of our net accounts receivable as we believe that substantially all of the risk exists at the point in time such accounts are identified as self-pay. The percentage used to reserve for all self-pay accounts is based on our collection history. We believe that we collect substantially all of our third-party insured receivables, which include receivables from governmental agencies.

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.

Patient accounts receivable can be impacted by the effectiveness of our collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. We also continually review the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions. If the actual collection percentage differed by 1% at December 31, 2019 from our estimated collection percentage as a result of a change in expected recoveries, net loss for the year ended December 31, 2019 would have changed by $53 million, and net accounts receivable at December 31, 2019 would have changed by $68 million. We also continually review our overall reserve adequacy by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as

82

by analyzing current period net revenue and admissions by payor classification, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Our policy is to write-off gross accounts receivable if the balance is under $10.00 or when such amounts are placed with outside collection agencies. We believe this policy accurately reflects our ongoing collection efforts and is consistent with industry practices. We had approximately $3.8 billion at December 31, 2019 and $4.7 billion December 31, 2018, being pursued by various outside collection agencies. We expect to collect less than 3%, net of estimated collection fees, of the amounts being pursued by outside collection agencies. As these amounts have been written-off, they are not included in our accounts receivable. Collections on amounts previously written-off are recognized as a recovery of net operating revenues when received. However, we take into consideration estimated collections of these future amounts written-off in determining the implicit price concessions used to measure the transaction price for the applicable portfolio of patient accounts receivable.

All of the following information is derived from our hospitals, excluding clinics, unless otherwise noted.

Patient accounts receivable from our hospitals represent approximately 98% of our total consolidated accounts receivable.

Days revenue outstanding, adjusted for the impact of receivables for state Medicaid supplemental payment programs, was 58 days at both December 31, 2019 and 2018.

Total gross accounts receivable (prior to allowance for contractual adjustments and implicit price concessions) was approximately $16.6 billion as of December 31, 2019 and approximately $17.2 billion as of December 31, 2018. The approximate percentage of total gross accounts receivable (prior to allowance for contractual adjustments and implicit price concessions) summarized by aging categories is as follows:

As of December 31, 2019:

	% of Gross Receivables
Payor	0 - 90 Days			90 - 180 Days			180 - 365 Days			Over 365 Days
Medicare		13	%		1	%		-	%		1	%
Medicaid		6	%		1	%		1	%		1	%
Managed Care and Other		27	%		4	%		3	%		2	%
Self-Pay		9	%		8	%		10	%		13	%

As of December 31, 2018:

	% of Gross Receivables
Payor	0 - 90 Days			90 - 180 Days			180 - 365 Days			Over 365 Days
Medicare		14	%		-	%		-	%		-	%
Medicaid		7	%		1	%		1	%		1	%
Managed Care and Other		26	%		4	%		3	%		3	%
Self-Pay		9	%		8	%		10	%		13	%

The approximate percentage of total gross accounts receivable (prior to allowances for contractual adjustments and implicit price concessions) summarized by payor is as follows:

	December 31,
	2019			2018
Insured receivables		59.5	%		60.0	%
Self-pay receivables		40.5			40.0
Total		100.0	%		100.0	%

83

The combined total at our hospitals and clinics for the estimated implicit price concessions for self-pay accounts receivable and allowances for other self-pay discounts and contractuals, as a percentage of gross self-pay receivables, was approximately 90% at both December 31, 2019 and December 31, 2018. If the receivables that have been written-off, but where collections are still being pursued by outside collection agencies, were included in both the allowances and gross self-pay receivables specified above, the percentage of combined allowances to total self-pay receivables would have been 94% at both December 31, 2019 and December 31, 2018.

Goodwill and Other Intangibles

Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. During 2017, we early adopted Accounting Standards Update, or ASU 2017-04, which allows a company to record a goodwill impairment when the reporting units carrying value exceeds the fair value determined in step one. Our most recent goodwill evaluation was performed during the fourth quarter of 2019 with an October 31, 2019 measurement date, which indicated no impairment.

At December 31, 2019, we had approximately $4.3 billion of goodwill recorded, all of which resides at our hospital operations reporting unit.

While no impairment was indicated in our annual goodwill evaluation as of the October 31, 2019 and October 31, 2018 measurement dates, the reduction in our fair value and the resulting goodwill impairment charges recorded in 2016 and 2017 reduced the carrying value of our hospital operations reporting unit to an amount equal to our estimated fair values as of such prior year measurement dates. This increases the risk that future declines in fair value could result in goodwill impairment. The determination of fair value in step one of our goodwill impairment analysis is based on an estimate of fair value for the hospital operations reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of our common stock or fair value of our long-term debt, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including further decline in our stock price or fair value of our long-term debt, lower than expected hospital volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of our fair value could result in a material impairment charge in the future.

Impairment or Disposal of Long-Lived Assets

Whenever events or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, we project the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the reported amounts are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimate based on valuation techniques available in the circumstances.

Professional Liability Claims

As part of our business of owning and operating hospitals, we are subject to legal actions alleging liability on our part. We accrue for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. We do not accrue for costs that are part of our corporate overhead, such as the costs of our in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, our historical claim reporting and payment patterns, the nature and

84

level of our hospital operations, and actuarially determined projections. The actuarially determined projections are based on our actual claim data, including historic reporting and payment patterns which have been gathered over an approximately 20-year period. As discussed below, since we purchase excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability we accrue does include an amount for the losses covered by our excess insurance. We also record a receivable for the expected reimbursement of losses covered by our excess insurance. Since we believe that the amount and timing of our future claims payments are reliably determinable, we discount the amount we accrue for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of our expected payments.

The net present value of the projected payments was discounted using a weighted-average risk-free rate 2.6%, 3.1%, and 2.2% in 2019, 2018 and 2017, respectively. This liability is adjusted for new claims information in the period such information becomes known to us. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as paid excess insurance premiums, and is presented within other operating expenses in the accompanying consolidated statements of loss.

Our processes for obtaining and analyzing claims and incident data are standardized across all of our hospitals and have been consistent for many years. We monitor the outcomes of the medical care services that we provide and for each reported claim, we obtain various information concerning the facts and circumstances related to that claim. In addition, we routinely monitor current key statistics and volume indicators in our assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between three and four years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent approximately 1.0% of the total liability at the end of any period.

For purposes of estimating our individual claim accruals, we utilize specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years, geography, and claims relating to the acquired HMA hospitals versus claims relating to our other hospitals. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses our company-specific historical claims data and other information. This company-specific data includes information regarding our business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

85

Based on these analyses, we determine our estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of management. Changes in reserving data or the trends and factors that influence reserving data may signal fundamental shifts in our future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since our methods and models use different types of data and we select our liability from the results of all of these methods, we typically cannot quantify the precise impact of such factors on our estimates of the liability. Due to our standardized and consistent processes for handling claims and the long history and depth of our company-specific data, our methodologies have historically produced reliably determinable estimates of ultimate paid losses. Management considers any changes in the amount and pattern of its historical paid losses up through the most recent reporting period to identify any fundamental shifts or trends in claim development experience in determining the estimate of professional liability claims. However, due to the subjective nature of this estimate and the impact that previously unforeseen shifts in actual claim experience can have, future estimates of professional liability could be adversely impacted when actual paid losses develop unexpectedly based on assumptions and settlement events that were not previously known or anticipated.

	Year Ended December 31,
	2019		2018		2017
Accrual for professional liability claims, beginning of year	$	650	$	711	$	788
Liability for insured claims (1)		(11)		(21)		4
Expense (income) related to:
Current accident year		115		161		149
Prior accident years		136		14		(4)
Expense (income) from discounting		12		(12)		(4)
Total incurred loss and loss expense (2)		263		163		141
Paid claims and expenses related to:
Current accident year		(1)		-		-
Prior accident years		(289)		(203)		(222)
Total paid claims and expenses		(290)		(203)		(222)
Accrual for professional liability claims, end of year	$	612	$	650	$	711

(1) The liability for insured claims is recorded on the consolidated balance sheet with a corresponding insurance recovery receivable.

(2) Total expense, including premiums for insured coverage, was $298 million in 2019, $199 million in 2018 and $184 million in 2017.

During the year ended December 31, 2019, we experienced a significant increase in the amounts paid to settle outstanding professional liability claims, compared to the same period in the prior year and to previous actuarially determined estimates. This increase in claims paid related to claims incurred in 2016 and prior years and was primarily related to divested hospitals. The settlement of these claims at amounts greater than the previously determined actuarial estimates resulted in us recording a $70 million change in estimate during the three months ended June 30, 2019, and an additional $20 million change in estimate during the three months ended September 30, 2019 based on updated actuarial estimates. No additional change in estimate related to these claims was recorded during the three months ended December 31, 2019.

We are primarily self-insured for these claims; however, we obtain excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of our self-insured retentions. Our excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of our professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per

86

occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 and before June 1, 2018 are self-insured up to $10 million per claim. Substantially all claims reported on or after June 1, 2018 are self-insured up to $15 million per claim. Management, on occasion, has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers us for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to at least $215 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated occurrence malpractice claims, there is an additional $50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $75 million of excess coverage for claims reported on or after June 1, 2015. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until our total aggregate coverage is met. Beginning June 1, 2018, this drop-down provision in the excess policies attaches over the $15 million per claim self-insured retention.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,” provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

Effective January 1, 2008, the former Triad hospitals were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims occurring on or after January 1, 2002 and reported on or after January 1, 2008. Substantially all losses for the former Triad hospitals in periods prior to May 1, 1999 were insured through a wholly-owned insurance subsidiary of HCA, Triad’s owner prior to that time, and excess loss policies maintained by HCA. HCA has agreed to indemnify the former Triad hospitals in respect of claims covered by such insurance policies arising prior to May 1, 1999. From May 1, 1999 through December 31, 2006, the former Triad hospitals obtained insurance coverage on a claims incurred basis from HCA’s wholly-owned insurance subsidiary with excess coverage obtained from other carriers that is subject to certain deductibles. Effective for claims incurred after December 31, 2006, Triad began insuring its claims from $1 million to $5 million through its wholly-owned captive insurance company, replacing the coverage provided by HCA. Substantially all claims occurring during 2007 were self-insured up to $10 million per claim.

Income Taxes

We must make estimates in recording provision for income taxes, including determination of deferred tax assets and deferred tax liabilities and any valuation allowances that might be required against the deferred tax assets. We believe that future income will enable us to realize certain deferred tax assets, subject to the valuation allowance we have established.

87

The total amount of unrecognized benefit that would impact the effective tax rate, if recognized, was approximately $1 million as of December 31, 2019. A total of approximately $1 million of interest and penalties is included in the amount of liability for uncertain tax positions at December 31, 2019. It is our policy to recognize interest and penalties related to unrecognized benefits in our consolidated statements of loss as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, we do not anticipate the change will have a material impact on our consolidated results of operations or consolidated financial position.

Our federal income tax returns for the 2009 and 2010 tax years have been settled with the Internal Revenue Service. The results of these examinations were not material to our consolidated results of operations or consolidated financial position. Our federal income tax returns for the 2014 and 2015 tax years remain under examination by the Internal Revenue Service. We believe the results of these examinations will not be material to our consolidated results of operations or consolidated financial position. We have extended the federal statute of limitations through December 31, 2020 for Community Health Systems, Inc. for the tax periods ended December 31, 2014 and 2015.

We have accounted for the effects of the Tax Act using reasonable estimates based on currently available information and our interpretations thereof, and the estimated impact of the Tax Act during the years ended December 31, 2019 and 2018. We finalized our accounting for the Tax Act in the fourth quarter of 2018 in accordance with the prescribed measurement period under SAB 118. See Note 5 of the Notes to Consolidated Financial Statements included under Part II, Item 8 of this Form 10-K for additional information.

Recent Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-15 to provide guidance on the accounting for implementation costs incurred in a cloud computing arrangement (CCA) that is a service contract. This ASU requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. We adopted this ASU on January 1, 2020, and do not expect the adoption of this ASU will have a material impact on our consolidated financial position and results of operations.

In June 2016, the FASB issued ASU 2016-13, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses, or CECL, model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. We adopted this ASU on January 1, 2020, and do not expect the adoption of this ASU will have a material impact on our consolidated financial position and results of operations.

FORWARD-LOOKING STATEMENTS

Some of the matters discussed in this Report include “forward-looking statements” within the meaning of the federal securities laws, which involve risks, assumptions and uncertainties. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “thinks,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors that may cause

88

our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, among other things:

• general economic and business conditions, both nationally and in the regions in which we operate;

• the impact of current or future federal and state health reform initiatives, including, without limitation, the Affordable Care Act, and the potential for the Affordable Care Act to be repealed, or found unconstitutional or otherwise invalidated, or for additional changes to the law, its implementation or its interpretation (including through executive orders and court challenges);

• the extent to and manner in which states support increases, decreases or changes in Medicaid programs, implement health insurance exchanges or alter the provision of healthcare to state residents through regulation or otherwise;

• the future and long-term viability of health insurance exchanges and potential changes to the beneficiary enrollment process;

• risks associated with our substantial indebtedness, leverage and debt service obligations, and the fact that a substantial portion of our indebtedness will mature and become due in the near future, including our ability to refinance such indebtedness on acceptable terms or to incur additional indebtedness, and our ability to remain in compliance with debt covenants;

• demographic changes;

• changes in, or the failure to comply with, federal, state or local laws or governmental regulations affecting our business;

• potential adverse impact of known and unknown government investigations, audits, and federal and state false claims act litigation and other legal proceedings;

• our ability, where appropriate, to enter into and maintain provider arrangements with payors and the terms of these arrangements, which may be further affected by the increasing consolidation of health insurers and managed care companies and vertical integration efforts involving payors and healthcare providers;

• changes in, or the failure to comply with, contract terms with payors and changes in reimbursement policies or rates paid by federal or state healthcare programs or commercial payors;

• any potential additional impairments in the carrying value of goodwill, other intangible assets, or other long-lived assets, or changes in the useful lives of other intangible assets;

• changes in inpatient or outpatient Medicare and Medicaid payment levels and methodologies;

• the effects related to the continued implementation of the sequestration spending reductions and the potential for future deficit reduction legislation;

• increases in the amount and risk of collectability of patient accounts receivable, including decreases in collectability which may result from, among other things, self-pay growth and difficulties in recovering payments for which patients are responsible, including co-pays and deductibles;

• the efforts of insurers, healthcare providers, large employer groups and others to contain healthcare costs, including the trend toward value-based purchasing;

• increases in wages as a result of inflation or competition for highly technical positions and rising supply and drug costs due to market pressure from pharmaceutical companies and new product releases;

89

• liabilities and other claims asserted against us, including self-insured malpractice claims;

• competition;

• our ability to attract and retain, at reasonable employment costs, qualified personnel, key management, physicians, nurses and other healthcare workers;

• trends toward treatment of patients in less acute or specialty healthcare settings, including ambulatory surgery centers or specialty hospitals;

• changes in medical or other technology;

• changes in U.S. GAAP;

• the availability and terms of capital to fund any additional acquisitions or replacement facilities or other capital expenditures;

• our ability to successfully make acquisitions or complete divestitures, including the disposition of hospitals and non-hospital businesses pursuant to our portfolio rationalization and deleveraging strategy, our ability to complete any such acquisitions or divestitures on desired terms or at all, the timing of the completion of any such acquisitions or divestitures, and our ability to realize the intended benefits from any such acquisitions or divestitures;

• the impact that changes in our relationships with joint venture or syndication partners could have on effectively operating our hospitals or ancillary services or in advancing strategic opportunities;

• our ability to successfully integrate any acquired hospitals, or to recognize expected synergies from acquisitions;

• the impact of seasonal severe weather conditions, including the timing and amount of insurance recoveries in relation to severe weather events;

• our ability to obtain adequate levels of insurance, including general liability, professional liability, and directors and officers liability insurance;

• timeliness of reimbursement payments received under government programs;

• effects related to pandemics, epidemics, or outbreaks of infectious diseases, including the coronavirus known as COVID-19;

• the impact of prior or potential future cyber-attacks or security breaches;

• any failure to comply with the terms of the Corporate Integrity Agreement;

• the concentration of our revenue in a small number of states;

• our ability to realize anticipated cost savings and other benefits from our current strategic and operational cost savings initiatives;

• changes in interpretations, assumptions and expectations regarding the Tax Cuts and Jobs Act; and

• the other risk factors set forth in this Form 10-K for the year ended December 31, 2019 and our other public filings with the SEC.

90

Although we believe that these forward-looking statements are based upon reasonable assumptions, these assumptions are inherently subject to significant regulatory, economic and competitive uncertainties and contingencies, which are difficult or impossible to predict accurately and may be beyond our control. Accordingly, we cannot give any assurance that our expectations will in fact occur, and we caution that actual results may differ materially from those in the forward-looking statements. Given these uncertainties, prospective investors are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are made as of the date of this filing. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to interest rate changes, primarily as a result of the ABL Facility which bears interest based on floating rates. In order to manage the volatility relating to the market risk, we entered into interest rate swap agreements to manage our exposure to these fluctuations, as described under the heading “Liquidity and Capital Resources” in Part II, Item 7 of this Form 10-K. We utilize risk management procedures and controls in executing derivative financial instrument transactions. We do not execute transactions or hold derivative financial instruments for trading purposes. Derivative financial instruments related to interest rate sensitivity of debt obligations are used with the goal of mitigating a portion of the exposure when it is cost effective to do so. As of December 31, 2019, our one outstanding interest rate swap agreement with a notional amount of $300 million exceeded our remaining variable rate debt.

A 1% change in interest rates on variable rate debt in excess of that amount covered by interest rate swaps would have resulted in interest expense fluctuating approximately $3 million in 2019, $11 million in 2018 and $27 million in 2017. On a prospective basis, a 1% change in interest rates on the remaining unhedged variable rate debt existing as of December 31, 2019, would result in interest expense fluctuating less than $1 million per year.

91

Item 8. Financial Statements and Supplementary Data

Index to Financial Statements

	Page
Community Health Systems, Inc. Consolidated Financial Statements:
Report of Independent Registered Public Accounting Firm		93
Consolidated Statements of Loss for the Years Ended December  31, 2019, 2018 and 2017		94
Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2019, 2018 and 2017		95
Consolidated Balance Sheets as of December 31, 2019 and 2018		96
Consolidated Statements of Stockholders’ (Deficit) Equity for the Years Ended December 31, 2019, 2018 and 2017		97
Consolidated Statements of Cash Flows for the Years Ended December  31, 2019, 2018 and 2017		98
Notes to Consolidated Financial Statements		99

92

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of

Community Health Systems, Inc.

Franklin, Tennessee

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Community Health Systems, Inc. and subsidiaries (the “Company”) as of December 31, 2019 and 2018, the related consolidated statements of loss, comprehensive loss, stockholders’ (deficit) equity, and cash flows, for each of the three years in the period ended December 31, 2019, and the related notes and the schedule listed in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 20, 2020, expressed an unqualified opinion on the Company’s internal control over financial reporting.

Change in Accounting Principle

As discussed in Note 1 to the financial statements, the Company has adopted Accounting Standards Codification Topic 842, “Leases”, using the modified retrospective adoption method on January 1, 2019.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Deloitte & Touche LLP

Nashville, Tennessee

February 20, 2020

We have served as the Company’s auditor since 1996.

93

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF LOSS

	Year Ended December 31,
	2019			2018			2017
	(In millions, except share and per share data)
Operating revenues (net of contractual allowances and discounts)							$	18,398
Provision for bad debts								3,045
Net operating revenues (see Note 1)	$	13,210		$	14,155			15,353
Operating costs and expenses:
Salaries and benefits		5,947			6,384			7,376
Supplies		2,151			2,355			2,672
Other operating expenses		3,303			3,496			3,864
Government and other legal settlements and related costs		93			11			(31	)
Electronic health records incentive reimbursement		(1	)		(4	)		(28	)
Lease cost and rent		321			337			394
Depreciation and amortization		608			700			861
Impairment and loss on sale of businesses, net		138			668			2,123
Total operating costs and expenses		12,560			13,947			17,231
Income from operations		650			208			(1,878	)
Interest expense, net of interest income of $3, $7, and $11 in 2019, 2018 and 2017, respectively		1,041			976			931
Loss (gain) from early extinguishment of debt		54			(31	)		40
Equity in earnings of unconsolidated affiliates		(15	)		(22	)		(16	)
Loss from continuing operations before income taxes		(430	)		(715	)		(2,833	)
Provision for (benefit from) income taxes		160			(11	)		(449	)
Loss from continuing operations		(590	)		(704	)		(2,384	)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-			-			(6	)
Impairment of hospitals sold or held for sale		-			-			(6	)
Loss from discontinued operations, net of taxes		-			-			(12	)
Net loss		(590	)		(704	)		(2,396	)
Less: Net income attributable to noncontrolling interests		85			84			63
Net loss attributable to Community Health Systems,
Inc. stockholders	$	(675	)	$	(788	)	$	(2,459	)
Basic loss per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	(5.93	)	$	(6.99	)	$	(21.89	)
Discontinued operations		-			-			(0.11	)
Net loss	$	(5.93	)		(6.99	)		(22.00	)
Diluted loss per share attributable to Community
Health Systems, Inc. common stockholders:
Continuing operations	$	(5.93	)	$	(6.99	)	$	(21.89	)
Discontinued operations		-			-			(0.11	)
Net loss	$	(5.93	)	$	(6.99	)	$	(22.00	)
Weighted-average number of shares outstanding:
Basic		113,739,046			112,728,274			111,769,821
Diluted		113,739,046			112,728,274			111,769,821

See accompanying notes to the consolidated financial statements.

94

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Year Ended December 31,
	2019			2018			2017
	(In millions)
Net loss	$	(590	)	$	(704	)	$	(2,396	)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax of $1, $6 and $10 for the years ended December 31, 2019, 2018 and 2017, respectively		(3	)		20			19
Net change in fair value of available-for-sale debt securities, net of tax		4			(2	)		8
Amortization and recognition of unrecognized pension cost components, net of tax of $0, $1 and $9 for the year ended December 31, 2019, 2018, and 2017, respectively		-			(1	)		14
Other comprehensive income		1			17			41
Comprehensive loss		(589	)		(687	)		(2,355	)
Less: Comprehensive income attributable to noncontrolling interests		85			84			63
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	$	(674	)	$	(771	)	$	(2,418	)

See accompanying notes to the consolidated financial statements.

95

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31, 2019			December 31, 2018
	(In millions, except share data)
ASSETS
Current assets:
Cash and cash equivalents	$	216		$	196
Patient accounts receivable (see Note 1)		2,258			2,352
Supplies		354			402
Prepaid income taxes		48			3
Prepaid expenses and taxes		193			196
Other current assets		358			400
Total current assets		3,427			3,549
Property and equipment
Land and improvements		560			597
Buildings and improvements		5,878			6,228
Equipment and fixtures		3,215			3,476
Property and equipment		9,653			10,301
Less accumulated depreciation and amortization		(4,045	)		(4,162	)
Property and equipment, net		5,608			6,139
Goodwill		4,328			4,559
Deferred income taxes		38			69
Other assets, net of accumulated amortization of $981 and $939 at December 31, 2019 and 2018, respectively		2,208			1,543
Total assets	$	15,609		$	15,859
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Current maturities of long-term debt	$	20		$	204
Current operating lease liabilities		136			-
Accounts payable		811			887
Accrued liabilities:
Employee compensation		594			627
Accrued interest		189			206
Other		532			468
Total current liabilities		2,282			2,392
Long-term debt		13,385			13,392
Deferred income taxes		200			26
Long-term operating lease liabilities		487			-
Other long-term liabilities		894			1,008
Total liabilities		17,248			16,818
Redeemable noncontrolling interests in equity of consolidated subsidiaries		502			504
Commitments and contingencies (Note 15)
STOCKHOLDERS’ DEFICIT
Community Health Systems, Inc. stockholders’ deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued		-			-
Common stock, $.01 par value per share, 300,000,000 shares authorized; 117,822,631 shares issued and outstanding at December 31, 2019, and 116,248,376 shares issued and outstanding at December 31, 2018		1			1
Additional paid-in capital		2,008			2,017
Accumulated other comprehensive loss		(9	)		(10	)
Accumulated deficit		(4,218	)		(3,543	)
Total Community Health Systems, Inc. stockholders’ deficit		(2,218	)		(1,535	)
Noncontrolling interests in equity of consolidated subsidiaries		77			72
Total stockholders’ deficit		(2,141	)		(1,463	)
Total liabilities and stockholders’ deficit	$	15,609		$	15,859

See accompanying notes to the consolidated financial statements.

96

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

				Community Health Systems, Inc. Stockholders
	Redeemable Noncontrolling Interests			Common Stock					Additional Paid-in Capital			Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Noncontrolling Interests			Total Stockholders’ (Deficit) Equity
				Shares			Amount
				(In millions, except share data)
Balance, December 31, 2016	$	554			113,876,580		$	1	$	1,975		$	(62	)	$	(299	)	$	113		$	1,728
Comprehensive income (loss)		38			-			-		-			41			(2,459	)		25			(2,393	)
Contributions from noncontrolling interests		-			-			-		-			-			-			5			5
Distributions to noncontrolling interests		(71	)		-			-		-			-			-			(29	)		(29	)
Purchase of subsidiary shares from noncontrolling interests		(4	)		-			-		(2	)		-			-			-			(2	)
Disposition of less-than-wholly owned hospital		2			-			-		-			-			-			(10	)		(10	)
Other reclassifications of noncontrolling interests		29																	(29	)		(29	)
Noncontrolling interests in acquired entity		1			-			-		-			-			-			-			-
Adjustment to redemption value of redeemable noncontrolling interests		(22	)		-			-		22			-			-			-			22
Distribution of Quorum Health Corporation		-			-			-		-			-			(3	)		-			(3	)
Cancellation of restricted stock for tax withholdings on vested shares		-			(560,098	)		-		(5	)		-			-			-			(5	)
Stock-based compensation		-			1,334,522			-		24			-			-			-			24
Balance, December 31, 2017		527			114,651,004			1		2,014			(21	)		(2,761	)		75			(692	)
Comprehensive income (loss)		54			-			-		-			17			(788	)		30			(741	)
Adoption of new accounting standards		-			-			-		-			(6	)		6			-			-
Contributions from noncontrolling interests		3			-			-		-			-			-			-			-
Distributions to noncontrolling interests		(68	)		-			-		-			-			-			(28	)		(28	)
Purchase of subsidiary shares from noncontrolling interests		(24	)		-			-		(4	)		-			-			(3	)		(7	)
Other reclassifications of noncontrolling interests		1			-			-		-			-			-			(2	)		(2	)
Noncontrolling interests in acquired entity		6			-			-		-			-			-			-			-
Adjustment to redemption value of redeemable noncontrolling interests		5			-			-		(5	)		-			-			-			(5	)
Cancellation of restricted stock for tax withholdings on vested shares		-			(293,735	)		-		(1	)		-			-			-			(1	)
Income tax payable increase from vesting of restricted shares		-			333			-		-			-			-			-			-
Stock-based compensation		-			1,890,774			-		13			-			-			-			13
Balance, December 31, 2018		504			116,248,376			1		2,017			(10	)		(3,543	)		72			(1,463	)
Comprehensive income (loss)		52			-			-		-			1			(675	)		33			(641	)
Contributions from noncontrolling interests		3			-			-		-			-			-			7			7
Distributions to noncontrolling interests		(68	)		-			-		-			-			-			(31	)		(31	)
Purchase of subsidiary shares from noncontrolling interests		(8	)		-			-		3			-			-			(6	)		(3	)
Other reclassifications of noncontrolling interests		(2	)		-			-		-			-			-			2			2
Adjustment to redemption value of redeemable noncontrolling interests		21			-			-		(21	)		-			-			-			(21	)
Cancellation of restricted stock for tax withholdings on vested shares		-			(298,182	)		-		(1	)		-			-			-			(1	)
Income tax payable increase from vesting of restricted shares		-			333			-		-			-			-			-			-
Stock-based compensation		-			1,872,104			-		10			-			-			-			10
Balance, December 31, 2019	$	502			117,822,631		$	1	$	2,008		$	(9	)	$	(4,218	)	$	77		$	(2,141	)

See accompanying notes to the consolidated financial statements.

97

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,
	2019			2018			2017
	(In millions)
Cash flows from operating activities:
Net loss	$	(590	)	$	(704	)	$	(2,396	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization		608			700			861
Deferred income taxes		203			(3	)		(454	)
Government and other legal settlements and related costs		51			11			9
Stock-based compensation expense		10			13			24
Impairment of hospitals sold or held for sale		-			-			6
Impairment and loss on sale of businesses, net		138			668			2,123
Loss (gain) from early extinguishment of debt		54			(31	)		40
Other non-cash expenses, net		182			38			35
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable		93			31			732
Supplies, prepaid expenses and other current assets		38			16			(33	)
Accounts payable, accrued liabilities and income taxes		(157	)		(163	)		(69	)
Payment of HMA legal settlement		-			(266	)		-
Other		(245	)		(36	)		(105	)
Net cash provided by operating activities		385			274			773
Cash flows from investing activities:
Acquisitions of facilities and other related businesses		(13	)		(26	)		(6	)
Purchases of property and equipment		(438	)		(527	)		(564	)
Proceeds from disposition of hospitals and other ancillary operations		604			405			1,692
Proceeds from sale of property and equipment		3			8			7
Purchases of available-for-sale debt securities and equity securities		(80	)		(78	)		(125	)
Proceeds from sales of available-for-sale debt securities and equity securities		92			114			208
Increase in other investments		(170	)		(141	)		(143	)
Net cash (used in) provided by investing activities		(2	)		(245	)		1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(1	)		(1	)		(5	)
Deferred financing costs and other debt-related costs		(46	)		(96	)		(66	)
Proceeds from noncontrolling investors in joint ventures		10			3			5
Redemption of noncontrolling investments in joint ventures		(11	)		(31	)		(6	)
Distributions to noncontrolling investors in joint ventures		(99	)		(96	)		(100	)
Proceeds from sale-lease back		60			-			-
Borrowings under credit agreements		37			28			841
Issuance of long-term debt		3,042			1,033			3,100
Proceeds from ABL Facility		202			797			105
Repayments of long-term indebtedness		(3,557	)		(2,033	)		(5,391	)
Net cash used in financing activities		(363	)		(396	)		(1,517	)
Net change in cash and cash equivalents		20			(367	)		325
Cash and cash equivalents at beginning of period		196			563			238
Cash and cash equivalents at end of period	$	216		$	196		$	563
Supplemental disclosure of cash flow information:
Interest payments	$	(1,011	)	$	(936	)	$	(852	)
Income tax refunds (payments), net	$	3		$	19		$	(4	)

See accompanying notes to the consolidated financial statements.

98

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.  BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business.    Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals in communities across the country. As of December 31, 2019, the Company owned or leased 102 hospitals, included in continuing operations, including two stand-alone rehabilitation or psychiatric hospitals, licensed for 16,240 beds in 18 states. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

As of December 31, 2019, Florida, Texas and Indiana represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated operating revenues, were 14.3% in both 2019 and 2018 and 14.0% in 2017. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated operating revenues, were 12.2% in 2019, 11.7% in 2018 and 10.9% in 2017. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated operating revenues, were 13.7% in 2019, 12.5% in 2018 and 11.6% in 2017.

Use of Estimates.    The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation.    The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from continuing operations from these subsidiaries are included in the consolidated amounts as presented on the consolidated statements of loss, along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the consolidated balance sheets.

Cost of Revenue.    Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $184 million, $181 million and $189 million for the years ended December 31, 2019, 2018 and 2017, respectively. Included in these corporate office costs is stock-based compensation of $10 million, $13 million and $24 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Cash Equivalents.    The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.

Supplies.    Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.

99

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Marketable Securities.    Prior to adoption of Accounting Standards Update (“ASU”) 2016-01 on January 1, 2018, the Company’s marketable securities were classified as trading or available-for-sale. Trading securities were reported at fair value with unrealized gains and losses included in earnings. Available-for-sale securities were carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. After adoption of ASU 2016-01 on January 1, 2018, the Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Equity securities are reported at fair value with changes in fair value included in earnings. Available-for-sale debt securities are carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized gain of $4 million and $8 million during the years ended December 31, 2019 and 2017, respectively, and an unrealized loss of $2 million during the year ended December 31, 2018, related to these available-for-sale debt securities.

Property and Equipment.    Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $219 million at both December 31, 2019 and 2018. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $20 million, $15 million and $11 million for the years ended December 31, 2019, 2018 and 2017, respectively. Purchases of property and equipment and internal-use software accrued in accounts payable and not yet paid were $93 million and $115 million at December 31, 2019 and 2018, respectively.

The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2019, the Company had non-cash investing activity of $6 million related to certain facility and equipment additions that were financed through finance leases and other debt.

Goodwill.    Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. As further discussed in Note 4, the Company recorded an impairment charge of $1.419 billion during the year ended December 31, 2017. There was no goodwill impairment charge during the years ended December 31, 2019 and 2018 as a result of the Company’s annual impairment evaluation.

Other Assets.    Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured malpractice general liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software and eight to ten years for major software projects, and included in amortization expense. Included in the increase in other investments in the consolidated statement of cash flows for the year ended December 31, 2019, was cash paid of approximately $28 million to increase investments in certain equity method investments.

100

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Revenue Recognition.    On January 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the FASB Accounting Standards Codification (“ASC”) as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, upon the Company’s adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore was included as a reduction to net operating revenues in 2019 and 2018. For changes in credit issues not assessed at the date of service, the Company prospectively recognizes those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required such provision to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately $3.9 billion as of January 1, 2018 was reclassified as a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated results of operations for the years ended December 31, 2019 and 2018, and the Company does not expect it to have a material impact on its consolidated results of operations on a prospective basis.

As part of the adoption of ASC 606, the Company elected two of the available practical expedients provided for in the standard. First, the Company does not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expenses all incremental customer contract acquisition costs as incurred because such costs are not material and would be amortized over a period less than one year.

Net Operating Revenues

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During the years ended December 31, 2019 and 2018, the impact of changes to the inputs used to determine the transaction price was considered immaterial to the current period.

States utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses.

101

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The Company’s net operating revenues during the years ended December 31, 2019 and 2018 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions):

	Year Ended December 31,
	2019		2018
Medicare	$	3,331	$	3,730
Medicaid		1,736		1,876
Managed Care and other third-party payors		8,014		8,349
Self-pay		129		200
Total	$	13,210	$	14,155

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts) by payor have been presented in the following table for the year ended December 31, 2017, as follows, consistent with the presentation prior to the adoption of ASC 606 on January 1, 2018 (in millions):

	Year Ended December 31, 2017
Medicare	$	4,188
Medicaid		1,900
Managed Care and other third-party payors		9,991
Self-pay		2,319
Total	$	18,398

Patient Accounts Receivable

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.

Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $83 million and $144 million as of December 31, 2019 and December 31, 2018, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due

102

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

from third-party payors were $137 million and $155 million as of December 31, 2019 and December 31, 2018, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2016.

Charity Care

In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government.

These charity care services are estimated to be $540 million, $491 million and $482 million for the years ended December 31, 2019, 2018 and 2017, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $66 million, $62 million and $62 million for the years ended December 31, 2019, 2018 and 2017, respectively. The estimated cost of these charity care services was determined using a ratio of cost to gross charges and applying that ratio to the gross charges associated with providing care to charity patients for the period.

During 2017 and culminating with the financial close process at December 31, 2017, the Company developed new accounting methodologies and processes to implement ASU 2014-09, the accounting standard for revenue recognition that was adopted by the Company effective January 1, 2018. By implementing new data extraction techniques and updated hindsight information on historical collection data, the Company was able to better estimate the net amount after contractual allowances owed by the third-party payor and what will be owed by the patient based on historical experience. Such updated information included portfolio-level data related to historical collection amounts on an individual hospital and patient level that previously had not been readily available. Using this information the Company created a new accounting process by which it can estimate contractual allowances on a per patient basis. In addition to this new accounting methodology, the Company also revised its methods of estimating contractual allowances to (1) expand the hindsight period over which the Company analyzes payors’ historical paid claims data to estimate contractual allowances, (2) expand the basis for payor denied claims to refine the hindsight reserve for such denials, and (3) adjust the contractual allowances for certain categories of commercial payors using more precise historical experience based on recent patterns of account reimbursement. Additionally, the Company evaluated the estimated collection of those amounts due from the patient as part of the Company’s estimate of the allowance for doubtful accounts. This analysis also included an evaluation of patient accounts receivable retained after the divestiture of 30 hospitals throughout 2017, and certain other revenues. Based on these new accounting processes and methodologies, the Company recorded a change in estimate during the three months ended December 31, 2017 to increase contractual allowances by approximately $197 million, and to record additional provision for bad debts and increase the allowance for doubtful accounts by $394 million. The total impact of the change in estimate recorded during the three months ended December 31, 2017 was a decrease to net operating revenues of $591 million.

Electronic Health Records Incentive Reimbursement.    The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate

103

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $1 million, $4 million and $28 million for the years ended December 31, 2019, 2018 and 2017, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the consolidated statements of loss. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately less than $1 million, $4 million and $41 million for the years ended December 31, 2019, 2018 and 2017, respectively. The Company recorded no deferred revenue in connection with the receipt of these cash payments at December 31, 2019, 2018 or 2017.

Leases.    On January 1, 2019, the Company adopted the cumulative accounting standard updates initially issued by the FASB in February 2016 that amend the accounting for leases and are codified as Accounting Standards Codification Topic 842 (“ASC 842”). These changes to the lease accounting model require operating leases be recorded on the balance sheet through recognition of a liability for the discounted present value of future fixed lease payments and a corresponding right-of-use (“ROU”) asset. The Company’s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a

104

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company elected the amended transition requirements allowed for by the FASB in ASU 2018-11, which provide entities relief by allowing them not to recast prior comparative periods from the adoption of ASC 842. As a result, the prior year comparative financial statements have not been restated to reflect the adoption of ASC 842. Additionally, the Company elected the package of practical expedients available in ASC 842 upon adoption whereby an entity need not reassess expired contracts for lease identification or classification as a finance or operating lease, or for the reassessment of initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. Certain of the Company’s lease agreements have lease and non-lease components, which for the majority of leases the Company accounts for separately when the actual lease and non-lease components are determinable. For equipment leases with immaterial non-lease components incorporated into the fixed rent payment, the Company accounts for the lease and non-lease components as a single lease component in determining the lease payment. Additionally, for certain individually insignificant equipment leases such as copiers, the Company applies a portfolio approach to effectively record the operating lease liability and ROU asset.

The adoption of ASC 842 had a material impact on the Company’s consolidated balance sheet through the recording of the operating lease liabilities and related ROU assets for leases in effect at January 1, 2019, but the adoption did not have a material impact on the Company’s consolidated statement of loss or consolidated statement of cash flows for the year ended December 31, 2019. The Company recorded approximately $673 million of operating lease liabilities and ROU assets on January 1, 2019 upon adoption of ASC 842, with no impact on accumulated deficit.

Physician Income Guarantees.    The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. The Company amortizes an asset over the life of the agreement. As of December 31, 2019 and 2018, the unamortized portion of these physician income guarantees was $20 million and $24 million, respectively, and is recorded in other assets in the consolidated balance sheet.

Concentrations of Credit Risk.    The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $268 million and $283 million at December 31, 2019 and 2018, respectively, representing 5% of consolidated net accounts receivable at both December 31, 2019 and 2018.

Accounting for the Impairment or Disposal of Long-Lived Assets.    During the year ended December 31, 2019, the Company recorded a total combined impairment charge and loss on disposal of approximately $138 million, of which (i) approximately $92 million was recorded to reduce the carrying value of closed hospitals and certain

105

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell and (ii) approximately $46 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals or where the Company is in discussions with potential buyers for divestiture at a sales price that indicates a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2019 is a net allocation of approximately $167 million of goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit. The Company will continue to evaluate the potential for further impairment of the long-lived assets of underperforming hospitals as well as evaluate offers for potential sales. Based on such analysis, additional impairment charges may be recorded in the future.

During the year ended December 31, 2018, the Company recorded a total combined impairment charge and loss on disposal of approximately $668 million, of which (i) approximately $423 million was recorded to reduce the carrying value of certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell, (ii) approximately $29 million was recorded to write-off the value of a promissory note received as consideration for the sale of three hospitals in 2017 where the buyer entered into bankruptcy proceedings, and (iii) approximately $216 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals that have ceased operations or where the Company was in discussions with potential buyers for divestiture at a sales price that indicated a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2018 is a net allocation of approximately $186 million of goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit.

Income Taxes.    The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statement of loss during the period in which the tax rate change becomes law.

Comprehensive Loss.    Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segment Reporting.    A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company’s acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services).

Derivative Instruments and Hedging Activities.    The Company records derivative instruments on the consolidated balance sheet as either an asset or liability measured at its fair value. Changes in a derivative’s fair value are recorded each period in earnings or other comprehensive income (“OCI”), depending on whether the derivative is designated and is effective as a hedged transaction, and on the type of hedge transaction. Changes in the fair value of derivative instruments recorded to OCI are reclassified to earnings in the period affected by the underlying hedged item. Any portion of the fair value of a derivative instrument determined to be ineffective

106

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

under the standard is recognized in current earnings. The Company has entered into several interest rate swap agreements and had one such agreement outstanding as of December 31, 2019. See Note 7 for further discussion about the swap transactions.

New Accounting Pronouncements.    In August 2018, the FASB issued ASU 2018-15 to provide guidance on the accounting for implementation costs incurred in a cloud computing arrangement that is accounted for as a service contract. This ASU requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

In June 2016, the FASB issued ASU 2016-13, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

2.  ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan, which was amended and restated as of March 14, 2018 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 15, 2018 (the “2009 Plan”).

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which did not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan included the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan were “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurred in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 had a 10-year contractual term, options granted in 2005 through 2007 had an eight-year contractual term and options granted since 2008 had a 10-year contractual term. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan.

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date.

107

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Options granted in 2011 or later have a 10-year contractual term. As of December 31, 2019, 5,308,206 shares of unissued common stock were reserved for future grants under the 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date.

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Year Ended December 31,
	2019		2018		2017
Effect on loss before income taxes	$	(10)	$	(13)	$	(24)
Effect on net loss	$	(8)	$	(10)	$	(16)

At December 31, 2019, $13 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 22 months. Of that amount, $1 million related to outstanding unvested stock options was expected to be recognized over a weighted-average period of 26 months and $12 million related to outstanding unvested restricted stock and restricted stock units was expected to be recognized over a weighted-average period of 21 months. There were no modifications to awards during the years ended December 31, 2019, 2018 and 2017.

The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the years ended December 31, 2019, 2018 and 2017:

	Year Ended December 31,
	2019			2018			2017
Expected volatility		68.4	%		N/A	%		N/A	%
Expected dividends		-			N/A			N/A
Expected term		5.6 years			N/A			N/A
Risk-free interest rate		2.6	%		N/A	%		N/A	%

In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients.

The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility.

The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience.

108

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows (in millions, except share and per share data):

	Shares			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value as of December 31, 2019
Outstanding at December 31, 2016		1,185,320		$	28.12
Granted		-			-
Exercised		-			-
Forfeited and cancelled		(69,653	)		33.52
Outstanding at December 31, 2017		1,115,667			31.56
Granted		-			-
Exercised		-			-
Forfeited and cancelled		(490,729	)		32.01
Outstanding at December 31, 2018		624,938			31.21
Granted		658,500			4.95
Exercised		-			-
Forfeited and cancelled		(173,304	)		23.04
Outstanding at December 31, 2019		1,110,134		$	16.90		5.6 years	$	-
Exercisable at December 31, 2019		486,134		$	32.26		1.0 years	$	-

The weighted-average grant date fair value of stock options granted during the year ended December 31, 2019 was $3.05. No stock options were granted during the years ended December 31, 2018 and 2017. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($2.90) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on December 31, 2019. This amount changes based on the market value of the Company’s common stock. There were no options exercised during the years ended December 31, 2019, 2018 and 2017. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options.

The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For such performance-based awards granted prior to March 1, 2017, performance objectives were measured over a one-year period, and, provided the target performance objective was attained, restrictions lapsed in one-third increments on each of the first three anniversaries of the award date. For performance-based awards granted on or after March 1, 2017, the performance objectives have been measured cumulatively over a three-year period. With respect to performance-based awards granted on or after March 1, 2017, if the applicable target performance objective is met at the end of the three-year period, then the portion of the restricted stock award subject to such performance objective will vest in full on the third anniversary of the award date. Additionally, for these awards, based on the level of achievement for the applicable performance objective within the parameters specified in the award

109

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

agreement, the number of shares to be issued in connection with the vesting of the award may be adjusted to decrease or increase the number of shares specified in the original award. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2009 Plan may lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance objectives that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied.

Restricted stock outstanding under the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2016		2,969,285		$	29.39
Granted		1,502,000			9.10
Vested		(1,586,855	)		33.91
Forfeited		(240,511	)		18.20
Unvested at December 31, 2017		2,643,919			16.17
Granted		1,987,000			4.54
Vested		(1,154,670	)		23.22
Forfeited		(167,342	)		10.29
Unvested at December 31, 2018		3,308,907			7.00
Granted		1,989,000			4.94
Vested		(1,160,667	)		8.89
Forfeited		(279,838	)		5.60
Unvested at December 31, 2019		3,857,402			5.47

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2009 Plan. Each of the Company’s then serving outside directors received grants under the 2009 Plan of 18,498 RSUs, 37,118 RSUs and 34,068 RSUs on March 1, 2017, 2018 and 2019, respectively. Each of the 2017, 2018 and 2019 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause.

110

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

RSUs outstanding under the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows:

	Shares			Weighted- Average Grant Date Fair Value
Unvested at December 31, 2016		120,386		$	22.06
Granted		110,988			9.19
Vested		(59,296	)		24.90
Forfeited		-			-
Unvested at December 31, 2017		172,078			12.78
Granted		296,944			4.58
Vested		(71,116	)		15.51
Forfeited		-			-
Unvested at December 31, 2018		397,906			6.17
Granted		306,612			4.99
Vested		(162,942	)		7.42
Forfeited		-			-
Unvested at December 31, 2019		541,576			5.13

3.  ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Acquisition and integration expenses related to prospective and closed acquisitions included in other operating expenses on the consolidated statements of loss were $2 million, $3 million and $2 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Effective June 1, 2019, one or more subsidiaries of the Company completed the acquisition of Northwest Mississippi Medical Center in Clarksdale, Mississippi. This healthcare system includes 181 licensed beds and other outpatient and ancillary services. The total cash consideration paid for operating assets was approximately $2 million with additional consideration of $9 million in assumed liabilities, for a total consideration of $11 million. This hospital was acquired in conjunction with the bankruptcy proceedings for the previous owner that acquired the hospital from the Company in 2017 as part of an agreement with the local county government associated with its lease of the hospital building. Based on the Company’s final purchase price allocation relating to this acquisition as of December 31, 2019, no goodwill has been recorded. Prior to the completion of the acquisition, the Company initiated a plan to sell this hospital and as such has classified this hospital as held for sale at December 31, 2019.

111

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Other Acquisitions

During the years ended December 31, 2019, 2018 and 2017, one or more subsidiaries of the Company paid approximately $8 million, $26 million and $6 million, respectively, to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the year ended December 31, 2019, the Company allocated approximately $4 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. In connection with these acquisitions, during the year ended December 31, 2018, the Company allocated approximately $10 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $22 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. The value of noncontrolling interests acquired in these acquisitions was $6 million. During the year ended December 31, 2017, the Company allocated approximately $2 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. No value was allocated to noncontrolling interests recorded in these acquisitions.

Divestitures

In April 2014, FASB issued ASU 2014-08, which changed the requirements for reporting discontinued operations. Under this accounting standard, a discontinued operation is a disposal that represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Additional disclosures are required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU was adopted on January 1, 2015 and is required to be applied on a prospective basis for disposals or components initially classified as held for sale after adoption. As a result, the following divestitures occurring subsequent to the date of adoption are included in continuing operations for the years ended December 31, 2019, 2018 and 2017.

The following table provides a summary of hospitals included in continuing operations that the Company divested during the years ended December 31, 2019, 2018, and 2017:

Hospital	Buyer	City, State	Licensed Beds		Effective Date
2019 Divestitures:
Bluefield Regional Medical Center	Princeton Community Hospital Association	Bluefield, WV		92	October 1, 2019
Lake Wales Medical Center	Adventist Health System	Lake Wales, FL		160	September 1, 2019
Heart of Florida Regional Medical Center	Adventist Health System	Davenport, FL		193	September 1, 2019
College Station Medical Center	St. Joseph Regional Health Center	College Station, TX		167	August 1, 2019
Tennova Healthcare – Lebanon	Vanderbilt University Medical Center	Lebanon, TN		245	August 1, 2019
Chester Regional Medical Center	Medical University Hospital Authority	Chester, SC		82	March 1, 2019
Carolinas Hospital System – Florence	Medical University Hospital Authority	Florence, SC		396	March 1, 2019
Springs Memorial Hospital	Medical University Hospital Authority	Lancaster, SC		225	March 1, 2019

112

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Hospital	Buyer	City, State	Licensed Beds		Effective Date
Carolinas Hospital System – Marion	Medical University Hospital Authority	Mullins, SC		124	March 1, 2019
Memorial Hospital of Salem County	Community Healthcare Associates, LLC	Salem, NJ		126	January 31, 2019
Mary Black Health System – Spartanburg	Spartanburg Regional Healthcare System	Spartanburg, SC		207	January 1, 2019
Mary Black Health System – Gaffney	Spartanburg Regional Healthcare System	Gaffney, SC		125	January 1, 2019
2018 Divestitures:
Sparks Regional Medical Center	Baptist Health	Fort Smith, AR		492	November 1, 2018
Sparks Medical Center – Van Buren	Baptist Health	Van Buren, AR		103	November 1, 2018
AllianceHealth Deaconess	INTEGRIS Health	Oklahoma City, OK		238	October 1, 2018
Munroe Regional Medical Center	Adventist Health System	Ocala, FL		425	August 1, 2018
Tennova Healthcare – Dyersburg Regional	West Tennessee Healthcare	Dyersburg, TN		225	June 1, 2018
Tennova Healthcare – Regional Jackson	West Tennessee Healthcare	Jackson, TN		150	June 1, 2018
Tennova Healthcare – Volunteer Martin	West Tennessee Healthcare	Martin, TN		100	June 1, 2018
Williamson Memorial Hospital	Mingo Health Partners, LLC	Williamson, WV		76	June 1, 2018
Byrd Regional Hospital	Allegiance Health Management	Leesville, LA		60	June 1, 2018
Tennova Healthcare – Jamestown	Rennova Health, Inc.	Jamestown, TN		85	June 1, 2018
Bayfront Health Dade City	Adventist Health System	Dade City, FL		120	April 1, 2018
2017 Divestitures:
Highlands Regional Medical Center	HCA Healthcare, Inc. (“HCA”)	Sebring, FL		126	November 1, 2017
Merit Health Northwest Mississippi	Curae Health, Inc.	Clarksdale, MS		181	November 1, 2017
Weatherford Regional Medical Center	HCA	Weatherford, TX		103	October 1, 2017
Brandywine Hospital	Reading Health System	Coatesville, PA		169	October 1, 2017
Chestnut Hill Hospital	Reading Health System	Philadelphia, PA		148	October 1, 2017
Jennersville Hospital	Reading Health System	West Grove, PA		63	October 1, 2017
Phoenixville Hospital	Reading Health System	Phoenixville, PA		151	October 1, 2017
Pottstown Memorial Medical Center	Reading Health System	Pottstown, PA		232	October 1, 2017
Yakima Regional Medical and Cardiac Center	Regional Health	Yakima, WA		214	September 1, 2017

113

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Hospital	Buyer	City, State	Licensed Beds		Effective Date
Toppenish Community Hospital	Regional Health	Toppenish, WA		63	September 1, 2017
Memorial Hospital of York	PinnacleHealth System	York, PA		100	July 1, 2017
Lancaster Regional Medical Center	PinnacleHealth System	Lancaster, PA		214	July 1, 2017
Heart of Lancaster Regional Medical Center	PinnacleHealth System	Lititz, PA		148	July 1, 2017
Carlisle Regional Medical Center	PinnacleHealth System	Carlisle, PA		165	July 1, 2017
Tomball Regional Medical Center	HCA	Tomball, TX		350	July 1, 2017
South Texas Regional Medical Center	HCA	Jourdanton, TX		67	July 1, 2017
Deaconess Hospital	MultiCare Health System	Spokane, WA		388	July 1, 2017
Valley Hospital	MultiCare Health System	Spokane Valley, WA		123	July 1, 2017
Lake Area Medical Center	CHRISTUS Health	Lake Charles, LA		88	June 30, 2017
Easton Hospital	Steward Health, Inc.	Easton, PA		196	May 1, 2017
Sharon Regional Health System	Steward Health, Inc.	Sharon, PA		258	May 1, 2017
Northside Medical Center	Steward Health, Inc.	Youngstown, OH		355	May 1, 2017
Trumbull Memorial Hospital	Steward Health, Inc.	Warren, OH		311	May 1, 2017
Hillside Rehabilitation Hospital	Steward Health, Inc.	Warren, OH		69	May 1, 2017
Wuesthoff Health System – Rockledge	Steward Health, Inc.	Rockledge, FL		298	May 1, 2017
Wuesthoff Health System – Melbourne	Steward Health, Inc.	Melbourne, FL		119	May 1, 2017
Sebastian River Medical Center	Steward Health, Inc.	Sebastian, FL		154	May 1, 2017
Stringfellow Memorial Hospital	The Health Care Authority of the City of Anniston	Anniston, AL		125	May 1, 2017
Merit Health Gilmore Memorial	Curae Health, Inc.	Amory, MS		95	May 1, 2017
Merit Health Batesville	Curae Health, Inc.	Batesville, MS		112	May 1, 2017

On May 1, 2017, one or more subsidiaries of the Company sold AllianceHealth Pryor (52 licensed beds) in Pryor, Oklahoma, and its associated assets to Ardent Health Services Inc. for approximately $1 million in cash. This hospital has been reported in the consolidated statements of loss in discontinued operations.

114

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Year Ended December 31, 2017
Net operating revenues	$	79
Loss from operations of entities sold or held for sale before income taxes		(10	)
Impairment of hospitals sold or held for sale		(8	)
Loss on sale, net		(1	)
Loss from discontinued operations, before taxes		(19	)
Income tax benefit		(7	)
Loss from discontinued operations, net of taxes	$	(12	)

As part of its ongoing evaluation of the fair value of the hospitals it is marketing for sale, the Company recorded an impairment charge on the carrying value of the long-lived assets at these hospitals in discontinued operations of $6 million, net of tax, for the year ended December 31, 2017. There was no impairment charge recorded for the years ended December 31, 2019 and 2018. Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

The following table discloses amounts included in the consolidated balance sheet for the hospitals classified as held for sale as of December 31, 2019 and 2018 (in millions):

	December 31,
	2019		2018
Other current assets	$	25	$	21
Other assets, net		262		154
Accrued liabilities		43		44

Financial and statistical data reported in this Annual Report on Form 10-K (“Form 10-K”) includes operating results for hospitals held for sale at December 31, 2019 and for the 53 hospitals that were divested during 2019, 2018 and 2017 through the effective date of each respective transaction. Summary financial results of these hospitals included in continuing operations for the periods included in the accompanying consolidated statements of loss are as follows (in millions):

	Year Ended December 31,
	2019			2018			2017
Loss from operations before income taxes	$	(105	)	$	(470	)	$	(703	)
Less: Loss attributable to noncontrolling interests		-			1			(2	)
Loss from operations before income taxes attributable to Community Health Systems, Inc. stockholders	$	(105	)	$	(471	)	$	(701	)

The operating results for these held for sale or divested hospitals included impairment charges of approximately $102 million, $415 million and $368 million that were allocated to the divestitures during the years ended December 31, 2019, 2018 and 2017, respectively.

115

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Other Hospital Closures

During the three months ended December 31, 2018, the Company completed the planned closure of Tennova – Physicians Regional Medical Center in Knoxville, Tennessee and Tennova – Lakeway Regional Medical Center in Morristown, Tennessee. The Company recorded an impairment charge of approximately $27 million during the three months ended December 31, 2018, to adjust the fair value of the supplies, inventory and long-lived assets of these hospitals, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

During the three months ended June 30, 2018, the Company completed the planned closure of Twin Rivers Regional Medical Center in Kennett, Missouri. The Company recorded an impairment charge of approximately $4 million during the three months ended June 30, 2018, to adjust the fair value of the supplies, inventory and long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

4.  GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2019 and 2018 are as follows (in millions):

Balance, beginning balance	2019			2018
Goodwill	$	7,373		$	7,537
Accumulated impairment losses		(2,814)			(2,814)
		4,559			4,723
Goodwill acquired as part of acquisitions during current year		4			22
Goodwill allocated to hospitals held for sale		(235	)		(186	)
Balance, end of year
Goodwill		7,142			7,373
Accumulated impairment losses		(2,814	)		(2,814	)
	$	4,328		$	4,559

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segment meets the criteria to be classified as a reporting unit. At December 31, 2019, after giving effect to 2019 divestiture activity, the Company had approximately $4.3 billion of goodwill recorded.

Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. During 2017, the Company early adopted ASU 2017-04, which allows a company to record a goodwill impairment when the reporting unit’s carrying value exceeds the fair value determined in step one. The Company performed its annual goodwill impairment evaluation during the fourth quarter of 2019 using the October 31, 2019 measurement date, which indicated no impairment.

The Company estimates the fair value of the reporting unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on

116

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.

While no impairment was indicated in the Company’s annual goodwill evaluations as of the October 31, 2019 and October 31, 2018 measurement dates, the reduction in the Company’s fair value and the resulting goodwill impairment charges recorded in 2016 and 2017 reduced the carrying value of the Company’s hospital operations reporting unit to an amount equal to its estimated fair values as of such prior year measurement dates. This increases the risk that future declines in fair value could result in goodwill impairment. The determination of fair value in the Company’s goodwill impairment analysis is based on an estimate of fair value for each reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of the Company’s common stock or fair value of long-term debt, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including further decline in the Company’s stock price or fair value of long-term debt, lower than expected hospital volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.

The determination of fair value of the Company’s hospital operations reporting unit as part of its goodwill impairment measurement represents a Level 3 fair value measurement in the fair value hierarchy due to its use of internal projections and unobservable measurement inputs.

Intangible Assets

No intangible assets other than goodwill were acquired during the years ended December 31, 2019 and 2018. The gross carrying amount of the Company’s other intangible assets subject to amortization was $1 million at both December 31, 2019 and 2018, and the net carrying amount was less than $1 million at December 31, 2019 and 2018. The carrying amount of the Company’s other intangible assets not subject to amortization was $63 million and $67 million at December 31, 2019 and 2018, respectively. Other intangible assets are included in other assets, net on the Company’s consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions.

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately one year. There are no expected residual values related to these intangible assets. Amortization expense on these intangible assets was less than $1 million, $3 million and $4 million during the years ended December 31, 2019, 2018 and 2017, respectively. Amortization expense on intangible assets is estimated to be less than $1 million in 2020.

The gross carrying amount of capitalized software for internal use was approximately $1.1 billion and $1.2 billion at December 31, 2019 and 2018, respectively, and the net carrying amount was approximately $321 million and $355 million at December 31, 2019 and 2018, respectively. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, for which the estimated amortization period is generally eight to ten years. There is no expected residual value for capitalized internal-use software. At December 31, 2019, there were approximately $42 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on

117

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

capitalized internal-use software was $121 million, $140 million and $178 million during the years ended December 31, 2019, 2018 and 2017, respectively. Amortization expense on capitalized internal-use software is estimated to be $114 million in 2020, $93 million in 2021, $55 million in 2022, $26 million in 2023, $22 million in 2024 and $11 million thereafter.

5.  INCOME TAXES

The provision for (benefit from) income taxes for loss from continuing operations consists of the following (in millions):

	Year Ended December 31,
	2019			2018			2017
Current:
Federal	$	(38	)	$	1		$	-
State		(5	)		(9	)		5
		(43	)		(8	)		5
Deferred:
Federal		179			50			(485	)
State		24			(53	)		31
		203			(3	)		(454	)
Total provision for (benefit from) income taxes for loss from continuing operations	$	160		$	(11	)	$	(449	)

The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions):

	Year Ended December 31,
	2019						2018						2017
	Amount			%			Amount			%			Amount			%
Benefit from income taxes at statutory federal rate	$	(90	)		21.0	%	$	(150	)		21.0	%	$	(991	)		35.0	%
State income taxes, net of federal income tax benefit		(104	)		24.3			(114	)		16.0			(10	)		0.3
Net income attributable to noncontrolling interests		(18	)		4.2			(18	)		2.5			(22	)		0.8
Change in valuation allowance		340			(79.2	)		212			(29.7	)		26			(0.9	)
Change in uncertain tax position		-			-			9			(1.3	)		-			-
Federal rate change		-			-			-			-			32			(1.1	)
Federal and state tax credits		-			-			(17	)		2.4			(5	)		0.1
Nondeductible goodwill		11			(2.6	)		30			(4.2	)		504			(17.8	)
Nondeductible settlements		-			-			22			(3.1	)		-			-
Nondeductible loss on divestiture		15			(3.5	)		-			-			-			-
Other		6			(1.4	)		15			(2.1	)		17			(0.6	)
Provision for (benefit from) income taxes and effective tax rate for loss from continuing operations	$	160			(37.2	) %	$	(11	)		1.5	%	$	(449	)		15.8	%

118

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The Company’s effective tax rates were (37.2)%, 1.5% and 15.8% for the years ended December 31, 2019, 2018 and 2017, respectively. The decrease in the Company’s effective tax rate for the year ended December 31, 2019, when compared to the year ended December 31, 2018, was primarily due to an increase in the valuation allowance recognized on (i) IRC Section 163(j) interest carryforwards and (ii) original issue discount deferred tax asset generated with the 2019 Exchange Offer. The decrease in the Company’s effective tax rate for the year ended December 31, 2018, when compared to the year ended December 31, 2017, was primarily due to the increase in valuation allowance recognized on IRC Section 163(j) interest carryforwards partially offset by the release of certain state valuation allowances on net operating loss carryforwards in certain jurisdictions.

Deferred income taxes are based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities under the provisions of the enacted tax laws. Deferred income taxes as of December 31, 2019 and 2018 consist of (in millions):

	December 31,
	2019					2018
	Assets			Liabilities		Assets			Liabilities
Net operating loss and credit carryforwards	$	775		$	-	$	743		$	-
Property and equipment		-			335		-			237
Self-insurance liabilities		48			-		69			-
Prepaid expenses		-			30		-			27
Intangibles		-			149		-			134
Investments in unconsolidated affiliates		-			57		-			55
Other liabilities		-			9		-			14
IRC Section 481(a) - mixed service cost		-			216		-			-
Long-term debt and interest		312			-		84			-
Accounts receivable		62			-		58			-
IRC Section 163(j) interest limitation		296			-		144			-
Accrued vacation		24			-		26			-
Accrued bonus		31			-		-			-
Other comprehensive income		5			-		4			-
Right-of-use assets		-			145		-			-
Right-of-use liability		149			-		-			-
Stock-based compensation		5			-		4			-
Deferred compensation		70			-		64			-
Other		51			-		15			-
Total		1,828			941		1,211			467
Valuation allowance		(1,049	)		-		(701	)		-
Total deferred income taxes	$	779		$	941	$	510		$	467

The Company believes that the net deferred tax assets will ultimately be realized, except as noted below. Its conclusion is based on its estimate of future taxable income and the expected timing of temporary difference reversals. The Company has gross federal net operating loss carryforwards of approximately $662 million and state net operating loss carryforwards of approximately $8.6 billion, which expire from 2020 to 2039. The Company’s tax affected federal and state net operating loss and credit carryforwards are approximately $169 million and $606 million, respectively. A valuation allowance of approximately $1.0 billion has been recognized for state net operating loss carryforwards, state credit carryforwards and federal and state deferred tax assets that the Company does not expect to be able to utilize prior to the expiration of the carryforward period.

119

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

With respect to the deferred tax liability pertaining to intangibles, as included above, goodwill purchased in connection with certain of the Company’s business acquisitions is amortizable for income tax reporting purposes. However, for financial reporting purposes, there is no corresponding amortization allowed with respect to such purchased goodwill.

The valuation allowance for federal and state jurisdictions where the Company concluded that the associated deferred tax assets would not be realized increased by $221 million and $127 million, respectively, for the year ended December 31, 2019, and increased by $151 million and $17 million, respectively, for the year ended December 31, 2018.

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $1 million as of December 31, 2019. A total of approximately $1 million of interest and penalties is included in the amount of the liability for uncertain tax positions at December 31, 2019. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its consolidated statements of loss as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position.

The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2019, 2018 and 2017 (in millions):

	Year Ended December 31,
	2019			2018		2017
Unrecognized tax benefit, beginning of year	$	29		$	18	$	18
Gross increases — tax positions in current period		10			11		-
Settlements		(13	)		-		-
Unrecognized tax benefit, end of year	$	26		$	29	$	18

The Company’s federal income tax returns for the 2009 and 2010 tax years have been settled with the Internal Revenue Service. The results of these examinations were not material to the Company’s consolidated results of operations or consolidated financial position. The Company’s federal income tax returns for the 2014 and 2015 tax years remain under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2020 for the tax periods ended December 31, 2014 and 2015.

Cash paid for income taxes, net of refunds received, resulted in a net refund of $3 million and $19 million during the years ended December 31, 2019 and 2018, respectively, and net cash paid of $4 million during the year ended December 31, 2017.

120

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

6.   LONG-TERM DEBT

Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions):

	December 31,
	2019			2018
Credit Facility:
Term H Loan	$	-		$	1,622
Revolving Credit Facility		-			-
8% Senior Notes due 2019		-			155
71⁄8% Senior Notes due 2020		-			121
51⁄8% Senior Secured Notes due 2021		1,000			1,000
67⁄8% Senior Notes due 2022		231			2,632
61⁄4% Senior Secured Notes due 2023		3,100			3,100
85⁄8% Senior Secured Notes due 2024		1,033			1,033
8% Senior Secured Notes due 2026		2,101			-
8% Senior Secured Notes due 2027		700			-
67⁄8% Senior Notes due 2028		1,700			-
97⁄8% Junior-Priority Secured Notes due 2023		1,770			1,770
81⁄8% Junior-Priority Secured Notes due 2024		1,355			1,355
ABL Facility		273			698
Finance lease and financing obligations		272			231
Other		17			43
Less: Unamortized deferred debt issuance costs and note premium		(147	)		(164	)
Total debt		13,405			13,596
Less: Current maturities		(20	)		(204	)
Total long-term debt	$	13,385		$	13,392

Credit Facility

The Company’s wholly-owned subsidiary, CHS/Community Health Systems, Inc. (“CHS”), had senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent (the “Credit Facility”), which at December 31, 2018 included (i) a revolving credit facility with commitments through January 27, 2021 of $425 million (the “Revolving Facility”), and (ii) a Term H facility due 2021 (the “Term H Facility). The Revolving Facility included a subfacility for letters of credit. The Revolving Facility was repaid in full and terminated in connection with the completion of the offering of the Additional 2026 Notes on November 19, 2019, as discussed below.

The loans under the Credit Facility bore interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the NYFRB Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. In addition, the margin in respect of the Revolving Facility was subject to adjustment determined by reference to a leverage-based pricing grid. Prior to the refinancing discussed below, loans in respect of the Revolving Facility accrued interest at a rate per annum equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. Prior to the refinancing discussed below, the

121

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Term H Loan accrued interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate borrowings. The Term H Loan was subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility was required to be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 75%, subject to reduction to a lower percentage based on the Company’s first lien net leverage ratio (as defined in the Credit Facility generally as the ratio of first lien net debt on the date of determination to the Company’s consolidated EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions were permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. There were no scheduled principal amortization payments on the Term H Facility after December 31, 2018.

The borrower under the Credit Facility was CHS. All of the obligations under the Credit Facility were unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees were secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries, and subject to the revolving asset-based loan facility (“the ABL Facility”). Such assets constituted substantially the same assets, subject to certain exceptions, that secured (i) on a first lien basis CHS’ obligations under the 5¹⁄₈% Senior Secured Notes due 2021, the 6¹⁄₄% Senior Secured Notes due 2023, the 8⁵⁄₈% Senior Secured Notes due 2024 and the 8% Senior Secured Notes due 2026 (in each case, as defined below) and (ii) on a junior-priority basis the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 and the 8¹⁄₈% Junior-Priority Secured Notes due 2024 (in each case, as defined below).

CHS agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to LIBOR borrowings under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit also received a customary fronting fee and other customary processing charges. CHS was obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

On February 15, 2019, the Company and CHS entered into Amendment No. 1 (the “Agreement”), among the Company, CHS, the subsidiary guarantors party thereto, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent, to the Credit Facility. The Credit Facility was amended by the Agreement, with requisite covenant lender approval, to amend the first lien net debt to EBITDA ratio financial covenant and to reduce the extended revolving credit commitments to $385 million. The amended financial covenant provided for a maximum first lien net debt to EBITDA ratio of 5.00 to 1.00 from July 1, 2018 through December 31, 2018, 5.25 to 1.00 from January 1, 2019 through December 31, 2019, 5.00 to 1.00 from January 1, 2020 through June 30, 2020, 4.50 to 1.00 from July 1, 2020 through September 30, 2020, and 4.25 to 1.00 thereafter. In addition, CHS agreed pursuant to the Agreement to further restrict its ability to make restricted payments. The revolving credit commitments terminated on November 19, 2019.

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of 8% Senior Secured Notes due March 15, 2026 (the “8% Senior Secured Notes due 2026”). The terms of the 8%

122

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Senior Secured Notes due 2026 are discussed below. Using the proceeds from the offering, the Company repaid the outstanding balance owed under the Term H Facility and paid fees and expenses related to the offering.

On November 19, 2019, CHS completed a tack-on offering of an additional $500 million aggregate principal amount of the 8% Senior Secured Notes due 2026 (the “Additional 2026 Notes”). Upon completion of such offering, $2.101 billion aggregate principal amount of 8% Senior Secured Notes due 2026 were outstanding. CHS used the proceeds from the Additional 2026 Notes to repay amounts outstanding under the Revolving Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7¹⁄₈% Senior Notes due July 15, 2020 (the “7¹⁄₈% Senior Notes due 2020”) and repay borrowings outstanding under the ABL Facility. CHS terminated the Revolving Facility upon consummation of the Additional 2026 Notes offering and the outstanding letters of credit were moved under the ABL Facility.

8% Senior Notes due 2019

On November 22, 2011, CHS completed a private offering of $1.0 billion aggregate principal amount of 8% Senior Notes due November 15, 2019 (the “8% Senior Notes due 2019”). The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8⁷⁄₈% Senior Notes due 2015 and related fees and expenses. On March 21, 2012, CHS completed an offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes due 2019, which were issued in a private placement (at a premium of 102.5%). The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8⁷⁄₈% Senior Notes due 2015, to pay related fees and expenses and for general corporate purposes. The 8% Senior Notes due 2019 bore interest at 8.000% per annum, payable semi-annually in arrears on May 15 and November 15 of each year. Interest on the 8% Senior Notes due 2019 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months.

On June 22, 2018, CHS issued approximately $1.770 billion aggregate principal amount of new 9⁷⁄₈% Junior-Priority Secured Notes due June 30, 2023 (the “9⁷⁄₈% Junior-Priority Secured Notes due 2023”) in exchange for the same amount of 8% Senior Notes due 2019. The terms of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 are described below. Following this exchange, CHS had $155 million aggregate principal amount of 8% Senior Notes due 2019 outstanding, which was repaid in full on November 15, 2019.

7¹⁄₈% Senior Notes due 2020

On July 18, 2012, CHS completed a public offering of $1.2 billion aggregate principal amount of 7¹⁄₈% Senior Notes due 2020. The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount of CHS’ then outstanding 8⁷⁄₈% Senior Notes due 2015, to pay for consents delivered in connection with a related tender offer, to pay related fees and expenses, and for general corporate purposes. The 7¹⁄₈% Senior Notes due 2020 bore interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15 of each year. Interest on the 7¹⁄₈% Senior Notes due 2020 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months.

On June 22, 2018, CHS issued approximately $1.079 billion aggregate principal amount of new 8¹⁄₈% Junior-Priority Secured Notes due June 30, 2024 (the “8¹⁄₈% Junior-Priority Secured Notes due 2024”) in exchange for the same amount of 7¹⁄₈% Senior Notes due 2020. The terms of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 are described below. Following this exchange, CHS had $121 million aggregate principal amount of 7¹⁄₈% Senior Notes due 2020 outstanding.

On December 4, 2019, CHS used the proceeds from the Additional 2026 Notes to repay the $121 million aggregate principal amount of the then outstanding 7¹⁄₈% Senior Notes due 2020.

123

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

5¹⁄₈% Senior Secured Notes due 2021

On January 27, 2014, CHS completed a private offering of $1.0 billion aggregate principal amount of 5¹⁄₈% Senior Secured Notes due August 1, 2021 (the “5¹⁄₈% Senior Secured Notes due 2021”). The net proceeds from this issuance were used to finance the Company’s acquisition by merger of Health Management Associates, Inc. (“HMA”). The 5¹⁄₈% Senior Secured Notes due 2021 bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on February 1 and August 1 of each year. Interest on the 5¹⁄₈% Senior Secured Notes due 2021 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 5¹⁄₈% Senior Secured Notes due 2021 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 5¹⁄₈% Senior Secured Notes due 2021 and the related guarantees are secured by shared (i) first-priority liens on the collateral (the “Non-ABL Priority Collateral”) that also secures on a first-priority basis CHS’ senior-priority secured notes and (ii) second-priority liens on the collateral (the “ABL-Priority Collateral”) that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 5¹⁄₈% Senior Secured Notes due 2021.

CHS is entitled, at its option, to redeem all or a portion of the 5¹⁄₈% Senior Secured Notes due 2021 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2019 to January 31, 2020		101.281 %
February 1, 2020 to January 31, 2021		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 5¹⁄₈% Senior Secured Notes due 2021, as a result of an exchange offer made by CHS, all of the 5¹⁄₈% Senior Secured Notes due 2021 issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 5¹⁄₈% Senior Secured Notes due 2021 (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 5¹⁄₈% Senior Secured Notes due 2021 shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

As discussed more fully in Note 16, the Company announced, on January 23, 2020, that CHS commenced a cash tender offer for any and all of the outstanding 5¹⁄₈% Senior Secured Notes due 2021 and issued a conditional notice of redemption to redeem all of the 5¹⁄₈% Senior Secured Notes due 2021 not purchased by CHS in the tender offer at a redemption price of 100.000% of the principal amount thereof plus accrued interest to, but not including, February 22, 2020.

6⁷⁄₈% Senior Notes due 2022

On January 27, 2014, CHS completed a private offering of $3.0 billion aggregate principal amount of 6⁷⁄₈% Senior Notes due February 1, 2022 (the “6⁷⁄₈% Senior Notes due 2022”). The net proceeds from this issuance were used to finance the HMA merger. The 6⁷⁄₈% Senior Notes due 2022 bear interest at a rate of 6.875% per annum, payable semiannually in arrears on February 1 and August 1 of each year. Interest on the 6⁷⁄₈% Senior

124

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Notes due 2022 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6⁷⁄₈% Senior Notes due 2022 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

CHS is entitled, at its option, to redeem all or a portion of the 6⁷⁄₈% Senior Notes due 2022 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2019 to January 31, 2020		101.719 %
February 1, 2020 to January 31, 2022		100.000 %

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⁷⁄₈% Senior Notes due 2022, as a result of an exchange offer made by CHS, all of the 6⁷⁄₈% Senior Notes due 2022 issued in January 2014 were exchanged in October 2014 for new notes (the “6⁷⁄₈% Exchange Notes”) having terms substantially identical in all material respects to the 6⁷⁄₈% Senior Notes due 2022 (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6⁷⁄₈% Senior Notes due 2022 shall be deemed to be the 6⁷⁄₈% Exchange Notes unless the context provides otherwise.

On June 22, 2018, CHS issued approximately $276 million aggregate principal amount of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 in exchange for approximately $368 million of 6⁷⁄₈% Senior Notes due 2022.

On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of 8% Senior Secured Notes due December 15, 2027 (the “8% Senior Secured Notes due 2027”) and approximately $1.7 billion aggregate principal amount of 6⁷⁄₈% Senior Notes due April 1, 2028 (the “6⁷⁄₈% Senior Notes due 2028”) in exchange for approximately $2.4 billion of 6⁷⁄₈% Senior Notes due 2022 (the “2019 Exchange Offer”). Following the 2019 Exchange Offer, CHS had approximately $231 million aggregate principal amount of 6⁷⁄₈% Senior Notes due 2022 outstanding.

6¹⁄₄% Senior Secured Notes due 2023

On March 16, 2017, CHS completed a public offering of $2.2 billion aggregate principal amount of 6¹⁄₄% Senior Secured Notes due March 31, 2023 (the “6¹⁄₄% Senior Secured Notes due 2023”). The net proceeds from this issuance were used to finance the purchase or redemption of $700 million aggregate principal amount of CHS’ then outstanding 5¹⁄₈% Senior Secured Notes due 2018 and related fees and expenses, and the repayment of $1.445 billion of the then outstanding Term F Facility. On May 12, 2017, CHS completed a tack-on offering of $900 million aggregate principal amount of 6¹⁄₄% Senior Secured Notes due 2023, increasing the total aggregate principal amount of 6¹⁄₄% Senior Secured Notes due 2023 to $3.1 billion. A portion of the net proceeds from this issuance were used to finance the repayment of approximately $713 million aggregate principal amount of CHS’ then outstanding Term A Facility and related fees and expenses. The tack-on notes have identical terms, other than issue date and issue price, as the 6¹⁄₄% Senior Secured Notes due 2023 issued on March 16, 2017. The 6¹⁄₄% Senior Secured Notes due 2023 bear interest at a rate of 6.250% per annum, payable semiannually in arrears on March 31 and September 30 of each year. Interest on the 6¹⁄₄% Senior Secured Notes due 2023 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6¹⁄₄% Senior Secured Notes due 2023 are scheduled to mature on March 31, 2023. The 6¹⁄₄% Senior Secured Notes due 2023 are unconditionally guaranteed on a senior-priority

125

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 6¹⁄₄% Senior Secured Notes due 2023 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral that also secures on a first-priority basis CHS’s senior-priority secured notes and (ii) second-priority liens on the ABL Collateral, in each case subject to permitted liens described in the indenture governing the 6¹⁄₄% Senior Secured Notes due 2023.    

CHS is entitled, at its option, to redeem all or a portion of the 6¹⁄₄% Senior Secured Notes due 2023 at any time prior to March 31, 2020, upon not less than 30 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6¹⁄₄% Senior Secured Notes due 2023 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6¹⁄₄% Senior Secured Notes due 2023. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 6¹⁄₄% Senior Secured Notes due 2023 at any time prior to March 31, 2020 using the net proceeds from certain equity offerings at the redemption price of 106.250% of the principal amount of the 6¹⁄₄% Senior Secured Notes due 2023 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 6¹⁄₄% Senior Secured Notes due 2023 at any time on or after March 31, 2020 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
March 31, 2020 to March 30, 2021		103.125 %
March 31, 2021 to March 30, 2022		101.563 %
March 31, 2022 to March 30, 2023		100.000 %

As discussed more fully in Note 16, approximately $426 million aggregate principal amount of 6¹⁄₄% Senior Secured Notes due 2023 were purchased in one or more privately negotiated transactions on February 6, 2020.

9⁷⁄₈% Junior-Priority Secured Notes due 2023

On June 22, 2018, CHS completed a private offering of $1.770 billion aggregate principal amount of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 in exchange for the same amount of 8% Senior Notes due 2019. The 9⁷⁄₈% Junior-Priority Secured Notes due 2023 bore interest at a rate of 11.000% per annum, solely for the period from the issue date of such 9⁷⁄₈% Junior-Priority Secured Notes due 2023 to, but excluding, June 22, 2019, after which they bear interest at a rate of 9.875% per annum. Interest is payable semi-annually in arrears on June 30 and December 31 of each year. The 9⁷⁄₈% Junior-Priority Secured Notes due 2023 are scheduled to mature on June 20, 2023. The 9⁷⁄₈% Junior-Priority Secured Notes due 2023 are unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 9⁷⁄₈% Junior-Priority Secured Notes due 2023 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 9⁷⁄₈% Junior-Priority Secured Notes due 2023.

126

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Prior to June 30, 2020, CHS may redeem some or all of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 9⁷⁄₈% Junior-Priority Secured Notes due 2023. In addition, at any time prior to June 30, 2020, CHS may redeem up to 40% of the aggregate principal amount of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 with the proceeds from certain equity offerings at the redemption price of 109.875%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After June 30, 2020, CHS is entitled, at its option, to redeem all or a portion of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
June 30, 2020 to June 29, 2021		107.406 %
June 30, 2021 to June 29, 2022		103.703 %
June 30, 2022 to June 29, 2023		100.000 %

8¹⁄₈% Junior-Priority Secured Notes due 2024

On June 22, 2018, CHS completed a private offering of $1.355 billion aggregate principal amount of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 in exchange for approximately $1.079 billion of 7¹⁄₈% Senior Notes due 2020 and approximately $368 million of 6⁷⁄₈% Senior Notes due 2022. The 8¹⁄₈% Junior-Priority Secured Notes due 2024 bear interest at a rate of 8.125% per annum, payable semi-annually in arrears on June 30 and December 31 of each year. The 8¹⁄₈% Junior-Priority Secured Notes due 2024 are scheduled to mature on June 20, 2024. The 8¹⁄₈% Junior-Priority Secured Notes due 2024 are unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 8¹⁄₈% Junior-Priority Secured Notes due 2024 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 8¹⁄₈% Junior-Priority Secured Notes due 2024.

Prior to June 30, 2021, CHS may redeem some or all of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8¹⁄₈% Junior-Priority Secured Notes due 2024. In addition, at any time prior to June 30, 2021, CHS may redeem up to 40% of the aggregate principal amount of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.125%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After June 30, 2021, CHS is entitled, at its option, to redeem all or a portion of the 8¹⁄₈% Junior-Priority Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any,

127

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
June 30, 2021 to June 29, 2022		104.063 %
June 30, 2022 to June 29, 2023		102.031 %
June 30, 2023 to June 29, 2024		100.000 %

The indentures governing each of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 and 8¹⁄₈% Junior-Priority Secured Notes due 2024 also prohibited CHS from purchasing, repurchasing, redeeming, defeasing or otherwise acquiring or retiring any outstanding 7¹⁄₈% Senior Notes due 2020 with: (a) cash or cash equivalents on hand as of the consummation of such 2018 exchange offers; (b) cash generated from operations; (c) proceeds from assets sales; or (d) proceeds from the issuance of, or in exchange for, secured debt, in each case, prior to May 15, 2020. CHS received a waiver from requisite holders of each series of the 9⁷⁄₈% Junior-Priority Secured Notes due 2023 and 8¹⁄₈% Junior-Priority Secured Notes due 2024 waiving these restrictions prior to consummating the 2019 Exchange Offer.

8⁵⁄₈% Senior Secured Notes due 2024

On July 6, 2018, CHS completed a private offering of $1.033 billion aggregate principal amount of 8⁵⁄₈% Senior Secured Notes due January 15, 2024 (the “8⁵⁄₈% Senior Secured Notes due 2024”). The 8⁵⁄₈% Senior Secured Notes due 2024 bear interest at a rate of 8.625% per annum payable semi-annually in arrears on January 15 and July 15 of each year. The 8⁵⁄₈% Senior Secured Notes due 2024 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS’ ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 8⁵⁄₈% Senior Secured Notes due 2024 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8⁵⁄₈% Senior Secured Notes due 2024.

Prior to January 15, 2021, CHS may redeem some or all of the 8⁵⁄₈% Senior Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8⁵⁄₈% Senior Secured Notes due 2024. In addition, at any time prior to January 15, 2021, CHS may redeem up to 40% of the aggregate principal amount of the 8⁵⁄₈% Senior Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.625%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After January 15, 2021, CHS is entitled, at its option, to redeem all or a portion of the 8⁵⁄₈% Senior Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
January 15, 2021 to January 14, 2022		104.313 %
January 15, 2022 to January 14, 2023		102.156 %
January 15, 2023 to January 14, 2024		100.000 %

128

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

8% Senior Secured Notes due 2026

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of the 8% Senior Secured Notes due 2026. The net proceeds from this issuance were used to finance the repayment of approximately $1.557 billion aggregate principal amount of CHS’ then outstanding Term H Facility and related fees and expenses. On November 19, 2019, CHS completed a tack-on offering of $500 million aggregate principal amount of the Additional 2026 Notes, increasing the total aggregate principal amount of the 8% Senior Secured Notes due 2026 to $2.101 billion. CHS used the proceeds from the Additional 2026 Notes to repay amounts outstanding under the Revolving Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7¹⁄₈% Senior Notes due 2020 and repay borrowings outstanding under the ABL Facility. The Additional 2026 Notes have identical terms, other than issue date, issue price and the date from which interest initially accrued, as the 8% Senior Secured Notes due 2026 issued on March 6, 2019. The 8% Senior Secured Notes due 2026 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. Interest on the 8% Senior Secured Notes due 2026 accrues from the initial issuance date of the 8% Senior Secured Notes due 2026. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 8% Senior Secured Notes due 2026 are scheduled to mature on March 15, 2026.

The 8% Senior Secured Notes due 2026 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2026 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2026.

Prior to March 15, 2022, CHS may redeem some or all of the 8% Senior Secured Notes due 2026 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026. In addition, at any time prior to March 15, 2022, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2026 with the proceeds from certain equity offerings at the redemption price of 108.000%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After March 15, 2022, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2026 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
March 15, 2022 to March 14, 2023		104.000 %
March 15, 2023 to March 14, 2024		102.000 %
March 15, 2024 to March 14, 2026		100.000 %

8% Senior Secured Notes due 2027

On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of the 8% Senior Secured Notes due 2027 in connection with the 2019 Exchange Offer. No cash proceeds were received from the

129

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

2019 Exchange Offer. The 8% Senior Secured Notes due 2027 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on June 15 and December 15 of each year. Interest on the 8% Senior Secured Notes due 2027 accrues from the initial issuance date of the 8% Senior Secured Notes due 2027. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 8% Senior Secured Notes due 2027 are scheduled to mature on December 15, 2027. The 8% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2027.

CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022 using the net proceeds from certain equity offerings at the redemption price of 108.000% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 8% Senior Secured Notes due 2027 at any time on or after December 15, 2022 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
December 15, 2022 to December 14, 2023		104.000 %
December 15, 2023 to December 14, 2024		102.000 %
December 15, 2024 to December 14, 2027		100.000 %

6⁷⁄₈% Senior Notes due 2028

On November 19, 2019, CHS issued approximately $1.7 billion aggregate principal amount of the 6⁷⁄₈% Senior Notes due 2028 in connection with the 2019 Exchange Offer. No cash proceeds were received in the 2019 Exchange Offer. The 6⁷⁄₈% Senior Notes due 2028 bear interest at a rate of 6.875% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Interest on the 6⁷⁄₈% Senior 2028 Notes accrues from the initial issuance date of the 6⁷⁄₈% Senior Notes due 2028. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6⁷⁄₈% Senior Notes due 2028 are scheduled to mature on April 1, 2028.

The 6⁷⁄₈% Senior Notes due 2028 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS.

CHS is entitled, at its option, to redeem all or a portion of the 6⁷⁄₈% Senior Notes due 2028 at any time prior to April 1, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal

130

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

amount of the 6⁷⁄₈% Senior Notes due 2028 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⁷⁄₈% Senior Notes due 2028. In addition, the Issuer may redeem up to 40% of the aggregate principal amount of the 6⁷⁄₈% Senior Notes due 2028 at any time prior to April 1, 2023 using the net proceeds from certain equity offerings at the redemption price of 106.875% of the principal amount of the 6⁷⁄₈% Senior Notes due 2028 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 6⁷⁄₈% Senior Notes due 2028 at any time on or after April 1, 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
April 1, 2023 to March 31, 2024		103.438 %
April 1, 2024 to March 31, 2025		101.719 %
April 1, 2025 to March 31, 2028		100.000 %

ABL Facility

On April 3, 2018, the Company and CHS entered into an asset-based loan (ABL) credit agreement (the “ABL Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders and other agents party thereto. Pursuant to the ABL Credit Agreement, the lenders have extended to CHS a revolving asset-based loan facility (the “ABL Facility”) in the maximum aggregate principal amount of $1.0 billion, subject to borrowing base capacity. On November 12, 2019, the Company and CHS entered into Amendment No. 2 to the ABL Facility, resulting in an increase of the portion of the commitments under the ABL Facility that are available in the form of letters of credit from $50 million to $200 million. CHS and all domestic subsidiaries of CHS that guarantee CHS’ other outstanding senior and senior secured indebtedness guarantee the obligations of CHS under the ABL Facility. Subject to certain exceptions, all obligations under the ABL Facility and the related guarantees are secured by a perfected first-priority security interest in substantially all of the receivables, deposit, collection and other accounts and contract rights, books, records and other instruments related to the foregoing of the Company, CHS and the guarantors, as well as a perfected junior-priority security interest in substantially all of the other assets of the Company, CHS and the guarantors, subject to customary exceptions and intercreditor arrangements. In connection with entering into the ABL Credit Agreement and the ABL Facility, the Company repaid in full and terminated its accounts receivable loan agreement with a group of lenders and banks. At December 31, 2019, the available borrowing base under the ABL Facility was $860 million, of which the Company had outstanding borrowings of $273 million and letters of credit issued of $145 million. The issued letters of credit were primarily in support of potential insurance-related claims and certain bonds.

Borrowings under the ABL Facility bear interest at a rate per annum equal to an applicable percentage, plus, at the Borrower’s option, either (a) an Alternative base rate or (b) a LIBOR rate. From and after December 31, 2018, the applicable percentage under the ABL Facility is determined based on excess availability as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of 1.25%, 1.50% and 1.75% for loans based on the Alternative base rate and 2.25%, 2.50% and 2.75% for loans based on the LIBOR rate. From and after September 30, 2018, the applicable commitment fee rate under the ABL Facility is determined based on average utilization as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of either 0.50% or 0.625% times the unused portion of the ABL Facility.

Principal amounts outstanding under the ABL Facility will be due and payable in full on April 3, 2023. The ABL Facility includes a 91-day springing maturity applicable if more than $250 million in the aggregate principal amount of the 5¹⁄₈% Senior Secured Notes due 2021, 6⁷⁄₈% Senior Notes due 2022 or 6¹⁄₄% Senior

131

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Secured Notes due 2023 or any indebtedness incurred to refinance the foregoing are scheduled to mature or similarly become due on a date prior to April 3, 2023. In such event, principal amounts outstanding under the ABL Facility will be accelerated and all amounts outstanding under the ABL Facility will become immediately due and payable.

The ABL Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) engage in mergers, acquisitions and asset sales, (7) conduct transactions with affiliates, (8) alter the nature of the Company’s, CHS’ or the guarantors’ businesses, (9) grant certain guarantees with respect to physician practices, (10) engage in sale and leaseback transactions or (11) change the Company’s fiscal year. The Company is also required to comply with a consolidated fixed coverage ratio, upon certain triggering events described below, and various affirmative covenants. The consolidated fixed coverage ratio is calculated as the ratio of (x) consolidated EBITDA (as defined in the ABL Facility) less capital expenditures to (y) the sum of consolidated interest expense (as defined in the ABL Facility), scheduled principal payments, income taxes and restricted payments made in cash or in permitted investments. For purposes of calculating the consolidated fixed charge coverage ratio, the calculation of consolidated EBITDA as defined in the ABL Facility is a trailing 12-month calculation that begins with the Company’s consolidated net income, with certain adjustments for interest, taxes, depreciation and amortization, net income attributable to noncontrolling interests, stock compensation expense, restructuring costs, and the financial impact of other non-cash or non-recurring items recorded during any such 12-month period. The consolidated fixed charge coverage ratio is a required covenant only in periods where the total borrowings outstanding under the ABL Facility reduce the amount available in the facility to less than the greater of (i) $95 million and (ii) 10% of the calculated borrowing base. As a result, in the event the Company has less than $95 million available under the ABL Facility, the Company would need to comply with the consolidated fixed charge coverage ratio. At December 31, 2019, the Company is not subject to the consolidated fixed charge coverage ratio as such triggering event had not occurred during the last twelve months ended December 31, 2019.

In addition, in the event the amount of borrowings and letters of credit outstanding at any time under the ABL Facility exceeds the borrowing base at such time, the Company will be required to, first, repay outstanding borrowings and, second, replace or cash collateralize outstanding letters of credit, in an aggregate amount sufficient to eliminate such excess.

Events of default under the ABL Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the ABL Facility Agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to an available cure and applicable grace periods, (4) bankruptcy and insolvency events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control (as defined), (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the ABL Agent or lenders under the ABL Facility.

Loss (Gain) from Early Extinguishment of Debt

The financing and repayment transactions discussed above resulted in a loss from early extinguishment of debt of $54 million and $40 million for the years ended December 31, 2019 and 2017, respectively, and a gain from the early extinguishment of debt of $31 million for the year ended December 31, 2018, and an after-tax loss of $42 million and $26 million for the years ended December 31, 2019 and 2017, respectively, and an after-tax gain of $23 million for the year ended December 31, 2018.

132

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Other Debt

As of December 31, 2019, other debt consisted primarily of other obligations maturing in various installments through 2024.

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to one interest swap agreement with a notional amount of approximately $300 million as of December 31, 2019. The Company receives a variable rate of interest on this swap based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. See Note 7 for additional information regarding these swaps.

As of December 31, 2019, the scheduled maturities of long-term debt outstanding, including finance lease obligations for each of the next five years and thereafter are as follows (in millions):

Year Ending December 31,	Amount
2020	$	20
2021		1,010
2022		237
2023		5,149
2024		2,393
Thereafter		4,743
Total maturities		13,552
Less: Deferred debt issuance costs		(132	)
Plus: Unamortized note premium		(15	)
Total long-term debt	$	13,405

The Company paid interest of $1.0 billion, $936 million and $852 million on borrowings during the years ended December 31, 2019, 2018 and 2017, respectively.

133

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

7.   FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of December 31, 2019 and 2018, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions):

	December 31, 2019				December 31, 2018
	Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Assets:
Cash and cash equivalents	$	216	$	216	$	196	$	196
Investments in equity securities		141		141		137		137
Available-for-sale debt securities		101		101		93		93
Trading securities		12		12		11		11
Liabilities:
Contingent Value Right		-		-		-		-
Credit Facility		-		-		1,602		1,564
8% Senior Notes due 2019		-		-		155		146
71⁄8% Senior Notes due 2020		-		-		121		100
51⁄8% Senior Secured Notes due 2021		990		1,003		984		934
67⁄8% Senior Notes due 2022		229		188		2,593		1,175
61⁄4% Senior Secured Notes due 2023		3,074		3,148		3,067		2,819
85⁄8% Senior Secured Notes due 2024		1,023		1,099		1,021		1,025
8% Senior Secured Notes due 2026		2,070		2,182		-		-
8% Senior Secured Notes due 2027		691		700		-		-
67⁄8% Senior Notes due 2028		1,678		1,700		-		-
97⁄8% Junior-Priority Secured Notes due 2023		1,754		1,539		1,750		1,380
81⁄8% Junior-Priority Secured Notes due 2024		1,340		1,113		1,338		976
ABL Facility and other debt		285		285		734		734

The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing through publicly available subscription services such as Bloomberg or from the administrative agent to the Credit Facility to determine fair values where relevant.

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

134

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Investments in equity securities.  Estimated fair value is based on closing price as quoted in public markets. Prior to the adoption of ASU 2016-01 on January 1, 2018, such investments were classified as either available-for-sale or trading securities.

Available-for-sale debt securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities.  Estimated fair value is based on closing price as quoted in public markets.

Contingent Value Right.  Estimated fair value is based on the closing price as quoted on the public market where the CVR was traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions.

8% Senior Notes due 2019.  Estimated fair value is based on the closing market price for these notes.

7¹⁄₈% Senior Notes due 2020.  Estimated fair value is based on the closing market price for these notes.

5¹⁄₈% Senior Secured Notes due 2021.  Estimated fair value is based on the closing market price for these notes.

6⁷⁄₈% Senior Notes due 2022.  Estimated fair value is based on the closing market price for these notes.

6¹⁄₄% Senior Secured Notes due 2023.  Estimated fair value is based on the closing market price for these notes.

8⁵⁄₈% Senior Secured Notes due 2024.  Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2026.  Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2027.  Estimated fair value is based on the closing market price for these notes.

6⁷⁄₈% Senior Secured Notes due 2028.  Estimated fair value is based on the closing market price for these notes.

9⁷⁄₈% Junior-Priority Secured Notes due 2023.  Estimated fair value is based on the closing market price for these notes.

8¹⁄₈% Junior-Priority Secured Notes due 2024.  Estimated fair value is based on the closing market price for these notes.

ABL Facility and other debt.  The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or

135

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements.

At December 31, 2019, the Company had one interest rate swap with a notional amount of approximately $300 million, a fixed interest rate of 2.892%, a termination date of August 30, 2020, and a fair value of approximately $2 million. The counterparty to the interest rate swap agreement exposes the Company to credit risk in the event of nonperformance by such counterparty. However, at December 31, 2019, the Company does not anticipate nonperformance by the counterparty. The Company does not hold or issue derivative financial instruments for trading purposes.

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the consolidated statement of financial position. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

Assuming no change in interest rates in effect as of December 31, 2019, less than $1 million of interest income resulting from the spread between the fixed and floating rates defined in the interest rate swap agreement will be recognized during the next 12 months.

The following tabular disclosure provides the amount of pre-tax (loss) gain recognized as a component of OCI during the years ended December 31, 2019, 2018 and 2017 (in millions):

	Amount of Pre-Tax (Loss) Gain Recognized in OCI (Effective Portion)
Derivatives in Cash Flow Hedging Relationships	Year Ended December 31,
	2019			2018		2017
Interest rate swaps	$	(3	)	$	17	$	2

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the consolidated statements of loss income during the years ended December 31, 2019, 2018 and 2017 (in millions):

Location of Loss Reclassified from AOCL into Income (Effective Portion)	Amount of Pre-Tax Loss Reclassified from AOCL into Income (Effective Portion)
	Year Ended December 31,
	2019		2018		2017
Interest expense, net	$	-	$	2	$	30

136

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The fair values of derivative instruments in the consolidated balance sheets as of December 31, 2019 and 2018 were as follows (in millions):

Asset Derivatives

Liability Derivatives

December 31, 2019

December 31, 2018

December 31, 2019

December 31, 2018

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments

Other assets, net

$

-

Other assets, net

$

3

Other long- term liabilities

$

2

Other long- term liabilities

$

2

8.   FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were no transfers between levels during the years ending December 31, 2019 or December 31, 2018.

137

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of December 31, 2019 and 2018 (in millions):

	December 31, 2019		Level 1		Level 2		Level 3
Investments in equity securities	$	141	$	141	$	-	$	-
Available-for-sale debt securities		101		-		101		-
Trading securities		12		-		12		-
Total assets	$	254	$	141	$	113	$	-
Fair value of interest rate swap agreements	$	2	$	-	$	2	$	-
Total liabilities	$	2	$	-	$	2	$	-
	December 31, 2018		Level 1		Level 2		Level 3
Investments in equity securities	$	137	$	137	$	-	$	-
Available-for-sale debt securities		93		-		93		-
Trading securities		11		-		11		-
Fair value of interest rate swap agreements		3		-		3		-
Total assets	$	244	$	137	$	107	$	-
Contingent Value Right (CVR)	$	-	$	-	$	-	$	-
Fair value of interest rate swap agreements		2		-		2		-
Total liabilities	$	2	$	-	$	2	$	-

Investments in Equity Securities, Available-for-Sale Debt Securities and Trading Securities

Investments in equity securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale debt securities and trading securities primarily consisted of bonds and notes issued by the United States government and its agencies and domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

138

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions):

	Amortized   Cost		Gross   Unrealized   Gains		Gross   Unrealized   Losses			Estimated Fair Values
As of December 31, 2019:
Debt securities
Government	$	54	$	1	$	(1	)	$	54
Corporate		33		1		-			34
Mortgage and asset-backed securities		13		-		-			13
Total	$	100	$	2	$	(1	)	$	101

	Amortized   Cost		Gross   Unrealized   Gains		Gross   Unrealized   Losses			Estimated Fair Values
As of December 31, 2018:
Debt securities
Government	$	54	$	-	$	(3	)	$	51
Corporate		34		-		(2	)		32
Mortgage and asset-backed securities		10		-		-			10
Total	$	98	$	-	$	(5	)	$	93

As of December 31, 2019 and 2018, investments with aggregate estimated fair values of approximately $51 million (71 investments) and $89 million (121 investments), respectively, generated the gross unrealized losses disclosed in the above table. At each reporting date, the Company performs an evaluation of impaired securities to determine if the unrealized losses are other-than-temporary. This evaluation considers a number of factors including, but not limited to, the length of time and extent to which the fair value has been less than cost, and management’s ability and intent to hold the securities until fair value recovers. Based on the results of this evaluation, management concluded that as of December 31, 2019, there were no other-than-temporary losses related to available-for-sale debt securities. The recent declines in value of the securities and/or length of time they have been below cost, as well as the Company’s ability and intent to hold the securities for a reasonable period of time sufficient for a projected recovery of fair value, have caused management to conclude that the securities, that have generated gross unrealized losses, were not other-than-temporarily impaired. Management will continue to monitor and evaluate the recoverability of the Company’s available-for-sale debt securities.

139

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The contractual maturities of debt-based securities held by the Company as of December 31, 2019 and 2018, excluding mutual fund holdings, are set forth in the table below (in millions). Expected maturities will differ from contractual maturities because the issuers of the debt securities may have the right to prepay their obligations without prepayment penalties.

	December 31, 2019				December 31, 2018
	Amortized Cost		Estimated Fair Values		Amortized Cost		Estimated Fair Values
Within 1 year	$	9	$	9	$	14	$	14
After 1 year and through year 5		19		20		20		19
After 5 years and through year 10		29		29		25		24
After 10 years		43		43		39		36

Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions):

	Year Ended December 31,
	2019		2018		2017
Realized gains	$	-	$	-	$	3
Realized losses		-		-		(2	)

Other investment income, which includes interest and dividends, related to all investment securities were $7 million, $7 million and $8 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Net gains and losses recognized during the years ended December 31, 2019 and 2018 for investments in equity securities, which are broken out between investments sold during the year and investments held at the end of the year, are summarized in the table below (in millions):

	Year Ended December 31,
	2019		2018
Net gains and (losses), beginning of year	$	15	$	(7	)
Less: Net gains and (losses) recognized during the year on equity securities sold during the year		2		1
Unrealized gains and (losses) recognized during the year on equity securities held, end of year	$	13		(8	)

Contingent Value Right (CVR)

The CVRs represented the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVRs were listed on the Nasdaq and the valuation of the CVRs was based on the quoted trading price for the CVRs on the last day of the period. Changes in the estimated fair value of the CVRs were recorded through the consolidated statements of loss. In January 2019, the CVRs were terminated and removed from listing with Nasdaq after the determination that no amount was payable under the CVR agreement.

CVR-related Liability

The CVR-related legal liability (prior to being reclassified as a current liability on the Company’s consolidated balance sheet as noted below) represented the Company’s estimate of fair value of the liability associated with

140

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

the legal matters assumed in the HMA merger, which at December 31, 2017 was included in other long-term liabilities in the accompanying consolidated balance sheet. This liability did not include those matters previously accrued by HMA as a probable contingency, which were settled and paid during the year ended December 31, 2015. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability. The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company classified the fair value measurement as a Level 3 measurement in the fair value hierarchy. Prior to December 31, 2018, changes in the fair value of the CVR related legal liability were recorded in future periods through the consolidated statements of loss.

At December 31, 2018, the CVR-related legal liability was zero after taking into account the Company’s payment of the amounts agreed to in the final global resolution and settlement of certain HMA legal matters during the three months ended December 31, 2018.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged.

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements had an immaterial effect on the fair value of the related asset or liability at December 31, 2019 and 2018.

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

9. LEASES

The Company utilizes operating and finance leases for the use of certain hospitals, medical office buildings, and medical equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Such costs are not included in the determination of the ROU asset or lease liability. Variable lease cost also includes escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other

141

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

measure of cost inflation. Most leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rate of rental payment. Certain leases also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the year ended December 31, 2019 are as follows (in millions):

Lease Cost	Year Ended December 31, 2019
Operating lease cost:
Operating lease cost	$	194
Short-term rent expense		114
Variable lease cost		18
Sublease income		(5	)
Total operating lease cost	$	321
Finance lease cost:
Amortization of right-of-use assets	$	12
Interest on finance lease liabilities		7
Total finance lease cost	$	19

Supplemental balance sheet information related to leases was as follows (in millions):

	Balance Sheet Classification	December 31, 2019
Operating Leases:
Operating Lease ROU Assets	Other assets, net	$	607
Finance Leases:
Finance Lease ROU Assets	Property and equipment
	Land and improvements	$	8
	Buildings and improvements		154
	Equipment and fixtures		11
	Property and equipment		173
	Less accumulated depreciation and amortization		(56	)
	Property and equipment, net	$	117
Current finance lease liabilities	Current maturities of long-term debt	$	6
Long-term finance lease liabilities	Long-term debt		107

142

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Supplemental cash flow and other information related to leases as of and for the year ended December 31, 2019 are as follows (dollars in millions):

Other information	Year Ended December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases (1)	$	167
Operating cash flows from finance leases		7
Financing cash flows from finance leases		9
Right-of-use assets obtained in exchange for new finance lease liabilities		2
Right-of-use assets obtained in exchange for new operating lease liabilities		122
Weighted-average remaining lease term:
Operating leases		6 years
Finance leases		20 years
Weighted-average discount rate:
Operating leases		9.1	%
Finance leases		5.6	%

(1) Included in the change in other operating assets and liabilities in the consolidated statement of cash flows.

On September 19, 2019, the Company completed the sale and leaseback of four medical office buildings for net proceeds of $56 million to Carter Validus Mission Critical REIT II, Inc. The buildings, with a combined total of 285,337 square feet, are located in three states and support a wide array of diagnostic, medical and surgical services in an outpatient setting for the respective nearby hospitals. Based on the Company’s assessment of the control transfer principle in these leased buildings, the transaction did not qualify for sale treatment and the related leases have been recorded as financing obligations in long-term debt in the Company’s consolidated balance sheet at December 31, 2019. In addition, on December 18, 2019, the Company completed the sale and leaseback of one medical office building for net proceeds of approximately $4 million to an affiliate of Catalyst Healthcare Real Estate. The 30,000 square foot building is located in Arkansas and supports a wide array of diagnostic, medical and surgical services in an outpatient setting for the nearby hospital. Based on the Company’s assessment of the control transfer principle in this leased building, the transaction does not qualify for sale treatment and the related lease has been recorded as a financing obligation in long-term debt in the accompanying consolidated balance sheet at December 31, 2019.

On December 22, 2016, the Company completed the sale and leaseback of ten medical office buildings for net proceeds of $159 million to HCP, Inc. The buildings, with a combined total of 756,183 square feet, are located in five states and support a wide array of diagnostic, medical and surgical services in an outpatient setting for the respective nearby hospitals. Because of the Company’s continuing involvement in these leased buildings, the transaction did not qualify for sale treatment and the related leases have been recorded as financing obligations in long-term debt in the Company’s consolidated balance sheet at December 31, 2018. Upon adoption of ASC 842 on January 1, 2019, the Company reevaluated the classification of these financing arrangements utilizing the new accounting requirements for sale-leasebacks in ASC 842, concluding that these financing arrangements continue to not qualify for sale treatment and therefore should continue to be classified as financing obligations in long-term debt. At December 31, 2019, six of these financing obligations remain outstanding and are included in the table below, with the other four medical office buildings having been divested in conjunction with the sale of the related hospital entity.

143

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions):

Year Ending December 31,	Operating			Finance			Financing Obligations
2020	$	184		$	12		$	12
2021		150			11			12
2022		115			9			12
2023		92			8			12
2024		71			8			13
Thereafter		213			156			114
Total minimum future payments		825			204			175
Less: Imputed interest		(202	)		(91	)		(16	)
Total liabilities		623			113			159
Less: Current portion		(136	)		(6	)		(1	)
Long-term liabilities	$	487		$	107		$	158

As previously disclosed in the Company’s 2018 Form 10-K, which followed the lease accounting in effect prior to adoption of ASC 842, future commitments relating to noncancellable operating and capital leases and financing obligations for the five years and period thereafter as of December 31, 2018 were as follows (in millions):

Year Ending December 31,	Operating(1)		Capital			Financing Obligations
2019	$	188	$	12		$	12
2020		157		10			9
2021		121		8			10
2022		98		7			10
2023		79		14			10
Thereafter		234		121			106
Total minimum future payments	$	877		172			157
Less: Imputed interest				(80	)		(18	)
Total capital lease and financing obligations				92			139
Less: Current portion				(8	)		(5	)
Long-term capital lease and financing obligations			$	84		$	134

(1) Minimum lease payments have not been reduced by minimum sublease rentals due in the future, which are considered immaterial.

As of December 31, 2019, there were approximately $29 million of assets underlying approved but pending leases that have not yet commenced, primarily for medical equipment.

10.  EMPLOYEE BENEFIT PLANS

The Company maintains various benefit plans, including defined contribution plans, defined benefit plans and deferred compensation plans, for which certain of the Company’s subsidiaries are the plan sponsors. The CHS/

144

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Community Health Systems, Inc. Retirement Savings Plan is a defined contribution plan which covers the majority of the Company’s employees. Employees at these locations whose employment is covered by collective bargaining agreements are generally eligible to participate in the CHS/Community Health Systems, Inc. Standard 401(k) Plan. Total expense to the Company under the 401(k) plans was $85 million, $90 million and $94 million for the years ended December 31, 2019, 2018 and 2017, respectively, and is recorded in salaries and benefits expense on the consolidated statements of loss.

The Company maintains unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability for the deferred compensation plans was $175 million and $163 million as of December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The Company had assets of $153 million and $146 million as of December 31, 2019 and 2018, respectively, in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans, consisting of equity securities of $23 million and $32 million as of December 31, 2019 and 2018, respectively, and company-owned life insurance contracts of $130 million and $114 million as of December 31, 2019 and 2018, respectively.

The Company provides an unfunded Supplemental Executive Retirement Plan (“SERP”) for certain members of its executive management. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the SERP. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations and net periodic cost in future periods. Benefits expense under the SERP was $7 million, $9 million and $16 million for the years ended December 31, 2019, 2018 and 2017, respectively. The accrued benefit liability for the SERP totaled $72 million and $66 million at December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used in determining net periodic cost for the years ended December 31, 2019 and 2018 were a discount rate of 4.2% and 3.4% and an annual salary increase of 3.0% and 2.0%. The Company had equity securities in a rabbi trust generally designated to pay benefits of the SERP in the amounts of $84 million and $74 million at December 31, 2019 and 2018, respectively. These amounts are included in other assets, net on the consolidated balance sheets.

During 2018, certain members of executive management of the Company that were participants in the SERP retired and met the requirements for payout of their SERP retirement benefit. The SERP payout provisions require payment to the participant in an actuarially determined lump sum amount six months after the participant retires from the Company. Such amounts were paid out of the rabbi trust. As required by the pension accounting rules in U.S. GAAP, the Company recognized a non-cash settlement loss of approximately $2 million during the year ended December 31, 2018. There was no settlement loss during the year ended December 31, 2019.

The Company maintains the CHS/Community Health Systems, Inc. Retirement Income Plan (“Pension Plan”), which is a defined benefit, non-contributory pension plan that covers certain employees at three of its formerly owned hospitals. The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of the Employee Retirement Income Security Act of 1974, as amended. The Company expects to make contributions of approximately $1 million to the Pension Plan in 2020. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the Pension Plan. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations, net periodic cost and funding requirements in future periods. Benefits expense under the Pension Plan was less than $1 million for both of the years ended December 31, 2019 and 2018, and was $7 million for the year ended December 31, 2017. The accrued benefit liability for the Pension Plan totaled $12 million and $11 million at December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used for determining the net periodic cost for the

145

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

year ended December 31, 2019 was a discount rate of 4.2% and the expected long-term rate of return on assets of 6.0%.

11.  STOCKHOLDERS’ DEFICIT

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of December 31, 2019, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

On November 6, 2015, the Company adopted an open market repurchase program for up to 10,000,000 shares of the Company’s common stock, not to exceed $300 million in repurchases. The repurchase program expired on November 6, 2018. During the year ended December 31, 2015, the Company repurchased and retired 532,188 shares at a weighted-average price of $27.31 per share, which is the cumulative number of shares repurchased and retired under this program. No shares were repurchased under this program during the years ended December 31, 2019, 2018 and 2017.

The Company is a holding company which operates through its subsidiaries. The Company’s ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.

The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of December 31, 2019, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $200 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments.

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions):

	Year Ended December 31,
	2019			2018			2017
Net loss attributable to Community Health Systems, Inc. stockholders	$	(675	)	$	(788	)	$	(2,459	)
Transfers to the noncontrolling interests:
Net increase (decrease) in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests		3			(4	)		(2	)
Net transfers to the noncontrolling interests		3			(4	)		(2	)
Change to Community Health Systems, Inc. stockholders’ deficit from net loss attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests	$	(672	)	$	(792	)	$	(2,461	)

146

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

12.  EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted (loss) earnings per share for loss from continuing operations, discontinued operations and net loss attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):

	Year Ended December 31,
	2019			2018			2017
Numerator:
Loss from continuing operations, net of taxes	$	(590	)	$	(704	)	$	(2,384	)
Less: Income attributable to noncontrolling interests, net of taxes		85			84			63
Loss from continuing operations attributable to Community Health Systems, Inc. common stockholders – basic and diluted	$	(675	)	$	(788	)	$	(2,447	)
Loss from discontinued operations, net of taxes	$	-		$	-		$	(12	)
Less: Loss from discontinued operations attributable to noncontrolling interests, net of taxes		-			-			-
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders – basic and diluted	$	-		$	-		$	(12	)
Denominator:
Weighted-average number of shares outstanding – basic		113,739,046			112,728,274			111,769,821
Effect of dilutive securities:
Restricted stock awards		-			-			-
Employee stock options		-			-			-
Other equity-based awards		-			-			-
Weighted-average number of shares outstanding – diluted		113,739,046			112,728,274			111,769,821

The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the years ended December 31, 2019, 2018 and 2017, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations during the years ended December 31, 2019, 2018 and 2017, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 133,866, 68,687 and 111,464, respectively.

	Year Ended December 31,
	2019		2018		2017
Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Employee stock options and restricted stock awards		3,508,968		2,152,408		3,008,919

147

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

13.  EQUITY INVESTMENTS

As of December 31, 2019, the Company owned equity interests of 38.0% in two hospitals in Macon, Georgia, in which HCA owns the majority interest. On December 31, 2016, the Company sold 80% of its ownership interest in the legal entity that owned and operated its home care agency business. As part of the divestiture of its controlling interest in the home care agency business, the Company recorded an equity method investment representing its remaining 20% ownership.

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As of December 31, 2019, the Company had a 14.5% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $199 million and $192 million at December 31, 2019 and 2018, respectively, and is included in other assets, net in the accompanying consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $15 million, $22 million and $16 million for the years ended December 31, 2019, 2018 and 2017, respectively.

14.  OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive loss by component for the years ended December 31, 2019 and 2018 (in millions, net of tax):

	Change in Fair Value of Interest Rate Swaps			Change in Fair Value of Available-for-Sale Debt Securities			Change in Unrecognized Pension Cost Components			Accumulated Comprehensive (Loss) Income
Balance as of December 31, 2018	$	5		$	(7	)	$	(8	)	$	(10	)
Other comprehensive (loss) income before reclassifications		(3	)		5			(1	)		1
Amounts reclassified from accumulated other comprehensive (loss) income		-			(1	)		1			-
Net current-period other comprehensive (loss) income		(3	)		4			-			1
Balance as of December 31, 2019	$	2		$	(3	)	$	(8	)	$	(9	)

148

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	Change in Fair Value of Interest Rate Swaps			Change in Fair Value of Available-for-Sale Debt Securities			Change in Unrecognized Pension Cost Components			Accumulated Comprehensive (Loss) Income
Balance as of December 31, 2017	$	(12	)	$	(2	)	$	(7	)	$	(21	)
Other comprehensive income (loss) before reclassifications		12			(2	)		(2	)		8
Amounts reclassified from accumulated other comprehensive income		8			-			1			9
Net current-period other comprehensive income (loss)		20			(2	)		(1	)		17
Adoption of ASU 2016-01 and 2018-02		(3	)		(3	)		-			(6	)
Balance as of December 31, 2018	$	5		$	(7	)	$	(8	)	$	(10	)

The following tables present a subtotal for each significant reclassification to net loss out of AOCL and the line item affected in the accompanying consolidated statements of loss for the years ended December 31, 2019 and 2018 (in millions):

	Amount reclassified from AOCL			Affected line item in the statement where net income (loss) is presented
Details about accumulated other comprehensive income (loss) components	Year Ended December 31, 2019
Gains and losses on cash flow hedges
Interest rate swaps	$	-		Interest expense, net
		-		Tax benefit
	$	-		Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1	)	Salaries and benefits
Settlement losses recognized		-		Salaries and benefits
		(1	)	Total before tax
		-		Tax benefit
	$	(1	)	Net of tax

149

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	Amount reclassified from AOCL			Affected line item in the statement where net (loss) income is presented
Details about accumulated other comprehensive (loss) income components	Year Ended December 31, 2018
Gains and losses on cash flow hedges
Interest rate swaps	$	(10	)	Interest expense, net
		2		Tax benefit
	$	(8	)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1	)	Salaries and benefits
Settlement losses recognized		(2	)	Salaries and benefits
		(3	)	Total before tax
		2		Tax benefit
	$	(1	)	Net of tax

15.  COMMITMENTS AND CONTINGENCIES

Construction and Other Capital Commitments.    Pursuant to a hospital purchase agreement in effect as of December 31, 2019, the Company is required to build replacement facilities in La Porte, Indiana and Knox, Indiana. The estimated construction costs, including equipment costs, for the La Porte and Starke replacement facilities are currently estimated to be approximately $128 million and $15 million, respectively, of which approximately $58 million has been incurred to date for the construction of La Porte. In addition, under other purchase agreements outstanding at December 31, 2019, the Company has committed to spend approximately $2 million for costs such as capital improvements, equipment, selected leases and physician recruiting. These commitments are required to be fulfilled generally over a five to seven-year period after acquisition. Through December 31, 2019, the Company has spent approximately $2 million related to these commitments.

Physician Recruiting Commitments.    As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there. Under such agreements, the Company is required to make payments to the physicians in excess of the amounts they earned in their practice up to the amount of the income guarantee. These income guarantee periods are typically for 12 months. Such payments are recoverable by the Company from physicians who do not fulfill their commitment period, which is typically three years, to the respective community. At December 31, 2019, the maximum potential amount of future payments under these guarantees in excess of the liability recorded is $19 million.

Professional Liability Claims.    As part of the Company’s business of owning and operating hospitals, it is subject to legal actions alleging liability on its part. The Company accrues for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. The Company does not accrue for costs that are part of corporate overhead, such as the costs of in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, historical claim reporting and payment patterns, the nature and level of hospital operations and actuarially determined projections. The actuarially determined projections are based on the Company’s actual claim data, including historic reporting and payment patterns which have been gathered over an approximate 20-year period.

150

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

As discussed below, since the Company purchases excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability it accrues does include an amount for the losses covered by its excess insurance. The Company also records a receivable for the expected reimbursement of losses covered by excess insurance. Since the Company believes that the amount and timing of its future claims payments are reliably determinable, it discounts the amount accrued for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of expected payments.

The net present value of the projected payments was discounted using a weighted-average risk-free rate of 2.6%, 3.1% and 2.2% in 2019, 2018 and 2017, respectively. This liability is adjusted for new claims information in the period such information becomes known. The Company’s estimated liability for professional and general liability claims was $612 million and $650 million as of December 31, 2019 and 2018, respectively. The estimated undiscounted claims liability was $663 million and $710 million as of December 31, 2019 and 2018, respectively. The current portion of the liability for professional and general liability claims was $169 million and $100 million as of December 31, 2019 and 2018, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, with the long-term portion recorded in other long-term liabilities. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as paid excess insurance premiums, and is presented within other operating expenses in the accompanying consolidated statements of loss.

The Company’s processes for obtaining and analyzing claims and incident data are standardized across all of its hospitals and have been consistent for many years. The Company monitors the outcomes of the medical care services that it provides and for each reported claim, the Company obtains various information concerning the facts and circumstances related to that claim. In addition, the Company routinely monitors current key statistics and volume indicators in its assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between three and four years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent approximately 1.0% of the total liability at the end of any period.

For purposes of estimating its individual claim accruals, the Company utilizes specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years, geography and claims relating to the acquired HMA hospitals versus claims relating to the Company’s other hospitals. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses company-specific historical claims data and other information. This company-specific data includes information regarding the Company’s business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

Based on these analyses the Company determines its estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of the management. Changes in reserving data or the trends and factors that influence reserving data may signal fundamental shifts in the Company’s future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since the Company’s methods and models use different types of data and the Company selects its liability from the results of all of these methods, it typically cannot quantify the precise impact of such factors on its estimates of the liability. Due to the Company’s

151

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

standardized and consistent processes for handling claims and the long history and depth of company-specific data, the Company’s methodologies have produced reliably determinable estimates of ultimate paid losses. Management considers any changes in the amount and pattern of its historical paid losses up through the most recent reporting period to identify any fundamental shifts or trends in claim development experience in determining the estimate of professional liability claims. However, due to the subjective nature of this estimate and the impact that previously unforeseen shifts in actual claim experience can have, future estimates of professional liability could be adversely impacted when actual paid losses develop unexpectedly based on assumptions and settlement events that were not previously known or anticipated.

During the nine months ended September 30, 2019, the Company experienced a significant increase in the amounts paid to settle outstanding professional liability claims, compared to the same period in the prior year and to previous actuarially determined estimates. This increase in claims paid related to claims incurred in 2016 and prior years and was primarily related to divested hospitals. The settlement of these claims at amounts greater than the previously determined actuarial estimates resulted in the Company recording a $70 million change in estimate during the three months ended June 30, 2019, and an additional $20 million change in estimate during the three months ended September 30, 2019 based on updated actuarial estimates. No additional change in estimate related to these claims was recorded during the three months ended December 31, 2019.

The Company is primarily self-insured for professional liability claims; however, the Company obtains excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of self-insured retentions. The Company’s excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of the Company’s professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 and before June 1, 2018 are self-insured up to $10 million per claim. Substantially all claims reported on or after June 1, 2018 are self-insured up to $15 million per claim. Management on occasion has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers the Company for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to at least $215 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated occurrence malpractice claims, there is an additional $50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $75 million of excess coverage for claims reported on or after June 1, 2015. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the Company’s self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until the Company’s total aggregate coverage is met. Beginning June 1, 2018, this drop-down provision in the excess policies attaches over the $15 million per claim self-insured retention.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,”

152

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

Effective January 1, 2008, the former Triad hospitals were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims occurring on or after January 1, 2002 and reported on or after January 1, 2008. Substantially all losses for the former Triad hospitals in periods prior to May 1, 1999 were insured through a wholly-owned insurance subsidiary of HCA, Triad’s owner prior to that time, and excess loss policies maintained by HCA. HCA has agreed to indemnify the former Triad hospitals in respect of claims covered by such insurance policies arising prior to May 1, 1999. From May 1, 1999 through December 31, 2006, the former Triad hospitals obtained insurance coverage on a claims incurred basis from HCA’s wholly-owned insurance subsidiary, with excess coverage obtained from other carriers that is subject to certain deductibles. Effective for claims incurred after December 31, 2006, Triad began insuring its claims from $1 million to $5 million through its wholly-owned captive insurance company, replacing the coverage provided by HCA. Substantially all claims occurring during 2007 were self-insured up to $10 million per claim.

Legal Matters.    The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

In connection with the spin-off of Quorum Health Corporation (“QHC”), the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to April 29, 2016, the closing date of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. Notwithstanding the foregoing, the Company is not required to indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with the corporate integrity agreement. Subsequent to the

153

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

spin-off of QHC, the Office of the Inspector General provided the Company with written assurance that it would look solely at QHC for compliance for its facilities under the Company’s Corporate Integrity Agreement; however, the Office of the Inspector General declined to enter into a separate corporate integrity agreement with QHC.

Probable Contingencies

Becker v. Community Health Systems, Inc. d/b/a Community Health Systems Professional Services Corporation d/b/a Community Health Systems d/b/a Community Health Systems PSC, Inc. d/b/a Rockwood Clinic P.S. and Rockwood Clinic, P.S. (Superior Court, Spokane, Washington). This suit was filed on February 29, 2012, by a former chief financial officer at Rockwood Clinic in Spokane, Washington. Becker claims he was wrongfully terminated for allegedly refusing to certify a budget for Rockwood Clinic in 2012. On February 29, 2012, he also filed an administrative complaint with the Department of Labor, Occupational Safety and Health Administration alleging that he is a whistleblower under Sarbanes-Oxley, which was dismissed by the agency and was appealed to an administrative law judge for a hearing that occurred on January 19-26, 2016. In a decision dated November 9, 2016, the law judge awarded Becker approximately $1.9 million for front pay, back pay and emotional damages with attorney fees to be later determined. The Company has appealed the award to the Administrative Review Board and is awaiting its decision. At a hearing on July 27, 2012, the trial court dismissed Community Health Systems, Inc. from the state case and subsequently certified the state case for an interlocutory appeal of the denial to dismiss his employer and the management company. The appellate court accepted the interlocutory appeal, and it was argued on April 30, 2014. On August 14, 2014, the court denied the Company’s appeal. On October 20, 2014, the Company filed a petition to review the denial with the Washington Supreme Court. The appeal was accepted and oral argument was heard on June 9, 2015. On September 15, 2015, the court denied the Company’s appeal and remanded to the trial court; a previous trial setting of September 12, 2016 has been vacated and not reset. On October 15, 2019, the Administrative Review Board released an order to show cause requiring Becker to file a brief to show cause why the Administrative Review Board should not remand the previous administrative decision for a new hearing before a new law judge. The appeal before the Administrative Review Board is still pending. The Company continues to vigorously defend these actions.

Empire Health Foundation v. CHS/Community Health Systems, Inc., CHS Washington Holdings, LLC, Spokane Washington Hospital Company, LLC, Spokane Valley Washington Hospital Company, LLC. This suit was filed in the United States District Court for the Eastern District of Washington on June 12, 2017 by Empire Health Foundation claiming Deaconess and Valley Hospitals failed to abide by charity care obligations allegedly existing in the 2008 Asset Purchase Agreement between Empire Health System and Company affiliates. The court granted in part and denied in part the hospitals’ motion to dismiss on October 11, 2017. All parties filed motions for summary judgment, and the court granted in part and denied in part both parties’ motions on February 27, 2019 and July 9, 2019. The Company settled this matter during the three months ended September 30, 2019 for $22 million (and recorded a liability equal to the settlement amount as of September 30, 2019), the settlement was paid during the three months ended December 31, 2019.

R2 Investments v Quorum Health Corporation; Community Health Systems, Inc.; Wayne T. Smith; W. Larry Cash; Thomas D. Miller; Michael J. Culotta; John A. Clerico; James S. Ely, III; John A. Fry; William Norris Jennings; Julia B. North; H. Mitchell Watson, Jr.; H. James Williams. This case was pending in the Circuit Court for Williamson County, Tennessee and was served on October 26, 2017. The plaintiff alleged common law fraud and violation of Tennessee securities fraud statutes in connection with its purchase of QHC stock and QHC senior secured notes. The court granted in part and denied in part the director defendants’ motion to dismiss and denied the remaining defendants’ motions to dismiss on May 11, 2018. The Company settled and paid this matter during the three months ended December 31, 2019.

154

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

2011 Class Action Shareholder Federal Securities Cases. Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on the Company’s motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint, which was filed on October 5, 2015. The Company’s motion to dismiss was filed on November 4, 2015 and oral argument was held on April 11, 2016. The Company’s motion to dismiss was granted on June 16, 2016 and on June 27, 2016, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals. The matter was heard on May 3, 2017. On December 13, 2017, the Sixth Circuit reversed the trial court’s dismissal of the case and remanded it to the District Court. The Company filed a renewed partial motion to dismiss on February 9, 2018, which was denied by the District Court on September 24, 2018. The Company also filed a petition for a writ of certiorari to the United States Supreme Court on April 18, 2018 seeking review of the Sixth Circuit’s decision. The United States Supreme Court denied the petition for a writ of certiorari on October 1, 2018. The District Court granted the Plaintiff’s motion for class certification on July 26, 2019. The Company filed a petition for permission to appeal the District Court’s class certification order in the Sixth Circuit Court of Appeals on August 9, 2019, and that petition was denied on October 23, 2019. Trial for this matter is set for December 1, 2020. On January 21, 2020, the Company and the Plaintiff filed a stipulation of settlement indicating to the District Court that the parties had reached agreement on the principal terms of a settlement for $53 million. The settlement is subject to the District Court’s final approval. The Company recorded a liability of $53 million at December 31, 2019 based on the proposed settlement agreement.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the years ended December 31, 2019 and 2018, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded.

	Probable Contingencies
Balance as of December 31, 2017	$	14
Expense		7
Reserve for insured claim		4
Cash payments		(6	)
Balance as of December 31, 2018		19
Expense		87
Reserve for insured claim		(4	)
Cash payments		(34	)
Balance as of December 31, 2019	$	68

In accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the consolidated balance sheet and are included in the table above. Due to the uncertainties

155

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the consolidated balance sheet.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $21 million and $2 million during the years ended December 31, 2019 and 2018, respectively, and are included in other operating expenses in the accompanying consolidated statements of loss.

Matters for which an Outcome Cannot be Assessed

For the following legal matter, due to the uncertainties surrounding the ultimate outcome of the case, the Company cannot at this time assess what the outcome may be and is further unable to reasonably estimate any loss or range of loss.

Steadfast Insurance Company, et al v. Community Health Systems, Inc., CHS/Community Health Systems, Inc., CHSPSC, LLC and Pecos Valley of New Mexico, LLC. This case is filed in the Superior Court for the State of Delaware and involve suits by four excess liability insurers seeking a declaration that a $73 million judgment rendered against Pecos Valley of New Mexico, LLC in Anne Sperling, et al v. Pecos Valley of New Mexico, LLC is not a covered loss as defined by the policies at issue. The Steadfast complaint was served on November 30, 2018. On December 13, 2018, Admiral Insurance Company, Endurance Specialty Insurance Ltd, and Illinois Union Insurance Company moved to intervene in the suit as petitioners. The Company has initiated counterclaims against each insurer, including for bad faith against Steadfast. The judgment against Pecos Valley of New Mexico, LLC, which is the subject of this litigation and which was rendered on September 5, 2018, in First Judicial Court of the State of New Mexico, is currently on appeal to the Court of Appeals of New Mexico. Trial of this matter is set for December 7, 2020. The Company believes the claims in the Steadfast litigation are without merit and will vigorously defend the case.

16.  SUBSEQUENT EVENTS

The Company has evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the consolidated financial statements.

On January 1, 2020, one or more subsidiaries of the Company sold Southside Regional Medical Center (300 licensed beds) in Petersburg, Virginia, Southampton Memorial Hospital (105 licensed beds) in Franklin, Virginia and Southern Virginia Regional Medical Center (80 licensed beds) in Emporia, Virginia and their associated assets to Bon Secours Mercy Health System pursuant to the terms of a definitive agreement which was entered into on October 28, 2019. The net proceeds from this sale were received at a preliminary closing on December 31, 2019.

On January 23, 2020, the Company announced that CHS commenced a cash tender offer for any and all of the outstanding 5¹⁄₈% Senior Secured Notes due 2021. As of the early tender deadline on February 5, 2020, approximately $632 million aggregate principal amount of 5¹⁄₈% Senior Secured Notes due 2021, or approximately 63.25% of the outstanding 5¹⁄₈% Senior Secured Notes due 2021, had been validly tendered and not validly withdrawn. In connection with the commencement of the cash tender offer, CHS issued to holders of the 5¹⁄₈% Senior Secured Notes due 2021 a conditional notice of redemption to redeem all of the 5¹⁄₈% Senior Secured Notes due 2021 not purchased by CHS in the tender offer at a redemption price of 100.000% of the principal amount thereof plus accrued interest to, but not including, February 22, 2020.

On January 30, 2020, one or more affiliates of the Company entered into definitive agreements for the sale of substantially all of the assets of each of Shands Live Oak Regional Medical Center (25 licensed beds) in Live Oak, Florida and Shands Starke Regional Medical Center (49 licensed beds) in Starke, Florida to affiliates of HCA.

156

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

On February 6, 2020, CHS completed a private offering of $1.462 billion aggregate principal amount of 6⁵⁄₈% Senior Secured Notes due February 15, 2025 (the “6⁵⁄₈% Senior Secured Notes due 2025”). CHS used the net proceeds of the offering of the 6⁵⁄₈% Senior Secured Notes due 2025 to (i) purchase any and all of its 5¹⁄₈% Senior Secured Notes due 2021 validly tendered and not validly withdrawn in the cash tender offer announced on January 23, 2020, (ii) redeem all of the 5¹⁄₈% Senior Secured Notes due 2021 that were not purchased pursuant to such tender offer, (iii) purchase in one or more privately negotiated transactions approximately $426 million aggregate principal amount of its 6¹⁄₄% Senior Secured Notes due 2023 and (iv) pay related fees and expenses. The 6⁵⁄₈% Senior Secured Notes due 2025 bear interest at a rate of 6.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2020. The 6⁵⁄₈% Senior Secured Notes are scheduled to mature on February 15, 2025. The 6⁵⁄₈% Senior Secured Notes due 2025 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS’ outstanding senior notes) and certain other long-term debt of CHS. The 6⁵⁄₈% Senior Secured Notes due 2025 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6⁵⁄₈% Senior Secured Notes due 2025.

157

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

17.  QUARTERLY FINANCIAL DATA (UNAUDITED)

	Quarter
	1st			2nd			3rd			4th			Total (2)
	(in millions, except share and per share data)
Year ended December 31, 2019:
Net operating revenues	$	3,376		$	3,302		$	3,246		$	3,286		$	13,210
Loss from continuing operations before income taxes		(94	)		(149	)		(72	)		(115	)		(430	)
Loss from continuing operations		(101	)		(146	)		2			(346	)		(590	)
Loss from discontinued operations		-			-			-			-			-
Net loss attributable to Community Health Systems, Inc.	$	(118	)	$	(167	)	$	(17	)	$	(373	)	$	(675	)
Basic loss per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(1.04	)	$	(1.47	)	$	(0.15	)	$	(3.27	)	$	(5.93	)
Discontinued operations		-			-			-			-			-
Net loss	$	(1.04	)	$	(1.47	)	$	(0.15	)	$	(3.27	)	$	(5.93	)
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(1.04	)	$	(1.47	)	$	(0.15	)	$	(3.27	)	$	(5.93	)
Discontinued operations		-			-			-			-			-
Net loss	$	(1.04	)	$	(1.47	)	$	(0.15	)	$	(3.27	)	$	(5.93	)
Weighted-average number of shares outstanding:
Basic		113,257,608			113,862,097			113,891,721			113,935,629			113,739,046
Diluted		113,257,608			113,862,097			113,891,721			113,935,629			113,739,046
Year ended December 31, 2018:
Net operating revenues	$	3,689		$	3,562		$	3,451		$	3,453		$	14,155
Loss from continuing operations before income taxes		(13	)		(129	)		(204	)		(369	)		(715	)
Loss from continuing operations		(6	)		(91	)		(308	)		(299	)		(704	)
Loss from discontinued operations		-			-			-			-			-
Net loss attributable to Community
Health Systems, Inc.	$	(25	)	$	(110	)	$	(325	)	$	(328	)	$	(788	)
Basic loss per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(0.22	)	$	(0.97	)	$	(2.88	)	$	(2.91	)	$	(6.99	)
Discontinued operations		-			-			-			-			-
Net loss	$	(0.22	)	$	(0.97	)	$	(2.88	)	$	(2.91	)	$	(6.99	)
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders (1):
Continuing operations	$	(0.22	)	$	(0.97	)	$	(2.88	)	$	(2.91	)	$	(6.99	)
Discontinued operations		-			-			-			-			-
Net loss	$	(0.22	)	$	(0.97	)	$	(2.88	)	$	(2.91	)	$	(6.99	)
Weighted-average number of shares outstanding:
Basic		112,291,496			112,837,944			112,865,482			112,909,869			112,728,274
Diluted		112,291,496			112,837,944			112,865,482			112,909,869			112,728,274

(1) Total per share amounts may not add due to rounding.

(2) Total quarterly amounts may not add due to rounding.

158

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

18.  SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The 6⁷⁄₈% Senior Notes due 2022, which are senior unsecured obligations of CHS, the 5¹⁄₈% Senior Secured Notes due 2021, and the 6¹⁄₄% Senior Secured Notes due 2023 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries. In addition, equity interests held by the Company in non-guarantor subsidiaries have been pledged as collateral under the Notes, except for equity interests held in three hospitals owned jointly with a non-profit, health organization. The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the consolidated financial statements of the Company, except as noted below:

• Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

• Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net.

• Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ deficit. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

• Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances.

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the ABL Facility and Receivables Facility that are further discussed in Note 6. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation.

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods have been revised to reflect the status of guarantors and non-guarantors as of December 31, 2019.

159

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Loss

Year Ended December 31, 2019

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
Net operating revenues	$	-		$	46		$	8,246		$	4,918		$	-		$	13,210
Operating costs and expenses:
Salaries and benefits		-			-			3,092			2,855			-			5,947
Supplies		-			-			1,444			707			-			2,151
Other operating expenses		-			-			2,289			1,014			-			3,303
Government and other legal settlements and related costs		-			-			93			-			-			93
Electronic health records incentive reimbursement		-			-			-			(1	)		-			(1	)
Lease cost and rent		-			-			168			153			-			321
Depreciation and amortization		-			-			383			225			-			608
Impairment and loss on sale of businesses, net		-			(2	)		121			19			-			138
Total operating costs and expenses		-			(2	)		7,590			4,972			-			12,560
Income (loss) from operations		-			48			656			(54	)		-			650
Interest expense, net		-			425			667			(51	)		-			1,041
Loss from early extinguishment of debt		-			54			-			-			-			54
Equity in earnings of unconsolidated affiliates		675			99			(26	)		-			(763	)		(15	)
(Loss) income before income taxes		(675	)		(530	)		15			(3	)		763			(430	)
Provision for (benefit from) income taxes		-			145			(6	)		21			-			160
Net (loss) income		(675	)		(675	)		21			(24	)		763			(590	)
Less: Net income attributable to noncontrolling interests		-			-			-			85			-			85
Net (loss) income attributable to Community Health Systems, Inc. stockholders	$	(675	)	$	(675	)	$	21		$	(109	)	$	763		$	(675	)

160

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Loss

Year Ended December 31, 2018

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
Net operating revenues	$	-		$	(5	)	$	8,111		$	6,049		$	-		$	14,155
Operating costs and expenses:
Salaries and benefits		-			-			3,030			3,354			-			6,384
Supplies		-			-			1,426			929			-			2,355
Other operating expenses		-			-			2,109			1,387			-			3,496
Government and other legal settlements and related costs		-			-			11			-			-			11
Electronic health records incentive reimbursement		-			-			(1	)		(3	)		-			(4	)
Lease cost and rent		-			-			166			171			-			337
Depreciation and amortization		-			-			414			286			-			700
Impairment and loss on sale of businesses, net		-			29			97			542			-			668
Total operating costs and expenses		-			29			7,252			6,666			-			13,947
(Loss) income from operations		-			(34	)		859			(617	)		-			208
Interest expense, net		-			425			494			57			-			976
(Gain) loss from early extinguishment of debt		-			(32	)		1			-			-			(31	)
Equity in earnings of unconsolidated affiliates		788			438			774			-			(2,022	)		(22	)
Loss before income taxes		(788	)		(865	)		(410	)		(674	)		2,022			(715	)
(Benefit from) provision for income taxes		-			(77	)		(7	)		73			-			(11	)
Net loss		(788	)		(788	)		(403	)		(747	)		2,022			(704	)
Less: Net income attributable to noncontrolling interests		-			-			-			84			-			84
Net loss attributable to Community Health Systems, Inc. stockholders	$	(788	)	$	(788	)	$	(403	)	$	(831	)	$	2,022		$	(788	)

161

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Loss

Year Ended December 31, 2017

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
Operating revenues (net of contractual allowances and discounts)	$	-		$	(22	)	$	9,421		$	8,999		$	-		$	18,398
Provision for bad debts		-			-			1,819			1,226			-			3,045
Net operating revenues		-			(22	)		7,602			7,773			-			15,353
Operating costs and expenses:
Salaries and benefits		-			-			3,092			4,284			-			7,376
Supplies		-			-			1,397			1,275			-			2,672
Other operating expenses		-			-			1,954			1,910			-			3,864
Government and other legal settlements and related costs		-			-			(31	)		-			-			(31	)
Electronic health records incentive reimbursement		-			-			(8	)		(20	)		-			(28	)
Rent		-			-			166			228			-			394
Depreciation and amortization		-			-			434			427			-			861
Impairment and loss on sale of businesses, net		-			-			608			1,515			-			2,123
Total operating costs and expenses		-			-			7,612			9,619			-			17,231
Loss from operations		-			(22	)		(10	)		(1,846	)		-			(1,878	)
Interest expense, net		-			327			489			115			-			931
Loss from early extinguishment of debt		-			40			-			-			-			40
Equity in earnings of unconsolidated affiliates		2,459			1,888			1,555			-			(5,918	)		(16	)
Loss from continuing operations before income taxes		(2,459	)		(2,277	)		(2,054	)		(1,961	)		5,918			(2,833	)
Provision for (benefit from) income taxes		-			182			(170	)		(461	)		-			(449	)
Loss from continuing operations		(2,459	)		(2,459	)		(1,884	)		(1,500	)		5,918			(2,384	)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale		-			-			(4	)		(2	)		-			(6	)
Impairment of hospitals sold or held for sale		-			-			(4	)		(2	)		-			(6	)
Loss from discontinued operations, net of taxes		-			-			(8	)		(4	)		-			(12	)
Net loss		(2,459	)		(2,459	)		(1,892	)		(1,504	)		5,918			(2,396	)
Less: Net income attributable to noncontrolling interests		-			-			-			63			-			63
Net loss attributable to Community Health Systems, Inc. stockholders	$	(2,459	)	$	(2,459	)	$	(1,892	)	$	(1,567	)	$	5,918		$	(2,459	)

162

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Comprehensive (Loss) Income

Year Ended December 31, 2019

	Parent Guarantor			Issuer			Other Guarantors		Non - Guarantors			Eliminations			Consolidated
	(In millions)
Net (loss) income	$	(675	)	$	(675	)	$	21	$	(24	)	$	763		$	(590	)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(3	)		(3	)		-		-			3			(3	)
Net change in fair value of available-for-sale debt securities, net of tax		4			4			4		-			(8	)		4
Amortization and recognition of unrecognized pension cost components, net of tax		-			-			-		-			-			-
Other comprehensive income		1			1			4		-			(5	)		1
Comprehensive (loss) income		(674	)		(674	)		25		(24	)		758			(589	)
Less: Comprehensive income attributable to noncontrolling interests		-			-			-		85			-			85
Comprehensive (loss) income attributable to
Community Health Systems, Inc. stockholders	$	(674	)	$	(674	)	$	25	$	(109	)	$	758		$	(674	)

Condensed Consolidating Statement of Comprehensive Loss

Year Ended December 31, 2018

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
Net loss	$	(788	)	$	(788	)	$	(403	)	$	(747	)	$	2,022		$	(704	)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		20			20			-			-			(20	)		20
Net change in fair value of available-for-sale debt securities, net of tax		(2	)		(2	)		(2	)		-			4			(2	)
Amortization and recognition of unrecognized pension cost components, net of tax		(1	)		(1	)		(1	)		-			2			(1	)
Other comprehensive income (loss)		17			17			(3	)		-			(14	)		17
Comprehensive loss		(771	)		(771	)		(406	)		(747	)		2,008			(687	)
Less: Comprehensive income attributable to noncontrolling interests		-			-			-			84			-			84
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	$	(771	)	$	(771	)	$	(406	)	$	(831	)	$	2,008		$	(771	)

163

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Comprehensive Loss

Year Ended December 31, 2017

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
Net loss	$	(2,459	)	$	(2,459	)	$	(1,892	)	$	(1,504	)	$	5,918		$	(2,396	)
Other comprehensive income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		19			19			-			-			(19	)		19
Net change in fair value of available-for-sale debt securities, net of tax		8			8			8			-			(16	)		8
Amortization and recognition of unrecognized pension cost components, net of tax		14			14			14			-			(28	)		14
Other comprehensive income		41			41			22			-			(63	)		41
Comprehensive loss		(2,418	)		(2,418	)		(1,870	)		(1,504	)		5,855			(2,355	)
Less: Comprehensive income attributable to noncontrolling interests		-			-			-			63			-			63
Comprehensive loss attributable to
Community Health Systems, Inc. stockholders	$	(2,418	)	$	(2,418	)	$	(1,870	)	$	(1,567	)	$	5,855		$	(2,418	)

164

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Balance Sheet

December 31, 2019

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-		$	-		$	142		$	74		$	-		$	216
Patient accounts receivable		-			-			1,822			436			-			2,258
Supplies		-			-			242			112			-			354
Prepaid income taxes		48			-			-			-			-			48
Prepaid expenses and taxes		-			-			152			41			-			193
Other current assets		-			-			72			286			-			358
Total current assets		48			-			2,430			949			-			3,427
Intercompany receivable		-			11,961			5,674			6,990			(24,625	)		-
Property and equipment, net		-			-			4,206			1,402			-			5,608
Goodwill		-			-			2,628			1,700			-			4,328
Deferred income taxes		38			-			-			-			-			38
Other assets, net		(4	)		-			1,203			1,009			-			2,208
Net investment in subsidiaries		-			21,736			12,433			-			(34,169	)		-
Total assets	$	82		$	33,697		$	28,574		$	12,050		$	(58,794	)	$	15,609
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-		$	-		$	18		$	2		$	-		$	20
Current operating lease liabilities		-			-			82			54			-			136
Accounts payable		-			11			518			282			-			811
Accrued interest		-			189			-			-			-			189
Accrued liabilities		-			1			650			475			-			1,126
Total current liabilities		-			201			1,268			813			-			2,282
Long-term debt		-			13,116			208			61			-			13,385
Intercompany payable		2,099			22,518			26,029			13,399			(64,045	)		-
Deferred income taxes		200			-			-			-			-			200
Long-term operating lease liabilities		-			-			265			222			-			487
Other long-term liabilities		1			2			580			311			-			894
Total liabilities		2,300			35,837			28,350			14,806			(64,045	)		17,248
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-			-			-			502			-			502
(Deficit) equity:
Community Health Systems, Inc. stockholders’ (deficit) equity:
Common stock		1			-			-			-			-			1
Additional paid-in capital		2,008			(487	)		198			(1,008	)		1,297			2,008
Accumulated other comprehensive (loss) income		(9	)		(9	)		(11	)		1			19			(9	)
(Accumulated deficit) retained earnings		(4,218	)		(1,644	)		37			(2,328	)		3,935			(4,218	)
Total Community Health Systems, Inc. stockholders’ (deficit) equity		(2,218	)		(2,140	)		224			(3,335	)		5,251			(2,218	)
Noncontrolling interests in equity of consolidated subsidiaries		-			-			-			77			-			77
Total (deficit) equity		(2,218	)		(2,140	)		224			(3,258	)		5,251			(2,141	)
Total liabilities and (deficit) equity	$	82		$	33,697		$	28,574		$	12,050		$	(58,794	)	$	15,609

165

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Balance Sheet

December 31, 2018

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-		$	-		$	132		$	64		$	-		$	196
Patient accounts receivable		-			-			1,844			508			-			2,352
Supplies		-			-			269			133			-			402
Prepaid income taxes		3			-			-			-			-			3
Prepaid expenses and taxes		-			-			134			62			-			196
Other current assets		-			-			84			316			-			400
Total current assets		3			-			2,463			1,083			-			3,549
Intercompany receivable		-			12,615			4,882			6,358			(23,855	)		-
Property and equipment, net		-			-			4,371			1,768			-			6,139
Goodwill		-			-			2,704			1,855			-			4,559
Deferred income taxes		69			-			-			-			-			69
Other assets, net		-			25			796			722			-			1,543
Net investment in subsidiaries		-			20,742			11,784			-			(32,526	)		-
Total assets	$	72		$	33,382		$	27,000		$	11,786		$	(56,381	)	$	15,859
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-		$	155		$	22		$	27		$	-		$	204
Accounts payable		-			-			574			313			-			887
Accrued interest		-			205			-			1			-			206
Accrued liabilities		-			1			531			563			-			1,095
Total current liabilities		-			361			1,127			904			-			2,392
Long-term debt		-			13,167			151			74			-			13,392
Intercompany payable		1,572			21,318			24,901			13,085			(60,876	)		-
Deferred income taxes		26			-			-			-			-			26
Other long-term liabilities		9			2			619			378			-			1,008
Total liabilities		1,607			34,848			26,798			14,441			(60,876	)		16,818
Redeemable noncontrolling interests in equity of consolidated subsidiaries		-			-			-			504			-			504
(Deficit) equity:
Community Health Systems, Inc. stockholders’ (deficit) equity:
Common stock		1			-			-			-			-			1
Additional paid-in capital		2,017			(329	)		193			(985	)		1,121			2,017
Accumulated other comprehensive loss		(10	)		(10	)		(11	)		(3	)		24			(10	)
(Accumulated deficit) retained earnings		(3,543	)		(1,127	)		20			(2,243	)		3,350			(3,543	)
Total Community Health Systems, Inc. stockholders’ (deficit) equity		(1,535	)		(1,466	)		202			(3,231	)		4,495			(1,535	)
Noncontrolling interests in equity of consolidated subsidiaries		-			-			-			72			-			72
Total (deficit) equity		(1,535	)		(1,466	)		202			(3,159	)		4,495			(1,463	)
Total liabilities and (deficit) equity	$	72		$	33,382		$	27,000		$	11,786		$	(56,381	)	$	15,859

166

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2019

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	(4	)	$	(348	)	$	600		$	137		$	-	$	385
Cash flows from investing activities:
Acquisitions of facilities and other related businesses		-			-			(6	)		(7	)		-		(13	)
Purchases of property and equipment		-			-			(366	)		(72	)		-		(438	)
Proceeds from disposition of hospitals and other ancillary operations		-			18			30			556			-		604
Proceeds from sale of property and equipment		-			-			1			2			-		3
Purchases of available-for-sale debt securities and equity securities		-			-			(19	)		(61	)		-		(80	)
Proceeds from sales of available-for-sale debt securities and equity securities		-			-			31			61			-		92
Increase in other investments		-			-			(123	)		(47	)		-		(170	)
Net cash provided by (used in) investing activities		-			18			(452	)		432			-		(2	)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(1	)		-			-			-			-		(1	)
Deferred financing costs and other debt-related costs		-			(46	)		-			-			-		(46	)
Proceeds from noncontrolling investors in joint ventures		-			-			-			10			-		10
Redemption of noncontrolling investments in joint ventures		-			-			-			(11	)		-		(11	)
Distributions to noncontrolling investors in joint ventures		-			-			-			(99	)		-		(99	)
Proceeds from sale-lease back		-			-			60			-			-		60
Changes in intercompany balances with affiliates, net		5			619			(189	)		(435	)		-		-
Borrowings under credit agreements		-			-			36			1			-		37
Issuance of long-term debt		-			3,042			-			-			-		3,042
Proceeds from ABL Facility		-			202			-			-			-		202
Repayments of long-term indebtedness		-			(3,487	)		(45	)		(25	)		-		(3,557	)
Net cash provided by (used in) financing activities		4			330			(138	)		(559	)		-		(363	)
Net change in cash and cash equivalents		-			-			10			10			-		20
Cash and cash equivalents at beginning of period		-			-			132			64			-		196
Cash and cash equivalents at end of period	$	-		$	-		$	142		$	74		$	-	$	216

167

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2018

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations		Consolidated
	(In millions)
Net cash provided by (used in) operating activities	$	40		$	(409	)	$	560		$	83		$	-	$	274
Cash flows from investing activities:
Acquisitions of facilities and other related businesses		-			-			(3	)		(23	)		-		(26	)
Purchases of property and equipment		-			-			(408	)		(119	)		-		(527	)
Proceeds from disposition of hospitals and other ancillary operations		-			-			1			404			-		405
Proceeds from sale of property and equipment		-			-			5			3			-		8
Purchases of available-for-sale debt securities and equity securities		-			-			(54	)		(24	)		-		(78	)
Proceeds from sales of available-for-sale debt securities and equity securities		-			-			79			35			-		114
Increase in other investments		-			(7	)		(112	)		(22	)		-		(141	)
Net cash (used in) provided by investing activities		-			(7	)		(492	)		254			-		(245	)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(1	)		-			-			-			-		(1	)
Deferred financing costs and other debt-related costs		-			(96	)		-			-			-		(96	)
Proceeds from noncontrolling investors in joint ventures		-			-			-			3			-		3
Redemption of noncontrolling investments in joint ventures		-			-			-			(31	)		-		(31	)
Distributions to noncontrolling investors in joint ventures		-			-			-			(96	)		-		(96	)
Changes in intercompany balances with affiliates, net		(39	)		99			176			(236	)		-		-
Borrowings under credit agreements		-			-			28			-			-		28
Issuance of long-term debt		-			1,033			-			-			-		1,033
Proceeds from ABL Facility		-			748			49			-			-		797
Repayments of long-term indebtedness		-			(1,368	)		(655	)		(10	)		-		(2,033	)
Net cash (used in) provided by financing activities		(40	)		416			(402	)		(370	)		-		(396	)
Net change in cash and cash equivalents		-			-			(334	)		(33	)		-		(367	)
Cash and cash equivalents at beginning of period		-			-			466			97			-		563
Cash and cash equivalents at end of period	$	-		$	-		$	132		$	64		$	-	$	196

168

COMMUNITY HEALTH SYSTEMS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Condensed Consolidating Statement of Cash Flows

Year Ended December 31, 2017

	Parent Guarantor			Issuer			Other Guarantors			Non - Guarantors			Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating activities	$	(12	)	$	(317	)	$	431		$	671		$	-	$	773
Cash flows from investing activities:
Acquisitions of facilities and other related businesses		-			-			(1	)		(5	)		-		(6	)
Purchases of property and equipment		-			-			(356	)		(208	)		-		(564	)
Proceeds from disposition of hospitals and other ancillary operations		-			-			122			1,570			-		1,692
Proceeds from sale of property and equipment		-			-			3			4			-		7
Purchases of available-for-sale debt securities and equity securities		-			-			(91	)		(34	)		-		(125	)
Proceeds from sales of available-for-sale debt securities and equity securities		-			-			172			36			-		208
Increase in other investments		-			-			(100	)		(43	)		-		(143	)
Net cash (used in) provided by investing activities		-			-			(251	)		1,320			-		1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements		(5	)		-			-			-			-		(5	)
Deferred financing costs and other debt-related costs		-			(65	)		(1	)		-			-		(66	)
Proceeds from noncontrolling investors in joint ventures		-			-			-			5			-		5
Redemption of noncontrolling investments in joint ventures		-			-			-			(6	)		-		(6	)
Distributions to noncontrolling investors in joint ventures		-			-			-			(100	)		-		(100	)
Changes in intercompany balances with affiliates, net		17			1,565			331			(1,913	)		-		-
Borrowings under credit agreements		-			795			30			16			-		841
Issuance of long-term debt		-			3,100			-			-			-		3,100
Proceeds from ABL Facility		-			-			105			-			-		105
Repayments of long-term indebtedness		-			(5,078	)		(285	)		(28	)		-		(5,391	)
Net cash provided by (used in) financing activities		12			317			180			(2,026	)		-		(1,517	)
Net change in cash and cash equivalents		-			-			360			(35	)		-		325
Cash and cash equivalents at beginning of period		-			-			106			132			-		238
Cash and cash equivalents at end of period	$	-		$	-		$	466		$	97		$	-	$	563

169

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Securities and Exchange Act of 1934, as amended, as of the end of the period covered by this report. Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be included in this report has been recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that the information required to be included in this report was accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There have been no changes in internal control over financial reporting that occurred during the period that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

Management’s report on internal control over financial reporting is included herein at page 171.

The attestation report from Deloitte & Touche LLP, our independent registered public accounting firm, on our internal control over financial reporting is included herein at page 172.

Item 9B. Other Information

None.

170

Management’s Report on Internal Control over Financial Reporting

We are responsible for the preparation and integrity of the consolidated financial statements appearing in our Annual Report on Form 10-K. The consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America and include amounts based on management’s estimates and judgments. All other financial information in this report has been presented on a basis consistent with the information included in the consolidated financial statements.

We are also responsible for establishing and maintaining adequate internal controls over financial reporting (as defined in Rule 13a-15(f) under the Securities and Exchange Act of 1934, as amended). We maintain a system of internal controls that is designed to provide reasonable assurance as to the fair and reliable preparation and presentation of the consolidated financial statements, as well as to safeguard assets from unauthorized use or disposition.

Our control environment is the foundation for our system of internal control over financial reporting and is embodied in our Code of Conduct. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal control over financial reporting is supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations.

The Audit and Compliance Committee of the Board of Directors, which is composed solely of outside directors, meets periodically with members of management, the internal auditors and the independent registered public accounting firm to review and discuss internal control over financial reporting and accounting and financial reporting matters. The independent registered public accounting firm and internal auditors report to the Audit and Compliance Committee and have full and free access to the Audit and Compliance Committee at any time.

We conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. We have concluded that our internal control over financial reporting was effective as of December 31, 2019, based on these criteria.

Deloitte & Touche LLP, an independent registered public accounting firm, has issued an attestation report on our internal control over financial reporting, which is included herein.

We do not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

171

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of

Community Health Systems, Inc.

Franklin, Tennessee

Opinion on Internal Control over Financial Reporting

We have audited the internal control over financial reporting of Community Health Systems, Inc., and subsidiaries (the “Company”) as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control – Integrated Framework (2013) issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements and financial statement schedule as of and for the year ended December 31, 2019, of the Company and our reports dated February 20, 2020, expressed an unqualified opinion on those financial statements and schedule and included an explanatory paragraph regarding the Company’s adoption of Accounting Standards Codification Topic 842, “Leases”.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

172

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Deloitte & Touche LLP

Nashville, Tennessee

February 20, 2020

173

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The Company has adopted a Code of Conduct that is applicable to all members of the Board of Directors and our officers, as well as employees of our subsidiaries. A copy of the current version of our Code of Conduct is available in the Company-Overview – Corporate Governance section of our internet website at www.chs.net/company-overview/corporate-governance. A copy of the Code of Conduct is also available in print, free of charge, to any stockholder who requests it by writing to Community Health Systems, Inc., Investor Relations, at 4000 Meridian Boulevard, Franklin, TN 37067. The Company intends to post amendments to or waivers, if any, from its Code of Conduct at this location on its website, in each case to the extent such amendment or waiver would otherwise require the filing of a Current Report on Form 8-K pursuant to Item 5.05 thereof.

The committee report of the Audit and Compliance Committee of the Board of Directors is presented below. The other information required by this Item is incorporated herein by reference to the Company’s definitive proxy statement to be filed under Regulation 14A in connection with the Annual Meeting of the Stockholders of the Company scheduled to be held on May 12, 2020, under “General Information,” “Members of the Board of Directors,” “Information About our Executive Officers,” and, if applicable, “Delinquent Section 16(a) Reports.”

AUDIT AND COMPLIANCE COMMITTEE REPORT

The Audit and Compliance Committee of the Board of Directors of the Company is composed of four directors, each of whom is “independent” as defined by the applicable listing standards of the New York Stock Exchange and Section 10A-3 of the Exchange Act. All of our Audit and Compliance Committee members meet the Securities and Exchange Commission definition of “audit committee financial expert.” The Audit and Compliance Committee operates under a written charter adopted by the Board of Directors, which is posted on our corporate website (www.chs.net) and which is reviewed by the Committee annually, in conjunction with the Committee’s annual self-evaluation. The Company’s management is responsible for its internal controls and the financial reporting process. Our independent registered public accounting firm, Deloitte & Touche LLP, is responsible for performing an independent audit of our consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States) and to issue its reports thereon. The Audit and Compliance Committee is responsible for, among other things, monitoring and overseeing these processes, and recommending to the Board of Directors: (i) that the audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K; and (ii) the selection of the independent registered public accounting firm to audit the consolidated financial statements of the Company.

In keeping with that responsibility, the Audit and Compliance Committee has reviewed and discussed the Company’s audited consolidated financial statements with management and with the independent registered public accounting firm, reviewed internal controls and accounting procedures and provided oversight review of the Company’s corporate compliance program. In addition, the Audit and Compliance Committee has discussed with the Company’s independent registered public accounting firm the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board.

The Audit and Compliance Committee discussed with the Company’s internal auditors and independent registered public accounting firm the overall scope and plans for their respective audits. The Audit and Compliance Committee met with the internal auditors and the independent registered public accounting firm with and without management present to discuss the results of their examinations, their evaluations of the Company’s internal controls and the overall quality of the Company’s financial reporting.

The Audit and Compliance Committee has received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent accountant’s communications with the audit committee concerning independence. The Audit and Compliance Committee has discussed with the independent registered public

174

accounting firm its independence and also has reviewed the amount of fees paid to the independent registered accounting firm for audit and non-audit services.

Based on the Audit and Compliance Committee’s discussions with management and the independent registered public accounting firm and the Audit and Compliance Committee’s review of the representations of management and the materials it received from the independent registered public accounting firm as described above, the Audit and Compliance Committee recommended to the Board of Directors that the audited consolidated financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 for filing with the SEC.

This report is respectfully submitted by the Audit and Compliance Committee of the Board of Directors.

THE AUDIT AND COMPLIANCE COMMITTEE

John A. Clerico

Michael Dinkins

James S. Ely III, Chair

Elizabeth T. Hirsch

H. James Williams, Ph.D.

175

Item 11. Executive Compensation

The information required by this Item is incorporated herein by reference to the Company’s definitive proxy statement to be filed under Regulation 14A in connection with the Annual Meeting of the Stockholders of the Company scheduled to be held on May 12, 2020 under “Executive Compensation,” “Compensation Committee Interlocks and Insider Participation,” “Non-Management Director Compensation,” and “Compensation Committee Report.”

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item is incorporated herein by reference to the Company’s definitive proxy statement to be filed under Regulation 14A in connection with the Annual Meeting of the Stockholders of the Company scheduled to be held on May 12, 2020 under “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information.”

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated herein by reference to the Company’s definitive proxy statement to be filed under Regulation 14A in connection with the Annual Meeting of the Stockholders of the Company scheduled to be held on May 12, 2020 under “General Information” and “Relationships and Certain Transactions Between the Company and Its Officers, Directors and 5% Beneficial Owners and Their Family Members.”

Item 14. Principal Accounting Fees and Services

The information required by this Item is incorporated herein by reference to the Company’s definitive proxy statement to be filed under Regulation 14A in connection with the Annual Meeting of the Stockholders of the Company scheduled to be held on May 12, 2020 under “Fees Paid to Auditors” and “Pre-Approval of Audit and Non-Audit Services.”

176

PART IV

Item 15. Exhibits and Financial Statement Schedules

Item 15(a) 1. Financial Statements

Reference is made to the index of financial statements and supplementary data under Item 8 in Part II.

Item 15(a) 2. Financial Statement Schedules

The following financial statement schedule is filed as part of this Form 10-K at page 194 hereof:

Schedule II – Valuation and Qualifying Accounts

All other schedules are omitted since the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto.

Item 15(a) 3. Exhibits

The following exhibits are either filed with this Report or incorporated herein by reference.

No.	Description
2.1	Agreement and Plan of Merger, dated as of July  29, 2013, by and among Health Management Associates, Inc., Community Health Systems, Inc. and FWCT-2 Acquisition Corporation (incorporated by reference to Exhibit  2.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed July 30, 2013 (No. 001-15925))
2.2	Amendment and Consent to Agreement and Plan of Merger, dated as of September 24, 2013, by and among Health Management Associates, Inc., Community Health Systems, Inc. and FWCT-2 Acquisition Corporation (incorporated by reference to Exhibit 2.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed September 25, 2013 (No. 001-15925))
2.3	Separation and Distribution Agreement, dated April  29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May  2, 2016 (No. 001-15925))
2.4	Tax Matters Agreement, dated April  29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May  2, 2016 (No. 001-15925))
2.5	Employee Matters Agreement, dated April  29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May  2, 2016 (No. 001-15925))
2.6	Amendment to the Employee Matters Agreement, effective as of April  29, 2016, by and between Community Health Systems, Inc. and Quorum Health Corporation (incorporated by reference to Exhibit 2.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed November 2, 2016 (No. 001-15925))
3.1	Form of Restated Certificate of Incorporation of Community Health Systems, Inc. (incorporated by reference to Exhibit 3.1 to Amendment No.  4 to Community Health Systems, Inc.’s Registration Statement on Form S-1/A filed June 8, 2000 (No. 333-31790))
3.2	Certificate of Amendment to the Restated Certificate of Incorporation of Community Health Systems, Inc., dated May  18, 2010 (incorporated by reference to Exhibit 3.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May 20, 2010 (No. 001-15925))

177

No.	Description
3.3	Amended and Restated By-laws of Community Health Systems, Inc. (as of December  7, 2016) (incorporated by reference to Exhibit 3.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed December  12, 2016 (No. 001-15925))
4.1	Form of Common Stock Certificate (incorporated by reference to Exhibit  4.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed May 7, 2014 (No. 001-15925))
4.2*	Description of Community Health Systems, Inc.’s Common Stock
4.3	Secured Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of January  27, 2014, by and among FWCT-2 Escrow Corporation, Regions Bank, as Trustee, and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit  4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.4	Form of 5.125% Senior Secured Note due 2021 (included in Exhibit 4.3)
4.5	Secured Notes Registration Rights Agreement, dated as of January  27, 2014, by and among FWCT-2 Escrow Corporation, Merrill Lynch, Pierce, Fenner  & Smith Incorporated and Credit Suisse Securities (USA) LLC, each as a representative of the initial purchasers (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.6	Secured Notes Registration Rights Agreement Joinder, dated as of January  27, 2014, by and among CHS/Community Health Systems, Inc., the subsidiaries party thereto, and Merrill Lynch, Pierce, Fenner  & Smith Incorporated and Credit Suisse Securities (USA) LLC, each as a representative of the initial purchasers thereto (incorporated by reference to Exhibit 4.7 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.7	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of January 27, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee, and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.8	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of June 30, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse, AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed August 1, 2014 (No. 001-15925))
4.9	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of December 1, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.41 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014 filed February 25, 2015 (No. 001-15925))
4.10	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed May 6, 2015 (No. 001-15925))

178

No.	Description
4.11	Fifth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of June 30, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed August 4, 2015 (No. 001-15925))
4.12	Sixth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of September 30, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed November 3, 2015 (No. 001-15925))
4.13	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of December 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.54 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2015 filed February 17, 2016 (No. 001-15925))
4.14	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed May 3, 2016 (No. 001-15925))
4.15	Ninth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of September 30, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed November 2, 2016 (No. 001-15925))
4.16	Tenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of April 12, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed May 2, 2018 (No. 001-15925))
4.17	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.18	Twelfth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))

179

No.	Description
4.19	Thirteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.20	Fourteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 5.125% Senior Secured Notes due 2021, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.12 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.21	Senior Notes Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of January  27, 2014, by and among FWCT-2 Escrow Corporation and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.22	Form of 6.875% Senior Note due 2022 (included in Exhibit 4.21)
4.23	Unsecured Notes Registration Rights Agreement, dated as of January  27, 2014, by and among FWCT-2 Escrow Corporation, Merrill Lynch, Pierce, Fenner  & Smith Incorporated and Credit Suisse Securities (USA) LLC, each as a representative of the initial purchasers (incorporated by reference to Exhibit 4.6 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.24	Unsecured Notes Registration Rights Agreement Joinder, dated as of January 27, 2014, by and among CHS/Community Health Systems, Inc., the subsidiaries party thereto, and Merrill Lynch, Pierce, Fenner & Smith Incorporated and Credit Suisse Securities (USA) LLC, each as a representative of the initial purchasers (incorporated by reference to Exhibit 4.8 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.25	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of January  27, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 28, 2014 (No. 001-15925))
4.26	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of June  30, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed August 1, 2014 (No. 001-15925))
4.27	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of December  1, 2014, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.46 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014 filed February 25, 2015 (No. 001-15925))
4.28	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March  31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 filed May 6, 2015 (No. 001-15925))

180

No.	Description
4.29	Fifth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of June  30, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 filed August 4, 2015 (No. 001-15925))
4.30	Sixth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of September  30, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed November 3, 2015 (No. 001-15925))
4.31	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of December 31, 2015, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.63 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2015 filed February 17, 2016 (No. 001-15925))
4.32	Eighth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March  31, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed May 3, 2016 (No. 001-15925))
4.33	Ninth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of September  30, 2016, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed November 2, 2016 (No. 001-15925))
4.34	Tenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of April  12, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed May 2, 2018 (No. 001-15925))
4.35	Eleventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.36	Twelfth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of March  31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.37	Thirteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of July  1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))

181

No.	Description
4.38	Fourteenth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.875% Senior Notes due 2022, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.13 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.39	Senior Secured Notes Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of March 16, 2017, by and among CHS/Community Health Systems, Inc. and Regions Bank, as Trustee (incorporated by reference to Exhibit 4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed March 16, 2017 (No. 001-15925))
4.40	Form of 6.250% Senior Secured Note due 2023 (included in Exhibit 4.39)
4.41	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated March  16, 2017, by and among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the Guarantors party thereto, Regions Bank, as Trustee, and Credit Suisse AG, as collateral agent (incorporated by reference to Exhibit  4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed March 16, 2017 (No. 001-15925))
4.42	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated May  12, 2017, by and among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the Guarantors party thereto, Regions Bank, as Trustee, and Credit Suisse AG, as collateral agent (incorporated by reference to Exhibit  4.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May 12, 2017 (No. 001-15925))
4.43	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of April 12, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed May 2, 2018 (No. 001-15925))
4.44	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.45	Fifth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.46	Sixth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))

182

No.	Description
4.47	Seventh Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 6.250% Senior Secured Notes due 2023, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.14 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.48	Indenture, dated as of June 22, 2018, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and as Junior-Priority Collateral Agent, relating to the 9.875% Junior-Priority Secured Notes due 2023 (incorporated by reference to Exhibit 4.01 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
4.49	Form of 9.875% Junior-Priority Secured Note due 2023 (included in Exhibit 4.48)
4.50	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 9.875% Junior-Priority Secured Notes due 2023, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.6 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.51	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 9.875% Junior-Priority Secured Notes due 2023, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.6 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.52	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 9.875% Junior-Priority Secured Notes due 2023, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.6 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.53	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 9.875% Junior-Priority Secured Notes due 2023, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.15 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.54	Indenture, dated as of June 22, 2018, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee and as Junior-Priority Collateral Agent, relating to the 8.125% Junior-Priority Secured Notes due 2024 (incorporated by reference to Exhibit 4.02 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
4.55	Form of 8.125% Junior-Priority Secured Note due 2024 (included in Exhibit 4.54)

183

No.	Description
4.56	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.125% Junior-Priority Secured Notes due 2024, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.7 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.57	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.125% Junior-Priority Secured Notes due 2024, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.7 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.58	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.125% Junior-Priority Secured Notes due 2024, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.7 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.59	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.125% Junior-Priority Secured Notes due 2024, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee and as Junior-Priority Collateral Agent (incorporated by reference to Exhibit 4.16 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.60	Indenture, dated as of July 6, 2018, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as trustee, and Credit Suisse AG, as collateral agent, relating to the 8.625% Senior Secured Notes due 2024 (incorporated by reference to Exhibit 4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed July 6, 2018 (No. 001-15925))
4.61	Form of 8.625% Senior Secured Note due 2024 (included in Exhibit 4.60)
4.62	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.625% Senior Secured Notes due 2024, dated as of October 3, 2018, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.8 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
4.63	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.625% Senior Secured Notes due 2024, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.8 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.64	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.625% Senior Secured Notes due 2024, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.8 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))

184

No.	Description
4.65	Fourth Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.625% Senior Secured Notes due 2024, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.17 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.66	Indenture, dated as of March  6, 2019, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as trustee, and Credit Suisse AG, as Collateral Agent, relating to the 8.000% Senior Secured Notes due 2026 (incorporated by reference to Exhibit 4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed March 6, 2019 (No. 001-15925))
4.67	Form of 8.000% Senior Secured Note due 2026 (included in Exhibit 4.66)
4.68	First Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Secured Notes due 2026, dated as of March 31, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.10 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed May 1, 2019 (No. 001-15925))
4.69	Second Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Secured Notes due 2026, dated as of July 1, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.9 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.70	Third Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Secured Notes due 2026, dated as of September 27, 2019, by and among CHS/Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.18 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
4.71	Supplemental Indenture relating to CHS/Community Health Systems, Inc.’s 8.000% Senior Secured Notes due 2026, dated as of November 19, 2019, by and among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto and Regions Bank, as Trustee and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Current Report on Form 8-K filed November 19, 2019 (No. 001-15925))
4.72	Indenture, dated as of November  19, 2019, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee, and Credit Suisse AG, as Collateral Agent, relating to the 8.000% Senior Secured Notes due 2027 (incorporated by reference to Exhibit 4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed November 19, 2019 (No. 001-15925))
4.73	Form of 8.000% Senior Secured Note due 2027 (included in Exhibit 4.72)
4.74	Indenture, dated as of November  19, 2019, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, and Regions Bank, as Trustee, relating to the 6.875% Senior Unsecured Notes due 2028 (incorporated by reference to Exhibit 4.2 to Community Health Systems, Inc.’s Current Report on Form 8-K filed November 19, 2019 (No. 001-15925))

185

No.	Description
4.75	Form of 6.875% Senior Unsecured Note due 2028 (included in Exhibit 4.74)
4.76	Indenture, dated as of February  6, 2020, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the guarantors party thereto, Regions Bank, as Trustee, and Credit Suisse AG, as Collateral Agent, relating to the 6.625% Senior Secured Notes due 2025 (incorporated by reference to Exhibit 4.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed February 6, 2020 (No. 001-15925))
4.77	Form of 6.625% Senior Secured Note due 2025 (included in Exhibit 4.76)
4.78	First Lien Intercreditor Agreement, dated as of August  17, 2012, among Credit Suisse AG, as Collateral Agent, Credit Suisse AG, as authorized representative, Regions Bank, as Trustee and authorized representative, and the additional authorized representatives party thereto (incorporated by reference to Exhibit 4.2 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed November 1, 2012 (No. 001-15925))
4.79	Amended and Restated ABL Intercreditor Agreement, dated as of June 22, 2018, among JPMorgan Chase Bank, N.A., as ABL Agent, Credit Suisse AG, as Senior-Priority Collateral Agent, Credit Suisse AG, as Senior-Priority Non-ABL Loan Agent, Regions Bank, as 2021 Secured Notes Trustee, 2023 Secured Notes Trustee, 2024 Secured Notes Trustee, 2025 Secured Notes Trustee, 2026 Secured Notes Trustee, 2027 Secured Notes Trustee, Junior-Priority Collateral Agent, 2023 Junior-Priority Secured Notes Trustee and 2024 Junior-Priority Secured Notes Trustee, CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiary guarantors party thereto and each additional agent from time to time party thereto (incorporated by reference to Exhibit 4.04 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
4.80	Junior-Priority Collateral Agreement, dated as of June 22, 2018, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiaries party thereto and Regions Bank, as junior-priority collateral agent (incorporated by reference to Exhibit 4.03 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
4.81	Senior-Junior Lien Intercreditor Agreement, dated as of June 22, 2018, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiaries party thereto, Credit Suisse AG, Cayman Islands Branch, as initial Senior-Priority Collateral Agent, Regions Bank, as initial Junior-Priority Collateral Agent and each additional agent from time to time party thereto (incorporated by reference to Exhibit 4.05 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
4.82	Junior-Priority Lien Pari Passu Intercreditor Agreement, dated as of June 22, 2018, among Regions Bank, as Collateral Agent, Regions Bank, in its capacity as Trustee under the 2023 Notes Indenture, Regions Bank, in its capacity as Trustee under the 2024 Notes Indenture and each additional authorized representative from time to time party thereto (incorporated by reference to Exhibit 4.06 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 25, 2018 (No. 001-15925))
10.1	Second Amended and Restated Guarantee and Collateral Agreement, dated as of July 25, 2007, as amended and restated as of November  5, 2010, as further amended as of August 17, 2012, and as further amended and restated as of November  19, 2019, among CHS/Community Health Systems, Inc., Community Health Systems, Inc., the subsidiary guarantors party thereto and Credit Suisse AG, as Collateral Agent (incorporated by reference to Exhibit  4.5 to Community Health Systems, Inc.’s Current Report on Form 8-K filed November 19, 2019 (No. 001-15925))

186

No.	Description
10.2	ABL Credit Agreement, dated as of April  3, 2018, among CHS/Community Health Systems, Inc., as the Borrower, Community Health Systems, Inc., as the Parent, the subsidiaries of the Borrower party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed April 3, 2018 (No. 001-15925))
10.3	Amendment No. 1 to ABL Credit Agreement, dated as of May  3, 2018, among CHS/Community Health Systems, Inc., as the Borrower, Community Health Systems, Inc., as the Parent, the subsidiaries of the Borrower party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed July 27, 2018 (No. 001-15925))
10.4*	Amendment No. 2 to ABL Credit Agreement, dated as of November  12, 2019, among CHS/Community Health Systems, Inc., as the Borrower, Community Health Systems, Inc., as the Parent, the subsidiaries of the Borrower party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent and Collateral Agent
10.5	Guarantee and Collateral Agreement to ABL Credit Agreement, dated as of April  3, 2018, among CHS/Community Health Systems, Inc., as the Borrower, Community Health Systems, Inc., as the Parent, the subsidiaries of the Borrower party thereto, and JPMorgan Chase Bank, N.A., as Collateral Agent (incorporated by reference to Exhibit 10.4 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 filed May 2, 2018 (No. 001-15925))
10.6†	Form of Indemnification Agreement between Community Health Systems, Inc. and its directors and executive officers (incorporated by reference to Exhibit 10.8 to Amendment No. 2 to Community Health Systems, Inc.’s Registration Statement on Form S-1/A filed May 2, 2000 (No. 333-31790))
10.7†	CHS/Community Health Systems, Inc. Amended and Restated Supplemental Executive Retirement Plan, as amended and restated as of January 1, 2009 (incorporated by reference to Exhibit 10.13 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008 filed February 27, 2009 (No. 001-15925))
10.8†	Amendment No. 1, dated as of September  13, 2011, to the CHS/Community Health Systems, Inc. Amended and Restated Supplemental Executive Retirement Plan, as amended and restated as of January 1, 2009 (incorporated by reference to Exhibit  10.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 filed October  28, 2011 (No. 001-15925))
10.9†	Amendment No. 2, dated as of January  1, 2014, to the CHS/Community Health Systems, Inc. Amended and Restated Supplemental Executive Retirement Plan, as amended and restated as of January  1, 2009 (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed May 7, 2014 (No. 001-15925))
10.10†	CHS/Community Health Systems, Inc. 2018 Supplemental Executive Retirement Plan, executed on May 15, 2018 and effective January  1, 2018 (incorporated by reference to Exhibit 10.5 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed July 27, 2018 (No. 001-15925))
10.11†	Supplemental Executive Retirement Plan Trust, dated June  1, 2005, by and between CHS/Community Health Systems, Inc., as grantor, and Wachovia Bank, N.A., as Trustee (incorporated by reference to Exhibit  10.3 to Community Health Systems, Inc.’s Current Report on Form 8-K filed June 1, 2005 (No. 001-15925))

187

No.	Description
10.12†*	Community Health Systems Supplemental Executive Benefits, dated December 31, 2008, as amended and restated as of April 1, 2015 and December 11, 2019
10.13†	CHS/Community Health Systems, Inc. Deferred Compensation Plan, amended and restated effective January  1, 2014 (incorporated by reference to Exhibit 10.25 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2013 filed February 26, 2014 (No. 001-15925))
10.14†	Community Health Systems Deferred Compensation Plan Trust, amended and restated effective February  26, 1999 (incorporated by reference to Exhibit 10.18 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2002 filed March 27, 2003 (No. 001-15925))
10.15†	CHS NQDCP, effective as of September  1, 2009 (incorporated by reference to Exhibit 4.2 to Community Health Systems, Inc.’s Registration Statement on Form S-8 filed December  11, 2009 (No. 333-163691))
10.16†	CHS NQDCP Adoption Agreement, executed as of August  11, 2009 (incorporated by reference to Exhibit 4.3 to Community Health Systems, Inc.’s Registration Statement on Form S-8 filed December  11, 2009 (No. 333-163691))
10.17†	Guarantee, dated December  9, 2009, made by Community Health Systems, Inc. in favor of CHS/Community Health Systems, Inc. with respect to CHS/Community Health Systems, Inc.’s payment obligations under the CHS/Community Health Systems, Inc. Deferred Compensation Plan and the NQDCP (incorporated by reference to Exhibit 4.4 to Community Health Systems, Inc.’s Registration Statement on Form S-8 filed December 11, 2009 (No. 333-163691))
10.18†	Community Health Systems, Inc. 2019 Employee Performance Incentive Plan (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed February 22, 2019 (No. 001-15925))
10.19†	Community Health Systems, Inc. Directors’ Fees Deferral Plan, as amended and restated as of December  10, 2008 (incorporated by reference to Exhibit 10.15 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008 filed February 27, 2009 (No. 001-15925))
10.20†	Community Health Systems, Inc. 2000 Stock Option and Award Plan, as amended and restated as of March  20, 2013 (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 filed July 31, 2013 (No. 001-15925))
10.21†	Form of Nonqualified Stock Option Agreement (Employee) for Community Health Systems, Inc. 2000 Stock Option and Award Plan (incorporated by reference to Exhibit 10.15 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2009 filed February 26, 2010 (No. 001-15925))
10.22†	Community Health Systems, Inc. 2009 Stock Option and Award Plan, as amended and restated as of March  14, 2018 (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed May  15, 2018 (No. 001-15925))
10.23†	Form of Nonqualified Stock Option Agreement (Employee) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (incorporated by reference to Exhibit 10.39 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2013 filed February 26, 2014 (No. 001-15925))

188

No.	Description
10.24†	Form of Restricted Stock Award Agreement for Community Health Systems, Inc. 2009 Stock Option and Award Plan (incorporated by reference to Exhibit 10.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 filed July 31, 2013 (No. 001-15925))
10.25†	Form of Performance Based Restricted Stock Award Agreement (Most Highly Compensated Executive Officers) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (for awards granted from March 1, 2016 through February 28, 2017) (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed May 3, 2016 (No. 001-15925))
10.26†	Form of Performance Based Restricted Stock Award Agreement (Senior Officers) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (for awards granted from March 1, 2017 through February 28, 2018) (incorporated by reference to Exhibit 10.2 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed May 2, 2017 (No. 001-15925))
10.27†	Form of Performance Based Restricted Stock Award Agreement (Senior Officers) for Community Health Systems, Inc. 2009 Stock Option and Award Plan (for awards granted beginning March 1, 2018) (incorporated by reference to Exhibit 10.46 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017 filed February 28, 2018 (No. 001-15925))
10.28†	Form of Director Restricted Stock Unit Award Agreement for Community Health Systems, Inc. 2009 Stock Option and Award Plan (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed October 30, 2019 (No. 001-15925))
10.29†	Form of Amended and Restated Change in Control Severance Agreement effective December  31, 2008 (incorporated by reference to Exhibit 10.22 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2008 filed February  27, 2009 (No. 001-15925))
10.30†	Form of Change in Control Severance Agreement (for executive officers appointed since January  1, 2009) (incorporated by reference to Exhibit 10.3 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed May 7, 2014 (No. 001-15925))
10.31	Participation Agreement entered into as of January  1, 2005, by and between Community Health Systems Professional Services Corporation and HealthTrust Purchasing Group, L.P. (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 7, 2005 (No. 001-15925))
10.32	Amendment effective as of January  1, 2015, by and between CHSPSC, LLC and HealthTrust Purchasing Group, L.P., to Participation Agreement entered into as of January  1, 2005, by and between Community Health Systems Professional Services Corporation and HealthTrust Purchasing Group, L.P. (incorporated by reference to Exhibit 10.36 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2014 filed February 25, 2015 (No. 001-15925))
10.33†	Consultancy Agreement, dated December  31, 2019, by and between CHSPSC, LLC and Thomas J. Aaron (incorporated by reference to Exhibit 10.1 to Community Health Systems, Inc.’s Current Report on Form 8-K filed January 2, 2020 (No. 001-15925))
10.34†*	Executive Deferred Compensation Award between Kevin Hammons and CHSPSC, LLC, dated December 12, 2017

189

No.	Description
10.35†	Executive Deferred Compensation Award between Dr. Lynn Simon and CHSPSC, LLC, dated December  12, 2017 (incorporated by reference to Exhibit 10.54 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2017 filed February 28, 2018 (No. 001-15925))
21*	List of Subsidiaries
23.1*	Consent of Deloitte & Touche LLP
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1	Corporate Integrity Agreement, Amended, dated September  21, 2018, between Community Health Systems, Inc. and the Office of Inspector General of the United States Department of Health and Human Services (incorporated by reference to Exhibit 99.1 to Community Health Systems, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 filed October 30, 2018 (No. 001-15925))
99.2	Order Approving Derivative Settlement and Order of Dismissal with Prejudice, dated January  17, 2017 and Stipulation of Settlement, dated November  18, 2016 (incorporated by reference to Exhibit 99.2 to Community Health Systems, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2016 filed February 21, 2017 (No. 001-15925))
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase
101.DEF*	XBRL Taxonomy Extension Definition Linkbase
101.LAB*	XBRL Taxonomy Extension Label Linkbase
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase

* Filed herewith.

** Furnished herewith.

† Indicates a management contract or compensatory plan or arrangement

190

Item 16. Form 10-K Summary

None.

191

SIGNATURES

Pursuant to the requirements of section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

COMMUNITY HEALTH SYSTEMS, INC.
By:	/s/ Wayne T. Smith
	Wayne T. Smith
	Chairman of the Board and Chief Executive Officer
Date: February 20, 2020

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Name	Title	Date
/s/ Wayne T. Smith Wayne T. Smith	Chairman of the Board and Chief Executive Officer	February 20, 2020
/s/ Kevin J. Hammons Kevin J. Hammons	Executive Vice President and Chief Financial Officer	February 20, 2020
/s/ Jason K. Johnson Jason K. Johnson	Senior Vice President and Chief Accounting Officer	February 20, 2020
/s/ Tim L. Hingtgen Tim L. Hingtgen	President, Chief Operating Officer and Director	February 20, 2020
/s/ John A. Clerico John A. Clerico	Director	February 20, 2020
/s/ Michael Dinkins Michael Dinkins	Director	February 20, 2020
/s/ James S. Ely III James S. Ely III	Director	February 20, 2020
/s/ John A. Fry John A. Fry	Director	February 20, 2020
/s/ Elizabeth T. Hirsch Elizabeth T. Hirsch	Director	February 20, 2020
/s/ William Norris Jennings, M.D. William Norris Jennings, M.D.	Director	February 20, 2020
/s/ K. Ranga Krishnan, MBBS K. Ranga Krishnan, MBBS	Director	February 20, 2020
/s/ Julia B. North Julia B. North	Director	February 20, 2020
/s/ H. James Williams, Ph.D. H. James Williams, Ph.D.	Director	February 20, 2020

192

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and the Board of Directors of

Community Health Systems, Inc.

Franklin, Tennessee

Opinion on the Financial Statement Schedule

We have audited the consolidated financial statements of Community Health Systems, Inc., and subsidiaries (the “Company”) as of December 31, 2019 and 2018, and for each of the three years in the period ended December 31, 2019, and the Company’s internal control over financial reporting as of December 31, 2019, and have issued our reports thereon dated February 20, 2020; such reports are included elsewhere in this Form 10-K. Our audits also included the consolidated financial statement schedule of the Company listed in the Index at Item 15. This financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statement schedule based on our audits. In our opinion, such financial statement schedule, when considered in relation to the financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ Deloitte & Touche LLP

Nashville, Tennessee

February 20, 2020

193

Community Health Systems, Inc. and Subsidiaries

Schedule II — Valuation and Qualifying Accounts

Description	Balance at Beginning of Year		Acquisitions and Dispositions		Charged to Costs and Expenses		Write-offs		Balance at End of Year
	(In millions)
Year ended December 31, 2019 allowance for doubtful accounts (1)	$	-	$	-	$	-	$	-	$	-
Year ended December 31, 2018 allowance for doubtful accounts (1)	$	-	$	-	$	-	$	-	$	-
Year ended December 31, 2017 allowance for doubtful accounts	$	3,773	$	(21)	$	3,054	$	(2,936)	$	3,870

(1) As discussed at Note 1 of the Notes of the Consolidated Financial Statements, on January 1, 2018, the Company adopted the new revenue recognition standard codified in ASC 606. Upon adoption of ASC 606, the allowance for doubtful accounts of approximately $3.9 billion was reclassified as a component of the net patient accounts receivable.

194

EX-4.2

Exhibit 4.2

DESCRIPTION OF THE REGISTRANT’S COMMON STOCK

REGISTERED PURSUANT TO SECTION 12 OF THE

SECURITIES EXCHANGE ACT OF 1934

The common stock of Community Health Systems, Inc. (the “Company”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended.

The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the actual terms and provisions contained in our Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), and our Amended and Restated By-laws (the “Bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K, of which this Exhibit 4.2 is a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware General Corporation Law (“DGCL”), for additional information.

Authorized Capital

We are authorized to issue up to 400,000,000 shares of capital stock, of which 300,000,000 may be shares of common stock, par value $0.01 per share, and 100,000,000 may be shares of preferred stock, par value $0.01 per share. All of the outstanding shares of our common stock are fully paid and nonassessable.

Voting Rights

Holders of our common stock are entitled to one vote for each share on all matters voted on by our stockholders. Holders of our common stock do not have cumulative voting rights in the election of directors.

Dividends

Subject to the preferences or other rights of any our preferred stock that may be issued from time to time, holders of our common stock are entitled to participate ratably in dividends on our common stock as declared by our board of directors.

Absence of Other Rights

Holders of our common stock do not have any preemptive right to subscribe for or purchase any of our securities of any class or kind. Holders of our common stock do not have any subscription, redemption or conversion privileges.

Liquidation Rights

Holders of our common stock are entitled to share ratably in all assets available for distribution to our stockholders in the event of our liquidation or dissolution, subject to distribution of the preferential amount, if any, to be distributed to holders of our preferred stock.

Listing

Our common stock is listed on the New York Stock Exchange under the symbol “CYH.”

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC.

Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Provisions of the DGCL

General

Certain provisions of our Certificate of Incorporation and Bylaws may delay or make more difficult acquisitions or changes of control of us that are not approved by our board of directors. These provisions could have the effect of

discouraging third parties from making proposals involving an acquisition or change of control of the Company, although these kinds of proposals, if made, might be considered desirable by a majority of our stockholders. These provisions may also have the effect of making it more difficult for third parties to cause the replacement of our current management without the concurrence of our board of directors.

Number of Directors; Removal; Vacancies

Our Certificate of Incorporation provides that the number of our directors will be determined from time to time exclusively by a vote of a majority of the members of our board of directors then in office. Our Certificate of Incorporation also provides that, subject to the rights of the holders of any series of preferred stock then outstanding, our board of directors has the exclusive right to fill vacancies, including vacancies created by an increase in the number of directors. This provision could have the effect of discouraging a potential acquiror from attempting to obtain control of us. Our Certificate of Incorporation further provides that, subject to the rights of the holders of any series of preferred stock then outstanding, any director elected prior to our 2010 annual meeting of stockholders or any director appointed to fill a vacancy of any director elected prior to the 2010 annual meeting of stockholders may be removed from office at any time, but only for cause, and any other director may be removed from office at any time, with or without cause, in each case at a meeting called for that purpose and only by the affirmative vote of the holders of a majority of the voting power of all of the shares of our capital stock then entitled to vote in the election of directors. This provision, in conjunction with the provision authorizing our board of directors to fill vacant directorships, could prevent our stockholders from removing certain incumbent directors without cause and filling the resulting vacancies with their own nominees.

Election of Directors

Our Bylaws provide that a nominee for director shall be elected to our board of directors if the votes cast for such nominee’s election exceed the votes cast against such nominee’s election; provided, however, that directors shall be elected by a plurality of the votes cast at any meeting of our stockholders for which (i) our Secretary receives a notice that a stockholder has nominated a person for election to our board of directors in compliance with the advance notice requirements for stockholder nominees set forth in our Bylaws and/or the proxy access requirements for stockholder nominees set forth in Section 15 of Article II of our Bylaws and (ii) such nomination has not been withdrawn by such stockholder on or before the 10th day before the Company first mails, provides or makes available its notice of meeting for such meeting to our stockholders. Our Certificate of Incorporation provides that, at each annual meeting of stockholders, all directors shall be elected for terms expiring at the next annual meeting of stockholders and until such director’s successor shall have been elected and qualified.

Special Meetings of Stockholders

Our Bylaws provide that special meetings of stockholders, for any purpose or purposes, may only be called by our board of directors, the chairman of our board of directors or our chief executive officer.

Advance Notice for Raising Business or Making Nominations at Meetings

Our Bylaws provide that no business may be transacted at any meeting of stockholders other than business that is properly brought before the meeting in accordance with our Bylaws. To be properly brought before a meeting of stockholders, any such business must be a proper matter for stockholder action, and must be (i) specified in the Company’s notice of meeting (or any supplement thereto), (ii) otherwise brought before the annual meeting by, or at the direction of, our board of directors (or any duly authorized committee thereof), or (iii) otherwise properly brought before the annual meeting by a stockholder who has given to the Company’s Secretary timely written notice, in proper form, of the stockholder’s intention to bring that business before the meeting. Our Bylaws further provide that only persons who are nominated by, or at the direction of, our board of directors, or who are nominated by (i) a stockholder who has given timely written notice, in proper form, to the Company’s Secretary prior to an annual meeting of stockholders or a special meeting called for the purpose of electing directors, or (ii) in accordance with the proxy access provisions set forth in the Bylaws are eligible for election as directors of the Company. These provisions could make it more difficult for our stockholders to raise matters affecting control of the Company, including tender offers, business combinations or the election or removal of directors, for a stockholder vote.

2

Amendments to the Company’s By-laws

Our Certificate of Incorporation and Bylaws provide that our board of directors and our stockholders (by affirmative vote of the holders of at least a majority of the voting power of all of issued and outstanding shares of our capital stock entitled to vote thereon) may adopt, amend, alter, rescind or repeal the bylaws of the Company.

Amendment of the Company’s Certificate of Incorporation

Any proposal to amend, alter, change or repeal any provision of our Certificate of Incorporation requires approval by the affirmative vote of both a majority of the members of our board of directors then in office and a majority of the voting power of all of issued and outstanding shares of our capital stock entitled to vote thereon.

Company Preferred Stock and Additional Company Common Stock

Under our Certificate of Incorporation, our board of directors has the authority to provide by board resolution for the issuance of preferred shares in one or more series and to fix the terms and conditions of each such series. The authorized shares of preferred stock, as well as authorized but unissued shares of common stock, are available for issuance without further action by our stockholders, unless stockholder action is required by applicable law or the rules of the New York Stock Exchange or any other stock exchange on which any class or series of our stock may then be listed.

These provisions give the our board of directors the power to issue preferred stock, or additional shares of common stock, that could, depending on the terms of the stock, either impede or facilitate the completion of a merger, tender offer or other takeover attempt. For example, issuing new shares might impede a business combination if the terms of those shares include voting rights which enable a holder to block business combinations; alternatively, issuing new shares might facilitate a business combination if those shares have general voting rights sufficient to cause an applicable percentage vote requirement to be satisfied.

Delaware Business Combination Statute

Under certain circumstances, Section 203 of the DGCL makes it more difficult for a person who would be an “interested stockholder” to effect various business combinations with a corporation for a three-year period. However our Certificate of Incorporation currently contains a provision pursuant to which the Company elects not to be governed by Section 203 of the DGCL.

Limitations on Directors’ Liability and Indemnification

Pursuant to authority conferred by Section 102 of the DGCL, Article SIXTH of the Company’s Certificate of Incorporation eliminates the personal liability of the Company’s directors to the Company or its stockholders for monetary damages for breach of fiduciary duty to the fullest extent permitted under the law of the State of Delaware, including the DGCL. Article SIXTH further provides that any future amendment to or repeal of its terms will not adversely affect any right or protection of any director of the Company with respect to acts or omissions of such director occurring prior to such repeal or amendment. Article SIXTH also incorporates any future amendments to Delaware law which further eliminate or limit the liability of directors.

In accordance with Section 145 of the DGCL, Article SEVENTH of the Company’s Certificate of Incorporation and certain provisions of the Company’s Bylaws grant the Company’s directors and officers a right to indemnification for all expenses relating to civil, criminal, administrative or investigative procedures to which they are a party (i) by reason of the fact that they are or were directors or officers of the Company or (ii) by reason of the fact that, while they are or were directors or officers of the Company, they are or were serving at the request of the Company as directors or officers of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan. Section 5 of Article VI of the Company’s Bylaws further provides for advancement of expenses to such indemnified persons.

The Company’s Bylaws authorize the Company to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a

3

director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit plan, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Company would have the power to indemnify such person against such liability under the provisions of the Company’s Bylaws. The Company has obtained insurance policies insuring its directors and officers against certain liabilities.

The Company has entered into Indemnification Agreements (the “Indemnification Agreements”) with its directors and executive officers. One of the purposes of the Indemnification Agreements is to attempt to specify the extent to which persons entitled to indemnification thereunder (the “Indemnitees”) may receive indemnification. Pursuant to the Indemnification Agreements, an Indemnitee is entitled to indemnification for claims arising out of or in connection with the service of Indemnitee as a director or officer of the Company or of an affiliate. In the case of an action or proceeding other than an action by or in the right of the Company, the Indemnification Agreements provide that Indemnitee is entitled to indemnification for claims relating to (i) the fact that Indemnitee is or was an officer or director of the Company or any other entity which Indemnitee is or was or will be serving at the request of the Company, or (ii) anything done or not done by Indemnitee in any such capacity. In the case of an action by or in the right of the Company, the Indemnification Agreements provide that Indemnitee is entitled to indemnification for claims relating to (i) the fact that Indemnitee is or was an officer or director of the Company or any affiliate or (ii) anything done or not done in such capacity. The Indemnification Agreements are in addition to and are not intended to limit any rights of indemnification which are available under the Company’s Certificate of Incorporation or the Company’s Bylaws, or otherwise. In addition to the rights to indemnification specified therein, the Indemnification Agreements are intended to increase the certainty of receipt by the Indemnitee of the benefits to which he or she is entitled by providing specific procedures relating to indemnification.

We believe that our Certificate of Incorporation and Bylaws and insurance are necessary to attract and retain qualified persons as directors and officers.

The limitation of liability and indemnification provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and other stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers as required or allowed by these indemnification provisions.

Forum Selection

Our Bylaws provide that, unless the Company consents in writing to the selection of an alternative forum, a state or federal court located within the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or (iv) any action asserting a claim governed by the internal affairs doctrine.

4

EX-10.4

Exhibit 10.4

AMENDMENT NO. 2 dated as of November 12, 2019 (this “Amendment”), to the ABL Credit Agreement dated as of April 3, 2018 (as amended by Amendment No. 1 dated as of May 3, 2018, and as further heretofore amended, supplemented, amended and restated or otherwise modified, the “ABL Credit Agreement”), among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Borrower”), COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (“Parent”), the lenders party thereto (the “Lenders”) and JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent for the Lenders.

PRELIMINARY STATEMENT

SECTION 1. Defined Terms. Capitalized terms used but not otherwise defined herein (including the Preliminary Statement hereto) shall have the meanings assigned thereto in the ABL Credit Agreement. The provisions of Section 1.02 of the ABL Credit Agreement are hereby incorporated by reference herein, mutatis mutandis. This Amendment shall be a “Loan Document” for all purposes of the ABL Credit Agreement and the other Loan Documents.

SECTION 2. Amendments to the ABL Credit Agreement. Subject to the satisfaction of the conditions set forth in Section 4 hereof, the ABL Credit Agreement is hereby amended as follows, effective as of the Amendment No. 2 Effective Date (as defined below):

(a) The definition of the term “Term Loan Credit Agreement” in Section 1.01 of the ABL Credit Agreement is hereby amended and restated in its entirety as follows:

“Term Loan Credit Agreement” shall mean the Fourth Amended and Restated Credit Agreement dated as of March 23, 2018, among, inter alia, Parent, the Borrower, the lenders from time to time party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and as the Term Loan Collateral Agent, as in effect immediately prior to the repayment in full of all indebtedness outstanding thereunder and the termination of all commitments thereunder.

(b) Section 2.23 of the ABL Credit Agreement is hereby amended by:

(i) adding the following to the end of paragraph (a) thereof: “To the extent agreed by the Borrower, the Administrative Agent and the applicable Issuing Bank and pursuant to procedures acceptable to the Administrative Agent, the Borrower may designate any Letter of Credit (as defined in the Term Loan Credit Agreement) to be a Letter of Credit under this Agreement. Any such designation shall be subject to the conditions set forth in Section 4.02 and in this

Section 2.23 and upon such designation and the satisfaction of such conditions, any such Letter of Credit (as defined in the Term Loan Credit Agreement) so designated shall be deemed to have been issued under this Agreement for all purposes.”; and

(ii) replacing “$50,000,000” in paragraph (b) thereof with “$200,000,000”.

(c) Schedule 2.01 of the ABL Credit Agreement is hereby amended by replacing the table titled “L/C Commitments” and inserting the following in lieu thereof:

L/C COMMITMENTS*

* on file with the agent

Each Issuing Bank party hereto agrees, by its execution of this Amendment, to amend its respective L/C Commitment as set forth above.

SECTION 3. Representations and Warranties. To induce the other parties hereto to enter into this Amendment, each of Parent and the Borrower hereby represents and warrants to each of the Lenders party hereto, the Administrative Agent, the Issuing Banks and the Collateral Agent that, after giving effect to this Amendment:

(a) The representations and warranties set forth in Article III of the ABL Credit Agreement and in each other Loan Document are true and correct in all material respects (or, in the case of representations and warranties qualified by materiality or Material Adverse Effect, in all respects) on and as of the Amendment No. 2 Effective Date with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects (or, in the case of the representations and warranties qualified by materiality or Material Adverse Effect, in all respects) as of such earlier date.

(b) No Default or Event of Default has occurred and is continuing.

(c) None of the Security Documents in effect on the Amendment No. 2 Effective Date will be rendered invalid, non-binding or unenforceable against any Loan Party as a result of this Amendment. The Guarantees created under such Security Documents will continue to guarantee the Obligations to the same extent as they guaranteed the Obligations immediately prior to the Amendment No. 2 Effective Date. The Liens created under such Security Documents will continue to secure the Obligations, and will continue to be perfected, in each case, to the same extent as they secured the Obligations or were perfected immediately prior to the Amendment No. 2 Effective Date.

SECTION 4. Effectiveness. This Amendment shall become effective on and as of the first date (the “Amendment No. 2 Effective Date”) after which:

2

(a) The Administrative Agent shall have received duly executed and delivered counterparts of this Amendment that, when taken together, bear the signatures of Parent, the Borrower and the Required Lenders; and

(b) All indebtedness outstanding under the Term Loan Credit Agreement shall have been repaid in full and all commitments thereunder shall have been terminated.

SECTION 5. Designation of Letters of Credit. Pursuant to Section 2.23 of the ABL Credit Agreement as amended hereby, the Borrower and the Administrative Agent hereby agree that as of the Amendment No. 2 Effective Date, each of the letters of credit identified hereto on Schedule I shall, from such date, be deemed to have been issued under the ABL Credit Agreement as contemplated by Section 2.23 thereof as amended hereby.

SECTION 6. Miscellaneous. Except as expressly set forth herein, this Amendment shall not constitute a waiver or amendment of, or otherwise affect the rights and remedies of the Administrative Agent, the Lenders or any other Secured Party under the ABL Credit Agreement or any other Loan Document. From and after the Amendment No. 2 Effective Date, any reference to the ABL Credit Agreement shall mean the ABL Credit Agreement as modified by this Amendment. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery by electronic transmission (e.g., “pdf”) of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment. This amendment shall be governed by, and construed in accordance with, the laws of the State of New York.

[Remainder of page intentionally left blank]

3

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the date first above written.

CHS/COMMUNITY HEALTH SYSTEMS, INC.,
By:	/s/ Kevin J. Hammons
	Name:	Kevin J. Hammons
	Title:	Senior Vice President, Assistant Chief Financial Officer, Chief Accounting Officer and Treasurer
COMMUNITY HEALTH SYSTEMS, INC.,
By:	/s/ Kevin J. Hammons
	Name:	Kevin J. Hammons
	Title:	Senior Vice President, Assistant Chief Financial Officer, Chief Accounting Officer and Treasurer

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

JPMORGAN CHASE BANK, N.A., as a Lender, an Issuing Bank and the Administrative Agent and Collateral Agent
By:	/s/ Dawn Lee Lum
	Name:	Dawn Lee Lum
	Title:	Executive Director

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

CITIBANK, N.A., as a Lender and an Issuing Bank
By:	/s/ David L. Smith
	Name:	David L. Smith
	Title:	Vice President and Director

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as a Lender and an Issuing Bank
By:	/s/ Judith Smith
	Name:	Judith Smith
	Title:	Authorized Signatory
By:	/s/ Lingzi Huang
	Name:	Lingzi Huang
	Title:	Authorized Signatory

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

BANK OF AMERICA, N.A., as a Lender and an Issuing Bank
By:	/s/ Steven L. Hipsman
	Name:  Steven L. Hipsman
	Title:    Senior Vice President

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

ROYAL BANK OF CANADA, as a Lender and an Issuing Bank
By:	/s/ Jeff Patchell
	Name:  Jeff Patchell
	Title:    Attorney In Fact

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender and an Issuing Bank
By:	/s/ Salvatore Tulumello
	Name:  Salvatore Tulumello
	Title:    Vice President

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

LENDER SIGNATURE PAGE TO THE CHS/COMMUNITY HEALTH SYSTEMS, INC. ABL CREDIT AGREEMENT
Name of Lender:*
By:
	Name:
	Title:
For Lenders requiring a second signature line:
By:
	Name:
	Title:

* On file with Agent

[Signature Page to Amendment No. 2 to the ABL Credit Agreement]

SCHEDULE I

* On file with Agent

EX-10.12

Exhibit 10.12

SUPPLEMENTAL

EXECUTIVE

BENEFITS

Original Document Effective as of December 31, 2008

Amended and Restated as of April 1, 2015 and December 11, 2019

INTRODUCTION

This document outlines the supplemental benefits for eligible executive employees of affiliates of Community Health Systems, Inc. (the “Company”), including the hospital companies whose operating results are consolidated with the Company’s operating results. Benefits are provided by the entity that employs the particular eligible executive (the “Employer”), provided, however, certain benefits are provided through group plans sponsored by the Employer or CHS/Community Health Systems, Inc.

Plan benefit categories are based upon your position with an affiliate of the Company. The following benefit categories are referenced throughout this summary:

Executive Corporate Vice Presidents (includes Vice Presidents (Officer) (elected by the Board of Directors of the Company), Regional Presidents, and Vice Presidents (Non-Officer)) and above

Group l Corporate Senior Directors/Directors

Facility Chief Executive Officers

Group 2 Corporate Senior Managers/Managers/Supervisors

Facility Chief Administrative Officers

Facility Chief Financial Officers

Facility Chief Nursing Officers

Facility Chief Operating Officers

Facility Assistant Chief Executive Officers

Facility Assistant Chief Financial Officers

Facility Assistant Chief Nursing Officers

Facility Administrators/Assistant Administrators

Benefit category determination is the exclusive right of the Employer at its sole discretion.

As used in this document, “Cause” means gross neglect of duties, which gross neglect continues more than 30 days after receiving written notice from the chief executive officer of the Company, its board of directors, or other officers of the Company or Employer of the actions or inactions constituting gross neglect; insubordination; intentional misconduct or deliberate disruption of the workplace and working environment; conviction of a felony; dishonesty, embezzlement, theft, or fraud committed in connection with employment resulting in substantial financial harm to the Company; the issuance of any final order for your removal as an employee or representative of the Company or Employer by any state or federal regulatory agency; and your material breach of any duty owed to the Company or Employer, including without limitation the duty of loyalty. “Cause” shall not include ordinary negligence or failure to act, whether due to an error in judgment or otherwise, if you have exercised substantial efforts in good faith to perform the duties reasonably assigned or appropriate to your position.

1

SURVIVOR BENEFITS

Survivor benefits are life insurance proceeds intended to provide cash to your beneficiary(ies) in the event of your death. These Survivor Benefits are provided through group-term life insurance or a combination of group-term life insurance and individually-owned life insurance policies, as determined by the plan sponsor.

Amount of Benefit.

The lesser of $2 million or:

Executive 4X Base Salary

Group 1 3X Base Salary

Group 2 2X Base Salary

POST-TERMINATION BENEFITS

Post-termination benefits are generally designed to provide supplemental retirement benefits. Eligibility (dependent upon the design of the particular plan, as amended from time to time) may include (or have included in the past) one or more of the following:

• the Employer/Community Health Systems, Inc. Deferred Compensation Plan (Corporate Vice President (Non-Officer) and above);

• the CHS/Community Health Systems, Inc. Supplemental Executive Retirement Plan, as amended and restated January 1, 2009, as subsequently amended (Elected Officers (Vice President (Officer) and above));

• the CHS/Community Health Systems, Inc. 2018 Supplemental Executive Retirement Plan effective January 1, 2018, as subsequently amended (Elected Officers (Vice President (Officer) and above));

• matching contributions under the CHS/Community Health Systems, Inc. 401(k) Plan; and

• any other qualified or non-qualified retirement plan of the Company or any affiliate.

You should refer to the underlying policies and/or plan documents relating to these benefits to learn more about eligibility and your right to post-termination benefits under these policies and plans.

2

SEVERANCE BENEFITS

Payout upon Termination (Salary and Vacation Time).

In the event you are terminated from your employment by your Employer, without Cause, severance benefits of a multiple of your then base monthly salary will be paid to you based upon your position, as shown in the schedule below:

Benefits Category	Severance Multiple
CEO	24 months
President	24 months
Executive Vice President	24 months
Senior Vice President	12 months
Regional President	12 months
Vice President (Officer)	12 months
Vice President (Non-Officer)	9 months
Group 1 (Corporate Senior Director/Director & Facility CEO)	6 months
Group 2 (Corporate Senior Manager/ Manager/Supervisors & Other Facility Key Hospital Management positions as defined on Addendum – Severance Benefits – Benefits Categories)	3 months

The vacation time payout for elected officers (Vice President (Officer) and above) (for whom no accruals are maintained) shall be based upon a reasonable estimate, to be determined by Employer, of the vacation time taken during the twelve month period preceding the date of termination.

Additional Payments (to be made no later than March 15^th of the year following termination)

In addition, if your employment is terminated without Cause, you will receive an additional amount of severance pay determined as follows:

Elected Officers (Vice President (Officer) and Above): the Employer shall pay the terminated individual, at the same time that the Employer makes annual bonus payments under the 2019 Employee Performance Incentive Plan (or any replacement or successor plan providing for similar benefits, collectively the “Incentive Plan”) to other senior executives, a pro rata portion of the annual bonus that would have been paid to the terminated individual under the Incentive Plan in respect of the year in which the termination date occurred had the terminated individual remained employed through the applicable payment date under the Incentive Plan, calculated by multiplying such amount by a fraction, the numerator of which is the number of days in the year though the termination date and the denominator of which is 365.

3

Termination within First 12 Months of Employment

If your employment is terminated without Cause before completing 12 full months of employment, you will only receive one-half of the salary benefits provided for above and none of the bonus benefit. Severance payments will be in the form of a lump sum payment or salary continuation, as determined by Employer, and subject to withholdings and other deductions as described below.

COBRA Payment Limitation

In addition to the severance benefits described above, terminated eligible executive employees who elect continuation health coverage under COBRA will be required to pay only the equivalent of the active employee premium for this coverage for a period of time equal to the time period applicable to such employee based on the above chart, subject to the eligibility provisions of COBRA coverage. The difference in the COBRA premium paid and the active employee premium will be reimbursed to the terminated eligible executive employee upon receipt of payment confirmation for the full monthly COBRA premium.

Release.

As a condition of providing any payments and/or benefits described above, you will be required to execute a comprehensive full and final release agreement satisfactory to the Company and substantially in the form attached as Attachment 1, as amended from time to time.

Equity Awards.

The terms of vesting and (in the case of stock options) exercisability with respect to outstanding equity awards following the termination of employment will be governed by the applicable award agreements and the Company’s 2009 Stock Option and Award Plan, as such plan is amended, restated and/or superseded from time to time.

4

ADDENDUM

Severance Benefits – Benefits Categories

To follow are the job titles associated with the benefits categories as outlined on page 3 (Severance Benefits):

Benefits Category	Associated Job Title(s)
CEO	Chief Executive Officer
President	President & Chief Operating Officer President of Clinical Operations & Chief Medical Officer
Executive VP	Executive Vice President & Chief Financial Officer Executive Vice President & General Counsel
Senior VP	All Senior Vice President positions
Regional President	All Regional Presidents
Vice President (Officer)	Vice President positions classified as Officer level (i.e., elected by the Company Board of Directors)
Vice President (Non-Officer)	All Vice President positions classified as Non-Officer level (i.e., not elected by the Company Board of Directors)
Group 1	Corporate Senior Director/Director level positions Facility Chief Executive Officer
Group 2	Corporate Senior Manager/Manager/Supervisor level positions Facility Key Hospital Management positions to include: Chief Administrative Officer, Chief Financial Officer, Chief Nursing Officer, Chief Operating Officer, Assistant Chief Executive Officer, Assistant Chief Financial Officer, Assistant Chief Nursing Officer, Administrator, Assistant Administrator

Attachment 1

RELEASE AGREEMENT

In consideration for Severance Benefits in the Supplemental Executive Benefits,                      (the “Employee”) enters into this Agreement. The Parties to this Agreement acknowledge that the Employer of the Employee is an indirect subsidiary of Community Health Systems, Inc. and that the benefits of this Agreement inure to it and the other Released Parties, as defined below in Section 4.

1.    Cessation of Employment. The Employee’s employment with the Employer ceased on the date specified at the end of this Agreement; The Employee has no right to employment or to contract with the Released Parties in the future and if such an employ and/or contract is entered into it may be voided without any liability.

2.    Consideration. The Employer agrees to pay the Employee a gross amount of $            , which is              months of the Employee’s current base salary, less applicable withholdings and deductions and in accordance with the Community Health Systems, Inc. Supplemental Benefits Plan (Supplemental Executive Benefits Plan consideration is guaranteed by CHS/Community Health Systems, Inc.).

Provided the Employee elects continuation coverage pursuant to the federal COBRA law, the Employee and the Employee’s current dependents may continue to enroll in the Employer’s group health insurances (medical, dental and/or vision). The Employee will pay the COBRA premium(s) and the Employer will reimburse the Employee the difference between the COBRA premium(s) and the premium(s) that the Employee would have paid had the Employee continued to be employed. This premium support is available through the elected COBRA period up to the later of the date specified in this Agreement or the date the Employee becomes eligible under a subsequent employers group health plan.

No Consideration shall be provided unless the Employee returns a signed copy of this Agreement, without proposing any changes to the Agreement, to the Employer, and any applicable revocation period under Section 4 has expired.

3.    No Admission of Liability. This Agreement is not an admission by the Released Parties of any liability or any legal violation.

4.    Release. The Employee, and on behalf of the Employee’s heirs, executors, administrators, personal representatives, successors, assigns, agents, servants, and attorneys (the “Releasing Parties”) releases and forever discharges, to the greatest extent permitted by law, the Employer, and any associated entities and persons including parent companies, subsidiaries, affiliates, successors, assigns, agents, management companies, servants, representatives, shareholders, lenders, members, directors, officers, staff members, and employees (the “Released Parties”) from any and all claims, causes of action, liabilities, covenants, agreements, obligations, damages, and/or demands of every nature, character, and description, without limitation in law, equity, or otherwise, which the Employee had, has, or may have (except as provided in this Section ), whether known or unknown, including under the Age Discrimination in Employment

i

Act (“ADEA”), Title VII of the Civil Rights Act, Equal Pay Act, Family and Medical Leave Act, Employee Retirement Income Security Act (unless vested), Genetic Information Nondiscrimination Act, Americans with Disabilities Act, Worker Adjustment Retraining and Notification Act, or other federal, state or local laws and regulations, and any claim for wrongful discharge, breach of contract, retaliation, infliction of emotional distress, or any other right or claim arising from or relating in any way to the Employee’s employment with the Company and/or the or cessation of that employment (collectively, the “Claims”), including all attorneys’ fees, costs, and expenses in connection with the Claims but excluding Claims under the Fair Labor Standards Act (“FLSA”) (as defined below).

The Employee agrees to waive any rights under any progressive discipline, grievance, and open door policies. The Employee warrants that the Employee knows of no facts that would serve as the basis for any of the Claims or legal violations. The Employee agrees the intent of this Section is to waive and release any and all claims, causes of action, liabilities, covenants, agreements, obligations, damages and/or demands of every nature, character, and description, without limitation in law, equity, or otherwise, which the Employee had, has, or hereafter may have (except as provided in this Section), known or unknown, against any of the Released Parties for any liability, whether vicarious, derivative, direct, or indirect; including any claims for damages (actual or punitive), back wages, future wages, commission payments, bonuses (target or other bonuses), reinstatement, accrued vacation, stock options (unless vested), past and future employee benefits (except any vested entitlement) including contributions to the Company’s employee benefit plans, compensatory damages, penalties, equitable relief, attorneys’ fees, costs of court, interest, and any and all other loss, expense, or damage of any kind related in any way to the Employee’s employment or separation.

As of the last payroll date prior to this Agreement, the Employee: (1) acknowledges having received all wages (including unpaid time and overtime) due under the Fair Labor Standards Act (as well as under any similar state or local laws referred to as the “FLSA”); and (2) does not claim that the Employer has violated or denied any of the Employee’s rights under the FLSA. The Employee and the Releasing Parties release and forever discharge, to the maximum extent permitted by law, the Employer and the other Released Parties from any FLSA claim(s), including attorneys’ fees, costs, liquidated damages and expenses incurred by the Releasing Parties in connection with such claim. If legally required, the Employee also agrees to enter into any waiver, settlement or other agreement related to the FLSA claim(s).

5.    Employee Age 40 or Over at Time of Acceptance—Review and Revocation Period. The Employee is advised to consult an attorney before signing this Agreement. The Employee has up to 21 days to review this offer of Agreement, sign it, and return it. By signing below, the Employee acknowledges having had the opportunity to read and review this Agreement, seek legal advice, and to voluntarily, without coercion, agree to it with the understanding of its significance and the consequences of its terms. Regardless, the Employee does not waive any rights or Claims under the ADEA that may arise after the date the Agreement is effective. If the Employee signs this Agreement, the Employee has seven (7) days to revoke the Agreement; if revoked, the Agreement shall be null and void, and the Employee must return any payments and other consideration provided under this Agreement. If the Employee does not revoke this Agreement, it shall be in full force and effect, and each party shall be obligated to its terms. The parties agree any changes made to this offer of Agreement (material or immaterial) will not restart or require another 21-day period for consideration by the Employee.

ii

6.    Indemnification. The Employee agrees to not directly or indirectly initiate or fiscally benefit from any legally releasable Claim(s) against the Released Parties. And the Employee agrees to indemnify the Released Parties for all attorney’s fees and expenses incurred by the Released Parties in defending such Claim(s) and in enforcing this Agreement.

7.    Nondisparagement. The Employee shall not engage in any conduct, verbal or otherwise, to disparage or harm the Released Parties’ reputations. Such conduct shall include, but not be limited to, any negative remarks made orally or in writing by the Employee about the Released Parties.

8.    Confidentiality of the Agreement. The Employee agrees that all terms of this Agreement are confidential. The Employee shall not discuss or disclose the terms of this Agreement to any entity or individual, including present or former employees of the Released Parties, the only exceptions being the Employee’s attorney, spouse, or personal accountant/tax adviser (this does not waive the Employee’s right to file a charge or communicate with the Equal Employment Opportunity Commission or any other government agency).

9.    Company Property and Confidential Information. The Employee has returned or will return within three (3) calendar days of the Separation Date all property and information, including originals and/or copies of documents relating to the business of the Released Parties. The Employee shall not directly or indirectly disclose to anyone, or use for the Employee’s own benefit or the benefit of anyone other than the Company, any “confidential information” received through the Employee’s employment. Company confidential information includes its business plans and files; management information; patient data; and any other related proprietary information. The Employee may use the Employee’s general knowledge of the industry for the Employee’s own benefit and occupation and may fully and fairly compete with the Company. If it appears the Employee will be compelled by law or judicial process to disclose any confidential information, the Employee shall immediately notify the Company in writing upon the Employee’s receipt of a subpoena or other legal process.

10.    Compliance Disclosure. In connection with the separation of the Employee’s employment, and pursuant to the Compliance Program and Code of Conduct, the Employee represents and warrants to the Released Parties that the Employee has complied with the Compliance Program and the Code of Conduct at all times, and the Employee has disclosed in writing to the Corporate Compliance Officer any and all instances of known or suspected violations of laws, rules, regulations, or corporate policy by the Released Parties. The Employee agrees to actively cooperate with the Released Parties on any questions relating to the Employee’s employment and compliance. Further, the Employee represents and warrants that the Employee has not brought and has no intention to bring any whistleblower or similar suits or claims (which terms shall include, but not be limited to, a qui tam action under the Federal False Claims Act and similar federal, state and local laws, rules and regulations) or disclosures to any governmental agency that would subject the Released Parties to any liability. The Employee also represents and warrants that the Employee knows of no facts that would give rise to any such whistleblower or similar lawsuits, claims, or disclosures to any governmental agency; provided that the foregoing

iii

is not intended and shall not be construed as limiting the right of the Employee to bring whistleblower or similar lawsuits or claims or to make such disclosures to any governmental agency. In the event the representations and warranties contained herein become inaccurate or untrue, the Employee agrees to notify the Corporate Compliance Officer, in writing, of the necessary corrections to make the representations and warranties accurate and true, prior to initiating any whistleblower or similar lawsuits, claims, or disclosures to any governmental agency. The Employee also agrees to indemnify the Released Parties against and hold the Released Parties harmless from any loss, cost, damage, or penalty incurred by the Released Parties as a result of any inaccuracy in or breach of the representations, warranties, or agreements contained herein.

11.    Intellectual Property. Intellectual Property or “IP” means any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, design, graphic, user interface, workflow, technique, know-how, trade secret, trademark, logo, slogan, trade dress, idea, or other intellectual property right whatsoever or any interest therein, whether or not patentable or registrable under copyright, trademark, or similar protections.

All IP the Employee solely or jointly conceived, created, discovered, developed, or reduced to practice during the Employee’s employment that (i) is or was related to the Company’s business, including any planned or reasonably anticipated future business, (ii) was developed, in whole or in part, using the Company’s time or its equipment, supplies, facilities, or confidential information, or (iii) resulted from any work the Employee performed for the Company, together with the related goodwill and benefits (collectively “Company IP”), are the Company’s exclusive proprietary and confidential information, and constitute works made for hire. The Employee hereby assigns to the Company all rights the Employee has, may have, or may acquire in the Company IP without additional compensation and warrants that the Employee has disclosed to the Company all Company IP and related information. The Employee agrees to perform all acts deemed necessary or desirable by the Company to permit and assist it in perfecting and enforcing the full benefits, enjoyment, rights, and title throughout the world in the Company IP, including, without limitation, execution of documents, assistance or cooperation in the registration and enforcement thereof. If the Company is unable to secure the Employee’s signature to any document required to apply for or execute any IP registration application or related documents (including improvements, renewals, extensions, continuations, divisions and continuations in part), the Employee permanently appoints the Company and its authorized representatives as the Employee’s agents and attorneys-in-fact to execute and file said documents and to do all other lawful acts to pursue IP or other rights with the same legal effect as if executed by the Employee.

12.    Miscellaneous Provisions. This Agreement is executed and delivered in the state of the Company’s principal location. The laws of such state apply, except for any rule of construction under which a contract may be construed against the drafter. Venue for any claim arising out of or related to this Agreement is in the jurisdiction of the Company’s principal offices. This is the entire agreement and understanding of the parties with respect to the subject matter. It supersedes all prior agreements and understandings of the parties; it may not be altered or amended except by mutual agreement evidenced by a writing signed by both parties and specifically identified as an amendment to this Agreement. No provisions of this Agreement are waived unless in writing and signed by both parties. This Agreement binds the parties and their respective heirs,

iv

executors, administrators, representatives, successors, and assigns. Neither party has made representations that are not contained herein on which either party relied upon in entering into this Agreement. Both parties have read and fully understand this Agreement and voluntarily enter into it. If any part of this Agreement is deemed to be unenforceable by a court of competent jurisdiction, except Section 6 in its entirety, then such part shall be severed from the Agreement and the rest of the Agreement shall remain in full force and effect. As to any unenforceable part, except Section 4 in its entirety, such court shall have the power to add or delete in its discretion any language necessary to make such provision enforceable to the maximum extent permitted by law, in which case such provision or part thereof shall not be severed, and the parties expressly agree to be bound by any such court reformed provision. Furthermore, if the release provided for in Section 4 of this Agreement is deemed to be void or otherwise unenforceable in its entirety by any court of competent jurisdiction, then the Employee shall not be entitled to consideration under this Agreement and shall immediately return/rescind such consideration and the Company will have a right to cease consideration and seek restitution, recoupment, and setoff for the recovery of any such consideration. This Agreement’s headings and captions are for convenience only and are not to be used in construing or interpreting this Agreement. The term “including” is used to list items by way of example and does not limit any term or provision. References to the singular and plural tenses are interchangeable.

13.    Date of Cessation of Employment:                                         

[Signature page follows]

v

SIGNATURES:

EMPLOYEE SIGNATURE:

EMPLOYEE NAME:

DATE SIGNED:

WITNESS’ SIGNATURE:

Employer to sign after employee returns Accepted Unchanged Offer

EMPLOYER:

By:

Name:

Title:

DATE SIGNED:

For convenience, this Agreement may be signed and electronically transmitted between the Parties and be as effective as a signed, paper agreement.

BENEFIT GUARANTOR: CHS/COMMUNITY HEALTH SYSTEMS, INC.

By:

Name:

Title

DATE SIGNED:

vi

EX-10.34

Exhibit 10.34

M E M O R A N D U M

TO:	Kevin Hammons, SVP, ACFO & Chief Accounting Officer
FROM:	Wayne T. Smith, Chairman & Chief Executive Officer
CC:	Ron Shafer, SVP, Human Resources
DATE:	December 12, 2017
SUBJECT:	Executive Deferred Compensation Award – CHSPSC, LLC Franklin Corporate Office

Effective January 2018, we are pleased to announce a special one-time Executive Deferred Compensation Award which has been designed to retain key talent within the organization and to further enhance your current compensation portfolio.    Subject to the conditions outlined below, the Award will be divided into two installment payments, with 40% of the award distributed eighteen months after the date of issuance and the remaining 60% to be distributed 36 months following the original issuance date. [Example, if the Executive Deferred Compensation Award is $100,000, the employee will receive $40,000 following 18 months of the original award date and the remaining $60,000 following 36 months of the original award date.] This discretionary award will be in monetary form that is not subject to market fluctuations and that you can choose to spend or invest at your discretion.

Your exceptional leadership and continued dedication are critical to the success of the organization and are recognized by your eligibility for this unique award. If you have any questions, please contact Ron Shafer or Leanne Reeves in the Corporate Human Resources Department.    

Your 2018 Executive Deferred Cash Award

Employee Name:	Kevin Hammons
Job Title:	SVP, ACFO & Chief Accounting Officer
2018 Deferred Compensation Award Amount:	$750,000
2018 Award Date:	January 1, 2018
1st Installment (40%) Issuance Date:	July 2019 / $300,000
2nd Installment (60%) Issuance Date:	January 2021 / $450,000

Award Eligibility

In order to be eligible for each installment payment from the Executive Deferred Compensation Award, you must have been employed as a full-time employee of CHSPSC or an affiliated facility on the installment issuance date (18 and/or 36 months post original issuance date as outlined above). Each payment will be made as soon as administratively possible following each installment date and will be subject to applicable taxes.

1

Exhibit 10.34

Change in Status/Position/Location

This special one-time award is based on your current position. If your position (other than a promotion within CHSPSC) and/or location change (other than one made by CHSPSC) subsequent to this notification, award amounts will be forfeited.

Agreement of Duties of: Loyalty, Non Competition & Non Solicitation

As an executive, you will learn non-public, proprietary information, such as business plans, medical information, referral sources, services, processes, contracts, marketing, finances, pricing and compensation of CHSPSC and its affiliated entities (CHS). As a condition of accepting this Award, you agree to work solely for CHS’ benefit. You may only use CHS proprietary information for CHS duties. And you agree to inform competing entities of your duties to CHS and to report in writing to your supervisor and to Compliance any business arrangement that might limit your duties to CHS in any way. After your employment ends, regardless of the reason, you agree to not directly or indirectly: (1) compete within 50 miles of the principal physical location of a CHS entity for one uninterrupted year and (2) not to solicit CHS employees that were employed by CHS during your CHS employ, anywhere. CHSPSC may enforce this agreement, by injunctive relief due to irreparable harm that a breach would cause, and otherwise and including the recovery of its attorney’s fees in doing so. This agreement is assignable by CHS upon written notice to you.

ACCEPTED:

/s/ Kevin Hammons	12/14/2017
Kevin Hammons	Date

2

EX-21

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Abilene Clinic Asset Holding Company, LLC (DE)
Abilene Hospital, LLC (DE)
Abilene Merger, LLC (DE)
Access Center Services, LLC (DE)
AF-CH-HH, LLC# (DE)
Affinity Cardio-Thoracic Specialists, LLC (DE)
Affinity Cardiovascular Specialists, LLC (DE)
Affinity Gastroenterology ASC, LLC* (DE)
Affinity Health Systems, LLC (DE)
Affinity Hospital, LLC (DE)	d/b/a Grandview Medical Center
Affinity Orthopedic Specialists, LLC (DE)
Affinity Physician Services, LLC (DE)
Affinity Radiation Therapy Services, LLC (DE)
Affinity Skilled Nursing, LLC (DE)
Alabama HMA Physician Management, LLC (AL)
Alaska Physician Services, LLC (DE)
Alice Regional Hospital Community Alliance, Inc. (TX)
Alliance Health Partners, LLC (MS)
Ambulance Services of Dyersburg, Inc. (TN)
Ambulance Services of McNairy, Inc. (TN)
Amory HMA Physician Management, LLC (MS)
Amory HMA, LLC (MS)
Angelo Community Healthcare Services, Inc. (TX)
Anniston HMA, LLC (AL)
Arizona ASC Management, Inc. (AZ)
Arizona DH, LLC (DE)
Arizona Medco, LLC (DE)
Arkansas HMA Regional Service Center, LLC (AR)
Arkansas Medical Imaging JV, LLC (DE)
ARMC, L.P. (DE)	d/b/a Abilene Regional Medical Center
ASC JV Holdings, LLC (DE)
Bartow HMA Physician Management, LLC (FL)
Bartow HMA, LLC (FL)
Batesville HMA Development, LLC (MS)
Batesville HMA Medical Group, LLC (MS)
Bayfront Ambulatory Surgical Center, LLC* (DE)
Bayfront Health Imaging Center, LLC* (DE)
Bayfront Health Urgent Care, LLC (DE)
Bayfront HMA Convenient Care, LLC* (FL)
Bayfront HMA Healthcare Holdings, LLC* (FL)
Bayfront HMA Home Health, LLC# (FL)
Bayfront HMA Investments, LLC* (FL)
Bayfront HMA Medical Center, LLC* (FL)	d/b/a Bayfront Health St. Petersburg
Bayfront HMA Physician Management, LLC* (FL)
Bayfront HMA Real Estate Holdings, LLC* (FL)

Page 1 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Bayfront HMA Wellness Center, LLC* (FL)
Beauco, LLC (DE)
Beaumont Medical Center, L.P. (DE)
Beaumont Regional, LLC (DE)
Berwick Clinic Company, LLC (DE)
Berwick Home Care Services, LLC# (DE)
Berwick Hospital Company, LLC (DE)	d/b/a Berwick Hospital Center
BH Trans Company, LLC (DE)
Biloxi H.M.A., LLC (MS)	d/b/a Merit Health Biloxi
Biloxi HMA Physician Management, LLC (MS)
Birmingham Holdings II, LLC (DE)
Birmingham Holdings, LLC (DE)
Birmingham Home Care Services, LLC# (DE)
Blackwell HMA, LLC (OK)
Blackwell HMPN, LLC (OK)
Blackwell Home Health & Hospice, LLC (OK)
Bluefield Holdings, LLC (DE)
Bluffton Health System LLC (DE)	d/b/a Bluffton Regional Medical Center
Bluffton Physician Services, LLC (DE)
Brandon HMA, LLC (MS)	d/b/a Merit Health Rankin
Brandon Physician Management, LLC (DE)
Brandywine Hospital Malpractice Assistance Fund, Inc. (PA)
Brazos Valley of Texas, L.P. (DE)
Brazos Valley Surgical Center, LLC (DE)
Brevard HMA ALF, LLC (FL)
Brevard HMA APO, LLC (FL)
Brevard HMA ASC, LLC (FL)
Brevard HMA Diagnostic Imaging, LLC (FL)
Brevard HMA HME, LLC (FL)
Brevard HMA Holdings, LLC (FL)
Brevard HMA Hospitals, LLC (FL)
Brevard HMA Investment Properties, LLC (FL)
Brevard HMA Nursing Home, LLC (FL)
Brooksville HMA Physician Management, LLC (FL)
Brownsville Clinic Corp. (TN)
Brownsville Hospital Corporation (TN)
Brownwood Asset Holding Company, LLC (DE)
Brownwood Hospital, L.P. (DE)	d/b/a Brownwood Regional Medical Center
Brownwood Medical Center, LLC (DE)
Bullhead City Clinic Corp. (AZ)
Bullhead City Hospital Corporation (AZ)	d/b/a Western Arizona Regional Medical Center
Bullhead City Hospital Investment Corporation (DE)
Bullhead City Imaging Corporation (AZ)
Bullhead Medical Plaza II, LLC# (AZ)

Page 2 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Bullhead Medical Plaza, Ltd.# (NV)
Cahaba Orthopedics, LLC (DE)
Campbell County HMA, LLC (TN)	d/b/a LaFollette Medical Center
Cardiology Associates of Spokane, LLC (DE)
Carlisle HMA Physician Management, LLC (PA)
Carlisle HMA Surgery Center, LLC (PA)
Carlisle HMA, LLC (PA)
Carlisle Medical Group, LLC (PA)
Carlsbad Medical Center, LLC (DE)	d/b/a Carlsbad Medical Center
Carolinas Holdings, LLC (DE)
Carolinas JV Holdings General, LLC (DE)
Carolinas JV Holdings II, LLC (DE)
Carolinas JV Holdings, L.P. (DE)
Carolinas Medical Alliance, Inc. (SC)
CDI JV, LLC# (DE)
Cedar Park Clinic Asset Holding Company, LLC (DE)
Cedar Park Health System, L.P.* (DE)	d/b/a Cedar Park Regional Medical Center
Cedar Park Regional Medical Group (TX)
Cedar Park Surgery Center, L.L.P.# (TX)
Center for Adult Healthcare, LLC (DE)
Center for Medical Interoperability, Inc. (DE)#
Center for Pain Management, LLC* (DE)
Central Florida HMA Holdings, LLC (DE)
Central Polk, LLC* (FL)
Central States HMA Holdings, LLC (DE)
Chester HMA Physician Management, LLC (SC)
Chester HMA, LLC (SC)
Chester Imaging, LLC (DE)
Chester Medical Group, LLC (SC)
Chester PPM, LLC (SC)
Chesterton Surgery Center, LLC* (DE)
Chestnut Hill Health System, LLC (DE)
Chestnut Knoll Home Health Care, L.P.# (PA)
CHHS Development Company, LLC (DE)
CHHS Holdings, LLC (DE)
CHHS Hospital Company, LLC (DE)
CHS Kentucky Holdings, LLC (DE)
CHS Mississippi State Political Action Committee (MS)
CHS Pennsylvania Holdings, LLC (DE)
CHS PSO, LLC (DE)
CHS Realty Holdings I, Inc. (TN)
CHS Realty Holdings II, Inc. (TN)
CHS Realty Holdings III, LLC (DE)
CHS Realty Holdings Joint Venture (TN)
CHS Receivables Funding, LLC (DE)

Page 3 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

CHS Tennessee Holdings, LLC (DE)
CHS Virginia Holdings, LLC (DE)
CHS Washington Holdings, LLC (DE)
CHS/Community Health Systems, Inc. (DE)
CHS/Community Health Systems, Inc. Political Action Committee
CHS-ASC, LLC (DE)
CHSPSC ACO 1, LLC (DE)
CHSPSC ACO 10, LLC (DE)
CHSPSC ACO 11, LLC (DE)
CHSPSC ACO 12, LLC (DE)
CHSPSC ACO 13, LLC (DE)
CHSPSC ACO 14, LLC (DE)
CHSPSC ACO 15, LLC (DE)
CHSPSC ACO 16, LLC (DE)
CHSPSC ACO 17, LLC (DE)
CHSPSC ACO 18, LLC (DE)
CHSPSC ACO 19, LLC (DE)
CHSPSC ACO 2, LLC (DE)
CHSPSC ACO 20, LLC (DE)
CHSPSC ACO 21, LLC (DE)
CHSPSC ACO 22, LLC (DE)
CHSPSC ACO 23, LLC (DE)
CHSPSC ACO 24, LLC (DE)
CHSPSC ACO 25, LLC (DE)
CHSPSC ACO 26, LLC (DE)
CHSPSC ACO 27, LLC (DE)
CHSPSC ACO 28, LLC (DE)
CHSPSC ACO 29, LLC (DE)
CHSPSC ACO 3, LLC (DE)
CHSPSC ACO 30, LLC (DE)
CHSPSC ACO 4, LLC (DE)
CHSPSC ACO 5, LLC (DE)
CHSPSC ACO 6, LLC (DE)
CHSPSC ACO 7, LLC (DE)
CHSPSC ACO 8, LLC (DE)
CHSPSC ACO 9, LLC (DE)
CHSPSC ACO Holdings, LLC (DE)
CHSPSC Leasing, Inc. (DE)
CHSPSC, LLC (DE)
Citrus HMA, LLC (FL)	d/b/a Bayfront Health Seven Rivers
Clarksdale HMA Physician Management, LLC (MS)
Clarksdale HMA, LLC (MS)	d/b/a Northwest Mississippi Medical Center
Clarksville Endoscopy Center, LLC* (DE)
Clarksville Health System, G.P.* (DE)	d/b/a Tennova Healthcare — Clarksville

Page 4 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Clarksville Holdings II, LLC (DE)
Clarksville Holdings, LLC (DE)
Clarksville Home Care Services, LLC# (DE)
Clarksville Imaging Center, LLC# (TN)
Clarksville Physician Services, G.P.* (DE)
Clarksville Surgicenter, LLC# (TN)
Cleveland Home Care Services, LLC# (DE)
Cleveland Hospital Company, LLC (TN)
Cleveland Medical Clinic, Inc. (TN)
Cleveland PHO, Inc. (TN)
Cleveland Tennessee Hospital Company, LLC (DE)	d/b/a Tennova Healthcare — Cleveland
Click to Care, LLC (FL)
Clinton HMA, LLC (OK)	d/b/a AllianceHealth Clinton
Clinton HMPN, LLC (OK)
Clinton Home Health & Hospice LLC# (OK)
Coast Imaging, LLC (MS)
Coatesville Hospital Corporation (PA)
Cocke County HMA, LLC (TN)	d/b/a Newport Medical Center
Coffee Hospital Management Associates, Inc. (TN)
College Station Clinic Asset Holding Company, LLC (DE)
College Station Diagnostic Clinic (TX)
College Station Hospital, L.P. (DE)
College Station Medical Center, LLC (DE)
College Station Merger, LLC (DE)
College Station RHC Company, LLC (DE)
Collier Boulevard HMA Physician Management, LLC (FL)
Collier HMA Facility Based Physician Management, LLC (FL)
Collier HMA Neurological Vascular Medical Group, LLC (FL)
Collier HMA Physician Management, LLC (FL)
Commonwealth Health Cancer Network, LLC* (DE)
Commonwealth Health Clinically Integrated Network, LLC (DE)
Commonwealth Health IDTF, LLC (DE)
Commonwealth Physician Network, LLC (DE)
Community GP Corp. (DE)
Community Health Care Partners, Inc. (MS)
Community Health Investment Company, LLC (DE)
Community Health Physicians Operations Holding Company, LLC (DE)
Community Health Systems Foundation (TN)
Community Health Systems, Inc. (DE)
Community Information Network, Inc.
Community Insurance Group SPC, LTD. (Cayman Islands)
Community LP Corp. (DE)
Compass Imaging, LLC (MS)

Page 5 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

CP Hospital GP, LLC (DE)
CP Premier Urgent Care JV, LLC# (DE)
CPLP, LLC (DE)
Credentialing Verification Services, LLC (DE)
Crestview Hospital Corporation* (FL)	d/b/a North Okaloosa Medical Center
Crestview Professional Condominiums Association, Inc.* (FL)
Crestview Surgery Center, L.P. (TN)
Crestwood Healthcare, L.P. (DE)	d/b/a Crestwood Medical Center
Crestwood Hospital LP, LLC (DE)
Crestwood Hospital, LLC (DE)
Crestwood Occupational Medicine/Convenient Care, LLC (DE)
Crestwood Physician Services, LLC (DE)
Crestwood Surgery Center, LLC* (DE)
Crossgates HMA Medical Group, LLC (MS)
Crossroads Healthcare Management, LLC# (TX)
Crystal River HMA Physician Management, LLC (FL)
CSMC, LLC (DE)
Dallas Phy Service, LLC (DE)
Dallas Physician Practice, L.P. (DE)
Day Surgery, Inc. (KS)
DCF (TX)
Deaconess Health System, LLC* (OK)
Deaconess Holdings, LLC (DE)
Deaconess Hospital Holdings, LLC (DE)
Deaconess Metropolitan Physicians, LLC (DE)
Deaconess Physician Services, LLC (DE)
Deming Home Care Services, LLC# (DE)
Desert Hospital Holdings, LLC (DE)
Detar Hospital, LLC (DE)
Detar/USP Surgery Center, LLC# (TX)
DFW Physerv, LLC (DE)
DH Cardiology, LLC (DE)
DHFW Holdings, LLC (DE)
Diagnostic Imaging Centers of NEPA, LLC# (PA)
Diagnostic Imaging Management of Brandywine Valley, LLC (PA)
Diagnostic Imaging of Brandywine Valley, LP (PA)
Dukes Health System, LLC (DE)	d/b/a Dukes Memorial Hospital
Dukes Physician Services, LLC (DE)
Dupont Hospital, LLC* (DE)	d/b/a Dupont Hospital
Durant H.M.A., LLC* (OK)	d/b/a AllianceHealth Durant
Durant HMA Home Health, LLC (OK)
Durant HMA Physician Management, LLC (OK)
Dyersburg Clinic Corp. (TN)

Page 6 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Dyersburg HBP Medical Group, LLC (DE)
Dyersburg Hospital Company, LLC (TN)
East Georgia HMA Physician Management, LLC (GA)
East Georgia Regional Medical Center, LLC* (GA)	d/b/a East Georgia Regional Medical Center
East Tennessee Clinic Corp. (TN)
East Tennessee Health Systems, Inc. (TN)
Easton Hospital Malpractice Assistance Fund, Inc. (PA)
El Dorado Home Care Services, LLC# (DE)
El Dorado Surgery Center, L.P.* (DE)
EL MED, LLC (DE)
Eligibility Screening Services, LLC (DE)
Empire Health Services (WA)
Emporia Clinic Corp. (VA)
Emporia Home Care Services, LLC# (DE)
Emporia Hospital Corporation (VA)
Enterprise Clinic, LLC (DE)
Fallbrook Hospital Corporation (DE)
Fayetteville Arkansas Hospital Company, LLC* (DE)	d/b/a Northwest Health Physicians’ Specialty Hospital
First Choice Health Plan of Mississippi, LLC# (MS)
Firstcare, Inc.# (IN)
Florida Endoscopy and Surgery Center, LLC* (FL)
Florida HMA Holdings, LLC (DE)
Florida HMA Regional Service Center, LLC (FL)
Florida West Coast Health Alliance, LLC* (DE)
Flowood Mississippi Imaging, LLC (DE)
Flowood River Oaks HMA Medical Group, LLC (MS)
FMG PrimeCare, LLC (DE)
Foley Clinic Corp. (AL)
Foley Hospital Corporation (AL)	d/b/a South Baldwin Regional Medical Center
Fort Smith HMA PBC Management, LLC (AR)
Fort Smith HMA Physician Management, LLC (AR)
Fort Smith HMA, LLC (AR)
Frankfort Health Partner, Inc. (IN)
Franklin Clinic Corp. (VA)
Franklin Home Care Services, LLC# (DE)
Franklin Hospital Corporation (VA)
FSED Management of Northwest Arkansas, LLC* (DE)
FSED Management of West Florida, LLC* (DE)
Gadsden HMA Physician Management, LLC* (AL)
Gadsden Home Care Services, LLC# (DE)
Gadsden Regional Medical Center, LLC (DE)	d/b/a Gadsden Regional Medical Center
Gadsden Regional Physician Group Practice, LLC (DE)
Gadsden Regional Primary Care, LLC (AL)
Gaffney Clinic Company, LLC (DE)

Page 7 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Gaffney H.M.A., LLC (SC)
Gaffney HMA Physician Management, LLC (SC)
Gaffney PPM, LLC (SC)
Gateway Medical Services, Inc. (FL)
Granbury Clinic Asset Holding Company, LLC (DE)
Granbury Hospital Corporation (TX)	d/b/a Lake Granbury Medical Center
Granbury Mammography JV, LLC# (DE)
Grandview Medical Group Research, LLC (DE)
GRB Real Estate, LLC (DE)
Greenbrier Valley Anesthesia, LLC (DE)
Greenbrier Valley Emergency Physicians, LLC (DE)
Greenbrier VMC, LLC (DE)	d/b/a Greenbrier Valley Medical Center
GRMC Holdings, LLC (DE)
Gulf Coast HMA Physician Management, LLC (FL)
Gulf Coast Hospital, L.P. (DE)
Gulf Coast Medical Center, LLC (DE)
Gulf Oaks Therapeutic Day School, LLC (MS)
Gulf South Surgery Center, LLC# (MS)
Gulfmed, Inc.# (MS)
Harborside Surgery Center, LLC# (FL)
Haines City HMA Physician Management, LLC (FL)
Haines City HMA Urgent Care, LLC (FL)
Haines City HMA, LLC* (FL)
Hallmark Healthcare Company, LLC (DE)
Hamlet PPM, LLC (NC)
Harris Managed Services, Inc. (AR)
Harrison HMA, LLC (MS)
Harton Clinic Company, LLC (DE)
Hartsville ENT, LLC (SC)
Hartsville HMA Physician Management, LLC (SC)
Hartsville PPM, LLC (SC)
Hattiesburg Home Care Services, LLC# (DE)
Health Management Associates, LLC (DE)
Health Management Associates, LP (DE)
Health Management General Partner I, LLC (DE)
Health Management General Partner, LLC (DE)
Health Management Information Technology, LLC (DE)
Health Management Intellectual Properties, LLC (TX)
Health Management Physician Associates, LLC (DE)
HealthTrust Purchasing Group, L.P.# (DE)
Healthwest Holdings, Inc. (AZ)
Heritage Healthcare Innovation Fund, LP# (DE)
Heritage Healthcare Innovation Fund II, LP# (DE)
Heritage Healthcare Innovation Fund III, LP# (DE)

Page 8 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Hernando HMA, LLC (FL)	d/b/a Bayfront Health Brooksville; Bayfront Health Spring Hill
Highland Health Systems, Inc. (TX)
Hill Country ASC Partners, L.L.C.# (TX)
Hill Regional Clinic Corp. (TX)
HIM Central Services, LLC (DE)
HMA ASC Holdings, LLC (DE)
HMA ASCOA Holdings, LLC (DE)
HMA Bayflite Services, LLC (FL)
HMA CAT, LLC (TX)
HMA Employee Disaster Relief Fund, Inc. (FL)
HMA Fentress County General Hospital, LLC (TN)
HMA Hospital Holdings, LP (DE)
HMA Lake Shore, Inc.* (FL)
HMA MRI, LLC (TX)
HMA Oklahoma Clearing Service, LLC (OK)
HMA Professional Services Group, LP (DE)
HMA Santa Rosa Medical Center, LLC (FL)	d/b/a Santa Rosa Medical Center
HMA Services GP, LLC (DE)
HMA/Solantic Joint Venture, LLC# (DE)
HMA-ASCOA Investments, LLC* (DE)
HMA-ASCOA Investments, LLC* (DE)
HMA-TRI Holdings, LLC (DE)
Hobbs Medco, LLC (DE)
HOF ASC Holdings, LLC (DE)
Hood Medical Group (TX)
Hood Medical Services, Inc. (TX)
Hospital Laundry Services, Inc.# (IN)
Hospital Management Associates, LLC (FL)
Hospital Management Services of Florida, LP (FL)
Hospital of Fulton, Inc. (KY)
Hospital of Morristown, LLC (TN)
Hot Springs Outpatient Surgery Center, G.P. (AR)
HP LRHS Land, LLC# (IN)
HTI Tucson Rehabilitation, Inc. (AZ)
Imaging JV Holdings, LLC (DE)
INACTCO, Inc. (DE)
Intermountain Medical Group, Inc. (PA)
IOM Health System, L.P.* (IN)	d/b/a Lutheran Hospital of Indiana
Jackson HMA North Medical Office Building, LLC (MS)
Jackson HMA, LLC (MS)	d/b/a Merit Health Central
Jackson Home Care Services, LLC# (DE)
Jackson Hospital Corporation (TN)
Jackson, Tennessee Hospital Company, LLC* (TN)
Jamestown HMA Physician Management, LLC (TN)

Page 9 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Jasper Medical Group, LLC (FL)
Jefferson ASC, LLC* (DE)
Jefferson County HMA, LLC (TN)	d/b/a Jefferson Memorial Hospital
Jennersville Regional Hospital Malpractice Assistance Fund, Inc. (PA)
Jourdanton Clinic Asset Holding Company, LLC (DE)
Jourdanton Hospital Corporation (TX)
Kay County Clinic Company, LLC (OK)
Kay County Hospital Corporation (OK)
Kay County Oklahoma Hospital Company, LLC (OK)	d/b/a AllianceHealth Ponca City
Kennett HMA Physician Management, LLC (MO)
Kennett HMA, LLC (MO)
Key West HMA Physician Management, LLC (FL)
Key West HMA, LLC (FL)	d/b/a Lower Keys Medical Center
Key West Home Health, LLC# (FL)
Key West Private Care, LLC# (FL)
Keystone HMA Property Management, LLC (PA)
Kirksville Academic Medicine, LLC (MO)
Kirksville Clinic Corp. (MO)
Kirksville Home Care Services, LLC# (MO)
Kirksville Hospital Company, LLC (DE)
Kirksville Missouri Hospital Company, LLC* (MO)	d/b/a Northeast Regional Medical Center
Kirksville Physical Therapy Services, LLC (DE)
Knox Hospital Company, LLC (DE)	d/b/a Starke Hospital
Knoxville HMA Cardiology PPM, LLC (TN)
Knoxville HMA Development, LLC (TN)
Knoxville HMA Family Services, LLC (TN)
Knoxville HMA Holdings, LLC (TN)
Knoxville HMA Homecare DME & Hospice, LLC (TN)
Knoxville HMA JV Holdings, LLC (TN)
Knoxville HMA Mission Services, LLC (TN)
Knoxville HMA Physician Management, LLC (TN)
Knoxville HMA Wellness Center, LLC (TN)
Knoxville Home Care Services, LLC# (DE)
Knoxville Rehabilitation Hospital, LLC# (DE)
Knoxville, Tennessee Turkey Creek MOB, LLC (DE)
Kosciusko Ambulance Services, LLC (DE)
Kosciusko Medical Group, LLC (DE)
La Porte and Starke EMS, LLC (DE)
La Porte Clinic Company, LLC (DE)
La Porte Health System, LLC (DE)
La Porte Home Care Services, LLC# (DE)
La Porte Hospital Company, LLC (DE)	d/b/a La Porte Hospital
La Porte Occupational Health Services, LLC (DE)
Lake Shore HMA Medical Group, LLC* (FL)

Page 10 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Lake Shore HMA, LLC* (FL)	d/b/a Shands Lake Shore Regional Medical Center
Lake Wales Clinic Corp. (FL)
Lake Wales Hospital Corporation (FL)
Lake Wales Hospital Investment Corporation (FL)
Lake Wales Imaging Center, LLC (DE)
Lakeland Home Care Services, LLC# (DE)
Lakeway Hospital Company, LLC (TN)
Lancaster Clinic Corp. (SC)
Lancaster HMA Physician Management, LLC (PA)
Lancaster HMA, LLC* (PA)
Lancaster Hospital Corporation (DE)
Lancaster Imaging Center, LLC (SC)
Lancaster Medical Group HMA, LLC (PA)
Lancaster Medical Group, LLC (PA)
Lancaster Outpatient Imaging, LLC (PA)
Langtree Endoscopy Center, LLC* (DE)
LaPorte Medical Group Surgical Center, LLC# (IN)
Laredo Clinic Asset Holding Company, LLC (DE)
Laredo Texas Hospital Company, L.P. (TX)	d/b/a Laredo Medical Center
Las Cruces ASC-GP, LLC (DE)
Las Cruces Home Care Services, LLC# (DE)
Las Cruces Medical Center, LLC (DE)	d/b/a Mountain View Regional Medical Center
Las Cruces Physician Services, LLC (DE)
Las Cruces Surgery Center — Telshor, LLC* (DE)
Las Cruces Surgery Center, L.P.* (DE)
Lea Regional Hospital, LLC (DE)	d/b/a Lea Regional Medical Center
Lebanon HMA Physician Management, LLC (TN)
Lebanon HMA Surgery Center, LLC (TN)
Lebanon HMA, LLC (TN)
Lehigh HMA Physician Management, LLC (FL)
Lehigh HMA, LLC (FL)
LHT Knoxville Properties, LLC# (DE)
Little Rock HMA, Inc. (AR)
Live Oak HMA Medical Group, LLC* (FL)
Live Oak HMA, LLC* (FL)	d/b/a Shands Live Oak Regional Medical Center
Logan Hospital Corporation (WV)
Logan, West Virginia Hospital Company, LLC (WV)
Lone Star HMA Physician Management, Inc. (TX)
Lone Star HMA, L.P. (DE)
Longview Clinic Operations Company, LLC (DE)
Longview Medical Center, L.P. (DE)	d/b/a Longview Regional Medical Center
Longview Merger, LLC (DE)

Page 11 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Louisburg HMA Physician Management, LLC (NC)
Lower Florida Keys Physician/Hospital Organization, Inc.# (FL)
LRH, LLC (DE)
Lufkin Clinic Asset Holding Company, LLC (DE)
Lutheran Health Imaging, LLC (DE)
Lutheran Health Network Investors, LLC* (DE)
Lutheran Health Network of Indiana, LLC (DE)
Lutheran Health Quality Alliance, LLC (DE)
Lutheran Medical Group, LLC (DE)
Lutheran Medical Office Park Phase II Property Owners Association, Inc. # (IN)
Lutheran Medical Office Park Property Owners Association, Inc.# (IN)
Lutheran Musculoskeletal Center, LLC* (DE)
Lutheran/TRMA Network, LLC# (IN)
Macon Healthcare, LLC# (DE)
Madison Cardiovascular Physician Services, LLC (DE)
Madison Clinic Corp. (TN)
Madison Health System, LLC# (DE)
Madison HMA Physician Management, LLC# (MS)
Madison HMA, LLC# (MS)	d/b/a Merit Health Madison
Marion Physician Services, LLC (DE)
Marshall County HMA, LLC (OK)	d/b/a AllianceHealth Madill
Marshall County HMPN, LLC (OK)
Martin Clinic Corp. (TN)
Martin Hospital Company, LLC (TN)
Mary Black HealthNetwork, Inc.# (SC)
Mary Black Health System LLC (DE)
Mary Black Medical Office Building Limited Partnership (SC)
Mary Black MOB II Limited Partnership (SC)
Mary Black Physician Services, LLC (DE)
Mary Black Physicians Group, LLC (DE)
Mat-Su Regional ASC GP, LLC (DE)
Mat-Su Regional Surgery Center, L.P. (DE)
Mat-Su Valley II, LLC* (AK)
Mat-Su Valley III, LLC* (AK)
Mat-Su Valley Medical Center, LLC* (AK)	d/b/a Mat-Su Regional Medical Center
Mayes County HMA, LLC (OK)
Mayes County HMPN, LLC (OK)
McKenna Court Homes, LLC (DE)
McNairy Clinic Corp. (TN)
McNairy Hospital Corporation (TN)
MCSA, L.L.C. (AR)
MDSave, Inc.# (DE)

Page 12 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Medical Center at Terrell, LLC (DE)
Medical Center of Brownwood, LLC (DE)
Medical Holdings, Inc. (KS)
MEDSTAT, LLC (IN)
Melbourne HMA Medical Group, LLC (FL)
Melbourne HMA, LLC (FL)
Mercy Cardiovascular Cath Lab, LLC# (PA)
Merger Legacy Holdings, LLC (DE)
Mesquite HMA General, LLC (DE)
Metro Knoxville HMA, LLC (TN)	d/b/a Turkey Creek Medical Center; North Knoxville Medical Center
MHS Ambulatory Surgery Center, Inc. (ND)
Michigan City MOB, LLC# (IN)
Middlebrook ASC, LLC (DE)
Midwest City HMA Physician Management, LLC* (OK)
Midwest Regional Medical Center, LLC* (OK)	d/b/a AllianceHealth Midwest
Minot Health Services, Inc. (ND)
Mississippi HMA Holdings I, LLC (DE)
Mississippi HMA Holdings II, LLC (DE)
Mississippi HMA Hospitalists, LLC (MS)
Mississippi HMA Regional Service Center, LLC (MS)
Moberly Hospital Company, LLC (DE)	d/b/a Moberly Regional Medical Center
Moberly Medical Clinics, Inc. (MO)
Moberly Physicians Corp. (MO)
Mooresville HMA Investors, LLC* (NC)
Mooresville HMA Physician Management, LLC (NC)
Mooresville Home Care Services, LLC# (DE)
Mooresville Hospital Management Associates, LLC (NC)	d/b/a Lake Norman Regional Medical Center
Mooresville PPM, LLC (NC)
Morristown Clinic Corp. (TN)
Morristown Professional Centers, Inc. (TN)
Morristown Surgery Center, LLC (TN)
Munroe HMA HMPN, LLC (FL)
Munroe HMA Holdings, LLC (FL)
Munroe HMA Hospital, LLC (FL)
Naples HMA, LLC (FL)	d/b/a Physicians Regional Medical Center — Pine Ridge; Physicians Regional Medical Center — Collier
Natchez Clinic Company, LLC (DE)
Natchez HBP Services, LLC (DE)
Natchez Hospital Company, LLC (DE)	d/b/a Merit Health Natchez
National Healthcare of England Arkansas, Inc. (AR)
National Healthcare of Leesville, Inc. (DE)
National Healthcare of Newport, Inc. (DE)
Navarro Hospital, L.P. (DE)	d/b/a Navarro Regional Hospital

Page 13 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Navarro Regional, LLC (DE)
NC-DSH, LLC (DE)
New Cedar Lake Surgery Center, LLC# (MS)
Newport Physician Clinics, Inc. (AR)
NHCI of Hillsboro, Inc. (TX)	d/b/a Hill Regional Hospital
North Carolina HMA Regional Service Center, LLC (NC)
North Okaloosa Clinic Corp. (FL)
North Okaloosa Home Health, LLC# (FL)
North Okaloosa Medical Corp.* (FL)
North Okaloosa Surgery Venture Corp. (FL)
Northampton Cardiology Clinic, LLC (DE)
Northampton Clinic Company, LLC (DE)
Northampton Hospital Company, LLC (DE)
Northampton Physician Services Corp. (PA)
Northampton Urgent Care, LLC (DE)
Northeast Medical Center, L.P. (DE)
Northern Indiana Oncology Center of Porter Memorial Hospital, LLC* (IN)
Northwest Allied Physicians, LLC (DE)
Northwest Arkansas Employees, LLC (DE)
Northwest Arkansas Hospitals, LLC (DE)	d/b/a Northwest Medical Center — Bentonville; Northwest Medical Center — Springdale; Willow Creek Women’s Hospital
Northwest Arkansas Paramed Transfer, LLC (DE)
Northwest Benton County Physician Services, LLC (DE)
Northwest Cardiology, LLC (DE)
Northwest HBP Medical Services, LLC (DE)
Northwest Hospital Cardiac Diagnostics, L.P. (TN)
Northwest Hospital, LLC (DE)	d/b/a Northwest Medical Center
Northwest Houghton Hospital, LLC (DE)
Northwest Imaging Associates, LLC (DE)
Northwest Indiana Health System, LLC* (DE)
Northwest Physicians, LLC (AR)
Northwest Sahuarita Hospital, LLC (DE)
Northwest-Sparks Quality Alliance, LLC (DE)
NOV Holdings, LLC (DE)
NRH, LLC (DE)
Oak Hill Clinic Corp. (WV)
Oak Hill Hospital Corporation (WV)	d/b/a Plateau Medical Center
Ohio Sleep Disorders Centers, LLC# (OH)
Oklahoma City ASC-GP, LLC (DE)
Olive Branch Clinic Corp. (MS)
Olive Branch Hospital, Inc. (MS)
One Boyertown Properties, L.P.# (PA)

Page 14 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Open Air of MSLOU, L.L.C. (LA)
Oro Valley Hospital, LLC (DE)	d/b/a Oro Valley Hospital
OsceolaSC, LLC* (DE)	d/b/a St. Cloud Regional Medical Center
Osler HMA Medical Group, LLC (FL)
Pacific Group ASC Division, Inc. (AZ)
Pacific Physicians Services, LLC (DE)
Palmer-Wasilla Health System, LLC (DE)
Palmetto Tri-County Medical Specialists, LLC (DE)
Panhandle Medical Center, LLC (DE)
Panhandle Surgical Hospital, L.P. (DE)
Parkway Regional Medical Clinic, Inc. (KY)
Pasco Hernando HMA Physician Management, LLC* (FL)
Pasco Regional Medical Center, LLC (FL)
Payson Healthcare Management, Inc. (AZ)
Payson Hospital Corporation (AZ)
PBEC HMA, Inc. (FL)
Peckville Hospital Company, LLC (DE)
Pecos Valley of New Mexico, LLC (DE)
Pennsylvania Hospital Company, LLC (DE)
Personal Home Health Care, LLC (TN)
Petersburg Clinic Company, LLC (VA)
Petersburg Home Care Services, LLC# (DE)
Petersburg Hospital Company, LLC (VA)
Phoenixville Hospital Company, LLC (DE)
Phoenixville Hospital Malpractice Assistance Fund, Inc. (PA)
Physician Practice Support, LLC (TN)
Physicians Regional Marco Island, LLC (FL)
Pinellas Surgery Center, LLC* (FL)
Piney Woods Healthcare System, L.P.* (DE)	d/b/a Woodland Heights Medical Center
Plymouth Hospital Corporation (NC)
Polk Medical Services, Inc. (TN)
Ponca City Home Care Services, LLC# (OK)
Poplar Bluff Physician Management, LLC (MO)
Poplar Bluff Regional Medical Center, LLC (MO)	d/b/a Poplar Bluff Regional Medical Center
Port Charlotte HMA Physician Management, LLC (FL)
Port Charlotte HMA, LLC (FL)	d/b/a Bayfront Health Port Charlotte
Porter Health Services, LLC (DE)
Porter Hospital, LLC* (DE)	d/b/a Porter Regional Hospital
Porter Physician Services, LLC (DE)
Pottstown Hospital Company, LLC (DE)
Pottstown Hospital Corporation (PA)
Pottstown Imaging Company, LLC (DE)
Pottstown Memorial Malpractice Assistance Fund, Inc. (PA)
Pottstown Professional Services Company, LLC (DE)
Precision Surgery Center, LLC (DE)

Page 15 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Preferential Health Network, Inc.# (SC)
Premier Care Super PHO, LLC (DE)
PremierCare of Northwest Arkansas, LLC (AR)
Procure Solutions, LLC (DE)
Professional Account Services Inc. (TN)
Punta Gorda HMA Physician Management, LLC (FL)
Punta Gorda HMA, LLC (FL)	d/b/a Bayfront Health Punta Gorda
Punta Gorda Medical Arts Center Association, Inc. (FL)
QHG Georgia Holdings II, LLC (DE)
QHG Georgia Holdings, Inc. (DE)
QHG Georgia, LP (GA)
QHG of Barberton, Inc. (OH)
QHG of Bluffton Company, LLC (DE)
QHG of Clinton County, Inc. (IN)
QHG of Enterprise, Inc. (AL)	d/b/a Medical Center Enterprise
QHG of Forrest County, Inc. (MS)
QHG of Fort Wayne Company, LLC (DE)
QHG of Hattiesburg, Inc. (MS)
QHG of Kenmare, Inc. (ND)
QHG of Lake City, Inc. (SC)
QHG of Minot, Inc. (ND)
QHG of Ohio, Inc. (OH)
QHG of South Carolina, Inc. (SC)
QHG of Spartanburg, Inc. (SC)
QHG of Springdale, Inc. (AR)
QHG of Texas, Inc. (TX)
QHG of Warsaw Company, LLC (DE)
Quorum ELF, Inc. (DE)
Quorum Health Services, Inc. (DE)
Rankin Cardiology Center, LLC (MS)
Regional Cancer Treatment Center, Ltd.# (TX)
Regional Cardiology Center, L.L.C. (MS)
Regional Cardiology Group, LLC (DE)
Regional Clinics of Longview (TX)
Regional Employee Assistance Program (TX)
Regional Hospital of Longview, LLC (DE)
Rehab Hospital of Fort Wayne General Partnership* (DE)
Revenue Cycle Service Center, LLC (DE)
River Oaks Hospital, LLC (MS)	d/b/a Merit Health River Oaks
River Oaks Management Company, LLC (MS)
River Oaks Medical Office Building, LLC (MS)
River Region Medical Corporation (MS)
Riverpark Community Cath Lab, LLC# (DE)
Riverview Regional Medical Center, LLC* (DE)
Rockledge HMA Convenient Care, LLC (FL)

Page 16 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Rockledge HMA Medical Group, LLC (FL)
Rockledge HMA Urgent Care, LLC (FL)
Rockledge HMA, LLC (FL)
Rockwood Clinic Real Estate Holdings, LLC (DE)
ROH, LLC (MS)	d/b/a Merit Health Woman’s Hospital
Ronceverte Physician Group, LLC (DE)
Rose City HMA Medical Group, LLC* (PA)
Rose City HMA, LLC* (PA)
Roswell Clinic Corp. (NM)
Roswell Hospital Corporation (NM)	d/b/a Eastern New Mexico Medical Center
Russell County Clinic Corp. (VA)
Russell County Medical Center, Inc. (VA)
Ruston Clinic Company, LLC (DE)
Ruston Hospital Corporation (DE)
Ruston Louisiana Hospital Company, LLC (DE)	d/b/a Northern Louisiana Medical Center
SACMC, LLC (DE)
Salem Clinic Corp. (NJ)
Salem Home Care Holdings, LLC (DE)
Salem Home Care Services, LLC (DE)
Salem Hospital Corporation (NJ)
Salem Medical Professionals, Inc. (NJ)
Samaritan Surgicenters of Arizona II, LLC (AZ)
San Angelo Ambulatory Surgery Center, Ltd.# (TX)
San Angelo Community Medical Center, LLC (DE)
San Angelo Hospital, L.P.# (DE)	d/b/a San Angelo Community Medical Center
San Angelo Medical, LLC (DE)
Santa Rosa HMA Physician Management, LLC (FL)
Santa Rosa HMA Urgent Care, LLC (FL)
Scott County HMA, LLC (TN)
Scranton Cardiovascular Physician Services, LLC (DE)
Scranton Clinic Company, LLC (DE)
Scranton Emergency Physician Services, LLC (DE)
Scranton GP Holdings, LLC (DE)
Scranton Holdings, LLC (DE)
Scranton Hospital Company, LLC (DE)	d/b/a Regional Hospital of Scranton
Scranton Hospitalist Physician Services, LLC (DE)
Scranton Quincy Ambulance, LLC (DE)
Scranton Quincy Clinic Company, LLC (DE)
Scranton Quincy Holdings, LLC (DE)
Scranton Quincy Home Care Services, LLC# (DE)
Scranton Quincy Hospital Company, LLC (DE)	d/b/a Moses Taylor Hospital
Scranton Quincy QRFS, LLC (DE)
Sebastian HMA Physician Management, LLC (FL)
Sebastian Home Care Services, LLC# (DE)
Sebastian Hospital, LLC (FL)

Page 17 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Sebastopol, LLC (DE)
Sebring HMA Physician Management, LLC (FL)
Sebring Hospital Management Associates, LLC (FL)
Seminole HMA, LLC (OK)	d/b/a AllianceHealth Seminole
Seminole HMPN, LLC (OK)
SEPA Integrated Providers Alliance, LLC (DE)
Sharon Clinic Company, LLC (DE)
Sharon Pennsylvania Holdings, LLC (DE)
Sharon Pennsylvania Hospital Company, LLC (DE)
Sharon Regional HBP Medical Group, LLC (DE)
Shelby Alabama Real Estate, LLC (DE)
Shelbyville Clinic Corp. (TN)
Shelbyville Home Care Services, LLC# (DE)
Shelbyville Hospital Company, LLC (TN)	d/b/a Tennova Healthcare — Shelbyville
Sherman Hospital, L.P. (DE)
Sherman Medical Center, LLC (DE)
Siloam Springs Arkansas Hospital Company, LLC (DE)	d/b/a Siloam Springs Regional Hospital
Siloam Springs Clinic Company, LLC (DE)
Siloam Springs Holdings, LLC (DE)
Silver Creek MRI, LLC (AZ)
SJ Home Care, LLC# (DE)
SkyRidge Clinical Associates, LLC (DE)
South Abilene Radiology, LLC (DE)
South Arkansas Physician Services, LLC (DE)
SouthCrest, L.L.C. (OK)
Southeast Alabama Maternity Center, LLC (AL)
Southeast HMA Holdings, LLC (DE)
Southern Health Network, Inc.# (DE)
Southern Texas Medical Center, LLC (DE)
Southside Physician Network, LLC (DE)
Southwest Florida HMA Holdings, LLC (DE)
Southwest Physicians Risk Retention Group, Inc. (SC)
Sparks PremierCare, L.L.C. (AR)
Spokane Valley Washington Hospital Company, LLC (DE)
Spokane Washington Hospital Company, LLC (DE)
Spring Hill HMA Medical Group, LLC (FL)
Springdale Home Care Services, LLC# (DE)
Sprocket Medical Management, LLC (TX)
SS ParentCo., LLC (DE)
St. Cloud Physician Management, LLC* (FL)
St. Joseph Health System, LLC* (DE)	d/b/a St. Joseph Health System
Starke HMA Medical Group, LLC* (FL)
Starke HMA, LLC* (FL)	d/b/a Shands Starke Regional Medical Center
Statesboro HMA Medical Group, LLC (GA)
Statesboro HMA Physician Management, LLC (GA)

Page 18 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Statesville HMA Medical Group, LLC (NC)
Statesville HMA Physician Management, LLC (NC)
Statesville HMA, LLC (NC)	d/b/a Davis Regional Medical Center
Statesville PPM, LLC (NC)
StrokeCareNow, LLC# (IN)
Summit Surgical Suites, LLC* (IN)
Supply Chain Shared Service Center, LLC (DE)
Surgery Center of Midwest City, LLC* (DE)
Surgical Center of Amarillo, LLC (DE)
Surgical Center of Carlsbad, LLC (DE)
Surgical Clinic Solutions, LLC# (AL)
Surgicare of Clarksville, LLC# (TN)
Surgicare of Independence, Inc. (MO)
Surgicare of San Leandro, Inc. (CA)
Surgicare of Sherman, Inc. (TX)
Surgicare Outpatient Center of Lake Charles, Inc. (LA)
Surgicenter of Johnson County, Inc. (KS)
Surgicenters of America, Inc. (AZ)
Susitna ASC Holdings, LLC* (DE)
Susitna Surgery Center, LLC* (DE)
Tennessee HMA Holdings, LP (DE)
Tennessee HMA Regional Service Center, LLC (TN)
Tennyson Holdings, LLC (DE)
Terrell Hospital, L.P. (DE)
Terrell Medical Center, LLC (DE)
Texas Bay Area Clinical Services, Inc.# (TX)
The Sleep Disorder Center of Wyoming Valley, LLC (PA)
The Surgery Center, LLC# (MS)
The Vicksburg Clinic, LLC (DE)
Timberland Medical Group (TX)
Tomball Ambulatory Surgery Center, L.P. (TX)
Tomball Clinic Asset Holding Company, LLC (DE)
Tomball Texas Equipment Ventures, LLC (TX)
Tomball Texas Holdings, LLC (DE)
Tomball Texas Hospital Company, LLC (DE)
Tomball Texas Ventures, LLC (DE)
Triad Healthcare System of Phoenix, L.P. (DE)
Triad Healthcare, LLC (DE)
Triad Holdings III, LLC (DE)
Triad Holdings IV, LLC (DE)
Triad Holdings V, LLC (DE)
Triad Indiana Holdings, LLC* (DE)
Triad Nevada Holdings, LLC (DE)
Triad of Alabama, LLC (DE)	d/b/a Flowers Hospital
Triad of Arizona (L.P.), Inc. (AZ)

Page 19 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Triad of Phoenix, Inc. (AZ)
Triad RC, Inc. (DE)
Triad-Arizona I, Inc. (AZ)
Triad-ARMC, LLC (DE)
Triad-Denton Hospital GP, LLC (DE)
Triad-Denton Hospital, L.P. (DE)
Triad-El Dorado, Inc. (AR)
Triad-Navarro Regional Hospital Subsidiary, LLC (DE)
Triad-South Tulsa Hospital Company, Inc. (OK)
Tri-Irish, Inc. (DE)
TROSCO, LLC (DE)
Tucson Home Care Services, LLC# (DE)
Tug Valley Healthcare Alliance, Inc. (WV)
Tullahoma HMA Physician Management, LLC (TN)
Tullahoma HMA, LLC (TN)	d/b/a Tennova Healthcare — Harton
Tunkhannock Hospital Company, LLC (DE)	d/b/a Tyler Memorial Hospital
Valley Advanced Imaging, LLC# (IN)
Valley Advanced MRI, LLC# (IN)
ValleyCare Cardiology Group, LLC (DE)
Valparaiso Home Care Services, LLC# (DE)
Van Buren H.M.A., LLC (AR)
Van Buren HMA Central Business Office, LLC (AR)
Vanderbilt-Gateway Cancer Center, G.P.# (DE)
Venice HMA, LLC (FL)	d/b/a Venice Regional Bayfront Health
Venice Home Care Services, LLC# (DE)
Vero Beach Florida ASC, LLC* (DE)
VHC Holdings, LLC (DE)
VHC Medical, LLC (DE)
Vicksburg Healthcare, LLC (DE)	d/b/a Merit Health River Region
Vicksburg HMA Physician Management, LLC (MS)
Victoria Ambulatory Surgery Center, L.P.# (DE)
Victoria Clinic Asset Holding Company, LLC (DE)
Victoria Hospital, LLC (DE)
Victoria of Texas, L.P. (DE)	d/b/a DeTar Hospital Navarro; DeTar Hospital North
Victoria Texas Home Care Services, LLC# (DE)
Virginia Care Company, LLC (DE)
Virginia Hospital Company, LLC (VA)
VirtualHealthConnect, LLC (DE)
Warren Ohio Hospital Company, LLC (DE)
Warren Ohio Physician Services, LLC (DE)
Warren Ohio Rehab Hospital Company, LLC (DE)
Warsaw Health System, LLC (DE)	d/b/a Kosciusko Community Hospital
Washington Clinic Corp. (MS)
Washington Hospital Corporation (MS)

Page 20 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

Washington Physician Corp. (MS)
WA-SPOK DH CRNA, LLC (DE)
WA-SPOK DH Urgent Care, LLC (DE)
WA-SPOK Kidney Care, LLC (DE)
WA-SPOK Medical Care, LLC (DE)
WA-SPOK Primary Care, LLC (DE)
WA-SPOK Pulmonary & Critical Care, LLC (DE)
WA-SPOK VH CRNA, LLC (DE)
WA-SPOK VH Urgent Care, LLC (DE)
Weatherford Hospital Corporation (TX)
Weatherford Texas Hospital Company, LLC (TX)
Webb County Texas Home Care Services, LLC# (DE)
Webb Hospital Corporation (DE)
Webb Hospital Holdings, LLC (DE)
Wesley Health System LLC (DE)	d/b/a Merit Health Wesley
Wesley HealthTrust, Inc. (MS)
Wesley Physician Services, LLC (DE)
West Grove Hospital Company, LLC (DE)
Western Arizona Regional Home Health and Hospice, LLC# (AZ)
Westmed (TX)
WHMC, LLC (DE)
Wilkes-Barre Academic Medicine, LLC (DE)
Wilkes-Barre Behavioral Hospital Company, LLC (DE)
Wilkes-Barre Behavioral Ventures, LLC (DE)
Wilkes-Barre Clinic Company, LLC (DE)
Wilkes-Barre Community Residential Unit, LLC (DE)
Wilkes-Barre Holdings, LLC (DE)
Wilkes-Barre Home Care Services, LLC# (DE)
Wilkes-Barre Hospital Company, LLC (DE)	d/b/a Wilkes-Barre General Hospital
Wilkes-Barre Intermountain Clinic, LLC (DE)
Wilkes-Barre Personal Care Services, LLC (DE)
Wilkes-Barre Radiation Oncology, LLC# (DE)
Wiregrass Clinic, LLC (DE)
Women & Children’s Hospital, LLC (DE)
Women’s Health Partners, LLC (DE)
Women’s Health Specialists of Birmingham, Inc. (AL)
Women’s Health Specialists of Carlisle, LLC (PA)
Woodland Heights Medical Center, LLC (DE)
Woodward Clinic Company, LLC (DE)
Woodward Health System, LLC (DE)	d/b/a AllianceHealth Woodward
Woodward Home Care Services, LLC# (DE)
Yakima HMA Physician Management, LLC (WA)
Yakima HMA, LLC (WA)
York Anesthesiology Physician Services, LLC (DE)

Page 21 of 22

Community Health Systems, Inc.

SUBSIDIARY LISTING

Exhibit 21

as of 12/31/19

(*) Majority position held in an entity with physicians, non-profit entities or both

(#) Minority position held in a non-consolidating entity

York Clinic Company, LLC (DE)

York Pathology Physician Services, LLC (DE)

York Pennsylvania Holdings, LLC (DE)

York Pennsylvania Hospital Company, LLC (DE)

Youngstown Ohio Hospital Company, LLC (DE)

Youngstown Ohio Laboratory Services Company, LLC (DE)

Youngstown Ohio Outpatient Services Company, LLC (DE)

Youngstown Ohio Physician Services Company, LLC (DE)

Youngstown Ohio PSC, LLC (DE)

Page 22 of 22

EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statement No. 333-230221 on Form S-3 and Registration Statement Nos. 333-61614, 333-100349, 333-107810, 333-121282, 333-144525, 333-163688, 333-163689, 333-163691, 333-176893, 333-188343, 333-190260, 333-197813, 333-207772, 333-212874, 333-214389, and 333-226455 on Form S-8 of our reports dated February 20, 2020, relating to the consolidated financial statements and consolidated financial statement schedule of Community Health Systems, Inc. and subsidiaries (the “Company”), and the effectiveness of the Company’s internal control over financial reporting, appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2019.

/s/ Deloitte & Touche LLP

Nashville, Tennessee

February 20, 2020

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Wayne T. Smith, certify that:

1. I have reviewed this annual report on Form 10-K of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Wayne T. Smith

Wayne T. Smith

Chairman of the Board

and Chief Executive Officer

Date: February 20, 2020

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Kevin J. Hammons, certify that:

1. I have reviewed this annual report on Form 10-K of Community Health Systems, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Kevin J. Hammons

Kevin J. Hammons

Executive Vice President and

Chief Financial Officer

Date: February 20, 2020

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Community Health Systems, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Wayne T. Smith, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Wayne T. Smith

Wayne T. Smith

Chairman of the Board and

Chief Executive Officer

February 20, 2020

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Community Health Systems, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kevin J. Hammons, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Kevin J. Hammons

Kevin J. Hammons

Executive Vice President and

Chief Financial Officer

February 20, 2020

XML

Fair Value (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in equity securities	$ 141	$ 137
Available-for-sale securities	101	93
Trading securities	12	11
Fair value of interest rate swap agreements		3
Total assets	254	244
Fair value of interest rate swap agreements	2	2
Total liabilities	2	2
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in equity securities	141	137
Total assets	141	137
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale securities	101	93
Trading securities	12	11
Fair value of interest rate swap agreements		3
Total assets	113	107
Fair value of interest rate swap agreements	2	2
Total liabilities	$ 2	$ 2

XML

Long-Term Debt (8.0% Senior Notes, Due 2019) (Narrative) (Details) - USD ($)		1 Months Ended		12 Months Ended
	Nov. 22, 2011	Jul. 18, 2012	Mar. 21, 2012	Dec. 31, 2019	Jun. 22, 2018
Debt Instrument [Line Items]
Long-term debt outstanding				$ 13,405,000,000
Senior Notes at 8.875%, Due 2015 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 1,000,000,000	$ 934,000,000	$ 850,000,000
Senior Notes at 8.0%, Due 2019 [Member]
Debt Instrument [Line Items]
Long-term debt outstanding					$ 155,000,000
Senior Notes at 8.0%, Due 2019 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Nov. 22, 2011
Debt instrument aggregate principal amount	$ 1,000,000,000
Debt instrument, maturity date				Nov. 15, 2019
Debt instrument stated interest rate	8.00%		8.00%
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member]
Debt Instrument [Line Items]
Debt instrument stated interest rate			8.00%
Senior Notes at 8.0, Due 2019, March 21, 2012 Secondary Offering [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Mar. 21, 2012
Debt instrument aggregate principal amount			$ 1,000,000,000
Debt instrument prepium percentage			102.50%
Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount					1,770,000,000
Junior-Priority Secured Notes At 9.875% Due 2023 [Member] | Junior-Priority Secured Notes [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Jun. 22, 2018
Debt instrument aggregate principal amount					$ 1,770,000,000
Debt instrument stated interest rate					11.00%

XML

Long-Term Debt (Credit Facility Narrative) (Details)							12 Months Ended
	Nov. 19, 2019 USD ($)	Mar. 06, 2019 USD ($)	Feb. 15, 2019 USD ($)	Apr. 03, 2018 USD ($)	May 12, 2017 USD ($)	Mar. 16, 2017 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Nov. 12, 2019 USD ($)	Jul. 06, 2018 USD ($)
Credit Facility, Type of Debt, Amendment No. 1 [Member]
Debt Instrument [Line Items]
First lien net debt to EBITDA, tier 1			5.00
First lien net debt to EBITDA, tier 2			5.25
First lien net debt to EBITDA, tier 3			5.00
First lien net debt to EBITDA, tier 4			4.50
First lien net debt to EBITDA, tier 5			4.25
Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity								$ 425,000,000
Credit Facility, Revolving Credit Loans [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage								0.50%
Credit Facility, Revolving Credit Loans [Member] | Credit Facility, Type of Debt, Amendment No. 1 [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 385,000,000
Debt instrument, maturity date			Nov. 19, 2019
Credit Facility, Term Loans [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Equivalent percentage of term loan facility related to net cash proceeds of certain asset sales and dispositions by company and its subsidiaries								100.00%
Equivalent percentage of term loan facility related to net cash proceeds of issuance of certain debt obligations or receivables based financing by company and its subsidiaries								100.00%
Equivalent percentage of term loan facility subject to reduction to lower percentage based on company leverage ratio								75.00%
Credit Facility, Term Loan A [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount					$ 713,000,000
Credit Facility, Term Loan F [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount						$ 1,445,000,000
Credit Facility, Term Loan H [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 1,557,000,000
ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 1,000,000,000
Aggregate principal amount for springing maturity				250,000,000
ABL Credit Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage								0.50%
ABL Credit Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage								0.625%
ABL Credit Agreement [Member] | ABL Facility [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity							$ 860,000,000
Line of credit outstanding amount							$ 273,000,000
Senior Secured Notes at 8.625%, Due 2024 [Member] | Senior Secured Notes [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount										$ 1,033,000,000
Debt instrument, offering date							Jul. 06, 2018
Debt instrument stated interest rate										8.625%
Senior Secured Notes at 8%, Due 2026 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 500,000,000
Senior Secured Notes at 8%, Due 2026 [Member] | Senior Secured Notes [Member]
Debt Instrument [Line Items]
Line of credit outstanding amount	2,101,000,000
Debt instrument, maturity date							Mar. 15, 2026
Debt instrument aggregate principal amount	2,101,000,000	$ 1,601,000,000
Debt instrument, offering date							Mar. 06, 2019
Debt instrument stated interest rate		8.00%
Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount	121,000,000
Senior Notes at 7.125%, Due 2020 [Member] | Senior Secured Notes [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 121,000,000
Alternate Base Rate [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								1.75%
Alternate Base Rate [Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								2.25%
Alternate Base Rate [Member] | ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one								1.25%
Percentage of the maximum commitment of excess availability, two								1.50%
Percentage of the maximum commitment of excess availability, three								1.75%
LIBOR [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								2.75%
LIBOR [Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								3.25%
LIBOR [Member] | ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Percentage of the maximum commitment of excess availability, one								2.25%
Percentage of the maximum commitment of excess availability, two								2.50%
Percentage of the maximum commitment of excess availability, three								2.75%
Three-Months LIBOR [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								1.00%
LIBOR Floor Rate[Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								1.00%
NYFRB Rate [Member] | Credit Facility, Revolving Credit Loans [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								0.50%
Alternate Base Rate Floor [Member] | Credit Facility, Term Loan H [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Debt instrument variable interest rate								2.00%
ABL Facility Customary Covenants [Member] | ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 95,000,000
Debt instrument variable interest rate				10.00%
Letter of Credit [Member] | ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Line of credit outstanding amount							$ 145,000,000
Letter of Credit [Member] | ABL Credit Agreement [Member] | Credit Facility, Type of Debt, Amendment No. 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity				$ 50,000,000					$ 200,000,000

XML

Income Taxes (Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefit, beginning of year	$ 29	$ 18	$ 18
Gross increases - tax positions in current period	10	11
Settlements	(13)
Unrecognized tax benefit, end of year	$ 26	$ 29	$ 18

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8.625% Senior Secured Notes due 2024) (Details) - Senior Secured Notes at 8.625%, Due 2024 [Member] - Senior Secured Notes [Member]		12 Months Ended
	Jul. 06, 2018	Dec. 31, 2019
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	108.625%
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage		104.313%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2021
Debt Instrument, Redemption Period, End Date		Jan. 14, 2022
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage		102.156%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2022
Debt Instrument, Redemption Period, End Date		Jan. 14, 2023
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Jan. 15, 2023
Debt Instrument, Redemption Period, End Date		Jan. 14, 2024

XML

Fair Value of Financial Instruments (Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax Gain (Loss) Recognized in OCI (Effective Portion)	$ (3)	$ 17	$ 2

XML

Long-Term Debt (Schedule of Early Redemption Prices on Junior-Priority Secured Notes due 2023) (Details) - Junior-Priority Secured Notes At 9.875% Due 2023 [Member] - Junior-Priority Secured Notes [Member]	12 Months Ended
	Dec. 31, 2019
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	107.406%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2020
Debt Instrument, Redemption Period, End Date	Jun. 29, 2021
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.703%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2021
Debt Instrument, Redemption Period, End Date	Jun. 29, 2022
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2022
Debt Instrument, Redemption Period, End Date	Jun. 29, 2023

XML

Fair Value (Net Gains and Losses Recognized for Investments in Equity Securities) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Equity Securities, FV-NI, Realized Gain (Loss)	$ 15	$ (7)
Available-for-sale Securities [Member]
Equity Securities, FV-NI, Realized Gain (Loss)	2	1
Held-to-maturity Securities [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss)	$ 13	$ (8)

XML

Long-Term Debt (6.25% Senior Secured Notes, Due 2023 Narrative) (Details) - USD ($)				12 Months Ended
	Feb. 06, 2020	May 12, 2017	Mar. 16, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Issuance of long-term debt				$ 3,042,000,000	$ 1,033,000,000	$ 3,100,000,000
Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Mar. 16, 2017
Debt instrument aggregate principal amount		$ 3,100,000,000	$ 2,200,000,000
Issuance of long-term debt		900,000,000
Debt instrument stated interest rate			6.25%
Senior Secured Notes [Member] | Senior Secured NotesAt 5.125% Due 2018 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount			$ 700,000,000
Secured Debt [Member] | Credit Facility, Term Loan F [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount			$ 1,445,000,000
Secured Debt [Member] | Credit Facility, Term Loan A [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 713,000,000
Subsequent Event [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 426,000,000
Subsequent Event [Member] | Secured Debt [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 426,000,000
Debt instrument stated interest rate	6.25%
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage			100.00%
Debt instrument redemption description				plus a "make-whole" premium, as described in the indenture governing the 6¼% Senior Secured Notes due 2023.
Minimum period notice for redemption of debt			30 days
Maximum period notice for redemption of debt			60 days
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount			40.00%
Debt instrument redemption price percentage			106.25%

XML

Other Comprehensive Income (Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	$ (10)	$ (21)
Other comprehensive income (loss) before reclassifications	1	8
Amounts reclassified from accumulated other comprehensive income		9
Other comprehensive income	1	17	$ 41
Adoption of ASU 2016-01 and 2018-02		(6)
Accumulated Other Comprehensive Income (Loss), Ending Balance	(9)	(10)	(21)
Change in Fair Value of Interest Rate Swaps [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	5	(12)
Other comprehensive income (loss) before reclassifications	(3)	12
Amounts reclassified from accumulated other comprehensive income		8
Other comprehensive income	(3)	20
Adoption of ASU 2016-01 and 2018-02		(3)
Accumulated Other Comprehensive Income (Loss), Ending Balance	2	5	(12)
Change in Fair Value of Available for Sale Debt Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(7)	(2)
Other comprehensive income (loss) before reclassifications	5	(2)
Amounts reclassified from accumulated other comprehensive income	(1)
Other comprehensive income	4	(2)
Adoption of ASU 2016-01 and 2018-02		(3)
Accumulated Other Comprehensive Income (Loss), Ending Balance	(3)	(7)	(2)
Change in Unrecognized Pension Cost Components [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Beginning Balance	(8)	(7)
Other comprehensive income (loss) before reclassifications	(1)	(2)
Amounts reclassified from accumulated other comprehensive income	1	1
Other comprehensive income		(1)
Accumulated Other Comprehensive Income (Loss), Ending Balance	$ (8)	$ (8)	$ (7)

XML

Accounting for Stock-Based Compensation (Narrative) (Details)				12 Months Ended
	Mar. 01, 2019 USD ($) shares	Mar. 01, 2018 USD ($) shares	Mar. 01, 2017 USD ($) shares	Dec. 31, 2019 USD ($) item $ / shares shares	Dec. 31, 2018 item shares	Dec. 31, 2017 item shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, unrecognized compensation costs on nonvested awards | $				$ 13,000,000
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				22 months
Employee service share-based compensation, nonvested awards, modifications to awards | item				0	0	0
Options exercised				0	0	0
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				26 months
Employee service share-based compensation, unrecognized compensation costs on nonvested stock options | $				$ 1,000,000
Weighted-average grant date fair value of stock options | $ / shares				$ 3.05
Share-based compensation arrangement by share-based payment award, options, grants in period				658,500	0	0
Share Price | $ / shares				$ 2.90
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				306,612	296,944	110,988
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,989,000	1,987,000	1,502,000
Restricted Stock and Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation total compensation cost not yet recognized, period for recognition				21 months
Employee service share-based compensation, unrecognized compensation costs on nonvested awards other than options | $				$ 12,000,000
Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights				one-third increments on each of the first three anniversaries of the award date
Unissued common stock reserved for grants				0
Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights				one-third increments on each of the first three anniversaries of the award date
Unissued common stock reserved for grants				5,308,206
Plan 2009 [Member] | Outside Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement award vesting rights				one-third increments on each of the first three anniversaries of the award date
Plan 2009 [Member] | Restricted Stock Units (RSUs) [Member] | Outside Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	34,068	37,118	18,498
Fair value of units granted | $	$ 170,000	$ 170,000	$ 170,000
Contractual Term of Option Granted Prior to 2005 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option granted				10 years
Contractual Term of Option Granted From 2005 Through 2007 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option granted				8 years
Contractual Term Of Option Granted Since 2008 [Member] | Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option granted				10 years
Contractual Term of Option Granted in 2011 or Later [Member] | Plan 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of option granted				10 years

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Restricted Stock, Activity) (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	3,308,907	2,643,919	2,969,285
Granted, Shares	1,989,000	1,987,000	1,502,000
Vested, Shares	(1,160,667)	(1,154,670)	(1,586,855)
Forfeited, Shares	(279,838)	(167,342)	(240,511)
Ending Balance, Unvested Shares	3,857,402	3,308,907	2,643,919
Beginning of Period, Weighted Average Grant Date Fair Value	$ 7.00	$ 16.17	$ 29.39
Granted, Weighted Average Grant Date Fair Value	4.94	4.54	9.10
Vested, Weighted Average Grant Date Fair Value	8.89	23.22	33.91
Forfeited, Weighted Average Grant Date Fair Value	5.60	10.29	18.20
End of Period, Weighted Average Grant Date Fair Value	$ 5.47	$ 7.00	$ 16.17

XML

Contingencies (Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies) (Details) - Pending Litigation [Member] - Other Probable Contingencies [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Loss Contingency Accrual [Roll Forward]
Beginning Balance	$ 19	$ 14
Expense	87	7
Reserve for insured claim	(4)	4
Cash payments	(34)	(6)
Ending Balance	$ 68	$ 19

XML

Acquisitions and Divestitures (Tables)

12 Months Ended

Dec. 31, 2019

Acquisitions and Divestitures [Line Items]

Schedule of Divestitures

			Licensed
Hospital	Buyer	City, State	Beds	Effective Date
2019 Divestitures:
Bluefield Regional Medical Center	Princeton Community Hospital Association	Bluefield, WV	92	October 1, 2019
Lake Wales Medical Center	Adventist Health System	Lake Wales, FL	160	September 1, 2019
Heart of Florida Regional Medical Center	Adventist Health System	Davenport, FL	193	September 1, 2019
College Station Medical Center	St. Joseph Regional Health Center	College Station, TX	167	August 1, 2019
Tennova Healthcare - Lebanon	Vanderbilt University Medical Center	Lebanon, TN	245	August 1, 2019
Chester Regional Medical Center	Medical University Hospital Authority	Chester, SC	82	March 1, 2019
Carolinas Hospital System - Florence	Medical University Hospital Authority	Florence, SC	396	March 1, 2019
Springs Memorial Hospital	Medical University Hospital Authority	Lancaster, SC	225	March 1, 2019
Carolinas Hospital System - Marion	Medical University Hospital Authority	Mullins, SC	124	March 1, 2019
Memorial Hospital of Salem County	Community Healthcare Associates, LLC	Salem, NJ	126	January 31, 2019
Mary Black Health System - Spartanburg	Spartanburg Regional Healthcare System	Spartanburg, SC	207	January 1, 2019
Mary Black Health System - Gaffney	Spartanburg Regional Healthcare System	Gaffney, SC	125	January 1, 2019
2018 Divestitures:
Sparks Regional Medical Center	Baptist Health	Fort Smith, AR	492	November 1, 2018
Sparks Medical Center - Van Buren	Baptist Health	Van Buren, AR	103	November 1, 2018
AllianceHealth Deaconess	INTEGRIS Health	Oklahoma City, OK	238	October 1, 2018
Munroe Regional Medical Center	Adventist Health System	Ocala, FL	425	August 1, 2018
Tennova Healthcare - Dyersburg Regional	West Tennessee Healthcare	Dyersburg, TN	225	June 1, 2018
Tennova Healthcare - Regional Jackson	West Tennessee Healthcare	Jackson, TN	150	June 1, 2018
Tennova Healthcare - Volunteer Martin	West Tennessee Healthcare	Martin, TN	100	June 1, 2018
			Licensed
Hospital	Buyer	City, State	Beds	Effective Date
Williamson Memorial Hospital	Mingo Health Partners, LLC	Williamson, WV	76	June 1, 2018
Byrd Regional Hospital	Allegiance Health Management	Leesville, LA	60	June 1, 2018
Tennova Healthcare - Jamestown	Rennova Health, Inc.	Jamestown, TN	85	June 1, 2018
Bayfront Health Dade City	Adventist Health System	Dade City, FL	120	April 1, 2018
2017 Divestitures:
Highlands Regional Medical Center	HCA Healthcare, Inc. (“HCA”)	Sebring, FL	126	November 1, 2017
Merit Health Northwest Mississippi	Curae Health, Inc.	Clarksdale, MS	181	November 1, 2017
Weatherford Regional Medical Center	HCA	Weatherford, TX	103	October 1, 2017
Brandywine Hospital	Reading Health System	Coatesville, PA	169	October 1, 2017
Chestnut Hill Hospital	Reading Health System	Philadelphia, PA	148	October 1, 2017
Jennersville Hospital	Reading Health System	West Grove, PA	63	October 1, 2017
Phoenixville Hospital	Reading Health System	Phoenixville, PA	151	October 1, 2017
Pottstown Memorial Medical Center	Reading Health System	Pottstown, PA	232	October 1, 2017
Yakima Regional Medical and Cardiac Center	Regional Health	Yakima, WA	214	September 1, 2017
Toppenish Community Hospital	Regional Health	Toppenish, WA	63	September 1, 2017
Memorial Hospital of York	PinnacleHealth System	York, PA	100	July 1, 2017
Lancaster Regional Medical Center	PinnacleHealth System	Lancaster, PA	214	July 1, 2017
Heart of Lancaster Regional Medical Center	PinnacleHealth System	Lititz, PA	148	July 1, 2017
Carlisle Regional Medical Center	PinnacleHealth System	Carlisle, PA	165	July 1, 2017
Tomball Regional Medical Center	HCA	Tomball, TX	350	July 1, 2017
South Texas Regional Medical Center	HCA	Jourdanton, TX	67	July 1, 2017
Deaconess Hospital	MultiCare Health System	Spokane, WA	388	July 1, 2017
Valley Hospital	MultiCare Health System	Spokane Valley, WA	123	July 1, 2017
Lake Area Medical Center	CHRISTUS Health	Lake Charles, LA	88	June 30, 2017
Easton Hospital	Steward Health, Inc.	Easton, PA	196	May 1, 2017
Sharon Regional Health System	Steward Health, Inc.	Sharon, PA	258	May 1, 2017
Northside Medical Center	Steward Health, Inc.	Youngstown, OH	355	May 1, 2017
Trumbull Memorial Hospital	Steward Health, Inc.	Warren, OH	311	May 1, 2017
Hillside Rehabilitation Hospital	Steward Health, Inc.	Warren, OH	69	May 1, 2017
Wuesthoff Health System – Rockledge	Steward Health, Inc.	Rockledge, FL	298	May 1, 2017
Wuesthoff Health System – Melbourne	Steward Health, Inc.	Melbourne, FL	119	May 1, 2017
Sebastian River Medical Center	Steward Health, Inc.	Sebastian, FL	154	May 1, 2017
Stringfellow Memorial Hospital	The Health Care Authority	Anniston, AL	125	May 1, 2017
	of the City of Anniston
Merit Health Gilmore Memorial	Curae Health, Inc.	Amory, MS	95	May 1, 2017
Merit Health Batesville	Curae Health, Inc.	Batesville, MS	112	May 1, 2017

Schedule of Net Operating Revenues and Loss and Assets and Liabilities Classified as Discontinued Operations

	Year Ended
	December 31, 2017
Net operating revenues	$	79
Loss from operations of entities sold or held for sale
before income taxes		(10)
Impairment of hospitals sold or held for sale		(8)
Loss on sale, net		(1)
Loss from discontinued operations, before taxes		(19)
Income tax benefit		(7)
Loss from discontinued operations, net of taxes	$	(12)

Schedule of Balance Sheet Items Classified as Held for Sale

	December 31,
	2019		2018
Other current assets	$	25	$	21
Other assets, net		262		154
Accrued liabilities		43		44

Hospitals Included in Continuing Operations [Member]

Acquisitions and Divestitures [Line Items]

Schedule of Operating Results included in Consolidated Statement of Income

	Year Ended December 31,
	2019		2018		2017
Loss from operations before income taxes	$	(105)	$	(470)	$	(703)
Less: Loss attributable to noncontrolling interests		-		1		(2)
Loss from operations before income taxes attributable
to Community Health Systems, Inc. stockholders	$	(105)	$	(471)	$	(701)

XML

Commitments and Contingencies (Policy)

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies [Abstract]

Legal Matters, Policy

Legal Matters.The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

XML

Leases

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Leases Disclosure

9. LEASES

The Company utilizes operating and finance leases for the use of certain hospitals, medical office buildings, and medical equipment. All lease agreements generally require the Company to pay maintenance, repairs, property taxes and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Such costs are not included in the determination of the ROU asset or lease liability. Variable lease cost also includes escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the Consumer Price Index or other measure of cost inflation. Most leases include one or more options to renew the lease at the end of the initial term, with renewal terms that generally extend the lease at the then market rate of rental payment. Certain leases also include an option to buy the underlying asset at or a short time prior to the termination of the lease. All such options are at the Company’s discretion and are evaluated at the commencement of the lease, with only those that are reasonably certain of exercise included in determining the appropriate lease term. The components of lease cost and rent expense for the year ended December 31, 2019 are as follows (in millions):

	Year Ended
Lease Cost	December 31, 2019
Operating lease cost:
Operating lease cost	$	194
Short-term rent expense		114
Variable lease cost		18
Sublease income		(5)
Total operating lease cost	$	321
Finance lease cost:
Amortization of right-of-use assets	$	12
Interest on finance lease liabilities		7
Total finance lease cost	$	19

Supplemental balance sheet information related to leases was as follows (in millions):

	Balance Sheet Classification	December 31, 2019
Operating Leases:
Operating Lease ROU Assets	Other assets, net	$	607
Finance Leases:
Finance Lease ROU Assets	Property and equipment
	Land and improvements	$	8
	Buildings and improvements		154
	Equipment and fixtures		11
	Property and equipment		173
	Less accumulated depreciation and amortization		(56)
	Property and equipment, net	$	117
Current finance lease liabilities	Current maturities of long-term debt	$	6
Long-term finance lease liabilities	Long-term debt		107

Supplemental cash flow and other information related to leases as of and for the year ended December 31, 2019 are as follows (dollars in millions):

	Year Ended
Other information	December 31, 2019
Cash paid for amounts included in the measurement
of lease liabilities:
Operating cash flows from operating leases (1)	$	167
Operating cash flows from finance leases		7
Financing cash flows from finance leases		9
Right-of-use assets obtained in exchange for new
finance lease liabilities		2
Right-of-use assets obtained in exchange for new
operating lease liabilities		122
Weighted-average remaining lease term:
Operating leases		6 years
Finance leases		20 years
Weighted-average discount rate:
Operating leases		9.1	%
Finance leases		5.6	%
__________
(1) Included in the change in other operating assets and libilities in the consolidated statement of cash flows.

On September 19, 2019, the Company completed the sale and leaseback of four medical office buildings for net proceeds of $56 million to Carter Validus Mission Critical REIT II, Inc. The buildings, with a combined total of 285,337 square feet, are located in three states and support a wide array of diagnostic, medical and surgical services in an outpatient setting for the respective nearby hospitals. Based on the Company’s assessment of the control transfer principle in these leased buildings, the transaction did not qualify for sale treatment and the related leases have been recorded as financing obligations in long-term debt in the Company’s consolidated balance sheet at December 31, 2019. In addition, on December 18, 2019, the Company completed the sale and leaseback of one medical office building for net proceeds of approximately $4 million to an affiliate of Catalyst Healthcare Real Estate. The 30,000 square foot building is located in Arkansas and supports a wide array of diagnostic, medical and surgical services in an outpatient setting for the nearby hospital. Based on the Company’s assessment of the control transfer principle in this leased building, the transaction does not qualify for sale treatment and the related lease has been recorded as a financing obligation in long-term debt in the accompanying consolidated balance sheet at December 31, 2019.

On December 22, 2016, the Company completed the sale and leaseback of ten medical office buildings for net proceeds of $159 million to HCP, Inc. The buildings, with a combined total of 756,183 square feet, are located in five states and support a wide array of diagnostic, medical and surgical services in an outpatient setting for the respective nearby hospitals. Because of the Company’s continuing involvement in these leased buildings, the transaction did not qualify for sale treatment and the related leases have been recorded as financing obligations in long-term debt in the Company’s consolidated balance sheet at December 31, 2018. Upon adoption of ASC 842 on January 1, 2019, the Company reevaluated the classification of these financing arrangements utilizing the new accounting requirements for sale-leasebacks in ASC 842, concluding that these financing arrangements continue to not qualify for sale treatment and therefore should continue to be classified as financing obligations in long-term debt. At December 31, 2019, six of these financing obligations remain outstanding and are included in the table below, with the other four medical office buildings having been divested in conjunction with the sale of the related hospital entity.

Commitments relating to noncancellable operating and finance leases and financing obligations for each of the next five years and thereafter are as follows (in millions):

					Financing
Year Ending December 31,	Operating		Finance		Obligations
2020	$	184	$	12	$	12
2021		150		11		12
2022		115		9		12
2023		92		8		12
2024		71		8		13
Thereafter		213		156		114
Total minimum future payments		825		204		175
Less:  Imputed interest		(202)		(91)		(16)
Total liabilities		623		113		159
Less:  Current portion		(136)		(6)		(1)
Long-term liabilities	$	487	$	107	$	158

As previously disclosed in the Company’s 2018 Form 10-K, which followed the lease accounting in effect prior to adoption of ASC 842, future commitments relating to noncancellable operating and capital leases and financing obligations for the five years and period thereafter as of December 31, 2018 were as follows (in millions):

						Financing
Year Ending December 31,	Operating (1)			Capital		Obligations
2019	$	188		$	12	$	12
2020		157			10		9
2021		121			8		10
2022		98			7		10
2023		79			14		10
Thereafter		234			121		106
Total minimum future payments	$	877			172		157
Less:  Imputed interest					(80)		(18)
Total capital lease and financing obligations			-		92		139
Less:  Current portion					(8)		(5)
Long-term capital lease and financing obligations			-	$	84	$	134

__________

(1)Minimum lease payments have not been reduced by minimum sublease rentals due in the future, which are considered immaterial.

As of December 31, 2019, there were approximately $29 million of assets underlying approved but pending leases that have not yet commenced, primarily for medical equipment.

XML

Basis of Presentation and Significant Accounting Policies

12 Months Ended

Dec. 31, 2019

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies Disclosure

1.  BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Business.    Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals in communities across the country. As of December 31, 2019, the Company owned or leased 102 hospitals, included in continuing operations, including two stand-alone rehabilitation or psychiatric hospitals, licensed for 16,240 beds in 18 states. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

As of December 31, 2019, Florida, Texas and Indiana represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated operating revenues, were 14.3% in both 2019 and 2018 and 14.0% in 2017. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated operating revenues, were 12.2% in 2019, 11.7% in 2018 and 10.9% in 2017. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated operating revenues, were 13.7% in 2019, 12.5% in 2018 and 11.6% in 2017.

Use of Estimates.    The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

Principles of Consolidation.    The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from continuing operations from these subsidiaries are included in the consolidated amounts as presented on the consolidated statements of loss, along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the consolidated balance sheets.

Cost of Revenue.    Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $184 million, $181 million and $189 million for the years ended December 31, 2019, 2018 and 2017, respectively. Included in these corporate office costs is stock-based compensation of $10 million, $13 million and $24 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Cash Equivalents.    The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.

Supplies.    Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.

Marketable Securities.    Prior to adoption of Accounting Standards Update (“ASU”) 2016-01 on January 1, 2018, the Company’s marketable securities were classified as trading or available-for-sale. Trading securities were reported at fair value with unrealized gains and losses included in earnings. Available-for-sale securities were carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. After adoption of ASU 2016-01 on January 1, 2018, the Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Equity securities are reported at fair value with changes in fair value included in earnings. Available-for-sale debt securities are carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized gain of $4 million and $8 million during the years ended December 31, 2019 and 2017, respectively, and an unrealized loss of $2 million during the year ended December 31, 2018, related to these available-for-sale debt securities.

Property and Equipment.    Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $219 million at both December 31, 2019 and 2018. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $20 million, $15 million and $11 million for the years ended December 31, 2019, 2018 and 2017, respectively. Purchases of property and equipment and internal-use software accrued in accounts payable and not yet paid were $93 million and $115 million at December 31, 2019 and 2018, respectively.

The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2019, the Company had non-cash investing activity of $6 million related to certain facility and equipment additions that were financed through finance leases and other debt.

Goodwill.    Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. As further discussed in Note 4, the Company recorded an impairment charge of $1.419 billion during the year ended December 31, 2017. There was no goodwill impairment charge during the years ended December 31, 2019 and 2018 as a result of the Company’s annual impairment evaluation.

Other Assets.    Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured malpractice general liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software and eight to ten years for major software projects, and included in amortization expense. Included in the increase in other investments in the consolidated statement of cash flows for the year ended December 31, 2019, was cash paid of approximately $28 million to increase investments in certain equity method investments.

Revenue Recognition.  On January 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the FASB Accounting Standards Codification (“ASC”) as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, upon the Company’s adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore was included as a reduction to net operating revenues in 2019 and 2018. For changes in credit issues not assessed at the date of service, the Company prospectively recognizes those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required such provision to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately $3.9 billion as of January 1, 2018 was reclassified as a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated results of operations for the years ended December 31, 2019 and 2018, and the Company does not expect it to have a material impact on its consolidated results of operations on a prospective basis.

As part of the adoption of ASC 606, the Company elected two of the available practical expedients provided for in the standard. First, the Company does not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expenses all incremental customer contract acquisition costs as incurred because such costs are not material and would be amortized over a period less than one year.

Net Operating Revenues

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During the years ended December 31, 2019 and 2018, the impact of changes to the inputs used to determine the transaction price was considered immaterial to the current period.

States utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses.

The Company’s net operating revenues during the years ended December 31, 2019 and 2018 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions):

	Year Ended December 31,
	2019			2018
Medicare	$	3,331	-	$	3,730
Medicaid		1,736			1,876
Managed Care and other third-party payors		8,014			8,349
Self-pay		129			200
Total	$	13,210		$	14,155

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts) by payor have been presented in the following table for the year ended December 31, 2017, as follows, consistent with the presentation prior to the adoption of ASC 606 on January 1, 2018 (in millions):

	Year Ended
	December 31, 2017
Medicare	$	4,188
Medicaid		1,900
Managed Care and other third-party payors		9,991
Self-pay		2,319
Total	$	18,398

Patient Accounts Receivable   

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.  

Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $83 million and $144 million as of December 31, 2019 and December 31, 2018, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due from third-party payors were $137 million and $155 million as of December 31, 2019 and December 31, 2018, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2016.

Charity Care

In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government.

These charity care services are estimated to be $540 million, $491 million and $482 million for the years ended December 31, 2019, 2018 and 2017, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $66 million, $62 million and $62 million for the years ended December 31, 2019, 2018 and 2017, respectively. The estimated cost of these charity care services was determined using a ratio of cost to gross charges and applying that ratio to the gross charges associated with providing care to charity patients for the period.

During 2017 and culminating with the financial close process at December 31, 2017, the Company developed new accounting methodologies and processes to implement ASU 2014-09, the accounting standard for revenue recognition that was adopted by the Company effective January 1, 2018. By implementing new data extraction techniques and updated hindsight information on historical collection data, the Company was able to better estimate the net amount after contractual allowances owed by the third-party payor and what will be owed by the patient based on historical experience. Such updated information included portfolio-level data related to historical collection amounts on an individual hospital and patient level that previously had not been readily available. Using this information the Company created a new accounting process by which it can estimate contractual allowances on a per patient basis. In addition to this new accounting methodology, the Company also revised its methods of estimating contractual allowances to (1) expand the hindsight period over which the Company analyzes payors’ historical paid claims data to estimate contractual allowances, (2) expand the basis for payor denied claims to refine the hindsight reserve for such denials, and (3) adjust the contractual allowances for certain categories of commercial payors using more precise historical experience based on recent patterns of account reimbursement. Additionally, the Company evaluated the estimated collection of those amounts due from the patient as part of the Company’s estimate of the allowance for doubtful accounts. This analysis also included an evaluation of patient accounts receivable retained after the divestiture of 30 hospitals throughout 2017, and certain other revenues. Based on these new accounting processes and methodologies, the Company recorded a change in estimate during the three months ended December 31, 2017 to increase contractual allowances by approximately $197 million, and to record additional provision for bad debts and increase the allowance for doubtful accounts by $394 million. The total impact of the change in estimate recorded during the three months ended December 31, 2017 was a decrease to net operating revenues of $591 million.

Electronic Health Records Incentive Reimbursement.The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $1 million, $4 million and $28 million for the years ended December 31, 2019, 2018 and 2017, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the consolidated statements of loss. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately less than $1 million, $4 million and $41 million for the years ended December 31, 2019, 2018 and 2017, respectively. The Company recorded no deferred revenue in connection with the receipt of these cash payments at December 31, 2019, 2018 or 2017.

Leases. On January 1, 2019, the Company adopted the cumulative accounting standard updates initially issued by the FASB in February 2016 that amend the accounting for leases and are codified as Accounting Standards Codification Topic 842 (“ASC 842”). These changes to the lease accounting model require operating leases be recorded on the balance sheet through recognition of a liability for the discounted present value of future fixed lease payments and a corresponding right-of-use (“ROU”) asset. The Company’s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

   The Company elected the amended transition requirements allowed for by the FASB in ASU 2018-11, which provide entities relief by allowing them not to recast prior comparative periods from the adoption of ASC 842. As a result, the prior year comparative financial statements have not been restated to reflect the adoption of ASC 842. Additionally, the Company elected the package of practical expedients available in ASC 842 upon adoption whereby an entity need not reassess expired contracts for lease identification or classification as a finance or operating lease, or for the reassessment of initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. Certain of the Company’s lease agreements have lease and non-lease components, which for the majority of leases the Company accounts for separately when the actual lease and non-lease components are determinable. For equipment leases with immaterial non-lease components incorporated into the fixed rent payment, the Company accounts for the lease and non-lease components as a single lease component in determining the lease payment. Additionally, for certain individually insignificant equipment leases such as copiers, the Company applies a portfolio approach to effectively record the operating lease liability and ROU asset.

   The adoption of ASC 842 had a material impact on the Company’s consolidated balance sheet through the recording of the operating lease liabilities and related ROU assets for leases in effect at January 1, 2019, but the adoption did not have a material impact on the Company’s consolidated statement of loss or consolidated statement of cash flows for the year ended December 31, 2019. The Company recorded approximately $673 million of operating lease liabilities and ROU assets on January 1, 2019 upon adoption of ASC 842, with no impact on accumulated deficit.

Physician Income Guarantees.    The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. The Company amortizes an asset over the life of the agreement. As of December 31, 2019 and 2018, the unamortized portion of these physician income guarantees was $20 million and $24 million, respectively, and is recorded in other assets in the consolidated balance sheet.

Concentrations of Credit Risk.    The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $268 million and $283 million at December 31, 2019 and 2018, respectively, representing 5% of consolidated net accounts receivable at both December 31, 2019 and 2018.

Accounting for the Impairment or Disposal of Long-Lived Assets.    During the year ended December 31, 2019, the Company recorded a total combined impairment charge and loss on disposal of approximately $138 million, of which (i) approximately $92 million was recorded to reduce the carrying value of closed hospitals and certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell and (ii) approximately $46 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals or where the Company is in discussions with potential buyers for divestiture at a sales price that indicates a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2019 is a net allocation of approximately $167 million of goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit. The Company will continue to evaluate the potential for further impairment of the long-lived assets of underperforming hospitals as well as evaluate offers for potential sales. Based on such analysis, additional impairment charges may be recorded in the future.

During the year ended December 31, 2018, the Company recorded a total combined impairment charge and loss on disposal of approximately $668 million, of which (i) approximately $423 million was recordedto reduce the carrying value of certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell, (ii) approximately $29 million was recorded to write-off the value of a promissory note received as consideration for the sale of three hospitals in 2017 where the buyer entered into bankruptcy proceedings, and (iii) approximately $216 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals that have ceased operations or where the Company was in discussions with potential buyers for divestiture at a sales price that indicated a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2018 is a net allocation of approximately $186 millionof goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit.

Income Taxes.    The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statement of loss during the period in which the tax rate change becomes law.

Comprehensive Loss.    Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segment Reporting.A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company's acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services).

Derivative Instruments and Hedging Activities.    The Company records derivative instruments on the consolidated balance sheet as either an asset or liability measured at its fair value. Changes in a derivative’s fair value are recorded each period in earnings or other comprehensive income (“OCI”), depending on whether the derivative is designated and is effective as a hedged transaction, and on the type of hedge transaction. Changes in the fair value of derivative instruments recorded to OCI are reclassified to earnings in the period affected by the underlying hedged item. Any portion of the fair value of a derivative instrument determined to be ineffective under the standard is recognized in current earnings. The Company has entered into several interest rate swap agreements and had one such agreement outstanding as of December 31, 2019. See Note 7 for further discussion about the swap transactions.

New Accounting Pronouncements.In August 2018, the FASB issued ASU 2018-15 to provide guidance on the accounting for implementation costs incurred in a cloud computing arrangement that is accounted for as a service contract. This ASU requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

In June 2016, the FASB issued ASU 2016-13, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

XML

Income Taxes

12 Months Ended

Dec. 31, 2019

Income Taxes [Abstract]

Income Taxes Disclosure

5.  INCOME TAXES

The provision for (benefit from) income taxes for loss from continuing operations consists of the following (in millions):

		Year Ended December 31,
	2019		2018		2017
Current:
Federal	$	(38)	$	1	$	-
State		(5)		(9)		5
		(43)		(8)		5
Deferred:
Federal		179		50		(485)
State		24		(53)		31
		203		(3)		(454)
Total provision for (benefit from) income taxes for loss
fromcontinuing operations	$	160	$	(11)	$	(449)

The following table reconciles the differences between the statutory federal income tax rate and the effective tax rate (dollars in millions):

	Year Ended December 31,
	2019				2018				2017
	Amount		%		Amount		%		Amount		%
Benefit from income
taxes at statutory federal rate	$	(90)	21.0	%	$	(150)	21.0	%	$	(991)	35.0	%
State income taxes, net of federal
income tax benefit		(104)	24.3			(114)	16.0			(10)	0.3
Net income attributable to
noncontrolling interests		(18)	4.2			(18)	2.5			(22)	0.8
Change in valuation allowance		340	(79.2)			212	(29.7)			26	(0.9)
Change in uncertain tax position		-	-			9	(1.3)			-	-
Federal rate change		-	-			-	-			32	(1.1)
Federal and state tax credits		-	-			(17)	2.4			(5)	0.1
Nondeductible goodwill		11	(2.6)			30	(4.2)			504	(17.8)
Nondeductible settlements		-	-			22	(3.1)			-	-
Nondeductible loss on divestiture		15	(3.5)			-	-			-	-
Other		6	(1.4)			15	(2.1)			17	(0.6)
Provision for (benefit from) income
taxes and effective tax rate for
loss from continuing operations	$	160	(37.2)	%	$	(11)	1.5	%	$	(449)	15.8	%

The Company’s effective tax rates were (37.2)%,  1.5% and 15.8% for the years ended December 31, 2019, 2018 and 2017, respectively. The decrease in the Company’s effective tax rate for the year ended December 31, 2019, when compared to the year ended December 31, 2018, was primarily due to an increase in the valuation allowance recognized on (i) IRC Section 163(j) interest carryforwards and (ii) original issue discount deferred tax asset generated with the 2019 Exchange Offer. The decrease in the Company’s effective tax rate for the year ended December 31, 2018, when compared to the year ended December 31, 2017, was primarily due to the increase in valuation allowance recognized on IRC Section 163(j) interest carryforwards partially offset by the release of certain state valuation allowances on net operating loss carryforwards in certain jurisdictions.

Deferred income taxes are based on the estimated future tax effects of differences between the financial statement and tax bases of assets and liabilities under the provisions of the enacted tax laws. Deferred income taxes as of December 31, 2019 and 2018 consist of (in millions):

	December 31,
	2019				2018
	Assets		Liabilities		Assets		Liabilities
Net operating loss and credit carryforwards	$	775	$	-	$	743	$	-
Property and equipment		-		335		-		237
Self-insurance liabilities		48		-		69		-
Prepaid expenses		-		30		-		27
Intangibles		-		149		-		134
Investments in unconsolidated affiliates		-		57		-		55
Other liabilities		-		9		-		14
IRC Section 481(a) - mixed service cost		-		216		-		-
Long-term debt and interest		312		-		84		-
Accounts receivable		62		-		58		-
IRC Section 163(j) interest limitation		296		-		144		-
Accrued vacation		24		-		26		-
Accrued bonus		31		-		-		-
Other comprehensive income		5		-		4		-
Right-of-use assets		-		145		-		-
Right-of-use liability		149		-		-		-
Stock-based compensation		5		-		4		-
Deferred compensation		70		-		64		-
Other		51		-		15		-
Total		1,828		941		1,211		467
Valuation allowance		(1,049)		-		(701)		-
Total deferred income taxes	$	779	$	941	$	510	$	467

The Company believes that the net deferred tax assets will ultimately be realized, except as noted below. Its conclusion is based on its estimate of future taxable income and the expected timing of temporary difference reversals. The Company has gross federal net operating loss carryforwards of approximately $662 million and state net operating loss carryforwards of approximately $8.6 billion, which expire from 2020 to 2039. The Company’s tax affected federal and state net operating loss and credit carryforwards are approximately $169 million and $606 million, respectively. A valuation allowance of approximately $1.0 billion has been recognized for state net operating loss carryforwards, state credit carryforwards and federal and state deferred tax assets that the Company does not expect to be able to utilize prior to the expiration of the carryforward period. With respect to the deferred tax liability pertaining to intangibles, as included above, goodwill purchased in connection with certain of the Company’s business acquisitions is amortizable for income tax reporting purposes. However, for financial reporting purposes, there is no corresponding amortization allowed with respect to such purchased goodwill.

The valuation allowance for federal and state jurisdictions where the Company concluded that the associated deferred tax assets would not be realized increased by $221 million and $127million, respectively, for the year ended December 31, 2019, and increased by $151 million and $17 million, respectively, for the year ended December 31, 2018.

The total amount of unrecognized benefit that would affect the effective tax rate, if recognized, was approximately $1 million as of December 31, 2019. A total of approximately $1 million of interest and penalties is included in the amount of the liability for uncertain tax positions at December 31, 2019. It is the Company’s policy to recognize interest and penalties related to unrecognized benefits in its consolidated statements of loss as income tax expense.

It is possible the amount of unrecognized tax benefit could change in the next 12 months as a result of a lapse of the statute of limitations and settlements with taxing authorities; however, the Company does not anticipate the change will have a material impact on the Company’s consolidated results of operations or consolidated financial position.

The following is a tabular reconciliation of the total amount of unrecognized tax benefit for the years ended December 31, 2019, 2018 and 2017 (in millions):

	Year Ended December 31,
	2019		2018		2017
Unrecognized tax benefit, beginning of year	$	29	$	18	$	18
Gross increases — tax positions in current period		10		11		-
Settlements		(13)		-		-
Unrecognized tax benefit, end of year	$	26	$	29	$	18

The Company’s federal income tax returns for the 2009 and 2010 tax years have been settled with the Internal Revenue Service. The results of these examinations were not material to the Company’s consolidated results of operations or consolidated financial position. The Company’s federal income tax returns for the 2014 and 2015 tax years remain under examination by the Internal Revenue Service. The Company believes the results of these examinations will not be material to its consolidated results of operations or consolidated financial position. The Company has extended the federal statute of limitations through December 31, 2020 for the tax periods ended December 31, 2014 and 2015.

Cash paid for income taxes, net of refunds received, resulted in a net refund of $3 million and $19 million during the years ended December 31, 2019 and 2018, respectively, and net cash paid of $4 million during the year ended December 31, 2017.

XML

Equity Investments

12 Months Ended

Dec. 31, 2019

Equity Investments [Abstract]

Equity Investments Disclosure

13.  EQUITY INVESTMENTS

As of December 31, 2019, the Company owned equity interests of 38.0% in two hospitals in Macon, Georgia, in which HCA owns the majority interest. On December 31, 2016, the Company sold 80% of its ownership interest in the legal entity that owned and operated its home care agency business. As part of the divestiture of its controlling interest in the home care agency business, the Company recorded an equity method investment representing its remaining 20% ownership.

In March 2005, the Company began purchasing items, primarily medical supplies, medical equipment and pharmaceuticals, under an agreement with HealthTrust Purchasing Group, L.P. (“HealthTrust”), a group purchasing organization in which the Company is a noncontrolling partner. As of December 31, 2019, the Company had a 14.5% ownership interest in HealthTrust.

The Company’s investment in all of its unconsolidated affiliates was $199 million and $192 million at December 31, 2019 and 2018, respectively, and is included in other assets, net in the accompanying consolidated balance sheets. Included in the Company’s results of operations is the Company’s equity in pre-tax earnings from all of its investments in unconsolidated affiliates, which was $15 million, $22 million and $16 million for the years ended December 31, 2019, 2018 and 2017, respectively.

XML

Quarterly Financial Data

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data [Abstract]

Quarterly Financial Data Disclosure

17.  QUARTERLY FINANCIAL DATA (UNAUDITED)

	Quarter
	1st		2nd		3rd		4th			Total (2)
	(in millions, except share and per share data)
Year ended December 31, 2019:
Net operating revenues	$	3,376	$	3,302	$	3,246	$	3,286	$	13,210
Loss from continuing operations
before income taxes		(94)		(149)		(72)		(115)		(430)
Loss from continuing operations		(101)		(146)		2		(346)		(590)
Loss from discontinued operations		-		-		-		-		-
Net loss attributable to Community
Health Systems, Inc.	$	(118)	$	(167)	$	(17)	$	(373)	$	(675)
Basic loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Discontinued operations		-		-		-		-		-
Net loss	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Diluted loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Discontinued operations		-		-		-		-		-
Net loss	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Weighted-average number of shares outstanding:
Basic		113,257,608		113,862,097		113,891,721		113,935,629		113,739,046
Diluted		113,257,608		113,862,097		113,891,721		113,935,629		113,739,046
Year ended December 31, 2018:
Net operating revenues	$	3,689	$	3,562	$	3,451	$	3,453	$	14,155
Loss from continuing operations
before income taxes		(13)		(129)		(204)		(369)		(715)
Loss from continuing operations		(6)		(91)		(308)		(299)		(704)
Loss from discontinued operations		-		-		-		-		-
Net loss attributable to Community
Health Systems, Inc.	$	(25)	$	(110)	$	(325)	$	(328)	$	(788)
Basic loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Discontinued operations		-		-		-		-		-
Net loss	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Diluted loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Discontinued operations		-		-		-		-		-
Net loss	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Weighted-average number of shares outstanding:
Basic		112,291,496		112,837,944		112,865,482		112,909,869		112,728,274
Diluted		112,291,496		112,837,944		112,865,482		112,909,869		112,728,274
(1) Total per share amounts may not add due to rounding.
(2) Total quarterly amounts may not add due to rounding.

XML

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (590)	$ (704)	$ (2,396)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	608	700	861
Deferred income taxes	203	(3)	(454)
Government and other legal settlements and related costs	51	11	9
Stock-based compensation expense	10	13	24
Impairment of hospitals sold or held for sale			6
Impairment and loss on sale of businesses, net	138	668	2,123
Loss (gain) from early extinguishment of debt	54	(31)	40
Other non-cash expenses, net	182	38	35
Changes in operating assets and liabilities, net of effects of acquisitions and divestitures:
Patient accounts receivable	93	31	732
Supplies, prepaid expenses and other current assets	38	16	(33)
Accounts payable, accrued liabilities and income taxes	(157)	(163)	(69)
Payment of HMA legal settlement		(266)
Other	(245)	(36)	(105)
Net cash provided by operating activities	385	274	773
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(13)	(26)	(6)
Purchases of property and equipment	(438)	(527)	(564)
Proceeds from disposition of hospitals and other ancillary operations	604	405	1,692
Proceeds from sale of property and equipment	3	8	7
Purchases of available-for-sale debt securities and equity securities	(80)	(78)	(125)
Proceeds from sales of available-for-sale debt securities and equity securities	92	114	208
Increase in other investments	(170)	(141)	(143)
Net cash (used in) provided by investing activities	(2)	(245)	1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(1)	(1)	(5)
Deferred financing costs and other debt-related costs	(46)	(96)	(66)
Proceeds from noncontrolling investors in joint ventures	10	3	5
Redemption of noncontrolling investments in joint ventures	(11)	(31)	(6)
Distributions to noncontrolling investors in joint ventures	(99)	(96)	(100)
Proceeds from sale-lease back	60
Borrowings under credit agreements	37	28	841
Issuance of long-term debt	3,042	1,033	3,100
Proceeds from ABL facility	202	797	105
Repayments of long-term indebtedness	(3,557)	(2,033)	(5,391)
Net cash used in financing activities	(363)	(396)	(1,517)
Net change in cash and cash equivalents	20	(367)	325
Cash and cash equivalents at beginning of period	196	563	238
Cash and cash equivalents at end of period	216	196	563
Supplemental disclosure of cash flow information:
Interest payments	(1,011)	(936)	(852)
Income tax refunds (payments), net	$ 3	$ 19	$ (4)

XML

Document and Entity Information - USD ($)

12 Months Ended

Dec. 31, 2019

Feb. 18, 2020

Jun. 30, 2019

Document and Entity Information [Abstract]

Document Type

10-K

Document Annual Report

true

Document Period End Date

Dec. 31, 2019

Document Transition Report

false

Entity File Number

001-15925

Entity Registrant Name

COMMUNITY HEALTH SYSTEMS INC

Entity Incorporation, State or Country Code

DE

Entity Tax Identification Number

13-3893191

Entity Address, Address Line One

4000 Meridian Boulevard

Entity Address, City or Town

Franklin

Entity Address, State or Province

TN

Entity Address, Postal Zip Code

37067

City Area Code

615

Local Phone Number

465-7000

Title of 12(b) Security

Common Stock, $.01 par value

Trading Symbol

CYH

Security Exchange Name

NYSE

Document Fiscal Year Focus

2019

Document Fiscal Period Focus

FY

Current Fiscal Year End Date

--12-31

Entity Central Index Key

0001108109

Amendment Flag

false

Entity Well-known Seasoned Issuer

Yes

Entity Voluntary Filers

No

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Filer Category

Accelerated Filer

Entity Small Business

false

Entity Emerging Growth Company

false

Entity Shell Company

false

Entity Public Float

$ 295,833,589

Entity Common Stock, Shares Outstanding

117,856,892

Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

  Certain information required for Part III of this annual report is incorporated by reference to portions of the Registrant’s definitive proxy statement for its 2020 annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2019.

XML

Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Comprehensive Loss [Abstract]
Net change in fair value of interest rate swaps, tax	$ 1	$ 6	$ 10
Amortization and recognition of unrecognized pension cost components, tax	$ 0	$ 1	$ 9

XML

Earnings Per Share (Schedule of Components of Denominator for Computation of Basic and Diluted Loss Per Share) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Numerator:
Loss from continuing operations, net of taxes	$ (346)	$ 2	$ (146)	$ (101)	$ (299)	$ (308)	$ (91)	$ (6)	$ (590)	[1]	$ (704)	[1]	$ (2,384)
Less: Income attributable to noncontrolling interests, net of taxes									85		84		63
Loss from continuing operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted									(675)		(788)		(2,447)
Loss from discontinued operations, net of taxes													(12)
Less: Loss from discontinued operations attributable to noncontrolling interests, net of taxes
Loss from discontinued operations attributable to Community Health Systems, Inc. common stockholders - basic and diluted													$ (12)
Effect of dilutive securities:
Weighted-average number of shares outstanding - basic	113,935,629	113,891,721	113,862,097	113,257,608	112,909,869	112,865,482	112,837,944	112,291,496	113,739,046	[1]	112,728,274	[1]	111,769,821
Restricted stock awards
Employee stock options
Other equity-based awards
Weighted-average number of shares outstanding - diluted	113,935,629	113,891,721	113,862,097	113,257,608	112,909,869	112,865,482	112,837,944	112,291,496	113,739,046	[1]	112,728,274	[1]	111,769,821

[1] Total quarterly amounts may not add due to rounding.

XML

Long-Term Debt (Schedule of Maturities of Long-Term Debt) (Details) $ in Millions	Dec. 31, 2019 USD ($)
Long-term Debt, Fiscal Year Maturity
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 20
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,010
Long-term Debt, Maturities, Repayments of Principal in Year Three	237
Long-term Debt, Maturities, Repayments of Principal in Year Four	5,149
Long-term Debt, Maturities, Repayments of Principal in Year Five	2,393
Long-term Debt, Maturities, Repayments of Principal after Year Five	4,743
Total maturities	13,552
Less: Deferred debt issuance costs	(132)
Plus Unamortized note premium	(15)
Total debt	$ 13,405

XML

Income Taxes (Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Differences between the statutory federal income tax rate and the effective tax rate
Benefit for income taxes at statutory federal rate, Amount	$ (90)	$ (150)	$ (991)
State income taxes, net of federal income tax benefit, Amount	(104)	(114)	(10)
Net income attributable to noncontrolling interests, Amount	(18)	(18)	(22)
Change in valuation allowance, Amount	340	212	26
Change in uncertain tax position, Amount		9
Federal rate change, Amount			32
Federal and state tax credits, Amount		(17)	(5)
Nondeductible goodwill, Amount	11	30	504
Nondeductible settlments, Amount		22
Nondeductible loss on divestiture, Amount	15
Other, Amount	6	15	17
Total provision for (benefit from) income taxes for loss from continuing operations	$ 160	$ (11)	$ (449)
Provision for income taxes at statutory federal rate, Percentage	21.00%	21.00%	35.00%
State income taxes, net of federal income tax benefit, Percentage	24.30%	16.00%	0.30%
Net income attributable to noncontrolling interests, Percentage	4.20%	2.50%	0.80%
Change in valuation allowance, Percentage	(79.20%)	(29.70%)	(0.90%)
Change in uncertain tax position, Percentage		(1.30%)
Federal rate change, Percentage			(1.10%)
Federal and state tax credits, Percentage		2.40%	0.10%
Nondeductible goodwill, Percentage	(2.60%)	(4.20%)	(17.80%)
Nondeductible settlements, Percentage		(3.10%)
Nondeductible loss on divestiture, Percentage	(3.50%)
Other, Percentage	(1.40%)	(2.10%)	(0.60%)
Benefit from income taxes from continuing operations, Percentage	(37.20%)	1.50%	15.80%

XML

Long-Term Debt (Junior-Priority Secured Notes At 9.875% due 2023 Narrative) (Details) - USD ($)		12 Months Ended
	Jun. 22, 2018	Dec. 31, 2019	Mar. 21, 2012	Nov. 22, 2011
Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 1,770,000,000
Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date		Jun. 22, 2018
Debt instrument aggregate principal amount	$ 1,770,000,000
Debt instrument stated interest rate	11.00%
Debt instrument redemption description		plus a "make-whole" premium, as described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023.
Senior Notes [Member] | Senior Notes at 8.0%, Due 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date		Nov. 22, 2011
Debt instrument aggregate principal amount				$ 1,000,000,000
Debt instrument stated interest rate			8.00%	8.00%
Debt Instrument, Redemption, Period One [Member] | Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%
Debt Instrument, Redemption, Period Two [Member] | Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days

XML

Leases (Components of Lease Cost and Rent Expense) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Operating lease cost	$ 194
Short-term rent expense	114
Variable lease cost	18
Sublease Income	(5)
Total operating lease cost	321
Finance lease cost:
Amortization of right-of-use assets	12
Interest on finance lease liabilities	7
Total finance lease cost	$ 19

XML

Acquisitions and Divestitures (Schedule of Divestitures) (Details) - item	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Bluefield Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	92
Effective Date	Oct. 01, 2019
Lake Wales Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	160
Effective Date	Sep. 01, 2019
Heart of Florida Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	193
Effective Date	Sep. 01, 2019
College Station Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	167
Effective Date	Aug. 01, 2019
Tennova Healthcare Lebanon [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	245
Effective Date	Aug. 01, 2019
Chester Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	82
Effective Date	Mar. 01, 2019
Carolinas Hospital System - Florence [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	396
Effective Date	Mar. 01, 2019
Springs Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	225
Effective Date	Mar. 01, 2019
Carolinas Hospital System - Marion [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	124
Effective Date	Mar. 01, 2019
Memorial Hospital of Salem County [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	126
Effective Date	Jan. 31, 2019
Mary Black Health System - Spartanburg [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	207
Effective Date	Jan. 01, 2019
Mary Black Health System - Gaffney [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds	125
Effective Date	Jan. 01, 2019
Sparks Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		492
Effective Date		Nov. 01, 2018
Sparks Medical Center - Van Buren [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		103
Effective Date		Nov. 01, 2018
AllianceHealth Deaconess [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		238
Effective Date		Oct. 01, 2018
Munroe Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		425
Effective Date		Aug. 01, 2018
Tennova Healthcare -Dyersburg Regional [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		225
Effective Date		Jun. 01, 2018
Tennova Healthcare - Regional Jackson [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		150
Effective Date		Jun. 01, 2018
Tennova Healthcare - Volunteer Martin [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		100
Effective Date		Jun. 01, 2018
Williamson Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		76
Effective Date		Jun. 01, 2018
Byrd Regional Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		60
Effective Date		Jun. 01, 2018
Tennova Healthcare - Jamestown [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		85
Effective Date		Jun. 01, 2018
Bayfront Health Dade City [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds		120
Effective Date		Apr. 01, 2018
Highlands Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			126
Effective Date			Nov. 01, 2017
Merit Health Northwest Mississippi [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			181
Effective Date			Nov. 01, 2017
Weatherford Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			103
Effective Date			Oct. 01, 2017
Brandywine Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			169
Effective Date			Oct. 01, 2017
Chestnut Hill Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			148
Effective Date			Oct. 01, 2017
Jennersville Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			63
Effective Date			Oct. 01, 2017
Phoenixville Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			151
Effective Date			Oct. 01, 2017
Pottstown Memorial Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			232
Effective Date			Oct. 01, 2017
Yakima Regional Medical and Cardiac Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			214
Effective Date			Sep. 01, 2017
Toppenish Community Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			63
Effective Date			Sep. 01, 2017
Memorial Hospital of York [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			100
Effective Date			Jul. 01, 2017
Lancaster Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			214
Effective Date			Jul. 01, 2017
Heart of Lancaster Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			148
Effective Date			Jul. 01, 2017
Carlisle Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			165
Effective Date			Jul. 01, 2017
Tomball Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			350
Effective Date			Jul. 01, 2017
South Texas Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			67
Effective Date			Jul. 01, 2017
Deaconess Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			388
Effective Date			Jul. 01, 2017
Valley Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			123
Effective Date			Jul. 01, 2017
Lake Area Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			88
Effective Date			Jun. 30, 2017
Easton Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			196
Effective Date			May 01, 2017
Sharon Regional Health System [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			258
Effective Date			May 01, 2017
Northside Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			355
Effective Date			May 01, 2017
Trumbull Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			311
Effective Date			May 01, 2017
Hillside Rehabilitation Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			69
Effective Date			May 01, 2017
Wuesthoff Health System - Rockledge [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			298
Effective Date			May 01, 2017
Wuesthoff Health System - Melbourne [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			119
Effective Date			May 01, 2017
Sebastian River Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			154
Effective Date			May 01, 2017
Stringfellow Memorial Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			125
Effective Date			May 01, 2017
Merit Health Gilmore Memorial [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			95
Effective Date			May 01, 2017
Merit Health Batesville [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of licensed beds			112
Effective Date			May 01, 2017

XML

Goodwill and Other Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Roll Forward]
Goodwill Gross, Balance, beginning period	$ 7,373	$ 7,537
Accumulated impairment losses, Balance, beginning of period	(2,814)	(2,814)
Goodwill, Balance, beginning of period	4,559	4,723
Goodwill acquired as part of acquisitions during current year	4	22
Goodwill allocated to hospitals held for sale	(235)	(186)
Goodwill Gross, Balance, end of period	7,142	7,373
Accumulated impairment losses, Balance, end of period	(2,814)	(2,814)
Goodwill, Balance, end of year	$ 4,328	$ 4,559

XML

Leases (Commitments Relating to Noncancellable Lease Obligations) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Operating Leases
2020	$ 184
2021	150
2022	115
2023	92
2024	71
Thereafter	213
Total minimum future payments	825
Less: Imputed interest	(202)
Total liabilities	623
Less: current portion	(136)
Long-term liabilities	487
Finance Leases
2020	12
2021	11
2022	9
2023	8
2024	8
Thereafter	156
Total minimum future payments	204
Less: Imputed interest	(91)
Total liabilities	113
Less: Current portion	(6)
Long-term liabilities	107
Financing Obligations
2020	12
2021	12
2022	12
2023	12
2024	13
Thereafter	114
Total minimum future payments	175
Less: Imputed interest	(16)
Total financing obligations	159
Less: Current portion	(1)
Long-term liabilities	$ 158
Lease Accounting Prior to Adoption of ASC 842 [Member]
Operating Leases
2019		$ 188
2020		157
2021		121
2022		98
2023		79
Thereafter		234
Total minimum future payments		877
Capital Leases
2019		12
2020		10
2021		8
2022		7
2023		14
Thereafter		121
Total minimum future payments		172
Less: Imputed interest		(80)
Total capital lease obligations		92
Less: Current portion		(8)
Long-term capital lease obligations		84
Financing Obligations
2019		12
2020		9
2021		10
2022		10
2023		10
Thereafter		106
Total minimum future payments		157
Less: Imputed interest		(18)
Total financing obligations		139
Less: Current portion		(5)
Long-term liabilities		$ 134

XML

Long-Term Debt (8% Senior Secured Notes, Due 2027 Narrative) (Details) - Senior Secured Notes At 8% Due 2027 [Member] - USD ($)		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2019
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%
Senior Secured Notes [Member]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%
Debt instrument redemption description		plus a "make-whole" premium, as described in the indenture governing the 8% Senior Secured Notes due 2027.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member]
Debt instrument redemption price percentage	100.00%	104.00%
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member]
Debt instrument redemption price percentage	108.00%	102.00%

XML

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies [Abstract]

Schedule of Reconciliation of the Beginning and Ending Liability Balances in Connection with Probable Contingencies

	Probable
	Contingencies
Balance as of December 31, 2017	$	14
Expense		7
Reserve for insured claim		4
Cash payments		(6)
Balance as of December 31, 2018		19
Expense		87
Reserve for insured claim		(4)
Cash payments		(34)
Balance as of December 31, 2019	$	68

XML

Leases (Tables)

12 Months Ended

Dec. 31, 2019

Leases [Abstract]

Components of Lease Cost and Rent Expense

	Year Ended
Lease Cost	December 31, 2019
Operating lease cost:
Operating lease cost	$	194
Short-term rent expense		114
Variable lease cost		18
Sublease income		(5)
Total operating lease cost	$	321
Finance lease cost:
Amortization of right-of-use assets	$	12
Interest on finance lease liabilities		7
Total finance lease cost	$	19

Supplemental Balance Sheet Information Related to Leases

	Balance Sheet Classification	December 31, 2019
Operating Leases:
Operating Lease ROU Assets	Other assets, net	$	607
Finance Leases:
Finance Lease ROU Assets	Property and equipment
	Land and improvements	$	8
	Buildings and improvements		154
	Equipment and fixtures		11
	Property and equipment		173
	Less accumulated depreciation and amortization		(56)
	Property and equipment, net	$	117
Current finance lease liabilities	Current maturities of long-term debt	$	6
Long-term finance lease liabilities	Long-term debt		107

Supplemental Cash Flow and Other Information Related to Leases

	Year Ended
Other information	December 31, 2019
Cash paid for amounts included in the measurement
of lease liabilities:
Operating cash flows from operating leases (1)	$	167
Operating cash flows from finance leases		7
Financing cash flows from finance leases		9
Right-of-use assets obtained in exchange for new
finance lease liabilities		2
Right-of-use assets obtained in exchange for new
operating lease liabilities		122
Weighted-average remaining lease term:
Operating leases		6 years
Finance leases		20 years
Weighted-average discount rate:
Operating leases		9.1	%
Finance leases		5.6	%
__________
(1) Included in the change in other operating assets and libilities in the consolidated statement of cash flows.

Commitments Relating to Noncancellable Operating and Finance Leases and Financing Obligations

					Financing
Year Ending December 31,	Operating		Finance		Obligations
2020	$	184	$	12	$	12
2021		150		11		12
2022		115		9		12
2023		92		8		12
2024		71		8		13
Thereafter		213		156		114
Total minimum future payments		825		204		175
Less:  Imputed interest		(202)		(91)		(16)
Total liabilities		623		113		159
Less:  Current portion		(136)		(6)		(1)
Long-term liabilities	$	487	$	107	$	158

Schedule of Future Minimum Lease Payments for Operating and Capital Leases

						Financing
Year Ending December 31,	Operating (1)			Capital		Obligations
2019	$	188		$	12	$	12
2020		157			10		9
2021		121			8		10
2022		98			7		10
2023		79			14		10
Thereafter		234			121		106
Total minimum future payments	$	877			172		157
Less:  Imputed interest					(80)		(18)
Total capital lease and financing obligations			-		92		139
Less:  Current portion					(8)		(5)
Long-term capital lease and financing obligations			-	$	84	$	134

__________

(1)Minimum lease payments have not been reduced by minimum sublease rentals due in the future, which are considered immaterial.

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 216	$ 196
Patient accounts receivable	2,258	2,352
Supplies	354	402
Prepaid income taxes	48	3
Prepaid expenses and taxes	193	196
Other current assets	358	400
Total current assets	3,427	3,549
Property and equipment, net	5,608	6,139
Goodwill	4,328	4,559	$ 4,723
Deferred income taxes	38	69
Other assets, net	2,208	1,543
Total assets	15,609	15,859
Current liabilities:
Current maturities of long-term debt	20	204
Current operating lease liabilities	136
Accounts payable	811	887
Accrued interest	189	206
Accrued liabilities	1,126	1,095
Total current liabilities	2,282	2,392
Long-term debt	13,385	13,392
Deferred income taxes	200	26
Long-term operating lease liabilities	487
Other long-term liabilities	894	1,008
Total liabilities	17,248	16,818
Redeemable noncontrolling interests in equity of consolidated subsidiaries	502	504
Community Health Systems, Inc. stockholders' deficit:
Preferred stock
Common stock	1	1
Additional paid-in capital	2,008	2,017
Accumulated other comprehensive (loss) income	(9)	(10)	(21)
(Accumulated deficit) retained earnings	(4,218)	(3,543)
Total Community Health Systems, Inc. stockholders' deficit	(2,218)	(1,535)
Noncontrolling interests in equity of consolidated subsidiaries	77	72
Total stockholders' deficit	(2,141)	(1,463)	$ (692)	$ 1,728
Total liabilities and stockholders' deficit	15,609	15,859
Consolidation, Eliminations [Member]
Current assets:
Intercompany receivable	(24,625)	(23,855)
Net investment in subsidiaries	(34,169)	(32,526)
Total assets	(58,794)	(56,381)
Current liabilities:
Intercompany payable	(64,045)	(60,876)
Total liabilities	(64,045)	(60,876)
Community Health Systems, Inc. stockholders' deficit:
Additional paid-in capital	1,297	1,121
Accumulated other comprehensive (loss) income	19	24
(Accumulated deficit) retained earnings	3,935	3,350
Total Community Health Systems, Inc. stockholders' deficit	5,251	4,495
Total stockholders' deficit	5,251	4,495
Total liabilities and stockholders' deficit	(58,794)	(56,381)
Parent Company [Member]
Current assets:
Prepaid income taxes	48	3
Total current assets	48	3
Deferred income taxes	38	69
Other assets, net	(4)
Total assets	82	72
Current liabilities:
Intercompany payable	2,099	1,572
Deferred income taxes	200	26
Other long-term liabilities	1	9
Total liabilities	2,300	1,607
Community Health Systems, Inc. stockholders' deficit:
Common stock	1	1
Additional paid-in capital	2,008	2,017
Accumulated other comprehensive (loss) income	(9)	(10)
(Accumulated deficit) retained earnings	(4,218)	(3,543)
Total Community Health Systems, Inc. stockholders' deficit	(2,218)	(1,535)
Total stockholders' deficit	(2,218)	(1,535)
Total liabilities and stockholders' deficit	82	72
Subsidiary Issuer [Member]
Current assets:
Intercompany receivable	11,961	12,615
Other assets, net		25
Net investment in subsidiaries	21,736	20,742
Total assets	33,697	33,382
Current liabilities:
Current maturities of long-term debt		155
Accounts payable	11
Accrued interest	189	205
Accrued liabilities	1	1
Total current liabilities	201	361
Long-term debt	13,116	13,167
Intercompany payable	22,518	21,318
Other long-term liabilities	2	2
Total liabilities	35,837	34,848
Community Health Systems, Inc. stockholders' deficit:
Additional paid-in capital	(487)	(329)
Accumulated other comprehensive (loss) income	(9)	(10)
(Accumulated deficit) retained earnings	(1,644)	(1,127)
Total Community Health Systems, Inc. stockholders' deficit	(2,140)	(1,466)
Total stockholders' deficit	(2,140)	(1,466)
Total liabilities and stockholders' deficit	33,697	33,382
Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	142	132
Patient accounts receivable	1,822	1,844
Supplies	242	269
Prepaid expenses and taxes	152	134
Other current assets	72	84
Total current assets	2,430	2,463
Intercompany receivable	5,674	4,882
Property and equipment, net	4,206	4,371
Goodwill	2,628	2,704
Other assets, net	1,203	796
Net investment in subsidiaries	12,433	11,784
Total assets	28,574	27,000
Current liabilities:
Current maturities of long-term debt	18	22
Current operating lease liabilities	82
Accounts payable	518	574
Accrued liabilities	650	531
Total current liabilities	1,268	1,127
Long-term debt	208	151
Intercompany payable	26,029	24,901
Long-term operating lease liabilities	265
Other long-term liabilities	580	619
Total liabilities	28,350	26,798
Community Health Systems, Inc. stockholders' deficit:
Additional paid-in capital	198	193
Accumulated other comprehensive (loss) income	(11)	(11)
(Accumulated deficit) retained earnings	37	20
Total Community Health Systems, Inc. stockholders' deficit	224	202
Total stockholders' deficit	224	202
Total liabilities and stockholders' deficit	28,574	27,000
Non-Guarantor Subsidiaries [Member]
Current assets:
Cash and cash equivalents	74	64
Patient accounts receivable	436	508
Supplies	112	133
Prepaid expenses and taxes	41	62
Other current assets	286	316
Total current assets	949	1,083
Intercompany receivable	6,990	6,358
Property and equipment, net	1,402	1,768
Goodwill	1,700	1,855
Other assets, net	1,009	722
Total assets	12,050	11,786
Current liabilities:
Current maturities of long-term debt	2	27
Current operating lease liabilities	54
Accounts payable	282	313
Accrued interest		1
Accrued liabilities	475	563
Total current liabilities	813	904
Long-term debt	61	74
Intercompany payable	13,399	13,085
Long-term operating lease liabilities	222
Other long-term liabilities	311	378
Total liabilities	14,806	14,441
Redeemable noncontrolling interests in equity of consolidated subsidiaries	502	504
Community Health Systems, Inc. stockholders' deficit:
Additional paid-in capital	(1,008)	(985)
Accumulated other comprehensive (loss) income	1	(3)
(Accumulated deficit) retained earnings	(2,328)	(2,243)
Total Community Health Systems, Inc. stockholders' deficit	(3,335)	(3,231)
Noncontrolling interests in equity of consolidated subsidiaries	77	72
Total stockholders' deficit	(3,258)	(3,159)
Total liabilities and stockholders' deficit	$ 12,050	$ 11,786

XML

Other Comprehensive Income

12 Months Ended

Dec. 31, 2019

Stockholders' Deficit [Abstract]

Other Comprehensive Income Disclosure

14.  OTHER COMPREHENSIVE INCOME

The following tables present information about items reclassified out of accumulated other comprehensive loss by component for the years ended December 31, 2019 and 2018 (in millions, net of tax):

			Change in		Change in
	Change in Fair		Fair Value of		Unrecognized		Accumulated Other
	Value of Interest		Available-for-Sale		Pension Cost		Comprehensive
	Rate Swaps		Debt Securities		Components		(Loss) Income
Balance as of December 31, 2018	$	5	$	(7)	$	(8)	$	(10)
Other comprehensive (loss)
income before reclassifications		(3)		5		(1)		1
Amounts reclassified from
accumulated other
comprehensive (loss) income		-		(1)		1		-
Net current-period other
comprehensive (loss) income		(3)		4		-		1
Balance as of December 31, 2019	$	2	$	(3)	$	(8)	$	(9)

			Change in		Change in
	Change in Fair		Fair Value of		Unrecognized		Accumulated Other
	Value of Interest		Available-for-Sale		Pension Cost		Comprehensive
	Rate Swaps		Debt Securities		Components		(Loss) Income
Balance as of December 31, 2017	$	(12)	$	(2)	$	(7)	$	(21)
Other comprehensive income
(loss) before reclassifications		12		(2)		(2)		8
Amounts reclassified from
accumulated other
comprehensive income		8		-		1		9
Net current-period other
comprehensive income (loss)		20		(2)		(1)		17
Adoption of ASU 2016-01 and 2018-02		(3)		(3)		-		(6)
Balance as of December 31, 2018	$	5	$	(7)	$	(8)	$	(10)

The following tables present a subtotal for each significant reclassification to net loss out of AOCL and the line item affected in the accompanying consolidated statements of loss for the years ended December 31, 2019 and 2018 (in millions):

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Year Ended		statement where net
comprehensive income (loss) components	December 31, 2019		income (loss) is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	-	Interest expense, net
		-	Tax benefit
	$	-	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Settlement losses recognized		-	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Year Ended		statement where net
comprehensive (loss) income components	December 31, 2018		(loss) income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(10)	Interest expense, net
		2	Tax benefit
	$	(8)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Settlement losses recognized		(2)	Salaries and benefits
		(3)	Total before tax
		2	Tax benefit
	$	(1)	Net of tax

XML

Supplemental Condensed Consolidating Financial Information

12 Months Ended

Dec. 31, 2019

Supplemental Condensed Consolidating Financial Information [Abstract]

Supplemental Condensed Consolidating Financial Information Disclosure

18.  SUPPLEMENTAL CONDENSED CONSOLIDATING FINANCIAL INFORMATION

The 6⅞% Senior Notes due 2022, which are senior unsecured obligations of CHS, the 5⅛% Senior Secured Notes due 2021, and the 6¼% Senior Secured Notes due 2023 (collectively, “the Notes”) are guaranteed on a senior basis by the Company and by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries. In addition, equity interests held by the Company in non-guarantor subsidiaries have been pledged as collateral under the Notes, except for equity interests held in three hospitals owned jointly with a non-profit, health organization.The Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or a sale of all of the subsidiary guarantor’s assets used in operations. The following condensed consolidating financial statements present Community Health Systems, Inc. (as parent guarantor), CHS (as the issuer), the subsidiary guarantors, the subsidiary non-guarantors and eliminations. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the consolidated financial statements of the Company, except as noted below:

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net.

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ deficit. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances.

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the ABL Facility and Receivables Facility that are further discussed in Note 6. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation.

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods have been revised to reflect the status of guarantors and non-guarantors as of December 31, 2019.

Condensed Consolidating Statement of Loss
Year Ended December 31, 2019
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net operating revenues	$	-	$	46	$	8,246	$	4,918	$	-	$	13,210
Operating costs and expenses:
Salaries and benefits		-		-		3,092		2,855		-		5,947
Supplies		-		-		1,444		707		-		2,151
Other operating expenses		-		-		2,289		1,014		-		3,303
Government and other legal settlements and
related costs		-		-		93		-		-		93
Electronic health records incentive reimbursement		-		-		-		(1)		-		(1)
Lease cost and rent		-		-		168		153		-		321
Depreciation and amortization		-		-		383		225		-		608
Impairment and loss on sale of businesses, net		-		(2)		121		19		-		138
Total operating costs and expenses		-		(2)		7,590		4,972		-		12,560
Income (loss) from operations		-		48		656		(54)		-		650
Interest expense, net		-		425		667		(51)		-		1,041
Loss from early extinguishment of debt		-		54		-		-		-		54
Equity in earnings of unconsolidated affiliates		675		99		(26)		-		(763)		(15)
(Loss) income before income taxes		(675)		(530)		15		(3)		763		(430)
Provision for (benefit from) income taxes		-		145		(6)		21		-		160
Net (loss) income		(675)		(675)		21		(24)		763		(590)
Less: Net income attributable to noncontrolling interests		-		-		-		85		-		85
Net (loss) income attributable to Community Health
Systems, Inc. stockholders	$	(675)	$	(675)	$	21	$	(109)	$	763	$	(675)

Condensed Consolidating Statement of Loss
Year Ended December 31, 2018
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net operating revenues	$	-	$	(5)	$	8,111	$	6,049	$	-	$	14,155
Operating costs and expenses:
Salaries and benefits		-		-		3,030		3,354		-		6,384
Supplies		-		-		1,426		929		-		2,355
Other operating expenses		-		-		2,109		1,387		-		3,496
Government and other legal settlements and
related costs		-		-		11		-		-		11
Electronic health records incentive reimbursement		-		-		(1)		(3)		-		(4)
Lease cost and rent		-		-		166		171		-		337
Depreciation and amortization		-		-		414		286		-		700
Impairment and loss on sale of businesses, net		-		29		97		542		-		668
Total operating costs and expenses		-		29		7,252		6,666		-		13,947
(Loss) income from operations		-		(34)		859		(617)		-		208
Interest expense, net		-		425		494		57		-		976
(Gain) loss from early extinguishment of debt		-		(32)		1		-		-		(31)
Equity in earnings of unconsolidated affiliates		788		438		774		-		(2,022)		(22)
Loss before income taxes		(788)		(865)		(410)		(674)		2,022		(715)
(Benefit from) provision for income taxes		-		(77)		(7)		73		-		(11)
Net loss		(788)		(788)		(403)		(747)		2,022		(704)
Less: Net income attributable to noncontrolling interests		-		-		-		84		-		84
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(788)	$	(788)	$	(403)	$	(831)	$	2,022	$	(788)

Condensed Consolidating Statement of Loss
Year Ended December 31, 2017
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(22)	$	9,421	$	8,999	$	-	$	18,398
Provision for bad debts		-		-		1,819		1,226		-		3,045
Net operating revenues		-		(22)		7,602		7,773		-		15,353
Operating costs and expenses:
Salaries and benefits		-		-		3,092		4,284		-		7,376
Supplies		-		-		1,397		1,275		-		2,672
Other operating expenses		-		-		1,954		1,910		-		3,864
Government and other legal settlements and
related costs		-		-		(31)		-		-		(31)
Electronic health records incentive reimbursement		-		-		(8)		(20)		-		(28)
Rent		-		-		166		228		-		394
Depreciation and amortization		-		-		434		427		-		861
Impairment and loss on sale of businesses, net		-		-		608		1,515		-		2,123
Total operating costs and expenses		-		-		7,612		9,619		-		17,231
Loss from operations		-		(22)		(10)		(1,846)		-		(1,878)
Interest expense, net		-		327		489		115		-		931
Loss from early extinguishment of debt		-		40		-		-		-		40
Equity in earnings of unconsolidated affiliates		2,459		1,888		1,555		-		(5,918)		(16)
Loss from continuing operations before
income taxes		(2,459)		(2,277)		(2,054)		(1,961)		5,918		(2,833)
Provision for (benefit from) income taxes		-		182		(170)		(461)		-		(449)
Loss from continuing operations		(2,459)		(2,459)		(1,884)		(1,500)		5,918		(2,384)
Discontinued operations, net of taxes:
Loss from operations of entities sold or
held for sale		-		-		(4)		(2)		-		(6)
Impairment of hospitals sold or held for sale		-		-		(4)		(2)		-		(6)
Loss from discontinued operations, net of taxes		-		-		(8)		(4)		-		(12)
Net loss		(2,459)		(2,459)		(1,892)		(1,504)		5,918		(2,396)
Less: Net income attributable to noncontrolling interests		-		-		-		63		-		63
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(2,459)	$	(2,459)	$	(1,892)	$	(1,567)	$	5,918	$	(2,459)

Condensed Consolidating Statement of Comprehensive (Loss) Income
Year Ended December 31, 2019
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net (loss) income	$	(675)	$	(675)	$	21	$	(24)	$	763	$	(590)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(3)		(3)		-		-		3		(3)
Net change in fair value of available-for-sale debt
securities, net of tax		4		4		4		-		(8)		4
Amortization and recognition of unrecognized pension
cost components, net of tax		-		-		-		-		-		-
Other comprehensive income		1		1		4		-		(5)		1
Comprehensive (loss) income		(674)		(674)		25		(24)		758		(589)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		85		-		85
Comprehensive (loss) income attributable to
Community Health Systems, Inc. stockholders	$	(674)	$	(674)	$	25	$	(109)	$	758	$	(674)

Condensed Consolidating Statement of Comprehensive Loss
Year Ended December 31, 2018
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(788)	$	(788)	$	(403)	$	(747)	$	2,022	$	(704)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		20		20		-		-		(20)		20
Net change in fair value of available-for-sale debt
securities, net of tax		(2)		(2)		(2)		-		4		(2)
Amortization and recognition of unrecognized pension
cost components, net of tax		(1)		(1)		(1)		-		2		(1)
Other comprehensive income (loss)		17		17		(3)		-		(14)		17
Comprehensive loss		(771)		(771)		(406)		(747)		2,008		(687)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		84		-		84
Comprehensive loss attributable to
Community Health Systems, Inc. stockholders	$	(771)	$	(771)	$	(406)	$	(831)	$	2,008	$	(771)

Condensed Consolidating Statement of Comprehensive Loss
Year Ended December 31, 2017
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(2,459)	$	(2,459)	$	(1,892)	$	(1,504)	$	5,918	$	(2,396)
Other comprehensive income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		19		19		-		-		(19)		19
Net change in fair value of available-for-sale debt
securities, net of tax		8		8		8		-		(16)		8
Amortization and recognition of unrecognized pension
cost components, net of tax		14		14		14		-		(28)		14
Other comprehensive income		41		41		22		-		(63)		41
Comprehensive loss		(2,418)		(2,418)		(1,870)		(1,504)		5,855		(2,355)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		63		-		63
Comprehensive loss attributable to
Community Health Systems, Inc. stockholders	$	(2,418)	$	(2,418)	$	(1,870)	$	(1,567)	$	5,855	$	(2,418)

Condensed Consolidating Balance Sheet
December 31, 2019
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	142	$	74	$	-	$	216
Patient accounts receivable		-		-		1,822		436		-		2,258
Supplies		-		-		242		112		-		354
Prepaid income taxes		48		-		-		-		-		48
Prepaid expenses and taxes		-		-		152		41		-		193
Other current assets		-		-		72		286		-		358
Total current assets		48		-		2,430		949		-		3,427
Intercompany receivable		-		11,961		5,674		6,990		(24,625)		-
Property and equipment, net		-		-		4,206		1,402		-		5,608
Goodwill		-		-		2,628		1,700		-		4,328
Deferred income taxes		38		-		-		-		-		38
Other assets, net		(4)		-		1,203		1,009		-		2,208
Net investment in subsidiaries		-		21,736		12,433		-		(34,169)		-
Total assets	$	82	$	33,697	$	28,574	$	12,050	$	(58,794)	$	15,609
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	-	$	18	$	2	$	-	$	20
Current operating lease liabilities		-		-		82		54		-		136
Accounts payable		-		11		518		282		-		811
Accrued interest		-		189		-		-		-		189
Accrued liabilities		-		1		650		475		-		1,126
Total current liabilities		-		201		1,268		813		-		2,282
Long-term debt		-		13,116		208		61		-		13,385
Intercompany payable		2,099		22,518		26,029		13,399		(64,045)		-
Deferred income taxes		200		-		-		-		-		200
Long-term operating lease liabilities		-		-		265		222		-		487
Other long-term liabilities		1		2		580		311		-		894
Total liabilities		2,300		35,837		28,350		14,806		(64,045)		17,248
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		502		-		502
(Deficit) equity:
Community Health Systems, Inc. stockholders’
(deficit) equity:
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,008		(487)		198		(1,008)		1,297		2,008
Accumulated other comprehensive (loss) income		(9)		(9)		(11)		1		19		(9)
(Accumulated deficit) retained earnings		(4,218)		(1,644)		37		(2,328)		3,935		(4,218)
Total Community Health Systems, Inc.
stockholders’ (deficit) equity		(2,218)		(2,140)		224		(3,335)		5,251		(2,218)
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		77		-		77
Total (deficit) equity		(2,218)		(2,140)		224		(3,258)		5,251		(2,141)
Total liabilities and (deficit) equity	$	82	$	33,697	$	28,574	$	12,050	$	(58,794)	$	15,609

Condensed Consolidating Balance Sheet
December 31, 2018
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	132	$	64	$	-	$	196
Patient accounts receivable		-		-		1,844		508		-		2,352
Supplies		-		-		269		133		-		402
Prepaid income taxes		3		-		-		-		-		3
Prepaid expenses and taxes		-		-		134		62		-		196
Other current assets		-		-		84		316		-		400
Total current assets		3		-		2,463		1,083		-		3,549
Intercompany receivable		-		12,615		4,882		6,358		(23,855)		-
Property and equipment, net		-		-		4,371		1,768		-		6,139
Goodwill		-		-		2,704		1,855		-		4,559
Deferred income taxes		69		-		-		-		-		69
Other assets, net		-		25		796		722		-		1,543
Net investment in subsidiaries		-		20,742		11,784		-		(32,526)		-
Total assets	$	72	$	33,382	$	27,000	$	11,786	$	(56,381)	$	15,859
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	155	$	22	$	27	$	-	$	204
Accounts payable		-		-		574		313		-		887
Accrued interest		-		205		-		1		-		206
Accrued liabilities		-		1		531		563		-		1,095
Total current liabilities		-		361		1,127		904		-		2,392
Long-term debt		-		13,167		151		74		-		13,392
Intercompany payable		1,572		21,318		24,901		13,085		(60,876)		-
Deferred income taxes		26		-		-		-		-		26
Other long-term liabilities		9		2		619		378		-		1,008
Total liabilities		1,607		34,848		26,798		14,441		(60,876)		16,818
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		504		-		504
(Deficit) equity:
Community Health Systems, Inc. stockholders’
(deficit) equity:
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,017		(329)		193		(985)		1,121		2,017
Accumulated other comprehensive loss		(10)		(10)		(11)		(3)		24		(10)
(Accumulated deficit) retained earnings		(3,543)		(1,127)		20		(2,243)		3,350		(3,543)
Total Community Health Systems, Inc.
stockholders’ (deficit) equity		(1,535)		(1,466)		202		(3,231)		4,495		(1,535)
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		72		-		72
Total (deficit) equity		(1,535)		(1,466)		202		(3,159)		4,495		(1,463)
Total liabilities and (deficit) equity	$	72	$	33,382	$	27,000	$	11,786	$	(56,381)	$	15,859

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2019
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(4)	$	(348)	$	600	$	137	$	-	$	385
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(6)		(7)		-		(13)
Purchases of property and equipment		-		-		(366)		(72)		-		(438)
Proceeds from disposition of hospitals
and other ancillary operations		-		18		30		556		-		604
Proceeds from sale of property and equipment		-		-		1		2		-		3
Purchases of available-for-sale debt securities
and equity securities		-		-		(19)		(61)		-		(80)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		31		61		-		92
Increase in other investments		-		-		(123)		(47)		-		(170)
Net cash provided by (used in)
investing activities		-		18		(452)		432		-		(2)
Cash flows from financing activities:
Repurchase of restricted stock shares for
payroll tax withholding requirements		(1)		-		-		-		-		(1)
Deferred financing costs and other debt-related
costs		-		(46)		-		-		-		(46)
Proceeds from noncontrolling investors in
joint ventures		-		-		-		10		-		10
Redemption of noncontrolling investments in
joint ventures		-		-		-		(11)		-		(11)
Distributions to noncontrolling investors in
joint ventures		-		-		-		(99)		-		(99)
Proceeds from sale-lease back		-		-		60		-		-		60
Changes in intercompany balances with
affiliates, net		5		619		(189)		(435)		-		-
Borrowings under credit agreements		-		-		36		1		-		37
Issuance of long-term debt		-		3,042		-		-		-		3,042
Proceeds from ABL Facility		-		202		-		-		-		202
Repayments of long-term indebtedness		-		(3,487)		(45)		(25)		-		(3,557)
Net cash provided by (used in)
financing activities		4		330		(138)		(559)		-		(363)
Net change in cash and cash equivalents		-		-		10		10		-		20
Cash and cash equivalents at beginning of period		-		-		132		64		-		196
Cash and cash equivalents at end of period	$	-	$	-	$	142	$	74	$	-	$	216

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2018
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash provided by (used in) operating
activities	$	40	$	(409)	$	560	$	83	$	-	$	274
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(3)		(23)		-		(26)
Purchases of property and equipment		-		-		(408)		(119)		-		(527)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		1		404		-		405
Proceeds from sale of property and equipment		-		-		5		3		-		8
Purchases of available-for-sale debt securities
and equity securities		-		-		(54)		(24)		-		(78)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		79		35		-		114
Increase in other investments		-		(7)		(112)		(22)		-		(141)
Net cash (used in) provided
by investing activities		-		(7)		(492)		254		-		(245)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(1)		-		-		-		-		(1)
Deferred financing costs and other
debt-related costs		-		(96)		-		-		-		(96)
Proceeds from noncontrolling investors in joint
ventures		-		-		-		3		-		3
Redemption of noncontrolling investments in joint
ventures		-		-		-		(31)		-		(31)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(96)		-		(96)
Changes in intercompany balances with
affiliates, net		(39)		99		176		(236)		-		-
Borrowings under credit agreements		-		-		28		-		-		28
Issuance of long-term debt		-		1,033		-		-		-		1,033
Proceeds from ABL Facility		-		748		49		-		-		797
Repayments of long-term indebtedness		-		(1,368)		(655)		(10)		-		(2,033)
Net cash (used in) provided by financing
activities		(40)		416		(402)		(370)		-		(396)
Net change in cash and cash equivalents		-		-		(334)		(33)		-		(367)
Cash and cash equivalents at beginning of period		-		-		466		97		-		563
Cash and cash equivalents at end of period	$	-	$	-	$	132	$	64	$	-	$	196

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2017
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(12)	$	(317)	$	431	$	671	$	-	$	773
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(1)		(5)		-		(6)
Purchases of property and equipment		-		-		(356)		(208)		-		(564)
Proceeds from disposition of hospitals and other
ancillary operations		-		-		122		1,570		-		1,692
Proceeds from sale of property and equipment		-		-		3		4		-		7
Purchases of available-for-sale debt securities
and equity securities		-		-		(91)		(34)		-		(125)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		172		36		-		208
Increase in other investments		-		-		(100)		(43)		-		(143)
Net cash (used in) provided by investing
activities		-		-		(251)		1,320		-		1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(5)		-		-		-		-		(5)
Deferred financing costs and other
debt-related costs		-		(65)		(1)		-		-		(66)
Proceeds from noncontrolling investors in joint
ventures		-		-		-		5		-		5
Redemption of noncontrolling investments in joint
ventures		-		-		-		(6)		-		(6)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(100)		-		(100)
Changes in intercompany balances with
affiliates, net		17		1,565		331		(1,913)		-		-
Borrowings under credit agreements		-		795		30		16		-		841
Issuance of long-term debt		-		3,100		-		-		-		3,100
Proceeds from ABL Facility		-		-		105		-		-		105
Repayments of long-term indebtedness		-		(5,078)		(285)		(28)		-		(5,391)
Net cash provided by (used in) financing
activities		12		317		180		(2,026)		-		(1,517)
Net change in cash and cash equivalents		-		-		360		(35)		-		325
Cash and cash equivalents at beginning of period		-		-		106		132		-		238
Cash and cash equivalents at end of period	$	-	$	-	$	466	$	97	$	-	$	563

XML

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (590)	$ (704)	$ (2,396)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(3)	20	19
Net change in fair value of available-for-sale debt securities, net of tax	4	(2)	8
Amortization and recognition of unrecognized pension cost components, net of tax		(1)	14
Other comprehensive income	1	17	41
Comprehensive loss	(589)	(687)	(2,355)
Less: Comprehensive income attributable to noncontrolling interests	85	84	63
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	$ (674)	$ (771)	$ (2,418)

XML

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($) $ in Millions	Redeemable Noncontrolling Interests (Non- Equity) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficiet [Member]	Noncontrolling Interest [Member]	Total
Equity, beginning balance at Dec. 31, 2016		$ 1	$ 1,975	$ (62)	$ (299)	$ 113	$ 1,728
Redeemable Noncontrolling Interests, beginning balance at Dec. 31, 2016	$ 554
Shares, outstanding, beginning balance at Dec. 31, 2016		113,876,580
Comprehensive income (loss)				41	(2,459)	25	(2,393)
Comprehensive income (loss) attributable to redeemable noncontrolling interest	38
Contributions from noncontrolling interests						5	5
Distributions to noncontrolling interests						(29)	(29)
Distributions to redeemable noncontrolling interests	(71)
Purchase of subsidiary shares from noncontrolling interests	(4)		(2)				(2)
Disposition of less-than-wholly owned hospital						(10)	(10)
Disposition of less-than-wholly owned hospital	2
Noncontrolling interests in acquired entity	1
Other reclassifications of noncontrolling interests						(29)	(29)
Other reclassifications of redeemable noncontrolling interests	29
Adjustment to redemption value of redeemable noncontrolling interests			22				22
Adjustment to redemption value of redeemable noncontrolling interests	(22)
Distribution of Quorum Health Corporation					(3)		(3)
Cancellation of restricted stock for tax withholdings on vested shares			(5)				(5)
Cancellation of restricted stock for tax withholdings on vested shares, shares		(560,098)
Stock-based compensation			24				24
Stock-based compensation, shares		1,334,522
Equity, ending balance at Dec. 31, 2017		$ 1	2,014	(21)	(2,761)	75	(692)
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2017	527
Shares, outstanding, ending balance at Dec. 31, 2017		114,651,004
Comprehensive income (loss)				17	(788)	30	(741)
Comprehensive income (loss) attributable to redeemable noncontrolling interest	54
Adoption of new accounting standards				(6)	6
Contributions from redeemable noncontrolling interests	3
Distributions to noncontrolling interests						(28)	(28)
Distributions to redeemable noncontrolling interests	(68)
Purchase of subsidiary shares from noncontrolling interests	(24)		(4)			(3)	(7)
Noncontrolling interests in acquired entity	6
Other reclassifications of noncontrolling interests						(2)	(2)
Other reclassifications of redeemable noncontrolling interests	1
Adjustment to redemption value of redeemable noncontrolling interests			(5)				(5)
Adjustment to redemption value of redeemable noncontrolling interests	5
Cancellation of restricted stock for tax withholdings on vested shares			(1)				(1)
Cancellation of restricted stock for tax withholdings on vested shares, shares		(293,735)
Income tax payable increase from vesting of restricted shares, shares		333
Stock-based compensation			13				13
Stock-based compensation, shares		1,890,774
Equity, ending balance at Dec. 31, 2018		$ 1	2,017	(10)	(3,543)	72	(1,463)
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2018	504						504
Shares, outstanding, ending balance at Dec. 31, 2018		116,248,376
Comprehensive income (loss)				1	(675)	33	(641)
Comprehensive income (loss) attributable to redeemable noncontrolling interest	52
Contributions from noncontrolling interests						7	7
Contributions from redeemable noncontrolling interests	3
Distributions to noncontrolling interests						(31)	(31)
Distributions to redeemable noncontrolling interests	(68)
Purchase of subsidiary shares from noncontrolling interests	(8)		3			(6)	(3)
Other reclassifications of noncontrolling interests						2	2
Other reclassifications of redeemable noncontrolling interests	(2)
Adjustment to redemption value of redeemable noncontrolling interests			(21)				(21)
Adjustment to redemption value of redeemable noncontrolling interests	21
Cancellation of restricted stock for tax withholdings on vested shares			(1)				(1)
Cancellation of restricted stock for tax withholdings on vested shares, shares		(298,182)
Income tax payable increase from vesting of restricted shares, shares		333
Stock-based compensation			10				10
Stock-based compensation, shares		1,872,104
Equity, ending balance at Dec. 31, 2019		$ 1	$ 2,008	$ (9)	$ (4,218)	$ 77	(2,141)
Redeemable Noncontrolling Interests, ending balance at Dec. 31, 2019	$ 502						$ 502
Shares, outstanding, ending balance at Dec. 31, 2019		117,822,631

XML

Leases (Supplemental Balance Sheet Information Related to Leases) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Operating Leases:
Operating Lease ROU Assets	$ 607
Finance Leases:
Property and equipment	9,653	$ 10,301
Less accumulated depreciation and amortization	(4,045)	(4,162)
Property and equipment, net	5,608	$ 6,139
Current finance lease liabilities	6
Long-term finance lease liabilities	107
Finance Lease ROU Assets [Member]
Finance Leases:
Property and equipment	173
Less accumulated depreciation and amortization	(56)
Property and equipment, net	117
Finance Lease ROU Assets [Member] | Land and Improvements [Member]
Finance Leases:
Property and equipment	8
Finance Lease ROU Assets [Member] | Building and Building Improvements [Member]
Finance Leases:
Property and equipment	154
Finance Lease ROU Assets [Member] | Equipment and Fixtures [Member]
Finance Leases:
Property and equipment	$ 11

XML

Long-Term Debt (Junior-Priority Secured Notes At 8.125% Due 2024 Narrative) (Details) - USD ($)				1 Months Ended	12 Months Ended
	Dec. 04, 2019	Nov. 19, 2019	Jun. 22, 2018	Jan. 27, 2014	Dec. 31, 2019	Jul. 18, 2012
Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 276,000,000
Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 121,000,000
Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 2,400,000,000
Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date					Jun. 22, 2018
Debt instrument stated interest rate			8.125%
Debt instrument redemption description					plus a "make-whole" premium, as described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024.
Minimum period notice for redemption of debt			15 days
Maximum period notice for redemption of debt			60 days
Junior Priority Secured Notes One [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 1,079,000,000
Junior Priority Secured Notes Two [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			1,355,000,000
Debt instrument redemption price percentage					100.00%
Senior Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date					Jul. 18, 2012
Extinguishment of debt amount	$ 121,000,000		1,079,000,000
Debt instrument stated interest rate						7.125%
Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date					Jan. 27, 2014
Debt instrument aggregate principal amount				$ 3,000,000,000
Extinguishment of debt amount			$ 368,000,000
Debt instrument stated interest rate				6.875%
Debt Instrument, Redemption, Period Two [Member] | Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount			40.00%
Debt instrument redemption price percentage			108.125%
Debt Instrument, Redemption, Period Two [Member] | Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Minimum period notice for redemption of debt				30 days
Maximum period notice for redemption of debt				60 days

XML

Acquisitions and Divestitures (Schedule of Net Operating Revenues and Loss and Assets and Liabilities Classified as Discontinued Operations) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Acquisitions and Divestitures [Abstract]
Net operating revenues	$ 79
Loss from operations of entities sold or held for sale before income taxes	(10)
Impairment of hospitals sold or held for sale	(8)
Loss on sale, net	(1)
Loss from discontinued operations, before taxes	(19)
Income tax benefit	(7)
Loss from discontinued operations, net of taxes	$ (12)

XML

Goodwill and Other Intangible Assets (Goodwill Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Other Intangible Assets [Abstract]
Goodwill	$ 4,328,000,000	$ 4,559,000,000	$ 4,723,000,000
Impairment of goodwill	$ 0	$ 0	$ 1,419,000,000

XML

Long-Term Debt (6.875% Senior Secured Notes, Due 2028 Narrative) (Details) - Senior Notes At 6.875% Due 2028 [Member] - Senior Notes [Member] - USD ($)		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2019
Debt instrument aggregate principal amount	$ 1,700,000,000
Debt instrument stated interest rate	6.875%
Debt instrument redemption description		plus a "make-whole" premium, as described in the indenture governing the 6⅞% Senior Notes due 2028.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt Instrument, Redemption, Period One [Member]
Debt instrument redemption price percentage	100.00%	103.438%
Debt Instrument, Redemption, Period Two [Member]
Debt instrument redemption price percentage	106.875%	101.719%

XML

Employee Benefit Plans (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Cost Recognized	$ 85,000,000	$ 90,000,000	$ 94,000,000
Liability for deferred compensation plans	175,000,000	163,000,000
Defined benefit plan, noncash settlement loss	0	2,000,000
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected contribution by employer	1,000,000
Net periodic benefit cost	1,000,000	1,000,000	7,000,000
Accrued benefits liabilities	$ 12,000,000	11,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rate	4.20%
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, rate of compensation increase	6.00%
Deferred Compensation Plans Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	$ 23,000,000	32,000,000
Deferred Compensation Company-Owned Life Insurance Contracts [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability for deferred compensation plans	130,000,000	114,000,000
Trust for Benefit of Employees [Member] | Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan assets designated to pay benefits of the deferred compensation plans	153,000,000	146,000,000
Supplemental Employee Retirement Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	7,000,000	9,000,000	$ 16,000,000
Accrued benefits liabilities	$ 72,000,000	$ 66,000,000
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, discount rate	4.20%	3.40%
Defined benefit plans and other post-retirement plans, weighted-average assumptions to determine net periodic cost, rate of compensation increase	3.00%	2.00%
Assets in a rabbi trust generally designated to pay benefits of the SERP	$ 84,000,000	$ 74,000,000

XML

Fair Value of Financial Instruments (Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Assets:
Investments in equity securities	$ 141	$ 137
Available-for-sale securities	101	93
Trading securities	12	11
Carrying Amount [Member]
Assets:
Cash and cash equivalents	216	196
Investments in equity securities	141	137
Available-for-sale securities	101	93
Trading securities	12	11
Carrying Amount [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure		1,602
Carrying Amount [Member] | Senior Notes [Member] | Senior Notes at 8.0%, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure		155
Carrying Amount [Member] | Senior Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure		121
Carrying Amount [Member] | Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	229	2,593
Carrying Amount [Member] | Senior Notes [Member] | Senior Notes At 6.875 Percent Due 2028 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,678
Carrying Amount [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125%, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	990	984
Carrying Amount [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	3,074	3,067
Carrying Amount [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,023	1,021
Carrying Amount [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,070
Carrying Amount [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 8% Due 2027 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	691
Carrying Amount [Member] | Junior-Priority Secured Notes [Member] | Junior Priority Secured Notes At 9.875 Percent Due 2023 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,754	1,750
Carrying Amount [Member] | Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,340	1,338
Carrying Amount [Member] | Receivables Facility and Other Debt, Type [Member] | ABL Facility and Other Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	285	734
Estimated Fair Value [Member]
Assets:
Cash and cash equivalents	216	196
Investments in equity securities	141	137
Available-for-sale securities	101	93
Trading securities	12	11
Estimated Fair Value [Member] | Credit Facility, Type of Debt [Member] | Credit Facility, Name [Member]
Liabilities:
Credit Facility, Fair Value Disclosure		1,564
Estimated Fair Value [Member] | Senior Notes [Member] | Senior Notes at 8.0%, Due 2019 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure		146
Estimated Fair Value [Member] | Senior Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure		100
Estimated Fair Value [Member] | Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	188	1,175
Estimated Fair Value [Member] | Senior Notes [Member] | Senior Notes At 6.875 Percent Due 2028 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,700
Estimated Fair Value [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 5.125%, Due 2021 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,003	934
Estimated Fair Value [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	3,148	2,819
Estimated Fair Value [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,099	1,025
Estimated Fair Value [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	2,182
Estimated Fair Value [Member] | Senior Secured Notes [Member] | Senior Secured Notes At 8% Due 2027 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	700
Estimated Fair Value [Member] | Junior-Priority Secured Notes [Member] | Junior Priority Secured Notes At 9.875 Percent Due 2023 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,539	1,380
Estimated Fair Value [Member] | Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Liabilities:
Notes Payable, Fair Value Disclosure	1,113	976
Estimated Fair Value [Member] | Receivables Facility and Other Debt, Type [Member] | ABL Facility and Other Debt [Member]
Liabilities:
Other Liabilities, Fair Value Disclosure	$ 285	$ 734

XML

Earnings Per Share (Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Increase in number of shares to diluted shares calculation if income would have been generated	133,866	68,687	111,464

XML

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Contingency [Abstract]
Effective income tax rate	(37.20%)	1.50%	15.80%
Unrecognized benefit that would affect the effective tax rate	$ 1
Amount of interest and penalties included in liabilities for uncertain tax positions	1
Income tax paid			$ 4
Income tax refund	$ 3	$ 19

XML

Other Comprehensive Income (Tables)

12 Months Ended

Dec. 31, 2019

Stockholders' Deficit [Abstract]

Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component

			Change in		Change in
	Change in Fair		Fair Value of		Unrecognized		Accumulated Other
	Value of Interest		Available-for-Sale		Pension Cost		Comprehensive
	Rate Swaps		Debt Securities		Components		(Loss) Income
Balance as of December 31, 2018	$	5	$	(7)	$	(8)	$	(10)
Other comprehensive (loss)
income before reclassifications		(3)		5		(1)		1
Amounts reclassified from
accumulated other
comprehensive (loss) income		-		(1)		1		-
Net current-period other
comprehensive (loss) income		(3)		4		-		1
Balance as of December 31, 2019	$	2	$	(3)	$	(8)	$	(9)

			Change in		Change in
	Change in Fair		Fair Value of		Unrecognized		Accumulated Other
	Value of Interest		Available-for-Sale		Pension Cost		Comprehensive
	Rate Swaps		Debt Securities		Components		(Loss) Income
Balance as of December 31, 2017	$	(12)	$	(2)	$	(7)	$	(21)
Other comprehensive income
(loss) before reclassifications		12		(2)		(2)		8
Amounts reclassified from
accumulated other
comprehensive income		8		-		1		9
Net current-period other
comprehensive income (loss)		20		(2)		(1)		17
Adoption of ASU 2016-01 and 2018-02		(3)		(3)		-		(6)
Balance as of December 31, 2018	$	5	$	(7)	$	(8)	$	(10)

Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Loss

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Year Ended		statement where net
comprehensive income (loss) components	December 31, 2019		income (loss) is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	-	Interest expense, net
		-	Tax benefit
	$	-	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Settlement losses recognized		-	Salaries and benefits
		(1)	Total before tax
		-	Tax benefit
	$	(1)	Net of tax

	Amount reclassified
	from AOCL		Affected line item in the
Details about accumulated other	Year Ended		statement where net
comprehensive (loss) income components	December 31, 2018		(loss) income is presented
Gains and losses on cash flow hedges
Interest rate swaps	$	(10)	Interest expense, net
		2	Tax benefit
	$	(8)	Net of tax
Amortization of defined benefit pension items
Prior service costs	$	(1)	Salaries and benefits
Settlement losses recognized		(2)	Salaries and benefits
		(3)	Total before tax
		2	Tax benefit
	$	(1)	Net of tax

XML

Fair Value (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

	December 31, 2019		Level 1		Level 2		Level 3
Investments in equity securities	$	141	$	141	$	-	$	-
Available-for-sale debt securities		101		-		101		-
Trading securities		12		-		12		-
Total assets	$	254	$	141	$	113	$	-
Fair value of interest rate swap agreements	$	2	$	-	$	2	$	-
Total liabilities	$	2	$	-	$	2	$	-
	December 31, 2018		Level 1		Level 2		Level 3
Investments in equity securities	$	137	$	137	$	-	$	-
Available-for-sale debt securities		93		-		93		-
Trading securities		11		-		11		-
Fair value of interest rate swap agreements		3		-		3		-
Total assets	$	244	$	137	$	107	$	-
Contingent Value Right (CVR)	$	-	$	-	$	-	$	-
Fair value of interest rate swap agreements		2		-		2		-
Total liabilities	$	2	$	-	$	2	$	-

Supplemental Information Regarding Available-for-Sale Debt Securities

			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Values
As of December 31, 2019:
Debt securities
Government	$	54	$	1	$	(1)	$	54
Corporate		33		1		-		34
Mortgage and asset-backed securities		13		-		-		13
Total	$	100	$	2	$	(1)	$	101

			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Values
As of December 31, 2018:
Debt securities
Government	$	54	$	-	$	(3)	$	51
Corporate		34		-		(2)		32
Mortgage and asset-backed securities		10		-		-		10
Total	$	98	$	-	$	(5)	$	93

Contractual Maturities of Debt Securities

	December 31, 2019				December 31, 2018
	Amortized		Estimated		Amortized		Estimated
	Cost		Fair Values		Cost		Fair Values
Within 1 year	$	9	$	9	$	14	$	14
After 1 year and through year 5		19		20		20		19
After 5 years and through year 10		29		29		25		24
After 10 years		43		43		39		36

Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities

	Year Ended December 31,
	2019		2018		2017
Realized gains	$	-	$	-	$	3
Realized losses		-		-		(2)

Net Gains and Losses Recognized for Investments in Equity Securities

	Year Ended December 31,
	2019		2018
Net gains and (losses), beginning of year	$	15	$	(7)
Less: Net gains and (losses) recognized during
the year on equity securities sold during the year		2		1
Unrealized gains and (losses) recognized during the
year on equity securities held, end of year	$	13		(8)

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Comprehensive (Loss) Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	$ (590)	$ (704)	$ (2,396)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(3)	20	19
Net change in fair value of available-for-sale debt securities, net of tax	4	(2)	8
Amortization and recognition of unrecognized pension cost components, net of tax		(1)	14
Other comprehensive income	1	17	41
Comprehensive loss	(589)	(687)	(2,355)
Less: Comprehensive income attributable to noncontrolling interests	85	84	63
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	(674)	(771)	(2,418)
Consolidation, Eliminations [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	763	2,022	5,918
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	3	(20)	(19)
Net change in fair value of available-for-sale debt securities, net of tax	(8)	4	(16)
Amortization and recognition of unrecognized pension cost components, net of tax		2	(28)
Other comprehensive income	(5)	(14)	(63)
Comprehensive loss	758	2,008	5,855
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	758	2,008	5,855
Parent Company [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	(675)	(788)	(2,459)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(3)	20	19
Net change in fair value of available-for-sale debt securities, net of tax	4	(2)	8
Amortization and recognition of unrecognized pension cost components, net of tax		(1)	14
Other comprehensive income	1	17	41
Comprehensive loss	(674)	(771)	(2,418)
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	(674)	(771)	(2,418)
Subsidiary Issuer [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	(675)	(788)	(2,459)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax	(3)	20	19
Net change in fair value of available-for-sale debt securities, net of tax	4	(2)	8
Amortization and recognition of unrecognized pension cost components, net of tax		(1)	14
Other comprehensive income	1	17	41
Comprehensive loss	(674)	(771)	(2,418)
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	(674)	(771)	(2,418)
Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	21	(403)	(1,892)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of available-for-sale debt securities, net of tax	4	(2)	8
Amortization and recognition of unrecognized pension cost components, net of tax		(1)	14
Other comprehensive income	4	(3)	22
Comprehensive loss	25	(406)	(1,870)
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	25	(406)	(1,870)
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income (Unaudited)
Net loss	(24)	(747)	(1,504)
Other comprehensive (loss) income, net of income taxes:
Comprehensive loss	(24)	(747)	(1,504)
Less: Comprehensive income attributable to noncontrolling interests	85	84	63
Comprehensive loss attributable to Community Health Systems, Inc. stockholders	$ (109)	$ (831)	$ (1,567)

XML

Long-Term Debt (Schedule of Early Redemption Prices on 6.25% Senior Secured Notes due 2023) (Details) - Senior Secured Notes at 6.25%, Due 2023 [Member] - Senior Secured Notes [Member]	12 Months Ended
	Dec. 31, 2019
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	103.125%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2020
Debt Instrument, Redemption Period, End Date	Mar. 30, 2021
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.563%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2021
Debt Instrument, Redemption Period, End Date	Mar. 30, 2022
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Mar. 31, 2022
Debt Instrument, Redemption Period, End Date	Mar. 30, 2023

XML

Long-Term Debt (6.875% Senior Notes, Due 2022 Narrative) (Details) - USD ($)			1 Months Ended	12 Months Ended
	Nov. 19, 2019	Jun. 22, 2018	Jan. 27, 2014	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term debt outstanding				$ 13,405,000,000
Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount	$ 2,400,000,000
Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount		$ 276,000,000
Senior Secured Notes At 8% Due 2027 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 700,000,000
Debt instrument stated interest rate	8.00%
Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Jan. 27, 2014
Debt instrument aggregate principal amount			$ 3,000,000,000
Long-term debt outstanding	$ 231,000,000
Debt instrument stated interest rate			6.875%
Extinguishment of debt amount		$ 368,000,000
Senior Notes [Member] | Senior Notes At 6.875% Due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount	$ 1,700,000,000
Debt instrument stated interest rate	6.875%
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date				Jun. 22, 2018
Debt instrument stated interest rate		8.125%
Minimum period notice for redemption of debt		15 days
Maximum period notice for redemption of debt		60 days
Debt Instrument, Redemption, Period One [Member] | Senior Notes [Member] | Senior Notes At 6.875% Due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument redemption period start date				Apr. 01, 2023
Debt instrument redemption period end date				Mar. 31, 2024
Debt Instrument, Redemption, Period Two [Member] | Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Minimum period notice for redemption of debt			30 days
Maximum period notice for redemption of debt			60 days
Debt Instrument, Redemption, Period Two [Member] | Senior Notes [Member] | Senior Notes At 6.875% Due 2028 [Member]
Debt Instrument [Line Items]
Debt instrument redemption period start date				Apr. 01, 2024
Debt instrument redemption period end date				Mar. 31, 2025

XML

Fair Value (Gross Realized Gains and Losses and Investment Income on Available-for-Sale Debt Securities) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Fair Value [Abstract]
Realized gains	$ 3
Realized losses	$ (2)

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2027) (Details) - Senior Secured Notes At 8% Due 2027 [Member] - Senior Secured Notes [Member]		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2019
Debt Instrument, Redemption, Period One [Member]
Debt Instrument Redemption Price Percentage	100.00%	104.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2022
Debt Instrument, Redemption Period, End Date		Dec. 14, 2023
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument Redemption Price Percentage	108.00%	102.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2023
Debt Instrument, Redemption Period, End Date		Dec. 14, 2024
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Dec. 15, 2024
Debt Instrument, Redemption Period, End Date		Dec. 14, 2027

XML

Fair Value (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019 USD ($) item	Dec. 31, 2018 USD ($) item	Dec. 31, 2017 USD ($)
Fair Value Disclosures [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	$ 51,000,000	$ 89,000,000
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions | item	71	121
Available-for-sale Securities [Member]
Fair Value Disclosures [Line Items]
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Credit Losses on Debt Securities Held	$ 0
Other Investment Income [Member]
Fair Value Disclosures [Line Items]
Investment Income, Interest and Dividend	$ 7,000,000	$ 7,000,000	$ 8,000,000

XML

Long-Term Debt (Schedule of Debt) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Nov. 19, 2019	Dec. 31, 2018	Jun. 22, 2018
Debt Instrument [Line Items]
Total debt	$ 13,405.0
Less: Unamortized deferred debt issuance costs and note premium	(147.0)		$ (164.0)
Less: Current maturities	(20.0)		(204.0)
Debt and lease obligations	13,405.0		13,596.0
Total long-term debt	13,385.0		13,392.0
Senior Notes at 8.0%, Due 2019 [Member]
Debt Instrument [Line Items]
Total debt				$ 155.0
Junior-Priority Secured Notes At 9.875% Due 2023 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	1,770.0		1,770.0
Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	1,355.0		1,355.0
ABL Credit Agreement [Member]
Debt Instrument [Line Items]
Debt and lease obligations	273.0		698.0
Secured Debt [Member] | Credit Facility, Term Loan H [Member]
Debt Instrument [Line Items]
Debt and lease obligations			1,622.0
Senior Notes [Member] | Senior Notes at 8.0%, Due 2019 [Member]
Debt Instrument [Line Items]
Debt and lease obligations			155.0
Senior Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Total debt				$ 121.0
Debt and lease obligations			121.0
Senior Notes [Member] | Senior Notes at 6.875%, Due 2022 [Member]
Debt Instrument [Line Items]
Total debt		$ 231.0
Debt and lease obligations	231.0		2,632.0
Senior Notes [Member] | Senior Notes At 6.875% Due 2028 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	1,700.0
Senior Secured Notes [Member] | Senior Secured Notes at 5.125%, Due 2021 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	1,000.0		1,000.0
Senior Secured Notes [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	3,100.0		3,100.0
Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	1,033.0		1,033.0
Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	2,101.0
Senior Secured Notes [Member] | Senior Secured Notes At 8% Due 2027 [Member]
Debt Instrument [Line Items]
Debt and lease obligations	700.0
Finance Lease And Financing Obligations [Member]
Debt Instrument [Line Items]
Debt and lease obligations	272.0		231.0
Other [Member]
Debt Instrument [Line Items]
Debt and lease obligations	$ 17.0		$ 43.0

XML

Income Taxes (Schedule of Components of Deferred Income Taxes) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Assets
Net operating loss and credit carryforwards	$ 775	$ 743
Self-insurance liabilities	48	69
Long-term debt and interest	312	84
Accounts receivable	62	58
IRC Section 163(j) interest limitation	296	144
Accrued vacation	24	26
Accrued bonus	31
Other comprehensive income	5	4
Right-of-use-liability	149
Stock-based compensation	5	4
Deferred compensation	70	64
Other	51	15
Total	1,828	1,211
Valuation Allowance	(1,049)	(701)
Total Deferred Income Tax Assets, Net	779	510
Liabilities
Property and equipment	335	237
Prepaid expenses	30	27
Intangibles	149	134
Investments in unconsolidated affiliates	57	55
Other liabilities	9	14
IRC Section 481(a) - mixed service cost	216
Right-of-use-assets	145
Total Deferred Income Tax Liabilities, Gross	$ 941	$ 467

XML

Fair Value of Financial Instruments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) contract
Maximum [Member]
Derivative [Line Items]
Interest income arising from spread in fixed and floating rates of interest rate swap agreements that will be recognized in next 12 months	$ 1
Interest Rate Swap [Member]
Derivative [Line Items]
Number of interest rate swaps | contract	1
Aggregate notional amount	$ 300
Derivative fixed interest rate	2.892%
Derivative termination date	Aug. 30, 2020
Derivative liability fair value	$ 2

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8.875% Junior-Priority Secured Notes due 2024) (Details) - Junior Priority Secured Notes At 8.875 Percent Due 2024 [Member] - Junior-Priority Secured Notes [Member]	12 Months Ended
	Dec. 31, 2019
Debt Instrument, Redemption, Period Three [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	104.063%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2021
Debt Instrument, Redemption Period, End Date	Jun. 29, 2022
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	102.031%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2022
Debt Instrument, Redemption Period, End Date	Jun. 29, 2023
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Jun. 30, 2023
Debt Instrument, Redemption Period, End Date	Jun. 29, 2024

XML

Other Comprehensive Income (Schedule of Amounts Reclassified Out of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net									$ 1,041		$ 976		$ 931
Tax benefit									(160)		11		449
Net loss attributable to Community Health Systems, Inc. stockholders	$ (373)	$ (17)	$ (167)	$ (118)	$ (328)	$ (325)	$ (110)	$ (25)	(675)	[1]	(788)	[1]	$ (2,459)
Reclassification, net of tax											(9)
Change in Fair Value of Interest Rate Swaps [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification, net of tax											(8)
Change in Fair Value of Interest Rate Swaps [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Interest expense, net											(10)
Tax benefit											2
Net loss attributable to Community Health Systems, Inc. stockholders											(8)
Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax									(1)		(1)
Accumulated Defined Benefit Plans Adjustment, Net Transition Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax											(2)
Change in Unrecognized Pension Cost Components [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification, Total before tax									(1)		(3)
Tax benefit											2
Reclassification, net of tax									$ (1)		$ (1)

[1] Total quarterly amounts may not add due to rounding.

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accounting for Stock-Based Compensation [Abstract]
Effect on loss before income taxes	$ (10)	$ (13)	$ (24)
Effect on net loss	$ (8)	$ (10)	$ (16)

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Restricted Stock Units, Activity) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Unvested Shares	397,906	172,078	120,386
Granted, Shares	306,612	296,944	110,988
Vested, Shares	(162,942)	(71,116)	(59,296)
Forfeited, Shares
Ending Balance, Unvested Shares	541,576	397,906	172,078
Beginning of Period, Weighted Average Grant Date Fair Value	$ 6.17	$ 12.78	$ 22.06
Granted, Weighted Average Grant Date Fair Value	4.99	4.58	9.19
Vested, Weighted Average Grant Date Fair Value	7.42	15.51	24.90
Forfeited, Weighted Average Grant Date Fair Value
End of Period, Weighted Average Grant Date Fair Value	$ 5.13	$ 6.17	$ 12.78

XML

Commitments and Contingencies (Professional Liability Claims Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
	Jun. 01, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Malpractice Insurance [Line Items]
Malpractice loss contingency, historical claims period used by actuary to estimate liability		20 years
Malpractice Loss Contingency, Discount Rate		2.60%	3.10%	2.20%
Malpractice Loss Contingency, Accrual, Discounted		$ 612	$ 650
Malpractice Loss Contingency, Accrual, Undiscounted		663	710
Malpractice Loss Contingency, Accrual, Discounted, Current		$ 169	$ 100
Malpractice loss contingency, settled claims as percent of total liability		1.00%
Professional and general liability self-insured claims reported prior to June 1, 2002, per occurrence [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		$ 1
Professional and general liability self-insured reported from June 1, 2002 through June 1, 2003, per occurrence [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		2
Professional and general liability self-insured reported from June 1, 2003 and before June 1, 2005, per occurrence [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		4
Professional and general liability self-insured claims reported on or after June 1, 2005, per occurrence [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		5
Professional and general liability claims reported on or after June 1, 2014 [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		10
Professional and general liability claims reported on or after June 1, 2003 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident		95
Professional and general liability claims reported on or after June 1, 2015 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident		215
Integrated occurrence claims reported on or after June 1, 2014 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Annual Coverage Limit		50
Integrated occurrence claims reported on or after June 1, 2015 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Annual Coverage Limit		75
Professional and general liability claims incurred and reported after January 1, 2008 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident		145
Professional and general liability claims incurred and reported after June 1, 2010 [Member]
Malpractice Insurance [Line Items]
Malpractice Insurance, Maximum Coverage Per Incident		195
Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		10
Triad professional and general liability self-insured claims during 2007 [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		$ 10
Minimum [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, average lag period from occurence to settlement		3 years
Malpractice loss contingency, self-insured retention		$ 10
Minimum [Member] | Professional and general liability self-insured claims under certain policy terms until Company total aggregate coverage is met if first aggregate layer becomes fully utilized [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention	$ 15
Minimum [Member] | Triad professional and general liability self-insured claims after December 31, 2006 [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		$ 1
Maximum [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, average lag period from occurence to settlement		4 years
Malpractice loss contingency, self-insured retention		$ 15
Maximum [Member] | Professional And General Liability Claims Incurred And Reported On Or After June 1, 2008 [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		15
Maximum [Member] | Triad professional and general liability self-insured claims after December 31, 2006 [Member]
Malpractice Insurance [Line Items]
Malpractice loss contingency, self-insured retention		$ 5

XML

Accounting for Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2019

Accounting for Stock-Based Compensation [Abstract]

Schedule of Share-based Compensation Expense

	Year Ended December 31,
	2019		2018		2017
Effect on loss before income taxes	$	(10)	$	(13)	$	(24)
Effect on net loss	$	(8)	$	(10)	$	(16)

Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions

	Year Ended December 31,
	2019		2018		2017
Expected volatility	68.4	%	N/A	%	N/A	%
Expected dividends	-		N/A		N/A
Expected term	5.6 years		N/A		N/A
Risk-free interest rate	2.6	%	N/A	%	N/A	%

Schedule of Share-based Compensation, Stock Options, Activity

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	December 31,
	Shares	Exercise Price		Term	2019
Outstanding at December 31, 2016	1,185,320	$	28.12
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(69,653)		33.52
Outstanding at December 31, 2017	1,115,667		31.56
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(490,729)		32.01
Outstanding at December 31, 2018	624,938		31.21
Granted	658,500		4.95
Exercised	-		-
Forfeited and cancelled	(173,304)		23.04
Outstanding at December 31, 2019	1,110,134	$	16.90	5.6 years	$	-
Exercisable at December 31, 2019	486,134	$	32.26	1.0 years	$	-

Schedule of Share-based Compensation, Restricted Stock, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2016	2,969,285	$	29.39
Granted	1,502,000		9.10
Vested	(1,586,855)		33.91
Forfeited	(240,511)		18.20
Unvested at December 31, 2017	2,643,919		16.17
Granted	1,987,000		4.54
Vested	(1,154,670)		23.22
Forfeited	(167,342)		10.29
Unvested at December 31, 2018	3,308,907		7.00
Granted	1,989,000		4.94
Vested	(1,160,667)		8.89
Forfeited	(279,838)		5.60
Unvested at December 31, 2019	3,857,402		5.47

Schedule of Share-based Compensation, Restricted Stock Units, Activity

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2016	120,386	$	22.06
Granted	110,988		9.19
Vested	(59,296)		24.90
Forfeited	-		-
Unvested at December 31, 2017	172,078		12.78
Granted	296,944		4.58
Vested	(71,116)		15.51
Forfeited	-		-
Unvested at December 31, 2018	397,906		6.17
Granted	306,612		4.99
Vested	(162,942)		7.42
Forfeited	-		-
Unvested at December 31, 2019	541,576		5.13

XML

Fair Value (Policy)

12 Months Ended

Dec. 31, 2019

Fair Value [Abstract]

Fair Value, Policy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1:  Quoted market prices in active markets for identical assets or liabilities.

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3:  Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during the years ending December 31, 2019 or December 31, 2018.

XML

Accounting for Stock-Based Compensation

12 Months Ended

Dec. 31, 2019

Accounting for Stock-Based Compensation [Abstract]

Accounting for Stock-Based Compensation Disclosure

2.  ACCOUNTING FOR STOCK-BASED COMPENSATION

Stock-based compensation awards have been granted under the Community Health Systems, Inc. Amended and Restated 2000 Stock Option and Award Plan, amended and restated as of March 20, 2013 (the “2000 Plan”), and the Community Health Systems, Inc. Amended and Restated 2009 Stock Option and Award Plan, which was amended and restated as of March 14, 2018 and approved by the Company’s stockholders at the annual meeting of stockholders held on May 15, 2018 (the “2009 Plan”).

The 2000 Plan allowed for the grant of incentive stock options intended to qualify under Section 422 of the Internal Revenue Code (the “IRC”), as well as stock options which did not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Prior to being amended in 2009, the 2000 Plan also allowed for the grant of phantom stock. Persons eligible to receive grants under the 2000 Plan included the Company’s directors, officers, employees and consultants. All options granted under the 2000 Plan were “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurred in one-third increments on each of the first three anniversaries of the award date. Options granted prior to 2005 had a 10-year contractual term, options granted in 2005 through 2007 had an eight-year contractual term and options granted since 2008 had a 10-year contractual term. Pursuant to the amendment and restatement of the 2000 Plan dated March 20, 2013, no further grants will be awarded under the 2000 Plan.

The 2009 Plan provides for the grant of incentive stock options intended to qualify under Section 422 of the IRC and for the grant of stock options which do not so qualify, stock appreciation rights, restricted stock, restricted stock units, performance-based shares or units and other share awards. Persons eligible to receive grants under the 2009 Plan include the Company’s directors, officers, employees and consultants. To date, all options granted under the 2009 Plan have been “nonqualified” stock options for tax purposes. Generally, vesting of these granted options occurs in one-third increments on each of the first three anniversaries of the award date. Options granted in 2011 or later have a 10-year contractual term. As of December 31, 2019, 5,308,206 shares of unissued common stock were reserved for future grants under the 2009 Plan.

The exercise price of all options granted under the 2000 Plan and the 2009 Plan has been equal to the fair value of the Company’s common stock on the option grant date. 

The following table reflects the impact of total compensation expense related to stock-based equity plans on the reported operating results for the respective periods (in millions):

	Year Ended December 31,
	2019		2018		2017
Effect on loss before income taxes	$	(10)	$	(13)	$	(24)
Effect on net loss	$	(8)	$	(10)	$	(16)

At December 31, 2019, $13 million of unrecognized stock-based compensation expense related to outstanding unvested stock options, restricted stock and restricted stock units (the terms of which are summarized below) was expected to be recognized over a weighted-average period of 22 months. Of that amount, $1 million related to outstanding unvested stock options was expected to be recognized over a weighted-average period of 26 months and $12 million related to outstanding unvested restricted stock and restricted stock units was expected to be recognized over a weighted-average period of 21 months. There were no modifications to awards during the years ended December 31, 2019, 2018 and 2017.

The fair value of stock options was estimated using the Black Scholes option pricing model with the following assumptions and weighted-average fair values during the years ended December 31, 2019, 2018 and 2017:

	Year Ended December 31,
	2019		2018		2017
Expected volatility	68.4	%	N/A	%	N/A	%
Expected dividends	-		N/A		N/A
Expected term	5.6 years		N/A		N/A
Risk-free interest rate	2.6	%	N/A	%	N/A	%

In determining the expected term, the Company examined concentrations of option holdings and historical patterns of option exercises and forfeitures, as well as forward-looking factors, in an effort to determine if there were any discernable employee populations. From this analysis, the Company identified two primary employee populations, one consisting of certain senior executives and the other consisting of substantially all other recipients.

The expected volatility rate was estimated based on historical volatility. In determining expected volatility, the Company also reviewed the market-based implied volatility of actively traded options of its common stock and determined that historical volatility utilized to estimate the expected volatility rate did not differ significantly from the implied volatility.

The expected term computation is based on historical exercise and cancellation patterns and forward-looking factors, where present, for each population identified. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company adjusts the estimated forfeiture rate to its actual experience.

Options outstanding and exercisable under the 2000 Plan and the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows (in millions, except share and per share data):

				Weighted-	Aggregate
				Average	Intrinsic
		Weighted-		Remaining	Value as of
		Average		Contractual	December 31,
	Shares	Exercise Price		Term	2019
Outstanding at December 31, 2016	1,185,320	$	28.12
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(69,653)		33.52
Outstanding at December 31, 2017	1,115,667		31.56
Granted	-		-
Exercised	-		-
Forfeited and cancelled	(490,729)		32.01
Outstanding at December 31, 2018	624,938		31.21
Granted	658,500		4.95
Exercised	-		-
Forfeited and cancelled	(173,304)		23.04
Outstanding at December 31, 2019	1,110,134	$	16.90	5.6 years	$	-
Exercisable at December 31, 2019	486,134	$	32.26	1.0 years	$	-

The weighted-average grant date fair value of stock options granted during the year ended December 31, 2019 was $3.05.  No stock options were granted during the years ended December 31, 2018 and 2017. The aggregate intrinsic value (calculated as the number of in-the-money stock options multiplied by the difference between the Company’s closing stock price on the last trading day of the reporting period ($2.90) and the exercise price of the respective stock options) in the table above represents the amount that would have been received by the option holders had all option holders exercised their options on December 31, 2019. This amount changes based on the market value of the Company’s common stock. There were no options exercised during the years ended December 31, 2019, 2018 and 2017. The aggregate intrinsic value of options vested and expected to vest approximates that of the outstanding options. 

The Company has also awarded restricted stock under the 2009 Plan to employees of certain subsidiaries. With respect to time-based vesting restricted stock that has been awarded under the 2009 Plan, the restrictions on these shares have generally lapsed in one-third increments on each of the first three anniversaries of the award date. In addition, certain of the restricted stock awards granted to the Company’s senior executives have contained performance objectives required to be met in addition to any time-based vesting requirements. If the applicable performance objectives are not attained, these awards will be forfeited in their entirety. For such performance-based awards granted prior to March 1, 2017, performance objectives were measured over a one-year period, and, provided the target performance objective was attained, restrictions lapsed in one-third increments on each of the first three anniversaries of the award date. For performance-based awards granted on or after March 1, 2017, the performance objectives have been measured cumulatively over a three-year period. With respect to performance-based awards granted on or after March 1, 2017, if the applicable target performance objective is met at the end of the three-year period, then the portion of the restricted stock award subject to such performance objective will vest in full on the third anniversary of the award date. Additionally, for these awards, based on the level of achievement for the applicable performance objective within the parameters specified in the award agreement, the number of shares to be issued in connection with the vesting of the award may be adjusted to decrease or increase the number of shares specified in the original award. Notwithstanding the above-mentioned performance objectives and vesting requirements, the restrictions with respect to restricted stock granted under the 2009 Plan may lapse earlier in the event of death, disability or termination of employment by the Company for any reason other than for cause of the holder of the restricted stock, or change in control of the Company. Restricted stock awards subject to performance objectives that have not yet been satisfied are not considered outstanding for purposes of determining earnings per share until the performance objectives have been satisfied. 

Restricted stock outstanding under the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows:

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2016	2,969,285	$	29.39
Granted	1,502,000		9.10
Vested	(1,586,855)		33.91
Forfeited	(240,511)		18.20
Unvested at December 31, 2017	2,643,919		16.17
Granted	1,987,000		4.54
Vested	(1,154,670)		23.22
Forfeited	(167,342)		10.29
Unvested at December 31, 2018	3,308,907		7.00
Granted	1,989,000		4.94
Vested	(1,160,667)		8.89
Forfeited	(279,838)		5.60
Unvested at December 31, 2019	3,857,402		5.47

Restricted stock units (“RSUs”) have been granted to the Company’s outside directors under the 2009 Plan. Each of the Company’s then serving outside directors received grants under the 2009 Plan of 18,498 RSUs, 37,118 RSUs and 34,068 RSUs on March 1, 2017, 2018 and 2019, respectively. Each of the 2017, 2018 and 2019 grants had a grant date fair value of approximately $170,000. Vesting of these RSUs occurs in one-third increments on each of the first three anniversaries of the award date or upon the director’s earlier cessation of service on the board, other than for cause.

RSUs outstanding under the 2009 Plan as of December 31, 2019, and changes during each of the years in the three-year period prior to December 31, 2019, were as follows:

		Weighted-
		Average Grant
	Shares	Date Fair Value
Unvested at December 31, 2016	120,386	$	22.06
Granted	110,988		9.19
Vested	(59,296)		24.90
Forfeited	-		-
Unvested at December 31, 2017	172,078		12.78
Granted	296,944		4.58
Vested	(71,116)		15.51
Forfeited	-		-
Unvested at December 31, 2018	397,906		6.17
Granted	306,612		4.99
Vested	(162,942)		7.42
Forfeited	-		-
Unvested at December 31, 2019	541,576		5.13

XML

Long-Term Debt

12 Months Ended

Dec. 31, 2019

Long-term Debt [Abstract]

Long-Term Debt Disclosure

6.  LONG-TERM DEBT

Long-term debt, net of unamortized debt issuance costs and discounts or premiums, consists of the following (in millions):

	December 31,
	2019		2018
Credit Facility:
Term H Loan	$	-	$	1,622
Revolving Credit Facility		-		-
8% Senior Notes due 2019		-		155
7⅛% Senior Notes due 2020		-		121
5⅛% Senior Secured Notes due 2021		1,000		1,000
6⅞% Senior Notes due 2022		231		2,632
6¼% Senior Secured Notes due 2023		3,100		3,100
8⅝% Senior Secured Notes due 2024		1,033		1,033
8% Senior Secured Notes due 2026		2,101		-
8% Senior Secured Notes due 2027		700		-
6⅞% Senior Notes due 2028		1,700		-
9⅞% Junior-Priority Secured Notes due 2023		1,770		1,770
8⅛% Junior-Priority Secured Notes due 2024		1,355		1,355
ABL Facility		273		698
Finance lease and financing obligations		272		231
Other		17		43
Less:  Unamortized deferred debt issuance costs and note premium		(147)		(164)
Total debt		13,405		13,596
Less: Current maturities		(20)		(204)
Total long-term debt	$	13,385	$	13,392

Credit Facility

The Company’s wholly-owned subsidiary, CHS/Community Health Systems, Inc. (“CHS”), had senior secured financing under a credit facility with a syndicate of financial institutions led by Credit Suisse, as administrative agent and collateral agent (the “Credit Facility”), which at December 31, 2018 included (i) a revolving credit facility with commitments through January 27, 2021 of $425 million (the “Revolving Facility”), and (ii) a Term H facility due 2021 (the “Term H Facility). The Revolving Facility included a subfacility for letters of credit. The Revolving Facility was repaid in full and terminated in connection with the completion of the offering of the Additional 2026 Notes on November 19, 2019, as discussed below.

The loans under the Credit Facility bore interest on the outstanding unpaid principal amount at a rate equal to an applicable percentage plus, at CHS’ option, either (a) an Alternate Base Rate (as defined) determined by reference to the greater of (1) the Prime Rate (as defined) announced by Credit Suisse or (2) the NYFRB Rate (as defined) plus 0.50% or (3) the adjusted London Interbank Offered Rate (“LIBOR”) on such day for a three-month interest period commencing on the second business day after such day plus 1% or (b) LIBOR. In addition, the margin in respect of the Revolving Facility was subject to adjustment determined by reference to a leverage-based pricing grid. Prior to the refinancing discussed below,  loans in respect of the Revolving Facility accrued interest at a rate per annum equal to LIBOR plus 2.75%, in the case of LIBOR borrowings, and Alternate Base Rate plus 1.75%, in the case of Alternate Base Rate borrowings. Prior to the refinancing discussed below, the Term H Loan accrued interest at a rate per annum equal to LIBOR plus 3.25%, in the case of LIBOR borrowings, and Alternate Base Rate plus 2.25%, in the case of Alternate Base Rate borrowings. The Term H Loan was subject to a 1.00% LIBOR floor and a 2.00% Alternate Base Rate floor.

The term loan facility was required to be prepaid in an amount equal to (1) 100% of the net cash proceeds of certain asset sales and dispositions by the Company and its subsidiaries, subject to certain exceptions and reinvestment rights, (2) 100% of the net cash proceeds of issuances of certain debt obligations or receivables-based financing by the Company and its subsidiaries, subject to certain exceptions, and (3) 75%, subject to reduction to a lower percentage based on the Company’s first lien net leverage ratio (as defined in the Credit Facility generally as the ratio of first lien net debt on the date of determination to the Company’s consolidated EBITDA, as defined, for the four quarters most recently ended prior to such date), of excess cash flow (as defined) for any year, subject to certain exceptions. Voluntary prepayments and commitment reductions were permitted in whole or in part, without any premium or penalty, subject to minimum prepayment or reduction requirements. There were no scheduled principal amortization payments on the Term H Facility after December 31, 2018.

The borrower under the Credit Facility was CHS. All of the obligations under the Credit Facility were unconditionally guaranteed by the Company and certain of its existing and subsequently acquired or organized domestic subsidiaries. All obligations under the Credit Facility and the related guarantees were secured by a perfected first priority lien or security interest in substantially all of the assets of the Company, CHS and each subsidiary guarantor, including equity interests held by the Company, CHS or any subsidiary guarantor, but excluding, among others, the equity interests of non-significant subsidiaries, syndication subsidiaries, securitization subsidiaries and joint venture subsidiaries, and subject to the revolving asset-based loan facility(“the ABL Facility”). Such assets constituted substantially the same assets, subject to certain exceptions, that secured (i) on a first lien basis CHS’ obligations under the 5⅛% Senior Secured Notes due 2021, the 6¼% Senior Secured Notes due 2023, the 8⅝% Senior Secured Notes due 2024 and the 8% Senior Secured Notes due 2026 (in each case, as defined below) and (ii) on a junior-priority basis the 9⅞% Junior-Priority Secured Notes due 2023 and the 8⅛% Junior-Priority Secured Notes due 2024 (in each case, as defined below).

CHS agreed to pay letter of credit fees equal to the applicable percentage then in effect with respect to LIBOR borrowings under the Revolving Facility times the maximum aggregate amount available to be drawn under all letters of credit outstanding under the subfacility for letters of credit. The issuer of any letter of credit issued under the subfacility for letters of credit also received a customary fronting fee and other customary processing charges. CHS was obligated to pay commitment fees of 0.50% per annum (subject to adjustment based upon the Company’s leverage ratio) on the unused portion of the Revolving Facility.

On February 15, 2019, the Company and CHS entered into Amendment No. 1 (the “Agreement”), among the Company, CHS, the subsidiary guarantors party thereto, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent, to the Credit Facility. The Credit Facility was amended by the Agreement, with requisite covenant lender approval, to amend the first lien net debt to EBITDA ratio financial covenant and to reduce the extended revolving credit commitments to $385 million. The amended financial covenant provided for a maximum first lien net debt to EBITDA ratio of 5.00 to 1.00 from July 1, 2018 through December 31, 2018, 5.25 to 1.00 from January 1, 2019 through December 31, 2019, 5.00 to 1.00 from January 1, 2020 through June 30, 2020, 4.50 to 1.00 from July 1, 2020 through September 30, 2020, and 4.25 to 1.00 thereafter. In addition, CHS agreed pursuant to the Agreement to further restrict its ability to make restricted payments. The revolving credit commitments terminated on November 19, 2019.

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of 8% Senior Secured Notes due March 15, 2026 (the “8% Senior Secured Notes due 2026”). The terms of the 8% Senior Secured Notes due 2026 are discussed below. Using the proceeds from the offering, the Company repaid the outstanding balance owed under the Term H Facility and paid fees and expenses related to the offering.

On November 19, 2019, CHS completed a tack-on offering of an additional $500 million aggregate principal amount of the 8% Senior Secured Notes due 2026 (the “Additional 2026 Notes”). Upon completion of such offering, $2.101 billion aggregate principal amount of 8% Senior Secured Notes due 2026 were outstanding.  CHS used the proceeds from the Additional 2026 Notes to repay amounts outstanding under the Revolving Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7⅛% Senior Notes due July 15, 2020 (the “7⅛% Senior Notes due 2020”) and repay borrowings outstanding under the ABL Facility. CHS terminated the Revolving Facility upon consummation of the Additional 2026 Notes offering and the outstanding letters of credit were moved under the ABL Facility.

8% Senior Notes due 2019

On November 22, 2011, CHS completed a private offering of $1.0 billion aggregate principal amount of 8% Senior Notes due November 15, 2019 (the “8% Senior Notes due 2019”). The net proceeds from this issuance, together with available cash on hand, were used to finance the purchase of up to $1.0 billion aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes due 2015 and related fees and expenses. On March 21, 2012, CHS completed an offering of an additional $1.0 billion aggregate principal amount of 8% Senior Notes due 2019, which were issued in a private placement (at a premium of 102.5%). The net proceeds from this issuance were used to finance the purchase of approximately $850 million aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes due 2015, to pay related fees and expenses and for general corporate purposes. The 8% Senior Notes due 2019 bore interest at 8.000% per annum, payable semi-annually in arrears on May 15 and November 15 of each year. Interest on the 8% Senior Notes due 2019 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months.

On June 22, 2018, CHS issued approximately $1.770 billion aggregate principal amount of new 9⅞% Junior-Priority Secured Notes due June 30, 2023 (the “9⅞% Junior-Priority Secured Notes due 2023”) in exchange for the same amount of 8% Senior Notes due 2019. The terms of the 9⅞% Junior-Priority Secured Notes due 2023 are described below. Following this exchange, CHS had $155 million aggregate principal amount of 8% Senior Notes due 2019 outstanding, which was repaid in full on November 15, 2019.

7⅛% Senior Notes due 2020

On July 18, 2012, CHS completed a public offering of $1.2 billion aggregate principal amount of 7⅛% Senior Notes due 2020. The net proceeds from this issuance were used to finance the purchase or redemption of $934 million aggregate principal amount of CHS’ then outstanding 8⅞% Senior Notes due 2015, to pay for consents delivered in connection with a related tender offer, to pay related fees and expenses, and for general corporate purposes. The 7⅛% Senior Notes due 2020 bore interest at 7.125% per annum, payable semiannually in arrears on July 15 and January 15 of each year. Interest on the 7⅛% Senior Notes due 2020 accrued from the date of original issuance. Interest was calculated on the basis of a 360-day year comprised of twelve 30-day months.

On June 22, 2018, CHS issued approximately $1.079 billion aggregate principal amount of new 8⅛% Junior-Priority Secured Notes due June 30, 2024 (the “8⅛% Junior-Priority Secured Notes due 2024”) in exchange for the same amount of 7⅛% Senior Notes due 2020. The terms of the 8⅛% Junior-Priority Secured Notes due 2024 are described below. Following this exchange, CHS had $121 million aggregate principal amount of 7⅛% Senior Notes due 2020 outstanding.

On December 4, 2019, CHS used the proceeds from the Additional 2026 Notes to repay the $121 million aggregate principal amount of the then outstanding 7⅛% Senior Notes due 2020.

5⅛% Senior Secured Notes due 2021

On January 27, 2014, CHS completed a private offering of $1.0 billion aggregate principal amount of 5⅛% Senior Secured Notes due August 1, 2021 (the “5⅛% Senior Secured Notes due 2021”). The net proceeds from this issuance were used to finance the Company’s acquisition by merger of Health Management Associates, Inc. (“HMA”). The 5⅛% Senior Secured Notes due 2021 bear interest at a rate of 5.125% per annum, payable semi-annually in arrears on February 1 and August 1 of each year. Interest on the 5⅛% Senior Secured Notes due 2021 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 5⅛% Senior Secured Notes due 2021 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under theABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 5⅛% Senior Secured Notes due 2021 and the related guarantees are secured by shared (i) first-priority liens on the collateral (the “Non-ABL Priority Collateral”) that also secures on a first-priority basis CHS’ senior-priority secured notes and (ii) second-priority liens on the collateral (the “ABL-Priority Collateral”) that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 5⅛% Senior Secured Notes due 2021.  

CHS is entitled, at its option, to redeem all or a portion of the 5⅛% Senior Secured Notesdue 2021 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 5⅛%  Senior Secured Notes due 2021, as a result of an exchange offer made by CHS, all of the 5⅛%  Senior Secured Notes due 2021 issued in January 2014 were exchanged in October 2014 for new notes (the “2021 Exchange Notes”) having terms substantially identical in all material respects to the 5⅛%  Senior Secured Notes due 2021 (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 5⅛% Senior Secured Notes due 2021 shall be deemed to be the 2021 Exchange Notes unless the context provides otherwise.

As discussed more fully in Note 16, the Company announced, on January 23, 2020, that CHS commenced a cash tender offer for any and all of the outstanding 5⅛% Senior Secured Notes due 2021 and issued a conditional notice of redemption to redeem all of the 5⅛% Senior Secured Notes due 2021 not purchased by CHS in the tender offer at a redemption price of 100.000% of the principal amount thereof plus accrued interest to, but not including, February 22, 2020.

6⅞% Senior Notes due 2022

On January 27, 2014, CHS completed a private offering of $3.0 billion aggregate principal amount of 6⅞% Senior Notes due February 1, 2022 (the “6⅞% Senior Notes due 2022”). The net proceeds from this issuance were used to finance the HMA merger. The 6⅞% Senior Notes due 2022 bear interest at a rate of 6.875% per annum, payable semiannually in arrears on February 1 and August 1 of each year. Interest on the 6⅞% Senior Notes due 2022 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6⅞% Senior Notes due 2022 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2022 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

Pursuant to a registration rights agreement entered into at the time of the issuance of the 6⅞% Senior Notes due 2022, as a result of an exchange offer made by CHS, all of the 6⅞% Senior Notes due 2022 issued in January 2014 were exchanged in October 2014 for new notes (the “6⅞% Exchange Notes”) having terms substantially identical in all material respects to the 6⅞% Senior Notes due 2022 (except that the exchange notes were issued under a registration statement pursuant to the 1933 Act). References to the 6⅞% Senior Notes due 2022 shall be deemed to be the 6⅞% Exchange Notes unless the context provides otherwise.

On June 22, 2018, CHS issued approximately $276 million aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 in exchange for approximately $368 million of 6⅞% Senior Notes due 2022.

On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of 8% Senior Secured Notes due December 15, 2027 (the “8% Senior Secured Notes due 2027”) and approximately $1.7 billion aggregate principal amount of 6⅞% Senior Notes due April 1, 2028 (the “6⅞% Senior Notes due 2028”) in exchange for approximately $2.4 billion of 6⅞% Senior Notes due 2022 (the “2019 Exchange Offer”).  Following the 2019 Exchange Offer, CHS had approximately $231 million aggregate principal amount of 6⅞% Senior Notes due 2022 outstanding.

6¼% Senior Secured Notes due 2023

On March 16, 2017, CHS completed a public offering of $2.2 billion aggregate principal amount of 6¼% Senior Secured Notes due March 31, 2023 (the “6¼% Senior Secured Notes due 2023”). The net proceeds from this issuance were used to finance the purchase or redemption of $700 million aggregate principal amount of CHS’ then outstanding 5⅛% Senior Secured Notes due 2018 and related fees and expenses, and the repayment of $1.445 billion of the then outstanding Term F Facility. On May 12, 2017, CHS completed a tack-on offering of $900 million aggregate principal amount of 6¼% Senior Secured Notes due 2023, increasing the total aggregate principal amount of 6¼% Senior Secured Notes due 2023 to $3.1 billion. A portion of the net proceeds from this issuance were used to finance the repayment of approximately $713 million aggregate principal amount of CHS’ then outstanding Term A Facility and related fees and expenses. The tack-on notes have identical terms, other than issue date and issue price, as the 6¼% Senior Secured Notes due 2023 issued on March 16, 2017. The 6¼% Senior Secured Notes due 2023 bear interest at a rate of 6.250% per annum, payable semiannually in arrears on March 31 and September 30 of each year. Interest on the 6¼% Senior Secured Notes due 2023 accrues from the date of original issuance. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6¼% Senior Secured Notes due 2023 are scheduled to mature on March 31, 2023. The 6¼% Senior Secured Notes due 2023 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under theABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 6¼% Senior Secured Notes due 2023 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral that also secures on a first-priority basis CHS’s senior-priority secured notes and (ii) second-priority liens on the ABL Collateral, in each case subject to permitted liens described in the indenture governing the 6¼% Senior Secured Notes due 2023.  

CHS is entitled, at its option, to redeem all or a portion of the 6¼% Senior Secured Notes due 2023 at any time prior to March 31, 2020, upon not less than 30 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6¼% Senior Secured Notes due 2023 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6¼% Senior Secured Notes due 2023. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 6¼% Senior Secured Notes due 2023 at any time prior to March 31, 2020 using the net proceeds from certain equity offerings at the redemption price of 106.250% of the principal amount of the 6¼% Senior Secured Notes due 2023 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 6¼% Senior Secured Notes due 2023 at any time on or after March 31, 2020 upon not less than 30 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
March 31, 2020 to March 30, 2021	103.125	%
March 31, 2021 to March 30, 2022	101.563	%
March 31, 2022 to March 30, 2023	100.000	%

As discussed more fully in Note 16, approximately $426 million aggregate principal amount of 6¼% Senior Secured Notes due 2023 were purchased in one or more privately negotiated transactions on February 6, 2020.

9⅞% Junior-Priority Secured Notes due 2023

On June 22, 2018, CHS completed a private offering of $1.770 billion aggregate principal amount of the 9⅞% Junior-Priority Secured Notes due 2023 in exchange for the same amount of 8% Senior Notes due 2019. The 9⅞% Junior-Priority Secured Notes due 2023 bore interest at a rate of 11.000% per annum, solely for the period from the issue date of such 9⅞% Junior-Priority Secured Notes due 2023 to, but excluding, June 22, 2019, after which they bear interest at a rate of 9.875% per annum. Interest is payable semi-annually in arrears on June 30 and December 31 of each year. The 9⅞% Junior-Priority Secured Notes due 2023 are scheduled to mature on June 20, 2023. The 9⅞% Junior-Priority Secured Notes due 2023 are unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS᾿ ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 9⅞% Junior-Priority Secured Notes due 2023 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023.

Prior to June 30, 2020, CHS may redeem some or all of the 9⅞% Junior-Priority Secured Notes due 2023 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 9⅞% Junior-Priority Secured Notes due 2023.In addition, at any time prior to June 30, 2020, CHS may redeem up to 40% of the aggregate principal amount of the 9⅞% Junior-Priority Secured Notes due 2023 with the proceeds from certain equity offerings at the redemption price of 109.875%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After June 30, 2020, CHS is entitled, at its option, to redeem all or a portion of the 9⅞% Junior-Priority Secured Notes due 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
June 30, 2020 to June 29, 2021	107.406	%
June 30, 2021 to June 29, 2022	103.703	%
June 30, 2022 to June 29, 2023	100.000	%

8⅛% Junior-Priority Secured Notes due 2024

On June 22, 2018, CHS completed a private offering of $1.355 billion aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 in exchange for approximately $1.079 billion of 7⅛% Senior Notes due 2020 and approximately $368 million of 6⅞% Senior Notes due 2022. The 8⅛% Junior-Priority Secured Notes due 2024 bear interest at a rate of 8.125% per annum, payable semi-annually in arrears on June 30 and December 31 of each year. The 8⅛% Junior-Priority Secured Notes due 2024 are scheduled to mature on June 20, 2024. The 8⅛% Junior-Priority Secured Notes due 2024 are unconditionally guaranteed on a junior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS᾿ ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 8⅛% Junior-Priority Secured Notes due 2024 and the related guarantees are secured by shared (i) second-priority liens on the Non-ABL Priority Collateral that secures on a first-priority basis the CHS’s senior-priority secured notes and (ii) third-priority liens on the ABL-Priority Collateral that secures on a first-priority basis the ABL Facility (and also secures on a second-priority basis CHS’s senior-priority secured notes), in each case subject to permitted liens described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024.

Prior to June 30, 2021, CHS may redeem some or all of the 8⅛% Junior-Priority Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8⅛% Junior-Priority Secured Notes due 2024. In addition, at any time prior to June 30, 2021, CHS may redeem up to 40% of the aggregate principal amount of the 8⅛% Junior-Priority Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.125%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After June 30, 2021, CHS is entitled, at its option, to redeem all or a portion of the 8⅛% Junior-Priority Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
June 30, 2021 to June 29, 2022	104.063	%
June 30, 2022 to June 29, 2023	102.031	%
June 30, 2023 to June 29, 2024	100.000	%

The indentures governing each of the 9⅞% Junior-Priority Secured Notes due 2023 and 8⅛% Junior-Priority Secured Notes due 2024 also prohibited CHS from purchasing, repurchasing, redeeming, defeasing or otherwise acquiring or retiring any outstanding 7⅛% Senior Notes due 2020 with: (a) cash or cash equivalents on hand as of the consummation of such 2018 exchange offers; (b) cash generated from operations; (c) proceeds from assets sales; or (d) proceeds from the issuance of, or in exchange for, secured debt, in each case, prior to May 15, 2020. CHS received a waiver from requisite holders of each series of the 9⅞% Junior-Priority Secured Notes due 2023 and 8⅛% Junior-Priority Secured Notes due 2024 waiving these restrictions prior to consummating the 2019 Exchange Offer.

8⅝% Senior Secured Notes due 2024

On July 6, 2018, CHS completed a private offering of $1.033 billion aggregate principal amount of 8⅝% Senior Secured Notes due January 15, 2024 (the “8⅝% Senior Secured Notes due 2024”). The 8⅝% Senior Secured Notes due 2024 bear interest at a rate of 8.625% per annum payable semi-annually in arrears on January 15 and July 15 of each year. The 8⅝% Senior Secured Notes due 2024 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under CHS᾿ ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 8⅝% Senior Secured Notes due 2024 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8⅝% Senior Secured Notes due 2024.  

Prior to January 15, 2021, CHS may redeem some or all of the 8⅝% Senior Secured Notes due 2024 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8⅝% Senior Secured Notes due 2024. In addition, at any time prior to January 15, 2021, CHS may redeem up to 40% of the aggregate principal amount of the 8⅝% Senior Secured Notes due 2024 with the proceeds from certain equity offerings at the redemption price of 108.625%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After January 15, 2021, CHS is entitled, at its option, to redeem all or a portion of the 8⅝% Senior Secured Notes due 2024 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
January 15, 2021 to January 14, 2022	104.313	%
January 15, 2022 to January 14, 2023	102.156	%
January 15, 2023 to January 14, 2024	100.000	%

8% Senior Secured Notes due 2026

On March 6, 2019, CHS completed a private offering of $1.601 billion aggregate principal amount of the 8% Senior Secured Notes due 2026. The net proceeds from this issuance were used to finance the repayment of approximately $1.557 billion aggregate principal amount of CHS’ then outstanding Term H Facility and related fees and expenses. On November 19, 2019, CHS completed a tack-on offering of $500 million aggregate principal amount of the Additional 2026 Notes, increasing the total aggregate principal amount of the 8% Senior Secured Notes due 2026 to $2.101 billion. CHS used the proceeds from the Additional 2026 Notes to repay amounts outstanding under the Revolving Facility, redeem all $121 million aggregate principal amount of CHS’ then outstanding 7⅛% Senior Notes due 2020 and repay borrowings outstanding under the ABL Facility. The Additional 2026 Notes have identical terms, other than issue date, issue price and the date from which interest initially accrued, as the 8% Senior Secured Notes due 2026 issued on March 6, 2019. The 8% Senior Secured Notes due 2026 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on March 15 and September 15 of each year. Interest on the 8% Senior Secured Notes due 2026 accrues from the initial issuance date of the 8% Senior Secured Notes due 2026. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 8% Senior Secured Notes due 2026 are scheduled to mature on March 15, 2026.

The 8% Senior Secured Notes due 2026 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2026 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2026.  

Prior to March 15, 2022, CHS may redeem some or all of the 8% Senior Secured Notes due 2026 at a redemption price equal to 100% of the principal amount of the notes redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2026. In addition, at any time prior to March 15, 2022, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2026 with the proceeds from certain equity offerings at the redemption price of 108.000%, plus accrued and unpaid interest, if any, to, but excluding, the applicable redemption date.

After March 15, 2022, CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2026 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
March 15, 2022 to March 14, 2023	104.000	%
March 15, 2023 to March 14, 2024	102.000	%
March 15, 2024 to March 14, 2026	100.000	%

8% Senior Secured Notes due 2027

On November 19, 2019, CHS issued approximately $700 million aggregate principal amount of the 8% Senior Secured Notes due 2027 in connection with the 2019 Exchange Offer. No cash proceeds were received from the 2019 Exchange Offer. The 8% Senior Secured Notes due 2027 bear interest at a rate of 8.000% per annum, payable semi-annually in arrears on June 15 and December 15 of each year. Interest on the 8% Senior Secured Notes due 2027 accrues from the initial issuance date of the 8% Senior Secured Notes due 2027. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 8% Senior Secured Notes due 2027 are scheduled to mature on December 15, 2027. The 8% Senior Secured Notes due 2027 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

The 8% Senior Secured Notes due 2027 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 8% Senior Secured Notes due 2027.  

CHS is entitled, at its option, to redeem all or a portion of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 8% Senior Secured Notes due 2027. In addition, CHS may redeem up to 40% of the aggregate principal amount of the 8% Senior Secured Notes due 2027 at any time prior to December 15, 2022 using the net proceeds from certain equity offerings at the redemption price of 108.000% of the principal amount of the 8% Senior Secured Notes due 2027 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 8% Senior Secured Notes due 2027 at any time on or after December 15, 2022 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
December 15, 2022 to December 14, 2023	104.000	%
December 15, 2023 to December 14, 2024	102.000	%
December 15, 2024 to December 14, 2027	100.000	%

6⅞% Senior Notes due 2028

On November 19, 2019, CHS issued approximately $1.7 billion aggregate principal amount of the 6⅞% Senior Notes due 2028 in connection with the 2019 Exchange Offer. No cash proceeds were received in the 2019 Exchange Offer. The 6⅞% Senior Notes due 2028 bear interest at a rate of 6.875% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. Interest on the 6⅞% Senior 2028 Notes accrues from the initial issuance date of the 6⅞% Senior Notes due 2028. Interest is calculated on the basis of a 360-day year comprised of twelve 30-day months. The 6⅞% Senior Notes due 2028 are scheduled to mature on April 1, 2028.

The 6⅞% Senior Notes due 2028 are unconditionally guaranteed on a senior-priority unsecured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS.

CHS is entitled, at its option, to redeem all or a portion of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023, upon not less than 15 nor more than 60 days’ notice, at a price equal to 100% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed plus accrued and unpaid interest, if any, plus a “make-whole” premium, as described in the indenture governing the 6⅞% Senior Notes due 2028. In addition, the Issuer may redeem up to 40% of the aggregate principal amount of the 6⅞% Senior Notes due 2028 at any time prior to April 1, 2023 using the net proceeds from certain equity offerings at the redemption price of 106.875% of the principal amount of the 6⅞% Senior Notes due 2028 redeemed, plus accrued and unpaid interest, if any.

CHS may redeem some or all of the 6⅞% Senior Notes due 2028 at any time on or after April 1, 2023 upon not less than 15 nor more than 60 days’ notice, at the following redemption prices (expressed as a percentage of principal amount on the redemption date), plus accrued and unpaid interest, if any, to the redemption date (subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date), if redeemed during the periods set forth below:

Period	Redemption Price
April 1, 2023 to March 31, 2024	103.438	%
April 1, 2024 to March 31, 2025	101.719	%
April 1, 2025 to March 31, 2028	100.000	%

ABL Facility

On April 3, 2018, the Company and CHS entered into an asset-based loan (ABL) credit agreement (the “ABL Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders and other agents party thereto. Pursuant to the ABL Credit Agreement, the lenders have extended to CHS a revolving asset-based loan facility (the “ABL Facility”) in the maximum aggregate principal amount of $1.0 billion, subject to borrowing base capacity. On November 12, 2019, the Company and CHS entered into Amendment No. 2 to the ABL Facility, resulting in an increase of the portion of the commitments under the ABL Facility that are available in the form of letters of credit from $50 million to $200 million. CHS and all domestic subsidiaries of CHS that guarantee CHS’ other outstanding senior and senior secured indebtedness guarantee the obligations of CHS under the ABL Facility. Subject to certain exceptions, all obligations under the ABL Facility and the related guarantees are secured by a perfected first-priority security interest in substantially all of the receivables, deposit, collection and other accounts and contract rights, books, records and other instruments related to the foregoing of the Company, CHS and the guarantors, as well as a perfected junior-priority security interest in substantially all of the other assets of the Company, CHS and the guarantors, subject to customary exceptions and intercreditor arrangements. In connection with entering into the ABL Credit Agreement and the ABL Facility, the Company repaid in full and terminated its accounts receivable loan agreement with a group of lenders and banks. At December 31, 2019, the available borrowing base under the ABL Facility was $860 million, of which the Company had outstanding borrowings of $273 million and letters of credit issued of $145 million. The issued letters of credit were primarily in support of potential insurance-related claims and certain bonds.

Borrowings under the ABL Facility bear interest at a rate per annum equal to an applicable percentage, plus, at the Borrower’s option, either (a) an Alternative base rate or (b) a LIBOR rate. From and after December 31, 2018, the applicable percentage under the ABL Facility is determined based on excess availability as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of 1.25%,  1.50% and 1.75% for loans based on the Alternative base rate and 2.25%,  2.50% and 2.75% for loans based on the LIBOR rate. From and after September 30, 2018, the applicable commitment fee rate under the ABL Facility is determined based on average utilization as a percentage of the maximum commitment amount under the ABL Facility at a rate per annum of either 0.50% or 0.625% times the unused portion of the ABL Facility.

Principal amounts outstanding under the ABL Facility will be due and payable in full on April 3, 2023. The ABL Facility includes a 91-day springing maturity applicable if more than $250 million in the aggregate principal amount of the 5⅛% Senior Secured Notes due 2021, 6⅞% Senior Notes due 2022 or 6¼% Senior Secured Notes due 2023 or any indebtedness incurred to refinance the foregoing are scheduled to mature or similarly become due on a date prior to April 3, 2023.  In such event, principal amounts outstanding under the ABL Facility will be accelerated and all amounts outstanding under the ABL Facility will become immediately due and payable.

The ABL Facility contains customary representations and warranties, subject to limitations and exceptions, and customary covenants restricting the Company’s ability, subject to certain exceptions, to, among other things (1) declare dividends, make distributions or redeem or repurchase capital stock, (2) prepay, redeem or repurchase other debt, (3) incur liens or grant negative pledges, (4) make loans and investments and enter into acquisitions and joint ventures, (5) incur additional indebtedness or provide certain guarantees, (6) engage in mergers, acquisitions and asset sales, (7) conduct transactions with affiliates, (8) alter the nature of the Company’s, CHS’ or the guarantors’ businesses, (9) grant certain guarantees with respect to physician practices, (10) engage in sale and leaseback transactions or (11) change the Company’s fiscal year. The Company is also required to comply with a consolidated fixed coverage ratio, upon certain triggering events described below, and various affirmative covenants. The consolidated fixed coverage ratio is calculated as the ratio of (x) consolidated EBITDA (as defined in the ABL Facility) less capital expenditures to (y) the sum of consolidated interest expense (as defined in the ABL Facility), scheduled principal payments, income taxes and restricted payments made in cash or in permitted investments. For purposes of calculating the consolidated fixed charge coverage ratio, the calculation of consolidated EBITDA as defined in the ABL Facility is a trailing 12-month calculation that begins with the Company’s consolidated net income, with certain adjustments for interest, taxes, depreciation and amortization, net income attributable to noncontrolling interests, stock compensation expense, restructuring costs, and the financial impact of other non-cash or non-recurring items recorded during any such 12-month period. The consolidated fixed charge coverage ratio is a required covenant only in periods where the total borrowings outstanding under the ABL Facility reduce the amount available in the facility to less than the greater of (i) $95 million and (ii) 10% of the calculated borrowing base. As a result, in the event the Company has less than $95 million available under the ABL Facility, the Company would need to comply with the consolidated fixed charge coverage ratio. At December 31, 2019, the Company is not subject to the consolidated fixed charge coverage ratio as such triggering event had not occurred during the last twelve months ended December 31, 2019.

In addition, in the event the amount of borrowings and letters of credit outstanding at any time under the ABL Facility exceeds the borrowing base at such time, the Company will be required to, first, repay outstanding borrowings and, second, replace or cash collateralize outstanding letters of credit, in an aggregate amount sufficient to eliminate such excess.

Events of default under the ABL Facility include, but are not limited to, (1) CHS’ failure to pay principal, interest, fees or other amounts under the ABL Facility Agreement when due (taking into account any applicable grace period), (2) any representation or warranty proving to have been materially incorrect when made, (3) covenant defaults subject, with respect to certain covenants, to an available cure and applicable grace periods, (4) bankruptcy and insolvency events, (5) a cross default to certain other debt, (6) certain undischarged judgments (not paid within an applicable grace period), (7) a change of control (as defined), (8) certain ERISA-related defaults and (9) the invalidity or impairment of specified security interests, guarantees or subordination provisions in favor of the ABL Agent or lenders under the ABL Facility.

Loss (Gain) from Early Extinguishment of Debt

The financing and repayment transactions discussed above resulted in a loss from early extinguishment of debt of $54 million and $40 million for the years ended December 31, 2019 and 2017, respectively, and a gain from the early extinguishment of debt of $31 million for the year ended December 31, 2018, and an after-tax loss of $42 million and $26 million for the years ended December 31, 2019 and 2017, respectively, and an after-tax gain of $23 million for the year ended December 31, 2018.

Other Debt

As of December 31, 2019, other debt consisted primarily of other obligations maturing in various installments through 2024.

To limit the effect of changes in interest rates on a portion of the Company’s long-term borrowings, the Company is a party to one interest swap agreement with a notional amount of approximately $300 million as of December 31, 2019. The Company receives a variable rate of interest on this swap based on the three-month LIBOR in exchange for the payment of a fixed rate of interest. See Note 7 for additional information regarding these swaps.

As of December 31, 2019, the scheduled maturities of long-term debt outstanding, including finance lease obligations for each of the next five years and thereafter are as follows (in millions):

Year Ending December 31,		Amount
2020	$	20
2021		1,010
2022		237
2023		5,149
2024		2,393
Thereafter		4,743
Total maturities		13,552
Less: Deferred debt issuance costs		(132)
Plus: Unamortized note premium		(15)
Total long-term debt	$	13,405

The Company paid interest of $1.0 billion, $936 million and $852 million on borrowings during the years ended December 31, 2019, 2018 and 2017, respectively.

XML

Employee Benefit Plans

12 Months Ended

Dec. 31, 2019

Employee Benefit Plans [Abstract]

Employee Benefit Plans Disclosure

10.  EMPLOYEE BENEFIT PLANS

The Company maintains various benefit plans, including defined contribution plans, defined benefit plans and deferred compensation plans, for which certain of the Company’s subsidiaries are the plan sponsors. The CHS/Community Health Systems, Inc. Retirement Savings Plan is a defined contribution plan which covers the majority of the Company’s employees. Employees at these locations whose employment is covered by collective bargaining agreements are generally eligible to participate in the CHS/Community Health Systems, Inc. Standard 401(k) Plan. Total expense to the Company under the 401(k) plans was $85 million, $90 million and $94 million for the years ended December 31, 2019, 2018 and 2017, respectively, and is recorded in salaries and benefits expense on the consolidated statements of loss.

The Company maintains unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability for the deferred compensation plans was $175 million and $163 million as of December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The Company had assets of $153 million and $146 million as of December 31, 2019 and 2018, respectively, in a non-qualified plan trust generally designated to pay benefits of the deferred compensation plans, consisting of equity securities of $23 million and $32 million as of December 31, 2019 and 2018, respectively, and company-owned life insurance contracts of $130 million and $114 million as of December 31, 2019 and 2018, respectively.

The Company provides an unfunded Supplemental Executive Retirement Plan (“SERP”) for certain members of its executive management. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the SERP. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations and net periodic cost in future periods. Benefits expense under the SERP was $7 million, $9 million and $16 million for the years ended December 31, 2019, 2018 and 2017, respectively. The accrued benefit liability for the SERP totaled $72 million and $66 million at December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used in determining net periodic cost for the years ended December 31, 2019 and 2018 were a discount rate of 4.2% and 3.4% and an annual salary increase of 3.0% and 2.0%. The Company had equity securities in a rabbi trust generally designated to pay benefits of the SERP in the amounts of $84 million and $74 million at December 31, 2019 and 2018, respectively. These amounts are included in other assets, net on the consolidated balance sheets.

During 2018, certain members of executive management of the Company that were participants in the SERP retired and met the requirements for payout of their SERP retirement benefit. The SERP payout provisions require payment to the participant in an actuarially determined lump sum amount six months after the participant retires from the Company. Such amounts were paid out of the rabbi trust. As required by the pension accounting rules in U.S. GAAP, the Company recognized a non-cash settlement loss of approximately $2 million during the year ended December 31, 2018. There was no settlement loss during the year ended December 31, 2019.

The Company maintains the CHS/Community Health Systems, Inc. Retirement Income Plan (“Pension Plan”), which is a defined benefit, non-contributory pension plan that covers certain employees at three of its formerly owned hospitals. The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of the Employee Retirement Income Security Act of 1974, as amended. The Company expects to make contributions of approximately $1 million to the Pension Plan in 2020. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for its net periodic costs for the Pension Plan. Variances from actuarially assumed rates will result in increases or decreases in benefit obligations, net periodic cost and funding requirements in future periods. Benefits expense under the Pension Plan was less than $1 million for both of the years ended December 31, 2019 and 2018, and was $7 million for the year ended December 31, 2017. The accrued benefit liability for the Pension Plan totaled $12 million and $11 million at December 31, 2019 and 2018, respectively, and is included in other long-term liabilities on the consolidated balance sheets. The weighted-average assumptions used for determining the net periodic cost for the year ended December 31, 2019 was a discount rate of 4.2% and the expected long-term rate of return on assets of 6.0%.

XML

Consolidated Statements of Loss - USD ($)	3 Months Ended																12 Months Ended
	Dec. 31, 2019		Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019		Dec. 31, 2018		Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Net operating revenues (see Note 1)	$ 3,286,000,000		$ 3,246,000,000		$ 3,302,000,000		$ 3,376,000,000		$ 3,453,000,000		$ 3,451,000,000		$ 3,562,000,000		$ 3,689,000,000		$ 13,210,000,000	[1]	$ 14,155,000,000	[1]	$ 15,353,000,000
Operating costs and expenses:
Salaries and benefits																	5,947,000,000		6,384,000,000		7,376,000,000
Supplies																	2,151,000,000		2,355,000,000		2,672,000,000
Other operating expenses																	3,303,000,000		3,496,000,000		3,864,000,000
Government and other legal settlements and related costs																	93,000,000		11,000,000		(31,000,000)
Electronic health records incentive reimbursement																	(1,000,000)		(4,000,000)		(28,000,000)
Lease cost and rent																	321,000,000		337,000,000		394,000,000
Depreciation and amortization																	608,000,000		700,000,000		861,000,000
Impairment and loss on sale of businesses, net																	138,000,000		668,000,000		2,123,000,000
Total operating costs and expenses																	12,560,000,000		13,947,000,000		17,231,000,000
Income from operations																	650,000,000		208,000,000		(1,878,000,000)
Interest expense, net of interest income of $3, $7, and $11 in 2019, 2018 and 2017, respectively																	1,041,000,000		976,000,000		931,000,000
Loss (gain) from early extinguishment of debt																	54,000,000		(31,000,000)		40,000,000
Equity in earnings of unconsolidated affiliates																	(15,000,000)		(22,000,000)		(16,000,000)
Loss from continuing operations before income taxes	(115,000,000)		(72,000,000)		(149,000,000)		(94,000,000)		(369,000,000)		(204,000,000)		(129,000,000)		(13,000,000)		(430,000,000)	[1]	(715,000,000)	[1]	(2,833,000,000)
Provision for (benefit from) income taxes																	160,000,000		(11,000,000)		(449,000,000)
Loss from continuing operations	(346,000,000)		2,000,000		(146,000,000)		(101,000,000)		(299,000,000)		(308,000,000)		(91,000,000)		(6,000,000)		(590,000,000)	[1]	(704,000,000)	[1]	(2,384,000,000)
Discontinued operations, net of taxes:
Loss from operations of entities sold or held for sale																					(6,000,000)
Impairment of hospitals sold or held for sale																	0		0		(6,000,000)
Loss from discontinued operations, net of taxes																					(12,000,000)
Net loss																	(590,000,000)		(704,000,000)		(2,396,000,000)
Less: Net income attributable to noncontrolling interests																	85,000,000		84,000,000		63,000,000
Net loss attributable to Community Health Systems, Inc. stockholders	$ (373,000,000)		$ (17,000,000)		$ (167,000,000)		$ (118,000,000)		$ (328,000,000)		$ (325,000,000)		$ (110,000,000)		$ (25,000,000)		$ (675,000,000)	[1]	$ (788,000,000)	[1]	$ (2,459,000,000)
Loss per share attributable to Community Health Systems, Inc. common stockholders:
Basic	$ (3.27)	[2]	$ (0.15)	[2]	$ (1.47)	[2]	$ (1.04)	[2]	$ (2.91)	[2]	$ (2.88)	[2]	$ (0.97)	[2]	$ (0.22)	[2]	$ (5.93)	[1],[2]	$ (6.99)	[1],[2]	$ (22.00)
Diluted	(3.27)		(0.15)		(1.47)		(1.04)		(2.91)		(2.88)		(0.97)		(0.22)		(5.93)	[1]	(6.99)	[1]	(22.00)
Basic loss per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	(3.27)	[2]	(0.15)	[2]	(1.47)	[2]	(1.04)	[2]	(2.91)	[2]	(2.88)	[2]	(0.97)	[2]	(0.22)	[2]	(5.93)	[1],[2]	(6.99)	[1],[2]	(21.89)
Discontinued operations																					(0.11)
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	$ (3.27)		$ (0.15)		$ (1.47)		$ (1.04)		$ (2.91)		$ (2.88)		$ (0.97)		$ (0.22)		$ (5.93)	[1]	$ (6.99)	[1]	(21.89)
Discontinued operations																					$ (0.11)
Weighted-average number of shares outstanding:
Basic	113,935,629		113,891,721		113,862,097		113,257,608		112,909,869		112,865,482		112,837,944		112,291,496		113,739,046	[1]	112,728,274	[1]	111,769,821
Diluted	113,935,629		113,891,721		113,862,097		113,257,608		112,909,869		112,865,482		112,837,944		112,291,496		113,739,046	[1]	112,728,274	[1]	111,769,821
Operating Revenues (Net of Contractual Allowances and Discounts) [Member]
Net operating revenues (see Note 1)																					$ 18,398,000,000
Provision for Bad Debts [Member]
Net operating revenues (see Note 1)																					$ 3,045,000,000

[1] Total quarterly amounts may not add due to rounding.

[2] Total per share amounts may not add due to rounding.

XML

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 216	$ 196
Patient accounts receivable	2,258	2,352
Supplies	354	402
Prepaid income taxes	48	3
Prepaid expenses and taxes	193	196
Other current assets	358	400
Total current assets	3,427	3,549
Property and equipment
Land and improvements	560	597
Buildings and improvements	5,878	6,228
Equipment and fixtures	3,215	3,476
Property and equipment	9,653	10,301
Less accumulated depreciation and amortization	(4,045)	(4,162)
Property and equipment, net	5,608	6,139
Goodwill	4,328	4,559
Deferred income taxes	38	69
Other assets, net of accumulated amortization of $981 and $939 at December 31, 2019 and 2018, respectively	2,208	1,543
Total assets	15,609	15,859
Current liabilities:
Current maturities of long-term debt	20	204
Current operating lease liabilities	136
Accounts payable	811	887
Accrued liabilities:
Employee compensation	594	627
Accrued interest	189	206
Other	532	468
Total current liabilities	2,282	2,392
Long-term debt	13,385	13,392
Deferred income taxes	200	26
Long-term operating lease liabilities	487
Other long-term liabilities	894	1,008
Total liabilities	17,248	16,818
Redeemable noncontrolling interests in equity of consolidated subsidiaries	502	504
Commitments and contingencies (Note 15)
Community Health Systems, Inc. stockholders' deficit:
Preferred stock, $.01 par value per share, 100,000,000 shares authorized; none issued
Common stock, $.01 par value per share, 300,000,000 shares authorized; 117,822,631 shares issued and outstanding at December 31, 2019, and 116,248,376 shares issued and outstanding at December 31, 2018	1	1
Additional paid-in capital	2,008	2,017
Accumulated other comprehensive loss	(9)	(10)
Accumulated deficit	(4,218)	(3,543)
Total Community Health Systems, Inc. stockholders' deficit	(2,218)	(1,535)
Noncontrolling interests in equity of consolidated subsidiaries	77	72
Total stockholders' deficit	(2,141)	(1,463)
Total liabilities and stockholders' deficit	$ 15,609	$ 15,859

XML

Basis of Presentation and Significant Accounting Policies (Policy)

12 Months Ended

Dec. 31, 2019

Basis of Presentation and Significant Accounting Policies [Abstract]

Basis of Accounting, Policy

Business.    Community Health Systems, Inc. is a holding company and operates no business in its own name. On a consolidated basis, Community Health Systems, Inc. and its subsidiaries (collectively the “Company”) own, lease and operate general acute care hospitals in communities across the country. As of December 31, 2019, the Company owned or leased 102 hospitals, included in continuing operations, including two stand-alone rehabilitation or psychiatric hospitals, licensed for 16,240 beds in 18 states. Throughout these notes to the consolidated financial statements, Community Health Systems, Inc. (the “Parent”) and its consolidated subsidiaries are referred to on a collective basis as the “Company.” This drafting style is not meant to indicate that the publicly-traded Parent or any particular subsidiary of the Parent owns or operates any asset, business, or property. The hospitals, operations and businesses described in this filing are owned and operated, and management services provided, by distinct and indirect subsidiaries of Community Health Systems, Inc.

As of December 31, 2019, Florida, Texas and Indiana represent the only areas of significant geographic concentration. Net operating revenues generated by the Company’s hospitals in Florida, as a percentage of consolidated operating revenues, were 14.3% in both 2019 and 2018 and 14.0% in 2017. Net operating revenues generated by the Company’s hospitals in Texas, as a percentage of consolidated operating revenues, were 12.2% in 2019, 11.7% in 2018 and 10.9% in 2017. Net operating revenues generated by the Company’s hospitals in Indiana, as a percentage of consolidated operating revenues, were 13.7% in 2019, 12.5% in 2018 and 11.6% in 2017.

Use of Estimates, Policy

Use of Estimates.    The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements. Actual results could differ from these estimates under different assumptions or conditions.

Consolidation, Policy

Principles of Consolidation.    The consolidated financial statements include the accounts of the Parent, its subsidiaries, all of which are controlled by the Parent through majority voting control, and variable interest entities for which the Company is the primary beneficiary. All intercompany accounts, profits and transactions have been eliminated. Noncontrolling interests in less-than-wholly-owned consolidated subsidiaries of the Parent are presented as a component of total equity to distinguish between the interests of the Parent and the interests of the noncontrolling owners. Revenues, expenses and income from continuing operations from these subsidiaries are included in the consolidated amounts as presented on the consolidated statements of loss, along with a net income measure that separately presents the amounts attributable to the controlling interests and the amounts attributable to the noncontrolling interests for each of the periods presented. Noncontrolling interests that are redeemable or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company are presented in mezzanine equity on the consolidated balance sheets.

Cost of Revenue, Policy

Cost of Revenue.    Substantially all of the Company’s operating costs and expenses are “cost of revenue” items. Operating costs that could be classified as general and administrative by the Company would include the Company’s corporate office costs at its Franklin, Tennessee office which were collectively $184 million, $181 million and $189 million for the years ended December 31, 2019, 2018 and 2017, respectively. Included in these corporate office costs is stock-based compensation of $10 million, $13 million and $24 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Cash Equivalents, Policy

Cash Equivalents.    The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents.

Supplies, Policy

Supplies.    Supplies, principally medical supplies, are stated at the lower of cost (first-in, first-out basis) or market.

Marketable Securities, Policy

Marketable Securities.    Prior to adoption of Accounting Standards Update (“ASU”) 2016-01 on January 1, 2018, the Company’s marketable securities were classified as trading or available-for-sale. Trading securities were reported at fair value with unrealized gains and losses included in earnings. Available-for-sale securities were carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. After adoption of ASU 2016-01 on January 1, 2018, the Company’s marketable securities consist of debt securities that are classified as trading or available-for-sale and equity securities. Equity securities are reported at fair value with changes in fair value included in earnings. Available-for-sale debt securities are carried at fair value as determined by quoted market prices, with unrealized gains and losses reported as a separate component of stockholders’ (deficit) equity. Trading securities are reported at fair value with unrealized gains and losses included in earnings. Other comprehensive loss, net of tax, included an unrealized gain of $4 million and $8 million during the years ended December 31, 2019 and 2017, respectively, and an unrealized loss of $2 million during the year ended December 31, 2018, related to these available-for-sale debt securities.

Property and Equipment, Policy

Property and Equipment.    Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the land and improvements (3 to 20 years), buildings and improvements (5 to 40 years) and equipment and fixtures (3 to 18 years). Costs capitalized as construction in progress were $219 million at both December 31, 2019 and 2018. Expenditures for renovations and other significant improvements are capitalized; however, maintenance and repairs which do not improve or extend the useful lives of the respective assets are charged to operations as incurred. Interest capitalized related to construction in progress was $20 million, $15 million and $11 million for the years ended December 31, 2019, 2018 and 2017, respectively. Purchases of property and equipment and internal-use software accrued in accounts payable and not yet paid were $93 million and $115 million at December 31, 2019 and 2018, respectively.

The Company also leases certain facilities and equipment under finance leases (see Note 9). Such assets are amortized on a straight-line basis over the lesser of the term of the lease or the remaining useful lives of the applicable assets. During the year ended December 31, 2019, the Company had non-cash investing activity of $6 million related to certain facility and equipment additions that were financed through finance leases and other debt.

Goodwill, Policy

Goodwill.    Goodwill represents the excess of the fair value of the consideration conveyed in the acquisition over the fair value of net assets acquired. Goodwill arising from business combinations is not amortized. Goodwill is required to be evaluated for impairment at the same time every year and when an event occurs or circumstances change such that it is more likely than not that impairment may exist. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. As further discussed in Note 4, the Company recorded an impairment charge of $1.419 billion during the year ended December 31, 2017. There was no goodwill impairment charge during the years ended December 31, 2019 and 2018 as a result of the Company’s annual impairment evaluation.

Other Assets, Policy

Other Assets.    Other assets consist of the insurance recovery receivable from excess insurance carriers related to the Company’s self-insured malpractice general liability and workers’ compensation insurance liability; costs to recruit physicians to the Company’s markets, which are deferred and expensed over the term of the respective physician recruitment contract, generally three years, and included in amortization expense; equity method investments; and capitalized internal-use software costs, which are expensed over the expected useful life, which is generally three years for routine software and eight to ten years for major software projects, and included in amortization expense. Included in the increase in other investments in the consolidated statement of cash flows for the year ended December 31, 2019, was cash paid of approximately $28 million to increase investments in certain equity method investments.

Revenue Recognition, Policy

Revenue Recognition.  On January 1, 2018, the Company adopted the new revenue recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the FASB Accounting Standards Codification (“ASC”) as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue.

The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, upon the Company’s adoption of ASC 606 the majority of what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore was included as a reduction to net operating revenues in 2019 and 2018. For changes in credit issues not assessed at the date of service, the Company prospectively recognizes those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required such provision to be presented separately as a component of net operating revenues. Additionally, upon adoption of ASC 606 the allowance for doubtful accounts of approximately $3.9 billion as of January 1, 2018 was reclassified as a component of net patient accounts receivable. Other than these changes in presentation on the consolidated statement of operations and consolidated balance sheet, the adoption of ASC 606 did not have a material impact on the consolidated results of operations for the years ended December 31, 2019 and 2018, and the Company does not expect it to have a material impact on its consolidated results of operations on a prospective basis.

As part of the adoption of ASC 606, the Company elected two of the available practical expedients provided for in the standard. First, the Company does not adjust the transaction price for any financing components as those were deemed to be insignificant. Additionally, the Company expenses all incremental customer contract acquisition costs as incurred because such costs are not material and would be amortized over a period less than one year.

Net Operating Revenues, Policy

Net Operating Revenues

Net operating revenues are recorded at the transaction price estimated by the Company to reflect the total consideration due from patients and third-party payors in exchange for providing goods and services in patient care. These services are considered to be a single performance obligation and have a duration of less than one year. Revenues are recorded as these goods and services are provided. The transaction price, which involves significant estimates, is determined based on the Company’s standard charges for the goods and services provided, with a reduction recorded for price concessions related to third party contractual arrangements as well as patient discounts and other patient price concessions. During the years ended December 31, 2019 and 2018, the impact of changes to the inputs used to determine the transaction price was considered immaterial to the current period.

States utilize supplemental reimbursement programs for the purpose of providing reimbursement to providers that is not specifically tied to an individual’s care, some of which offsets a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from the Centers for Medicare & Medicaid Services and are funded with a combination of state and federal resources, including, in certain instances, fees or taxes levied on the providers. Under these supplemental programs, the Company recognizes revenue and related expenses in the period in which amounts are estimable and collection is reasonably assured. Reimbursement under these programs is reflected in net operating revenues and fees, taxes or other program-related costs are reflected in other operating expenses.

The Company’s net operating revenues during the years ended December 31, 2019 and 2018 have been presented in the following table based on an allocation of the estimated transaction price with the patient between the primary patient classification of insurance coverage (in millions):

	Year Ended December 31,
	2019			2018
Medicare	$	3,331	-	$	3,730
Medicaid		1,736			1,876
Managed Care and other third-party payors		8,014			8,349
Self-pay		129			200
Total	$	13,210		$	14,155

Operating revenues, net of contractual allowances and discounts (but before the provision for bad debts) by payor have been presented in the following table for the year ended December 31, 2017, as follows, consistent with the presentation prior to the adoption of ASC 606 on January 1, 2018 (in millions):

	Year Ended
	December 31, 2017
Medicare	$	4,188
Medicaid		1,900
Managed Care and other third-party payors		9,991
Self-pay		2,319
Total	$	18,398

Patient Accounts Receivable. Policy

Patient Accounts Receivable   

Patient accounts receivable are recorded at net realizable value based on certain assumptions determined by each payor. For third-party payors including Medicare, Medicaid, and Managed Care, the net realizable value is based on the estimated contractual reimbursement percentage, which is based on current contract prices or historical paid claims data by payor. For self-pay accounts receivable, which includes patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience without regard to aging category. These estimates are adjusted for estimated conversions of patient responsibility portions, expected recoveries and any anticipated changes in trends.  

Patient accounts receivable can be impacted by the effectiveness of the Company’s collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Company also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Company has recorded amounts due to third-party payors of $83 million and $144 million as of December 31, 2019 and December 31, 2018, respectively, and these amounts are included in accrued liabilities-other in the accompanying consolidated balance sheets. Amounts due from third-party payors were $137 million and $155 million as of December 31, 2019 and December 31, 2018, respectively, and are included in other current assets in the accompanying consolidated balance sheets. Substantially all Medicare and Medicaid cost reports are final settled through 2016.

Charity Care, Policy

Charity Care

In the ordinary course of business, the Company renders services to patients who are financially unable to pay for hospital care. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges for those patients who are financially unable to pay and that otherwise do not qualify for reimbursement from a governmental program are not reported in net operating revenues, and are thus classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the federal poverty level guidelines, as established by the federal government.

These charity care services are estimated to be $540 million, $491 million and $482 million for the years ended December 31, 2019, 2018 and 2017, respectively, representing the value (at the Company’s standard charges) of these charity care services that are excluded from net operating revenues. The estimated cost incurred by the Company to provide these charity care services to patients who are unable to pay was approximately $66 million, $62 million and $62 million for the years ended December 31, 2019, 2018 and 2017, respectively. The estimated cost of these charity care services was determined using a ratio of cost to gross charges and applying that ratio to the gross charges associated with providing care to charity patients for the period.

During 2017 and culminating with the financial close process at December 31, 2017, the Company developed new accounting methodologies and processes to implement ASU 2014-09, the accounting standard for revenue recognition that was adopted by the Company effective January 1, 2018. By implementing new data extraction techniques and updated hindsight information on historical collection data, the Company was able to better estimate the net amount after contractual allowances owed by the third-party payor and what will be owed by the patient based on historical experience. Such updated information included portfolio-level data related to historical collection amounts on an individual hospital and patient level that previously had not been readily available. Using this information the Company created a new accounting process by which it can estimate contractual allowances on a per patient basis. In addition to this new accounting methodology, the Company also revised its methods of estimating contractual allowances to (1) expand the hindsight period over which the Company analyzes payors’ historical paid claims data to estimate contractual allowances, (2) expand the basis for payor denied claims to refine the hindsight reserve for such denials, and (3) adjust the contractual allowances for certain categories of commercial payors using more precise historical experience based on recent patterns of account reimbursement. Additionally, the Company evaluated the estimated collection of those amounts due from the patient as part of the Company’s estimate of the allowance for doubtful accounts. This analysis also included an evaluation of patient accounts receivable retained after the divestiture of 30 hospitals throughout 2017, and certain other revenues. Based on these new accounting processes and methodologies, the Company recorded a change in estimate during the three months ended December 31, 2017 to increase contractual allowances by approximately $197 million, and to record additional provision for bad debts and increase the allowance for doubtful accounts by $394 million. The total impact of the change in estimate recorded during the three months ended December 31, 2017 was a decrease to net operating revenues of $591 million.

Electronic Health Records Incentive Reimbursement, Policy

Electronic Health Records Incentive Reimbursement.    The federal government has implemented a number of regulations and programs designed to promote the use of electronic health records (“EHR”) technology and, pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), established requirements for a Medicare and Medicaid incentive payments program for eligible hospitals and professionals that adopt and meaningfully use certified EHR technology. The Company utilizes a gain contingency model to recognize EHR incentive payments. Recognition occurs when the eligible hospitals adopt or demonstrate meaningful use of certified EHR technology for the applicable payment period and have available the Medicare cost report information for the relevant full cost report year used to determine the final incentive payment.

Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology. Since the information for the relevant full Medicare cost report year is available at the time of attestation, the incentive income from resolving the gain contingency is recognized when eligible hospitals adopt, implement, upgrade or demonstrate meaningful use of certified EHR technology.

Medicare EHR incentive payments are calculated based on the Medicare cost report information for the full cost report year that began during the federal fiscal year in which meaningful use is demonstrated. Since the necessary information is only available at the end of the relevant full Medicare cost report year and after the cost report is settled, the incentive income from resolving the gain contingency is recognized when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year to determine the final incentive payment is available.

In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the gain for EHR incentive payments is deferred until all recognition criteria described above are met.

Eligibility for annual Medicare incentive payments is dependent on providers successfully attesting to the meaningful use of EHR technology. Medicaid incentive payments are available to providers in the first payment year that they adopt, implement or upgrade certified EHR technology; however, providers must demonstrate meaningful use of such technology in any subsequent payment years to qualify for additional incentive payments. Medicaid EHR incentive payments are fully funded by the federal government and administered by the states; however, the states are not required to offer EHR incentive payments to providers.

The Company recognized approximately $1 million, $4 million and $28 million for the years ended December 31, 2019, 2018 and 2017, respectively, of incentive reimbursement for HITECH incentives from Medicare and Medicaid related to certain of the Company’s hospitals and for certain of the Company’s employed physicians that have demonstrated meaningful use of certified EHR technology or have completed attestations to their adoption or implementation of certified EHR technology. These incentive reimbursements are presented as a reduction of operating costs and expenses on the consolidated statements of loss. The Company received cash related to the incentive reimbursement for HITECH incentives of approximately less than $1 million, $4 million and $41 million for the years ended December 31, 2019, 2018 and 2017, respectively. The Company recorded no deferred revenue in connection with the receipt of these cash payments at December 31, 2019, 2018 or 2017.

Leases

Leases. On January 1, 2019, the Company adopted the cumulative accounting standard updates initially issued by the FASB in February 2016 that amend the accounting for leases and are codified as Accounting Standards Codification Topic 842 (“ASC 842”). These changes to the lease accounting model require operating leases be recorded on the balance sheet through recognition of a liability for the discounted present value of future fixed lease payments and a corresponding right-of-use (“ROU”) asset. The Company’s accounting for finance leases remained substantially unchanged from its prior accounting for capital leases. The ROU asset recorded at commencement of the lease represents the right to use the underlying asset over the lease term in exchange for the lease payments. Leases with an initial term of 12 months or less that do not have an option to purchase the underlying asset that is deemed reasonably certain to be exercised are not recorded on the balance sheet; rather, rent expense for these leases is recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease. When readily determinable, the Company uses the interest rate implicit in a lease to determine the present value of future lease payments. For leases where the implicit rate is not readily determinable, the Company’s incremental borrowing rate is utilized. The Company calculates its incremental borrowing rate on a quarterly basis using a third-party financial model that estimates the rate of interest the Company would have to pay to borrow an amount equal to the total lease payments on a collateralized basis over a term similar to the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

   The Company elected the amended transition requirements allowed for by the FASB in ASU 2018-11, which provide entities relief by allowing them not to recast prior comparative periods from the adoption of ASC 842. As a result, the prior year comparative financial statements have not been restated to reflect the adoption of ASC 842. Additionally, the Company elected the package of practical expedients available in ASC 842 upon adoption whereby an entity need not reassess expired contracts for lease identification or classification as a finance or operating lease, or for the reassessment of initial direct costs. The Company has not elected the practical expedient to use hindsight to determine the lease term for its leases at transition. Certain of the Company’s lease agreements have lease and non-lease components, which for the majority of leases the Company accounts for separately when the actual lease and non-lease components are determinable. For equipment leases with immaterial non-lease components incorporated into the fixed rent payment, the Company accounts for the lease and non-lease components as a single lease component in determining the lease payment. Additionally, for certain individually insignificant equipment leases such as copiers, the Company applies a portfolio approach to effectively record the operating lease liability and ROU asset.

   The adoption of ASC 842 had a material impact on the Company’s consolidated balance sheet through the recording of the operating lease liabilities and related ROU assets for leases in effect at January 1, 2019, but the adoption did not have a material impact on the Company’s consolidated statement of loss or consolidated statement of cash flows for the year ended December 31, 2019. The Company recorded approximately $673 million of operating lease liabilities and ROU assets on January 1, 2019 upon adoption of ASC 842, with no impact on accumulated deficit.

Physician Income Guarantees, Policy

Physician Income Guarantees.    The Company enters into physician recruiting agreements under which it supplements physician income to a minimum amount over a period of time, typically one year, while the physicians establish themselves in the community. As part of the agreements, the physicians are committed to practice in the community for a period of time, typically three years, which extends beyond their income guarantee period. The Company records an asset and liability for the estimated fair value of minimum revenue guarantees on new agreements. Adjustments to the ultimate value of the guarantee paid to physicians are recognized in the period that the change in estimate is identified. The Company amortizes an asset over the life of the agreement. As of December 31, 2019 and 2018, the unamortized portion of these physician income guarantees was $20 million and $24 million, respectively, and is recorded in other assets in the consolidated balance sheet.

Concentrations of Credit Risk, Policy

Concentrations of Credit Risk.    The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s facilities and non-governmental third-party payors, Medicare represents the only significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare was $268 million and $283 million at December 31, 2019 and 2018, respectively, representing 5% of consolidated net accounts receivable at both December 31, 2019 and 2018.

Accounting for the Impairment or Disposal of Long-Lived Assets, Policy

Accounting for the Impairment or Disposal of Long-Lived Assets.    During the year ended December 31, 2019, the Company recorded a total combined impairment charge and loss on disposal of approximately $138 million, of which (i) approximately $92 million was recorded to reduce the carrying value of closed hospitals and certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell and (ii) approximately $46 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals or where the Company is in discussions with potential buyers for divestiture at a sales price that indicates a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2019 is a net allocation of approximately $167 million of goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit. The Company will continue to evaluate the potential for further impairment of the long-lived assets of underperforming hospitals as well as evaluate offers for potential sales. Based on such analysis, additional impairment charges may be recorded in the future.

During the year ended December 31, 2018, the Company recorded a total combined impairment charge and loss on disposal of approximately $668 million, of which (i) approximately $423 million was recordedto reduce the carrying value of certain hospitals that have been sold or deemed held for sale based on the difference between the carrying value of the hospital disposal groups compared to estimated fair value less costs to sell, (ii) approximately $29 million was recorded to write-off the value of a promissory note received as consideration for the sale of three hospitals in 2017 where the buyer entered into bankruptcy proceedings, and (iii) approximately $216 million was recorded primarily to adjust the carrying value of other long-lived assets at several underperforming hospitals that have ceased operations or where the Company was in discussions with potential buyers for divestiture at a sales price that indicated a fair value below carrying value. Included in the carrying value of the hospital disposal groups at December 31, 2018 is a net allocation of approximately $186 millionof goodwill allocated from the hospital operations reporting unit goodwill based on a calculation of the disposal groups’ relative fair value compared to the total reporting unit.

Income Taxes, Policy

Income Taxes.    The Company accounts for income taxes under the asset and liability method, in which deferred income tax assets and liabilities are recognized for the tax consequences of “temporary differences” by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in the consolidated statement of loss during the period in which the tax rate change becomes law.

Comprehensive Loss, Policy

Comprehensive Loss.    Comprehensive loss is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.

Segment Reporting, Policy

Segment Reporting.A public company is required to report annual and interim financial and descriptive information about its reportable operating segments. Operating segments, as defined, are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Aggregation of similar operating segments into a single reportable operating segment is permitted if the businesses have similar economic characteristics and meet the criteria established by U.S. GAAP. The Company operates a single operating segment represented by hospital operations (which includes the Company's acute care hospitals and related healthcare entities that provide inpatient and outpatient healthcare services).

Derivative Instruments and Hedging Activities, Policy

Derivative Instruments and Hedging Activities.    The Company records derivative instruments on the consolidated balance sheet as either an asset or liability measured at its fair value. Changes in a derivative’s fair value are recorded each period in earnings or other comprehensive income (“OCI”), depending on whether the derivative is designated and is effective as a hedged transaction, and on the type of hedge transaction. Changes in the fair value of derivative instruments recorded to OCI are reclassified to earnings in the period affected by the underlying hedged item. Any portion of the fair value of a derivative instrument determined to be ineffective under the standard is recognized in current earnings. The Company has entered into several interest rate swap agreements and had one such agreement outstanding as of December 31, 2019. See Note 7 for further discussion about the swap transactions.

New Accounting Pronouncements, Policy

New Accounting Pronouncements.In August 2018, the FASB issued ASU 2018-15 to provide guidance on the accounting for implementation costs incurred in a cloud computing arrangement that is accounted for as a service contract. This ASU requires entities to account for such costs consistent with the guidance on capitalizing costs associated with developing or obtaining internal-use software. The ASU is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

In June 2016, the FASB issued ASU 2016-13, which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. This ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years, with early adoption permitted. The Company adopted this ASU on January 1, 2020, and does not expect the adoption of this ASU will have a material impact on its consolidated financial position and results of operations.

XML

Earnings Per Share

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Earnings Per Share Disclosure

12.  EARNINGS PER SHARE

The following table sets forth the components of the numerator and denominator for the computation of basic and diluted (loss) earnings per share for loss from continuing operations, discontinued operations and net loss attributable to Community Health Systems, Inc. common stockholders (in millions, except share data):

	Year Ended December 31,
	2019		2018		2017
Numerator:
Loss from continuing operations, net of taxes	$	(590)	$	(704)	$	(2,384)
Less: Income attributable
to noncontrolling interests, net of taxes		85		84		63
Loss from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(675)	$	(788)	$	(2,447)
Loss from discontinued operations, net of taxes	$	-	$	-	$	(12)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	-	$	-	$	(12)
Denominator:
Weighted-average number of shares outstanding — basic		113,739,046		112,728,274		111,769,821
Effect of dilutive securities:
Restricted stock awards		-		-		-
Employee stock options		-		-		-
Other equity-based awards		-		-		-
Weighted-average number of shares outstanding — diluted		113,739,046		112,728,274		111,769,821

The Company generated a loss from continuing operations attributable to Community Health Systems, Inc. common stockholders for the years ended December 31, 2019, 2018 and 2017, so the effect of dilutive securities is not considered because their effect would be antidilutive. If the Company had generated income from continuing operations during the years ended December 31, 2019, 2018 and 2017, the effect of restricted stock awards, employee stock options, and other equity-based awards on the diluted shares calculation would have been an increase in shares of 133,866,  68,687 and 111,464, respectively.

	Year Ended December 31,
	2019		2018		2017
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		3,508,968		2,152,408		3,008,919

XML

Subsequent Events

12 Months Ended

Dec. 31, 2019

Subsequent Events [Abstract]

Subsequent Events Disclosure

16.  SUBSEQUENT EVENTS 

The Company has evaluated all material events occurring subsequent to the balance sheet date for events requiring disclosure or recognition in the consolidated financial statements.

On January 1, 2020, one or more subsidiaries of the Company sold Southside Regional Medical Center (300 licensed beds) in Petersburg, Virginia, Southampton Memorial Hospital (105 licensed beds) in Franklin, Virginia and Southern Virginia Regional Medical Center (80 licensed beds) in Emporia, Virginia and their associated assets to Bon Secours Mercy Health System pursuant to the terms of a definitive agreement which was entered into on October 28, 2019. The net proceeds from this sale were received at a preliminary closing on December 31, 2019.

On January 23, 2020, the Company announced that CHS commenced a cash tender offer for any and all of the outstanding 5⅛% Senior Secured Notes due 2021. As of the early tender deadline on February 5, 2020, approximately $632 million aggregate principal amount of 5⅛% Senior Secured Notes due 2021, or approximately 63.25% of the outstanding 5⅛% Senior Secured Notes due 2021, had been validly tendered and not validly withdrawn. In connection with the commencement of the cash tender offer, CHS issued to holders of the 5⅛% Senior Secured Notes due 2021 a conditional notice of redemption to redeem all of the 5⅛% Senior Secured Notes due 2021 not purchased by CHS in the tender offer at a redemption price of 100.000% of the principal amount thereof plus accrued interest to, but not including, February 22, 2020.

On January 30, 2020, one or more affiliates of the Company entered into definitive agreements for the sale of substantially all of the assets of each of Shands Live Oak Regional Medical Center (25 licensed beds) in Live Oak, Florida and Shands Starke Regional Medical Center (49 licensed beds) in Starke, Florida to affiliates of HCA.

On February 6, 2020, CHS completed a private offering of $1.462 billion aggregate principal amount of 6⅝% Senior Secured Notes due February 15, 2025 (the “6⅝% Senior Secured Notes due 2025”). CHS used the net proceeds of the offering of the 6⅝% Senior Secured Notes due 2025 to (i) purchase any and all of its 5⅛% Senior Secured Notes due 2021 validly tendered and not validly withdrawn in the cash tender offer announced on January 23, 2020, (ii) redeem all of the 5⅛% Senior Secured Notes due 2021 that were not purchased pursuant to such tender offer, (iii) purchase in one or more privately negotiated transactions approximately $426 million aggregate principal amount of its 6¼% Senior Secured Notes due 2023 and (iv) pay related fees and expenses. The 6⅝% Senior Secured Notes due 2025 bear interest at a rate of 6.625% per annum, payable semi-annually in arrears on February 15 and August 15 of each year, commencing on August 15, 2020. The 6⅝% Senior Secured Notes are scheduled to mature on February 15, 2025. The 6⅝% Senior Secured Notes due 2025 are unconditionally guaranteed on a senior-priority secured basis by the Company and each of the CHS current and future domestic subsidiaries that provide guarantees under the ABL Facility, any capital market debt securities of CHS (including CHS᾿ outstanding senior notes) and certain other long-term debt of CHS. The 6⅝% Senior Secured Notes due 2025 and the related guarantees are secured by shared (i) first-priority liens on the Non-ABL Priority Collateral and (ii) second-priority liens on the ABL Priority Collateral that secures on a first-priority basis the ABL Facility, in each case subject to permitted liens described in the indenture governing the 6⅝% Senior Secured Notes due 2025.

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net cash (used in) provided by operating activities	$ 385	$ 274	$ 773
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(13)	(26)	(6)
Purchases of property and equipment	(438)	(527)	(564)
Proceeds from disposition of hospitals and other ancillary operations	604	405	1,692
Proceeds from sale of property and equipment	3	8	7
Purchases of available-for-sale debt securities and equity securities	(80)	(78)	(125)
Proceeds from sales of available-for-sale debt securities and equity securities	92	114	208
Increase in other investments	(170)	(141)	(143)
Net cash (used in) provided by investing activities	(2)	(245)	1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(1)	(1)	(5)
Deferred financing costs and other debt-related costs	(46)	(96)	(66)
Proceeds from noncontrolling investors in joint ventures	10	3	5
Redemption of noncontrolling investments in joint ventures	(11)	(31)	(6)
Distributions to noncontrolling investors in joint ventures	(99)	(96)	(100)
Proceeds from sale-lease back	60
Borrowings under credit agreements	37	28	841
Issuance of long-term debt	3,042	1,033	3,100
Proceeds from ABL facility	202	797	105
Repayments of long-term indebtedness	(3,557)	(2,033)	(5,391)
Net cash used in financing activities	(363)	(396)	(1,517)
Net change in cash and cash equivalents	20	(367)	325
Cash and cash equivalents at beginning of period	196	563	238
Cash and cash equivalents at end of period	216	196	563
Parent Company [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(4)	40	(12)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll tax withholding requirements	(1)	(1)	(5)
Changes in intercompany balances with affiliates, net	5	(39)	17
Net cash used in financing activities	4	(40)	12
Subsidiary Issuer [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	(348)	(409)	(317)
Cash flows from investing activities:
Proceeds from disposition of hospitals and other ancillary operations	18
Increase in other investments		(7)
Net cash (used in) provided by investing activities	18	(7)
Cash flows from financing activities:
Deferred financing costs and other debt-related costs	(46)	(96)	(65)
Changes in intercompany balances with affiliates, net	619	99	1,565
Borrowings under credit agreements			795
Issuance of long-term debt	3,042	1,033	3,100
Proceeds from ABL facility	202	748
Repayments of long-term indebtedness	(3,487)	(1,368)	(5,078)
Net cash used in financing activities	330	416	317
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	600	560	431
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(6)	(3)	(1)
Purchases of property and equipment	(366)	(408)	(356)
Proceeds from disposition of hospitals and other ancillary operations	30	1	122
Proceeds from sale of property and equipment	1	5	3
Purchases of available-for-sale debt securities and equity securities	(19)	(54)	(91)
Proceeds from sales of available-for-sale debt securities and equity securities	31	79	172
Increase in other investments	(123)	(112)	(100)
Net cash (used in) provided by investing activities	(452)	(492)	(251)
Cash flows from financing activities:
Deferred financing costs and other debt-related costs			(1)
Changes in intercompany balances with affiliates, net	(189)	176	331
Proceeds from sale-lease back	60
Borrowings under credit agreements	36	28	30
Proceeds from ABL facility		49	105
Repayments of long-term indebtedness	(45)	(655)	(285)
Net cash used in financing activities	(138)	(402)	180
Net change in cash and cash equivalents	10	(334)	360
Cash and cash equivalents at beginning of period	132	466	106
Cash and cash equivalents at end of period	142	132	466
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash (used in) provided by operating activities	137	83	671
Cash flows from investing activities:
Acquisitions of facilities and other related businesses	(7)	(23)	(5)
Purchases of property and equipment	(72)	(119)	(208)
Proceeds from disposition of hospitals and other ancillary operations	556	404	1,570
Proceeds from sale of property and equipment	2	3	4
Purchases of available-for-sale debt securities and equity securities	(61)	(24)	(34)
Proceeds from sales of available-for-sale debt securities and equity securities	61	35	36
Increase in other investments	(47)	(22)	(43)
Net cash (used in) provided by investing activities	432	254	1,320
Cash flows from financing activities:
Proceeds from noncontrolling investors in joint ventures	10	3	5
Redemption of noncontrolling investments in joint ventures	(11)	(31)	(6)
Distributions to noncontrolling investors in joint ventures	(99)	(96)	(100)
Changes in intercompany balances with affiliates, net	(435)	(236)	(1,913)
Borrowings under credit agreements	1		16
Repayments of long-term indebtedness	(25)	(10)	(28)
Net cash used in financing activities	(559)	(370)	(2,026)
Net change in cash and cash equivalents	10	(33)	(35)
Cash and cash equivalents at beginning of period	64	97	132
Cash and cash equivalents at end of period	$ 74	$ 64	$ 97

XML

Stockholders' Deficit (Tables)

12 Months Ended

Dec. 31, 2019

Stockholders' Deficit [Abstract]

Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit

	Year Ended December 31,
	2019		2018		2017
Net loss attributable to Community Health Systems,
Inc. stockholders	$	(675)	$	(788)	$	(2,459)
Transfers to the noncontrolling interests:
Net increase (decrease) in Community Health
Systems, Inc. paid-in-capital for
purchase of subsidiary partnership interests		3		(4)		(2)
Net transfers to the noncontrolling interests		3		(4)		(2)
Change to Community Health Systems, Inc.
stockholders’ deficit from net loss attributable to
Community Health Systems, Inc. stockholders
and transfers to noncontrolling interests	$	(672)	$	(792)	$	(2,461)

XML

Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2019

Debt Instrument [Line Items]

Schedule of Debt

	December 31,
	2019		2018
Credit Facility:
Term H Loan	$	-	$	1,622
Revolving Credit Facility		-		-
8% Senior Notes due 2019		-		155
7⅛% Senior Notes due 2020		-		121
5⅛% Senior Secured Notes due 2021		1,000		1,000
6⅞% Senior Notes due 2022		231		2,632
6¼% Senior Secured Notes due 2023		3,100		3,100
8⅝% Senior Secured Notes due 2024		1,033		1,033
8% Senior Secured Notes due 2026		2,101		-
8% Senior Secured Notes due 2027		700		-
6⅞% Senior Notes due 2028		1,700		-
9⅞% Junior-Priority Secured Notes due 2023		1,770		1,770
8⅛% Junior-Priority Secured Notes due 2024		1,355		1,355
ABL Facility		273		698
Finance lease and financing obligations		272		231
Other		17		43
Less:  Unamortized deferred debt issuance costs and note premium		(147)		(164)
Total debt		13,405		13,596
Less: Current maturities		(20)		(204)
Total long-term debt	$	13,385	$	13,392

Schedule of Maturities of Long-term Debt

Year Ending December 31,		Amount
2020	$	20
2021		1,010
2022		237
2023		5,149
2024		2,393
Thereafter		4,743
Total maturities		13,552
Less: Deferred debt issuance costs		(132)
Plus: Unamortized note premium		(15)
Total long-term debt	$	13,405

Senior Secured Notes at 5.125%, Due 2021 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2019 to January 31, 2020	101.281	%
February 1, 2020 to January 31, 2021	100.000	%

Senior Notes at 6.875%, Due 2022 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
February 1, 2019 to January 31, 2020	101.719	%
February 1, 2020 to January 31, 2022	100.000	%

Senior Secured Notes at 6.25%, Due 2023 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
March 31, 2020 to March 30, 2021	103.125	%
March 31, 2021 to March 30, 2022	101.563	%
March 31, 2022 to March 30, 2023	100.000	%

Junior-Priority Secured Notes At 9.875% Due 2023 [Member] | Junior-Priority Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
June 30, 2020 to June 29, 2021	107.406	%
June 30, 2021 to June 29, 2022	103.703	%
June 30, 2022 to June 29, 2023	100.000	%

Junior Priority Secured Notes At 8.875 Percent Due 2024 [Member] | Junior-Priority Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
June 30, 2021 to June 29, 2022	104.063	%
June 30, 2022 to June 29, 2023	102.031	%
June 30, 2023 to June 29, 2024	100.000	%

Senior Secured Notes at 8.625%, Due 2024 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
January 15, 2021 to January 14, 2022	104.313	%
January 15, 2022 to January 14, 2023	102.156	%
January 15, 2023 to January 14, 2024	100.000	%

Senior Secured Notes at 8%, Due 2026 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
March 15, 2022 to March 14, 2023	104.000	%
March 15, 2023 to March 14, 2024	102.000	%
March 15, 2024 to March 14, 2026	100.000	%

Senior Secured Notes At 8% Due 2027 [Member] | Senior Secured Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
December 15, 2022 to December 14, 2023	104.000	%
December 15, 2023 to December 14, 2024	102.000	%
December 15, 2024 to December 14, 2027	100.000	%

Senior Notes At 6.875% Due 2028 [Member] | Senior Notes [Member]

Debt Instrument [Line Items]

Schedule of Early Redemption Prices on Notes

Period	Redemption Price
April 1, 2023 to March 31, 2024	103.438	%
April 1, 2024 to March 31, 2025	101.719	%
April 1, 2025 to March 31, 2028	100.000	%

XML

Supplemental Condensed Consolidating Financial Information (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019 item
Supplemental Condensed Consolidating Financial Information [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%
Number of hospitals jointly owned with non-profit health organizations	3

XML

Quarterly Financial Data (Tables)

12 Months Ended

Dec. 31, 2019

Quarterly Financial Data [Abstract]

Schedule of Quarterly Financial Data

	Quarter
	1st		2nd		3rd		4th			Total (2)
	(in millions, except share and per share data)
Year ended December 31, 2019:
Net operating revenues	$	3,376	$	3,302	$	3,246	$	3,286	$	13,210
Loss from continuing operations
before income taxes		(94)		(149)		(72)		(115)		(430)
Loss from continuing operations		(101)		(146)		2		(346)		(590)
Loss from discontinued operations		-		-		-		-		-
Net loss attributable to Community
Health Systems, Inc.	$	(118)	$	(167)	$	(17)	$	(373)	$	(675)
Basic loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Discontinued operations		-		-		-		-		-
Net loss	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Diluted loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Discontinued operations		-		-		-		-		-
Net loss	$	(1.04)	$	(1.47)	$	(0.15)	$	(3.27)	$	(5.93)
Weighted-average number of shares outstanding:
Basic		113,257,608		113,862,097		113,891,721		113,935,629		113,739,046
Diluted		113,257,608		113,862,097		113,891,721		113,935,629		113,739,046
Year ended December 31, 2018:
Net operating revenues	$	3,689	$	3,562	$	3,451	$	3,453	$	14,155
Loss from continuing operations
before income taxes		(13)		(129)		(204)		(369)		(715)
Loss from continuing operations		(6)		(91)		(308)		(299)		(704)
Loss from discontinued operations		-		-		-		-		-
Net loss attributable to Community
Health Systems, Inc.	$	(25)	$	(110)	$	(325)	$	(328)	$	(788)
Basic loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Discontinued operations		-		-		-		-		-
Net loss	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Diluted loss per share attributable to
Community Health Systems, Inc. common
stockholders(1):
Continuing operations	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Discontinued operations		-		-		-		-		-
Net loss	$	(0.22)	$	(0.97)	$	(2.88)	$	(2.91)	$	(6.99)
Weighted-average number of shares outstanding:
Basic		112,291,496		112,837,944		112,865,482		112,909,869		112,728,274
Diluted		112,291,496		112,837,944		112,865,482		112,909,869		112,728,274
(1) Total per share amounts may not add due to rounding.
(2) Total quarterly amounts may not add due to rounding.

XML

Long-Term Debt (8% Senior Secured Notes, Due 2026 Narrative) (Details) - USD ($)			12 Months Ended
	Nov. 19, 2019	Mar. 06, 2019	Dec. 31, 2019
Senior Secured Notes at 8%, Due 2026 [Member]
Debt instrument aggregate principal amount	$ 500,000,000
Credit Facility, Term Loan H [Member]
Extinguishment of debt amount		$ 1,557,000,000
Senior Notes at 7.125%, Due 2020 [Member]
Extinguishment of debt amount	121,000,000
Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Debt instrument, offering date			Mar. 06, 2019
Debt instrument aggregate principal amount	2,101,000,000	$ 1,601,000,000
Debt instrument stated interest rate		8.00%
Debt instrument redemption description			plus a "make-whole" premium, as described in the indenture governing the 8% Senior Secured Notes due 2026.
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount		40.00%
Debt instrument redemption price percentage		108.00%
Senior Secured Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Extinguishment of debt amount	$ 121,000,000
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Debt instrument redemption price percentage			104.00%
Debt Instrument, Redemption, Period Two [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Debt instrument redemption price percentage			102.00%
Debt Instrument, Redemption, Period Three [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8%, Due 2026 [Member]
Debt instrument redemption price percentage			100.00%

XML

Leases (Narrative) (Details) $ in Millions				12 Months Ended
	Dec. 18, 2019 USD ($) ft² item	Sep. 19, 2019 USD ($) ft² state item	Dec. 22, 2016 USD ($) ft² state item	Dec. 31, 2019 USD ($) item
Capital Leased Assets [Line Items]
Proceeds from sale-lease back				$ 60
Operating lease right of use asset pending leases that have not yet commenced				$ 29
HCP, Inc. [Member]
Capital Leased Assets [Line Items]
Number of medical office buildings divested | item			10	4
Proceeds from sale-lease back			$ 159
Area of real estate property | ft²			756,183
Number of financing obligations remain outstanding | item				6
Number of states the buildings are located | state			5
Carter Validus Mission Critical REIT II, Inc [Member]
Capital Leased Assets [Line Items]
Number of medical office buildings divested | item		4
Proceeds from sale-lease back		$ 56
Area of real estate property | ft²		285,337
Number of states the buildings are located | state		3
Catalyst Healthcare Real Estate [Member] | Arkansas [Member]
Capital Leased Assets [Line Items]
Number of medical office buildings divested | item	1
Proceeds from sale-lease back	$ 4
Area of real estate property | ft²	30,000

XML

Acquisitions and Divestitures (Schedule of Operating Results included in Consolidated Statement of Income) (Details) - Hospitals Included in Continuing Operations [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loss from operations before income taxes	$ (105)	$ (470)	$ (703)
Less: Loss attributable to noncontrolling interests		1	(2)
Loss from operations before income taxes attributable to Community Health Systems, Inc. stockholders	$ (105)	$ (471)	$ (701)

XML

Income Taxes (Schedule of Provision for (Benefit) from Income Taxes for Income from Continuing Operations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal	$ (38)	$ 1
State	(5)	(9)	$ 5
Total, Current	(43)	(8)	5
Deferred:
Federal	179	50	(485)
State	24	(53)	31
Total, Deferred	203	(3)	(454)
Total provision for (benefit from) income taxes for loss from continuing operations	$ 160	$ (11)	$ (449)

XML

Stockholders' Deficit (Schedule of Impact of Noncontrolling Interest to Stockholders' Deficit) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Stockholders' Deficit [Abstract]
Net loss attributable to Community Health Systems, Inc. stockholders	$ (373)	$ (17)	$ (167)	$ (118)	$ (328)	$ (325)	$ (110)	$ (25)	$ (675)	[1]	$ (788)	[1]	$ (2,459)
Net increase (decrease) in Community Health Systems, Inc. paid-in-capital for purchase of subsidiary partnership interests									3		(4)		(2)
Net transfers to the noncontrolling interests									3		(4)		(2)
Change to Community Health Systems, Inc. stockholders' deficit from net loss attributable to Community Health Systems, Inc. stockholders and transfers to noncontrolling interests									$ (672)		$ (792)		$ (2,461)

[1] Total quarterly amounts may not add due to rounding.

XML

Long-Term Debt (Other Debt Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($) contract	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
Interest paid on borrowings	$ 1,011	$ 936	$ 852
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Number of interest rate swaps | contract	1
Aggregate notional amount	$ 300
Interest Rate Swap, Currently Effective [Member]
Debt Instrument [Line Items]
Aggregate notional amount	$ 300

XML

Quarterly Financial Data (Schedule of Quarterly Financial Data) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended																12 Months Ended
	Dec. 31, 2019		Sep. 30, 2019		Jun. 30, 2019		Mar. 31, 2019		Dec. 31, 2018		Sep. 30, 2018		Jun. 30, 2018		Mar. 31, 2018		Dec. 31, 2019	[1]	Dec. 31, 2018	[1]	Dec. 31, 2017
Quarterly Financial Data [Abstract]
Net operating revenues	$ 3,286		$ 3,246		$ 3,302		$ 3,376		$ 3,453		$ 3,451		$ 3,562		$ 3,689		$ 13,210		$ 14,155		$ 15,353
Income (loss) from continuing operations before income taxes	(115)		(72)		(149)		(94)		(369)		(204)		(129)		(13)		(430)		(715)		(2,833)
Income (loss) from continuing operations, net of taxes	(346)		2		(146)		(101)		(299)		(308)		(91)		(6)		(590)		(704)		(2,384)
Loss from discontinued operations, net of taxes																					(12)
Net income (loss) attributable to Community Health Systems, Inc. stockholders	$ (373)		$ (17)		$ (167)		$ (118)		$ (328)		$ (325)		$ (110)		$ (25)		$ (675)		$ (788)		$ (2,459)
Basic loss per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	$ (3.27)	[2]	$ (0.15)	[2]	$ (1.47)	[2]	$ (1.04)	[2]	$ (2.91)	[2]	$ (2.88)	[2]	$ (0.97)	[2]	$ (0.22)	[2]	$ (5.93)	[2]	$ (6.99)	[2]	$ (21.89)
Discontinued operations																					(0.11)
Net loss	(3.27)	[2]	(0.15)	[2]	(1.47)	[2]	(1.04)	[2]	(2.91)	[2]	(2.88)	[2]	(0.97)	[2]	(0.22)	[2]	(5.93)	[2]	(6.99)	[2]	(22.00)
Diluted loss per share attributable to Community Health Systems, Inc. common stockholders:
Continuing operations	(3.27)		(0.15)		(1.47)		(1.04)		(2.91)		(2.88)		(0.97)		(0.22)		(5.93)		(6.99)		(21.89)
Discontinued operations																					(0.11)
Net loss	$ (3.27)		$ (0.15)		$ (1.47)		$ (1.04)		$ (2.91)		$ (2.88)		$ (0.97)		$ (0.22)		$ (5.93)		$ (6.99)		$ (22.00)
Weighted-average number of shares outstanding:
Basic	113,935,629		113,891,721		113,862,097		113,257,608		112,909,869		112,865,482		112,837,944		112,291,496		113,739,046		112,728,274		111,769,821
Diluted	113,935,629		113,891,721		113,862,097		113,257,608		112,909,869		112,865,482		112,837,944		112,291,496		113,739,046		112,728,274		111,769,821

[1] Total quarterly amounts may not add due to rounding.

[2] Total per share amounts may not add due to rounding.

XML

Acquisitions and Divestitures (Divestitures Narrative) (Details) $ in Millions		3 Months Ended		12 Months Ended
	May 01, 2017 USD ($) item	Dec. 31, 2018 USD ($)	Jun. 30, 2018 USD ($)	Dec. 31, 2019 USD ($) item	Dec. 31, 2018 USD ($) item	Dec. 31, 2017 USD ($) item
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and loss on sale of businesses, net				$ 138	$ 668	$ 2,123
Proceeds from disposition of hospitals and other ancillary operations				$ 604	$ 405	$ 1,692
Number of Hospitals Sold | item						30
Divested Through 2018 and 2017 [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of Hospitals Sold | item				53	53	53
Tennova Physicians Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and loss on sale of businesses, net		$ 27
Twin Rivers Regional Medical Center [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and loss on sale of businesses, net			$ 4
AllianceHealth Pryor [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal date				May 01, 2017
Proceeds from disposition of hospitals and other ancillary operations	$ 1
Number of licensed beds | item	52
Hospitals Included in Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment and loss on sale of businesses, net				$ 102	$ 415	$ 368

XML

Equity Investments (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Equity method investment	$ 199	$ 192
Equity in earnings of unconsolidated affiliates	$ 15	$ 22	$ 16
Three Hospitals in Macon Georgia, [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage	38.00%
HealthTrust [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment ownership percentage	14.50%
Home Care [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest sold				80.00%
Equity method investment ownership percentage				20.00%
Disposal date	Dec. 31, 2016

XML

Basis of Presentation and Significant Accounting Policies (Schedule of Net Operating Revenue) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues	$ 3,286	$ 3,246	$ 3,302	$ 3,376	$ 3,453	$ 3,451	$ 3,562	$ 3,689	$ 13,210	[1]	$ 14,155	[1]	$ 15,353
Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues									13,210		14,155
Prior to Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues													18,398
Medicare [Member] | Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues									3,331		3,730
Medicare [Member] | Prior to Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues													4,188
Medicaid [Member] | Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues									1,736		1,876
Medicaid [Member] | Prior to Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues													1,900
Managed Care And Other Third Party Payors [Member] | Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues									8,014		8,349
Managed Care And Other Third Party Payors [Member] | Prior to Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues													9,991
Self-Pay [Member] | Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues									$ 129		$ 200
Self-Pay [Member] | Prior to Adoption of ASC 606 [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Net operating revenues													$ 2,319

[1] Total quarterly amounts may not add due to rounding.

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Compensation, Stock Options, Activity) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares			1,185,320
Exercised, Shares	0	0	0
Beginning of Period, Weighted Average Exercise Price			$ 28.12
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	624,938	1,115,667
Granted, Shares	658,500	0	0
Forfeited and cancelled, Shares	(173,304)	(490,729)	(69,653)
Ending Balance, Shares	1,110,134	624,938	1,115,667
Beginning of Period, Weighted Average Exercise Price	$ 31.21	$ 31.56
Granted, Weighted Average Exercise Price	4.95
Forfeited and Cancelled, Weighted Average Exercise Price	23.04	32.01	$ 33.52
End of Period, Weighted Average Exercise Price	$ 16.90	$ 31.21	$ 31.56
Weighted Average Remaining Contractual Term	5 years 7 months 6 days
Exercisable, Shares	486,134
Exercisable, Weighted Average Exercise Price	$ 32.26
Exercisable, Weighted Average Remaining Contractual Term	1 year

XML

Contingencies (Contingencies Narrative) (Details)				3 Months Ended			12 Months Ended
	Jan. 21, 2020 USD ($)	Nov. 30, 2018 USD ($) plaintiff	Nov. 09, 2016 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Loss Contingencies [Line Items]
Change in settlement liability claims estimate amount				$ 0	$ 20,000,000	$ 70,000,000
Pending Litigation [Member] | Litigation Matters For Which An Outcome Cannot Be Assessed [Member]
Loss Contingencies [Line Items]
Loss contingency, number of plaintiffs | plaintiff		4
Loss contingency damages sought value		$ 73,000,000
Pending Litigation [Member] | Legal Matters Where Negative Outcome is Known or Probable [Member]
Loss Contingencies [Line Items]
Attorneys' fees and other costs incurred							$ 21,000,000	$ 2,000,000
U.S. ex re. Baker vs. Community Health Systems, Inc. [Member]
Loss Contingencies [Line Items]
Judgment awarded			$ 1,900,000
Empire Health Foundation Vs Community Health Systems Inc [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Judgment awarded					$ 22,000,000
Class Action Shareholder Federal Securities Cases [Member]
Loss Contingencies [Line Items]
Liability based on the proposed settlement agreement				$ 53,000,000			$ 53,000,000
Class Action Shareholder Federal Securities Cases [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Judgment awarded	$ 53,000,000

XML

Fair Value (Supplemental Information Regarding Available-for-Sale Debt Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis, Total	$ 100
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	2
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(1)
Available-for-sale Securities	101	$ 93
Available-for-sale Securities, Amortized Cost Basis, Total		98
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(5)
Available-for-sale Securities		93
Government [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis, Total	54
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	1
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	(1)
Available-for-sale Securities	54
Corporate [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis, Total	33	34
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	1
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax		(2)
Available-for-sale Securities	34	32
Mortgage and Asset-Backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis, Total	13
Available-for-sale Securities	$ 13
Available-for-sale Equity Securities, Amortized Cost Basis, Total		10
Available-for-sale Securities, Equity Securities		10
Government and Corporate [Member]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Debt Securities, Amortized Cost Basis, Total		54
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax		(3)
Available-for-sale Securities		$ 51

XML

Long-Term Debt (7.125% Senior Notes, Due 2020) (Narrative) (Details) - USD ($)					1 Months Ended		12 Months Ended
	Dec. 04, 2019	Nov. 19, 2019	Jun. 22, 2018	Nov. 22, 2011	Jul. 18, 2012	Mar. 21, 2012	Dec. 31, 2019
Debt Instrument [Line Items]
Long-term debt outstanding							$ 13,405,000,000
Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount		$ 121,000,000
Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 276,000,000
Senior Notes [Member] | Senior Notes at 8.875%, Due 2015 [Member]
Debt Instrument [Line Items]
Extinguishment of debt amount				$ 1,000,000,000	$ 934,000,000	$ 850,000,000
Senior Notes [Member] | Senior Notes at 7.125%, Due 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date							Jul. 18, 2012
Long-term debt outstanding			121,000,000
Extinguishment of debt amount	$ 121,000,000		$ 1,079,000,000
Debt instrument stated interest rate					7.125%
Junior-Priority Secured Notes [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date							Jun. 22, 2018
Debt instrument stated interest rate			8.125%
Junior Priority Secured Notes One [Member] | Junior-Priority Secured Notes at 8.125% Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument aggregate principal amount			$ 1,079,000,000

XML

Long-Term Debt (Schedule of Early Redemption Prices on 5.125% Senior Secured Notes due 2021) (Details) - Senior Secured Notes at 5.125%, Due 2021 [Member] - Senior Secured Notes [Member]		12 Months Ended
	Jan. 27, 2014	Dec. 31, 2019
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage		101.281%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2019
Debt Instrument, Redemption Period, End Date		Jan. 31, 2020
Debt Instrument, Redemption, Period Six [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage		100.00%
Debt Instrument, Redemption Period, Start Date		Feb. 01, 2020
Debt Instrument, Redemption Period, End Date		Jan. 31, 2021

XML

Income Taxes (Operating Loss Carryforwards Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, valuation allowance	$ 1,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss and credit carryforwards	662
Operating loss carryforwards expected to be utilized	169
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss and credit carryforwards	8,600
Operating loss carryforwards expected to be utilized	$ 606
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Jan. 01, 2020
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration date	Dec. 31, 2039

XML

Long-Term Debt (Schedule of Early Redemption Prices on 6.875% Senior Notes Due 2028) (Details) - Senior Notes At 6.875% Due 2028 [Member] - Senior Notes [Member]		12 Months Ended
	Nov. 19, 2019	Dec. 31, 2019
Debt Instrument, Redemption, Period One [Member]
Debt instrument redemption price percentage	100.00%	103.438%
Debt instrument redemption period start date		Apr. 01, 2023
Debt instrument redemption period end date		Mar. 31, 2024
Debt Instrument, Redemption, Period Two [Member]
Debt instrument redemption price percentage	106.875%	101.719%
Debt instrument redemption period start date		Apr. 01, 2024
Debt instrument redemption period end date		Mar. 31, 2025
Debt Instrument, Redemption, Period Three [Member]
Debt instrument redemption price percentage		100.00%
Debt instrument redemption period start date		Apr. 01, 2025
Debt instrument redemption period end date		Mar. 31, 2028

XML

Fair Value of Financial Instruments (Schedule of Effective Portion of the Pre-tax Loss (Gain) Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Pre-Tax (Gain) Loss Reclassified from AOCL into Income (Effective Portion)	$ 2	$ 30

XML

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2019

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Other Intangible Assets Disclosure

4.  GOODWILL AND OTHER INTANGIBLE ASSETS  

Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2019 and 2018 are as follows (in millions):

Balance, beginning balance	2019		2018
Goodwill	$	7,373	$	7,537
Accumulated impairment losses		(2,814)		(2,814)
		4,559		4,723
Goodwill acquired as part of acquisitions during current year		4		22
Goodwill allocated to hospitals held for sale		(235)		(186)
Balance, end of year
Goodwill		7,142		7,373
Accumulated impairment losses		(2,814)		(2,814)
	$	4,328	$	4,559

Goodwill is allocated to each identified reporting unit, which is defined as an operating segment or one level below the operating segment (referred to as a component of the entity). Management has determined that the Company’s operating segment meets the criteria to be classified as a  reporting unit. At December 31, 2019, after giving effect to 2019 divestiture activity, the Company had approximately $4.3 billion of goodwill recorded.

Goodwill is evaluated for impairment annually and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. During 2017, the Company early adopted ASU 2017-04, which allows a company to record a goodwill impairment when the reporting unit’s carrying value exceeds the fair value determined in step one. The Company performed its annual goodwill impairment evaluation during the fourth quarter of 2019 using the October 31, 2019 measurement date, which indicated no impairment.

The Company estimates the fair value of the reporting unit using both a discounted cash flow model as well as a market multiple model. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s estimate of a market participant’s weighted-average cost of capital. These models are both based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions.

While no impairment was indicated in the Company’s annual goodwill evaluations as of the October 31, 2019 and October 31, 2018 measurement dates, the reduction in the Company’s fair value and the resulting goodwill impairment charges recorded in 2016 and 2017 reduced the carrying value of the Company’s hospital operations reporting unit to an amount equal to its estimated fair values as of such prior year measurement dates. This increases the risk that future declines in fair value could result in goodwill impairment. The determination of fair value in the Company’s goodwill impairment analysis is based on an estimate of fair value for each reporting unit utilizing known and estimated inputs at the evaluation date. Some of those inputs include, but are not limited to, the most recent price of the Company’s common stock or fair value of long-term debt, estimates of future revenue and expense growth, estimated market multiples, expected capital expenditures, income tax rates, and costs of invested capital. Future estimates of fair value could be adversely affected if the actual outcome of one or more of these assumptions changes materially in the future, including further decline in the Company’s stock price or fair value of long-term debt, lower than expected hospital volumes, higher market interest rates or increased operating costs. Such changes impacting the calculation of fair value could result in a material impairment charge in the future.

The determination of fair value of the Company’s hospital operations reporting unit as part of its goodwill impairment measurement represents a Level 3 fair value measurement in the fair value hierarchy due to its use of internal projections and unobservable measurement inputs.

Intangible Assets

No intangible assets other than goodwill were acquired during the years ended December 31, 2019 and 2018. The gross carrying amount of the Company’s other intangible assets subject to amortization was $1 million at both December 31, 2019 and 2018, and the net carrying amount was less than $1 million at December 31, 2019 and 2018. The carrying amount of the Company’s other intangible assets not subject to amortization was $63 million and $67 million at December 31, 2019 and 2018, respectively. Other intangible assets are included in other assets, net on the Company’s consolidated balance sheets. Substantially all of the Company’s intangible assets are contract-based intangible assets related to operating licenses, management contracts, or non-compete agreements entered into in connection with prior acquisitions. 

The weighted-average remaining amortization period for the intangible assets subject to amortization is approximately one year. There are noexpected residual values related to these intangible assets. Amortization expense on these intangible assets was less than $1 million, $3 million and $4 million during the years ended December 31, 2019, 2018 and 2017, respectively. Amortization expense on intangible assets is estimated to be less than $1 million in 2020.     

The gross carrying amount of capitalized software for internal use was approximately  $1.1 billion and $1.2 billion at December 31, 2019 and 2018, respectively, and the net carrying amount was approximately $321 million and $355 million at December 31, 2019 and 2018, respectively. The estimated amortization period for capitalized internal-use software is generally three years, except for capitalized costs related to significant system conversions, for which the estimated amortization period is generally eight to ten years.  There is no expected residual value for capitalized internal-use software.  At December 31, 2019, there were approximately $42 million of capitalized costs for internal-use software that is currently in the development stage and will begin amortization once the software project is complete and ready for its intended use. Amortization expense on capitalized internal-use software was $121 million, $140 million and $178 million during the years ended December 31, 2019, 2018 and 2017, respectively. Amortization expense on capitalized internal-use software is estimated to be $114 million in 2020, $93 million in 2021, $55 million in 2022, $26 million in 2023, $22 million in 2024 and $11 million thereafter.

XML

Fair Value

12 Months Ended

Dec. 31, 2019

Fair Value [Abstract]

Fair Value Disclosure

8.  FAIR VALUE

Fair Value Hierarchy

Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, the Company utilizes the U.S. GAAP fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

The inputs used to measure fair value are classified into the following fair value hierarchy:

Level 1:  Quoted market prices in active markets for identical assets or liabilities.

Level 2:  Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3:  Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting the Company’s own assumptions.

In instances where the determination of the fair value hierarchy measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment of factors specific to the asset or liability. Transfers between levels within the fair value hierarchy are recognized by the Company on the date of the change in circumstances that requires such transfer. There were notransfers between levels during the years ending December 31, 2019 or December 31, 2018.

The following table sets forth, by level within the fair value hierarchy, the financial assets and liabilities recorded at fair value on a recurring basis as of December 31, 2019 and 2018 (in millions):

	December 31, 2019		Level 1		Level 2		Level 3
Investments in equity securities	$	141	$	141	$	-	$	-
Available-for-sale debt securities		101		-		101		-
Trading securities		12		-		12		-
Total assets	$	254	$	141	$	113	$	-
Fair value of interest rate swap agreements	$	2	$	-	$	2	$	-
Total liabilities	$	2	$	-	$	2	$	-
	December 31, 2018		Level 1		Level 2		Level 3
Investments in equity securities	$	137	$	137	$	-	$	-
Available-for-sale debt securities		93		-		93		-
Trading securities		11		-		11		-
Fair value of interest rate swap agreements		3		-		3		-
Total assets	$	244	$	137	$	107	$	-
Contingent Value Right (CVR)	$	-	$	-	$	-	$	-
Fair value of interest rate swap agreements		2		-		2		-
Total liabilities	$	2	$	-	$	2	$	-

Investments in Equity Securities, Available-for-Sale Debt Securities and Trading Securities

Investments in equity securities and trading securities classified as Level 1 are measured using quoted market prices. Level 2 available-for-sale debt securities and trading securities primarily consisted of bonds and notes issued by the United States government and its agencies and domestic and foreign corporations. The estimated fair values of these securities are determined using various valuation techniques, including a multi-dimensional relational model that incorporates standard observable inputs and assumptions such as benchmark yields, reported trades, broker/dealer quotes, issuer spreads, benchmark securities, bids/offers and other pertinent reference data.

Supplemental information regarding the Company’s available-for-sale debt securities (all of which had no withdrawal restrictions) is set forth in the table below (in millions):

			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Values
As of December 31, 2019:
Debt securities
Government	$	54	$	1	$	(1)	$	54
Corporate		33		1		-		34
Mortgage and asset-backed securities		13		-		-		13
Total	$	100	$	2	$	(1)	$	101

			Gross		Gross		Estimated
	Amortized		Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Values
As of December 31, 2018:
Debt securities
Government	$	54	$	-	$	(3)	$	51
Corporate		34		-		(2)		32
Mortgage and asset-backed securities		10		-		-		10
Total	$	98	$	-	$	(5)	$	93

As of December 31, 2019 and 2018, investments with aggregate estimated fair values of approximately $51 million (71 investments) and $89 million (121 investments), respectively, generated the gross unrealized losses disclosed in the above table. At each reporting date, the Company performs an evaluation of impaired securities to determine if the unrealized losses are other-than-temporary. This evaluation considers a number of factors including, but not limited to, the length of time and extent to which the fair value has been less than cost, and management’s ability and intent to hold the securities until fair value recovers. Based on the results of this evaluation, management concluded that as of December 31, 2019, there were no other-than-temporary losses related to available-for-sale debt securities. The recent declines in value of the securities and/or length of time they have been below cost, as well as the Company’s ability and intent to hold the securities for a reasonable period of time sufficient for a projected recovery of fair value, have caused management to conclude that the securities, that have generated gross unrealized losses, were not other-than-temporarily impaired. Management will continue to monitor and evaluate the recoverability of the Company’s available-for-sale debt securities.

The contractual maturities of debt-based securities held by the Company as of December 31, 2019 and 2018, excluding mutual fund holdings, are set forth in the table below (in millions). Expected maturities will differ from contractual maturities because the issuers of the debt securities may have the right to prepay their obligations without prepayment penalties.

	December 31, 2019				December 31, 2018
	Amortized		Estimated		Amortized		Estimated
	Cost		Fair Values		Cost		Fair Values
Within 1 year	$	9	$	9	$	14	$	14
After 1 year and through year 5		19		20		20		19
After 5 years and through year 10		29		29		25		24
After 10 years		43		43		39		36

Gross realized gains and losses on sales of available-for-sale debt securities are summarized in the table below (in millions):

	Year Ended December 31,
	2019		2018		2017
Realized gains	$	-	$	-	$	3
Realized losses		-		-		(2)

Other investment income, which includes interest and dividends, related to all investment securities were $7 million, $7 million and $8 million for the years ended December 31, 2019, 2018 and 2017, respectively. 

Net gains and losses recognized during the years ended December 31, 2019 and 2018 for investments in equity securities, which are broken out between investments sold during the year and investments held at the end of the year, are summarized in the table below (in millions):

	Year Ended December 31,
	2019		2018
Net gains and (losses), beginning of year	$	15	$	(7)
Less: Net gains and (losses) recognized during
the year on equity securities sold during the year		2		1
Unrealized gains and (losses) recognized during the
year on equity securities held, end of year	$	13		(8)

Contingent Value Right (CVR)

The CVRs represented the estimate of the fair value for the contingent consideration paid to HMA shareholders as part of the HMA merger. The CVRs were listed on the Nasdaq and the valuation of the CVRs was based on the quoted trading price for the CVRs on the last day of the period. Changes in the estimated fair value of the CVRs were recorded through the consolidated statements of loss. In January  2019, the CVRs were terminated and removed from listing with Nasdaq after the determination that no amount was payable under the CVR agreement.

CVR-related Liability

The CVR-related legal liability (prior to being reclassified as a current liability on the Company’s consolidated balance sheet as noted below) represented the Company’s estimate of fair value of the liability associated with the legal matters assumed in the HMA merger, which at December 31, 2017 was included in other long-term liabilities in the accompanying consolidated balance sheet. This liability did not include those matters previously accrued by HMA as a probable contingency, which were settled and paid during the year ended December 31, 2015. To develop the estimate of fair value, the Company engaged an independent third-party valuation firm to measure the liability. The valuation was made utilizing the Company’s estimates of future outcomes for each legal case and simulating future outcomes based on the timing, probability and distribution of several scenarios using a Monte Carlo simulation model. Other inputs were then utilized for discounting the liability to the measurement date. The HMA legal matters underlying this fair value estimate were evaluated by management to determine the likelihood and impact of each of the potential outcomes. Using that information, as well as the potential correlation and variability associated with each case, a fair value was determined for the estimated future cash outflows to conclude or settle the HMA legal matters included in the analysis, excluding legal fees (which are expensed as incurred). Because of the unobservable nature of the majority of the inputs used to value the liability, the Company classified the fair value measurement as a Level 3 measurement in the fair value hierarchy. Prior to December 31, 2018, changes in the fair value of the CVR related legal liability were recorded in future periods through the consolidated statements of loss.

At December 31, 2018, the CVR-related legal liability was zero after taking into account the Company’s payment of the amounts agreed to in the final global resolution and settlement of certain HMA legal matters during the three months ended December 31, 2018.

Fair Value of Interest Rate Swap Agreements

The valuation of the Company’s interest rate swap agreements is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flows of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. The fair value of interest rate swap agreements are determined by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates based on observable market forward interest rate curves and the notional amount being hedged.

The Company incorporates CVAs to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements. The CVA on the Company’s interest rate swap agreements had an immaterial effect on the fair value of the related asset or liability at December 31, 2019 and 2018.

The majority of the inputs used to value the Company’s interest rate swap agreements, including the forward interest rate curves and market perceptions of the Company’s credit risk used in the CVAs, are observable inputs available to a market participant. As a result, the Company has determined that the interest rate swap valuations are classified in Level 2 of the fair value hierarchy.

XML

Supplemental Condensed Consolidating Financial Information (Policy)

12 Months Ended

Dec. 31, 2019

Supplemental Condensed Consolidating Financial Information [Abstract]

Guarantor Financial Information Policy

The accounting policies used in the preparation of this financial information are consistent with those elsewhere in the consolidated financial statements of the Company, except as noted below:

•Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets.

•Cash flows from intercompany transactions are presented in cash flows from financing activities, as changes in intercompany balances with affiliates, net.

•Income tax expense is allocated from the parent guarantor to the income producing operations (other guarantors and non-guarantors) and the issuer through stockholders’ deficit. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes.

•Interest expense, net has been presented to reflect net interest expense and interest income from outstanding long-term debt and intercompany balances.

The Company’s intercompany activity consists primarily of daily cash transfers for purposes of cash management, the allocation of certain expenses and expenditures paid for by the Parent on behalf of its subsidiaries, and the push down of investment in its subsidiaries. This activity also includes the intercompany transactions between consolidated entities as part of the ABL Facility and Receivables Facility that are further discussed in Note 6. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany transactions do not represent revenue generating transactions. All intercompany transactions eliminate in consolidation.

From time to time, subsidiaries of the Company sell and/or repurchase noncontrolling interests in consolidated subsidiaries, which may change subsidiaries between guarantors and non-guarantors. Amounts for prior periods have been revised to reflect the status of guarantors and non-guarantors as of December 31, 2019.

XML

Acquisitions and Divestitures (Policy)

12 Months Ended

Dec. 31, 2019

Acquisitions and Divestitures [Abstract]

Acquisitions Policy

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

XML

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill

Balance, beginning balance	2019		2018
Goodwill	$	7,373	$	7,537
Accumulated impairment losses		(2,814)		(2,814)
		4,559		4,723
Goodwill acquired as part of acquisitions during current year		4		22
Goodwill allocated to hospitals held for sale		(235)		(186)
Balance, end of year
Goodwill		7,142		7,373
Accumulated impairment losses		(2,814)		(2,814)
	$	4,328	$	4,559

XML

Earnings Per Share (Schedule of Antidilutive Securities) (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Employee stock options and restricted stock awards excluded from computation of earnings per share amount	3,508,968	2,152,408	3,008,919

XML

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)	3 Months Ended									12 Months Ended						24 Months Ended
	Dec. 31, 2019 USD ($) state item	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2019 USD ($) segment state item		Dec. 31, 2018 USD ($)		Dec. 31, 2017 USD ($) item	Dec. 31, 2016	Dec. 31, 2019 USD ($) state item	Jan. 01, 2019 USD ($)	Jan. 01, 2018 USD ($)
Business Description [Abstract]
Number of hospitals owned and leased by the Company | item	102									102						102
Number of licensed beds | item	16,240									16,240						16,240
Number of stand alone rehabilitation or psychiatric hospitals | item	2									2						2
Number of states in which entity operates | state	18									18						18
Cost of Revenue, Policy [Abstract]
Corporate office costs										$ 184,000,000		$ 181,000,000		$ 189,000,000
Stock-based compensation expense										10,000,000		13,000,000		24,000,000
Marketable Securities, Policy [Abstract]
Net change in fair value of available-for-sale debt securities, net of tax										4,000,000		(2,000,000)		8,000,000
Property and Equipment, Policy [Abstract]
Construction in Progress, Gross	$ 219,000,000				$ 219,000,000					219,000,000		219,000,000				$ 219,000,000
Interest Costs Capitalized										20,000,000		15,000,000		11,000,000
Purchases of property and equipment accrued in accounts payable										93,000,000		115,000,000
Goodwill, Policy [Abstract]
Impairment of goodwill										0		0		1,419,000,000
Other Assets, Policy [Abstract]
Cash paid to increase investments in certain equity method investments										28,000,000
Third-Party Reimbursement [Abstract]
Amounts due to third party payors	83,000,000				144,000,000					83,000,000		144,000,000				83,000,000
Amounts due from third party payors	137,000,000				155,000,000					137,000,000		155,000,000				137,000,000
Net Operating Revenues, Policy [Abstract]
Value of charity care services at the Company's standard charges included in contractual allowances										540,000,000		491,000,000		482,000,000
Estimated cost incurred by Company to provide charity care services										66,000,000		62,000,000		$ 62,000,000
Allowance for Doubtful Accounts, Policy [Abstract]
Number of Hospitals Sold | item														30
Electronic Health Records Reimbursement, Policy [Abstract]
Electronic health records incentive reimbursement under HITECH										1,000,000		4,000,000		$ 28,000,000
Electronic Health Records Incentive Reimbursement, Cash Received										1,000,000		4,000,000		41,000,000
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances	2,258,000,000				2,352,000,000					2,258,000,000		2,352,000,000				2,258,000,000
Decrease in net operating revenues	3,286,000,000	$ 3,246,000,000	$ 3,302,000,000	$ 3,376,000,000	3,453,000,000	$ 3,451,000,000	$ 3,562,000,000	$ 3,689,000,000		13,210,000,000	[1]	14,155,000,000	[1]	15,353,000,000
Accounting for the Impairment or Disposal of Long-Lived Assets
Goodwill allocated to hospital disposal group held for sale	235,000,000				186,000,000					235,000,000		186,000,000				235,000,000
Impairment and loss on sale of businesses, net										$ 138,000,000		668,000,000		2,123,000,000
Segment Reporting, Policy [Abstract]
Number of reportable segments | segment										1
New Accounting Pronouncements, Policy [Abstract]
Operating lease right-of-use asset	607,000,000									$ 607,000,000						607,000,000
Operating lease liability	623,000,000									623,000,000						623,000,000
Adoption of ASC 606 [Member]
Net Operating Revenues, Policy [Abstract]
Provision for contractual allowance included in net operating revenues														197,000,000
Allowance for doubtful patient accounts									$ 394,000,000					394,000,000
Concentration of Credit Risk, Policy [Abstract]
Decrease in net operating revenues										13,210,000,000		14,155,000,000
ASU 2016-02 [Member]
New Accounting Pronouncements, Policy [Abstract]
Operating lease right-of-use asset																	$ 673,000,000
Operating lease liability																	$ 673,000,000
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances																		$ 3,900,000,000
Medicare [Member]
Concentration of Credit Risk, Policy [Abstract]
Accounts receivable, net of contractual allowances	268,000,000				283,000,000					268,000,000		283,000,000				$ 268,000,000
Accounts receivable net of contractual allowances, percent																5.00%
Medicare [Member] | Adoption of ASC 606 [Member]
Concentration of Credit Risk, Policy [Abstract]
Decrease in net operating revenues										3,331,000,000		3,730,000,000
Electronic Health Records Incentive Reimbursements [Member]
Electronic Health Records Reimbursement, Policy [Abstract]
Deferred Revenue	0				0				0	0		0		$ 0		$ 0
Maximum [Member]
Physician Income Guarantees, Policy [Abstract]
Finite-Lived Intangible Assets, Net	1,000,000				1,000,000					$ 1,000,000		1,000,000				1,000,000
Capitalized Internal Use Software, Significant System Conversions [Member] | Minimum [Member]
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life										8 years
Capitalized Internal Use Software, Significant System Conversions [Member] | Maximum [Member]
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life										10 years
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life										3 years
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member]
Other Assets, Policy [Abstract]
Finite-Lived Intangible Assets, Weighted-Average Useful Life										1 year
Physician recruitment contracts [Member]
Physician Income Guarantees, Policy [Abstract]
Physicians recruitment agreement period										1 year
Term of Physician Recruitment Contract										3 years
Finite-Lived Intangible Assets, Net	20,000,000				24,000,000					$ 20,000,000		$ 24,000,000				20,000,000
Land Improvements [Member] | Minimum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										3 years
Land Improvements [Member] | Maximum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										20 years
Building and Building Improvements [Member] | Minimum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										5 years
Building and Building Improvements [Member] | Maximum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										40 years
Equipment and Fixtures [Member] | Minimum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										3 years
Equipment and Fixtures [Member] | Maximum [Member]
Property and Equipment, Policy [Abstract]
Property, Plant and Equipment, Useful Life										18 years
Certain Facility [Member]
Property and Equipment, Policy [Abstract]
Non-cash investing activity through capital leases										$ 6,000,000
Sales Revenue, Net [Member] | Adoption of ASC 606 [Member]
Concentration of Credit Risk, Policy [Abstract]
Decrease in net operating revenues									$ (591,000,000)
Geographic Concentration Risk [Member] | Florida [Member] | Sales Revenue, Net [Member]
Business Description [Abstract]
Concentration Risk, Percentage										14.30%		14.30%		14.00%
Geographic Concentration Risk [Member] | Texas [Member] | Sales Revenue, Net [Member]
Business Description [Abstract]
Concentration Risk, Percentage										12.20%		11.70%		10.90%
Geographic Concentration Risk [Member] | Indiana [Member] | Sales Revenue, Net [Member]
Business Description [Abstract]
Concentration Risk, Percentage										13.70%		12.50%		11.60%
Certain Hospitals [Member]
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale										$ 138,000,000		$ 668,000,000
Goodwill allocated to hospital disposal group held for sale	$ 167,000,000				$ 186,000,000					167,000,000		186,000,000				$ 167,000,000
Certain Hospitals [Member] | Hospitals Sold or Deemed Held for Sale [Member]
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale										92,000,000		423,000,000
Certain Hospitals [Member] | Write-Off Promissory Note Received as Consideration For the Sale of Hospitals [Member]
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale												29,000,000
Certain Hospitals [Member] | Adjustment for Carrying Value of Other Long-Lived Assets at Underperforming Hospitals [Member]
Accounting for the Impairment or Disposal of Long-Lived Assets
Impairment of long-lived assets held for sale										$ 46,000,000		$ 216,000,000
Home Care [Member]
Segment Reporting, Policy [Abstract]
Percentage of Ownership Interest Sold															80.00%

[1] Total quarterly amounts may not add due to rounding.

XML

Accounting for Stock-Based Compensation (Schedule of Share-based Payment Awards, Stock Options, Valuation Assumptions) (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	68.40%
Expected term	5 years 7 months 6 days
Risk-free interest rate	2.60%

XML

Commitments and Contingencies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Physician Recruiting Commitments [Abstract]
Physician recruiting commitment, physician income guarantee period	12 months
Physician recruiting commitment, period of recoverability of physician income guarantee for noncommitment	3 years
Physician recruiting commitment, maximum potential future payments in excess of liability recorded	$ 19
La Porte, Indiana hospital [Member]
Construction and Other Capital Commitments [Abstract]
Capital commitment, post-acquisition estimated cost of replacement hospital	128
Construction and other capital commitments incurred	58
Knox, Indiana hospital [Member]
Construction and Other Capital Commitments [Abstract]
Capital commitment, post-acquisition estimated cost of replacement hospital	15
All other purchase commitments [Member]
Construction and Other Capital Commitments [Abstract]
Capital commitment, post-acquisition estimated cost of replacement hospital	2
Construction and other capital commitments incurred	$ 2
Minimum [Member] | All other purchase commitments [Member]
Construction and Other Capital Commitments [Abstract]
Capital commitment, future period after acquisition for completing open capital improvement projects	5 years
Maximum [Member] | All other purchase commitments [Member]
Construction and Other Capital Commitments [Abstract]
Capital commitment, future period after acquisition for completing open capital improvement projects	7 years

XML

Subsequent Events (Narrative) (Details) - Subsequent Event [Member]	Feb. 06, 2020 USD ($)	Feb. 05, 2020 USD ($)	Jan. 30, 2020 item	Jan. 01, 2020 item
Petersburg, Virginia [Member] | Southside Regional Medical Center [Member]
Subsequent Event [Line Items]
Number of licensed beds				300
Franklin, Virginia [Member] | Southampton Memorial Hospital [Member]
Subsequent Event [Line Items]
Number of licensed beds				105
Emporia, Virginia [Member] | Southern Virginia Regional Medical Center [Member]
Subsequent Event [Line Items]
Number of licensed beds				80
Live Oak, Florida [Member] | Shands Live Oak Regional Medical Center [Member]
Subsequent Event [Line Items]
Number of licensed beds			25
Starke, Florida [Member] | Shands Starke Regional Medical Center [Member]
Subsequent Event [Line Items]
Number of licensed beds			49
Secured Debt [Member] | Senior Secured Notes at 5.125%, Due 2021 [Member]
Subsequent Event [Line Items]
Debt instrument aggregate principal amount | $		$ 632,000,000
Debt instrument stated interest rate		5.125%
Debt instrument redemption price percentage		100.00%
Percentage of outstanding debt validly tendered and not validly withdrawn		63.25%
Secured Debt [Member] | Senior Secured Notes at 6.625% Due 2025 [Member]
Subsequent Event [Line Items]
Debt instrument aggregate principal amount | $	$ 1,462,000,000
Debt instrument stated interest rate	6.625%
Secured Debt [Member] | Senior Secured Notes at 6.25%, Due 2023 [Member]
Subsequent Event [Line Items]
Extinguishment of debt amount | $	$ 426,000,000
Debt instrument stated interest rate	6.25%

XML

Acquisitions and Divestitures (Acquisitions Narrative) (Details) $ in Millions		12 Months Ended
	Jun. 01, 2019 USD ($) item	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Acquisitions and Divestitures [Line Items]
Acquisition and integration expenses related to prospective and closed acquisitions		$ 2	$ 3	$ 2
Goodwill		4,328	4,559	4,723
Physician Practices Clinics and Other Ancillary Businesses [Member]
Acquisitions and Divestitures [Line Items]
Business acquisition, cost of acquired entity, purchase price		8	26	6
Purchase price allocation, property and equipment		4	10	2
Business acquisition, purchase price allocation, intangible assets, other than goodwill		$ 4	22	4
Business Combination, Assumed Noncontrolling Interest, Fair Value			6	0
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value			$ 6	$ 0
Northwest Mississippi Medical Center [Member]
Acquisitions and Divestitures [Line Items]
Business acquisition, cost of acquired entity, purchase price	$ 11
Business acquisition number of licensed beds | item	181
Business acquisition cash paid for operating assets	$ 2
Business acquisition liabilities assumed	$ 9

XML

Long-Term Debt (5.125% Senior Notes, Due 2021 Narrative) (Details) - Senior Secured Notes [Member] - Senior Secured Notes at 5.125%, Due 2021 [Member] - USD ($)		1 Months Ended	12 Months Ended
	Jan. 27, 2014	Jan. 27, 2014	Dec. 31, 2019
Debt Instrument [Line Items]
Debt instrument, offering date			Jan. 27, 2014
Debt instrument aggregate principal amount	$ 1,000,000,000	$ 1,000,000,000
Debt instrument stated interest rate	5.125%	5.125%
Debt instrument redemption price percentage	100.00%
Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Minimum period notice for redemption of debt		30 days
Maximum period notice for redemption of debt		60 days

XML

Fair Value (Contractual Maturities of Debt Securities) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Fair Value [Abstract]
Within 1 year, Amortized Cost	$ 9	$ 14
After 1 year and through year 5, Amortized Cost	19	20
After 5 years and through year 10, Amortized Cost	29	25
After 10 years, Amortized Cost	43	39
Within 1 year, Fair Value	9	14
After 1 year and through year 5, Fair Value	20	19
After 5 years and through year 10, Fair Value	29	24
After 10 years, Fair Value	$ 43	$ 36

XML

Long-Term Debt (Schedule of Early Redemption Prices on 6.785% Senior Notes due 2022) (Details) - Senior Notes at 6.875%, Due 2022 [Member] - Senior Notes [Member]	12 Months Ended
	Dec. 31, 2019
Debt Instrument, Redemption, Period Four [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	101.719%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2019
Debt Instrument, Redemption Period, End Date	Jan. 31, 2020
Debt Instrument, Redemption, Period Five [Member]
Debt Instrument, Redemption [Line Items]
Debt Instrument Redemption Price Percentage	100.00%
Debt Instrument, Redemption Period, Start Date	Feb. 01, 2020
Debt Instrument, Redemption Period, End Date	Jan. 31, 2022

XML

Income Taxes (Valuation Allowance Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Federal [Member]
Valuation Allowance [Line Items]
Valuation allowance increase	$ 221	$ 151
State and Local Jurisdiction [Member]
Valuation Allowance [Line Items]
Valuation allowance increase	$ 127	$ 17

XML

Fair Value of Financial Instruments (Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet) (Details) - Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Other Assets [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives designated as hedging instruments		$ 3
Other Long-term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives designated as hedging instruments	$ 2	$ 2

XML

Long-Term Debt (Schedule of Early Redemption Prices on 8% Senior Secured Notes due 2026) (Details) - Senior Secured Notes at 8%, Due 2026 [Member] - Senior Secured Notes [Member]		12 Months Ended
	Mar. 06, 2019	Dec. 31, 2019
Debt instrument redemption price percentage	108.00%
Debt Instrument, Redemption, Period One [Member]
Debt instrument redemption price percentage		104.00%
Debt instrument redemption period start date		Mar. 15, 2022
Debt instrument redemption period end date		Mar. 14, 2023
Debt Instrument, Redemption, Period Two [Member]
Debt instrument redemption price percentage		102.00%
Debt instrument redemption period start date		Mar. 15, 2023
Debt instrument redemption period end date		Mar. 14, 2024
Debt Instrument, Redemption, Period Three [Member]
Debt instrument redemption price percentage		100.00%
Debt instrument redemption period start date		Mar. 15, 2024
Debt instrument redemption period end date		Mar. 14, 2026

XML

Acquisitions and Divestitures

12 Months Ended

Dec. 31, 2019

Acquisitions and Divestitures [Abstract]

Acquisitions and Divestitures Disclosure

3.  ACQUISITIONS AND DIVESTITURES

Acquisitions

The Company accounts for all transactions that represent business combinations using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the Company obtains control in the acquiree. Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded when identified. Goodwill is determined as the excess of the fair value of the consideration conveyed in the acquisition over the fair value of the net assets acquired.

Acquisition and integration expenses related to prospective and closed acquisitions included in other operating expenses on the consolidated statements of loss were $2 million, $3 million and $2 million for the years ended December 31, 2019, 2018 and 2017, respectively.

Effective June 1, 2019, one or more subsidiaries of the Company completed the acquisition of Northwest Mississippi Medical Center in Clarksdale, Mississippi. This healthcare system includes 181 licensed beds and other outpatient and ancillary services. The total cash consideration paid for operating assets was approximately $2 million with additional consideration of $9 million in assumed liabilities, for a total consideration of $11 million. This hospital was acquired in conjunction with the bankruptcy proceedings for the previous owner that acquired the hospital from the Company in 2017 as part of an agreement with the local county government associated with its lease of the hospital building. Based on the Company’s final purchase price allocation relating to this acquisition as of December 31, 2019, no goodwill has been recorded. Prior to the completion of the acquisition, the Company initiated a plan to sell this hospital and as such has classified this hospital as held for sale at December 31, 2019.

Other Acquisitions

During the years ended December 31, 2019, 2018 and 2017, one or more subsidiaries of the Company paid approximately $8 million, $26 million and $6 million, respectively, to acquire the operating assets and related businesses of certain physician practices, clinics and other ancillary businesses that operate within the communities served by the Company’s affiliated hospitals. In connection with these acquisitions, during the year ended December 31, 2019, the Company allocated approximately $4 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. In connection with these acquisitions, during the year ended December 31, 2018, the Company allocated approximately $10 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $22 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. The value of noncontrolling interests acquired in these acquisitions was $6 million. During the year ended December 31, 2017, the Company allocated approximately $2 million of the consideration paid to property and equipment and net working capital and the remainder, approximately $4 million consisting of intangible assets that do not qualify for separate recognition, to goodwill. No value was allocated to noncontrolling interests recorded in these acquisitions.

Divestitures

In April 2014, FASB issued ASU 2014-08, which changed the requirements for reporting discontinued operations. Under this accounting standard, a discontinued operation is a disposal that represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. Additional disclosures are required for significant components of the entity that are disposed of or are held for sale but do not qualify as discontinued operations. This ASU was adopted on January 1, 2015 and is required to be applied on a prospective basis for disposals or components initially classified as held for sale after adoption. As a result, the following divestitures occurring subsequent to the date of adoption are included in continuing operations for the years ended December 31, 2019, 2018 and 2017.

The following table provides a summary of hospitals included in continuing operations that the Company divested during the years ended December 31, 2019, 2018, and 2017:

			Licensed
Hospital	Buyer	City, State	Beds	Effective Date
2019 Divestitures:
Bluefield Regional Medical Center	Princeton Community Hospital Association	Bluefield, WV	92	October 1, 2019
Lake Wales Medical Center	Adventist Health System	Lake Wales, FL	160	September 1, 2019
Heart of Florida Regional Medical Center	Adventist Health System	Davenport, FL	193	September 1, 2019
College Station Medical Center	St. Joseph Regional Health Center	College Station, TX	167	August 1, 2019
Tennova Healthcare - Lebanon	Vanderbilt University Medical Center	Lebanon, TN	245	August 1, 2019
Chester Regional Medical Center	Medical University Hospital Authority	Chester, SC	82	March 1, 2019
Carolinas Hospital System - Florence	Medical University Hospital Authority	Florence, SC	396	March 1, 2019
Springs Memorial Hospital	Medical University Hospital Authority	Lancaster, SC	225	March 1, 2019
Carolinas Hospital System - Marion	Medical University Hospital Authority	Mullins, SC	124	March 1, 2019
Memorial Hospital of Salem County	Community Healthcare Associates, LLC	Salem, NJ	126	January 31, 2019
Mary Black Health System - Spartanburg	Spartanburg Regional Healthcare System	Spartanburg, SC	207	January 1, 2019
Mary Black Health System - Gaffney	Spartanburg Regional Healthcare System	Gaffney, SC	125	January 1, 2019
2018 Divestitures:
Sparks Regional Medical Center	Baptist Health	Fort Smith, AR	492	November 1, 2018
Sparks Medical Center - Van Buren	Baptist Health	Van Buren, AR	103	November 1, 2018
AllianceHealth Deaconess	INTEGRIS Health	Oklahoma City, OK	238	October 1, 2018
Munroe Regional Medical Center	Adventist Health System	Ocala, FL	425	August 1, 2018
Tennova Healthcare - Dyersburg Regional	West Tennessee Healthcare	Dyersburg, TN	225	June 1, 2018
Tennova Healthcare - Regional Jackson	West Tennessee Healthcare	Jackson, TN	150	June 1, 2018
Tennova Healthcare - Volunteer Martin	West Tennessee Healthcare	Martin, TN	100	June 1, 2018
			Licensed
Hospital	Buyer	City, State	Beds	Effective Date
Williamson Memorial Hospital	Mingo Health Partners, LLC	Williamson, WV	76	June 1, 2018
Byrd Regional Hospital	Allegiance Health Management	Leesville, LA	60	June 1, 2018
Tennova Healthcare - Jamestown	Rennova Health, Inc.	Jamestown, TN	85	June 1, 2018
Bayfront Health Dade City	Adventist Health System	Dade City, FL	120	April 1, 2018
2017 Divestitures:
Highlands Regional Medical Center	HCA Healthcare, Inc. (“HCA”)	Sebring, FL	126	November 1, 2017
Merit Health Northwest Mississippi	Curae Health, Inc.	Clarksdale, MS	181	November 1, 2017
Weatherford Regional Medical Center	HCA	Weatherford, TX	103	October 1, 2017
Brandywine Hospital	Reading Health System	Coatesville, PA	169	October 1, 2017
Chestnut Hill Hospital	Reading Health System	Philadelphia, PA	148	October 1, 2017
Jennersville Hospital	Reading Health System	West Grove, PA	63	October 1, 2017
Phoenixville Hospital	Reading Health System	Phoenixville, PA	151	October 1, 2017
Pottstown Memorial Medical Center	Reading Health System	Pottstown, PA	232	October 1, 2017
Yakima Regional Medical and Cardiac Center	Regional Health	Yakima, WA	214	September 1, 2017
Toppenish Community Hospital	Regional Health	Toppenish, WA	63	September 1, 2017
Memorial Hospital of York	PinnacleHealth System	York, PA	100	July 1, 2017
Lancaster Regional Medical Center	PinnacleHealth System	Lancaster, PA	214	July 1, 2017
Heart of Lancaster Regional Medical Center	PinnacleHealth System	Lititz, PA	148	July 1, 2017
Carlisle Regional Medical Center	PinnacleHealth System	Carlisle, PA	165	July 1, 2017
Tomball Regional Medical Center	HCA	Tomball, TX	350	July 1, 2017
South Texas Regional Medical Center	HCA	Jourdanton, TX	67	July 1, 2017
Deaconess Hospital	MultiCare Health System	Spokane, WA	388	July 1, 2017
Valley Hospital	MultiCare Health System	Spokane Valley, WA	123	July 1, 2017
Lake Area Medical Center	CHRISTUS Health	Lake Charles, LA	88	June 30, 2017
Easton Hospital	Steward Health, Inc.	Easton, PA	196	May 1, 2017
Sharon Regional Health System	Steward Health, Inc.	Sharon, PA	258	May 1, 2017
Northside Medical Center	Steward Health, Inc.	Youngstown, OH	355	May 1, 2017
Trumbull Memorial Hospital	Steward Health, Inc.	Warren, OH	311	May 1, 2017
Hillside Rehabilitation Hospital	Steward Health, Inc.	Warren, OH	69	May 1, 2017
Wuesthoff Health System – Rockledge	Steward Health, Inc.	Rockledge, FL	298	May 1, 2017
Wuesthoff Health System – Melbourne	Steward Health, Inc.	Melbourne, FL	119	May 1, 2017
Sebastian River Medical Center	Steward Health, Inc.	Sebastian, FL	154	May 1, 2017
Stringfellow Memorial Hospital	The Health Care Authority	Anniston, AL	125	May 1, 2017
	of the City of Anniston
Merit Health Gilmore Memorial	Curae Health, Inc.	Amory, MS	95	May 1, 2017
Merit Health Batesville	Curae Health, Inc.	Batesville, MS	112	May 1, 2017

On May 1, 2017, one or more subsidiaries of the Company sold AllianceHealth Pryor (52 licensed beds) in Pryor, Oklahoma, and its associated assets to Ardent Health Services Inc. for approximately $1 million in cash. This hospital has been reported in the consolidated statements of loss in discontinued operations.

Net operating revenues and loss from discontinued operations for the respective periods are as follows (in millions):

	Year Ended
	December 31, 2017
Net operating revenues	$	79
Loss from operations of entities sold or held for sale
before income taxes		(10)
Impairment of hospitals sold or held for sale		(8)
Loss on sale, net		(1)
Loss from discontinued operations, before taxes		(19)
Income tax benefit		(7)
Loss from discontinued operations, net of taxes	$	(12)

As part of its ongoing evaluation of the fair value of the hospitals it is marketing for sale, the Company recorded an impairment charge on the carrying value of the long-lived assets at these hospitals in discontinued operations of $6 million, net of tax, for the year ended December 31, 2017. There was no impairment charge recorded for the years ended December 31, 2019 and 2018. Interest expense was allocated to discontinued operations based on sale proceeds available for debt repayment.

The following table discloses amounts included in the consolidated balance sheet for the hospitals classified as held for sale as of December 31, 2019 and 2018 (in millions):

	December 31,
	2019		2018
Other current assets	$	25	$	21
Other assets, net		262		154
Accrued liabilities		43		44

Financial and statistical data reported in this Annual Report on Form 10-K (“Form 10-K”) includes operating results for hospitals held for sale at December 31, 2019 and for the 53 hospitals that were divested during 2019, 2018 and 2017 through the effective date of each respective transaction. Summary financial results of these hospitals included in continuing operations for the periods included in the accompanying consolidated statements of loss are as follows (in millions):

	Year Ended December 31,
	2019		2018		2017
Loss from operations before income taxes	$	(105)	$	(470)	$	(703)
Less: Loss attributable to noncontrolling interests		-		1		(2)
Loss from operations before income taxes attributable
to Community Health Systems, Inc. stockholders	$	(105)	$	(471)	$	(701)

The operating results for these held for sale or divested hospitals included impairment charges of approximately $102 million, $415 million and $368 million that were allocated to the divestitures during the years ended December 31, 2019, 2018 and 2017, respectively.

Other Hospital Closures

During the three months ended December 31, 2018, the Company completed the planned closure of Tennova – Physicians Regional Medical Center in Knoxville, Tennessee and Tennova – Lakeway Regional Medical Center in Morristown, Tennessee. The Company recorded an impairment charge of approximately $27 million during the three months ended December 31, 2018, to adjust the fair value of the supplies, inventory and long-lived assets of these hospitals, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

During the three months ended June 30, 2018, the Company completed the planned closure of Twin Rivers Regional Medical Center in Kennett, Missouri. The Company recorded an impairment charge of approximately $4 million during the three months ended June 30, 2018, to adjust the fair value of the supplies, inventory and long-lived assets of this hospital, including property and equipment and capitalized software costs, based on their estimated fair value and future utilization.

XML

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments Disclosure

7.  FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of financial instruments has been estimated by the Company using available market information as of December 31, 2019 and 2018, and valuation methodologies considered appropriate. The estimates presented in the table below are not necessarily indicative of amounts the Company could realize in a current market exchange (in millions):

	December 31, 2019				December 31, 2018
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	216	$	216	$	196	$	196
Investments in equity securities		141		141		137		137
Available-for-sale debt securities		101		101		93		93
Trading securities		12		12		11		11
Liabilities:
Contingent Value Right		-		-		-		-
Credit Facility		-		-		1,602		1,564
8% Senior Notes due 2019		-		-		155		146
7⅛% Senior Notes due 2020		-		-		121		100
5⅛% Senior Secured Notes due 2021		990		1,003		984		934
6⅞% Senior Notes due 2022		229		188		2,593		1,175
6¼% Senior Secured Notes due 2023		3,074		3,148		3,067		2,819
8⅝% Senior Secured Notes due 2024		1,023		1,099		1,021		1,025
8% Senior Secured Notes due 2026		2,070		2,182		-		-
8% Senior Secured Notes due 2027		691		700		-		-
6⅞% Senior Notes due 2028		1,678		1,700		-		-
9⅞%Junior-Priority Secured Notes due 2023		1,754		1,539		1,750		1,380
8⅛% Junior-Priority Secured Notes due 2024		1,340		1,113		1,338		976
ABL Facility and other debt		285		285		734		734

The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing through publicly available subscription services such as Bloomberg or from the administrative agent to the Credit Facility to determine fair values where relevant.

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Prior to the adoption of ASU 2016-01 on January 1, 2018, such investments were classified as either available-for-sale or trading securities.

Available-for-sale debt securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities.  Estimated fair value is based on closing price as quoted in public markets.

Contingent Value Right.  Estimated fair value is based on the closing price as quoted on the public market where the CVR was traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions.

8% Senior Notes due 2019.  Estimated fair value is based on the closing market price for these notes.

7⅛% Senior Notes due 2020.  Estimated fair value is based on the closing market price for these notes.

5⅛% Senior Secured Notes due 2021.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes due 2022.  Estimated fair value is based on the closing market price for these notes.

6¼% Senior Secured Notes due 2023.  Estimated fair value is based on the closing market price for these notes.

8⅝% Senior Secured Notes due 2024. Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2026. Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2027. Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Secured Notes due 2028. Estimated fair value is based on the closing market price for these notes.

9⅞% Junior-Priority Secured Notes due 2023. Estimated fair value is based on the closing market price for these notes.

8⅛%Junior-Priority Secured Notes due 2024. Estimated fair value is based on the closing market price for these notes.

ABL Facility and other debt.  The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements.

At December 31, 2019, the Company had one interest rate swap with a notional amount of approximately $300 million, a fixed interest rate of 2.892%, a termination date of August 30, 2020, and a fair value of approximately $2 million. The counterparty to the interest rate swap agreement exposes the Company to credit risk in the event of nonperformance by such counterparty. However, at December 31, 2019, the Company does not anticipate nonperformance by the counterparty. The Company does not hold or issue derivative financial instruments for trading purposes.

The Company is exposed to certain risks relating to its ongoing business operations. The risk managed by using derivative instruments is interest rate risk. Companies are required to recognize all derivative instruments as either assets or liabilities at fair value in the consolidated statement of financial position. For derivative instruments that are designated and qualify as cash flow hedges, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on the derivative representing either ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

Assuming no change in interest rates in effect as of December 31, 2019, less than $1million of interest income resulting from the spread between the fixed and floating rates defined in the interest rate swap agreement will be recognized during the next 12 months.

The following tabular disclosure provides the amount of pre-tax (loss) gain recognized as a component of OCI during the years ended December 31, 2019, 2018 and 2017 (in millions):

	Amount of Pre-Tax (Loss) Gain
	Recognized in OCI (Effective Portion)
	Year Ended December 31,
Derivatives in Cash Flow Hedging Relationships	2019		2018		2017
Interest rate swaps	$	(3)	$	17	$	2

The following tabular disclosure provides the location of the effective portion of the pre-tax loss reclassified from accumulated other comprehensive loss (“AOCL”) into interest expense on the consolidated statements of loss income during the years ended December 31, 2019, 2018 and 2017 (in millions):

	Amount of Pre-Tax Loss Reclassified
	from AOCL into Income (Effective Portion)
Location of Loss Reclassified from	Year Ended December 31,
AOCL into Income (Effective Portion)	2019		2018		2017
Interest expense, net	$	-	$	2	$	30

The fair values of derivative instruments in the consolidated balance sheets as of December 31, 2019 and 2018 were as follows (in millions):

Asset Derivatives

Liability Derivatives

December 31, 2019

December 31, 2018

December 31, 2019

December 31, 2018

Balance

Balance

Balance

Balance

Sheet

Sheet

Sheet

Sheet

Location

Fair Value

Location

Fair Value

Location

Fair Value

Location

Fair Value

Derivatives

designated as

Other

Other

Other

Other

hedging

assets,

assets,

long-term

long-term

instruments

net

$

-

net

$

3

liabilities

$

2

liabilities

$

2

XML

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2019

Income Taxes [Abstract]

Schedule of Provision for (Benefit) from Income Taxes for Income from Continuing Operations

		Year Ended December 31,
	2019		2018		2017
Current:
Federal	$	(38)	$	1	$	-
State		(5)		(9)		5
		(43)		(8)		5
Deferred:
Federal		179		50		(485)
State		24		(53)		31
		203		(3)		(454)
Total provision for (benefit from) income taxes for loss
fromcontinuing operations	$	160	$	(11)	$	(449)

Schedule of Reconciliation between the Statutory Federal Income Tax Rate and the Effective Tax Rate

	Year Ended December 31,
	2019				2018				2017
	Amount		%		Amount		%		Amount		%
Benefit from income
taxes at statutory federal rate	$	(90)	21.0	%	$	(150)	21.0	%	$	(991)	35.0	%
State income taxes, net of federal
income tax benefit		(104)	24.3			(114)	16.0			(10)	0.3
Net income attributable to
noncontrolling interests		(18)	4.2			(18)	2.5			(22)	0.8
Change in valuation allowance		340	(79.2)			212	(29.7)			26	(0.9)
Change in uncertain tax position		-	-			9	(1.3)			-	-
Federal rate change		-	-			-	-			32	(1.1)
Federal and state tax credits		-	-			(17)	2.4			(5)	0.1
Nondeductible goodwill		11	(2.6)			30	(4.2)			504	(17.8)
Nondeductible settlements		-	-			22	(3.1)			-	-
Nondeductible loss on divestiture		15	(3.5)			-	-			-	-
Other		6	(1.4)			15	(2.1)			17	(0.6)
Provision for (benefit from) income
taxes and effective tax rate for
loss from continuing operations	$	160	(37.2)	%	$	(11)	1.5	%	$	(449)	15.8	%

Schedule of Components of Deferred Income Taxes

	December 31,
	2019				2018
	Assets		Liabilities		Assets		Liabilities
Net operating loss and credit carryforwards	$	775	$	-	$	743	$	-
Property and equipment		-		335		-		237
Self-insurance liabilities		48		-		69		-
Prepaid expenses		-		30		-		27
Intangibles		-		149		-		134
Investments in unconsolidated affiliates		-		57		-		55
Other liabilities		-		9		-		14
IRC Section 481(a) - mixed service cost		-		216		-		-
Long-term debt and interest		312		-		84		-
Accounts receivable		62		-		58		-
IRC Section 163(j) interest limitation		296		-		144		-
Accrued vacation		24		-		26		-
Accrued bonus		31		-		-		-
Other comprehensive income		5		-		4		-
Right-of-use assets		-		145		-		-
Right-of-use liability		149		-		-		-
Stock-based compensation		5		-		4		-
Deferred compensation		70		-		64		-
Other		51		-		15		-
Total		1,828		941		1,211		467
Valuation allowance		(1,049)		-		(701)		-
Total deferred income taxes	$	779	$	941	$	510	$	467

Schedule of Reconciliation of the Total Amount of Unrecognized Tax Benefit

	Year Ended December 31,
	2019		2018		2017
Unrecognized tax benefit, beginning of year	$	29	$	18	$	18
Gross increases — tax positions in current period		10		11		-
Settlements		(13)		-		-
Unrecognized tax benefit, end of year	$	26	$	29	$	18

XML

Basis of Presentation and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of Net Operating Revenues

	Year Ended
	December 31, 2017
Medicare	$	4,188
Medicaid		1,900
Managed Care and other third-party payors		9,991
Self-pay		2,319
Total	$	18,398

Adoption of ASC 606 [Member]

Schedule of Net Operating Revenues

	Year Ended December 31,
	2019			2018
Medicare	$	3,331	-	$	3,730
Medicaid		1,736			1,876
Managed Care and other third-party payors		8,014			8,349
Self-pay		129			200
Total	$	13,210		$	14,155

XML

Fair Value of Financial Instruments (Policy)

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments, Policy

The carrying value of the Company’s long-term debt in the above table is presented net of unamortized deferred debt issuance costs. The estimated fair value is determined using the methodologies discussed below in accordance with accounting standards related to the determination of fair value based on the U.S. GAAP fair value hierarchy as discussed in Note 8. The estimated fair value for financial instruments with a fair value that does not equal its carrying value is considered a Level 1 valuation. The Company utilizes the market approach and obtains indicative pricing through publicly available subscription services such as Bloomberg or from the administrative agent to the Credit Facility to determine fair values where relevant.

Cash and cash equivalents.  The carrying amount approximates fair value due to the short-term maturity of these instruments (less than three months).

Investments in equity securities. Estimated fair value is based on closing price as quoted in public markets. Prior to the adoption of ASU 2016-01 on January 1, 2018, such investments were classified as either available-for-sale or trading securities.

Available-for-sale debt securities.  Estimated fair value is based on closing price as quoted in public markets or other various valuation techniques.

Trading securities.  Estimated fair value is based on closing price as quoted in public markets.

Contingent Value Right.  Estimated fair value is based on the closing price as quoted on the public market where the CVR was traded.

Credit Facility.  Estimated fair value is based on publicly available trading activity and supported with information from the Company’s bankers regarding relevant pricing for trading activity among the Company’s lending institutions.

8% Senior Notes due 2019.  Estimated fair value is based on the closing market price for these notes.

7⅛% Senior Notes due 2020.  Estimated fair value is based on the closing market price for these notes.

5⅛% Senior Secured Notes due 2021.  Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Notes due 2022.  Estimated fair value is based on the closing market price for these notes.

6¼% Senior Secured Notes due 2023.  Estimated fair value is based on the closing market price for these notes.

8⅝% Senior Secured Notes due 2024. Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2026. Estimated fair value is based on the closing market price for these notes.

8% Senior Secured Notes due 2027. Estimated fair value is based on the closing market price for these notes.

6⅞% Senior Secured Notes due 2028. Estimated fair value is based on the closing market price for these notes.

9⅞% Junior-Priority Secured Notes due 2023. Estimated fair value is based on the closing market price for these notes.

8⅛%Junior-Priority Secured Notes due 2024. Estimated fair value is based on the closing market price for these notes.

ABL Facility and other debt.  The carrying amount of the ABL Facility and all other debt approximates fair value due to the nature of these obligations.

Interest rate swaps.  The fair value of interest rate swap agreements is the amount at which they could be settled, based on estimates calculated by the Company using a discounted cash flow analysis based on observable market inputs and validated by comparison to estimates obtained from the counterparty. The Company incorporates credit valuation adjustments (“CVAs”) to appropriately reflect both its own nonperformance or credit risk and the respective counterparty’s nonperformance or credit risk in the fair value measurements. In adjusting the fair value of its interest rate swap agreements for the effect of nonperformance or credit risk, the Company has considered the impact of any netting features included in the agreements.

XML

Consolidated Statements of Loss (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Consolidated Statements of Loss [Abstract]
Interest income	$ 3	$ 7	$ 11

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Consolidated Balance Sheets [Abstract]
Accumulated amortization	$ 981	$ 939
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	117,822,631	116,248,376
Common stock, shares outstanding	117,822,631	116,248,376

XML

Stockholders' Deficit

12 Months Ended

Dec. 31, 2019

Stockholders' Deficit [Abstract]

Stockholders' Deficit Disclosure

11.  STOCKHOLDERS’ DEFICIT

Authorized capital shares of the Company include 400,000,000 shares of capital stock consisting of 300,000,000 shares of common stock and 100,000,000 shares of preferred stock. Each of the aforementioned classes of capital stock has a par value of $0.01 per share. Shares of preferred stock, none of which were outstanding as of December 31, 2019, may be issued in one or more series having such rights, preferences and other provisions as determined by the Board of Directors without approval by the holders of common stock.

On November 6, 2015, the Company adopted an open market repurchase program for up to 10,000,000 shares of the Company’s common stock, not to exceed $300 million in repurchases. The repurchase program expired on November 6, 2018. During the year ended December 31, 2015, the Company repurchased and retired 532,188 shares at a weighted-average price of $27.31 per share, which is the cumulative number of shares repurchased and retired under this program. No shares were repurchased under this program during the years ended December 31, 2019, 2018 and 2017.

The Company is a holding company which operates through its subsidiaries. The Company’s ABL Facility and the indentures governing each series of the Company’s outstanding notes contain various covenants under which the assets of the subsidiaries of the Company are subject to certain restrictions relating to, among other matters, dividends and distributions, as referenced in the paragraph below.

The ABL Facility and the indentures governing each series of the Company’s outstanding notes restrict the Company’s subsidiaries from, among other matters, paying dividends and making distributions to the Company, which thereby limits the Company’s ability to pay dividends and/or repurchase stock. As of December 31, 2019, under the most restrictive test in these agreements (and subject to certain exceptions), the Company has approximately $200 million of capacity to pay permitted dividends and/or repurchase shares of stock or make other restricted payments.

The following schedule discloses the effects of changes in the Company’s ownership interest in its less-than-wholly-owned subsidiaries on Community Health Systems, Inc. stockholders’ deficit (in millions):

	Year Ended December 31,
	2019		2018		2017
Net loss attributable to Community Health Systems,
Inc. stockholders	$	(675)	$	(788)	$	(2,459)
Transfers to the noncontrolling interests:
Net increase (decrease) in Community Health
Systems, Inc. paid-in-capital for
purchase of subsidiary partnership interests		3		(4)		(2)
Net transfers to the noncontrolling interests		3		(4)		(2)
Change to Community Health Systems, Inc.
stockholders’ deficit from net loss attributable to
Community Health Systems, Inc. stockholders
and transfers to noncontrolling interests	$	(672)	$	(792)	$	(2,461)

XML

Commitments and Contingencies

12 Months Ended

Dec. 31, 2019

Commitments And Contingencies [Abstract]

Commitments and Contingencies Disclosure

15.  COMMITMENTS AND CONTINGENCIES

Construction and Other Capital Commitments.     Pursuant to a hospital purchase agreement in effect as of December 31, 2019, the Company is required to build replacement facilities in La Porte, Indiana and Knox, Indiana. The estimated construction costs, including equipment costs, for the La Porte and Starke replacement facilities are currently estimated to be approximately $128 million and $15 million, respectively, of which approximately $58 million has been incurred to date for the construction of La Porte. In addition, under other purchase agreements outstanding at December 31, 2019, the Company has committed to spend approximately $2 million for costs such as capital improvements, equipment, selected leases and physician recruiting. These commitments are required to be fulfilled generally over a five to seven-year period after acquisition. Through December 31, 2019, the Company has spent approximately $2 million related to these commitments.

Physician Recruiting Commitments.    As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there. Under such agreements, the Company is required to make payments to the physicians in excess of the amounts they earned in their practice up to the amount of the income guarantee. These income guarantee periods are typically for 12 months. Such payments are recoverable by the Company from physicians who do not fulfill their commitment period, which is typically three years, to the respective community. At December 31, 2019, the maximum potential amount of future payments under these guarantees in excess of the liability recorded is $19 million.

Professional Liability Claims.    As part of the Company’s business of owning and operating hospitals, it is subject to legal actions alleging liability on its part. The Company accrues for losses resulting from such liability claims, as well as loss adjustment expenses that are out-of-pocket and directly related to such liability claims. These direct out-of-pocket expenses include fees of outside counsel and experts. The Company does not accrue for costs that are part of corporate overhead, such as the costs of in-house legal and risk management departments. The losses resulting from professional liability claims primarily consist of estimates for known claims, as well as estimates for incurred but not reported claims. The estimates are based on specific claim facts, historical claim reporting and payment patterns, the nature and level of hospital operations and actuarially determined projections. The actuarially determined projections are based on the Company’s actual claim data, including historic reporting and payment patterns which have been gathered over an approximate 20-year period. As discussed below, since the Company purchases excess insurance on a claims-made basis that transfers risk to third-party insurers, the liability it accrues does include an amount for the losses covered by its excess insurance. The Company also records a receivable for the expected reimbursement of losses covered by excess insurance. Since the Company believes that the amount and timing of its future claims payments are reliably determinable, it discounts the amount accrued for losses resulting from professional liability claims using the risk-free interest rate corresponding to the timing of expected payments.

The net present value of the projected payments was discounted using a weighted-average risk-free rate of 2.6%,  3.1% and 2.2% in 2019, 2018 and 2017, respectively. This liability is adjusted for new claims information in the period such information becomes known. The Company’s estimated liability for professional and general liability claims was $612 million and $650 million as of December 31, 2019 and 2018, respectively. The estimated undiscounted claims liability was $663 million and $710 million as of December 31, 2019 and 2018, respectively. The current portion of the liability for professional and general liability claims was $169 million and $100 million as of December 31, 2019 and 2018, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets, with the long-term portion recorded in other long-term liabilities. Professional malpractice expense includes the losses resulting from professional liability claims and loss adjustment expense, as well as paid excess insurance premiums, and is presented within other operating expenses in the accompanying consolidated statements of loss.

The Company’s processes for obtaining and analyzing claims and incident data are standardized across all of its hospitals and have been consistent for many years. The Company monitors the outcomes of the medical care services that it provides and for each reported claim, the Company obtains various information concerning the facts and circumstances related to that claim. In addition, the Company routinely monitors current key statistics and volume indicators in its assessment of utilizing historical trends. The average lag period between claim occurrence and payment of a final settlement is between three and four years, although the facts and circumstances of individual claims could result in the timing of such payments being different from this average. Since claims are paid promptly after settlement with the claimant is reached, settled claims represent approximately 1.0% of the total liability at the end of any period.

For purposes of estimating its individual claim accruals, the Company utilizes specific claim information, including the nature of the claim, the expected claim amount, the year in which the claim occurred and the laws of the jurisdiction in which the claim occurred. Once the case accruals for known claims are determined, information is stratified by loss layers and retentions, accident years, reported years, geography and claims relating to the acquired HMA hospitals versus claims relating to the Company’s other hospitals. Several actuarial methods are used against this data to produce estimates of ultimate paid losses and reserves for incurred but not reported claims. Each of these methods uses company-specific historical claims data and other information. This company-specific data includes information regarding the Company’s business, including historical paid losses and loss adjustment expenses, historical and current case loss reserves, actual and projected hospital statistical data, a variety of hospital census information, employed physician information, professional liability retentions for each policy year, geographic information and other data.

Based on these analyses the Company determines its estimate of the professional liability claims. The determination of management’s estimate, including the preparation of the reserve analysis that supports such estimate, involves subjective judgment of the management. Changes in reserving data or the trends and factors that influence reserving data may signal fundamental shifts in the Company’s future claim development patterns or may simply reflect single-period anomalies. Even if a change reflects a fundamental shift, the full extent of the change may not become evident until years later. Moreover, since the Company’s methods and models use different types of data and the Company selects its liability from the results of all of these methods, it typically cannot quantify the precise impact of such factors on its estimates of the liability. Due to the Company’s standardized and consistent processes for handling claims and the long history and depth of company-specific data, the Company’s methodologies have produced reliably determinable estimates of ultimate paid losses. Management considers any changes in the amount and pattern of its historical paid losses up through the most recent reporting period to identify any fundamental shifts or trends in claim development experience in determining the estimate of professional liability claims. However, due to the subjective nature of this estimate and the impact that previously unforeseen shifts in actual claim experience can have, future estimates of professional liability could be adversely impacted when actual paid losses develop unexpectedly based on assumptions and settlement events that were not previously known or anticipated.

During the nine months ended September 30, 2019, the Company experienced a significant increase in the amounts paid to settle outstanding professional liability claims, compared to the same period in the prior year and to previous actuarially determined estimates. This increase in claims paid related to claims incurred in 2016 and prior years and was primarily related to divested hospitals. The settlement of these claims at amounts greater than the previously determined actuarial estimates resulted in the Company recording a $70 million change in estimate during the three months ended June 30, 2019, and an additional $20 million change in estimate during the three months ended September 30, 2019 based on updated actuarial estimates. No additional change in estimate related to these claims was recorded during the three months ended December 31, 2019.

The Company is primarily self-insured for professional liability claims; however, the Company obtains excess insurance that transfers the risk of loss to a third-party insurer for claims in excess of self-insured retentions. The Company’s excess insurance is underwritten on a claims-made basis. For claims reported prior to June 1, 2002, substantially all of the Company’s professional and general liability risks were subject to a less than $1 million per occurrence self-insured retention and for claims reported from June 1, 2002 through June 1, 2003, these self-insured retentions were $2 million per occurrence. Substantially all claims reported after June 1, 2003 and before June 1, 2005 are self-insured up to $4 million per claim. Substantially all claims reported on or after June 1, 2005 and before June 1, 2014 are self-insured up to $5 million per claim. Substantially all claims reported on or after June 1, 2014 and before June 1, 2018 are self-insured up to $10 million per claim. Substantially all claims reported on or after June 1, 2018 are self-insured up to $15 million per claim. Management on occasion has selectively increased the insured risk at certain hospitals based upon insurance pricing and other factors and may continue that practice in the future. Excess insurance for all hospitals has been purchased through commercial insurance companies and generally covers the Company for liabilities in excess of the self-insured retentions. The excess coverage consists of multiple layers of insurance, the sum of which totals up to $95 million per occurrence and in the aggregate for claims reported on or after June 1, 2003, up to $145 million per occurrence and in the aggregate for claims reported on or after January 1, 2008, up to $195 million per occurrence and in the aggregate for claims reported on or after June 1, 2010, and up to at least $215 million per occurrence and in the aggregate for claims reported on or after June 1, 2015. In addition, for integrated occurrence malpractice claims, there is an additional $50 million of excess coverage for claims reported on or after June 1, 2014 and an additional $75 million of excess coverage for claims reported on or after June 1, 2015. For certain policy years prior to June 1, 2014, if the first aggregate layer of excess coverage becomes fully utilized, then the Company’s self-insured retention will increase to $10 million per claim for any subsequent claims in that policy year until the Company’s total aggregate coverage is met. Beginning June 1, 2018, this drop-down provision in the excess policies attaches over the $15 million per claim self-insured retention.

Effective June 1, 2014, the hospitals acquired from HMA were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims reported on or after June 1, 2014 except for physician-related claims with an occurrence date prior to June 1, 2014. Prior to June 1, 2014, the former HMA hospitals obtained insurance coverage through a wholly-owned captive insurance subsidiary and a risk retention group subsidiary which are domiciled in the Cayman Islands and South Carolina, respectively. Those insurance subsidiaries, which are collectively referred to as the “Insurance Subsidiaries,” provided (i) claims-made coverage to all of the former HMA hospitals and (ii) occurrence-basis coverage to most of the physicians employed by the former HMA hospitals. The employed physicians not covered by the Insurance Subsidiaries generally maintained claims-made policies with unrelated third party insurance companies. To mitigate the exposure of the program covering the former HMA hospitals and other healthcare facilities, the Insurance Subsidiaries bought claims-made reinsurance policies from unrelated third parties for claims above self-retention levels of $10 million or $15 million per claim, depending on the policy year.

Effective January 1, 2008, the former Triad hospitals were insured on a claims-made basis as described above and through commercial insurance companies as described above for substantially all claims occurring on or after January 1, 2002 and reported on or after January 1, 2008. Substantially all losses for the former Triad hospitals in periods prior to May 1, 1999 were insured through a wholly-owned insurance subsidiary of HCA, Triad’s owner prior to that time, and excess loss policies maintained by HCA. HCA has agreed to indemnify the former Triad hospitals in respect of claims covered by such insurance policies arising prior to May 1, 1999. From May 1, 1999 through December 31, 2006, the former Triad hospitals obtained insurance coverage on a claims incurred basis from HCA’s wholly-owned insurance subsidiary, with excess coverage obtained from other carriers that is subject to certain deductibles. Effective for claims incurred after December 31, 2006, Triad began insuring its claims from $1 million to $5 million through its wholly-owned captive insurance company, replacing the coverage provided by HCA. Substantially all claims occurring during 2007 were self-insured up to $10 million per claim.

Legal Matters.The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental matters, including the matters described herein, will have a material adverse effect on the consolidated financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in pending legal, regulatory and governmental matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period.

With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, and/or the preliminary nature of, certain legal, regulatory and governmental matters.

In connection with the spin-off of Quorum Health Corporation (“QHC”), the Company agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to April 29, 2016, the closing date of the spin-off, including (i) certain claims and proceedings that were known to be outstanding at or prior to the consummation of the spin-off and involved multiple facilities and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to QHC’s healthcare facilities prior to the closing date of the spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by the Company, including professional liability and employer practices. Notwithstanding the foregoing, the Company is not required to indemnify QHC in respect of any claims or proceedings arising out of or related to the business operations of Quorum Health Resources, LLC at any time or QHC’s compliance with the corporate integrity agreement. Subsequent to the spin-off of QHC, the Office of the Inspector General provided the Company with written assurance that it would look solely at QHC for compliance for its facilities under the Company’s Corporate Integrity Agreement; however, the Office of the Inspector General declined to enter into a separate corporate integrity agreement with QHC.

Probable Contingencies

Becker v. Community Health Systems, Inc. d/b/a Community Health Systems Professional Services Corporation d/b/a Community Health Systems d/b/a Community Health Systems PSC, Inc. d/b/a Rockwood Clinic P.S. and Rockwood Clinic, P.S. (Superior Court, Spokane, Washington). This suit was filed on February 29, 2012, by a former chief financial officer at Rockwood Clinic in Spokane, Washington. Becker claims he was wrongfully terminated for allegedly refusing to certify a budget for Rockwood Clinic in 2012. On February 29, 2012, he also filed an administrative complaint with the Department of Labor, Occupational Safety and Health Administration alleging that he is a whistleblower under Sarbanes-Oxley, which was dismissed by the agency and was appealed to an administrative law judge for a hearing that occurred on January 19-26, 2016. In a decision dated November 9, 2016, the law judge awarded Becker approximately $1.9 million for front pay, back pay and emotional damages with attorney fees to be later determined. The Company has appealed the award to the Administrative Review Board and is awaiting its decision. At a hearing on July 27, 2012, the trial court dismissed Community Health Systems, Inc. from the state case and subsequently certified the state case for an interlocutory appeal of the denial to dismiss his employer and the management company. The appellate court accepted the interlocutory appeal, and it was argued on April 30, 2014. On August 14, 2014, the court denied the Company’s appeal. On October 20, 2014, the Company filed a petition to review the denial with the Washington Supreme Court. The appeal was accepted and oral argument was heard on June 9, 2015. On September 15, 2015, the court denied the Company’s appeal and remanded to the trial court; a previous trial setting of September 12, 2016 has been vacated and not reset. On October 15, 2019, the Administrative Review Board released an order to show cause requiring Becker to file a brief to show cause why the Administrative Review Board should not remand the previous administrative decision for a new hearing before a new law judge. The appeal before the Administrative Review Board is still pending. The Company continues to vigorously defend these actions.

Empire Health Foundation v. CHS/Community Health Systems, Inc., CHS Washington Holdings, LLC, Spokane Washington Hospital Company, LLC, Spokane Valley Washington Hospital Company, LLC. This suit was filed in the United States District Court for the Eastern District of Washington on June 12, 2017 by Empire Health Foundation claiming Deaconess and Valley Hospitals failed to abide by charity care obligations allegedly existing in the 2008 Asset Purchase Agreement between Empire Health System and Company affiliates. The court granted in part and denied in part the hospitals’ motion to dismiss on October 11, 2017. All parties filed motions for summary judgment, and the court granted in part and denied in part both parties’ motions on February 27, 2019 and July 9, 2019. The Company settled this matter during the three months ended September 30, 2019 for $22 million (and recorded a liability equal to the settlement amount as of September 30, 2019), the settlement was paid during the three months ended December 31, 2019.

R2 Investments v Quorum Health Corporation; Community Health Systems, Inc.; Wayne T. Smith; W. Larry Cash; Thomas D. Miller; Michael J. Culotta; John A. Clerico; James S. Ely, III; John A. Fry; William Norris Jennings; Julia B. North; H. Mitchell Watson, Jr.; H. James Williams. This case was pending in the Circuit Court for Williamson County, Tennessee and was served on October 26, 2017. The plaintiff alleged common law fraud and violation of Tennessee securities fraud statutes in connection with its purchase of QHC stock and QHC senior secured notes. The court granted in part and denied in part the director defendants’ motion to dismiss and denied the remaining defendants’ motions to dismiss on May 11, 2018. The Company settled and paid this matter during the three months ended December 31, 2019.

2011 Class Action Shareholder Federal Securities Cases.  Three purported class action cases have been filed in the United States District Court for the Middle District of Tennessee; namely, Norfolk County Retirement System v. Community Health Systems, Inc., et al., filed May 9, 2011; De Zheng v. Community Health Systems, Inc., et al., filed May 12, 2011; and Minneapolis Firefighters Relief Association v. Community Health Systems, Inc., et al., filed June 21, 2011. All three seek class certification on behalf of purchasers of the Company’s common stock between July 27, 2006 and April 11, 2011 and allege that misleading statements resulted in artificially inflated prices for the Company’s common stock. In December 2011, the cases were consolidated for pretrial purposes and NYC Funds and its counsel were selected as lead plaintiffs/lead plaintiffs’ counsel. In lieu of ruling on the Company’s motion to dismiss, the court permitted the plaintiffs to file a first amended consolidated class action complaint, which was filed on October 5, 2015. The Company’s motion to dismiss was filed on November 4, 2015 and oral argument was held on April 11, 2016. The Company’s motion to dismiss was granted on June 16, 2016 and on June 27, 2016, the plaintiffs filed a notice of appeal to the Sixth Circuit Court of Appeals. The matter was heard on May 3, 2017. On December 13, 2017, the Sixth Circuit reversed the trial court’s dismissal of the case and remanded it to the District Court. The Company filed a renewed partial motion to dismiss on February 9, 2018, which was denied by the District Court on September 24, 2018.  The Company also filed a petition for a writ of certiorari to the United States Supreme Court on April 18, 2018 seeking review of the Sixth Circuit’s decision. The United States Supreme Court denied the petition for a writ of certiorari on October 1, 2018. The District Court granted the Plaintiff’s motion for class certification on July 26, 2019. The Company filed a petition for permission to appeal the District Court’s class certification order in the Sixth Circuit Court of Appeals on August 9, 2019, and that petition was denied on October 23, 2019. Trial for this matter is set for December 1, 2020. On January 21, 2020, the Company and the Plaintiff filed a stipulation of settlement indicating to the District Court that the parties had reached agreement on the principal terms of a settlement for $53 million. The settlement is subject to the District Court’s final approval.The Company recorded a liability of $53 million at December 31, 2019 based on the proposed settlement agreement.

Summary of Recorded Amounts

The table below presents a reconciliation of the beginning and ending liability balances (in millions) during the years ended December 31, 2019 and 2018, with respect to the Company’s determination of the contingencies of the Company in respect of which an accrual has been recorded.

	Probable
	Contingencies
Balance as of December 31, 2017	$	14
Expense		7
Reserve for insured claim		4
Cash payments		(6)
Balance as of December 31, 2018		19
Expense		87
Reserve for insured claim		(4)
Cash payments		(34)
Balance as of December 31, 2019	$	68

In accordance with applicable accounting guidance, the Company establishes a liability for litigation, regulatory and governmental matters for which, based on information currently available, the Company believes that a negative outcome is known or is probable and the amount of the loss is reasonably estimable. For all such matters (whether or not discussed in this contingencies footnote), such amounts have been recorded in other accrued liabilities on the consolidated balance sheet and are included in the table above. Due to the uncertainties and difficulty in predicting the ultimate resolution of these contingencies, the actual amount could differ from the estimated amount reflected as a liability on the consolidated balance sheet.

In the aggregate, attorneys’ fees and other costs incurred but not included in the table above related to probable contingencies, and CVR-related contingencies accounted for at fair value, totaled $21 million and $2 million during the years ended December 31, 2019 and 2018, respectively, and are included in other operating expenses in the accompanying consolidated statements of loss.

Matters for which an Outcome Cannot be Assessed

For the following legal matter, due to the uncertainties surrounding the ultimate outcome of the case, the Company cannot at this time assess what the outcome may be and is further unable to reasonably estimate any loss or range of loss.

Steadfast Insurance Company, et al v. Community Health Systems, Inc., CHS/Community Health Systems, Inc., CHSPSC, LLC and Pecos Valley of New Mexico, LLC. This case is filed in the Superior Court for the State of Delaware and involve suits by four excess liability insurers seeking a declaration that a $73 million judgment rendered against Pecos Valley of New Mexico, LLC in Anne Sperling, et al v. Pecos Valley of New Mexico, LLC is not a covered loss as defined by the policies at issue. The Steadfast complaint was served on November 30, 2018. On December 13, 2018, Admiral Insurance Company, Endurance Specialty Insurance Ltd, and Illinois Union Insurance Company moved to intervene in the suit as petitioners. The Company has initiated counterclaims against each insurer, including for bad faith against Steadfast. The judgment against Pecos Valley of New Mexico, LLC, which is the subject of this litigation and which was rendered on September 5, 2018, in First Judicial Court of the State of New Mexico, is currently on appeal to the Court of Appeals of New Mexico. Trial of this matter is set for December 7, 2020. The Company believes the claims in the Steadfast litigation are without merit and will vigorously defend the case.

XML

Schedule II - Qualifying and Valuation Accounts

12 Months Ended

Dec. 31, 2019

Schedule II - Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts Disclosure

Community Health Systems, Inc. and Subsidiaries
Schedule II — Valuation and Qualifying Accounts
	Balance at		Acquisitions		Charged to				Balance
	Beginning		and		Costs and				at End
Description	of Year		Dispositions		Expenses		Write-offs		of Year
		(In millions)
Year ended December 31, 2019
allowance for doubtful accounts (1)	$	-	$	-	$	-	$	-	$	-
Year ended December 31, 2018
allowance for doubtful accounts (1)	$	-	$	-	$	-	$	-	$	-
Year ended December 31, 2017
allowance for doubtful accounts	$	3,773	$	(21)	$	3,054	$	(2,936)	$	3,870

__________

(1) As discussed at Note 1 of the Notes of the Consolidated Financial Statements, on January 1, 2018, the Company adopted the new revenue recognition standard codified in ASC 606. Upon adoption of ASC 606, the allowance for doubtful accounts of approximately $3.9 billion was reclassified as a component of the net patient accounts receivable.

XML

Supplemental Condensed Consolidating Financial Information (Tables)

12 Months Ended

Dec. 31, 2019

Supplemental Condensed Consolidating Financial Information [Abstract]

Schedule of Condensed Consolidating Statement of Loss

Condensed Consolidating Statement of Loss
Year Ended December 31, 2019
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net operating revenues	$	-	$	46	$	8,246	$	4,918	$	-	$	13,210
Operating costs and expenses:
Salaries and benefits		-		-		3,092		2,855		-		5,947
Supplies		-		-		1,444		707		-		2,151
Other operating expenses		-		-		2,289		1,014		-		3,303
Government and other legal settlements and
related costs		-		-		93		-		-		93
Electronic health records incentive reimbursement		-		-		-		(1)		-		(1)
Lease cost and rent		-		-		168		153		-		321
Depreciation and amortization		-		-		383		225		-		608
Impairment and loss on sale of businesses, net		-		(2)		121		19		-		138
Total operating costs and expenses		-		(2)		7,590		4,972		-		12,560
Income (loss) from operations		-		48		656		(54)		-		650
Interest expense, net		-		425		667		(51)		-		1,041
Loss from early extinguishment of debt		-		54		-		-		-		54
Equity in earnings of unconsolidated affiliates		675		99		(26)		-		(763)		(15)
(Loss) income before income taxes		(675)		(530)		15		(3)		763		(430)
Provision for (benefit from) income taxes		-		145		(6)		21		-		160
Net (loss) income		(675)		(675)		21		(24)		763		(590)
Less: Net income attributable to noncontrolling interests		-		-		-		85		-		85
Net (loss) income attributable to Community Health
Systems, Inc. stockholders	$	(675)	$	(675)	$	21	$	(109)	$	763	$	(675)

Condensed Consolidating Statement of Loss
Year Ended December 31, 2018
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Net operating revenues	$	-	$	(5)	$	8,111	$	6,049	$	-	$	14,155
Operating costs and expenses:
Salaries and benefits		-		-		3,030		3,354		-		6,384
Supplies		-		-		1,426		929		-		2,355
Other operating expenses		-		-		2,109		1,387		-		3,496
Government and other legal settlements and
related costs		-		-		11		-		-		11
Electronic health records incentive reimbursement		-		-		(1)		(3)		-		(4)
Lease cost and rent		-		-		166		171		-		337
Depreciation and amortization		-		-		414		286		-		700
Impairment and loss on sale of businesses, net		-		29		97		542		-		668
Total operating costs and expenses		-		29		7,252		6,666		-		13,947
(Loss) income from operations		-		(34)		859		(617)		-		208
Interest expense, net		-		425		494		57		-		976
(Gain) loss from early extinguishment of debt		-		(32)		1		-		-		(31)
Equity in earnings of unconsolidated affiliates		788		438		774		-		(2,022)		(22)
Loss before income taxes		(788)		(865)		(410)		(674)		2,022		(715)
(Benefit from) provision for income taxes		-		(77)		(7)		73		-		(11)
Net loss		(788)		(788)		(403)		(747)		2,022		(704)
Less: Net income attributable to noncontrolling interests		-		-		-		84		-		84
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(788)	$	(788)	$	(403)	$	(831)	$	2,022	$	(788)

Condensed Consolidating Statement of Loss
Year Ended December 31, 2017
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
	(In millions)
Operating revenues (net of contractual
allowances and discounts)	$	-	$	(22)	$	9,421	$	8,999	$	-	$	18,398
Provision for bad debts		-		-		1,819		1,226		-		3,045
Net operating revenues		-		(22)		7,602		7,773		-		15,353
Operating costs and expenses:
Salaries and benefits		-		-		3,092		4,284		-		7,376
Supplies		-		-		1,397		1,275		-		2,672
Other operating expenses		-		-		1,954		1,910		-		3,864
Government and other legal settlements and
related costs		-		-		(31)		-		-		(31)
Electronic health records incentive reimbursement		-		-		(8)		(20)		-		(28)
Rent		-		-		166		228		-		394
Depreciation and amortization		-		-		434		427		-		861
Impairment and loss on sale of businesses, net		-		-		608		1,515		-		2,123
Total operating costs and expenses		-		-		7,612		9,619		-		17,231
Loss from operations		-		(22)		(10)		(1,846)		-		(1,878)
Interest expense, net		-		327		489		115		-		931
Loss from early extinguishment of debt		-		40		-		-		-		40
Equity in earnings of unconsolidated affiliates		2,459		1,888		1,555		-		(5,918)		(16)
Loss from continuing operations before
income taxes		(2,459)		(2,277)		(2,054)		(1,961)		5,918		(2,833)
Provision for (benefit from) income taxes		-		182		(170)		(461)		-		(449)
Loss from continuing operations		(2,459)		(2,459)		(1,884)		(1,500)		5,918		(2,384)
Discontinued operations, net of taxes:
Loss from operations of entities sold or
held for sale		-		-		(4)		(2)		-		(6)
Impairment of hospitals sold or held for sale		-		-		(4)		(2)		-		(6)
Loss from discontinued operations, net of taxes		-		-		(8)		(4)		-		(12)
Net loss		(2,459)		(2,459)		(1,892)		(1,504)		5,918		(2,396)
Less: Net income attributable to noncontrolling interests		-		-		-		63		-		63
Net loss attributable to Community Health
Systems, Inc. stockholders	$	(2,459)	$	(2,459)	$	(1,892)	$	(1,567)	$	5,918	$	(2,459)

Schedule of Condensed Consolidating Statement of Comprehensive (Loss) Income

Condensed Consolidating Statement of Comprehensive (Loss) Income
Year Ended December 31, 2019
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net (loss) income	$	(675)	$	(675)	$	21	$	(24)	$	763	$	(590)
Other comprehensive (loss) income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		(3)		(3)		-		-		3		(3)
Net change in fair value of available-for-sale debt
securities, net of tax		4		4		4		-		(8)		4
Amortization and recognition of unrecognized pension
cost components, net of tax		-		-		-		-		-		-
Other comprehensive income		1		1		4		-		(5)		1
Comprehensive (loss) income		(674)		(674)		25		(24)		758		(589)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		85		-		85
Comprehensive (loss) income attributable to
Community Health Systems, Inc. stockholders	$	(674)	$	(674)	$	25	$	(109)	$	758	$	(674)

Condensed Consolidating Statement of Comprehensive Loss
Year Ended December 31, 2018
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(788)	$	(788)	$	(403)	$	(747)	$	2,022	$	(704)
Other comprehensive income (loss), net of income taxes:
Net change in fair value of interest rate swaps, net of tax		20		20		-		-		(20)		20
Net change in fair value of available-for-sale debt
securities, net of tax		(2)		(2)		(2)		-		4		(2)
Amortization and recognition of unrecognized pension
cost components, net of tax		(1)		(1)		(1)		-		2		(1)
Other comprehensive income (loss)		17		17		(3)		-		(14)		17
Comprehensive loss		(771)		(771)		(406)		(747)		2,008		(687)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		84		-		84
Comprehensive loss attributable to
Community Health Systems, Inc. stockholders	$	(771)	$	(771)	$	(406)	$	(831)	$	2,008	$	(771)

Condensed Consolidating Statement of Comprehensive Loss
Year Ended December 31, 2017
	Parent Guarantor		Issuer		Other Guarantors		Non - Guarantors		Eliminations		Consolidated
		(In millions)
Net loss	$	(2,459)	$	(2,459)	$	(1,892)	$	(1,504)	$	5,918	$	(2,396)
Other comprehensive income, net of income taxes:
Net change in fair value of interest rate swaps, net of tax		19		19		-		-		(19)		19
Net change in fair value of available-for-sale debt
securities, net of tax		8		8		8		-		(16)		8
Amortization and recognition of unrecognized pension
cost components, net of tax		14		14		14		-		(28)		14
Other comprehensive income		41		41		22		-		(63)		41
Comprehensive loss		(2,418)		(2,418)		(1,870)		(1,504)		5,855		(2,355)
Less: Comprehensive income attributable to
noncontrolling interests		-		-		-		63		-		63
Comprehensive loss attributable to
Community Health Systems, Inc. stockholders	$	(2,418)	$	(2,418)	$	(1,870)	$	(1,567)	$	5,855	$	(2,418)

Schedule of Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet
December 31, 2019
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	142	$	74	$	-	$	216
Patient accounts receivable		-		-		1,822		436		-		2,258
Supplies		-		-		242		112		-		354
Prepaid income taxes		48		-		-		-		-		48
Prepaid expenses and taxes		-		-		152		41		-		193
Other current assets		-		-		72		286		-		358
Total current assets		48		-		2,430		949		-		3,427
Intercompany receivable		-		11,961		5,674		6,990		(24,625)		-
Property and equipment, net		-		-		4,206		1,402		-		5,608
Goodwill		-		-		2,628		1,700		-		4,328
Deferred income taxes		38		-		-		-		-		38
Other assets, net		(4)		-		1,203		1,009		-		2,208
Net investment in subsidiaries		-		21,736		12,433		-		(34,169)		-
Total assets	$	82	$	33,697	$	28,574	$	12,050	$	(58,794)	$	15,609
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	-	$	18	$	2	$	-	$	20
Current operating lease liabilities		-		-		82		54		-		136
Accounts payable		-		11		518		282		-		811
Accrued interest		-		189		-		-		-		189
Accrued liabilities		-		1		650		475		-		1,126
Total current liabilities		-		201		1,268		813		-		2,282
Long-term debt		-		13,116		208		61		-		13,385
Intercompany payable		2,099		22,518		26,029		13,399		(64,045)		-
Deferred income taxes		200		-		-		-		-		200
Long-term operating lease liabilities		-		-		265		222		-		487
Other long-term liabilities		1		2		580		311		-		894
Total liabilities		2,300		35,837		28,350		14,806		(64,045)		17,248
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		502		-		502
(Deficit) equity:
Community Health Systems, Inc. stockholders’
(deficit) equity:
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,008		(487)		198		(1,008)		1,297		2,008
Accumulated other comprehensive (loss) income		(9)		(9)		(11)		1		19		(9)
(Accumulated deficit) retained earnings		(4,218)		(1,644)		37		(2,328)		3,935		(4,218)
Total Community Health Systems, Inc.
stockholders’ (deficit) equity		(2,218)		(2,140)		224		(3,335)		5,251		(2,218)
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		77		-		77
Total (deficit) equity		(2,218)		(2,140)		224		(3,258)		5,251		(2,141)
Total liabilities and (deficit) equity	$	82	$	33,697	$	28,574	$	12,050	$	(58,794)	$	15,609

Condensed Consolidating Balance Sheet
December 31, 2018
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	-	$	-	$	132	$	64	$	-	$	196
Patient accounts receivable		-		-		1,844		508		-		2,352
Supplies		-		-		269		133		-		402
Prepaid income taxes		3		-		-		-		-		3
Prepaid expenses and taxes		-		-		134		62		-		196
Other current assets		-		-		84		316		-		400
Total current assets		3		-		2,463		1,083		-		3,549
Intercompany receivable		-		12,615		4,882		6,358		(23,855)		-
Property and equipment, net		-		-		4,371		1,768		-		6,139
Goodwill		-		-		2,704		1,855		-		4,559
Deferred income taxes		69		-		-		-		-		69
Other assets, net		-		25		796		722		-		1,543
Net investment in subsidiaries		-		20,742		11,784		-		(32,526)		-
Total assets	$	72	$	33,382	$	27,000	$	11,786	$	(56,381)	$	15,859
LIABILITIES AND (DEFICIT) EQUITY
Current liabilities:
Current maturities of long-term debt	$	-	$	155	$	22	$	27	$	-	$	204
Accounts payable		-		-		574		313		-		887
Accrued interest		-		205		-		1		-		206
Accrued liabilities		-		1		531		563		-		1,095
Total current liabilities		-		361		1,127		904		-		2,392
Long-term debt		-		13,167		151		74		-		13,392
Intercompany payable		1,572		21,318		24,901		13,085		(60,876)		-
Deferred income taxes		26		-		-		-		-		26
Other long-term liabilities		9		2		619		378		-		1,008
Total liabilities		1,607		34,848		26,798		14,441		(60,876)		16,818
Redeemable noncontrolling interests in
equity of consolidated subsidiaries		-		-		-		504		-		504
(Deficit) equity:
Community Health Systems, Inc. stockholders’
(deficit) equity:
Common stock		1		-		-		-		-		1
Additional paid-in capital		2,017		(329)		193		(985)		1,121		2,017
Accumulated other comprehensive loss		(10)		(10)		(11)		(3)		24		(10)
(Accumulated deficit) retained earnings		(3,543)		(1,127)		20		(2,243)		3,350		(3,543)
Total Community Health Systems, Inc.
stockholders’ (deficit) equity		(1,535)		(1,466)		202		(3,231)		4,495		(1,535)
Noncontrolling interests in equity of
consolidated subsidiaries		-		-		-		72		-		72
Total (deficit) equity		(1,535)		(1,466)		202		(3,159)		4,495		(1,463)
Total liabilities and (deficit) equity	$	72	$	33,382	$	27,000	$	11,786	$	(56,381)	$	15,859

Schedule of Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2019
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(4)	$	(348)	$	600	$	137	$	-	$	385
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(6)		(7)		-		(13)
Purchases of property and equipment		-		-		(366)		(72)		-		(438)
Proceeds from disposition of hospitals
and other ancillary operations		-		18		30		556		-		604
Proceeds from sale of property and equipment		-		-		1		2		-		3
Purchases of available-for-sale debt securities
and equity securities		-		-		(19)		(61)		-		(80)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		31		61		-		92
Increase in other investments		-		-		(123)		(47)		-		(170)
Net cash provided by (used in)
investing activities		-		18		(452)		432		-		(2)
Cash flows from financing activities:
Repurchase of restricted stock shares for
payroll tax withholding requirements		(1)		-		-		-		-		(1)
Deferred financing costs and other debt-related
costs		-		(46)		-		-		-		(46)
Proceeds from noncontrolling investors in
joint ventures		-		-		-		10		-		10
Redemption of noncontrolling investments in
joint ventures		-		-		-		(11)		-		(11)
Distributions to noncontrolling investors in
joint ventures		-		-		-		(99)		-		(99)
Proceeds from sale-lease back		-		-		60		-		-		60
Changes in intercompany balances with
affiliates, net		5		619		(189)		(435)		-		-
Borrowings under credit agreements		-		-		36		1		-		37
Issuance of long-term debt		-		3,042		-		-		-		3,042
Proceeds from ABL Facility		-		202		-		-		-		202
Repayments of long-term indebtedness		-		(3,487)		(45)		(25)		-		(3,557)
Net cash provided by (used in)
financing activities		4		330		(138)		(559)		-		(363)
Net change in cash and cash equivalents		-		-		10		10		-		20
Cash and cash equivalents at beginning of period		-		-		132		64		-		196
Cash and cash equivalents at end of period	$	-	$	-	$	142	$	74	$	-	$	216

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2018
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash provided by (used in) operating
activities	$	40	$	(409)	$	560	$	83	$	-	$	274
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(3)		(23)		-		(26)
Purchases of property and equipment		-		-		(408)		(119)		-		(527)
Proceeds from disposition of hospitals
and other ancillary operations		-		-		1		404		-		405
Proceeds from sale of property and equipment		-		-		5		3		-		8
Purchases of available-for-sale debt securities
and equity securities		-		-		(54)		(24)		-		(78)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		79		35		-		114
Increase in other investments		-		(7)		(112)		(22)		-		(141)
Net cash (used in) provided
by investing activities		-		(7)		(492)		254		-		(245)
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(1)		-		-		-		-		(1)
Deferred financing costs and other
debt-related costs		-		(96)		-		-		-		(96)
Proceeds from noncontrolling investors in joint
ventures		-		-		-		3		-		3
Redemption of noncontrolling investments in joint
ventures		-		-		-		(31)		-		(31)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(96)		-		(96)
Changes in intercompany balances with
affiliates, net		(39)		99		176		(236)		-		-
Borrowings under credit agreements		-		-		28		-		-		28
Issuance of long-term debt		-		1,033		-		-		-		1,033
Proceeds from ABL Facility		-		748		49		-		-		797
Repayments of long-term indebtedness		-		(1,368)		(655)		(10)		-		(2,033)
Net cash (used in) provided by financing
activities		(40)		416		(402)		(370)		-		(396)
Net change in cash and cash equivalents		-		-		(334)		(33)		-		(367)
Cash and cash equivalents at beginning of period		-		-		466		97		-		563
Cash and cash equivalents at end of period	$	-	$	-	$	132	$	64	$	-	$	196

Condensed Consolidating Statement of Cash Flows
Year Ended December 31, 2017
	Parent				Other		Non -
	Guarantor		Issuer		Guarantors		Guarantors		Eliminations		Consolidated
	(In millions)
Net cash (used in) provided by operating
activities	$	(12)	$	(317)	$	431	$	671	$	-	$	773
Cash flows from investing activities:
Acquisitions of facilities and other related
businesses		-		-		(1)		(5)		-		(6)
Purchases of property and equipment		-		-		(356)		(208)		-		(564)
Proceeds from disposition of hospitals and other
ancillary operations		-		-		122		1,570		-		1,692
Proceeds from sale of property and equipment		-		-		3		4		-		7
Purchases of available-for-sale debt securities
and equity securities		-		-		(91)		(34)		-		(125)
Proceeds from sales of available-for-sale
debt securities and equity securities		-		-		172		36		-		208
Increase in other investments		-		-		(100)		(43)		-		(143)
Net cash (used in) provided by investing
activities		-		-		(251)		1,320		-		1,069
Cash flows from financing activities:
Repurchase of restricted stock shares for payroll
tax withholding requirements		(5)		-		-		-		-		(5)
Deferred financing costs and other
debt-related costs		-		(65)		(1)		-		-		(66)
Proceeds from noncontrolling investors in joint
ventures		-		-		-		5		-		5
Redemption of noncontrolling investments in joint
ventures		-		-		-		(6)		-		(6)
Distributions to noncontrolling investors in joint
ventures		-		-		-		(100)		-		(100)
Changes in intercompany balances with
affiliates, net		17		1,565		331		(1,913)		-		-
Borrowings under credit agreements		-		795		30		16		-		841
Issuance of long-term debt		-		3,100		-		-		-		3,100
Proceeds from ABL Facility		-		-		105		-		-		105
Repayments of long-term indebtedness		-		(5,078)		(285)		(28)		-		(5,391)
Net cash provided by (used in) financing
activities		12		317		180		(2,026)		-		(1,517)
Net change in cash and cash equivalents		-		-		360		(35)		-		325
Cash and cash equivalents at beginning of period		-		-		106		132		-		238
Cash and cash equivalents at end of period	$	-	$	-	$	466	$	97	$	-	$	563

XML

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2018
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 3,773
Acquisitions and Dispositions	(21)
Charged to Costs and Expenses	3,054
Write-offs	(2,936)
Balance at End of Year	$ 3,870
Patient accounts receivable, net of allowance for doubtful accounts		$ 2,258	$ 2,352
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Patient accounts receivable, net of allowance for doubtful accounts				$ 3,900

XML

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2019

Earnings Per Share [Abstract]

Schedule of Components of Denominator for Computation of Basic and Diluted Loss Per Share

	Year Ended December 31,
	2019		2018		2017
Numerator:
Loss from continuing operations, net of taxes	$	(590)	$	(704)	$	(2,384)
Less: Income attributable
to noncontrolling interests, net of taxes		85		84		63
Loss from continuing operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	(675)	$	(788)	$	(2,447)
Loss from discontinued operations, net of taxes	$	-	$	-	$	(12)
Less: Loss from discontinued operations attributable
to noncontrolling interests, net of taxes		-		-		-
Loss from discontinued operations attributable to
Community Health Systems, Inc. common
stockholders — basic and diluted	$	-	$	-	$	(12)
Denominator:
Weighted-average number of shares outstanding — basic		113,739,046		112,728,274		111,769,821
Effect of dilutive securities:
Restricted stock awards		-		-		-
Employee stock options		-		-		-
Other equity-based awards		-		-		-
Weighted-average number of shares outstanding — diluted		113,739,046		112,728,274		111,769,821

Schedule of Antidilutive Securities

	Year Ended December 31,
	2019		2018		2017
Dilutive securities outstanding not included in
the computation of earnings per
share because their effect is antidilutive:
Employee stock options and restricted stock awards		3,508,968		2,152,408		3,008,919

XML

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2019

Fair Value of Financial Instruments [Abstract]

Schedule of Estimated Fair Value of Financial Instruments, by Balance Sheet Grouping

	December 31, 2019				December 31, 2018
	Carrying		Estimated Fair		Carrying		Estimated Fair
	Amount		Value		Amount		Value
Assets:
Cash and cash equivalents	$	216	$	216	$	196	$	196
Investments in equity securities		141		141		137		137
Available-for-sale debt securities		101		101		93		93
Trading securities		12		12		11		11
Liabilities:
Contingent Value Right		-		-		-		-
Credit Facility		-		-		1,602		1,564
8% Senior Notes due 2019		-		-		155		146
7⅛% Senior Notes due 2020		-		-		121		100
5⅛% Senior Secured Notes due 2021		990		1,003		984		934
6⅞% Senior Notes due 2022		229		188		2,593		1,175
6¼% Senior Secured Notes due 2023		3,074		3,148		3,067		2,819
8⅝% Senior Secured Notes due 2024		1,023		1,099		1,021		1,025
8% Senior Secured Notes due 2026		2,070		2,182		-		-
8% Senior Secured Notes due 2027		691		700		-		-
6⅞% Senior Notes due 2028		1,678		1,700		-		-
9⅞%Junior-Priority Secured Notes due 2023		1,754		1,539		1,750		1,380
8⅛% Junior-Priority Secured Notes due 2024		1,340		1,113		1,338		976
ABL Facility and other debt		285		285		734		734

Schedule of Pre-tax Gain (Loss) Recognized as a Component of Other Comprehensive Income

	Amount of Pre-Tax (Loss) Gain
	Recognized in OCI (Effective Portion)
	Year Ended December 31,
Derivatives in Cash Flow Hedging Relationships	2019		2018		2017
Interest rate swaps	$	(3)	$	17	$	2

Schedule of Effective Portion of the Pre-tax Loss (Gain) Reclassified from AOCL into Interest Expense on the Consolidated Statements of Income

	Amount of Pre-Tax Loss Reclassified
	from AOCL into Income (Effective Portion)
Location of Loss Reclassified from	Year Ended December 31,
AOCL into Income (Effective Portion)	2019		2018		2017
Interest expense, net	$	-	$	2	$	30

Schedule of the Fair Value of Derivative Instruments in the Consolidated Balance Sheet

Asset Derivatives

Liability Derivatives

December 31, 2019

December 31, 2018

December 31, 2019

December 31, 2018

Balance

Balance

Balance

Balance

Sheet

Sheet

Sheet

Sheet

Location

Fair Value

Location

Fair Value

Location

Fair Value

Location

Fair Value

Derivatives

designated as

Other

Other

Other

Other

hedging

assets,

assets,

long-term

long-term

instruments

net

$

-

net

$

3

liabilities

$

2

liabilities

$

2

XML

Supplemental Condensed Consolidating Financial Information (Schedule of Condensed Consolidating Statement of Loss) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Condensed Consolidating Statements of Income
Net operating revenues	$ 3,286,000,000	$ 3,246,000,000	$ 3,302,000,000	$ 3,376,000,000	$ 3,453,000,000	$ 3,451,000,000	$ 3,562,000,000	$ 3,689,000,000	$ 13,210,000,000	[1]	$ 14,155,000,000	[1]	$ 15,353,000,000
Operating costs and expenses:
Salaries and benefits									5,947,000,000		6,384,000,000		7,376,000,000
Supplies									2,151,000,000		2,355,000,000		2,672,000,000
Other operating expenses									3,303,000,000		3,496,000,000		3,864,000,000
Government and other legal settlements and related costs									93,000,000		11,000,000		(31,000,000)
Electronic health records incentive reimbursement									(1,000,000)		(4,000,000)		(28,000,000)
Lease cost and rent									321,000,000		337,000,000		394,000,000
Depreciation and amortization									608,000,000		700,000,000		861,000,000
Impairment and loss on sale of businesses, net									138,000,000		668,000,000		2,123,000,000
Total operating costs and expenses									12,560,000,000		13,947,000,000		17,231,000,000
Income from operations									650,000,000		208,000,000		(1,878,000,000)
Interest expense, net									1,041,000,000		976,000,000		931,000,000
(Gain) loss from early extinguishment of debt									54,000,000		(31,000,000)		40,000,000
Equity in earnings of unconsolidated affiliates									(15,000,000)		(22,000,000)		(16,000,000)
Loss from continuing operations before income taxes	(115,000,000)	(72,000,000)	(149,000,000)	(94,000,000)	(369,000,000)	(204,000,000)	(129,000,000)	(13,000,000)	(430,000,000)	[1]	(715,000,000)	[1]	(2,833,000,000)
(Benefit from) provision for income taxes									160,000,000		(11,000,000)		(449,000,000)
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest	(346,000,000)	2,000,000	(146,000,000)	(101,000,000)	(299,000,000)	(308,000,000)	(91,000,000)	(6,000,000)	(590,000,000)	[1]	(704,000,000)	[1]	(2,384,000,000)
Loss from operations of entities sold or held for sale													(6,000,000)
Impairment of hospitals sold or held for sale									0		0		(6,000,000)
Loss from discontinued operations, net of taxes													(12,000,000)
Net loss									(590,000,000)		(704,000,000)		(2,396,000,000)
Less: Net income attributable to noncontrolling interests									85,000,000		84,000,000		63,000,000
Net loss attributable to Community Health Systems, Inc. stockholders	$ (373,000,000)	$ (17,000,000)	$ (167,000,000)	$ (118,000,000)	$ (328,000,000)	$ (325,000,000)	$ (110,000,000)	$ (25,000,000)	(675,000,000)	[1]	(788,000,000)	[1]	(2,459,000,000)
Consolidation, Eliminations [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates									(763,000,000)		(2,022,000,000)		(5,918,000,000)
Loss from continuing operations before income taxes									763,000,000		2,022,000,000		5,918,000,000
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest													5,918,000,000
Net loss									763,000,000		2,022,000,000		5,918,000,000
Net loss attributable to Community Health Systems, Inc. stockholders									763,000,000		2,022,000,000		5,918,000,000
Parent Company [Member]
Operating costs and expenses:
Equity in earnings of unconsolidated affiliates									675,000,000		788,000,000		2,459,000,000
Loss from continuing operations before income taxes									(675,000,000)		(788,000,000)		(2,459,000,000)
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest													(2,459,000,000)
Net loss									(675,000,000)		(788,000,000)		(2,459,000,000)
Net loss attributable to Community Health Systems, Inc. stockholders									(675,000,000)		(788,000,000)		(2,459,000,000)
Subsidiary Issuer [Member]
Condensed Consolidating Statements of Income
Net operating revenues									46,000,000		(5,000,000)		(22,000,000)
Operating costs and expenses:
Impairment and loss on sale of businesses, net									(2,000,000)		29,000,000
Total operating costs and expenses									(2,000,000)		29,000,000
Income from operations									48,000,000		(34,000,000)		(22,000,000)
Interest expense, net									425,000,000		425,000,000		327,000,000
(Gain) loss from early extinguishment of debt									54,000,000		(32,000,000)		40,000,000
Equity in earnings of unconsolidated affiliates									99,000,000		438,000,000		1,888,000,000
Loss from continuing operations before income taxes									(530,000,000)		(865,000,000)		(2,277,000,000)
(Benefit from) provision for income taxes									145,000,000		(77,000,000)		182,000,000
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest													(2,459,000,000)
Net loss									(675,000,000)		(788,000,000)		(2,459,000,000)
Net loss attributable to Community Health Systems, Inc. stockholders									(675,000,000)		(788,000,000)		(2,459,000,000)
Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues									8,246,000,000		8,111,000,000		7,602,000,000
Operating costs and expenses:
Salaries and benefits									3,092,000,000		3,030,000,000		3,092,000,000
Supplies									1,444,000,000		1,426,000,000		1,397,000,000
Other operating expenses									2,289,000,000		2,109,000,000		1,954,000,000
Government and other legal settlements and related costs									93,000,000		11,000,000		(31,000,000)
Electronic health records incentive reimbursement											(1,000,000)		(8,000,000)
Lease cost and rent									168,000,000		166,000,000		166,000,000
Depreciation and amortization									383,000,000		414,000,000		434,000,000
Impairment and loss on sale of businesses, net									121,000,000		97,000,000		608,000,000
Total operating costs and expenses									7,590,000,000		7,252,000,000		7,612,000,000
Income from operations									656,000,000		859,000,000		(10,000,000)
Interest expense, net									667,000,000		494,000,000		489,000,000
(Gain) loss from early extinguishment of debt											1,000,000
Equity in earnings of unconsolidated affiliates									(26,000,000)		774,000,000		1,555,000,000
Loss from continuing operations before income taxes									15,000,000		(410,000,000)		(2,054,000,000)
(Benefit from) provision for income taxes									(6,000,000)		(7,000,000)		(170,000,000)
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest													(1,884,000,000)
Loss from operations of entities sold or held for sale													(4,000,000)
Impairment of hospitals sold or held for sale													(4,000,000)
Loss from discontinued operations, net of taxes													(8,000,000)
Net loss									21,000,000		(403,000,000)		(1,892,000,000)
Net loss attributable to Community Health Systems, Inc. stockholders									21,000,000		(403,000,000)		(1,892,000,000)
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues									4,918,000,000		6,049,000,000		7,773,000,000
Operating costs and expenses:
Salaries and benefits									2,855,000,000		3,354,000,000		4,284,000,000
Supplies									707,000,000		929,000,000		1,275,000,000
Other operating expenses									1,014,000,000		1,387,000,000		1,910,000,000
Electronic health records incentive reimbursement									(1,000,000)		(3,000,000)		(20,000,000)
Lease cost and rent									153,000,000		171,000,000		228,000,000
Depreciation and amortization									225,000,000		286,000,000		427,000,000
Impairment and loss on sale of businesses, net									19,000,000		542,000,000		1,515,000,000
Total operating costs and expenses									4,972,000,000		6,666,000,000		9,619,000,000
Income from operations									(54,000,000)		(617,000,000)		(1,846,000,000)
Interest expense, net									(51,000,000)		57,000,000		115,000,000
Loss from continuing operations before income taxes									(3,000,000)		(674,000,000)		(1,961,000,000)
(Benefit from) provision for income taxes									21,000,000		73,000,000		(461,000,000)
Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest													(1,500,000,000)
Loss from operations of entities sold or held for sale													(2,000,000)
Impairment of hospitals sold or held for sale													(2,000,000)
Loss from discontinued operations, net of taxes													(4,000,000)
Net loss									(24,000,000)		(747,000,000)		(1,504,000,000)
Less: Net income attributable to noncontrolling interests									85,000,000		84,000,000		63,000,000
Net loss attributable to Community Health Systems, Inc. stockholders									$ (109,000,000)		$ (831,000,000)		(1,567,000,000)
Operating Revenues (Net of Contractual Allowances and Discounts) [Member]
Condensed Consolidating Statements of Income
Net operating revenues													18,398,000,000
Operating Revenues (Net of Contractual Allowances and Discounts) [Member] | Subsidiary Issuer [Member]
Condensed Consolidating Statements of Income
Net operating revenues													(22,000,000)
Operating Revenues (Net of Contractual Allowances and Discounts) [Member] | Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues													9,421,000,000
Operating Revenues (Net of Contractual Allowances and Discounts) [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues													8,999,000,000
Provision for Bad Debts [Member]
Condensed Consolidating Statements of Income
Net operating revenues													3,045,000,000
Provision for Bad Debts [Member] | Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues													1,819,000,000
Provision for Bad Debts [Member] | Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statements of Income
Net operating revenues													$ 1,226,000,000

[1] Total quarterly amounts may not add due to rounding.

XML

Leases (Supplemental Cash Flow and Other Information Related to Leases) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2019 USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases	$ 167
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases	7
Cash paid for amounts included in the measurement of lease liabilities: Financing cash flows from finance leases	9
Right-of-use assets obtained in exchange for new finance lease liabilities	2
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 122
Weighted-average remaining lease term: Operating leases	6 years
Weighted-average remaining lease term: Finance leases	20 years
Weighted-average discount rate: Operating leases	9.10%
Weighted-average discount rate: Finance leases	5.60%

XML

Long-Term Debt (8.625% Senior Secured Notes, Due 2024 Narrative) (Details) - USD ($)		12 Months Ended
	Jul. 06, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Issuance of long-term debt		$ 3,042,000,000	$ 1,033,000,000	$ 3,100,000,000
Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, offering date		Jul. 06, 2018
Debt instrument aggregate principal amount	$ 1,033,000,000
Debt instrument stated interest rate	8.625%
Maximum principal redeemable using proceeds from a public equity offering, as a percentage of principal amount	40.00%
Debt instrument redemption price percentage	108.625%
Debt instrument redemption description		plus a "make-whole" premium, as described in the indenture governing the 8⅝% Senior Secured Notes due 2024.
Minimum period notice for redemption of debt	15 days
Maximum period notice for redemption of debt	60 days
Debt Instrument, Redemption, Period One [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage	100.00%
Debt Instrument, Redemption, Period Three [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage		104.313%
Debt Instrument, Redemption, Period Four [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage		102.156%
Debt Instrument, Redemption, Period Five [Member] | Senior Secured Notes [Member] | Senior Secured Notes at 8.625%, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument redemption price percentage		100.00%

XML

Acquisitions and Divestitures (Schedule of Balance Sheet Items Classified as Held for Sale) (Details) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Acquisitions and Divestitures [Abstract]
Other current assets	$ 25	$ 21
Other assets, net	262	154
Accrued liabilities	$ 43	$ 44

XML

Goodwill and Other Intangible Assets (Intangible Assets Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 1,000,000	$ 1,000,000
Net, intangible asset not subject to amortization	63,000,000	67,000,000
Gross carrying amount of capitalized software	1,100,000,000	1,200,000,000
Capitalized computer software, net	321,000,000	355,000,000
Capitalized computer software, development stage costs	$ 42,000,000
Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization period	1 year
Acquired finite-lived intangible asset, residual value	$ 0
Amortization expense	1,000,000	3,000,000	$ 4,000,000
Capitalized Internal Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, residual value	0
Amortization expense	121,000,000	140,000,000	$ 178,000,000
Amortization expense for 2020	114,000,000
Amortization expense for 2021	93,000,000
Amortization expense for 2022	55,000,000
Amortization expense for 2023	26,000,000
Amortization expense for 2024	22,000,000
Amortization expense thereafter	$ 11,000,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization period	3 years
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization period	8 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived intangible assets, net	$ 1,000,000	$ 1,000,000
Maximum [Member] | Finite-Lived Intangible Assets, Except Capitalized Internal-Use Software [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for 2020	$ 1,000,000
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization period	10 years

XML

Long-Term Debt (Loss (gain) from Early Extinguishment of Debt Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Extinguishment of Debt Disclosures [Abstract]
Loss (gain) from early extinguishment of debt	$ 54	$ (31)	$ 40
Loss (gain) on extinguishment of debt, net of tax	$ 42	$ (23)	$ 26

XML

Stockholders' Deficit (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Nov. 06, 2015
Class of Stock [Line Items]
Total capital stock, shares authorized	400,000,000
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value per share	$ 0.01	$ 0.01
Preferred stock, par value per share	$ 0.01	$ 0.01
Preferred stock, shares outstanding	0
Maximum amount of dividends or stock repurchases permissible under the Credit Facility	$ 200
Open Market Repurchase Program for Common Stock, Adopted November 6, 2015 [Member]
Class of Stock [Line Items]
Maximum number of shares authorized for repurchase					10,000,000
Maximum value of shares authorized under repurchase program					$ 300
Number of shares repurchased and retired	0	0	0	532,188
Weighted-average price of repurchased and retired shares, per share				$ 27.31